UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

____________________

FORM 40-F

[X]

Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934

 

or

[   ]

Annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934


For the fiscal year ended

 

 

Commission File Number

 

____________________

Burcon NutraScience Corporation
(Exact name of Registrant as specified in its charter)

British Columbia

8731

Not Applicable

(Province or other jurisdiction of

(Primary Standard Industrial Classification

(I.R.S. Employer

incorporation or organization)

Code Number)

Identification Number)

1946 West Broadway
Vancouver, British Columbia, Canada V6J 1Z2
(604) 733-0896
(Address and telephone number of Registrant's principal executive offices)

____________________

DL Services Inc.

701 5th Avenue Suite 6100

Seattle, WA 98104

(206) 903-8800


(Name, address (including zip code) and telephone number (including
area code) of agent for service in the United States)

____________________

 


Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

     

Common Shares, without par value

BRCN

The NASDAQ Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

For annual reports, indicate by check mark the information filed with this Form:

[  ] Annual information form

[  ] Audited annual financial statements

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: N/A

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. [  ] Yes [X] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [  ] Yes      [  ] No

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company [ ]

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. [  ]

The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. [  ]


EXPLANATORY NOTE

Burcon NutraScience Corporation (the "Company" or the "Registrant") is a Canadian issuer eligible to file its registration statement pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on Form 40-F pursuant to the multi-jurisdictional disclosure system of the Exchange Act. The Company is a "foreign private issuer" as defined in Rule 3b-4 under the Exchange Act. Equity securities of the Company are accordingly exempt from Sections 14(a), 14(b), 14(c), 14(f) and 16 of the Exchange Act pursuant to Rule 3a12-3.


FORWARD LOOKING STATEMENTS

The Exhibits incorporated by reference into this Registration Statement of the Registrant may contain "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws (collectively referred to herein as "forward-looking statements"). All statements other than statements of fact may be deemed to be forward-looking statements, including statements with regard to expected financial performance, strategy and business conditions. The words "believe", "plan", "intend", "estimate", "expect", "anticipate", "continue", or "potential", and similar expressions, as well as future or conditional verbs such as "will", "should", "would", and "could" often identify forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information available to management as of the respective dates set forth in the Exhibits incorporated by reference into this Registration Statement, including reasonable assumptions, estimates, internal and external analysis and opinions of management considering its experience, perception of trends, current conditions and expected developments as well as other factors that management believed to be relevant as at the date such statements were made. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated or implied in such forward-looking statements, including, without limitation, those described in the Registrant's Annual Information Form for the year ended March 31, 2020, attached hereto as Exhibit 99.10.

The Registrant and management caution readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. Although the Registrant believes that the expectations reflected in the forward-looking statements were reasonable as of the time such forward-looking statements were made, it can give no assurance that such expectations will prove to have been correct. The Registrant and management assume no obligation to update or revise them to reflect new events or circumstances except as required by applicable securities laws.

DIFFERENCES IN UNITED STATES AND CANADIAN REPORTING PRACTICES

The Registrant is permitted, under a multijurisdictional disclosure system adopted by the United States, to prepare this report in accordance with Canadian disclosure requirements, which are different from those of the United States. The Registrant prepares its consolidated financial statements, which are filed with this report on Form 40-F in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and the audit is subject to Canadian auditing and auditor independence standards.

PRINCIPAL DOCUMENTS

In accordance with General Instruction B.(1) of Form 40-F, the Registrant hereby incorporates by reference Exhibits 99.1 through 99.46 inclusive, as set forth in the Exhibit Index attached hereto.

In accordance with General Instruction D.(5) of Form 40-F, the Company hereby incorporates by reference Exhibit 99.47 through Exhibit 99.48, as set forth in the Exhibit Index attached hereto.

In accordance with General Instruction D.(9) of Form 40-F, the Registrant has filed the written consent of certain experts named in the foregoing Exhibits as Exhibit 99.49, as set forth in the Exhibit Index attached hereto.

TAX MATTERS

Purchasing, holding, or disposing of securities of the Registrant may have tax consequences under the laws of the United States and Canada that are not described in this Registration Statement on Form 40-F.

DESCRIPTION OF COMMON SHARES

The required disclosure is included under the heading "Description of Capital Structure" in the Registrant's Annual Information Form for the year ended March 31, 2020, attached hereto as Exhibit 99.10.

OFF-BALANCE SHEET ARRANGEMENTS

The Registrant has no off-balance sheet arrangements.


CURRENCY

Unless otherwise indicated, all dollar amounts in this Registration Statement on Form 40-F are in United States dollars. The exchange rate of Canadian dollars into United States dollars, on March 31, 2020, based upon the daily exchange rate as quoted by the Bank of Canada was U.S.$1.00 = Cdn.$1.4187.


CONTRACTUAL OBLIGATIONS

The following table lists, as of March 31, 2020, information with respect to the Registrant's known contractual obligations (in thousands):

 

Payments due by period

Contractual Obligations

Total

Less than 1 year

1-3 years

3-5 years

More than 5 years

Long-Term Debt Obligations1

8,404 569 7,835 - -

Capital (Finance) Lease Obligations

- - - - -

Operating Lease Obligations

30 23 7 - -

Purchase Obligations

47 47 - - -

Other Long-Term Liabilities Reflected on the Company's Balance Sheet under the GAAP of the primary financial statements

- - - - -

Total

8,481 639 7,842 - -

1 Long-Term Debt Obligations relate to the Company’s convertible debentures. The payments include principal and interest due if the principal amount outstanding at March 31, 2020 remained outstanding for the periods shown.

NASDAQ STATEMENT OF CORPORATE GOVERNANCE DIFFERENCES

As a Canadian corporation listed on the NASDAQ, we are not required to comply with most of the NASDAQ's corporate governance standards, and instead may comply with Canadian corporate governance practices. However, we are required to disclose the significant differences between our corporate governance practices and the requirements applicable to U.S. domestic companies listed on the NASDAQ. These significant differences are disclosed on our website at https://burcon.ca/investors/governance/. Except as disclosed on our website, we are in compliance with the NASDAQ corporate governance standards in all significant respects.

UNDERTAKING

The Registrant undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to the securities registered pursuant to Form 40-F or transactions in said securities.

CONSENT TO SERVICE OF PROCESS

The Registrant has concurrently filed a Form F-X in connection with the class of securities to which this Registration Statement relates.


Any change to the name or address of the Registrant's agent for service shall be communicated promptly to the Commission by amendment to the Form F-X referencing the file number of the Registrant.

 


SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Burcon NutraScience Corporation

 

 

 

 

 

 

 

By:

/s/  Johann F. Tergesen

 

 

Name: Johann F. Tergesen

Date: May 14, 2021

 

Title: President & CEO



EXHIBIT INDEX

The following documents are being filed with the Commission as Exhibits to this Registration Statement:

Exhibit

Description

   

99.1

News Release dated May 4, 2020

   

99.2

Letter Agreement dated April 21, 2020 between the Burcon NutraScience Corporation, Merit Functional Foods Corporation, RBT Holdco Ltd. And 10039406 Manitoba Ltd.

   

99.3

Guarantee dated April 24, 2020 between Burcon NutraScience Corporation and Export Development Canada

   

99.4

Guarantee dated April 24, 2020 between Burcon NutraScience Corporation and Export Development Canada

   

99.5

News Release dated June 22, 2020

   

99.6

Consolidated Financial Statements of Burcon NutraScience Corporation for the years ended March 31, 2020 and 2019

   

99.7

Management's Discussion and Analysis of Burcon NutraScience Corporation for the years ended March 31, 2020 and 2019

   

99.8

Certification of Annual Filings in connection with filing of MD&A and Financial Statements by CFO dated June 29, 2020

   

99.9

Certification of Annual Filings in connection with filing of MD&A and Financial Statements by CEO dated June 29, 2020

   

99.10

Annual Information Form of Burcon NutraScience Corporation for the year ended March 31, 2020

   

99.11

News Release dated June 29, 2020

   

99.12

Notice of Meeting of Shareholders dated July 3, 2020

   

99.13

News Release dated July 6, 2020

   

99.14

Notice of Meeting of Shareholders dated July 30, 2020

   

99.15

Management Information Circular of Burcon NutraScience Corporation dated July 30, 2020

   

99.16

Form of Proxy for Meeting to be held on September 17, 2020

   

99.17

Voting Instruction Form for Meeting of Shareholders to be held on September 17, 2020

   

99.18

News Release dated August 10, 2020

   

99.19

Unaudited Condensed Consolidated Interim Financial Statements of Burcon NutraScience Corporation for the three months ended June 30, 2020 and 2019

   

99.20

Management's Discussion and Analysis of Burcon NutraScience Corporation for the three months ended June 30, 2020 and 2019

   

99.21

Certification of Interim Filings in connection with filing of MD&A and Financial Statements by CFO dated August 14, 2020

   

99.22

Certification of Interim Filings in connection with filing of MD&A and Financial Statements by CEO dated August 14, 2020

   

99.23

Material Change Report dated August 17, 2020

   

99.24

Repayable Contribution Agreement dated effective February 24, 2020 for the Agriinnovate Program dated between Her Majesty the Queen in Right of Canada, Merit Functional Foods Corporation, 11410083 Canada Ltd., Burcon NutraScience Holdings Corp., RBT Holdco Ltd. and 10039406 Manitoba Ltd.




Exhibit

Description

   

99.25

Termination of License and Production Agreement dated August 7, 2020 between Burcon NutraScience Corporation and Burcon NutraScience (MB) Corp. and Archer-Daniels-Midland Company

   

99.26

News Release dated August 27, 2020

   

99.27

News Release dated September 2, 2020

   

99.28

Material Change Report dated September 4, 2020

   

99.29

Amended and Restated Unanimous Shareholders Agreement dated August 27, 2020 among Burcon NutraScience Holdings Corp., Tirem Holdings Inc., Merit Functional Foods Corporation and Tirem Holdings Limited Partnership, by its general partner Tirem Holdings GP Inc., Burcon NutraScience Corporation and certain other parties

   

99.30

Amended and Restated License and Production Agreement dated August 27, 2020 between Burcon NutraScience Corporation, Burcon NutraScience (MB) Corp. and Merit Functional Foods Corporation

   

99.31

News Release dated September 18, 2020

   

99.32

Report of Voting Results of the Annual Meeting of Shareholders held on September 17, 2020

   

99.33

Unaudited Condensed Consolidated Interim Financial Statements of Burcon NutraScience Corporation for the three and six months ended September 30, 2020 and 2019

   

99.34

Management's Discussion and Analysis of Burcon NutraScience Corporation for the three and six months ended September 30, 2020 and 2019

   

99.35

Certification of Interim Filings in connection with filing of MD&A and Financial Statements by CFO dated November 16, 2020

   

99.36

Certification of Interim Filings in connection with filing of MD&A and Financial Statements by CEO dated November 16, 2020

   

99.37

News Release dated December 7, 2020

   

99.38

News Release dated January 29, 2021

   

99.39

News Release dated February 9, 2021

   

99.40

Unaudited Condensed Consolidated Interim Financial Statements of Burcon NutraScience Corporation for the three and nine months ended December 31, 2020 and 2019

   

99.41

Management's Discussion and Analysis of Burcon NutraScience Corporation for the three and nine months ended December 31, 2020 and 2019

   

99.42

Certification of Interim Filings in connection with filing of MD&A and Financial Statements by CFO dated February 16, 2021

   

99.43

Certification of Interim Filings in connection with filing of MD&A and Financial Statements by CEO dated February 16, 2021

   

99.44

News Release dated February 16, 2021

   

99.45

News Release dated March 4, 2021

   
99.46 News Release dated April 12, 2021
   
99.47 Certificate of Continuation of Registrant
   
99.48 Articles of Registrant
   

99.49

Consent of PricewaterhouseCoopers LLP




News Release

Merit Functional Foods Expanding Production Capacity

Arranges $85 Million Debt Financing Package

Vancouver, May 4, 2020 / - Burcon NutraScience Corporation ("Burcon") (TSX:BU, OTCQB:BUROF), a global technology leader in the development of plant-based proteins, is pleased to announce that its joint venture company, Merit Functional Foods Corporation ("Merit Functional Foods" or "Merit") has secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada, Farm Credit Canada and the Canadian Imperial Bank of Commerce.

"We are thrilled with Merit's decision to expand production capacity at Merit's state-of-the-art plant protein production facility currently under construction," said Johann F. Tergesen, Burcon's president and chief executive officer, adding, "We are equally thrilled that Merit has arranged such a substantial debt funding package."

Merit Functional Foods is building a 94,000 square foot production facility in Winnipeg to produce high quality pea and canola proteins. The state-of-the-art facility, which is scheduled to be completed in Q4 2020 will be the only commercial facility in the world with the capability to produce food grade canola proteins. This financing will support Merit Functional Foods' growth plans and allow for expansion of their pea and canola protein production capacity.

Merit's product portfolio currently consists of three product family offerings: pea protein, non-GMO canola protein, and MeritPro™, a unique lineup of nutritionally complete protein blends. Its entire portfolio aligns with a number of consumer label preferences, including allergen-free, gluten-free, non-dairy, non-GMO, and vegan.

Export Development Canada (EDC) is a financial Crown corporation dedicated to helping Canadian companies of all sizes succeed on the world stage. EDC's mandate is to support and develop Canada's export trade by helping Canadian companies respond to international business opportunities including those in the cleantech and agriculture sectors.  As Canada's largest financier of clean technologies they provide insurance and financial services, bonding products and small business solutions to Canadian exporters and investors and their international buyers while adhering to a commitment to sustainable and responsible business.

Farm Credit Canada (FCC) is also a federal Crown corporation and Canada's leading agriculture and food lender, with a loan portfolio of more than $38 billion.  FCC provides flexible, competitively priced financing, specifically designed for the agriculture and food industries. 

To facilitate the financing, Burcon has provided a short-term letter of credit in the amount of $6.5 million, which will remain in place until no later than September 30, 2020, and also provided a $4 million guarantee of Merit's debt obligations.


About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 280 issued patents and more than 260 additional patent applications, developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 28, 2019 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements. CLARISOY is a trademark of Archer Daniels Midland Company.

Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca  www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM




Burcon NutraScience Holdings Corp.
1946 West Broadway

Vancouver, BC

V6J 1Z2

April 21, 2020

Merit Functional Foods Corporation
1601 C Silver Avenue

Winnipeg, Manitoba

R3J 4A1

Attention:  Ryan Bracken and Barry Tomiski


Re:  LC and Loan in the Amount of C$6,500,000

We are pleased to confirm that we are prepared to procure the LC (as defined below) and to make a loan to you in the above amount for the purposes described below in accordance with the terms and conditions set forth in this letter agreement (this "Agreement").

Terms used in this Agreement with initial capitals will have the meanings ascribed to them in this Agreement.

1. Loan Parties

The lender will be Burcon NutraScience Holdings Corp. (the "Lender"), a corporation incorporated under the laws of Canada, having a place of business at the address set out for it above.

The borrower will be Merit Functional Foods Corporation (the "Borrower"), a corporation incorporated under the laws of Canada, having a place of business at the address set out for it above.

RBT Holdco Ltd. ("RBT") and 10039406 Manitoba Ltd. ("Shaun Crew Holdco" and together with RBT, the "Other Shareholders") have also agreed to be bound by the terms of this Agreement.

The Other Shareholders and the Borrower are sometimes individually referred to as an "Obligor" and collectively the "Obligors".

2. LC, Loan and Purposes

In connection with the terms of the EDC Term Sheet (EDC Ref. No. : 72661) and funding by Export Development Canada ("EDC") (the "EDC Loan"), the Borrower must fulfill various obligations including, without limitation, establishment and maintenance of a Cost Overrun Account (as defined in the EDC Term Sheet) in the amount of [commercially sensitive information redacted].  C$6,500,000 of this amount is permitted to be funded by way of letter of credit.  The Lender has agreed to assist the Borrower to fulfill this obligation by obtaining a letter of credit from HSBC Bank Canada with EDC as named beneficiary (the "LC"), subject to the terms and conditions contained in this Agreement.


- 2 -

Delivery and ongoing maintenance of the LC by the Lender (or a designated affiliate) shall constitute a loan hereunder to and for the benefit of the Borrower.  As a condition precedent to the Lender (or a designated affiliate) procuring and thereafter delivering the LC to EDC, the Borrower hereby agrees to execute and deliver this Agreement to evidence the loan in the above-described amount of C$6,500,000 (the "Loan").

3. Availability of Loan and Term of LC

In consideration of the Lender (or a designated affiliate) procuring the delivery of the LC to EDC on or before April 22, 2020 or such later date on which the initial funding of the EDC Loan is to occur (the "Advance Date"), the Borrower hereby acknowledges and agrees that it is indebted to the Lender for the entire amount of the Loan from the Advance Date and obligated to pay interest on the Loan in accordance with the terms of this Agreement.

The commitment by the Lender to maintain the LC will terminate on the earlier of: (i)[commercially sensitive information redacted]; and (ii) September 30, 2020, unless extended by mutual agreement in writing of the Borrower and the Lender (the "Term").  [commercially sensitive information redacted].

If the LC is terminated or revoked by the Lender at any time prior to or at the expiry of the Term, then the principal amount of the Loan shall be deemed to have been repaid in full and the only payment obligation owing by the Borrower shall be the payment of interest pursuant to Section 4 below.

4. Interest

The principal amount of the Loan outstanding from time to time shall bear interest, both before and after maturity, default and judgment, at the rate of 5% per annum, compounded annually, and is payable by the Borrower by way of a lump sum balloon payment due at the end of the Term (the "Interest Payment Date").

Interest on amounts outstanding under the Loan shall accrue daily on the basis of actual number of days elapsed in the year of 365 days (or 366 days in a leap-year).

Interest on overdue interest under the Loan shall only accrue after demand and judgment at the same rate per annum and shall be payable on the first day of the next following monthly following the Interest Payment Date. 

All calculations of interest shall be made by the Lender, and such calculations shall, in the absence of manifest mathematical error, be final, conclusive and binding on the Borrower.  The indebtedness of the Borrower in respect of the Loan made by the Lender to the Borrower and interest payable hereunder shall, absent manifest mathematical error, be conclusively evidenced by the books and records of the Lender.

5. Shareholder Loan and cancellation of LC


- 3 -

If [commercially sensitive information redacted]  and neither of the Other Shareholders of the Borrower are able to deliver a letter of credit in favour of EDC (which satisfies the requirements of the EDC Term Sheet) for their entire pro rata share of the LC amount (namely, 40% of C$6,500,000 for RBT and 20% C$6,500,000 for Shaun Crew Holdco) by September 30, 2020, then the Lender and the Other Shareholders will have the option, however shall not be obligated, to contribute their pro rata share of the amount equal to C$6,500,000 plus the interest accrued thereon up to September 30, 2020, as a capital contribution in the form of a shareholder loan (the "Shareholder Loan") to the Borrower (and contemporaneously terminate the LC and request EDC to return same to the Lender).  The shareholding interest of those shareholders making such contribution in the Borrower shall increase proportionately with the amount of such contribution made on behalf of the Other Shareholders that did not contribute, in accordance with the terms of Article 5 of the unanimous shareholders agreement dated May 23, 2019 made among RBT, Shaun Crew Holdco, the Lender and the Borrower (the "USA").  For the avoidance of doubt, if the Lender contributes the full Shareholder Loan amount, the Lender's shareholding interest in the Borrower will be adjusted in accordance with the following formula:

($6,500,000 plus total other amounts contributed by the Lender as of September 30, 2020) divided by (total amounts contributed by the Lender and the Other Shareholders as of September 30, 2020 plus $6,500,000).  For clarity, to the extent that interest accrued on the LC amount up to September 30, 2020 is contributed in addition to the $6,500,000, it shall be included in this calculation as well.

A numerical example setting out the change in shareholdings of the Lender and Other Shareholders if the Lender contributes the full Shareholder Loan amount is set out in Schedule "A" to this Agreement.

The Shareholder Loan shall be on terms substantially similar to the terms of the existing outstanding shareholder loans advanced to the Borrower prior to the date hereof.  Upon the termination of the LC, the Borrower shall repay the interest owing under the Loan out of the balance of the Shareholder Loan.

6. Draw(s) on the LC

If EDC (or any nominee on behalf of EDC) makes a draw ("Draw") on the LC prior to September 30, 2020 and each of the Other Shareholders of the Borrower are unable to reimburse the Lender for such Other Shareholder's entire pro rata share of the  amount of the Draw (namely, 40% of the Draw amount for RBT and 20% of the Draw amount for Shaun Crew Holdco) within ten (10) Business Days of receipt by the Other Shareholders of a written demand for payment by the Lender, the full Draw amount will be deemed a capital contribution ("Deemed Capital Contribution") in the form of a Shareholder Loan (in lieu of a making an actual cash contribution in the Borrower) by the Lender and the Lender's shareholding interest in the Borrower shall increase proportionately with such Deemed Capital Contribution in accordance with the terms of Article 5 of the USA (adapted, mutatis mutandis for the purposes of the Deemed Capital Contribution).  For the avoidance of doubt, the Lender's shareholding interest in the Borrower will be adjusted in accordance with the following formula in the event that EDC makes a Draw equal to the full LC Amount:


- 4 -

($6,500,000 plus total amounts contributed by the Lender as of the date of the Deemed Capital Contribution) divided by (total amounts contributed by all the Lender and the Other Shareholders as of the date of the Deemed Capital Contribution plus $6,500,000). 

A numerical example setting out the change in shareholdings of the Lender and Other Shareholders if the Lender contributes the full Shareholder Loan amount is set out in Schedule "A" to this Agreement.

The Shareholder Loan shall be on terms substantially similar to the terms of the existing outstanding shareholder loans advanced to the Borrower prior to the date hereof, with such revisions as are necessary to reflect the Deemed Capital Contribution nature of the loan investment.

7. Conditions Precedent to Delivery of the LC

The LC shall not be delivered to EDC until satisfaction of the following conditions, which conditions precedent are included for the sole benefit of the Lender and are subject to waiver in whole or in part only by the Lender in its discretion:

(a) This Agreement shall have been executed and delivered by the Borrower and the Other Shareholders.

(b) All of the representations and warranties of each Obligor in this Agreement shall be true and correct as at the date hereof, and each Obligor shall have complied with all covenants on its part to be performed in this Agreement.

(c) No Event of Default shall have occurred and no event shall have occurred or condition exist which would, with the giving of notice or the passage of time or both, constitute an Event of Default.

8. Representations and Warranties

Each Obligor represents and warrants to the Lender, and acknowledges that the Lender is relying upon such representations and warranties in making the LC and Loan available, that as of this date:

(a) Each Obligor is duly incorporated, organized and validly subsisting under the laws of its jurisdiction of incorporation and is in good standing under the laws of each jurisdiction in which it carries on business or has assets.

(b) Each Obligor has all requisite corporate power and authority and all necessary licences and governmental approvals required to own and operate its business as currently conducted, to borrow, to give guarantees, to give security for such borrowing/guarantees and to otherwise to perform its obligations under this Agreement.

(c) All written information provided to the Lender by any Obligor in connection with the LC and Loan, including, without limitation, information relating to the financial position of the Obligors, is, in all material respects, true, complete and accurate.


- 5 -

(d) There are no actions or suits pending or, to the best of the Obligor's knowledge, threatened against or affecting the Borrower which, if determined against its interests would (i) result in a material adverse change in its financial position or its business or affairs or its title to, or interest in, its properties, or (ii) impair its ability to meet its liabilities or perform its obligations and covenants under this Agreement.

(e) Neither the execution nor the delivery of this Agreement nor the performance by the Obligor of any of its obligations hereunder or thereunder has resulted or will result in a breach of, or constitute a default under, any indenture, agreement or instrument to which it is a party or by which it is bound or be in contravention of its constating documents, by-laws or resolutions of its directors or shareholders.

The representations and warranties in this Agreement or contained in any certificates or documents delivered to the Lender pursuant to this Agreement shall not merge in or be prejudiced by and shall survive the delivery of the LC and advance of the Loan and shall continue in full force and effect so long as the LC is outstanding and any amounts are owing by the Obligors to the Lender.

9. Covenants

The Borrower and each Obligor covenant and agree with the Lender that:

(a) The Borrower shall use the LC solely to fulfill its obligation to maintain the Cost Overrun Account as required by the EDC Loan.

(b) If [commercially sensitive information redacted] or if the Lender converts the LC amount into a capital contribution (by Shareholder Loan) into the Borrower, the Borrower shall use such amount solely to fulfill its obligation to maintain the Cost Overrun Account as required by the EDC Loan.

(c) Each Obligor shall do, observe and perform or cause to be done, observed or performed all of its obligations under this Agreement.

(d) Each Obligor shall, forthwith upon becoming aware of the same, promptly advise the Lender of any Event of Default or non-compliance with the requirements of this Agreement.

(e) The Borrower shall indemnify the Lender against all losses, damages, expenses and liabilities incurred or sustained by the Lender as a result of any failure by the Borrower to fulfil the terms and conditions of this Agreement.

(f) Each Obligor shall, at the request of the Lender, execute and deliver or cause to be executed and delivered, all such other loan documents as the Lender may require from time to time, and all such other documents, instruments or certificates as the Lender may reasonably require from time to time for the purpose of giving full effect to this Agreement.


- 6 -

10. Events of Default

Upon the happening of any of the following events (each an "Event of Default"), the Lender may, by notice in writing to the Borrower, terminate the LC, require immediate payment of all amounts owing under this Agreement and enforce all of its rights and remedies under the USA in connection with Sections 5 and 6 of this Agreement:

(a) If the Borrower fails to pay to the Lender any amount of interest due on the Interest Payment Date for a period of fifteen (15) days after such interest is due.

(b) Except as set forth in (1) above, if any Obligor commits a default under or breaches any of the covenants on its part to be performed in this Agreement or pursuant to this Agreement (including pursuant to Sections 5 and 6 of this Agreement) and such default or breach continues for a period of ten (10) Business Days or more.

(c) If an order is made or an effective resolution is passed for the winding-up, liquidation, reorganization or dissolution of any Obligor, or if any Obligor makes a general assignment for the benefit of creditors or proposal under the Bankruptcy and Insolvency Act (Canada), or under similar legislation in any other jurisdiction, or is declared bankrupt, or if a custodian or a sequestrator or a receiver or a receiver and manager or any other officer with similar powers is appointed for the Borrower or its property or any portion of such property which is, in the Lender's opinion, substantial.

(d) If any representation or warranty made by any Obligor in this Agreement or any related document, agreement or certificate, is found to be false or incorrect in any way so as to make it materially misleading when made.

(e) If this Agreement for any reason ceases to be in full force and effect or is declared null and void, or the validity or enforceability of this Agreement is contested by any Obligor, or any Obligor denies that it has any further liability or obligation hereunder or thereunder.

11. Miscellaneous

(a) Defined Terms:

"Business Day" means any day of the year, other than a Saturday, Sunday or any day on which Canadian chartered banks are closed for business in Vancouver, British Columbia or Winnipeg, Manitoba.

(b) Any notice, direction or other communication required or permitted to be given under this Agreement shall be in writing and given by delivering it or sending it by facsimile or other similar form of recorded communication addressed:


- 7 -


(a) if to any Obligor, to it at:

 

1601 C Silver Avenue

Winnipeg, MB  R3J 4A1

   

Attention:

Co-CEO's

   

Telephone:

(204) 998-8884

 

 

(b) if to the Lender, to it at:

 

1946 West Broadway

Vancouver, BC

V6J 1Z2

   

Attention:

Johann F. Tergesen

   

Telephone:

604-733-0896

Facsimile:

604-733-8821

Any communication shall be deemed to have been validly and effectively given (i) if personally delivered, on the date of such delivery if such date is a Business Day and such delivery was made prior to 4:00 p.m. (Vancouver time), (ii) if transmitted by facsimile or similar means of recorded communication on the Business Day following the date of transmission.  Any party may change its address for service from time to time by notice given in accordance with the foregoing and any subsequent notice shall be sent to the party at its changed address.

(c) Prior to issuance of the LC, the Borrower shall reimburse the Lender for all bank charges and costs for obtaining the LC and for all reasonable costs, fees and out-of-pocket expenses (including fees and expenses of legal, tax and other advisors) reasonably and properly incurred by it in connection with its preparation, negotiation and execution of this Agreement and all costs incurred by the Lender in enforcing its rights hereunder, including, without limitation, the fees and disbursements of counsel to the Lender.

(d) All dollar amounts referred to in this Agreement shall be deemed to refer to Canadian dollars. 

(e) This Agreement may not be assigned by any Obligor without the prior written consent of the Lender.

This Agreement shall be governed by and interpreted and enforced in accordance with the laws of the Province of British Columbia and the Laws of Canada applicable therein.

In this Agreement: (i) reference to any body corporate shall include successors thereto, whether by way of amalgamation or otherwise; (ii) references to any statute, enactment or legislation or to any section or provision thereof include a reference to any order, ordinance, regulation, rule or by-law or proclamation made under or pursuant to that statute, enactment or legislation and all amendments, modifications, consolidations, re-enactments or replacements thereof or substitutions therefor from time to time; and (iii) reference to any agreement, instrument, permit or other document shall include reference to such agreement, instrument, permit or other document as the same may from time to time be amended, supplemented or restated.


- 8 -

As the context requires, words importing the singular number shall include the plural and vice versa, and words importing gender including the masculine, feminine and neuter genders.  All accounting terms not otherwise specifically defined in this Agreement shall be construed in accordance with generally accepted accounting principles consistently applied.

[execution page(s) follow]


- 9 -

Please evidence your agreement to and acceptance of this Agreement by signing and returning the enclosed copy on or before April 21, 2020.

    Yours truly,

 

 

BURCON NUTRASCIENCE HOLDINGS CORP.

 

By:

"Johann F. Tergesen"

Authorized Signatory

The undersigned Borrower agrees to and accepts this Agreement on and subject to its terms and conditions, as of April 21, 2020.

 

 

MERIT FUNCTIONAL FOODS CORPORATION

 

By:

"Ryan Bracken"

Authorized Signatory

The undersigned Obligors agree to and accept this Agreement on and subject to its terms and conditions, as of April 21, 2020.

 

 

RBT HOLDCO LTD.

 

By:

"Barry Tomiski"

Authorized Signatory

 

 

 

10039406 MANITOBA LTD.

 

 

"Shaun W. Crew"

Authorized Signatory



 

SCHEDULE "A"

[commercially sensitive information redacted]





GUARANTEE

THIS GUARANTEE is dated as of the 24th day of April, 2020.

BETWEEN:

BURCON NUTRASCIENCE CORPORATION

(the "Guarantor")

- and -

EXPORT DEVELOPMENT CANADA

(the "Lender")

CONTEXT:

A. Pursuant to a Loan Agreement dated as of April 24, 2020, between Merit Functional Foods Corporation, as borrower (the "Borrower") and the Lender, as senior lender, and Export Development Canada, as subordinated lender (as may be amended, modified, supplemented, replaced restated or amended and restated from time to time, the "Loan Agreement"), the Lender has agreed to advance certain loans to the Borrower or has established certain credit facilities in favour of the Borrower.

B. The Loan Agreement requires that the Guarantor execute and deliver to the Lender a guarantee of all of the indebtedness, liabilities and obligations of the Borrower under the Loan Agreement and a postponement of claim with respect to the indebtedness, liabilities and obligations owed by the Borrower to the Guarantor from time to time.

C. It is in the interests of the Guarantor that the Lender extends credit to the Borrower from time to time and the Guarantor will receive economic and other benefits from the extension of credit, and therefore the Guarantor is willing to execute and deliver this Guarantee to and in favour of the Lender.

THEREFORE, the Guarantor agrees with the Lender as follows:

1. Interpretation

1.1 Definitions. All capitalized terms not defined in this Guarantee shall have the meaning given to them in the Loan Agreement. In this Guarantee the following terms have the following meanings:

1.1.1 "Agreed Currency" is defined in Section 4.

1.1.2 "[commercially sensitive information redacted] Funding" has the meaning given to it in the Loan Agreement.

1.1.3 "[commercially sensitive information redacted] Replacement Equity" has the meaning given to it in the Loan Agreement.

1.1.4 "Applicable Law" means, at any time, with respect to any Person, property, transaction or event, all applicable laws, statutes, regulations, treaties, judgments and decrees and (whether or not having the force of law) all applicable official directives, rules, consents, approvals, by-laws, permits, authorizations, guidelines, order and policies of any Governmental Authority having authority over that Person, property, transaction or event.


- 2 -

1.1.5 "Base Case Financial Model" has the meaning given to it in the Loan Agreement.

1.1.6 "Borrower" is defined in the "Context", above.

1.1.7 "Business Day" means a day which is not a Saturday or Sunday on which banks are generally open for business in Toronto, Ontario and Winnipeg, Manitoba.

1.1.8 "Costs to Complete Certificate" has the meaning given to it in the Loan Agreement.

1.1.9 "Default" has the meaning given to it in the Loan Agreement.

1.1.10 "Deficiency" has the meaning given to it in the Loan Agreement.

1.1.11 "Event of Default" has the meaning given to it in the Loan Agreement.

1.1.12 "Governmental Authority":

1.1.12.1 any federal, provincial, state, local, municipal, regional, territorial, aboriginal, or other government, governmental or public department, branch, ministry, or court, domestic or foreign, including any district, agency, commission, board, arbitration panel or authority and any subdivision of any of them exercising or entitled to exercise any administrative, executive, judicial, ministerial, prerogative, legislative, regulatory or taxing authority or power of any nature; and

1.1.12.2 any quasi-governmental or private body exercising any regulatory, expropriation or taxing authority under or for the account of any Governmental Authority as identified in Section 1.1.12.1 above, and any subdivision of any of them.

1.1.13 "Guarantee" means this joint and several guarantee, as it may be amended, modified, supplemented, replaced, amended, restated or amended and restated by written agreement between the Parties.

1.1.14 "Guaranteed Indebtedness" means the aggregate of, without duplication:

1.1.14.1 the Loan Obligations;

1.1.14.2 interest (including interest on overdue interest, compounded monthly) on unpaid amounts due under this Guarantee calculated from the date on which those amounts were originally demanded until payment in full, both before and after judgment, at the rates and in the currency applicable to the Loan Obligations; and

1.1.14.3 all costs and expenses incurred by the Lender in enforcing any rights under this Guarantee.

1.1.15 "Guarantor" is defined in the recital of the Parties, above.

1.1.16 "Lender" is defined in the recital of the Parties, above.


- 3 -

1.1.17 "Loan Agreement" is defined in the "Context", above.

1.1.18 "Loan Documents" has the meaning given to it in the Loan Agreement.

1.1.19 "Loan Obligations" has the meaning given to it in the Loan Agreement.

1.1.20 "Notice" means any notice, demand, request, consent, approval or other communication that is required or permitted by this Guarantee to be given or made by a Party.

1.1.21 "Other Currency" is defined in Section 4.

1.1.22 "Parties" means the Guarantor and the Lender, collectively, and "Party" means any one of them.

1.1.23 "Person" will be broadly interpreted and includes:

1.1.23.1 a natural person, whether acting in his or her own capacity, or in his or her capacity as executor, administrator, estate trustee, trustee or personal or legal representative, and the heirs, executors, administrators, estate trustees, trustees or other personal or legal representatives of a natural person;

1.1.23.2 a corporation or a company of any kind, a partnership of any kind, a sole proprietorship, a trust, a joint venture, an association, an unincorporated association, an unincorporated syndicate, an unincorporated organization or any other association, organization or entity of any kind; and

1.1.23.3 a Governmental Authority.

1.1.24 "Personal Guarantees" has the meaning given to it in the Loan Agreement.

1.1.25 "Project Account" has the meaning given to it in the Loan Agreement.

1.1.26  "Post-Termination Indemnity" is defined in Section 15.

1.1.27 "Security Documents" means those security documents, instruments and agreements, including guarantees, delivered pursuant to the Loan Agreement to secure the Loan Obligations.

1.2 Entire Agreement. This Guarantee, together with the other Loan Documents, constitutes the entire agreement between the Parties pertaining to the subject matter of this Guarantee and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties, and there are no representations, warranties or other agreements between the Parties, express or implied in connection with the subject matter of this Guarantee except as specifically set out in this Guarantee or in any of the other Loan Documents. No Party has been induced to enter into this Guarantee in reliance on, and there will be no liability assessed, either in tort or contract, with respect to, any warranty, representation, opinion, advice or assertion of fact, except to the extent it has been reduced to writing and included as a term in this Guarantee or in the Loan Documents.

1.3 Time of Day. Unless otherwise specified, references to time of day or date mean the local time or date in the City of Winnipeg, Province of Manitoba. 


- 4 -

1.4 Business Day. Whenever any payment to be made or action to be taken under this Guarantee is required to be made or taken on a day other than a Business Day, the payment is to be made or action taken on the next Business Day following.

1.5 Governing Law. This Guarantee is governed by, and is to be construed and interpreted in accordance with, the laws of the Province of Manitoba and the laws of Canada applicable in that Province.

1.6 Certain Rules of Interpretation.

1.6.1 In this Guarantee, words signifying the singular number include the plural and vice versa, and words signifying gender include all genders. Every use of the word "including" in this Guarantee is to be construed as meaning "including, without limitation".

1.6.2 The division of this Guarantee into Articles and Sections, the insertion of headings and the provision of a table of contents are for convenience of reference only and do not affect the construction or interpretation of this Guarantee.

1.6.3 References in this Guarantee to an Article, Section or Schedule are to be construed as references to an Article, Section or Schedule of or to this Guarantee unless otherwise specified.

1.6.4 Unless otherwise specified, any reference in this Guarantee to any statute includes all regulations made under or in connection with that statute from time to time, and is to be construed as a reference to that statute as amended, supplemented or replaced from time to time.

2. Guarantee

2.1 The Guarantor unconditionally and irrevocably guarantees to the Lender full and prompt payment and satisfaction when due, whether at stated maturity, by required payment, by acceleration, declaration, demand or otherwise, and at all times following when due, of all Guaranteed Indebtedness. The Guarantor's maximum aggregate liability under this Guarantee is limited to Four Million Dollars ($4,000,000.00). The Lender and the Guarantor agree that the Guarantor has delivered guarantees under the Loan Agreement as well as the FCC Loan Agreement in respect of the potential for [commercially sensitive information redacted] to fund all or any part of Ten Million Dollars ($10,000,000.00) under the [commercially sensitive information redacted]Program (collectively, such guarantees executed by the Guarantor shall be referred to as the "[commercially sensitive information redacted] Guarantees" and each an "[commercially sensitive information redacted] Guarantee"). The Lender agrees that proceeds paid to any of the Lender, Export Development Canada in its capacity as subordinate lender or FCC from any [commercially sensitive information redacted] Guarantee shall be distributed in accordance with Section 3.03 of the Intercreditor Agreement.  The Lender agrees that any payment made by the Guarantor to the Lender, Export Development Canada in it capacity as subordinate lender or FCC under any [commercially sensitive information redacted] Guarantee shall reduce the liability of the Guarantor on a dollar for dollar basis under all [commercially sensitive information redacted] Guarantees.  For greater certainty, and notwithstanding that multiple [commercially sensitive information redacted] Guarantees may be executed and delivered by the Guarantor,  the maximum aggregate liability of the Guarantor under its [commercially sensitive information redacted] Guarantees in favour of the Lender, Export Development Canada in its capacity as subordinate lender and FCC, collectively, shall be Four Million Dollars ($4,000,000.00) plus interest and costs.


- 5 -

2.2 At any time after the advance of any portion of the [commercially sensitive information redacted] Funding into the Project Account, at the request of the Borrower or the Guarantor, the maximum aggregate limited liability under this Guarantee and the Personal Guarantees shall be reduced pro-rata by an amount in the aggregate equal to the portion of the [commercially sensitive information redacted] Funding deposited into the Project Account on a dollar for dollar basis, provided, however, that there shall be no such reduction (a) in the event a Default or Event of Default has occurred or is continuing or would result from such reduction of the guaranteed amounts; and (b) in the event that a continuing Deficiency has been identified in the most current Costs to Complete Certificate existing at the time of such request..

2.3 At any time after the earlier of the date on which (a) all of the [commercially sensitive information redacted] Funding has been funded into the Project Account; and (b) the [commercially sensitive information redacted]Replacement Equity is funded to the Project Account, and provided that the Base Case Financial Model evidences a positive ending cash balance of at least Ten Thousand Dollars ($10,000) on a monthly basis, at the request of the Borrower or the Guarantor this Guarantee shall be terminated and released and the Lender shall confirm such termination and release in writing, provided, however, that there shall be no such termination and release in the event a Default or Event of Default has occurred or is continuing or would result from such termination and release.

3. Payment

The Guarantor must make payments to the Lender of the amount of the liability of the Guarantor for the Guaranteed Indebtedness immediately after demand to do so is made in writing. The demand will be conclusively deemed to have been effectively made when Notice is provided to the Guarantor under Section 30.2 of this Guarantee.

4. Currency

The Guarantor agrees that payments under this Guarantee on account of the Guaranteed Indebtedness will be made in the currency (the "Agreed Currency") in which the Guaranteed Indebtedness is payable, and if any payment is received in another currency (the "Other Currency"), that payment will constitute a discharge of the liability of the Guarantor under this Guarantee only to the extent of the amount of the Agreed Currency which the Lender may under its normal procedures purchase with the amount of the Other Currency received by it on the Business Day next following the receipt and after deducting any costs of exchange.

5. Guarantee Unconditional

The obligations of the Guarantor under this Guarantee are unconditional and absolute and, without limiting the generality of the foregoing, will not be released, discharged, limited or otherwise affected by (and the Guarantor waives, to the fullest extent permitted by Applicable Law):

5.1 any modification or amendment of or supplement to the obligations of the Borrower under the Loan Agreement or the Guaranteed Indebtedness, including any increase or decrease in the principal, the rates of interest, other amounts payable under them, or any change in the nature or form of the credit provided and any amendment to the covenants or other provisions contained in the Loan Agreement or any Loan Document;

5.2 any termination, invalidity, unenforceability or release by the Lender of any of its rights against the Borrower or against any other Person or of any Loan Document;


- 6 -

5.3 any increase, reduction, renewal, extension, substitution or other change in, or discontinuance of, the terms relating to the Guaranteed Indebtedness or to any credit extended by the Lender to the Borrower under the Loan Agreement; any agreement to any proposal or scheme of arrangement concerning, or granting any extensions of time or any other indulgences or concessions to, the Borrower or any other Person; abstaining from taking, perfecting or registering any Security Documents; allowing any Security Documents to lapse, whether by failing to make or maintain any registration or otherwise; or any neglect or omission by the Lender in respect of, or in the course of, doing any of these things;

5.4 the existence of any claim, set-off or other rights which the Guarantor may have at any time against the Borrower, the Lender, or any other Person, whether in connection with this Guarantee or any unrelated transactions;

5.5 any change in the financial condition of the Guarantor, the Borrower or any other Person, including insolvency and bankruptcy;

5.6 any release, substitution or addition of any co-signer, endorser or other guarantor of the Guaranteed Indebtedness or any declaration by the other Person that it is no longer bound by its co-signature, endorsement or guarantee, as applicable;

5.7 any event, whether or not attributable to the Lender, that may be considered to have caused or accelerated the bankruptcy or insolvency of the Borrower or any other Person, or to have resulted in the initiation of any of those proceedings;

5.8 any failure by the Lender to abide by any of the terms and conditions of the Loan Agreement or the other Loan Documents with, or to meet any of its obligations or duties owed to, the Guarantor, the Borrower or any other Person, or any breach of any duty, whether as a fiduciary or otherwise, that exists or is alleged to exist between the Lender and the Guarantor, the Borrower or any other Person;

5.9 the benefit of any law which provides that the obligation of a guarantor must not be larger in amount, or in other respects more burdensome, than that of the principal obligation or which reduces a guarantor's obligation in proportion to the principal obligation;

5.10 any defence arising from the invalidity, illegality or lack of enforceability of the Guaranteed Indebtedness or any part of it, or of any security or guarantee relating to the Guaranteed Indebtedness, or because of any incapacity, lack of authority, or other defence of the Borrower or any other Person, or because of any limitation, postponement, prohibition, subordination or other restriction on the Lender's right to payment of the Guaranteed Indebtedness or any part of it, or because of the termination, invalidity, unenforceability or cessation from any cause of the liability of the Borrower or the Guarantor or any other Person with respect to all or any part of the Guaranteed Indebtedness, or because of any act or omission of the Lender or others, whether occasioned by their own fault or otherwise, which directly or indirectly results in the discharge or release of the Borrower or any other Person, or of all or any part of the Guaranteed Indebtedness or any security or guarantee for the Guaranteed Indebtedness, whether by contract, operation of law or otherwise, except as a result of the payment by the Borrower or the Guarantor to the Lender in full of the Guaranteed Indebtedness, including all interest and expenses as provided for in this Guarantee;

5.11 any defence arising from any failure by the Lender to obtain, perfect or maintain a perfected or prior (or any) security interest in or lien or encumbrance upon any property of either of the Borrower or any other Person, or because of any interest of the Lender in any property, whether as owner of that property or as the holder of a security interest in that property or lien or encumbrance on that property, being invalidated, voided, declared fraudulent or preferential or otherwise set aside, or because of any impairment by the Lender of any right to recourse or collateral;


- 7 -

5.12 any change of effective control of the Borrower or the Guarantor;

5.13 any other act or omission to act or delay of any kind by the Borrower, the Lender or any other Person, or any other circumstance, whether similar or dissimilar to the foregoing, which might, but for the provisions of this Section 5, constitute a legal or equitable discharge, limitation or reduction of the Guarantor's obligations under this Guarantee, other than the payment or extinguishment in full of all of the Guaranteed Indebtedness and the termination of all credit facilities and any lending commitment; or

5.14 any major or minor amendments or modifications to, or any restatement, renewal, replacement or extension of the Loan Agreement or any Loan Document, or of any other Loan Agreement, terms letter or other document between the Lender and the Borrower.

To the extent permitted by Applicable Law, the foregoing provisions apply, and the foregoing waivers will be effective, even if the effect of any action, or failure to take action, by the Lender is to destroy or diminish the Guarantor's subrogation rights, the Guarantor's rights to proceed against the Borrower for reimbursement, the Guarantor's rights to recover contribution from any other guarantor or any other right or remedy but, for greater certainty, shall not affect the Guarantor's right to recover any contribution or payment or part of any contribution or payment made by the Guarantor to the Lender pursuant to this Guarantee that is in excess of the actual amount of the Guaranteed Indebtedness.

6. Dealings With the Borrower

The Lender may grant extensions of time or other indulgences, take and give up securities, accept compositions, grant releases and discharges and otherwise deal with the Borrower and with other Persons and securities as the Lender sees fit, and the Lender may apply all monies received by it from the Borrower or others or from any security upon that part of the Guaranteed Indebtedness as it may think best, without the consent of, or notice to, the Guarantor or any other Person and without prejudice to, or in any way limiting or lessening, the liability of the Guarantor under this Guarantee. Without limiting the generality of the foregoing, the Guarantor authorizes and empowers the Lender, in its sole and unfettered discretion, without any notice to such Guarantor or any other Person or entity, to exercise any right or remedy which the Lender has or may have against the Borrower or any other Person, or with respect to any security, whether real, personal or intangible, for the Guaranteed Indebtedness, without affecting in any way the liability of the Guarantor under this Guarantee, and the Guarantor will be liable to the Lender for any deficiency resulting from the exercise by the Lender of any right or remedy.

7. Recourse Against the Borrower

The Lender is not bound to exhaust its recourse against the Borrower, any other guarantor or other Person or under any other security before being entitled to payment from the Guarantor under this Guarantee.

8. Settlement of Accounts

Any account settled or stated between the Lender and the Borrower will be accepted by the Guarantor as prima facie evidence that the amount appearing due by the Borrower to the Lender in that account is so due, except for manifest error.


- 8 -

9. Change in Composition of the Borrower

No change in the name, objects, capital stock, constitution, ownership or control of the Borrower, and no other circumstance, including the Borrower being amalgamated with another corporation, or any amendments, supplement to or replacement of the Loan Agreement or any other Loan Document, or any circumstance affecting the Borrower or the Guarantor which might otherwise provide a legal or equitable defence to the Guarantor or a discharge of this Guarantee, will affect or in any way limit or lessen the liability of the Guarantor under this Guarantee.

10. Guarantee of all Monies Borrowed

All monies and credits borrowed or obtained by the Borrower from the Lender under or in connection with the Loan Agreement or any of the other Loan Documents will be deemed to form part of the Guaranteed Indebtedness despite any incapacity, disability or lack or limitation of status or power of the Borrower or of the directors, officers or employees of the Borrower, or that the Borrower may not be a legal entity, or any irregularity, defect or informality in the borrowing or obtaining of those monies or credits. All advances, renewals and credits made or granted by the Lender purportedly to or for the Borrower under the Loan Agreement after the bankruptcy or insolvency of the Borrower will be deemed to form part of the Guaranteed Indebtedness.

11. Principal Debtor

Any amount of Guaranteed Indebtedness which may not be recoverable from the Guarantor by the Lender under this Guarantee on the basis of a guarantee will be recoverable by the Lender from the Guarantor as principal debtor of that amount, and that amount will be paid to the Lender immediately after demand for that amount as provided in this Guarantee.

12. Continuing Guarantee

This Guarantee is a continuing, absolute, unconditional and irrevocable guarantee of all of the Guaranteed Indebtedness, will apply to all of the Guaranteed Indebtedness, and will remain in full force and effect until all of the Guaranteed Indebtedness has been paid in full. This Guarantee will not be considered as wholly or partially satisfied by the payment or liquidation at any time of any sum of money for the time being due or remaining unpaid to the Lender.

13. No Subrogation

Until all the Guaranteed Indebtedness, interest and expenses have been paid in full, the Guarantor will have no right of subrogation to, and waives, to the fullest extent permitted by law, any right to enforce any remedy which the Lender now has or may have after this Guarantee takes effect against the Borrower in respect of the Guaranteed Indebtedness, and the Guarantor waives any benefit of, and any right to participate in, any security, whether charging real or personal property, now or in the future held by the Lender for the Guaranteed Indebtedness until the time that all Guaranteed Indebtedness, interest and expenses as referred to in this Guarantee are paid in full. If the Lender receives from the Guarantor a payment or payments on account of the liability of the Guarantor under this Guarantee, the Guarantor will not be entitled to claim contribution or indemnity from the Borrower until the claims of the Lender against the Borrower have been paid in full or the Lender has waived its rights in respect of those claims.

14. Stay of Acceleration

If acceleration of the time for payment of any amount payable by the Borrower in respect of the Guaranteed Indebtedness is stayed upon the insolvency, bankruptcy or reorganization of the Borrower, or any moratorium affecting the payment of the Guaranteed Indebtedness, all of the amounts owing under the Loan Agreement otherwise subject to acceleration will nonetheless be payable by the Guarantor under this Guarantee immediately upon demand by the Lender.


- 9 -

15. Revival of Guaranteed Indebtedness and Liability

The Guarantor agrees that, if at any time, all or any part of any payment previously applied by the Lender to any Guaranteed Indebtedness is or must be rescinded or returned by the Lender for any reason, including the insolvency, bankruptcy, or reorganization of the Borrower, or if any indebtedness arises from any indemnity of the Borrower in favour of the Lender under the Loan Agreement which survives the termination of the Loan Agreement (a "Post-Termination Indemnity"), then the Guaranteed Indebtedness will, for the purpose of this Guarantee:

15.1 to the extent that the payment is or must be rescinded or returned, be deemed to have continued in existence, despite the application by the Lender, and this Guarantee will continue to be effective or be reinstated, as the case may be, as to that Guaranteed Indebtedness, all as though the application by the Lender had not been made; and

15.2 extend to the Post-Termination Indemnity.

For greater certainty, this Section 15 shall not survive or apply in the event of the termination and release of this Guarantee pursuant to Section 2.3 of this Guarantee.

16. Assignment and Postponement 

Intentionally deleted.

17. Representations and Warranties

The Guarantor represents and warrants to the Lender, upon which representations and warranties the Lender specifically relies, that all representations and warranties pertaining to or made by the Guarantor contained in the Loan Agreement are true, correct and complete.

18. Bound by Loan Agreement

The Guarantor agrees to be bound by the covenants in the Loan Agreement as they relate to the Guarantor.

19. Copy of Loan Agreement

The Guarantor acknowledges that it has been provided with a duly executed copy of the Loan Agreement, including any amendments to the Loan Agreement.

20. Annual Acknowledgment of Representations and Warranties

Upon the written request of the Lender, the Guarantor will, within 30 days of the Lender's request, provide the Lender with a written acknowledgment, in form satisfactory to the Lender, that all of the representations and warranties in the Loan Agreement and any Loan Document pertaining to the Guarantor remain in full force and effect in all material respects as if made and given on the date of delivery of that acknowledgment except for representations and warranties given as of a specified date, which shall be in full force and effect in all material respects as of such date.


- 10 -

21. Liquidation/Insolvency

In case of liquidation, winding up or bankruptcy of the Borrower, whether voluntary or involuntary, or if the Borrower makes a bulk sale of any of its assets within the bulk transfer provisions of any applicable legislation or any arrangement with creditors, whether voluntary or involuntary, the Lender has the right to rank for its full claims and receive all dividends or other payments in respect of its claims in priority to the Guarantor until its claims have been paid in full, and the Guarantor will continue to be liable under this Guarantee up to the amount guaranteed, less any payments made by the Guarantor, for any balance of the Guaranteed Indebtedness which may be owing to the Lender. In the event of the valuation by the Lender of its security, that valuation will not, as between the Lender and the Guarantor, be considered as a purchase of its security, or as payment or satisfaction or reduction of the Guaranteed Indebtedness or any part of it. The provisions of this Section will not in any way limit or lessen the liability of the Guarantor under any other Section of this Guarantee.

22. Expenses

The Guarantor will from time to time, upon demand by the Lender, immediately pay to the Lender all reasonable expenses (including legal fees on a solicitor and his own client basis) incurred by the Lender in the preparation of this Guarantee and the preservation or enforcement of any of its rights under this Guarantee, and those amounts which are outstanding will be added to the Guaranteed Indebtedness.

23. Additional Security

This Guarantee is in addition and without prejudice to any security of any kind, including any other guarantees, held by the Lender at any time in respect of the Guaranteed Indebtedness and any other rights or remedies that the Lender might have.

24. Taxes

All payments to be made by the Guarantor under this Guarantee will be made without set-off or counterclaim and without deduction for any taxes, levies, duties, fees, deductions, withholdings, restrictions or conditions of any kind. If Applicable Laws require a deduction or withholding to be made, the Guarantor will pay to the Lender an additional amount as is necessary to ensure the Lender receives the full amount the Lender would have received if no deduction or withholding had been made.

25. Disclosure

25.1 The Guarantor acknowledges that it possesses all information with respect to the Borrower that is material to this Guarantee, and that the Lender does not have any obligation to disclose to it any information which it may now possess, or may possess after this Guarantee takes effect, concerning the Borrower.

25.2 The Lender may from time to time give any credit or other information about the Guarantor to, or receive that information from, any credit bureau, reporting agency or other similar Person.

26. Conflict

In the event of a conflict in or between the provisions of this Guarantee and the provisions of the Loan Agreement then, despite anything contained in this Guarantee, the provisions of the Loan Agreement will prevail and the provisions of this Guarantee will be deemed to be amended to the extent necessary to eliminate the conflict.


- 11 -

27. Termination

Subject to Section 15 of this Guarantee, upon payment in full of all present and future outstanding indebtedness, liabilities and obligations of the Borrower under the Loan Agreement, the cancellation of any credit facilities and the termination of all obligations of the Lender under the Loan Agreement and the Loan Documents, this Guarantee shall be released and discharged, and if this occurs the Lender will, upon the written request of and at the expense of the Guarantor, execute and deliver to the Guarantor a release and discharge of this Guarantee.

28. No Set-Off

The amount of the Guarantor's liability under this Guarantee is not to be subject to any deduction, withholding, set-off or counterclaim by the Guarantor for any reason at any time.

29. Amalgamation

The Guarantor acknowledges that if it amalgamates with any other corporation or corporations, then:

29.1 the indebtedness, liabilities and obligations created by this Guarantee will become the indebtedness, liabilities and obligations of the amalgamated corporation; and

29.2 the term "Guarantor", where used in this Guarantee, will extend to and include each of the amalgamating corporations and the amalgamated corporation.

30. General Terms

30.1 Time of Essence. Time is of the essence in all respects of this Guarantee.

30.2 Notices. Any notice, demand, request, consent, approval or other communication which is required or permitted under this Guarantee will be made or given by the parties on the terms set out in the Loan Agreement and to the Guarantor at:

       BURCON NUTRASCIENCE CORPORATION

 Attn: Johann F. Tergesen

 1946 West Broadway

 Vancouver, British Columbia  V6J 1Z2

 Facsimile: 604-733-8821

30.3 Severability. Each provision of this Guarantee is distinct and severable. If any provision of this Guarantee, in whole or in part, is or becomes illegal, invalid or unenforceable in any jurisdiction, the illegality, invalidity or unenforceability of that provision will not affect the legality, validity or enforceability of the remaining provisions of this Guarantee, or the legality, validity or enforceability of that provision in any other jurisdiction. 

30.4 Submission to Jurisdiction. Each of the Parties irrevocably submits and attorns to the exclusive jurisdiction of the courts of the Province of Manitoba to determine all issues, whether at law or in equity, arising from this Guarantee. To the extent permitted by Applicable Law, each of the Parties irrevocably waives any objection (including any claim of inconvenient forum) to the venue of any legal proceeding arising out of or relating to this Guarantee in the courts of that Province, or that the subject matter of this Guarantee may not be enforced in those courts, and irrevocably agrees not to seek, and waives any right to, judicial review by any court which may be called upon to enforce the judgment of the courts referred to in this Section 30.4, of the substantive merits of any such suit, action or proceeding. To the extent a Party has or in the future may acquire any immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself or its property, that Party irrevocably waives that immunity in respect of its obligations under this Guarantee.


- 12 -

30.5 Amendment. No supplement, modification, amendment, discharge or termination of this Guarantee is binding unless it is executed in writing by the Parties hereto.

30.6 Waiver. No delay on the part of the Lender in exercising any of its options, powers or rights, or partial or single exercise of them, will constitute a waiver of them. No waiver of any of its rights under this Guarantee, and no modification or amendment of this Guarantee, will be deemed to be made by the Lender unless it is in writing, duly signed on behalf of the Lender, and each waiver, if any, will apply only with respect to the specific instance involved, and will in no way impair the rights of the Lender or the liabilities of the Guarantor to the Lender in any other respect at any other time.

30.7 Further Assurances. Each Party will, at the requesting Party's cost, execute and deliver any further agreements and documents and provide any further assurances as may be reasonably required by the other Party to give effect to this Guarantee and, without limiting the generality of the foregoing, will do or cause to be done all acts and things, execute and deliver or cause to be executed and delivered all agreements and documents and provide such assurances, undertakings and information as may be required from time to time by any Governmental Authority or stock exchanges having jurisdiction over the affairs of a Party or as may be required under applicable securities legislation.

30.8 Assignment and Enurement.

30.8.1 The Lender may from time to time, and without the consent of the Guarantor, assign or transfer all or any of the Guaranteed Indebtedness owing to the Lender or any interest in the Guaranteed Indebtedness to any Person, and may assign and transfer all or any of its rights under this Guarantee, provided that the assignment or transfer is permitted in accordance with Section 12.9.3 of the Loan Agreement and includes the Lender's interest in the Guarantor's Loan Documents, and provided that the Person agrees to be bound by the terms of this Guarantee. Despite any assignment or transfer or any subsequent assignment or transfer, any Guaranteed Indebtedness or part of it so transferred or assigned will be and will remain Guaranteed Indebtedness for the purposes of this Guarantee and any immediate and successive assignee or transferee of any Guaranteed Indebtedness or any interest in the Guaranteed Indebtedness will, to the extent of the interest so assigned or transferred, be entitled to the benefit of, and the right to enforce, this Guarantee to the same extent as if that Person was the Lender.

30.8.2 Except as provided in Section 30.8.1 above, neither this Guarantee, nor any right or obligation under this Guarantee, may be assigned by either Party without the prior consent of the other Party. This Guarantee enures to the benefit of and is binding upon the Parties and their respective successors and permitted assigns.

30.9 Counterparts and Electronic Delivery. This Guarantee may be executed and delivered by the Parties in one or more counterparts, each of which will be an original, and each of which may be delivered by facsimile, e-mail or other functionally equivalent electronic means of transmission, and those counterparts will together constitute one and the same instrument.

30.10 Remedies Cumulative. The rights and remedies under this Guarantee are cumulative and are in addition to, and not in substitution for, any other rights and remedies available at law or in equity or otherwise. No single or partial exercise by a Party of any right or remedy precludes or otherwise affects the exercise of any other right or remedy to which that Party may be entitled.


- 13 -

30.11 Intentionally Deleted.

30.12 Acknowledgment and Waiver. The Guarantor:

30.12.1 acknowledges receiving a copy of this Guarantee; and

30.12.2 waives all rights to receive from the Lender a copy of any financing statement, financing change statement or verification statement filed or issued, as the case may be, at any time in respect of this Guarantee or any amendments to this Guarantee. 

THE REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK.


- 14 -

Each of the Parties has executed and delivered this Guarantee, as of the date noted at the beginning of the Guarantee.

BURCON NUTRASCIENCE CORPORATION

Per: "Johann F. Tergesen"                                            

Name: Johann F. Tergesen
Title: President & Chief Executive Officer

Per: "Jade Cheng"                                                            

Name: Jade Cheng
Title: Chief Financial Officer

EXPORT DEVELOPMENT CANADA

Per: "Trystan Glynn-Morris"                                          

Name: Trystan Glynn-Morris
Title: Project Finance Manager

Per: "Jean-Philippe Nolet"                                            

Name: Jean-Philippe Nolet
Title: Director, Renewables & Sustainable Technologies, Structured & Project Finance

Signature Page - Guarantee (EDC Senior Loan Facility)





GUARANTEE

THIS GUARANTEE is dated as of the 24th day of April, 2020.

BETWEEN:

BURCON NUTRASCIENCE CORPORATION

(the "Guarantor")

- and -

EXPORT DEVELOPMENT CANADA

(the "Lender")

CONTEXT:

A. Pursuant to a Loan Agreement dated as of April 24, 2020, between Merit Functional Foods Corporation, as borrower (the "Borrower") and the Lender, as subordinate lender, and Export Development Canada, as senior lender (as may be amended, modified, supplemented, replaced restated or amended and restated from time to time, the "Loan Agreement"), the Lender has agreed to advance certain loans to the Borrower or has established certain credit facilities in favour of the Borrower.

B. The Loan Agreement requires that the Guarantor execute and deliver to the Lender a guarantee of all of the indebtedness, liabilities and obligations of the Borrower under the Loan Agreement and a postponement of claim with respect to the indebtedness, liabilities and obligations owed by the Borrower to the Guarantor from time to time.

C. It is in the interests of the Guarantor that the Lender extends credit to the Borrower from time to time and the Guarantor will receive economic and other benefits from the extension of credit, and therefore the Guarantor is willing to execute and deliver this Guarantee to and in favour of the Lender.

THEREFORE, the Guarantor agrees with the Lender as follows:

1. Interpretation

1.1 Definitions. All capitalized terms not defined in this Guarantee shall have the meaning given to them in the Loan Agreement. In this Guarantee the following terms have the following meanings:

1.1.1 "Agreed Currency" is defined in Section 4.

1.1.2 "[commercially sensitive information redacted] Funding" has the meaning given to it in the Loan Agreement.

1.1.3 "[commercially sensitive information redacted] Replacement Equity" has the meaning given to it in the Loan Agreement.

1.1.4 "Applicable Law" means, at any time, with respect to any Person, property, transaction or event, all applicable laws, statutes, regulations, treaties, judgments and decrees and (whether or not having the force of law) all applicable official directives, rules, consents, approvals, by-laws, permits, authorizations, guidelines, order and policies of any Governmental Authority having authority over that Person, property, transaction or event.


- 2 -

1.1.5 "Base Case Financial Model" has the meaning given to it in the Loan Agreement.

1.1.6 "Borrower" is defined in the "Context", above.

1.1.7 "Business Day" means a day which is not a Saturday or Sunday on which banks are generally open for business in Toronto, Ontario and Winnipeg, Manitoba.

1.1.8 "Costs to Complete Certificate" has the meaning given to it in the Loan Agreement.

1.1.9 "Default" has the meaning given to it in the Loan Agreement.

1.1.10 "Deficiency" has the meaning given to it in the Loan Agreement.

1.1.11 "Event of Default" has the meaning given to it in the Loan Agreement.

1.1.12 "Governmental Authority":

1.1.12.1 any federal, provincial, state, local, municipal, regional, territorial, aboriginal, or other government, governmental or public department, branch, ministry, or court, domestic or foreign, including any district, agency, commission, board, arbitration panel or authority and any subdivision of any of them exercising or entitled to exercise any administrative, executive, judicial, ministerial, prerogative, legislative, regulatory or taxing authority or power of any nature; and

1.1.12.2 any quasi-governmental or private body exercising any regulatory, expropriation or taxing authority under or for the account of any Governmental Authority as identified in Section 1.1.12.1 above, and any subdivision of any of them.

1.1.13 "Guarantee" means this joint and several guarantee, as it may be amended, modified, supplemented, replaced, amended, restated or amended and restated by written agreement between the Parties.

1.1.14 "Guaranteed Indebtedness" means the aggregate of, without duplication:

1.1.14.1 the Loan Obligations;

1.1.14.2 interest (including interest on overdue interest, compounded monthly) on unpaid amounts due under this Guarantee calculated from the date on which those amounts were originally demanded until payment in full, both before and after judgment, at the rates and in the currency applicable to the Loan Obligations; and

1.1.14.3 all costs and expenses incurred by the Lender in enforcing any rights under this Guarantee.

1.1.15 "Guarantor" is defined in the recital of the Parties, above.

1.1.16 "Lender" is defined in the recital of the Parties, above.


- 3 -

1.1.17 "Loan Agreement" is defined in the "Context", above.

1.1.18 "Loan Documents" has the meaning given to it in the Loan Agreement.

1.1.19 "Loan Obligations" has the meaning given to it in the Loan Agreement.

1.1.20 "Notice" means any notice, demand, request, consent, approval or other communication that is required or permitted by this Guarantee to be given or made by a Party.

1.1.21 "Other Currency" is defined in Section 4.

1.1.22 "Parties" means the Guarantor and the Lender, collectively, and "Party" means any one of them.

1.1.23 "Person" will be broadly interpreted and includes:

1.1.23.1 a natural person, whether acting in his or her own capacity, or in his or her capacity as executor, administrator, estate trustee, trustee or personal or legal representative, and the heirs, executors, administrators, estate trustees, trustees or other personal or legal representatives of a natural person;

1.1.23.2 a corporation or a company of any kind, a partnership of any kind, a sole proprietorship, a trust, a joint venture, an association, an unincorporated association, an unincorporated syndicate, an unincorporated organization or any other association, organization or entity of any kind; and

1.1.23.3 a Governmental Authority.

1.1.24 "Personal Guarantees" has the meaning given to it in the Loan Agreement.

1.1.25 "Project Account" has the meaning given to it in the Loan Agreement.

1.1.26  "Post-Termination Indemnity" is defined in Section 15.

1.1.27 "Security Documents" means those security documents, instruments and agreements, including guarantees, delivered pursuant to the Loan Agreement to secure the Loan Obligations.

1.2 Entire Agreement. This Guarantee, together with the other Loan Documents, constitutes the entire agreement between the Parties pertaining to the subject matter of this Guarantee and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties, and there are no representations, warranties or other agreements between the Parties, express or implied in connection with the subject matter of this Guarantee except as specifically set out in this Guarantee or in any of the other Loan Documents. No Party has been induced to enter into this Guarantee in reliance on, and there will be no liability assessed, either in tort or contract, with respect to, any warranty, representation, opinion, advice or assertion of fact, except to the extent it has been reduced to writing and included as a term in this Guarantee or in the Loan Documents.

1.3 Time of Day. Unless otherwise specified, references to time of day or date mean the local time or date in the City of Winnipeg, Province of Manitoba. 


- 4 -

1.4 Business Day. Whenever any payment to be made or action to be taken under this Guarantee is required to be made or taken on a day other than a Business Day, the payment is to be made or action taken on the next Business Day following.

1.5 Governing Law. This Guarantee is governed by, and is to be construed and interpreted in accordance with, the laws of the Province of Manitoba and the laws of Canada applicable in that Province.

1.6 Certain Rules of Interpretation.

1.6.1 In this Guarantee, words signifying the singular number include the plural and vice versa, and words signifying gender include all genders. Every use of the word "including" in this Guarantee is to be construed as meaning "including, without limitation".

1.6.2 The division of this Guarantee into Articles and Sections, the insertion of headings and the provision of a table of contents are for convenience of reference only and do not affect the construction or interpretation of this Guarantee.

1.6.3 References in this Guarantee to an Article, Section or Schedule are to be construed as references to an Article, Section or Schedule of or to this Guarantee unless otherwise specified.

1.6.4 Unless otherwise specified, any reference in this Guarantee to any statute includes all regulations made under or in connection with that statute from time to time, and is to be construed as a reference to that statute as amended, supplemented or replaced from time to time.

2. Guarantee

2.1 The Guarantor unconditionally and irrevocably guarantees to the Lender full and prompt payment and satisfaction when due, whether at stated maturity, by required payment, by acceleration, declaration, demand or otherwise, and at all times following when due, of all Guaranteed Indebtedness. The Guarantor's maximum aggregate liability under this Guarantee is limited to Four Million Dollars ($4,000,000.00). The Lender and the Guarantor agree that the Guarantor has delivered guarantees under the Loan Agreement as well as the FCC Loan Agreement in respect of the potential for [commercially sensitive information redacted] to fund all or any part of Ten Million Dollars ($10,000,000.00) under the [commercially sensitive information redacted] Program (collectively, such guarantees executed by the Guarantor shall be referred to as the "[commercially sensitive information redacted] Guarantees" and each an "[commercially sensitive information redacted] Guarantee"). The Lender agrees that proceeds paid to any of the Lender, Export Development Canada in its capacity as senior lender or FCC from any [commercially sensitive information redacted] Guarantee shall be distributed in accordance with Section 3.03 of the Intercreditor Agreement.  The Lender agrees that any payment made by the Guarantor to the Lender, Export Development Canada in it capacity as senior lender or FCC under any [commercially sensitive information redacted] Guarantee shall reduce the liability of the Guarantor on a dollar for dollar basis under all [commercially sensitive information redacted] Guarantees.  For greater certainty, and notwithstanding that multiple [commercially sensitive information redacted] Guarantees may be executed and delivered by the Guarantor,  the maximum aggregate liability of the Guarantor under its [commercially sensitive information redacted] Guarantees in favour of the Lender, Export Development Canada in its capacity as senior lender and FCC, collectively, shall be Four Million Dollars ($4,000,000.00) plus interest and costs.


- 5 -

2.2 At any time after the advance of any portion of the [commercially sensitive information redacted] Funding into the Project Account, at the request of the Borrower or the Guarantor, the maximum aggregate limited liability under this Guarantee and the Personal Guarantees shall be reduced pro-rata by an amount in the aggregate equal to the portion of the [commercially sensitive information redacted] Funding deposited into the Project Account on a dollar for dollar basis, provided, however, that there shall be no such reduction (a) in the event a Default or Event of Default has occurred or is continuing or would result from such reduction of the guaranteed amounts; and (b) in the event that a continuing Deficiency has been identified in the most current Costs to Complete Certificate existing at the time of such request..

2.3 At any time after the earlier of the date on which (a) all of the [commercially sensitive information redacted] Funding has been funded into the Project Account; and (b) the [commercially sensitive information redacted] Replacement Equity is funded to the Project Account, and provided that the Base Case Financial Model evidences a positive ending cash balance of at least Ten Thousand Dollars ($10,000) on a monthly basis, at the request of the Borrower or the Guarantor this Guarantee shall be terminated and released and the Lender shall confirm such termination and release in writing, provided, however, that there shall be no such termination and release in the event a Default or Event of Default has occurred or is continuing or would result from such termination and release.

3. Payment

The Guarantor must make payments to the Lender of the amount of the liability of the Guarantor for the Guaranteed Indebtedness immediately after demand to do so is made in writing. The demand will be conclusively deemed to have been effectively made when Notice is provided to the Guarantor under Section 30.2 of this Guarantee.

4. Currency

The Guarantor agrees that payments under this Guarantee on account of the Guaranteed Indebtedness will be made in the currency (the "Agreed Currency") in which the Guaranteed Indebtedness is payable, and if any payment is received in another currency (the "Other Currency"), that payment will constitute a discharge of the liability of the Guarantor under this Guarantee only to the extent of the amount of the Agreed Currency which the Lender may under its normal procedures purchase with the amount of the Other Currency received by it on the Business Day next following the receipt and after deducting any costs of exchange.

5. Guarantee Unconditional

The obligations of the Guarantor under this Guarantee are unconditional and absolute and, without limiting the generality of the foregoing, will not be released, discharged, limited or otherwise affected by (and the Guarantor waives, to the fullest extent permitted by Applicable Law):

5.1 any modification or amendment of or supplement to the obligations of the Borrower under the Loan Agreement or the Guaranteed Indebtedness, including any increase or decrease in the principal, the rates of interest, other amounts payable under them, or any change in the nature or form of the credit provided and any amendment to the covenants or other provisions contained in the Loan Agreement or any Loan Document;

5.2 any termination, invalidity, unenforceability or release by the Lender of any of its rights against the Borrower or against any other Person or of any Loan Document;


- 6 -

5.3 any increase, reduction, renewal, extension, substitution or other change in, or discontinuance of, the terms relating to the Guaranteed Indebtedness or to any credit extended by the Lender to the Borrower under the Loan Agreement; any agreement to any proposal or scheme of arrangement concerning, or granting any extensions of time or any other indulgences or concessions to, the Borrower or any other Person; abstaining from taking, perfecting or registering any Security Documents; allowing any Security Documents to lapse, whether by failing to make or maintain any registration or otherwise; or any neglect or omission by the Lender in respect of, or in the course of, doing any of these things;

5.4 the existence of any claim, set-off or other rights which the Guarantor may have at any time against the Borrower, the Lender, or any other Person, whether in connection with this Guarantee or any unrelated transactions;

5.5 any change in the financial condition of the Guarantor, the Borrower or any other Person, including insolvency and bankruptcy;

5.6 any release, substitution or addition of any co-signer, endorser or other guarantor of the Guaranteed Indebtedness or any declaration by the other Person that it is no longer bound by its co-signature, endorsement or guarantee, as applicable;

5.7 any event, whether or not attributable to the Lender, that may be considered to have caused or accelerated the bankruptcy or insolvency of the Borrower or any other Person, or to have resulted in the initiation of any of those proceedings;

5.8 any failure by the Lender to abide by any of the terms and conditions of the Loan Agreement or the other Loan Documents with, or to meet any of its obligations or duties owed to, the Guarantor, the Borrower or any other Person, or any breach of any duty, whether as a fiduciary or otherwise, that exists or is alleged to exist between the Lender and the Guarantor, the Borrower or any other Person;

5.9 the benefit of any law which provides that the obligation of a guarantor must not be larger in amount, or in other respects more burdensome, than that of the principal obligation or which reduces a guarantor's obligation in proportion to the principal obligation;

5.10 any defence arising from the invalidity, illegality or lack of enforceability of the Guaranteed Indebtedness or any part of it, or of any security or guarantee relating to the Guaranteed Indebtedness, or because of any incapacity, lack of authority, or other defence of the Borrower or any other Person, or because of any limitation, postponement, prohibition, subordination or other restriction on the Lender's right to payment of the Guaranteed Indebtedness or any part of it, or because of the termination, invalidity, unenforceability or cessation from any cause of the liability of the Borrower or the Guarantor or any other Person with respect to all or any part of the Guaranteed Indebtedness, or because of any act or omission of the Lender or others, whether occasioned by their own fault or otherwise, which directly or indirectly results in the discharge or release of the Borrower or any other Person, or of all or any part of the Guaranteed Indebtedness or any security or guarantee for the Guaranteed Indebtedness, whether by contract, operation of law or otherwise, except as a result of the payment by the Borrower or the Guarantor to the Lender in full of the Guaranteed Indebtedness, including all interest and expenses as provided for in this Guarantee;

5.11 any defence arising from any failure by the Lender to obtain, perfect or maintain a perfected or prior (or any) security interest in or lien or encumbrance upon any property of either of the Borrower or any other Person, or because of any interest of the Lender in any property, whether as owner of that property or as the holder of a security interest in that property or lien or encumbrance on that property, being invalidated, voided, declared fraudulent or preferential or otherwise set aside, or because of any impairment by the Lender of any right to recourse or collateral;


- 7 -

5.12 any change of effective control of the Borrower or the Guarantor;

5.13 any other act or omission to act or delay of any kind by the Borrower, the Lender or any other Person, or any other circumstance, whether similar or dissimilar to the foregoing, which might, but for the provisions of this Section 5, constitute a legal or equitable discharge, limitation or reduction of the Guarantor's obligations under this Guarantee, other than the payment or extinguishment in full of all of the Guaranteed Indebtedness and the termination of all credit facilities and any lending commitment; or

5.14 any major or minor amendments or modifications to, or any restatement, renewal, replacement or extension of the Loan Agreement or any Loan Document, or of any other Loan Agreement, terms letter or other document between the Lender and the Borrower.

To the extent permitted by Applicable Law, the foregoing provisions apply, and the foregoing waivers will be effective, even if the effect of any action, or failure to take action, by the Lender is to destroy or diminish the Guarantor's subrogation rights, the Guarantor's rights to proceed against the Borrower for reimbursement, the Guarantor's rights to recover contribution from any other guarantor or any other right or remedy but, for greater certainty, shall not affect the Guarantor's right to recover any contribution or payment or part of any contribution or payment made by the Guarantor to the Lender pursuant to this Guarantee that is in excess of the actual amount of the Guaranteed Indebtedness.

6. Dealings With the Borrower

The Lender may grant extensions of time or other indulgences, take and give up securities, accept compositions, grant releases and discharges and otherwise deal with the Borrower and with other Persons and securities as the Lender sees fit, and the Lender may apply all monies received by it from the Borrower or others or from any security upon that part of the Guaranteed Indebtedness as it may think best, without the consent of, or notice to, the Guarantor or any other Person and without prejudice to, or in any way limiting or lessening, the liability of the Guarantor under this Guarantee. Without limiting the generality of the foregoing, the Guarantor authorizes and empowers the Lender, in its sole and unfettered discretion, without any notice to such Guarantor or any other Person or entity, to exercise any right or remedy which the Lender has or may have against the Borrower or any other Person, or with respect to any security, whether real, personal or intangible, for the Guaranteed Indebtedness, without affecting in any way the liability of the Guarantor under this Guarantee, and the Guarantor will be liable to the Lender for any deficiency resulting from the exercise by the Lender of any right or remedy.

7. Recourse Against the Borrower

The Lender is not bound to exhaust its recourse against the Borrower, any other guarantor or other Person or under any other security before being entitled to payment from the Guarantor under this Guarantee.

8. Settlement of Accounts

Any account settled or stated between the Lender and the Borrower will be accepted by the Guarantor as prima facie evidence that the amount appearing due by the Borrower to the Lender in that account is so due, except for manifest error.


- 8 -

9. Change in Composition of the Borrower

No change in the name, objects, capital stock, constitution, ownership or control of the Borrower, and no other circumstance, including the Borrower being amalgamated with another corporation, or any amendments, supplement to or replacement of the Loan Agreement or any other Loan Document, or any circumstance affecting the Borrower or the Guarantor which might otherwise provide a legal or equitable defence to the Guarantor or a discharge of this Guarantee, will affect or in any way limit or lessen the liability of the Guarantor under this Guarantee.

10. Guarantee of all Monies Borrowed

All monies and credits borrowed or obtained by the Borrower from the Lender under or in connection with the Loan Agreement or any of the other Loan Documents will be deemed to form part of the Guaranteed Indebtedness despite any incapacity, disability or lack or limitation of status or power of the Borrower or of the directors, officers or employees of the Borrower, or that the Borrower may not be a legal entity, or any irregularity, defect or informality in the borrowing or obtaining of those monies or credits. All advances, renewals and credits made or granted by the Lender purportedly to or for the Borrower under the Loan Agreement after the bankruptcy or insolvency of the Borrower will be deemed to form part of the Guaranteed Indebtedness.

11. Principal Debtor

Any amount of Guaranteed Indebtedness which may not be recoverable from the Guarantor by the Lender under this Guarantee on the basis of a guarantee will be recoverable by the Lender from the Guarantor as principal debtor of that amount, and that amount will be paid to the Lender immediately after demand for that amount as provided in this Guarantee.

12. Continuing Guarantee

This Guarantee is a continuing, absolute, unconditional and irrevocable guarantee of all of the Guaranteed Indebtedness, will apply to all of the Guaranteed Indebtedness, and will remain in full force and effect until all of the Guaranteed Indebtedness has been paid in full. This Guarantee will not be considered as wholly or partially satisfied by the payment or liquidation at any time of any sum of money for the time being due or remaining unpaid to the Lender.

13. No Subrogation

Until all the Guaranteed Indebtedness, interest and expenses have been paid in full, the Guarantor will have no right of subrogation to, and waives, to the fullest extent permitted by law, any right to enforce any remedy which the Lender now has or may have after this Guarantee takes effect against the Borrower in respect of the Guaranteed Indebtedness, and the Guarantor waives any benefit of, and any right to participate in, any security, whether charging real or personal property, now or in the future held by the Lender for the Guaranteed Indebtedness until the time that all Guaranteed Indebtedness, interest and expenses as referred to in this Guarantee are paid in full. If the Lender receives from the Guarantor a payment or payments on account of the liability of the Guarantor under this Guarantee, the Guarantor will not be entitled to claim contribution or indemnity from the Borrower until the claims of the Lender against the Borrower have been paid in full or the Lender has waived its rights in respect of those claims.

14. Stay of Acceleration

If acceleration of the time for payment of any amount payable by the Borrower in respect of the Guaranteed Indebtedness is stayed upon the insolvency, bankruptcy or reorganization of the Borrower, or any moratorium affecting the payment of the Guaranteed Indebtedness, all of the amounts owing under the Loan Agreement otherwise subject to acceleration will nonetheless be payable by the Guarantor under this Guarantee immediately upon demand by the Lender.


- 9 -

15. Revival of Guaranteed Indebtedness and Liability

The Guarantor agrees that, if at any time, all or any part of any payment previously applied by the Lender to any Guaranteed Indebtedness is or must be rescinded or returned by the Lender for any reason, including the insolvency, bankruptcy, or reorganization of the Borrower, or if any indebtedness arises from any indemnity of the Borrower in favour of the Lender under the Loan Agreement which survives the termination of the Loan Agreement (a "Post-Termination Indemnity"), then the Guaranteed Indebtedness will, for the purpose of this Guarantee:

15.1 to the extent that the payment is or must be rescinded or returned, be deemed to have continued in existence, despite the application by the Lender, and this Guarantee will continue to be effective or be reinstated, as the case may be, as to that Guaranteed Indebtedness, all as though the application by the Lender had not been made; and

15.2 extend to the Post-Termination Indemnity.

For greater certainty, this Section 15 shall not survive or apply in the event of the termination and release of this Guarantee pursuant to Section 2.3 of this Guarantee.

16. Assignment and Postponement 

Intentionally deleted.

17. Representations and Warranties

The Guarantor represents and warrants to the Lender, upon which representations and warranties the Lender specifically relies, that all representations and warranties pertaining to or made by the Guarantor contained in the Loan Agreement are true, correct and complete.

18. Bound by Loan Agreement

The Guarantor agrees to be bound by the covenants in the Loan Agreement as they relate to the Guarantor.

19. Copy of Loan Agreement

The Guarantor acknowledges that it has been provided with a duly executed copy of the Loan Agreement, including any amendments to the Loan Agreement.

20. Annual Acknowledgment of Representations and Warranties

Upon the written request of the Lender, the Guarantor will, within 30 days of the Lender's request, provide the Lender with a written acknowledgment, in form satisfactory to the Lender, that all of the representations and warranties in the Loan Agreement and any Loan Document pertaining to the Guarantor remain in full force and effect in all material respects as if made and given on the date of delivery of that acknowledgment except for representations and warranties given as of a specified date, which shall be in full force and effect in all material respects as of such date.


- 10 -

21. Liquidation/Insolvency

In case of liquidation, winding up or bankruptcy of the Borrower, whether voluntary or involuntary, or if the Borrower makes a bulk sale of any of its assets within the bulk transfer provisions of any applicable legislation or any arrangement with creditors, whether voluntary or involuntary, the Lender has the right to rank for its full claims and receive all dividends or other payments in respect of its claims in priority to the Guarantor until its claims have been paid in full, and the Guarantor will continue to be liable under this Guarantee up to the amount guaranteed, less any payments made by the Guarantor, for any balance of the Guaranteed Indebtedness which may be owing to the Lender. In the event of the valuation by the Lender of its security, that valuation will not, as between the Lender and the Guarantor, be considered as a purchase of its security, or as payment or satisfaction or reduction of the Guaranteed Indebtedness or any part of it. The provisions of this Section will not in any way limit or lessen the liability of the Guarantor under any other Section of this Guarantee.

22. Expenses

The Guarantor will from time to time, upon demand by the Lender, immediately pay to the Lender all reasonable expenses (including legal fees on a solicitor and his own client basis) incurred by the Lender in the preparation of this Guarantee and the preservation or enforcement of any of its rights under this Guarantee, and those amounts which are outstanding will be added to the Guaranteed Indebtedness.

23. Additional Security

This Guarantee is in addition and without prejudice to any security of any kind, including any other guarantees, held by the Lender at any time in respect of the Guaranteed Indebtedness and any other rights or remedies that the Lender might have.

24. Taxes

All payments to be made by the Guarantor under this Guarantee will be made without set-off or counterclaim and without deduction for any taxes, levies, duties, fees, deductions, withholdings, restrictions or conditions of any kind. If Applicable Laws require a deduction or withholding to be made, the Guarantor will pay to the Lender an additional amount as is necessary to ensure the Lender receives the full amount the Lender would have received if no deduction or withholding had been made.

25. Disclosure

25.1 The Guarantor acknowledges that it possesses all information with respect to the Borrower that is material to this Guarantee, and that the Lender does not have any obligation to disclose to it any information which it may now possess, or may possess after this Guarantee takes effect, concerning the Borrower.

25.2 The Lender may from time to time give any credit or other information about the Guarantor to, or receive that information from, any credit bureau, reporting agency or other similar Person.

26. Conflict

In the event of a conflict in or between the provisions of this Guarantee and the provisions of the Loan Agreement then, despite anything contained in this Guarantee, the provisions of the Loan Agreement will prevail and the provisions of this Guarantee will be deemed to be amended to the extent necessary to eliminate the conflict.


- 11 -

27. Termination

Subject to Section 15 of this Guarantee, upon payment in full of all present and future outstanding indebtedness, liabilities and obligations of the Borrower under the Loan Agreement, the cancellation of any credit facilities and the termination of all obligations of the Lender under the Loan Agreement and the Loan Documents, this Guarantee shall be released and discharged, and if this occurs the Lender will, upon the written request of and at the expense of the Guarantor, execute and deliver to the Guarantor a release and discharge of this Guarantee.

28. No Set-Off

The amount of the Guarantor's liability under this Guarantee is not to be subject to any deduction, withholding, set-off or counterclaim by the Guarantor for any reason at any time.

29. Amalgamation

The Guarantor acknowledges that if it amalgamates with any other corporation or corporations, then:

29.1 the indebtedness, liabilities and obligations created by this Guarantee will become the indebtedness, liabilities and obligations of the amalgamated corporation; and

29.2 the term "Guarantor", where used in this Guarantee, will extend to and include each of the amalgamating corporations and the amalgamated corporation.

30. General Terms

30.1 Time of Essence. Time is of the essence in all respects of this Guarantee.

30.2 Notices. Any notice, demand, request, consent, approval or other communication which is required or permitted under this Guarantee will be made or given by the parties on the terms set out in the Loan Agreement and to the Guarantor at:

       BURCON NUTRASCIENCE CORPORATION

 Attn: Johann F. Tergesen

 1946 West Broadway

 Vancouver, British Columbia  V6J 1Z2

 Facsimile: 604-733-8821

30.3 Severability. Each provision of this Guarantee is distinct and severable. If any provision of this Guarantee, in whole or in part, is or becomes illegal, invalid or unenforceable in any jurisdiction, the illegality, invalidity or unenforceability of that provision will not affect the legality, validity or enforceability of the remaining provisions of this Guarantee, or the legality, validity or enforceability of that provision in any other jurisdiction. 

30.4 Submission to Jurisdiction. Each of the Parties irrevocably submits and attorns to the exclusive jurisdiction of the courts of the Province of Manitoba to determine all issues, whether at law or in equity, arising from this Guarantee. To the extent permitted by Applicable Law, each of the Parties irrevocably waives any objection (including any claim of inconvenient forum) to the venue of any legal proceeding arising out of or relating to this Guarantee in the courts of that Province, or that the subject matter of this Guarantee may not be enforced in those courts, and irrevocably agrees not to seek, and waives any right to, judicial review by any court which may be called upon to enforce the judgment of the courts referred to in this Section 30.4, of the substantive merits of any such suit, action or proceeding. To the extent a Party has or in the future may acquire any immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself or its property, that Party irrevocably waives that immunity in respect of its obligations under this Guarantee.


- 12 -

30.5 Amendment. No supplement, modification, amendment, discharge or termination of this Guarantee is binding unless it is executed in writing by the Parties hereto.

30.6 Waiver. No delay on the part of the Lender in exercising any of its options, powers or rights, or partial or single exercise of them, will constitute a waiver of them. No waiver of any of its rights under this Guarantee, and no modification or amendment of this Guarantee, will be deemed to be made by the Lender unless it is in writing, duly signed on behalf of the Lender, and each waiver, if any, will apply only with respect to the specific instance involved, and will in no way impair the rights of the Lender or the liabilities of the Guarantor to the Lender in any other respect at any other time.

30.7 Further Assurances. Each Party will, at the requesting Party's cost, execute and deliver any further agreements and documents and provide any further assurances as may be reasonably required by the other Party to give effect to this Guarantee and, without limiting the generality of the foregoing, will do or cause to be done all acts and things, execute and deliver or cause to be executed and delivered all agreements and documents and provide such assurances, undertakings and information as may be required from time to time by any Governmental Authority or stock exchanges having jurisdiction over the affairs of a Party or as may be required under applicable securities legislation.

30.8 Assignment and Enurement.

30.8.1 The Lender may from time to time, and without the consent of the Guarantor, assign or transfer all or any of the Guaranteed Indebtedness owing to the Lender or any interest in the Guaranteed Indebtedness to any Person, and may assign and transfer all or any of its rights under this Guarantee, provided that the assignment or transfer is permitted in accordance with Section 12.9.3 of the Loan Agreement and includes the Lender's interest in the Guarantor's Loan Documents, and provided that the Person agrees to be bound by the terms of this Guarantee. Despite any assignment or transfer or any subsequent assignment or transfer, any Guaranteed Indebtedness or part of it so transferred or assigned will be and will remain Guaranteed Indebtedness for the purposes of this Guarantee and any immediate and successive assignee or transferee of any Guaranteed Indebtedness or any interest in the Guaranteed Indebtedness will, to the extent of the interest so assigned or transferred, be entitled to the benefit of, and the right to enforce, this Guarantee to the same extent as if that Person was the Lender.

30.8.2 Except as provided in Section 30.8.1 above, neither this Guarantee, nor any right or obligation under this Guarantee, may be assigned by either Party without the prior consent of the other Party. This Guarantee enures to the benefit of and is binding upon the Parties and their respective successors and permitted assigns.

30.9 Counterparts and Electronic Delivery. This Guarantee may be executed and delivered by the Parties in one or more counterparts, each of which will be an original, and each of which may be delivered by facsimile, e-mail or other functionally equivalent electronic means of transmission, and those counterparts will together constitute one and the same instrument.

30.10 Remedies Cumulative. The rights and remedies under this Guarantee are cumulative and are in addition to, and not in substitution for, any other rights and remedies available at law or in equity or otherwise. No single or partial exercise by a Party of any right or remedy precludes or otherwise affects the exercise of any other right or remedy to which that Party may be entitled.


- 13 -

30.11 Intentionally Deleted.

30.12 Acknowledgment and Waiver. The Guarantor:

30.12.1 acknowledges receiving a copy of this Guarantee; and

30.12.2 waives all rights to receive from the Lender a copy of any financing statement, financing change statement or verification statement filed or issued, as the case may be, at any time in respect of this Guarantee or any amendments to this Guarantee. 

THE REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK.


- 14 -

Each of the Parties has executed and delivered this Guarantee, as of the date noted at the beginning of the Guarantee.

BURCON NUTRASCIENCE CORPORATION

Per: "Johann F. Tergesen"                                            

Name: Johann F. Tergesen
Title: President & Chief Executive Officer

Per: "Jade Cheng"                                                            

Name: Jade Cheng
Title:  Chief Financial Officer

EXPORT DEVELOPMENT CANADA

Per: "Trystan Glynn-Morris"                                          

Name: Trystan Glynn-Morris
Title: Project Finance Manager

Per: "Jean-Philippe Nolet"                                            

Name: Jean-Philippe Nolet
Title: Director, Renewables & Sustainable Technologies, Structured & Project Finance

Signature Page - Guarantee (EDC Subordinate Loan Facility)




News Release

Burcon JV Company Merit Functional Foods

Secures Additional $10 Million Funding

Vancouver, June 22, 2020 / - Burcon NutraScience Corporation ("Burcon") (TSX:BU, OTCQB:BUROF), a global technology leader in the development of plant-based proteins, is pleased to announce that its joint venture company, Merit Functional Foods Corporation ("Merit Functional Foods" or "Merit") has secured additional debt financing of $10 million in the form of a 10-year interest free loan from Agriculture and Agri-Food Canada (the "AIP Loan"). 

"With today's announcement, Merit has further strengthened its financial position as it drives forward to complete its state-of-the-art plant protein production facility in Winnipeg," said Johann F. Tergesen, Burcon's president and chief executive officer, adding, "Merit fully anticipates future increases in demand and is well positioned to increase planned capacity when the time is right."

The interest free loan, repayable over 10 years, was approved under Agriculture and Agri-Food Canada's AgriInnovate Program.  Merit has now secured a combined $95 million debt financing package from a consortium of lenders including Export Development Canada, Farm Credit Canada, Agriculture and Agri-Food Canada, and the Canadian Imperial Bank of Commerce.  Burcon expects that the $4 million guarantee Burcon previously provided to help facilitate Merit's debt financing, will be released in stages over time as Merit draws down on the $10 million AIP Loan announced today.

Merit Functional Foods is building a 94,000 square foot production facility in Winnipeg, Manitoba to produce high quality pea and canola proteins. The state-of-the-art facility, which is scheduled to be completed in Q4 2020 will be the only commercial facility in the world with the capability to produce food grade canola proteins. This financing will further support Merit Functional Foods' growth plans and allow for expansion of their pea and canola protein capacity. 

Merit's product portfolio currently consists of three product family offerings: pea protein, non-GMO canola protein, and MeritPro™, a unique lineup of nutritionally complete protein blends. Its entire portfolio aligns with a number of consumer label preferences, including allergen-free, gluten-free, non-dairy, non-GMO, non-soy and vegan.

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.


Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 28, 2019 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements. CLARISOY is a trademark of Archer Daniels Midland Company.

Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca

www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



 

 

Burcon NutraScience Corporation

Consolidated Financial Statements

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 



Independent auditor’s report

To the Shareholders of Burcon NutraScience Corporation

________________________________________________________________________________________________

Our opinion

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of Burcon NutraScience Corporation and its subsidiaries (together, the Company) as at March 31, 2020 and 2019, and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS).

What we have audited

The Company’s consolidated financial statements comprise:

 the consolidated balance sheets as at March 31, 2020 and 2019;

 the consolidated statements of operations and comprehensive loss for the years then ended;

 the consolidated statements of changes in shareholders’ equity for the years then ended;

 the consolidated statements of cash flows for the years then ended; and

 the notes to the consolidated financial statements, which include a summary of significant accounting policies.

________________________________________________________________________________________________

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the consolidated financial statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada. We have fulfilled our other ethical responsibilities in accordance with these requirements.

________________________________________________________________________________________________
Other information

Management is responsible for the other information. The other information comprises the Management’s Discussion and Analysis.

   
 

PricewaterhouseCoopers LLP

PricewaterhouseCoopers Place, 250 Howe Street, Suite 1400, Vancouver, British Columbia, Canada V6C 3S7
T: +1 604 806 7000, F: +1 604 806 7806

“PwC” refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership.

 



Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

________________________________________________________________________________________________
Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company’s financial reporting process.

________________________________________________________________________________________________
Auditor’s responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.



As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

 Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

 Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.

 Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

 Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.

 Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

 Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor’s report is Kevin Bromley.

(Signed) “PricewaterhouseCoopers LLP”

Chartered Professional Accountants

Vancouver, British Columbia, Canada

June 29, 2020


BURCON NUTRASCIENCE CORPORATION

Consolidated Balance Sheets

As at March 31, 2020 and March 31, 2019

(Prepared in Canadian dollars)

 

 


    March 31, 2020     March 31, 2019  
    $     $  
ASSETS            
Current assets            
    Cash and cash equivalents   15,030,988     489,215  
    Amounts receivable (notes 4 and 11)   332,248     126,605  
    Inventory   132,142     -  
    Prepaid expenses   289,278     307,997  
    15,784,656     923,817  
             
Property and equipment (note 3)    470,504     284,689  
Deferred development costs – net of accumulated amortization of $nil (2019 - $nil)   1,554,584     -  
Investment in and loan to Merit Functional Foods Corporation (note 4)    12,204,538     -  
Goodwill   1,254,930     1,254,930  
             
    31,269,212     2,463,436  
             
LIABILITIES            
Current liabilities            
Accounts payable and accrued liabilities (note 11)   1,067,251     633,209  
Short-term loan (note 6)   -     1,250,000  
Derivative liability (note 5)   -     5,384  
Convertible note (note 5)   -     1,990,686  
Deferred revenue   275,578     -  
Accrued interest (notes 5 and 6)   249,310     564,251  
    1,592,139     4,443,530  
             
Convertible debentures (note 5)   6,731,350     -  
    8,323,489     4,443,530  
             
SHAREHOLDERS’ EQUITY (note 7)            
Capital stock   98,046,103     73,361,133  
Contributed surplus   9,030,861     9,001,467  
Options   9,673,821     9,184,852  
Warrants   1,792,168     199,117  
Convertible debentures (note 5)   2,762,927     -  
Deficit   (98,360,157 )   (93,726,663 )
             
    22,945,723     (1,980,094 )
             
    31,269,212     2,463,436  
Subsequent events (note 16)            

Approved by the Board of Directors

 

   

“Douglas Gilpin”

“D. Lorne Tyrrell”

_________________________________

_________________________________

Director

Director

The accompanying notes are an integral part of these consolidated financial statements.


BURCON NUTRASCIENCE CORPORATION

Consolidated Statements of Operations and Comprehensive Loss

Years ended March 31, 2020 and 2019


(Prepared in Canadian dollars)

 

    2020     2019  
    $     $  
             
REVENUE            
Royalty income (note 1(b))   31,134     40,177  
             
EXPENSES            
Research and development (note 8)   721,851     1,692,519  
Intellectual property   846,137     1,217,949  
General and administrative (notes 9 and 11)   2,186,273     1,681,882  
             
    3,754,261     4,592,350  
             
LOSS FROM OPERATIONS   (3,723,127 )   (4,552,173 )
             
INTEREST AND OTHER INCOME (notes 4 and 11)   247,918     77,177  
             
MANAGEMENT FEE INCOME (notes 4 and 11 )   364,210     14,896  
             
SHARE OF LOSS IN MERIT FUNCTIONAL FOODS CORPORATION (note 4)   (939,806 )   -  
             
INTEREST EXPENSE (notes 5, 6 and 11)   (589,277 )   (324,259 )
             
FOREIGN EXCHANGE GAIN   2,153     6,982  
             
LOSS ON DISPOSAL OF EQUIPMENT   (949 )   -  
             
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITY (note 5)   5,384     -  
             
LOSS AND COMPREHENSIVE LOSS FOR THE YEAR   (4,633,494 )   (4,777,377 )
             
BASIC AND DILUTED LOSS PER SHARE (note 10)   (0.06 )   (0.11 )

The accompanying notes are an integral part of these consolidated financial statements.


BURCON NUTRASCIENCE CORPORATION

Consolidated Statements of Changes in Shareholders’ Equity

Years ended March 31, 2020 and 2019


(Prepared in Canadian dollars)

 

    Number of
fully paid
common
shares
    Capital
stock
$
    Contributed
surplus
$
    Options
$
    Warrants
$
    Convertible
debentures
$
    Deficit
$
    Total
shareholders’
equity
$
 
                                                 
Balance - March 31, 2018   43,941,536     73,361,133     7,599,389     10,329,057     4,723     -     (88,949,286 )   2,345,016  
                                                 
Loss and comprehensive loss for the year   -     -     -     -     -           (4,777,377 )   (4,777,377 )
                                                 
Options cancelled   -     -     1,397,355     (1,397,355 )   -     -     -     -  
                                                 
Warrants issued   -     -     -     -     199,117     -     -     199,117  
                                                 
Warrants expired   -     -     4,723     -     (4,723 )   -     -     -  
                                                 
Stock-based compensation expense   -     -     -     253,150     -     -     -     253,150  
                                                 
Balance - March 31, 2019   43,941,536     73,361,133     9,001,467     9,184,852     199,117     -     (93,726,663 )   (1,980,094 )
                                                 
Loss and comprehensive loss for the year   -     -     -     -     -     -     (4,633,494 )   (4,633,494 )
                                                 
Shares issued   51,503,003     25,149,059     -     -     -     -     -     25,149,059  
                                                 
Share issue costs   -     (1,398,921 )   -     -     -     -     -     (1,398,921 )
                                                 
Options exercised   173,000     118,350     -     (47,279 )   -     -     -     71,071  
                                                 
Options cancelled   -     -     29,394     (29,394 )   -           -     -  
                                                 
Warrants issued   -     -     -     -     2,030,058           -     2,030,058  
                                                 
Warrant issue costs   -     -     -     -     (237,890 )         -     (237,890 )
                                                 
Warrants exercised   1,182,099     816,482     -     -     (284,538 )         -     531,944  
                                                 
Warrant adjustment   -     -     -     -     85,421     -     -     85,421  
                                                 
Convertible debentures   -     -     -     -     -     2,762,927     -     2,762,927  
                                                 
Stock-based compensation expense   -     -     -     565,642     -     -     -     565,642  
                                                 
Balance – March 31, 2020   96,799,638     98,046,103     9,030,861     9,673,821     1,792,168     2,762,927     (98,360,157 )   22,945,723  

The accompanying notes are an integral part of these consolidated financial statements.


BURCON NUTRASCIENCE CORPORATION

Consolidated Statements of Cash Flows

Years ended March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

    2020     2019  
    $     $  
             
CASH FLOWS FROM OPERATING ACTIVITIES            
Loss for the year   (4,633,494 )   (4,777,377 )
Items not affecting cash            
Amortization of property and equipment   37,290     100,248  
Unrealized foreign exchange gain   (1,798 )   (2,261 )
Interest accretion   (144,343 )   -  
Interest expense   472,020     324,259  
Change in fair value of derivative liability   (5,384 )   -  
Share of loss in Merit Functional Foods Corporation   939,806     -  
Loss on disposal of equipment   949     -  
Financing expense   85,420     145,214  
Stock-based compensation expense   514,983     253,148  
    (2,734,551 )   (3,956,769 )
Changes in non-cash working capital items            
Amounts receivable   (205,643 )   27,684  
Inventory   (132,142 )   -  
Prepaid expenses   18,719     (77,392 )
Accounts payable and accrued liabilities   39,806     (140,469 )
Deferred revenue   275,578     -  
    (2,738,233 )   (4,146,946 )
             
CASH FLOWS FROM INVESTING ACTIVITIES            
Investment in Merit Functional Foods Corporation   (13,000,000 )   -  
Development costs deferred   (1,467,076 )   -  
Acquisition of property and equipment   (101,187 )   (18,555 )
    (14,568,263 )   (18,555 )
             
CASH FLOWS FROM FINANCING ACTIVITIES            
Issue of capital stock   25,752,074     -  
Issue of warrants   1,780,752     -  
Issue of convertible debentures   9,500,000     -  
Issue costs   (1,381,417 )   (18,410 )
Short-term loan   250,000     1,250,000  
Repayment of convertible note   (2,508,520 )   -  
Repayment of short-term loan   (1,546,418 )   -  
    31,846,471     1,231,590  
             
FOREIGN EXCHANGE GAIN ON CASH AND CASH EQUIVALENTS   1,798     2,261  
             
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   14,541,773     (2,931,650 )
             
CASH AND CASH EQUIVALENTS – BEGINNING OF YEAR   489,215     3,420,865  
             
CASH AND CASH EQUIVALENTS – END OF YEAR   15,030,988     489,215  
             
INTEREST RECEIVED   79,812     18,018  

The accompanying notes are an integral part of these consolidated financial statements.


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

1. Nature of operations

Burcon NutraScience Corporation (“Burcon” or the “Company”) is an incorporated entity headquartered in Vancouver, British Columbia, Canada.

Burcon is a research and development company that has developed plant protein extraction and purification technology in the field of functional, renewable plant proteins. The Company has an extensive portfolio of composition, application and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.

a) Peazazz®, Peazac®, Puratein®, Supertein® and Nutratein®

Burcon has developed novel pea proteins that it has branded Peazazz® and Peazac®. In 2017, Peazazz® and Peazac® pea proteins achieved US self-affirmed GRAS (“Generally Recognized As Safe”) status, and the US Food and Drug Administration (“US-FDA”) formally acknowledged receipt of Burcon’s GRAS notification for Peazazz® and Peazac® in October 2019.

Burcon has developed three canola protein products, Puratein®, Supertein® and Nutratein®. In 2008, Puratein® and Supertein® achieved US self-affirmed GRAS status, and the US-FDA formally acknowledged receipt of Burcon’s GRAS notification for Puratein® and Supertein® in 2010.

On May 23, 2019, Burcon, entered into a shareholders’ agreement with two other entities to become shareholders of Merit Functional Foods Corporation (“Merit Foods”), to build a new commercial production facility in Western Canada to produce its pea and canola protein products. See note 4 for further details.

On May 23, 2019, Burcon entered into a license agreement with Merit Foods granting Merit Foods an exclusive, royalty-bearing, worldwide license to use and exploit Burcon’s pea, pulse, and canola protein technologies required to produce, market and sell Burcon’s pea, pulse and canola proteins (collectively the “Products”). See note 4 for further details.

b) CLARISOY®

Burcon has a 20-year Soy Agreement with ADM to license its CLARISOY® technology to ADM on an exclusive basis to produce, market and sell CLARISOY® soy protein worldwide. The terms of the Soy Agreement include the license to ADM of all intellectual property, including know-how and trade secrets concerning the manufacture and use of CLARISOY®, the engineering and design by ADM of an initial commercial CLARISOY® production plant and a royalty structure that incorporates financial incentives for ADM to expand sales globally. ADM will make royalty payments to Burcon on the sales of CLARISOY® under the Soy Agreement. Maintaining the CLARISOY® soy protein patent portfolio during the term of the Soy Agreement is the responsibility of Burcon. Since signing the agreement, Burcon has filed additional patent applications to seek important commercial protection for the production and use of CLARISOY®. ADM has elected to include these applications to the license and, if granted, could lengthen the royalty term under the Soy Agreement to at least the year 2035. In November

1


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

2016, ADM confirmed that it has fully commissioned the first full-scale CLARISOY® production facility at its North American headquarters in Decatur, Illinois.

c) COVID-19

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020. Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread. Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses. In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver. To-date, the COVID-19 pandemic has not had significant adverse effect on Burcon’s business.

2. Significant accounting policies

Basis of presentation

These consolidated financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the IFRS Interpretations Committee (“IFRIC”).

The Company has consistently applied the same accounting policies throughout all periods presented. The board of directors approved these consolidated financial statements on June 25, 2020.

Principles of consolidation

These consolidated financial statements include the accounts of the Company and its subsidiaries, Burcon NutraScience (MB) Corp. (“Burcon-MB”) and Burcon NutraScience Holdings Corp. (“Burcon Holdings”). A subsidiary is an entity in which the Company has control, directly or indirectly. Under IFRS 10, an investor controls an investee if and only if the investor has power over the investee, exposure, or rights, to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect the amount of the investor's returns. All material intercompany transactions and balances have been eliminated on consolidation.

Details of the Company’s subsidiaries at March 31, 2020 are as follows:

 

Place of

Interest

 

 

incorporation

%

Principal activity

       

Burcon NutraScience (MB) Corp.

Manitoba, Canada 100 Research and development

Burcon NutraScience Holdings Corp.

Canada 100 Investment holding

2


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

Investment in Associates

An associate is an entity over which the Company has significant influence. Significant influence is the power to participate in the financial and operating policy of the investee without the power to control or jointly control those policies.

The results and assets and liabilities of associates are incorporated in these consolidated financial statements using the equity method of accounting. Under the equity method, an investment in an associate is initially recognized in the consolidated balance sheets at cost and adjusted thereafter to recognize the Company’s share of the profit or loss and other comprehensive income of the associate. Changes in the net assets of the associate other than profit or loss and other comprehensive income are not accounted for unless such changes resulted in changes in ownership interest held by the Company. When the Company’s share of losses of an associate or a joint venture exceeds the Company’s interest in the associate, which includes any long-term interests that, in substance, form part of the Company’s net investment in the associate, the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate.

The Company determines whether it is necessary to recognize any impairment loss with respect to the Company’s investment in an associate. When necessary, the carrying amount of the investment is tested for impairment by comparing the recoverable amount with it’s carrying amount of the investment. Any reversal of that impairment loss is recognized to the extent that the recoverable amount of the investment subsequently increases.

Revenue recognition

The Company recognizes revenue when the amount of revenue can be reliably measured, and it is probable that future economic benefits will flow to the Company. The Company may earn revenues from licensing agreements under which third parties are granted rights to use the Company’s technologies.

If the substantive rights to the technologies are retained by the Company, or the Company has remaining performance obligations under the licensing agreements, and as such not all of the risks and rewards have been transferred to the licensee, the Company recognizes amounts received or receivable as royalties when earned on an accrual basis.

At the point when all of the risks and rewards associated with the use of the technologies have, in substance, been relinquished under the licensing agreements, the Company recognizes the fair value of future payments expected to be received as proceeds from the sale of the technologies in the consolidated statements of operations and comprehensive loss, once the expected future payments can be reliably measured.

3


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

Upfront payments and similar non-refundable payments received under these agreements are initially recognized as deferred revenue. Subsequently, if the Company recognizes royalty revenue, the amounts deferred are recognized as revenue on a straight-line basis over the estimated period royalties are expected to be earned commencing in the period royalties are first recognized as revenue. Otherwise, the deferred amounts are recognized as sale proceeds at the date of sale of the technologies.

License agreements may consist of multiple elements and provide for varying consideration terms, such as upfront payments and milestone or similar payments. Revenue arrangements with multiple elements are reviewed in order to determine whether the multiple elements can be divided into separate units of accounting. If separable, the consideration received is allocated among the separate units of accounting based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units. Otherwise, the applicable revenue recognition criteria are applied to the revenue arrangement as a single unit.

Accounting estimates

The preparation of consolidated financial statements in accordance with IFRS requires management to apply judgment when making estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, the reported amount of revenue and expenses during the reporting period, and disclosures made in the accompanying notes to the consolidated financial statements. Actual results may differ from those estimates.

The significant areas where management’s judgment is applied are in determining the fair value of stock-based compensation (see note 7 for assumptions used by management), derivative liability (see note 5 for assumptions used by management), whether all criteria for deferring development costs are met, the point at which amortization of development costs commences, the expense allocation to deferred development costs and the recoverable amount of goodwill, and the discount rate used to fair value the loans receivable from Merit Functional Foods following their modification (note 4).

Cash and cash equivalents

Cash and cash equivalents consist of cash on deposit with banks and highly liquid short-term interest bearing securities with maturities at the date of purchase of three months or less.

Financial instruments

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial assets and liabilities are offset and the net amount is reported in the consolidated balance sheets when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.

4


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

At initial recognition, the Company classifies its financial instruments in one of the following categories: amortized cost, fair value through profit or loss, and fair value through other comprehensive income.

Derivatives are recognized initially and subsequently at fair value. Transaction costs are expensed in the consolidated statements of operations and comprehensive loss. Gains and losses arising from changes in fair value are presented in the consolidated statements of operations and comprehensive loss, through profit or loss, in the period in which they arise.

Financial assets carried at amortized cost, which include loans and receivables are initially recognized at the amount expected to be received, less a provision for the expected credit loss. Subsequently, financial assets carried at amortized cost are measured at amortized cost using the effective interest method less a provision for the expected credit loss. The Company classifies its cash and cash equivalents and amounts receivable as financial assets carried at amortized cost.

Other financial liabilities are initially recognized at the amount required to be paid, less, when material, a discount to reduce the payables to fair value. Subsequently, other financial liabilities are measured at amortized cost using the effective interest method.

At each reporting date, the Company assesses whether there is objective evidence that a financial asset is impaired. If such evidence exists, the Company recognizes an impairment loss, as follows:

Financial assets carried at amortized cost: the impairment loss is the difference between the carrying value of the asset and the amortized cost of the financial asset, less the expected credit loss. The carrying amount of the asset is reduced by this amount which is recognized in the consolidated statements of operations and comprehensive loss, through profit or loss. Impairment losses on financial assets carried at amortized cost are reversed in subsequent periods if the amount of the expected credit loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized.

Transaction costs of an equity transaction are accounted for as a deduction from equity to the extent that they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided. Qualifying transaction costs incurred prior to the Company’s year-end in anticipation of an issuance of equity instruments subsequent to the Company’s year-end are deferred on the consolidated balance sheets until the equity instruments are issued.

Property and equipment

Property and equipment are recorded at cost less accumulated amortization. The Company provides for amortization using the declining balance method at the following annual rates:

Equipment

20%

Computer equipment

30%

5


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

Inventories

Inventories are recorded at the lower of cost and net realizable value.

Impairment of long-lived assets

The Company tests property and equipment for impairment whenever events or circumstances indicate that the carrying value of an asset or group of assets may not be recoverable. Intangible assets that are not being amortized are tested annually for impairment and also if the Company identifies indicators of impairment. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash-generating units). The evaluation is based on the higher of the asset’s fair value less costs of disposal and its value in use, which is the present value of future cash flows expected to be derived from the asset in its current state. An impairment loss is recognized in the period it is determined to the extent that the carrying value exceeds the higher of fair value less costs to sell and value in use of the asset or group of assets.

Research and development costs

Research costs are expensed in the period incurred. Development costs are also expensed in the period incurred unless the related process is clearly defined and the costs attributable thereto can be reliably measured; the technical feasibility of the process has been established so that it will be available for use or sale; management has indicated its intention to produce and market, or use, the process; an ability to use or sell the process exists; the process will generate probable future economic benefits; and adequate resources exist, or are expected to be available, to complete the development and to use or sell the process.

Goodwill

Goodwill represents the excess at the date of acquisition of the cost of the acquired business over the fair values attributed to the underlying net tangible assets and the identifiable intangible assets. Goodwill is not amortized.

On at least an annual basis, or when circumstances indicate the carrying value of goodwill may not be recoverable, the Company subjects goodwill to an impairment test. For impairment testing purposes, the carrying value of goodwill is allocated to the group of assets that realize the benefits of the acquisition. The impairment assessment is performed by comparing the carrying value of the group of assets, including the allocated carrying value of goodwill, to the higher of its fair value less costs to sell and its value in use, which is the present value of future cash flows expected to be derived from the group of assets in their current state. If the carrying amount of the group of assets exceeds the recoverable amount, an impairment loss is charged to operations in the period such impairment is identified, allocated first to reducing the carrying amount of the goodwill allocated to the group, and then to the other assets of the group.

6


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

Income taxes

The Company uses the balance sheet liability method of accounting for income taxes. Under this method, current income taxes are recognized for the estimated income taxes payable for the current period. Deferred income tax assets and liabilities are recognized in the current period for temporary differences between the tax and accounting bases of assets and liabilities as well as for the benefit of losses available to be carried forward to future years for tax purposes. Deferred income tax assets and liabilities are measured using substantively enacted tax rates and laws expected to apply in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets are recognized only to the extent they are considered probable to be realized.

Government assistance

The Company carries out research and development in Canada that is eligible for Scientific Research and Experimental Development (“SR&ED”) Investment Tax Credits (“ITC”) at both the federal and provincial level. The Company has recognized the refundable portion of ITC at the provincial level but has not recognized the benefits of ITC at the federal level because realization of these benefits is not probable at this time. The Company’s determination of ITC involves uncertainty with respect to management’s interpretation of complex tax regulations. The ITC claims are subject to review and acceptance by the Canada Revenue Agency prior to collection.

Stock-based compensation

The Company accounts for stock-based compensation granted to employees using the fair value method calculated using the Black-Scholes option pricing model. Stock-based compensation granted to non-employees is measured at the fair value of the goods and services received unless the fair value cannot be measured reliably, in which case the amount is measured using the fair value of the options granted. For options granted to employees and those providing similar services, including officers and directors, the compensation cost is measured at the fair value of the equity instrument granted at the date of grant and is expensed to operations over the award’s vesting period. When stock options are exercised, capital stock is credited by the sum of the consideration paid and by the related portion previously recorded in options. Additional information related to the stock option plan and the assumptions used in the Black-Scholes option pricing model are provided in note 7(c).

Earnings (loss) per share

Basic earnings (loss) per share is computed by dividing the net earnings (loss) for the period available to common shareholders by the weighted average number of common shares outstanding during the period. The Company applies the treasury stock method to calculate diluted earnings (loss) per share. Diluted earnings (loss) per share excludes all dilutive potential common shares if their effect is anti-dilutive.

7


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

Foreign currency translation

a) Functional and presentation currency

Items included in the financial statements of each consolidated entity are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). These consolidated financial statements are presented in Canadian dollars, which is the Company’s and its subsidiary’s functional currency.

b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the date of the transactions. Generally, foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at period- end exchange rates of monetary assets and liabilities denominated in currencies other than an operation’s functional currency are recognized in the consolidated statements of operations and comprehensive loss.

Newly adopted accounting standards and amendments

IFRS 16 - Leases

Effective April 1, 2019, the Company has adopted IFRS 16 - Leases, which requires, among other things, leases to recognize leases traditionally recorded as operating leases in the same manner as a financing lease.

The Company applied IFRS 16 on a modified retrospective basis and it did not have a significant impact on the consolidated financial statements.

8


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)


 

3. Property and equipment

          Computer        
    Equipment     equipment     Total  
    $     $     $  
                   
Cost at March 31, 2019   3,777,382     85,662     3,863,044  
Current period additions   241,683     19,218     260,901  
Current period disposals   -     (3,764 )   (3,764 )
Cost at March 31, 2020   4,019,065     101,116     4,120,181  
                   
Accumulated amortization at March 31, 2019    3,501,562     76,793     3,578,355  
Current period amortization   68,916     5,221     74,137  
Current period disposals   -     (2,815 )   (2,815 )
Accumulated amortization at March 31, 2020   3,570,478     79,199     3,649,677  
                   
Net book value at March 31, 2020   448,587     21,917     470,504  
                   
                   
          Computer        
    Equipment     equipment     Total  
    $     $     $  
                   
Cost at March 31, 2018   3,770,739     85,662     3,856,401  
Current period additions   6,643     -     6,643  
Cost at March 31, 2019   3,777,382     85,662     3,863,044  
                   
Accumulated amortization at March 31, 2018    3,405,115     72,992     3,478,107  
Current period amortization    96,447     3,801     100,248  
Accumulated amortization at March 31, 2019   3,501,562     76,793     3,578,355  
                   
Net book value at March 31, 2019   275,820     8,869     284,689  



4. Investment in and loan to Merit Functional Foods Corporation

On May 23, 2019, Burcon, through a new wholly-owned subsidiary incorporated on May 22, 2019, Burcon Holdings, entered into a shareholders’ agreement (the “Shareholders’ Agreement”) with two other entities to become shareholders of Merit Foods, to build and own a new commercial production facility in Western Canada to produce, sell, market and distribute Burcon’s Peazazz® and Peazac® pea proteins, Burcon’s Puratein®, Supertein® and Nutratein® canola proteins, as well as Burcon’s new pea and canola protein blends that it has branded Nutratein-PS and Nutratein-TZ.

Burcon Holdings holds 40% of the issued and outstanding shares of Merit Foods, and the two other parties hold 40% and 20%, respectively. Each shareholder made its respective capital loan advances in June, September, December 2019 and February 2020 by way of shareholder loans totalling $32.5 million (the “Merit Shareholder Loans”).

9


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

Summary financial position for Merit Foods as at March 31, 2020

    As at March 31,  
    2020  
    $  
Current assets   5,828,739  
Non-current assets   36,056,689  
Current liabilities   11,369,931  
Non-current liabilities   6,653,724  
       

Summary financial results for Merit Foods      
       
    Period ended  
    March 31,  
    20201  
    $  
       
Total revenue   375,312  
Loss and comprehensive loss for the period   (2,349,515 )

As at March 31, 2020, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans.

    Investment in     Capital     Loan receivable     Total net  
    Share capital     Contribution     $     investment  
    $     $           $  
                         
At inception   1     -     11,000,000     11,000,001  
Modification to loan terms         8,871,512     (8,871,512 )   -  
Capital loan advance   -     1,613,002     386,998     2,000,000  
Share of loss in Merit Foods   -     (939,806 )   -     (939,806 )
Interest accretion   -     -     144,343     144,343  
                         
Net Investment in Merit
Foods, March 31, 2020
  1     9,544,708     2,659,829     12,204,538  


__________________________________
1 Merit Foods was incorporated on May 15, 2019. As a result, information in this table represents certain financial information of Merit Foods from the date of its incorporation to March 31, 2020.

10


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

On inception, the Merit Shareholder Loans were recorded as loan receivable. In December 2019, the terms of the Merit Shareholder Loans were finalized. The loans are non-interest bearing, unsecured, subordinated to Merit Foods’ other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder’s loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts. As a result, Burcon recalculated the fair value at that date, resulting in a reduction of the fair value of the loan receivable that was transferred to a capital contribution account. Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest. The Company has recorded interest accretion of $144,343 from the inception date of these loans to March 31, 2020.

On May 23, 2019, Burcon entered into a license agreement (the “License Agreement”) with Merit Foods granting Merit Foods an exclusive, royalty-bearing, worldwide license to use and exploit Burcon’s Products. Under the terms of the License Agreement, Merit Foods will have the exclusive rights across all geographic regions and all product uses for Burcon’s pulse protein (including pea) and canola protein technologies (the “License”). Burcon will receive running royalties on the net revenue (as defined in the License Agreement) from the sales of the Products by Merit Foods. Burcon will be responsible for the technology transfer to Merit Foods, and will also provide assistance, under a services agreement, to support the design, construction and commissioning of the commercial protein production facility.

Merit Foods has agreed to develop, build and commission an initial production facility within a specified amount of time to manufacture the Products. Merit Foods will also, within a specified time period, provide written notice to Burcon to advise whether it will or will not increase its annual production capacity of the Products to develop, build and commission a full commercial scale production facility (the “Full Commercial Production Facility”). If Merit Foods expands production to the Full Commercial Production Facility, the royalty rate will reduce to a lower percentage rate. The royalty rate may also reduce if the exclusive license is converted to a non-exclusive license or if a certain Burcon patent does not grant within a specified time.

The License Agreement has a term of the greater of twenty years and the last to expire of Burcon patents that are being used to produce products under the License Agreement. The License Agreement provides Burcon with the right to convert the exclusive license to a non-exclusive license under certain conditions. As long as the License is exclusive, Burcon will be responsible for the filing, prosecution and maintenance of Burcon patent rights in certain countries.

Burcon has a services agreement (the “Services Agreement”) with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement. For the period March 31, 2020, included in interest and other income is $464,780 (2019 - $nil) for technical services provided and sample production by the Company to Merit Foods, of which $110,594 was included in amounts receivable at March 31, 2020 (March 31, 2019 - $nil).

11


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

In May 2020, Burcon announced that Merit Foods has secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada (“EDC”), Farm Credit Canada and the Canadian Imperial Bank of Commerce. Merit Foods’ shareholders, including Burcon Holdings, were required to pledge their shares in Merit Foods as security under the loan facilities from EDC. In connection with the loan facilities from EDC, Merit Foods must fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility. $6.5 million of this amount is permitted to be funded by way of a letter of credit (“LC”). To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada (“HSBC”) in April 2020, which is secured by a term deposit with HSBC in the same amount. In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the “Loan Agreement”) with Merit Foods in the amount of $6.5 million (the “Loan”). The Loan and the commitment by Burcon Holdings to maintain the LC will terminate no later than September 30, 2020, unless extended by mutual agreement. The Loan bears interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term. Under the Loan Agreement, Burcon Holdings has the option to contribute the amount of the Loan as a capital contribution to Merit Foods in certain circumstances including if the other shareholders of Merit Foods are unable to deliver a letter of credit in favour of EDC for their entire pro rata share of the LC amount by September 30, 2020. If EDC draws on the LC prior to September 30, 2020 and each of the other shareholders of Merit Foods are unable to reimburse Burcon Holdings for such other shareholder’s entire pro rata share of the amount of such draw within the time period set out in the Loan Agreement, then the draw amount will be deemed a capital contribution by Burcon Holdings and its shareholding interest in Merit Foods will be increased.

In addition, Burcon has provided a guarantee in favour of EDC’s senior loan facility and subordinate loan facility to Merit Foods (the “Guarantees”), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC and Merit Foods. The aggregate maximum liability of Burcon under the Guarantees is limited to $4.0 million. The Guarantees contain provision dealing with when Burcon’s guarantee may be reduced in the event that Merit Foods is able to obtain certain other government sources of funding, subject to certain conditions being met.

5. Convertible debentures and convertible note

Convertible debentures

On December 10, 2019, the Company issued convertible debentures (the “Debentures”) through a non-brokered private placement for an aggregate principal amount of $9.5 million. Certain directors and an officer of the Company subscribed for Debentures totalling $2 million in principal amount. Each Debenture consists of $1,000 principal amount, bears interest at a rate of 8.5% per annum, payable semi-annually in arrears and is unsecured. The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon will be payable in cash on December 10, 2022. The Debentures will be convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share. Burcon has the right, at its sole discretion, to force the conversion of the Debentures if the shares trade at or above $2.15 for a period of 14 consecutive trading days. The Company incurred issue costs of $228,432, of which $156,600 were finder’s fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders.

12


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

The Debentures are a level 3 financial liability with an embedded conversion feature. As a result, the debt and equity components were bifurcated, and the instrument valued to par at the issuance date. The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option. From the date of issuance, the liability component is accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive loss. The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641. The residual amount of $2,762,927 was recognized within equity as the value of the conversion option. For the year ended March 31, 2020, the Company recorded interest expense of $472,020.

Convertible note

The Company had a convertible note (the “Note”) with Large Scale Investments Limited (“Large Scale’), a wholly owned subsidiary of Firewood Elite Limited (“Firewood”), for the principal amount of $2.0 million (the “Principal Amount”). Firewood, a related party of Burcon that has significant influence over the Company, is wholly owned by Mr. Alan Chan, a director of the Company.

The Note bore interest at 8% per annum, compounded monthly. The Principal Amount and accrued interest were payable on the earlier of May 12, 2019, the occurrence of an event of default as set out in the Note (the “Maturity Date”), or voluntary prepayment by the Company. Under the Note, Large Scale could convert the Principal Amount in whole or in part at $4.01 per share into common shares of the Company commencing on or after July 1, 2016 and up to and including the Maturity Date. Pursuant to the terms of the Note, the conversion price was adjusted upon completion of Burcon’s rights offering that completed in 2016 to $3.99 per share and further adjusted upon the completion of Burcon’s 2018 Rights Offering (note 7(a)) to $3.94 per share.

Burcon had the right, before the Maturity Date, upon written notice to Large Scale of not less than thirty days, to prepay in cash all or any portion of the Principal Amount by paying to Large Scale an amount equal to the Principal Amount to be prepaid multiplied by 110%. The payment of the Principal Amount and all accrued and unpaid interest thereon would be subordinated in right of payment to any amount owing in respect of secured indebtedness of the Company.

On May 21, 2019, the Company and Large Scale amended (the “Amendment”) the Note’s Maturity Date to June 21, 2019. The Amendment also provided Large Scale with the right to offset any amounts due to it under the Note against any obligations of Large Scale to pay for subscription proceeds of any rights offering that Burcon may conduct.

In connection with the 2019 Rights Offering (note 7(a)), Large Scale exercised its right to offset the amounts due under the Note against its obligations to pay for subscription proceeds under the 2019 Rights Offering. The offset was completed on June 25, 2019. The total amount offset under the Note included the principal amount and accrued interest of $2,565,022.

The conversion option was recorded as a derivative liability (note 14). Under the terms of the Note, there are certain conditions where the conversion price may be adjusted. Therefore, in accordance with IFRS, an obligation to issue shares for a price that is not fixed must be classified as a derivative liability and measured at fair value, with changes recognized in change in fair value of conversion option in the consolidated statement of operations and comprehensive loss.

13


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

The conversion and prepayment options were recorded as a net derivative liability and measured at fair value, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss. The fair value of the conversion and prepayment options was estimated based on a methodology for pricing convertible bonds using the Partial Differential Equation Method, with the following initial assumptions: expected volatility of 63%; expected dividend per share of $nil; risk-free rate of 0.60%, entity-specific credit spread, and expected life of 3 years. The assumptions as at March 31, 2019 were as follows: expected volatility of 99%, expected dividend per share of $nil; risk-free rate of 1.63%, initial entity-specific credit spread adjusted by the movement in the option adjusted spread of the Canada High Yield Index, and expected life of 1.1 years. The initial fair value of the net derivative liability was estimated as $189,705 as at the issue date of the Note. As at March 31, 2019, the fair value of the net derivative liability was estimated to be $5,384. Upon the offset by Large Scale of its obligations to pay for subscription proceeds under the 2019 Rights Offering, the net derivative liability was expensed during fiscal 2020 as financing expense.

6. Short-term loan

On November 13, 2018, the Company entered into a loan agreement with Large Scale to provide Burcon with an unsecured loan for up to $1.0 million (the “Loan”). On March 27, 2019, Burcon and Large Scale amended the loan (the “Loan Amendment”) to increase the principal amount available to $1.5 million. The Loan Amendment provided the Lender with the right to offset any amount due to it under the Note against any obligations of the Lender to pay for subscription proceeds of any rights offering that Burcon may conduct. During the three months ended June 30, 2019, the Company drew down $250,000 to the maximum principal amount available under the Loan.

The Loan bore interest at 18% per annum on the amount drawn, and 3% per annum on the undrawn portion. Burcon paid Large Scale a commitment fee of 1%, or $15,000, on the principal amount available under the Loan. The amounts drawn on the Loan and the accrued interest was payable on the earlier of June 3, 2019, the occurrence of an event of default as set out in the Loan, or voluntary prepayment by the Company.

In connection with the 2019 Rights Offering (note 7(a)), Large Scale exercised its right to offset the amounts due under the Loan against its obligations to pay for subscription proceeds under the 2019 Rights Offering. The offset was completed on June 25, 2019 for $1,436,629 against the principal amount. The balance of the principal amount of $63,371 and accrued interest of $107,173 was repaid to Large Scale in cash on June 28, 2019.

14


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

7. Shareholders’ equity

a) Capital stock

Authorized

Unlimited number of common shares without par value

Equity Offering

On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the “Units”) at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the “Offering”) and net proceeds of $10.3 million.

Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share (a “Warrant Share”) until February 19, 2022 at an exercise price of $2.00 per Warrant Share. The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model and has been included in Warrants. As March 31, 2020, all of the Warrants were outstanding.

The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents’ Warrants) entitling the agents to purchase up to 519,386 common shares. Each Agent’s Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022. The fair value of the Agents’ Warrants was estimated at $249,305 using the Black-Scholes pricing model and has been included in Warrants. At March 31, 2020, all of the Agents’ Warrants were outstanding.

In addition to the Agents’ Warrants, the Company incurred total issue costs of $1.2 million related to the Offering.

2019 Rights Offering

On June 25, 2019, the Company completed a rights offering (the “2019 Rights Offering”) for 44,083,203 common shares at $0.35 per common share for gross proceeds of $15,429,121, and net proceeds of $15,284,430. Burcon issued to each shareholder as of the record date of May 30, 2019 one transferrable right (the “2019 Rights”) for each common share held by such shareholder. Every 2019 Right entitled the holder thereof to purchase one common share in the Company at a price of $0.35 per common share.

The Company’s directors, officers and persons controlling over 10% of the common shares of the Company agreed to exercise at least all of the 2019 Rights they were issued in connection with the 2019 Rights Offering for 14,306,740 common shares, representing 32.5% of the 2019 Rights Offering.

15


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

Of the net proceeds of the 2019 Rights Offering, $2,565,022 were used to repay the convertible note and accrued interest to Large Scale (note 5) and $1,607,183 has been used to repay the Loan and accrued interest to Large Scale (note 6).

2018 Rights Offering

On February 13, 2018, the Company completed a rights offering (the “2018 Rights Offering”) for 6,114,361 common shares at $0.57 per common share for gross proceeds of $3,485,186, and net proceeds of $3.4 million. As consideration for providing a standby guarantee to purchase such common shares that were available to be purchased that would have resulted in a minimum of 4,728,397 common shares being issued under the 2018 Rights Offering, Dr. Allan Yap (“Dr. Yap”), the Company’s former Chairman and Chief Executive Officer, received share purchase warrants (“Standby Warrants”) to acquire up to 1,182,099 common shares at an exercise price of $0.69 per common share that would be exercisable up to February 13, 2020. Pursuant to the terms of the Standby Warrants, the exercise price was adjusted upon completion of the 2019 Rights Offering from $0.69 per share to $0.45 per share. Burcon recorded a warrant valuation adjustment of $85,420 during fiscal 2020. The Standby Warrants were exercised during fiscal 2020.

b) Contributed surplus

Contributed surplus comprises the value ascribed to expired warrants and options and forfeited vested options, previously categorized in either warrants or options, as applicable, within shareholders’ equity.

c) Options

The Company has a stock option plan in which all directors, officers, employees and consultants of the Company and its subsidiary are eligible to participate.

At March 31, 2020, 4,507,606 (2019 - 3,953,739) options to purchase common stock are outstanding from the stock option plan. These options, when vested under the terms of the plan, are exercisable at prices ranging between $0.23 and $9.60 per common share. An additional 5,172,357 (2019 - 440,414) options may be granted in future years under this plan. Unless otherwise determined by the board of directors, the options have a term of 10 years from the date of grant. The vesting terms are determined at the discretion of the board of directors at the time of grant. All grants are recognized using graded vesting, with each vesting tranche being valued separately, and the fair value of each tranche recognized over its respective vesting period.

16


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

          2020           2019  
          Weighted           Weighted  
          average           average  
    Number of     exercise     Number of     exercise  
    options     price     options     price  
          $           $  
Outstanding - Beginning of year   3,953,739     3.46     3,595,549     4.32  
Granted   757,000     1.88     680,000     0.23  
Exercised   (173,000 )   0.41     -     -  
Cancelled   (30,133 )   1.96     (321,810 )   6.20  
                         
Outstanding - End of year   4,507,606     3.32     3,953,739     3.46  

The following table summarizes information about stock options outstanding and exercisable at March 31, 2020:

    Options outstanding     Options exercisable  
    Number     Weighted     Weighted     Number     Weighted  
    outstanding     average     average     exercisable     average  
Range of   at March     remaining     exercise     at March     exercise  
exercise prices   31,     contractual     price     31,     price  
    2020     life           2020        
$         (years)     $           $  
0.23 - 0.69   926,333     8.45     0.41     508,992     0.46  
1.88 - 4.16   2,763,773     6.24     2.54     2,286,773     2.68  
6.78 - 9.60   817,500     0.20     9.27     817,500     9.27  
                               
    4,507,606     5.60     3.32     3,613,265     3.86  

The fair value of each option is estimated as at the date of grant or other measurement date using the Black-Scholes option pricing model and the following weighted average assumptions:

    2020     2019  
Dividend yield   0.0%     0.0%  
Expected volatility   75.1%     72.8%  
Risk-free interest rate   1.3%     1.8%  
Expected forfeitures   7.7%     8.1%  
Expected average option term (years)   7.9     7.8  

The expected forfeitures are based on historical forfeitures. The expected volatility is based on historical volatility and also historical volatilities of a group of comparable public companies. The risk-free rate of return is the yield on a zero-coupon Canadian treasury bill of a term consistent with the expected average option term. The expected average option term is the average expected period to exercise, based on the historical activity patterns for each individually vesting tranche.

17


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

The weighted average fair value of the options granted during the year ended March 31, 2020 was $1.36 (2019 - $0.16) per option.

Included in research and development expenses is $16,757 (2019 - $118,912) (note 8) and in general and administrative expenses (salaries and benefits) is $469,472 (2019 - $134,236) (note 9) of stock-based compensation.

8. Research and development


    2020     2019  
    $     $  
             
Salaries and benefits (note 7)   549,714     1,143,105  
Laboratory operation   88,663     284,629  
Rent   39,924     87,157  
Analyses and testing   24,143     64,416  
Amortization of property and equipment   14,672     98,339  
Travel and meals   4,735     14,873  
             
    721,851     1,692,519  

9. General and administrative


    2020     2019  
    $     $  
             
Salaries and benefits (note 7)   1,350,824     955,551  
Professional fees   274,356     116,094  
Office supplies and services (note 11)   165,050     190,708  
Investor relations   131,646     67,437  
Financing expense (notes 6 and 7(a))   88,920     189,977  
Travel and meals   66,225     51,622  
Other   81,963     79,499  
Transfer agent and filing fees   27,289     30,994  
             
    2,186,273     1,681,882  

18


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

10. Basic and diluted loss per share

The following table sets forth the computation of basic and diluted loss per share:


    2020     2019  
    $     $  
             
Loss for the year, being loss attributable to common shareholders - basic and diluted   (4,633,494 )   (4,777,377 )
             
Weighted average common shares - basic and diluted   78,935,751     43,941,536  
             
Basic and diluted loss per share   (0.06 )   (0.11 )

For the years ended March 31, 2020 and 2019, the Company excluded all potential common share equivalents from the diluted loss per share calculation as they were anti-dilutive.

11. Related party transactions

The Company engaged an entity that is related by virtue of common officers for the following related party transactions:

Included in general and administrative expenses (office supplies and services) for the year ended March 31, 2020 is $75,006 (2019 - $75,006) for office space rental.

For the year ended March 31, 2020, included in general and administrative expenses (management fees) are $1,181 (2019 - $142), for services provided to the Company. At March 31, 2020, $11 (2019 - $22) of this amount is included in accounts payable and accrued liabilities. For the year ended March 31, 2020, included in interest and other income is $14,197 (2019 - $14,896) for management services provided by the Company. At March 31, 2020, $1,785 (2019 - $670), of this amount is included in amounts receivable.

Burcon has a Services Agreement with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement. (See note 4 for details).

Certain directors and an officer subscribed for $2.0 million of the Debentures.

Burcon had the Loan (note 6) and Note (note 5) with Large Scale, a company that is wholly owned by Firewood. For the year ended March 31, 2020, included in interest expense is $56,502 (2019 - $277,842) related to the Note and $60,756 (2019 - $46,417) related to the Loan. Included in accrued interest as at March 31, 2020 is $nil (March 31, 2019 - $517,833) for the Note and $nil (March 31, 2019 - $46,418) for the Loan. During the year ended March 31, 2019, the Company recorded a commitment fee of $15,000 as financing expense (note 6) in connection with the Loan.

Upon completion of the 2019 Rights Offering, the exercise price for the share purchase warrants issued to Dr. Yap was adjusted from $0.69 per share to $0.45 per share. The Company recorded $85,420 as financing expense during fiscal 2020.

19


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

12. Key management compensation

Key management includes the Company’s Chief Executive Officer and Chief Operating Officer. Remuneration of directors and key management personnel comprises:

    2020     2019  
    $     $  
             
Short-term benefits   387,822     363,778  
Option-based awards   372,223     66,458  
             
    760,045     430,236  

Short-term benefits comprise salaries, director fees and employment benefits.

Option-based awards represent the cost to the group of senior management and directors’ participation in the incentive stock option plan, as measured by the fair value of instruments granted accounted for in accordance with IFRS 2, Share-based Payment. For details of these plans refer to note 7 to the consolidated financial statements.

13. Income taxes

The recovery of income taxes differs from the amount obtained by applying the statutory Canadian federal and provincial income tax rates to loss for the year as follows:

    2020     2019  
    $     $  
             
Recovery of income taxes based on the combined statutory income tax rate of 27.00% (2019 – 27.00%)   (1,251,000 )   (1,290,000 )
Deferred income tax assets not recognized   1,384,000     1,230,000  
Financing costs   (316,000 )   (12,000 )
Non-deductible items and tax adjustments   183,000     72,000  
             
Recovery of income taxes   -     -  

20


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

As at March 31, 2020 the Company has non-capital losses of approximately $58,032,000 (2019 - $52,941,000) available to reduce taxable income in future years. These losses expire as follows:

    $  
       
2026   800,000  
2027   1,124,000  
2028   1,344,000  
2029   1,596,000  
2030   2,691,000  
2031   4,358,000  
2032   5,327,000  
2033   4,606,000  
2034   5,507,000  
2035   5,623,000  
2036   4,895,000  
2037   4,612,000  
2038   5,303,000  
2039   5,215,000  
2040   5,031,000  
       
    58,032,000  

In addition, the Company has SR&ED expenditures of approximately $15,130,000 available to carry forward indefinitely.

ITCs of $5,221,000 may be used to offset deferred income taxes otherwise payable and expiring between 2021 and 2040.

Included in interest and other income is $18,655 (2019 - $87,362) of refundable ITCs, which is included in amounts receivable at March 31, 2020.

The tax effects of temporary differences that give rise to deferred income tax assets are as follows:

    2020     2019  
    $     $  
             
Deferred income tax assets (liability)            
SR&ED expenditures   4,073,000     4,048,000  
Losses from operations carried forward   15,668,000     14,293,000  
Investment in Merit Foods   215,000     -  
Deferred development costs   (386,000 )   -  
Interest expense   (2,000 )   82,000  
Financing costs   334,000     60,000  
Property and equipment   132,000     168,000  
             
Unrecognized deferred income tax assets   20,034,000     18,651,000  

Management believes the realization of income tax benefits related to these losses and other potential deferred income tax assets is uncertain at this time and cannot be viewed as probable. Accordingly, the Company has not recognized these deferred income tax assets.

21


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

14. Financial instruments

Credit risk

The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable. The Company’s cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks. The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks.

Interest rate risk

All of the Company’s financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, the Note and the Loan that bear interest at fixed interest rates. Burcon’s cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk. For the year ended March 31, 2020, the weighted average interest rate earned on the Company’s cash and cash equivalents was 1.92% per annum (2019 – 1.68% per annum). The impact of a 1% strengthening or weakening of interest rates on the Company’s cash and cash equivalents at March 31, 2020 is estimated to be a $150,000 increase or decrease in interest income per year.

Liquidity risk

The Company manages liquidity risk through the management of its capital structure (note 15). It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations. The Company’s estimated minimum contractual undiscounted cash flow requirement for its financial liabilities at March 31, 2020 is $11,092,139, of which $1,592,139 is due within the next 12 months.

Fair value

The fair value of the Company’s short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and accrued interest, approximates their carrying values due to the short-term maturities of these financial instruments.

The fair value of the loan to Merit Foods approximates the carrying value as at March 31, 2020 given the risk profile of Merit Foods has not changed substantially since the issue date of the loan to Merit Foods.

22


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

The carrying values and fair values of financial instruments, by class, are as follows as at March 31, 2020 and 2019:

As at March 31, 2020                        
    At fair value     Financial     Financial     Fair value  
    through     assets at     liabilities at        
    profit or loss     amortized     amortized        
          cost     cost        
Financial assets   $     $     $     $  
Cash and cash equivalents   -     15,030,988     -     15,030,988  
Amounts receivable   -     332,248     -     332,248  
Loan to Merit Foods   -     2,659,830     -     2,659,830  
Total   -     18,023,066     -     18,023,066  
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,067,251     1,067,251  
Accrued interest   -     -     249,310     249,310  
Deferred revenue   -     -     275,578     275,578  
Convertible debentures   -     -     6,731,350     6,731,350  
Total   -     -     8,323,489     8,323,489  

                         
As at March 31, 2019                        
    At fair value     Financial     Financial     Fair value  
    through profit     assets at     liabilities at        
    or loss     amortized     amortized        
          cost     cost        
Financial assets   $     $     $     $  
Cash and cash equivalents   -     489,215     -     489,215  
Amounts receivable   -     126,605     -     126,605  
Total   -     615,820     -     615,820  
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     633,209     633,209  
Short-term loan   -     -     1,250,000     1,250,000  
Convertible note   -     -     1,990,686     1,990,686  
Accrued interest   -     -     564,251     564,251  
Derivative liability   5,384     -     -     5,384  
Total   5,384     -     4,438,146     4,443,530  

23


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

Currency risk

The Company has not hedged its exposure to currency fluctuations. As at March 31, 2020 and 2019, the Company is exposed to currency risk through the following assets and liabilities denominated in U.S. dollars:

    March 31,     March 31,  
    2020     2019  
             
U.S. Dollars            
Cash and cash equivalents $ 21,819   $ 48,219  
Amounts receivable   2,528     8,826  
Accounts payable and accrued liabilities   (40,556 )   (27,502 )
Net exposure $ (16,209 ) $ 29,543  
             
Canadian dollar equivalent $ (22,996 ) $ 39,479  

Based on the above net exposure at March 31, 2020, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $2,000 (March 31, 2019 - $4,000) in the Company’s loss from operations.

15. Capital disclosures

The Company considers its capital to be its shareholders’ equity.

The Company manages its capital structure to have sufficient resources available to meet day-to-day operating requirements, continue as a going concern and fund its research and development program. The Company is dependent on non-operating sources of cash, primarily from issuing equity and debt, to fund its operations and research development programs. The Company monitors its capital and the expected cash flows required to achieve its business objectives to determine its future financing needs. It seeks additional capital when deemed appropriate, but there is no assurance that it will be able to secure the necessary capital when required.

The Company is not subject to externally imposed capital requirements and there has been no change with respect to the overall capital risk management strategy during the year ended March 31, 2020.

24


BURCON NUTRASCIENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020 and 2019

(Prepared in Canadian dollars)

 

16. Subsequent events Subsequent to the year-end:

a) $960,000 of convertible debentures were converted at $1.05 for 914,283 common shares.

b) The Company provided a short-term LC in the amount of $6.5 million and also provided a $4 million guarantee of Merit Foods’ debt obligations. See note 4 for details.

25



MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

 

(All amounts following are expressed in Canadian dollars unless otherwise indicated.)

This Management's Discussion and Analysis ("MD&A") has been prepared as at June 29, 2020 to provide a meaningful understanding of Burcon NutraScience Corporation's ("Burcon" or the "Company") operations, performance, and financial condition for the year ended March 31, 2020.  The following information should be read in conjunction with the Company's audited consolidated financial statements and related notes, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the IFRS Interpretations Committee ("IFRS IC").  Additional information relating to Burcon, including the Company's Annual Information Form ("AIF"), is available on SEDAR at www.sedar.com

FORWARD-LOOKING STATEMENTS

This MD&A contains certain "forward-looking statements" and "forward-looking information" as defined under applicable Canadian and U.S. securities laws (collectively, "forward-looking statements").  All statements, other than statements of historical fact, are forward-looking statements.  When used in this MD&A the words "estimate", "project", "believe", "anticipate", "intend", "expect", "plan", "predict", "may", "should", "will", or the negatives of these words or other variations thereof and comparable terminology are intended to identify forward-looking statements.  The forward-looking statements pertain to, among other things:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

The forward-looking statements are based on a number of key expectations and assumptions made by management of the Company, including, but not limited to:

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on such forward-looking statements.  The forward-looking statements reflect the Company's current views with respect to future events based on currently available information and are inherently subject to risks and uncertainties.  Many factors, both known and unknown could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements contained in this MD&A, including, but not limited to:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected.  The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Although the Company has attempted to identify important factors that could cause actual results to differ materially from forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated, described or intended.  The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect changes in assumptions or the occurrence of anticipated or unanticipated events, except as required by law.

The Company qualifies all the forward-looking statements contained in this MD&A by the foregoing cautionary statements.

OVERVIEW OF THE COMPANY AND ITS BUSINESS

Since 1999, Burcon has developed an extensive portfolio of composition, application, and process patents originating from our core protein extraction and purification technology.  Our technology cover novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation ("Merit Foods") was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a commercial production facility in Manitoba, Canada where it will produce, under license, Burcon's novel pea and canola protein ingredients.  Burcon's CLARISOY® soy protein is under license to Archer Daniels Midland Company ("ADM").  Our products are targeted at the multi-billion-dollar protein ingredient market and are particularly suited to health and wellness applications.  Our environmentally friendly and sustainable technologies have been developed at our own research facility led by our team of highly specialized scientists and engineers.  Our patent portfolio currently consists of 287 issued patents worldwide, including 70 issued U.S. patents, and in excess of 250 additional patent applications, 43 of which are U.S. patent applications.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

NEW PROTEIN BLENDS

On May 23, 2019, Burcon introduced its new pea protein and canola protein blends:  Nutratein-PS and Nutratein-TZ.  These new protein blends have exceptional functional characteristics, low allergenicity, and a nutritional value that exceed those of the standard pea proteins available on the market today.

Canola is grown for its highly prized oil, with heart-healthy properties and renowned culinary qualities.  Up until now, after the pressing the oil from canola, the residual meal has predominantly been sold as animal feed.  Burcon's technology unlocks the protein from canola meal for human consumption in the form of highly purified protein ingredients with exceptional functional properties and unique nutritional value.  Burcon extracts and purifies two distinctly different canola protein fractions branded under the names Puratein® and Supertein®, both of which achieved US self-affirmed GRAS ("Generally Recognized As Safe") status in 2008, and the US Food and Drug Administration ("US-FDA") formally acknowledged receipt of Burcon's GRAS notification for Puratein® and Supertein® in 2010.

Field peas offer important advantages to consumers, and to farmers as their production is environmentally friendly while being a good source of protein, with numerous applications in dairy-free foods, vegetarian foods, meat analogues, sports and slimming foods, senior nutrition and clinical nutrition products.  Burcon's Peazazz® pea protein has exceptionally clean flavour characteristics and is well-suited for use in beverages, dairy alternative products, meal replacements and meat analogues, as well as a variety of other healthy and great tasting food and beverage product applications.  Burcon successfully obtained self-affirmed GRAS status for its Peazazz® and Peazac® pea protein products in 2017 and the US-FDA formally acknowledged receipt of Burcon's GRAS notification for Peazazz® and Peazac® in October 2019.

While pea is a good source of protein, its nutritional value falls below that of animal protein such as dairy protein or egg protein, due to its low levels of the amino acids, methionine, and cysteine.  In contrast, Burcon's canola protein is uniquely rich in these same amino acids.  By blending Burcon's pea and canola proteins, Burcon can offer plant protein ingredients with a nutritional value equaling or exceeding that of animal proteins like dairy and egg. 

The method accepted by the US-FDA, Food and Agriculture Organization and the World Health Organization for evaluating the nutritional qualify of a protein is referred to the Protein Digestibility Corrected Amino Acid Score ("PDCAAS"), with the highest possible score being 1.0.  The protein in cow's milk and eggs are examples of proteins with a PDCAAS of 1.0.  Peas have a PDCAAS score of less than 0.8; however, Burcon's blends of pea and canola protein have PDCAAS of 1.0, equaling the gold standard of dairy protein.

Burcon's blend of its Peazazz® pea protein and Supertein® canola protein, branded as Nutratein-PS, has a clean flavour profile with high solubility, making it suitable for fortifying dairy-alternative beverages such as almond milk, or to formulate a stand-alone beverage with a nutritional value consistent with cow's milk.  Burcon's blend of its Peazac® pea protein, and Supertein® canola protein, has been branded Nutratein-TZ, which has functional properties that are ideally suited in the formulation of plant-based meat products such as veggie burgers, or veggie sausages.  Both Nutratein products are over 90% pure protein.

MERIT FUNCTIONAL FOODS CORPORATION

On May 23, 2019, Burcon, through its newly-formed wholly-owned subsidiary, Burcon NutraScience Holdings Corp. ("Burcon Holdings"), entered into a shareholders agreement (the "Shareholders Agreement") with RBT Holdco Ltd. ("RBT Holdco") and 10039406 Manitoba Ltd. ("Crew Holdco") (RBT Holdco and Crew Holdco together referred to as the "Partners") to become shareholders of Merit Functional Foods Corporation ("Merit Foods").  The business of Merit Foods is the commercial production, sales, marketing and distribution worldwide of Burcon's pea protein, pulse protein and canola protein products.  Merit Foods is currently building and commissioning an initial protein production facility (the "Flex Production Facility") in Western Canada. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Burcon Holdings holds 40%, RBT Holdco holds 40% and Crew Holdco holds 20% of the issued and outstanding shares of Merit Foods.  Each of Ryan Bracken and Barry Tomiski (and their respective family) beneficially owns a 50% interest in RBT Holdco.  Crew Holdco is wholly owned by Shaun Crew and his family.  Messrs. Bracken, Tomiski and Crew are veterans of the agri-foods industry, most notably demonstrated by the rapid growth and successful sale of Hemp Oil Canada Inc. ("HOCI").  Originally founded by Mr. Crew in 1998, HOCI grew to become the world's largest producer and processor of bulk hemp foods products and ingredients.  Messrs. Bracken, Tomiski and Crew's association with HOCI ended with the recent acquisition of FHF Holdings Ltd. (the parent company of Manitoba Harvest Hemp Foods including HOCI) by Tilray Inc. 

Under the Shareholders Agreement, Burcon Holdings may agree to provide additional capital to Merit Foods, either as an equity contribution or as a shareholder loan, to finance budget increases and/or scope changes in the development, construction and commission of the Flex Production Facility, but is not obligated to do so.  Burcon Holdings may agree to provide additional support to Merit Foods in connection with such financing.  Support may come in the form of additional capital contributions by way of a further equity contribution or as a shareholder loan, a limited recourse guarantee or otherwise. 

On May 23, 2019, Burcon entered into a license and production agreement (the "License Agreement') with Merit Foods to license the technology required to produce, market and sell Burcon's pulse protein ingredients, including Peazazz® and Peazac® pea proteins and Burcon's canola proteins, Supertein®, Puratein® and Nutratein® (collectively the "Products").  Under the terms of the License Agreement, Merit Foods has the exclusive rights over Burcon's pulse proteins (including pea) and canola protein technologies across all geographic regions and all product uses (the "License").  Burcon will receive running royalties on the net revenue (as defined in the License Agreement) from the sales of the Products by Merit Foods.  Burcon will be responsible for the technology transfer to Merit Foods and is also providing assistance, under a services agreement, to support the design, construction and commissioning of the commercial protein production facility.

Under the License Agreement, Merit Foods is to develop, build and commission an initial production facility in Western Canada within a specified amount of time to manufacture the Products.  Merit Foods will also, within a specified time period, provide written notice to Burcon to advise whether it will or will not increase its annual production capacity of the Products to develop, build and commission a full commercial scale production facility (the "Full Commercial Production Facility").  If Merit Foods expands production to the Full Commercial Production Facility, the royalty rate will be reduced to a lower percentage rate.  The royalty rate may also be reduced if the exclusive license is converted to a non-exclusive license or if a certain Burcon patent does not grant within a specified time.

The License Agreement has a term of the greater of twenty years and the last to expire of Burcon patents that are being used to produce products under the License Agreement.  The License Agreement provides Burcon with the right to convert the exclusive license to a non-exclusive license under certain conditions.  As long as the License is exclusive, Burcon is responsible for the filing, prosecution and maintenance of Burcon patent rights in certain countries. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement. 

In accordance with the Shareholders Agreement, Burcon Holdings and the Partners made their capital loan advances (the "Initial Capital Loan Advances") in June 2019 by way of shareholder loans to Merit Foods in the aggregate of $10.0 million.  Burcon Holdings and the Partners made further loan advances to Merit Foods in the amounts of $10.0 million in September 2019, $7.5 million in December 2019 and $5.0 million in February 2020 (the "Additional Capital Loan Advances") (the Initial Capital Loan Advances and the Additional Capital Loan Advances, together referred to as the "Merit Shareholder Loans").  To-date, all the shareholders of Merit Foods have contributed an aggregate of $32.5 million into Merit Foods.

As at March 31, 2020, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans. 

(in thousands of dollars):

    Investment in Share capital
    Capital
Contribution

    Loan receivable
    Total net
investment

 
                         
At inception   -     -     11,000     11,000  
Modification to loan terms   -     8,872     (8,872 )   -  
Capital loan advance   -     1,613     387     2,000  
Share of loss in Merit foods   -     (940 )   -     (940 )
Interest accretion   -     -     145     145  
                         
Net Investment in Merit Foods, March 31, 2020   -     9,545     2,660     12,205  

On inception, the Merit Shareholder Loans were recorded as a loan receivable.  In December 2019, the terms of the Merit Shareholder Loans were finalized.  They are non-interest bearing, unsecured, subordinated to Merit Foods' other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder's loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts.  As a result, Burcon recalculated the fair value at this date, resulting in a reduction of the fair value was been transferred to a capital contribution account.  Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest.  The Company has recorded $144,343 of notional interest from the inception date of these loans to March 31, 2020.

During the second fiscal quarter, Merit Foods completed the purchase of the land, on which the Flex Production Facility is being constructed.  In May 2020, Merit Foods announced that it is expanding the production capacity of the Flex Production Facility currently under construction in Winnipeg, Manitoba.  The design changes of the facility will facilitate future production capacity expansions and the larger footprint of the Flex Production Facility will enable Merit Foods to economically scale the throughput as compared to the initial capacity.  Merit Foods is building a 94,000 square foot production facility to produce the Products and the Flex Production Facility is expected to be completed in the fourth calendar quarter of 2020.  Merit Foods believes it will be the only commercial facility in the world with the capability to produce food grade non-GMO canola proteins. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

On January 10, 2020, Merit Foods announced it has received a co-investment from Protein Industries Canada ("PIC") to help facilitate the rapid growth of Merit Foods.  PIC is an industry-led, not-for-profit organization committed to positioning Canada as a global source of high-quality plant protein ingredients.  It is one of Canada's five innovation superclusters, which are government-initiated efforts to significantly boost Canada's job market, GDP, research and innovations.

In May 2020, Burcon announced that Merit Foods has secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada ("EDC"), Farm Credit Canada ("FCC") and the Canadian Imperial Bank of Commerce.  Merit Foods' shareholders, including Burcon Holdings, were required to pledge their shares in Merit Foods as security under the loan facilities from EDC.  In connection with the loan facilities from EDC, Merit Foods must fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility.  $6.5 million of this amount is permitted to be funded by way of a letter of credit ("LC").  To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada ("HSBC") in April 2020, which is secured by a term deposit with HSBC in the same amount.  In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the "Loan Agreement") with Merit Foods in the amount of $6.5 million (the "Loan").  The Loan and the commitment by Burcon Holdings to maintain the LC will terminate no later than September 30, 2020, unless extended by mutual agreement.  The Loan bears interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term.  Under the Loan Agreement, Burcon Holdings has the option to contribute the amount of the Loan as a capital contribution to Merit Foods in certain circumstances including if the other shareholders of Merit Foods are unable to deliver a letter of credit in favour of EDC for their entire pro rata share of the LC amount by September 30, 2020.  If EDC draws on the LC prior to September 30, 2020 and each of the other shareholders of Merit Foods are unable to reimburse Burcon Holdings for such other shareholder's entire pro rata share of the amount of such draw within the time period set out in the Loan Agreement, then the draw amount will be deemed a capital contribution by Burcon Holdings and Burcon Holding's shareholding interest in Merit Foods will be increased. 

In addition, Burcon has provided a guarantee in favour of EDC's senior loan facility and subordinate loan facility to Merit Foods (the "Guarantees"), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC and Merit Foods.  The aggregate maximum liability of Burcon under the Guarantees is limited to $4.0 million.  The Guarantees contain provisions dealing with when Burcon's guarantee may be reduced in the event that Merit Foods is able to obtain certain other government sources of funding, subject to certain conditions being met.

In June 2020, Burcon announced that Merit Foods has secured additional debt financing of $10 million in the form of a 10-year interest-free loan from Agriculture and Agri-Food Canada's Agrilnnovate Program ("AIP").  Merit has now secured a total of $99.2 million financing package from the Government of Canada that includes the financing noted above from EDC, FCC, AIP and PIC.

As noted above, Burcon has a 40% investment in Merit Functional Foods Corporation.  There is no contingent issuance of securities by the equity investee that might significantly affect Burcon's share of profit or loss.  The following is the summarized financial information of the investee:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Summary financial information of Merit Foods

(in thousands of dollars)

    Period ended
March 31, 20201 
    Nine months ended
March 31, 2019
 
             
Total assets (as at March 31, 2020)   41,885     N/A  
Total liabilities (as at March 31, 2020)   18,024     N/A  
Total revenue   375     N/A  
Loss and comprehensive loss for the period   (2,350 )   N/A  

Merit Foods has placed purchase orders for long lead-time processing equipment that will be incorporated into the Flex Production Facility and initiated collaboration discussions with several strategic food and beverage companies.  In addition, Merit Foods has added key hires and is well into the process of building out its management team.  Merit's management, together with Burcon's technical and engineering team in Winnipeg, plus third-party engineers and consultants, are working on the development of the Flex Production Facility.

Merit Foods debuted the company and its plant-based protein product portfolio of pea, non-GMO canola and MeritPro, and brand at SupplySide West trade show on October 16 - 19, 2019 in Las Vegas, Nevada.  At the show, Merit sampled almond milk prepared with Peazazz® and MeritPro HS

NESTLE COLLABORATION

On January 24, 2020, the Company announced that Burcon, Nestlé and Merit Foods have entered into a joint development agreement to tailor Burcon and Merit's plant-based proteins for use in Nestlé food and beverage applications.  The joint agreement commences what is intended to be a long-term relationship among the parties covering ongoing innovation and the future supply of Burcon and Merit's plant-based proteins from the Flex Production Facility.  The partnership combines Nestlé's expertise in the development, production and commercialization of plant-based foods and beverages with Burcon's proprietary plant protein extraction and purification technology, while leveraging Merit Foods' plant protein production capabilities.  The aim of the joint development is to tailor the functionality of Burcon and Merit's plant proteins, to be supplied from Merit's Flex Production Facility, for use by Nestlé in plant-based meat and dairy alternatives.  The Winnipeg Technical Centre has been working with Nestlé's scientists and food developers to tailor Burcon's pea and canola proteins for product development.

CONVERTIBLE DEBENTURES

On December 10, 2019, the Company issued convertible debentures (the "Debentures") through a non-brokered private placement for an aggregate principal amount of $9.5 million.  Certain directors and an officer of the Company subscribed for Debentures totaling $2 million in principal amount.  Each Debenture consists of $1,000 principal amount, bears interest at a rate of 8.5% per annum, payable semi-annually in arrears and be unsecured.  The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon will be payable in cash on December 10, 2022.  The Debentures will be convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share.  Burcon will have the right, at its sole discretion, to force the conversion of the Debentures if the shares trade at or above $2.15 for a period of 14 consecutive trading days.  The Company incurred issue costs of $228,432, of which $156,600 were finder's fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders. 

____________________________________
1Merit Foods was incorporated on May 15, 2019.  As a result, information in this table represents certain financial information of Merit Foods from the date of its incorporation to March 31, 2020.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

The Debentures are a level 3 financial liability with an embedded conversion feature.  As a result, the debt and equity components were bifurcated and the instrument valued to par at the issuance date.  The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option.  From the date of issuance, the liability component is accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive loss.  The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641.  The residual amount of $2,762,927 was recognized within equity as the value of the conversion option.  For the year ended March 31, 2020, the Company recorded interest expense of $472,020.

The Company utilized a portion of the net proceeds from the Debentures to make further

Additional Capital Loan Advances to Merit Foods of $3.0 million in December 2019 and $2.0 million in February 2020.

Subsequent to March 31, 2020, $960,000 of convertible debentures were converted and 914,283 common shares were issued.

EQUITY OFFERING

On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the "Units") at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the "Offering") and net proceeds of $10.3 million.

Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant").  Each Warrant is exercisable to acquire one common share (a "Warrant Share") until February 19, 2022 at an exercise price of $2.00 per Warrant Share.  The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model and has been included in Warrants.  All Warrants were outstanding as at March 31, 2020.

The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents' Warrants) entitling the agents to purchase up to 519,386 common shares.  Each Agent's Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022.  The fair value of the Agents' Warrants was estimated at $249,305 using the Black-Scholes pricing model and has been included in Warrants.  All Agents' Warrants were outstanding as at  March 31, 2020.

In addition to the Agents' Warrants, the Company incurred total issue costs of $1.2 million related to the Offering.

The Company intends to use the net proceeds of the Offering for further development of its extraction and purification technologies and pursue new related products, pursue and develop new applications from functional attributes of Burcon's proteins and carry out research on protein extraction from various plant sources.  Burcon will also continue work to tailor its plant-based proteins for use in Nestlé food and beverage applications.  Burcon also intends to use the net proceeds to maintain, further strengthen and expand the Company's intellectual property portfolio.  Burcon is obligated to prosecute and maintain its soy patent portfolio under its License and Production Agreement (the "Soy Agreement") with ADM (see CLARISOY® section) and its pea and canola patent portfolios under its License Agreement with Merit foods.  Additionally, Burcon intends to continue to file additional patent applications to protect discoveries arising from its research and development activities.  Burcon also intends to use the net proceeds for expansion initiatives and to provide for general working capital.   


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

RIGHTS OFFERINGS

2019 Rights Offering

On June 25, 2019, the Company completed a rights offering (the "2019 Rights Offering") for 44,083,203 common shares at $0.35 per common share for gross proceeds of $15,429,121 and net proceeds of $15.3 million.  Burcon issued to each shareholder as of the record date of May 30, 2019 one transferrable right (the "2019 Rights") for each common share held by such shareholder.  Every 2019 Right entitled the holder thereof to purchase one common share in the Company at a price of $0.35 per common share. 

The Company's directors, officers and persons controlling over 10% of the common shares of the Company, (collectively, the "Insiders") agreed to exercise at least all of the 2019 Rights they were issued in connection with the 2019 Rights Offering for 14,306,740 common shares, representing 32.5% of the 2019 Rights Offering.

Of the net proceeds of the 2019 Rights Offering, $2,565,022 has been used to repay the convertible note and accrued interest to Large Scale and $1,607,183 has been used to repay the Loan and accrued interest to Large Scale.  Burcon also made its Initial Capital Loan Advance of $4.0 million to Merit Foods in June 2019 and its Additional Capital Loan Advance of $4.0 million to Merit Foods in September 2019.

2018 Rights Offering

On February 13, 2018, the Company completed a rights offering (the "2018 Rights Offering") for 6,114,361 common shares at $0.57 per common share for gross proceeds of $3,485,186, and net proceeds of $3.4 million.  As consideration for providing a standby guarantee to purchase such common shares that were available to be purchased that would have resulted in a minimum of 4,728,397 common shares being issued under the 2018 Rights Offering, Dr. Allan Yap ("Dr. Yap"), the Company's former Chairman and Chief Executive Officer, received share purchase warrants ("Standby Warrants") to acquire up to 1,182,099 common shares at an exercise price of $0.69 per common share that were exercisable up to February 13, 2020.  Pursuant to the terms of the Standby Warrants, the exercise price was adjusted upon completion of the 2019 Rights Offering from $0.69 per share to $0.45 per share.  Burcon recorded a warrant valuation adjustment of $85,421 during fiscal 2020.  The Standby Warrants were fully exercised during fiscal 2020.

CONVERTIBLE NOTE

The Company had a convertible note (the "Note") with Large Scale Investments Limited ("Large Scale'), a wholly owned subsidiary of Firewood Elite Limited ("Firewood"), for the principal amount of $2.0 million (the "Principal Amount").  Firewood, through its shareholdings in Large Scale and Great Intelligence Limited ("Great Intelligence"), has significant influence over the Company, and is wholly owned by Mr. Alan Chan, a director of the Company.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

The Note bore interest at 8% per annum, compounded monthly.  The Principal Amount and accrued interest were payable on the earlier of May 12, 2019, the occurrence of an event of default as set out in the Note (the "Maturity Date"), or voluntary prepayment by the Company.  Under the Note, Large Scale could convert the Principal Amount in whole or in part at $4.01 per share into common shares of the Company commencing on or after July 1, 2016 and up to and including the Maturity Date.  Pursuant to the terms of the Note, the conversion price was adjusted upon completion of Burcon's rights offering that completed in 2016 to $3.99 per share and further adjusted upon the completion of Burcon's 2018 Rights Offering to $3.94 per share. 

Burcon had the right, before the Maturity Date, upon written notice to Large Scale of not less than thirty days, to prepay in cash all or any portion of the Principal Amount by paying to Large Scale an amount equal to the Principal Amount to be prepaid multiplied by 110%.  The payment of the Principal Amount and all accrued and unpaid interest thereon would be subordinated in right of payment to any amount owing in respect of secured indebtedness of the Company.   

On May 21, 2019, the Company and Large Scale amended (the "Amendment") the Note's Maturity Date to June 21, 2019.  The Amendment also provided Large Scale with the right to offset any amounts due to it under the Note against any obligations of Large Scale to pay for subscription proceeds of any rights offering that Burcon may conduct.

In connection with the 2019 Rights Offering, Large Scale exercised its right to offset the amounts due under the Note against its obligations to pay for subscription proceeds under the 2019 Rights Offering.  The offset was completed on June 25, 2019.  The total amount offset under the Note included the principal amount and accrued interest of $2,565,022.

The conversion option was recorded as a derivative liability.  Under the terms of the Note, there are certain conditions where the conversion price may be adjusted.  Therefore, in accordance with International Financial Reporting Standards ("IFRS"), an obligation to issue shares for a price that is not fixed must be classified as a derivative liability and measured at fair value, with changes recognized in change in fair value of conversion option in the consolidated statement of operations and comprehensive loss.

The conversion and prepayment options were recorded as a net derivative liability and measured at fair value, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss.  The fair value of the conversion and prepayment options was estimated based on a methodology for pricing convertible bonds using the Partial Differential Equation Method, with the following initial assumptions:  expected volatility of 63%; expected dividend per share of nil; risk-free rate of 0.60%, entity-specific credit spread, and expected life of 3 years.  The assumptions as at March 31, 2019 were as follows:  expected volatility of 99%, expected dividend per share of nil; risk-free rate of 1.63%, initial entity-specific credit spread adjusted by the movement in the option adjusted spread of the Canada High Yield Index, and expected life of 1.1 years.  The initial fair value of the net derivative liability was estimated as $189,705 as at the issue date of the Note.  As at March 31, 2019, the fair value of the net derivative liability was estimated to be $5,384.  Upon the offset by Large Scale of its obligations to pay for subscription proceeds under the 2019 Rights Offering, the net derivative liability was expensed as financing expense during fiscal 2020.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

SHORT-TERM LOAN

On November 13, 2018, the Company entered into a loan agreement with Large Scale to provide Burcon with an unsecured loan for up to $1.0 million (the "Short-term Loan").  On March 27, 2019, Burcon and Large Scale amended the loan (the "Loan Amendment") to increase the principal amount available to $1.5 million.  The Loan Amendment provided the Lender with the right to offset any amount due to it under the Note against any obligations of the Lender to pay for subscription proceeds of any rights offering that Burcon may conduct.  During the three months ended June 30, 2019, the Company drew down $250,000 to the maximum principal amount available under the Loan. 

The Short-term Loan bore interest at 18% per annum on the amount drawn, and 3% per annum on the undrawn portion.  Burcon paid Large Scale a commitment fee of 1%, or $15,000, on the principal amount available under the Short-term Loan.  The amounts drawn on the Short-term Loan and the accrued interest was payable on the earlier of June 3, 2019, the occurrence of an event of default as set out in the Short-term Loan, or voluntary prepayment by the Company.   

In connection with the 2019 Rights Offering, Large Scale exercised its right to offset the amounts due under the Short-term Loan against its obligations to pay for subscription proceeds under the 2019 Rights Offering.  The offset was completed on June 25, 2019 for $1,436,629 against the principal amount.  The balance of the balance of the principal amount of $63,371and accrued interest of $107,173 was repaid to Large Scale in cash on June 28, 2019.

COVID-19

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  To-date, the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations or Merit Foods' construction progress.

NEW DIRECTOR APPOINTMENT

In July 2019, Burcon appointed Mr. Calvin Chi Leung Ng as a director of its board.  Mr. Ng is a director or Large Scale and Great Intelligence.  Mr. Ng is the group legal counsel for ITC Properties Limited, a real estate property development and investment company.  Mr. Ng has over 20 years' experience of advising on and executing corporate and commercial transactions in law firms and private sectors. 

CLARISOY®

Burcon has a 20-year Soy Agreement with ADM, under which ADM has an exclusive license to produce, market and sell CLARISOY® soy protein worldwide.  In November 2016, ADM confirmed that it has fully commissioned the first full-scale CLARISOY® production facility at its North American headquarters in Decatur, Illinois. 

CLARISOY® 100 is a transparent, isolated soy protein and enables 100 percent soluble protein fortification in beverage applications with a pH below 4.0.  CLARISOY® 150 is specially processed for use in beverage systems with a pH of less than 4.0 with cloud systems or beverages neutralized to a pH of 7.0 or higher.  Due to its clean flavor and high solubility in higher pH ranges, CLARISOY® 150 allows for greater use of soy protein in mildly flavored neutral beverages such as meal replacement and weight management products.  The new product enables beverage manufacturers to formulate up to 10 grams of protein per serving.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

After ADM's acquisition of WILD Flavors GmbH in 2014, it formed a new business unit, WILD Flavors and Specialty Ingredients, which includes ADM's own specialty ingredients food and wellness division.  The CLARISOY® portfolio is being produced, marketed and sold by this new business unit.  Their marketing activities were supported by CLARISOY® samples produced at ADM's semi-works plant for market-building activities, and for product development by ADM's global customer base.

Since the launch of CLARISOY® 100, ADM has launched several CLARISOY® variants that exhibit various product characteristics to suit different applications. 

Among the variations of CLARISOY® ADM has developed, ADM focused on marketing CLARISOY® as an economical, high-quality plant-based dairy alternative that provides greater cost stability and comparable nutrition.  ADM's team has developed and demonstrated products to showcase CLARISOY®'s ability to deliver reliable performance in a wide range of applications, including fortifying vegan applications with a dairy-free protein source without compromising taste. 

Since signing the Soy Agreement, Burcon has filed additional patent applications to seek important commercial protection for the production and use of CLARISOY®.  ADM has elected to include these applications to the license and, if granted, could lengthen the royalty term under the Soy Agreement to at least the year 2035.  Since March 2013, Burcon has been granted seventeen U.S. patents covering its soy protein composition and extraction and purification processes.

Burcon has not received any significant royalty revenues from ADM's sales of CLARISOY®.  For the year ended March 31, 2020, Burcon recorded royalty revenues of $31,134 (2019 - $40,177).  While ADM has announced that it has successfully commissioned the first full-scale commercial CLARISOY® production facility, future sales and royalties cannot be ascertained at this time.

During the year, patenting work continued to further strengthen the CLARISOY® patent portfolio. 

Other

During fiscal 2018, Burcon applied for accreditation from Health Canada's Office of Controlled Substances to conduct research for the future commercial production of purified cannabinoid extracts.  Burcon subsequently modified its intentions regarding potential cannabis research opportunities to focus instead on cannabis protein extraction and intends to pursue partnering opportunities with growers and suppliers of hemp and cannabis input materials accordingly.  The Company was issued a research license under the Cannabis Act by Health Canada in June 2019.  Given its focus on other business initiatives, Burcon does not plan to conduct research in cannabinoid extracts in the coming fiscal year.

Burcon continued work to further the development of a new plant-based protein process, as well as limited research work on protein extraction from various plant sources to explore potential new commercial and patenting opportunities.  Burcon's extraction and purification technologies are versatile and may be adapted to process a range of oilseed and non-oilseed meals to produce specialty proteins, such as flax and hemp.  The demand for plant-based proteins continues to grow and Burcon believes there may be niche market opportunities for its specialty protein ingredients. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

INTELLECTUAL PROPERTY

Burcon's patent strategy is to seek protection for new technologies as well as further protecting current technologies.  Over the years, Burcon has filed patent applications in various countries over its inventions.  Burcon's patent applications can be grouped into three categories:

During the year, Burcon received one patent grant for a patent covering the technology for the production of Peazazz® pea protein and two patent grants for patents covering the technologies for the production of CLARISOY® soy protein.  Burcon continued the maintenance and prosecution of its patent applications during fiscal 2020. 

Burcon currently holds 70 U.S. issued patents over its canola, soy, pea and flax protein processing technologies and canola and soy protein isolate applications, as well as canola and soy patents covering composition of matter.  In addition, Burcon has a further 43 patent applications currently filed with the U.S. Patent and Trademark Office.

As of the date of this MD&A, Burcon's patents and patent applications cover over 50 distinct inventions.  Burcon has also filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  Together with patents issued in other countries, Burcon now holds a total of 287 issued patents covering inventions that include the 70 granted U.S. patents.  Currently, Burcon has over 250 additional patent applications that are being reviewed by the respective patent offices in various countries. 

SUMMARY OF OPERATING RESULTS

Years ended March 31 (in thousands of dollars, except share and per-share amounts)

    Year ended March 31  
    2020     2019  
Royalty income   31     40  
Loss for the year   (4,634 )   (4,777 )
Basic and diluted loss per share   (0.06 )   (0.11 )
Total assets   31,269     2,463  
Total long-term liabilities   6,731     -  
Weighted average shares outstanding (thousands)   78,936     43,942  

 

RESULTS OF OPERATIONS

As at March 31, 2020, Burcon has not yet generated any significant revenues from its technology.  For the year ended March 31, 2020, the Company recorded a loss of $4,633,494 ($0.06 per share), as compared to $4,777,377 ($0.11 per share) in fiscal 2019.  Included in the loss amounts are the following non-cash items:  stock-based compensation expense of $514,983 (2019 - $253,148), share of loss in Merit Foods of $939,806 (2019 - $nil), financing expense of $85,420 (2019 - $145,213), change in fair value of convertible note derivative liability of $5,384 (2019 - $nil), amortization of property and equipment of $37,290 (2019 - $100,248), unrealized foreign exchange gain of $1,798 (2019 - $2,261),  interest accretion of $144,343 (2019 - $nil), interest expense of $472,020 (2019 - $324,259) and loss on disposal of equipment of $949 (2019 - $nil).


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

The following provides a comparative analysis of significant changes in major expenditures items.

Research and development expenses

Components of research and development ("R&D") expenditures are as follows:

(in thousands of dollars) 

    Year ended March 31,  
    2020     2019  
Salaries and benefits   550     1,143  
Laboratory operation   89     285  
Rent   39     88  
Analyses and testing   24     64  
Amortization of property and equipment   15     98  
Travel and meals   5     15  
    722     1,693  

Effective July 1, 2019, the Company determined that it had met all the criteria of deferring development costs ("DDC") with respect to its pea and canola proteins and has been deferring its expenditures relating to pea and canola to deferred development costs.  For the year ended March 31, 2020, it has deferred approximately $861,000 of R&D costs.  Under the Services Agreement with Merit Foods, Burcon also has been producing inventory saleable to Merit Foods' potential customers for product evaluation.  This has contributed to about $250,000 R&D costs that have been allocated to inventory production.  Before the cost deferral and allocation to inventory production, total R&D costs increased by about $148,000.  The increase is due primarily to salary increases, offset by a decrease in amortization expense. 

Intellectual property expenses

(in thousands of dollars)

    Year ended March 31,  
    2020     2019  
Patent fees and expenses   840     1,216  
Trademark   6     2  
    846     1,218  

 

As noted in the R&D section, the Company began deferring costs related to its pea and canola technology in the second quarter of the fiscal year, including related patent fees and expenses.  During the year ended March 31, 2020, Burcon deferred about $694,000 of patent fees and expenses for its pea and canola patent portfolio to deferred development costs.  Before the cost deferral, patent fees and expenses increased by about $318,000, due mostly to higher patenting activity in the pea and canola portfolios.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Burcon's patent strategy is to seek protection for new technologies as well as further protecting current technologies.  Over the years, Burcon believes it has developed a dynamic and extensive patent portfolio and has filed patent applications in various countries over its inventions.  From inception, Burcon has expended $19.5 million on patent legal fees and disbursements to strengthen its patent portfolio in various countries of the world and file patent applications for new inventions.

General and administrative ("G&A") expenses

(in thousands of dollars) 

    Year ended March 31,  
    2020     2019  
Salaries and benefits   1,351     956  
Professional fees   274     116  
Investor relations   132     67  
Office supplies and services   165     191  
Travel and meals   66     52  
Other   82     79  
Transfer agent and filing fees   27     31  
Financing expense   89     190  
    2,186     1,682  

 

Salaries and benefits

Included in salaries and benefits for the year ended March 31, 2020 is stock-based compensation expense of $470,000 (2019 -$134,000).  The higher stock-based compensation expense incurred this year is due primarily to options granted to directors that vested immediately and had a higher valuation over options granted in fiscal 2019.

The balance of the increase is due mostly to the hiring of an administrative employee during the year. 

Professional fees

Professional fees increased by $158,000 over last year.  The increase is attributable to higher legal fees of $78,000 related to agreements with Nestle and with Merit Foods.  Consulting fees also increased by about $49,000,  due mostly to the write-off of about $33,000 of engineering consulting costs incurred in prior years that have been determined not to be usable for the Flex Production Facility, as well as the valuation fees related to the Debentures in the current quarter.  Audit-related expenses increased by $31,000, with current year audit fees increasing by about $16,000 and a credit received in fiscal 2019 of about $15,000 due to the suspension of the Company's U.S. reporting obligations.

Investor relations

Investor relations expenses increased by $65,000 over last year.  The increase is due to higher U.S. investor relations consulting fees, as well as higher travel expenses.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Financing expense

As noted in the 2018 Rights Offering section, Burcon recorded $85,000 during this year related to the revaluation of the Standby Warrants issued from the 2018 Rights Offering.

Burcon recorded a non-cash financing expense of $145,000 in fiscal 2019 related to the warrants issued from the following the issuance of the Standby Warrants from the 2018 Rights Offering.

LIQUIDITY AND FINANCIAL POSITION

At March 31, 2020, the Company had cash and cash equivalents of $15.0 million.  As noted above, $6.5 million has been utilized to secure the $6.5 million LC issued in favour of the EDC.  The LC and the related security are expected to be terminated no later than September 30, 2020, unless extended by mutual agreement between Burcon Holdings and Merit Foods.  In addition, Burcon has issued a Guarantee for a maximum amount of $4.0 million in favour of EDC for its loan facilities with Merit Foods (see p. 7).  The Guarantee may be reduced in the event that Merit Foods is able to obtain certain other government sources of funding.  Assuming the LC terminates by September 30, 2020 and Burcon's guarantee with the EDC is released within the next 12 months, management estimates the cash resources to be sufficient to fund its operations to September 2022.  The estimated date excludes proceeds from outstanding convertible securities and royalty revenues from its license agreements.  If Burcon does not receive sufficient royalties from its license agreements, Burcon will require additional capital beyond this date to meet its business objectives, although there is no assurance that additional financing will be available on acceptable terms, if at all.

During the year ended March 31, 2020, Burcon recorded royalty revenues of $31,000 (2019 - $40,000).  As noted above, ADM confirmed in November 2016 that it had successfully commissioned the first full-scale CLARISOY® production facility.  However, future royalty revenues that may be derived from the full-scale commercial facility cannot be ascertained at this time. 

The net cash used in operations during the year ended March 31, 2020 was $2,738,000, as compared to $4,147,000 last year.  The decrease in the net cash used in operations of $1,409,000 is mainly attributed to changes in non-cash working capital items that contributed to $186,000 of the decrease, higher management fee income of $349,000, interest and other income of $26,000, R&D expenses of $1,725,000 and intellectual property expenses that were capitalized or allocated to inventory production, offset by higher R&D expenses of $197,000, G&A expenses of $229,000, intellectual property expenses of $322,000, interest expense of $117,000, a decrease in royalty income of $9,000 and realized foreign exchange gain of $4,000.   

At March 31, 2020, Burcon had working capital of $14.2 million (March 31, 2019 - negative working capital of $3.5 million).  As at March 31, 2020, Burcon was not committed to significant capital expenditures.  Burcon may incur up to $500,000 in additional capital expenditures if modifications or further upgrades are required to the Winnipeg Technical Centre ("WTC").  Burcon is continuing to limit the prosecution of certain patent applications and defer the maintenance fees for certain non-core patent applications.  This does not affect the strength of Burcon's patent portfolio.  Burcon expects to expend up to $1.5 million in patent expenditures for the next fiscal year.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

FINANCIAL INSTRUMENTS

The Company's financial instruments are its cash and cash equivalents, amounts receivable, loan to Merit Foods, and accounts payable and accrued liabilities, accrued interest, deferred revenue, and convertible debentures.

Credit risk

The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable.  The Company's cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks.  The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks.

Interest rate risk

All of the Company's financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, the Note and the Loan that bear interest at fixed interest rates.  Burcon's cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk.  For the year ended March 31, 2020, the weighted average interest rate earned on the Company's cash and cash equivalents was 1.92% per annum (2019 - 1.68% per annum).  The impact of a 1% strengthening or weakening of interest rates on the Company's cash and cash equivalents at March 31, 2020 is estimated to be a $150,000 increase or decrease in interest income per year.

Liquidity risk

The Company manages liquidity risk through the management of its capital structure.  It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations.  The Company's estimated minimum contractual undiscounted cash flow requirement for its financial liabilities at March 31, 2020 is $11.1 million, of which $1.6 million is due within the next 12 months. 

Fair value

The fair value of the Company's short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities, accrued interest and deferred revenue approximates their carrying values due to the short-term maturities of these financial instruments.

The fair value of the loan to Merit Foods approximates the carrying value as at March 31, 2020 given the risk profile of Merit Foods has not changed substantially since the issue date of the loan to Merit Foods.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

The carrying values and fair values of financial instruments, by class, are as follows as at March 31, 2020 and March 31, 2019:

(in thousands of dollars)

As at March 31, 2020                        
    At fair value through profit or loss     Financial assets at amortized cost     Financial liabilities at amortized cost     Fair value  
                         
Financial assets                        
Cash and cash equivalents   -     15,031     -     15,031  
Amounts receivable   -     332     -     332  
Loan to Merit Functional Foods Corp.   -     2,660     -     2,660  
Total   -     18,023     -     18,023  
                         
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,067     1,067  
Accrued interest   -     -     249     249  
Deferred revenue   -     -     276     276  
Convertible debentures   -     -     6,731     6,731  
Total   -     -     8,323     8,323  

As at March 31, 2019                        
    At fair value through profit or loss     Financial assets at amortized cost     Financial liabilities at amortized cost     Fair value  
                         
Financial assets                        
Cash and cash equivalents   -     489     -     489  
Amounts receivable   -     127     -     127  
Total   -     616     -     616  
                         
Financial liabilities                        
Accounts payable and accrued  liabilities   -     -     633     633  
Short-term loan   -     -     1,250     1,250  
Convertible note    -     -     1,991     1,991  
Accrued interest   -     -     564     564  
Derivative liability   5     -     -     5  
Total   5     -     4,438     4,443  


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Currency risk

The Company has not hedged its exposure to currency fluctuations.  As at March 31, 2020 and March 31, 2019, the Company is exposed to currency risk through the following assets and liabilities denominated in U.S. dollars:

    Marc 31, 2020     March 31, 2019  
U.S. Dollars (in thousands)            
Cash and cash equivalents   22     48  
Amounts receivable   3     9  
Accounts payable and accrued liabilities   (45 )   (28 )
Net exposure   (21 )   29  
             
Canadian dollar equivalent (in thousands)   (30 )   39  

Based on the above net exposure at March 31, 2020, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $3,000 (March 31, 2019 - $4,000) in the Company's loss from operations.

OUTSTANDING SHARE DATA

As at March 31, 2020, Burcon had 96,799,638 common shares outstanding, 4,507,606 stock options outstanding exercisable at a weighted average exercise price of $3.32 per share, 4,229,286 share purchase warrants that were convertible to an equal number of common shares at an exercise price of $2.00 per share, and convertible debentures that were convertible to 9,047,619 common shares. 

As at the date of this MD&A, Burcon has 97,713,921 common shares outstanding, and 4,507,606 stock options that are convertible to an equal number of shares at a weighted average exercise price of $3.32 per share, 4,229,286 share purchase warrants that are convertible to an equal number of common shares at an exercise price of $2.00 per share, and convertible debentures that are convertible to 8,133,333 common shares. 

QUARTERLY FINANCIAL DATA

(Derived from unaudited interim financial statements.  All figures in thousands of dollars, except per-share amounts)

    Three months ended  
    March 31,      December 31,     September 30,     June 30,  
    2020     2019     2019     2019  
Revenue, foreign exchange gain, interest and other income   226     221     172     27  
Loss for the period   (1,816 )   (788 )   (697 )   (1,332 )
Basic and diluted loss per share   (0.02 )   (0.01 )   (0.01 )   (0.03 )


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019


    Three months ended  
    March 31,      December 31,      September 30,     June 30,  
    2019     2018     2018     2018  
Revenue, foreign exchange gain, interest and other income   105     34     15     24  
Loss for the period   (1,245 )   (1,155 )   (1,301 )   (1,076 )
Basic and diluted loss per share   (0.03 )   (0.03 )   (0.03 )   (0.02 )

Included in the first quarter of this year is a gain of $5,000 for the change in the fair value of the derivative liability related to the Note.  Included in the losses of the first, second, third and fourth quarters of this year, and the first, second and third and fourth quarter of fiscal 2019 are $33,000, $17,000, $12,000, $424,000, $68,000, $65,000, $60,000, and $60,000, respectively, of stock-based compensation expense. 

Included in the second and fourth quarter of fiscal 2019 are foreign exchange losses of $5,000 and $6,000, respectively.  Included in the fourth quarter of this year, the first and third quarter of fiscal 2019 are foreign exchange gains of $3,000, $6,000, $12,000, respectively.  Included in the first quarter of this year is a valuation adjustment of $85,000 from the change in exercise price of the warrants issued under the 2018 Rights Offering.  Included in the second quarter of fiscal 2019 is non-cash financing expense of $145,000 related to the difference between the fair value of the standby warrants issued and the derivative liability pursuant to the 2018 Rights Offering.     

RELATED PARTY TRANSACTIONS

Burcon engaged Burcon Group Limited, a company that is related by virtue of common directors, for the following related party transactions:

Included in general and administrative expenses (office supplies and services) for the year ended March 31, 2020 is $75,006 (2019 - $75,006) for office space rental.

For the year ended March 31, 2020, included in general and administrative expenses (management fees) is $1,181 (2019 - $142) for administrative services provided to the Company.  At March 31, 2020, $11 (March 31, 2019 - $22) of this amount is included in accounts payable and accrued liabilities.  For the year ended March 31, 2020, included in interest and other income is $14,197 (2019 - $14,896) for legal and accounting services provided by the Company.  At March 31, 2020, $1,785 (March 31, 2019 - $670) of this amount is included in amounts receivable.   

Burcon has a Services Agreement with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  For the period March 31, 2020, included in interest and other income is $464,780 (2019 - $nil) for technical services provided and sample production by the Company to Merit Foods, of which $110,594 was included in amounts receivable at March 31, 2020 (March 31, 2019 - $nil). 

Certain directors and an officer of the Company subscribed for $2.0 million of the Debentures.

Burcon had the Loan and Note with Large Scale, a company that is wholly owned by Firewood.  For the year ended March 31, 2020, included in interest expense is $56,502 (2019 - $277,842) related to the Note and $60,756 (2019 - $46,417) related to the Loan.  Included in accrued interest as at March 31, 2020 is $nil (March 31, 2019 - $517,833) for the Note and $nil (March 31, 2019 - $46,418) for the Loan.  During the year ended March 31, 2019, the Company recorded a commitment fee of $15,000 as financing expense in connection with the Loan.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Upon completion of the 2019 Rights Offering, the exercise price for the share purchase warrants issued to Dr. Yap was adjusted from $0.69 per share to $0.45 per share.  The Company recorded $85,421 as a financing expense during fiscal 2020.

CRITICAL ACCOUNTING ESTIMATES

The consolidated financial statements have been prepared in accordance with IFRS as issued by the International Accounting Standard Board (IASB) and interpretations issued by the IFRS IC. 

The preparation of consolidated financial statements in accordance with IFRS requires management to apply judgment when making estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, the reported amount of expenses during the reporting period, and disclosures made in the accompanying notes to the financial statements.  Actual results could differ from those estimates.

The significant areas where management's judgment is applied is in determining the fair value of stock-based compensation, loan to Merit Foods, loan component of the Debentures and goodwill.

NEWLY ADOPTED ACCOUNTING STANDARDS

Effective April 1, 2019, the Company adopted IFRS 16, - Leases, which requires, among other things, leases to recognize leases traditionally recorded as operating leases in the same manner as a financing lease. 

The Company applied IFRS 16 on a modified retrospective basis and it did not have a significant impact on the consolidated financial statements.

NASDAQ LISTING

During fiscal 2018, the Nasdaq Stock Market LLC ("Nasdaq") notified the Company that it did not meet certain continued listing requirements of the Nasdaq Global Market, including the minimum bid price requirement and the shareholders' equity requirement and that the Company would be subject to delisting if such requirements were not met within a certain time period.  The Company submitted an appeal to the Nasdaq Hearing Panel and transferred its listing for its common shares to The Nasdaq Capital Market on February 7, 2018. 

After careful consideration, the board of directors of Burcon determined that it was in the overall best interest of the Company to withdraw the appeal of the delisting.  The decision was based on several factors, including the board's assessment of the probability of the Company regaining compliance with the continued listing requirements, an analysis of the benefits of continued listing weighed against the onerous regulatory burden and significant costs associated with maintaining continued listing, and the fact that the Nasdaq Capital Market only provided a secondary trading platform as the Company has no intention of raising capital in the US market.  On April 24, 2018, the Company informed the Panel that it would withdraw its appeal of the delisting.  Burcon's shares suspended trading on the Nasdaq Capital Market effective at the open of business on April 27, 2018. 

The Company filed a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934) with the United States Securities and Exchange Commission (the "SEC") on June 4, 2018 to delist the Company's common shares from the Nasdaq Capital Market and to deregister its common shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").  The delisting became effective on June 14, 2018 and the deregistration will become effective ninety days from June 4, 2018.  The Company also filed a Form 15 on June 15, 2018 with the SEC to suspend its reporting obligations under Section 15(d) of the Exchange Act.  The Company's reporting obligations with the SEC were suspended upon the filing of the Form 15 and shall remain suspended for as long as the Company continues to meet the criteria for such suspension on the first day of any subsequent fiscal year.  After the delisting, the Company's common shares were quoted for trading in the United States on the OTC Pink Open Market operated by OTC Markets Group, under the ticker "BUROF".


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

On February 10, 2020, the Company's common shares were listed on the OTCQB Venture Market under the ticker "BUROF".

DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING

The Chief Executive Officer and Chief Financial Officer, as well as other executives, have designed disclosure control and procedures ("DC&P"), or have caused them to be designed under their supervision, to provide reasonable assurance that material information relating to the Company has been made known to them.  The officers have evaluated the effectiveness and design of its DC&P as at March 31, 2020 and have determined these controls to be effective. 

These officers are also responsible for designing and maintaining internal controls over financial reporting ("ICFR") or have caused them to be designed under their supervision, to provide reasonable assurance regarding the reliability of the Company's ICFR.  They have evaluated and determined these internal controls and procedures over financial reporting as at March 31, 2020 and concluded they are effective.  They have also concluded that there were no significant changes in the ICFR that occurred during the year ended March 31, 2020 that could have materially affected, or are reasonably likely to materially affect, the Company's DC&P and ICFR.

RISKS AND UNCERTAINTIES

The Company is subject to a number of risks and uncertainties that can significantly affect its financial condition and future operations.  Key risks are outlined below.  In addition, a detailed explanation of the risk factors which we face is provided in our AIF for the year ended March 31, 2020 under the section titled "Risk Factors", which is incorporated by reference herein.  The AIF is available at www.sedar.com

Patents and proprietary rights - Burcon's success will depend, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of others or having others infringe on its rights.  Burcon has filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  As at the date of this MD&A, Burcon has been granted a total of 287 patents in various countries covering a number of key processes and uses of Burcon's soy, pea, canola and flax protein products as functional food and beverage ingredients.  Of those patents, 70 have been granted in the United States.  Although Burcon expends significant resources and efforts to patent its discoveries and innovations, there can be no assurance that our patent applications will result in the issuance of patents, or any patents issued to Burcon will provide it with adequate protection or any competitive advantages, or that such patents will not be successfully challenged by third parties.  Burcon cannot be assured that competitors will not independently develop products similar to the Company's products or manufacture products designed to circumvent the exclusive patent rights granted to the Company.  Further, Burcon may need to incur significant expenditures in prosecuting claims against others whom it believes are infringing on its rights and by defending claims of intellectual property infringement brought by its competitors and others.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Development and commercialization - The long-term success of Puratein®, Supertein® and Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea protein  and Nutratein® pea protein/canola protein blend products hinges upon market acceptance by food and feed ingredient manufacturers and suppliers in numerous product applications.  Although Burcon has formed Merit Foods with the Partners to commercialize Burcon's pea and canola proteins, the commercial products manufactured using Burcon's protein and extraction technologies must exhibit certain functional and nutritional characteristics to garner any market share in the industries that are targeted.  There can be no assurance that Burcon's products will meet industry standards.  Even though Puratein®, Supertein® and  Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be found to be functionally acceptable in product applications, there is no assurance that they will obtain market acceptance and within a reasonable time frame.  Burcon's products have only been produced in small scale batches, and the majority of food or feed ingredient manufacturers will require a substantial testing phase and demonstration of consistent delivery and production capabilities for commercialization.  Although Merit Foods has commenced construction of the planned production facility for Burcon's pea and canola proteins, the construction may be delayed or may not be completed on time.  Therefore, it will be some time before product sales of pea and canola protein will occur.  Until large batches of products can be supplied, market acceptance of Puratein®, Supertein®, and Nutratein® canola proteins, and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be delayed.

There are many large companies in the marketplace that manufacture and produce mature and well-known protein ingredients that have been used for many years.  These companies also possess far greater financial, marketing and human resources than Burcon.  Products such as dried egg white and soy protein isolate have been used in the food processing industry for years with successful results.  These protein ingredients are proven to be functional, technologically sound, readily available and reliable

History of operating losses and financing requirements- Burcon has accumulated net losses of approximately $98.4 million from its date of incorporation through March 31, 2020.  While Merit Foods' Flex Production Facility is under construction for the production of Burcon's pea and canola proteins, it will be some time before product sales of pea and canola protein will occur.  There is no assurance that the production facility will be built on time or within budget or that Burcon will be able to make the transition to commercial production.  Burcon cannot predict if it will ever achieve profitability and, if it does, it may not be able to sustain or increase its profitability.  While ADM has successfully commissioned the first full-scale commercial CLARISOY® production facility, Burcon has not yet reported significant cash royalty revenue.  Although Burcon expects to receive royalty payments from ADM pursuant to the Soy Agreement, the timing and amount of these future royalty payments cannot be ascertained at this time.  In the absence of a definitive time for when sales of products will be significant, Burcon expects such losses to increase as it continues to commercialize its products, its research and development and product and its product application trials.  Burcon expects to continue to incur substantial losses for the foreseeable future.  The commercial success of any of Burcon's products will depend on whether they receive public and industry acceptance as a food ingredient and dietary supplement, and whether they may be sold at competitive prices or are able to obtain sufficient royalty revenue from licensing, which adequately exceeds Burcon's production or business costs.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

Developing Burcon's products and conducting product application trials is capital intensive.  Since acquiring its subsidiary in October 1999, Burcon has raised gross proceeds of approximately $102.4 million from the sale or issuance of equity securities and $9.5 million from the issuance of convertible debentures.  As at March 31, 2020, Burcon had approximately $15.0 million in cash and cash equivalents.  Burcon believes that it has sufficient capital to fund the current level of operations through September 2022.  Although Burcon has sufficient funds to operate until September 2022, it will need to raise additional capital on acceptable terms in order for the Company to meet its business objectives and fund its operations. 

COVID-19 - Pandemic Risk - The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  While economies began to slowly reopen starting in June 2020, governments have taken a phased approach and it is not expected that economies will fully return to its pre-COVID-19 state until a vaccine has been developed to treat the virus.  The duration and effects of the COVID-19 pandemic are unknown at this time.  Even though governments worldwide, including Canada have implemented significant monetary and fiscal relief programs designed to stabilize their economies, it is too early to predict the efficacy of such programs at this time.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  While the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations to date, it is not possible to predict how long the pandemic will last and whether the financial and business conditions of Burcon and Merit Foods will be impacted in future periods. 

OUTLOOK

For the coming year, Burcon's primary objective is to support Merit Foods to build and commission the pea protein and canola protein production facility and to support market development activities for its protein products, which will include: 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Years ended March 31, 2020 and 2019

In addition, Burcon will also:



Form 52-109F1

Certification of annual filings - full certificate

I, Jade Cheng, the Chief Financial Officer of Burcon NutraScience Corporation, certify the following:

1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the "annual filings") of Burcon NutraScience Corporation (the "issuer") for the financial year ended March 31, 2020.

2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, for the period covered by the annual filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the annual filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer. 

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the financial year end

(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the annual filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework:  The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Internal Control - Integrated Framework (2013) issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 N/A


5.3 N/A


6. Evaluation: The issuer's other certifying officer(s) and I have

(a) evaluated, or caused to be evaluated under our supervision, the effectiveness of the issuer's DC&P at the financial year end and the issuer has disclosed in its annual MD&A our conclusions about the effectiveness of DC&P at the financial year end based on that evaluation; and

(b) evaluated, or caused to be evaluated under our supervision, the effectiveness of the issuer's ICFR at the financial year end and the issuer has disclosed in its annual MD&A

(i) our conclusions about the effectiveness of ICFR at the financial year end based on that evaluation; and

(ii) N/A

7. Reporting changes in ICFR: The issuer has disclosed in its annual MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2020 and ended on March 31, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

8. Reporting to the issuer's auditors and board of directors or audit committee: The issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of ICFR, to the issuer's auditors, and the board of directors or the audit committee of the board of directors any fraud that involves management or other employees who have a significant role in the issuer's ICFR. 

Date:  June 29, 2020

"Jade Cheng"

_______________________

Jade Cheng

Chief Financial Officer

2



Form 52-109F1

Certification of annual filings - full certificate

I, Johann F. Tergesen, the Chief Executive Officer of Burcon NutraScience Corporation, certify the following:

1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the "annual filings") of Burcon NutraScience Corporation (the "issuer") for the financial year ended March 31, 2020.

2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, for the period covered by the annual filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the annual filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer. 

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the financial year end

(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the annual filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework:  The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Internal Control - Integrated Framework (2013) issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 N/A



5.3 N/A

6. Evaluation: The issuer's other certifying officer(s) and I have

(a) evaluated, or caused to be evaluated under our supervision, the effectiveness of the issuer's DC&P at the financial year end and the issuer has disclosed in its annual MD&A our conclusions about the effectiveness of DC&P at the financial year end based on that evaluation; and

(b) evaluated, or caused to be evaluated under our supervision, the effectiveness of the issuer's ICFR at the financial year end and the issuer has disclosed in its annual MD&A

(i) our conclusions about the effectiveness of ICFR at the financial year end based on that evaluation; and

(ii) N/A

7. Reporting changes in ICFR: The issuer has disclosed in its annual MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2020 and ended on March 31, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

8. Reporting to the issuer's auditors and board of directors or audit committee: The issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of ICFR, to the issuer's auditors, and the board of directors or the audit committee of the board of directors any fraud that involves management or other employees who have a significant role in the issuer's ICFR. 

Date:  June 29, 2020

"Johann F. Tergesen"

_______________________

Johann F. Tergesen

Chief Executive Officer

2



BURCON NUTRASCIENCE CORPORATION
1946 West Broadway
Vancouver, B.C.
V6J 1Z2

Telephone: (604) 733-0896

Facsimile: (604) 733-8821

ANNUAL INFORMATION FORM
FOR THE YEAR ENDED MARCH 31, 2020

June 29, 2020


TABLE OF CONTENTS

   
PRELIMINARY NOTES 1
   
Effective Date of Information 1
   
Forward Looking Statements 1
   
Currency 4
   
Glossary 4
   
CORPORATE STRUCTURE 5
   
INTERCORPORATE RELATIONSHIPS 5
   
GENERAL DEVELOPMENT OF THE BUSINESS 5
   
Pea 17
   
Canola 19
   
Pea Protein/Canola Protein Blends 19
   
Soy 20
   
Specialty Proteins and Phytochemical Extractions 21
   
DESCRIPTION OF THE BUSINESS 22
   
Functional Value 22
Nutritional Value 23
   
Pea 23
   
Peazazz® 24
Peazac® 26
   
Pea Protein Production 26
   
Canola 27
   
Canola Protein 28
Puratein® Canola Protein 29
Supertein® Canola Protein 29
Nutratein® Canola Protein 30
   
Pea Protein/Canola Protein Blends 30
   
Soy 31

(i)



Soy Protein 31
CLARISOY® 32
Soy Protein Production 33
   
Research and Development 33
   
Objectives 34
   
Marketing Strategies 35
   
Plant Protein 36
Pea Protein 38
Canola Protein 39
Pea Protein/Canola Protein Blends 39
Soy Protein 39
   
Intellectual Property 40
Patents 40
Granted U.S. Patents 40
Soy 41
Canola 41
Pea 42
Flax 42
Patent Strategy 42
Trade-marks 42
   
Facilities 43
   
Personnel 43
   
Competitive Conditions 44
   
Environmental Matters 46
   
Regulatory Approval For Marketing CLARISOY® 46
   
Regulatory Approval For Marketing Peazazz® and Peazac® 48
   
Obtaining Regulatory Approval For Marketing Puratein®, Supertein® and Nutratein® Canola Proteins 48
United States 49
Puratein® and Supertein® 49
Nutratein® Canola Protein 51
Europe 52
Puratein®, Supertein®, and Nutratein® Canola Proteins 52
Canada 53
Puratein®, Supertein® & Nutratein® Canola Proteins 53
   
Regulatory Approval For Pea Protein/Canola Protein (Nutratein®) Products 54
   
Risk Factors 54
Patents and Proprietary Rights 54
Protection of Intellectual Property is Expensive 55
The Timeline for Development and Commercialization of New Food Products Can Be Long 57

(ii)



Burcon Has a History of Net Losses and Negative Operating Cash Flow and May Never Achieve Profitability 57
Market Conditions 58
Financing Requirements 58
Product and Market Related Risks 59
Consumer Acceptance 60
Government Regulatory Approval 60
Rapid Technological Change 60
Significant Competition 61
Lack of Commercial Manufacturing Experience 61
Ability to Hire and Retain Key Personnel 61
Reliance on Key Personnel 61
Product Liability 62
Nasdaq Listing 62
COVID-19 - Pandemic Risk 64
   
DIVIDEND RECORD AND POLICY 64
   
DESCRIPTION OF CAPITAL STRUCTURE 64
   
MARKET FOR SECURITIES 65
   
PRIOR SALES 66
   
Options 67
   
Warrants 68
   
DIRECTORS AND OFFICERS 68
   
Directors and Officers 68
   
Committees 74
   
Aggregate Ownership of Securities 74
   
Biographies of Directors and Officers 74
   
Cease Trade Orders, Bankruptcies, Penalties or Sanctions 78
   
Conflicts of Interest 80
   
TRANSFER AGENTS AND REGISTRARS 81
   
MATERIAL CONTRACTS 81
   
Unanimous Shareholders Agreement 83

(iii)



   
Merit Foods License and Production Agreement 84
   
Services Agreement with Merit Foods 85
   
Loan Agreement with Large Scale Investments Limited 85
   
Standby Commitment Agreement with Allan Yap 86
   
Convertible Note Purchase Agreement with Large Scale Investments Limited 86
   
License and Production Agreement with ADM 87
   
INTERESTS OF EXPERTS 88
   
AUDIT COMMITTEE AND DISCLOSURE UNDER NATIONAL INSTRUMENT 52-110 88
   
Composition of the Audit Committee 88
   
Audit Committee Oversight 89
   
Pre-Approval Policies and Procedures 89
   
External Auditor Service Fees 89
   
ADDITIONAL INFORMATION 90
   
GLOSSARY 91
SCHEDULE "A" 95
AUDIT COMMITTEE CHARTER 95

(iv)


PRELIMINARY NOTES

Effective Date of Information

All information in this Annual Information Form ("AIF") is as of March 31, 2020 unless otherwise indicated.

Forward Looking Statements

This AIF contains certain "forward-looking statements" and "forward-looking information" as defined under applicable Canadian and US securities laws (collectively, "forward-looking statements") which may include, but are not limited to, statements with respect to possible events, conditions, acquisitions, or results of operations that are based on assumptions about future conditions and courses of action and include future oriented financial information with respect to prospective results of operations, financial position or cash flows that is presented either as a forecast or a projection, and also include, but are not limited to, statements with respect to the future financial and operating performance of the Company.  All statements, other than statements of historical fact, are forward-looking statements.  When used in this AIF the words "estimate", "budget", "project", "believe", "anticipate", "intend", "expect", "plan", "projects", "predict", "may", "should", "will", or the negatives of these words or other variations thereof and comparable terminology or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved are intended to identify forward-looking statements. The forward-looking statements pertain to, among other things:


- 2 -

The forward-looking statements are based on a number of key expectations and assumptions made by management of the Company, including, but not limited to:


- 3 -

Although the Company believes that the factors and assumptions used to develop the forward-looking statements are reasonable, undue reliance should not be placed on such forward-looking statements. The forward-looking statements reflect the Company's current views with respect to future events based on currently available information and are inherently subject to risks and uncertainties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements contained in this AIF, including, but not limited to:


- 4 -

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected.  The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Although the Company has attempted to identify important factors that could cause actual results to differ materially from forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated, described or intended.  The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect changes in assumptions or the occurrence of anticipated or unanticipated events, except as required by law.

The Company qualifies all the forward-looking statements contained in this AIF by the foregoing cautionary statements.

Material risk factors that could cause actual results to differ materially from the forward-looking information are contained under the heading "Risk Factors" beginning on page 54.

Currency

All dollar amounts in this AIF are expressed in Canadian dollars, unless otherwise indicated.

Glossary

Certain terms used herein are defined in the attached Glossary.


- 5 -

CORPORATE STRUCTURE

Burcon NutraScience Corporation ("Burcon" or the "Company") was incorporated under the Business Corporations Act (Yukon) on November 3, 1998 under the name "Burcon Capital Corp." and extra-provincially registered in British Columbia on February 5, 1999.  Burcon changed its name to "Burcon NutraScience Corporation" on October 18, 1999.  The head office of Burcon is located at 1946 West Broadway, Vancouver, B.C., V6J 1Z2. The registered office of Burcon is located at Suite 200, Financial Plaza, 204 Lambert Street, Whitehorse, Yukon, Y1A 3T2.

INTERCORPORATE RELATIONSHIPS

Burcon owns 100% of the issued and outstanding shares of its subsidiary, Burcon NutraScience (MB) Corp. ("Burcon-MB") which was incorporated under the Corporations Act (Manitoba) on February 28, 1992 under the name B.M.W. Canola Inc.  Its name was changed to Burcon NutraScience (MB) Corp. on May 30, 2000.

Burcon owns 100% of the issued and outstanding shares of its subsidiary, Burcon NutraScience Holdings Corp. ("Burcon Holdings") which was incorporated under the Canada Business Corporations Act on May 22, 2019.  Burcon Holdings owns 40% of the issued and outstanding shares of Merit Functional Foods Corporation (formerly Burcon Functional Foods Corporation).  On May 15, 2019, Burcon Functional Foods Corporation was incorporated under the Canada Business Corporations Act.  Its name was changed to Merit Functional Foods Corporation on June 20, 2019. 

GENERAL DEVELOPMENT OF THE BUSINESS 

Burcon was formed in November 1998 as a venture capital pool corporation whose principal business was to identify and evaluate assets, properties or businesses for acquisition.  On October 8, 1999 Burcon acquired Burcon-MB.

Since October 1999, Burcon has raised gross proceeds of approximately $102.4 million through the sale of equity securities on both a public and private basis, the exercise of stock options and share purchase warrants, through rights offerings to existing shareholders and issuance of convertible securities.  The proceeds have been used, and will continue to be used, to fund research, development, regulatory recognition and commercialization of Burcon's patented and patent-pending protein extraction and purification technologies.  Burcon's technologies not only enable the production of plant protein ingredients but also relate to applications of the proteins produced therefrom into products, including food and beverages.


- 6 -

 Burcon's common shares were listed on the Toronto Stock Exchange (the "TSX") in June 2009.  Prior thereto, Burcon's common shares were listed on the TSX Venture Exchange (the"TSXV").              The Company's common shares are also listed on the OTCQB Venture Market under the symbol "BUROF" and the Frankfurt Stock Exchange under the symbol "BNE".

 On October 27, 2011, Burcon's common shares commenced trading on The NASDAQ Global Market ("NASDAQ Global Market") under the symbol "BUR".  On June 8, ,2017, the Company received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC ("NASDAQ") notifying the Company that it was not in compliance with Listing Rule 5450(b)(2), which requires the listed securities of the Company to maintain a minimum market value of US$50 million.  The Company had not met the requirement for a period of 30 consecutive business days prior to receipt of the NASDAQ letter.    On August 21, 2017, the Company received a second letter from NASDAQ notifying the Company that it was not in compliance with Listing Rule 5450(a)(1), which requires the listed securities of the Company to maintain a minimum bid price of US$1 per share.  The Company had not met the requirement for a period of 30 consecutive business days prior to receipt of the second NASDAQ letter.  The receipt of the two NASDAQ letters did not result in the immediate delisting of the Company's common shares from the NASDAQ Global Market.  The Company had a compliance period of 180 calendar days or until December 5, 2017 and February 19, 2018, to regain compliance with NASDAQ's minimum market value of listed securities requirement and minimum bid price requirement, respectively.  On December 6, 2017, the Company received notification from NASDAQ stating the Company did not meet the December 5, 2017 deadline to regain compliance with NASDAQ's minimum market value of listed securities requirement.  NASDAQ stated that the Company's common shares would be delisted from the NASDAQ Global Market at the opening of business on December 15, 2017 unless the Company submitted a request to appeal the determination to the NASDAQ hearing Panel (the "Panel") by December 13, 2017.  On the same day, the Company received a further letter from NASDAQ notifying the Company that it was not in compliance with Listing Rule 5450(b)(2)(C), which requires the listed securities of the Company to maintain a minimum market value of publicly held shares of US$15 million.  The Company had not met the requirement for a period of 30 consecutive business days prior to receipt of the second NASDAQ letter on December 6, 2017.  The Company submitted an appeal to the Panel together with a plan for regaining compliance with the various continued listing requirements. 

 On February 5, 2018 the Company received notification from the Panel granting the Panel's approval for the Company to transfer its listing for its common shares from the NASDAQ Global Market to The NASDAQ Capital Market ("NASDAQ Capital Market").  Trading on the Company's common shares on the NASDAQ Capital Market became effective on February 7, 2018.  The Panel subjected the continued listing of the Company's shares on the NASDAQ Capital Market to certain conditions, including closing its 2018 Rights Offering (defined below) and having shareholders' equity of over US$2.5 million on or before February 16, 2018.  On February 14, 2018, Burcon announced that the 2018 Rights Offering had closed.  However, because the 2018 Rights Offering was not fully subscribed, the Company was required to provide additional submissions to the Panel in support of its compliance plan.  On April 24, 2018, the Company withdrew its appeal of the delisting.  The board of directors of Burcon determined that it was in the overall best interest of the Company to withdraw the appeal of the delisting.  The decision was based on several factors, including the board's assessment of the probability of the Company regaining compliance with the continued listing requirements, an analysis of the benefits of continued listing weighed against the onerous regulatory burden and significant costs associated with maintaining the continued listing.  On April 27, 2018, the Company's common shares were suspended from trading on the NASDAQ Capital Market.    The Company filed a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934) with the United States Securities and Exchange Commission (the "SEC") on June 4, 2018 to delist the Company's common shares from the NASDAQ Capital Market and to deregister its common shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").  The delisting became effective on June 14, 2018 and the deregistration became effective ninety days after June 4, 2018.  On June 15, 2018, the Company filed a Form 15 with the SEC to suspend its reporting obligations under Section 15(d) of the Exchange Act.  The Company's reporting obligations with the SEC were suspended upon the filing of the Form 15 and shall remain suspended for as long as the Company continues to meet the criteria for such suspension on the first day of any subsequent fiscal year.  After the delisting of the common shares from the NASDAQ Capital Market, the common shares of Burcon were quoted for trading in the United States on the OTC Pink Open Market operated by OTC Markets Group, under the ticker "BUROF".  In February 2020, the Company announced that the common shares began trading on the OTCQB Venture Market under the same symbol. 


- 7 -

On April 7, 2016, Burcon announced that it had entered into a convertible note purchase agreement pursuant to which it would issue a convertible note (the "Note") to Large Scale Investments Limited ("Large Scale"), a wholly-owned subsidiary of PT International Development Corporation Limited ("PT International") at the time,  for the principal amount of $2,000,000 (the "Principal Amount").  On September 28, 2018, Firewood Elite Limited ("Firewood"), a company wholly-owned by Mr. Alan Chan, a director of Burcon, acquired all the outstanding shares of Large Scale and Great Intelligence Limited (both of which are shareholders of Burcon) from PT International.  On May 21, 2019, the Company announced that Burcon and Large Scale amended the Note (the "Amendment") to extend the maturity date of the Note from May 11, 2019 to June 21, 2019. 


- 8 -

Under the Note, Large Scale could convert the Principal Amount in whole or in part into common shares in the capital of Burcon at any time commencing on or after July 1, 2016 and up to and including the Maturity Date.  When issued, the conversion price of the Note was $4.01 per common share, which represented a premium of approximately 24% over the volume weighted average trading price of the common shares on the TSX for the 5 trading days immediately before April 7, 2016 (the "Conversion Price").  Burcon also had the right, before the Maturity Date, upon written notice to the Lender of not less than thirty (30) days, to prepay in cash all or any portion of the Principal Amount by paying to the Lender an amount equal to the Principal Amount to be prepaid multiplied by 110%.  At any time on or after July 1, 2016 and up to the end of such 30-day notice period, Large Scale had the right to convert the Principal Amount in full or in part, into common shares at the Conversion Price.  The Note was and any common shares issued upon the conversion of the Note would have been subject to a four month hold period under applicable Canadian securities laws.  Upon completion of the 2018 Rights Offering (as defined below), the Conversion Price of the Note was adjusted effective immediately after the 2018 Record Date (as defined below).  After the adjustment, the Conversion Price was reduced to $3.94 per common share. 

Funding by Large Scale and the issuance of the Note occurred on May 12, 2016.  The Note bore interest at a rate of 8% per annum, calculated daily, compounded monthly.  Interest accrued on the Principal Amount and was payable on the earlier of June 21, 2019, the occurrence of an event of default as set out in the Note, or voluntary prepayment by Burcon (the "Maturity Date"). 

The Amendment also provided Large Scale with a right to offset any amounts due to it under the Note against any obligations of Large Scale to pay for subscription proceeds of any rights offering that Burcon may conduct.

In connection with the 2019 Rights Offering (as defined below), Large Scale exercised its right to offset the amounts due under the Note against its obligations to pay for subscription proceeds under the offering.  The offset was completed on June 25, 2019.  The total amount offset under the Note included the Principal Amount and accrued interest in the amount of $2,565,022.

On January 5, 2018, Burcon announced that it would be offering rights (the "2018 Rights Offering") to holders of its common shares of record at the close of business on January 16, 2018 (the "2018 Record Date").  Pursuant to the 2018 Rights Offering, each holder of common shares on the 2018 Record Date received one transferable right for each common share held.  Every 4 rights entitled a holder to purchase one common share at a price of $0.57 per share.  Burcon announced on February 14, 2018 that it had completed the Rights Offering.  The 2018 Rights Offering was not fully subscribed and Burcon issued 6,114,361 common shares at a price of $0.57 per common share for aggregate gross proceeds to Burcon of $3,485,186. 


- 9 -

Allan Yap, Burcon's Chairman and Chief Executive Officer at the time, acted as guarantor of the 2018 Rights Offering, having agreed to purchase from Burcon such number of common shares available to be purchased, but not otherwise subscribed for, that would result in 4,728,397 of common shares being issued under the 2018 Rights Offering (the "2018 Standby Commitment"). As the total number of common shares subscribed for under the 2018 Rights Offering exceeded the number of common shares guaranteed by Allan Yap, Mr. Yap was not required to fulfill his obligations under the 2018 Standby Commitment. 

As compensation for providing the 2018 Standby Commitment, Allan Yap received non-transferrable common share purchase warrants (the "2018 Standby Warrants") entitling him to acquire up to 1,182,099 common shares. The exercise price under the 2018 Standby Warrants was $0.69 per common share. The 2018 Standby Warrants had an expiry date of two years after the closing of the 2018 Rights Offering, being February 13, 2020.  In accordance with the policies of the TSX, the issuance of the 2018 Standby Warrants to Allan Yap was subject to shareholder approval.  Shareholder approval was received at Burcon's annual and special meeting held in September, 2018.  Upon completion of the 2019 Rights Offering (as defined below), the exercise price of the 2018 Standby Warrants was adjusted effective immediately after the 2019 Record Date (as defined below).  After the adjustment, the exercise price of the 2019 Standby Warrants was reduced to $0.45 per common share.  Mr. Yap exercised all of the 2018 Standby Warrants prior to the expiry to purchase 1,182,099 common shares.

On November 13, 2018, Burcon announced that it entered into a loan agreement (the "Loan Agreement") pursuant to which Large Scale, at the time and currently a wholly-owned subsidiary of Firewood, provided Burcon with an unsecured loan (the "Loan") of up to $1,000,000 (the "Initial Loan Amount") for a term of 180 days from the Loan Closing Date (defined below). 

On March 27, 2019, Burcon and Large Scale amended (the "Loan Amendment") the Loan Agreement, pursuant to which Large Scale agreed to increase the Initial Loan Amount to Burcon by $500,000 (together with the Initial Loan, the "Loan Amount").

Burcon drew $500,000 of the Loan Amount as of December 5, 2018 (the "Loan Closing Date") and $500,000 on January 31, 2019.  Burcon then drew $250,000 of the Loan Amount on each of March 29, 2019 and April 24, 2019, respectively.  Large Scale was paid a $10,000 commitment fee, representing of 1% of the Initial Loan Amount on the Loan Closing Date and a further $5,000 on the additional $500,000 of principal amount made available under the Loan Amendment.  The drawn portion of the Loan Amount bore interest at a rate of 18% per annum (the "Loan Principal Balance").  Up to $1,000,000 of the undrawn portions of the Loan Amount bore interest at a rate of 3% per annum (the "Undrawn Amount") and any Undrawn Amount exceeding $1,000,000 bore interest at a rate of 3% per annum from March 27, 2019 until the Loan Maturity Date. 


- 10 -

The Loan Amendment also provided Large Scale with a right to offset any amounts due to it under the Note against any obligations of Large Scale and/or its nominees to pay for subscription proceeds of any rights offering that Burcon may conduct.

In connection with the 2019 Rights Offering (as defined below), Large Scale exercised its right to offset the amounts due under the Loan against its obligations to pay for subscription proceeds under the offering.  The offset was completed on June 25, 2019.  The total amount offset under the Loan was $1,436,629.  The remaining accrued interest in the amount of $170,555 under the Loan was paid by Burcon in cash to Large Scale on June 28, 2019.

On May 23, 2019, Burcon announced that it would be offering rights (the "2019 Rights Offering") to holders of its common shares of record at the close of business on May 30, 2019 (the "2019 Record Date").  Pursuant to the 2019 Rights Offering, each holder of common shares on the 2019 Record Date received one transferable right for each common share held.  Each right entitled a holder to purchase one common share at a price of $0.35 per share.  Burcon announced on June 26, 2019 that it had completed the Rights Offering.  The 2019 Rights Offering was fully subscribed and Burcon issued 44,083,203 common shares at a price of $0.35 per common share for aggregate gross proceeds to Burcon of $15,429,121. After the closing of the 2019 Rights Offering, Burcon had 88,166,406 common shares outstanding.  From the gross proceeds of the 2019 Rights Offering, Burcon repaid the Principal Amount and accrued interest outstanding under the Note and the Loan Amount by way of offset as described above.  Burcon used a portion of the remaining gross proceeds to make the Initial Capital Contribution and the Additional Capital Contribution under the Shareholders' Agreement (as defined below).

On May 23, 2019, Burcon's wholly-owned subsidiary, Burcon NutraScience Holdings Corp., entered into a shareholders agreement (the "Shareholders Agreement") with RBT Holdco Ltd. ("RBT Holdco") and 10039406 Manitoba Ltd. ("Crew Holdco") (RBT Holdco and Crew Holdco together referred to as the "JV Partners")  to become shareholders of Merit Functional Foods Corporation (formerly Burcon Functional Foods Corporation) ("Merit Foods").  Currently, Burcon Holdings holds 40%, RBT Holdco holds 40% and Crew Holdco holds 20% of the issued and outstanding common shares of Merit Foods.  Each of Ryan Bracken and Barry Tomiski (and their respective family) beneficially owns a 50% interest in RBT Holdco.  Crew Holdco is wholly-owned by Shaun Crew and his family.  The business of Merit Foods is the commercial production, sales, marketing and distribution worldwide of Burcon's pea protein, pulse protein and canola protein products.  Pursuant to the Shareholders Agreement, the parties agreed that on or before July 2, 2019, Burcon Holdings and the JV Partners will make a capital contribution to Merit Foods by way of shareholder loans and/or subscription of shares in the aggregate of $10,000,000.  Burcon Holdings agreed to make a capital contribution of $4,000,000 to Merit Foods (less certain deductions for certain expenses), while RBT Holdco and Crew Holdco agreed to contribute $4,000,000 and $2,000,000, respectively (each an "Initial Capital Contribution").  The Initial Capital Contribution was made by each of Burcon Holdings, RBT Holdco and Crew Holdco prior to the July 2, 2019 deadline under the Shareholders Agreement.  Burcon Holdings' Initial Capital Contribution was made on June 28, 2019. 


- 11 -

Provided that the Shareholders Agreement had not been previously terminated, the parties agreed to make further contributions to Merit Foods on or before September 3, 2019 in the aggregate amount of $10,000,000.  Burcon Holdings agreed to contribute a further $4,000,000 to Merit Foods, while RBT Holdco and Crew Holdco agreed to contribute $4,000,000 and $2,000,000, respectively (each an "Additional Capital Contribution").  Each of Burcon Holdings, RBT Holdco and Crew Holdco made their respective Additional Capital Contribution prior to the September 3, 2019 deadline.  Since September 3, 2019, Burcon Holdings has made further capital contributions to Merit Foods, together with RBT Holdco and Crew Holdco.  On December 12, 2019 and February 3, 2020, Burcon Holdings contributed a further $3,000,000 and $2,000,000, respectively, to Merit Foods.  Since September 3, 2019, the JV Partners also contributed an aggregate of $7.5 million to maintain their respective shareholding interests in Merit Foods.  To date, the shareholders of Merit Foods have contributed an aggregate of $32.5 million into Merit Foods. 

The Shareholders Agreement contains provisions to deal with the management of Merit Foods, and sets out matters requiring board of directors' approval or shareholder approval.  It also sets out the rights of the parties with respect to restrictions on transfers, transfers to third parties and what happens in the event of a takeover bid.

On May 23, 2019, Burcon and its wholly-owned subsidiary, Burcon-MB entered into a license and production agreement with Merit Foods (the "Merit License and Production Agreement").  Under the Merit License and Production Agreement, Burcon has granted an exclusive, royalty-bearing, worldwide license (the "Merit License") to Merit Foods to use and exploit Burcon's pea, pulse and canola protein technologies to make, have made, use and market and sell Burcon's pea, pulse and canola proteins (the "Merit Licensed Products"). 


- 12 -

Merit Foods has agreed to develop, build and commission an initial production facility in the Province of Manitoba within a specified amount of time to manufacture the Merit Licensed Products (the "Flex Production Facility").  Merit Foods will also, within a time specified under the Merit License and Production Agreement, provide written notice (the "Notice") to Burcon to advise whether it will or will not increase its annual production capacity of the Merit Licensed Products to develop, build and commission a full commercial scale production facility ("Full-Commercial Production Facility").  The Merit License and Production Agreement provides Burcon with the right to convert the exclusive license to a non-exclusive license under certain conditions. 

In consideration of the Merit License, Merit Foods will pay to Burcon running royalties based on the net revenue (as defined in the Merit License and Production Agreement) in relation to the sale of the Merit Licensed Products which fall within the scope of the Burcon Technology.  Once a sale in the Flex Production Facility occurs, Merit Foods will pay to Burcon royalties based on a percentage of net revenue from the sale of Products.  If Merit Foods expands production to the Full-Commercial Production Facility the royalty rate will be reduced to a lower percentage rate.  The royalty rate may also be reduced if the exclusive license is converted to a non-exclusive license or if a certain Burcon patent does not grant within a specified time.

If the exclusive license is converted to a non-exclusive license, Burcon will be entitled to make, have made, use, market and sell Merit Licensed Products on a non-exclusive basis and to grant any such rights to any other person.  Merit Foods will grant to Burcon an irrevocable, non-exclusive, royalty bearing license, with a right to sublicense, to use certain intellectual property developed by Merit Foods ("Merit Foods Improvements") to make, have made, use, market or sell the Products worldwide.    If the license is converted to a non-exclusive license and Burcon chooses to use the Merit Foods Improvements, the aggregate royalties payable by Burcon to Merit Foods in any year will not exceed the aggregate royalties payable by Merit Foods to Burcon in the same year. 

As long as the Merit License is exclusive, Burcon will be responsible for filing, prosecution and maintenance of Burcon patent rights in certain countries.  While the Merit License is exclusive, Merit Foods shall have the right to defend any action in which the validity of any Burcon patent right is raised in any jurisdiction.  If Merit Foods does not exercise such right, Burcon shall have the right but not the obligation to assume such defence.

The Merit License and Production Agreement has a term of the greater of twenty years and the last to expire of Burcon patents that are being used to produce products under the Merit License and Production Agreement.   


- 13 -

On May 23, 2019, Burcon, Burcon-MB and Merit Foods entered into a services agreement (the "Services Agreement") pursuant to which Burcon and Burcon-MB will provide certain services (the "Services") to Merit Foods in support of Merit Foods' business.  The Services will commence on July 3, 2019 and the agreement will have an initial term ending on June 30, 2022.  Under the Services Agreement, Burcon and Burcon-MB will provide general management/administrative/technical services, research and analytical services and sample production services.  The Services will be charged to Merit Foods based on rates set out in the Services Agreement. 

On November 25, 2019 Burcon announced a non-brokered private placement of convertible debentures (the "Convertible Debentures") for an aggregate principal amount of up to $4 million and subsequently, on November 28, 2019, Burcon announced that the aggregate principal amount had increased from $4 million to $9.5 million (the "Convertible Debenture Offering").

Mr. Johann Tergesen, Mr. Peter Kappel and Dr. Lorne Tyrrell, insiders of Burcon, agreed to and subscribed for Convertible Debentures totaling $2 million in principal amount.

Each Convertible Debenture consists of $1,000 principal amount, bears interest at a rate of 8.5% per annum, payable semi-annually in arrears, and is unsecured.  The principal amount outstanding under the Convertible Debentures and all accrued and unpaid interest thereon will be payable in cash thirty-six (36) months from the date of issuance of the Convertible Debentures.  The Convertible Debentures will be convertible at the option of the holder, in whole or in part, into Shares at the Conversion Price, which represents approximately a 30% premium to the volume weighted average trading price of the Shares on the TSX for the five days immediately preceding November 25, 2019. 

Burcon, will have the right, at its sole discretion, to force the conversion of the Convertible Debentures if the Shares trade at or above $2.15 per share for a period of 14 consecutive trading days.  The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures were subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws.

Burcon paid a cash finder's fee in connection with the Convertible Debenture Offering to certain finders of $156,600, representing 4.5% of the gross proceeds received from certain investors introduced to Burcon by the finders. 


- 14 -

The Offering closed on December 10, 2019.  The issuance of Convertible Debentures to insiders under the Convertible Debenture Offering was considered a related party transaction under Multilateral Instrument 61-101. Burcon relied on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(a) of Multilateral Instrument 61-101 on the basis that the participation in the Offering by insiders did not exceed 25% of Burcon's market capitalization.

On January 24, 2020, Burcon announced that the Company, Société Des Produits Nestlé Sa ("Nestlé") and Merit Foods had entered into a joint development agreement to tailor Burcon and Merit Foods' novel plant-based proteins for use in Nestlé food and beverage applications. The aim of the joint development is to tailor the functionality of Burcon and Merit's plant-proteins, to be supplied from Merit Foods' production facility, for use by Nestlé in plant-based meat and dairy alternatives.

On January 28, 2020, the Company announced that it had entered into an agreement with a syndicate of underwriters co-led by Canaccord Genuity Corp. and Beacon Securities Limited (the "Underwriters") pursuant to which the Underwriters agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 6,452,000 units (the "Units") at a price of $1.55 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of $10,000,000 (the "2020 Offering").

The Company granted the Underwriter an option (the "Over-Allotment Option"), to purchase up to an additional 967,800 Units at a price of $1.55 per Unit, exercisable at any time, for a period of 30 days after and including the Closing Date. The Over-Allotment Option was exercisable to acquire Units, Common Shares and/or Warrants (or any combination thereof) at the discretion of the Underwriter.

On February 19, 2020, the Company closed the 2020 Offering for gross proceeds of $11,500,690. The Underwriters purchased from the Company, on a bought deal basis, the Units at the Offering Price per Unit for gross proceeds of $10,000,600. The Underwriters also exercised the over-allotment option in full and purchased an additional 967,800 Units at a price of $1.55 for additional gross proceeds to the Company of $1,500,090.

Each Unit consists of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"). Each Warrant will be exercisable to acquire one Common Share (a "Warrant Share") for a period of 24 months following the closing of the Offering (the "Closing") at an exercise price of $2.00 per Warrant Share.


- 15 -

The Units were offered by way of a short form prospectus filed in all provinces of Canada, except Prince Edward Island, Newfoundland and Labrador, and Quebec.

In connection with the 2020 Offering, Burcon paid the Underwriters a cash commission of $805,048, representing 7% of gross proceeds of the 2020 Offering and 519,386 Warrants (the "Underwriters' Warrants"), representing 7% of the number of Units sold in the 2020 Offering.  Each Underwriters' Warrant will be exercisable to acquire one Common Share (a "Underwriters' Warrant Share") for a period of 24 months following the Closing at an exercise price of $2.00 per Underwriters' Warrant Share. 

On May 4, 2020, Burcon announced that Merit Foods has secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada, Farm Credit Canada and the Canadian Imperial Bank of Commerce.  To facilitate the financing, Burcon has provided a short-term letter of credit in the amount of $6.5 million, which will remain in place until no later than September 30, 2020, and also provided a $4 million guarantee of Merit Foods' debt obligations (the "Guarantee").  See "Material Contracts".

On June 22, 2020, Burcon announced that Merit Foods has secured additional debt financing of $10 million in the form of a 10-year interest free loan from Agriculture and Agri-Food Canada (the "AIP Loan").  The interest free loan, repayable over 10 years, was approved under Agriculture and Agri-Food Canada's AgriInnovate Program.  Burcon expects that the $4 million guarantee described above will be released in stages over time as Merit Foods draws down on the $10 million AIP Loan.

The Company's fiscal year end is March 31. During fiscal years 2018 to 2020, Burcon raised or borrowed a total of approximately $42.0 million in capital as follows:

 In February, 2018, Burcon completed the 2018 Rights Offering and raised gross proceeds of approximately $3.5 million as described above.

 In November 2018, Burcon entered into the Loan Agreement which was subsequently amended in March 2019 to borrow $1.5 million from Large Scale as described above.

 In June 2019, Burcon completed the 2019 Rights Offering and raised gross proceeds of approximately $15.4 million as described above.

 In December 2019, Burcon issued Convertible Debentures and raised gross proceeds of $9.5 million as described above.


- 16 -

 In February 2020, Burcon completed the 2020 Offering and raised gross proceeds of approximately $11.5 million as described above.

 In February 2020, Mr. Allan Yap exercised warrants to purchase 1,182,099 common shares of the Company for proceeds of approximately $532,000 as described above.

 During the fiscal year, certain officers, directors and an employee exercised options to purchase common shares of the Company for proceeds of $71,070.

The proceeds raised from the transactions described above have been used and will continue to be used to:

 further develop Burcon's protein extraction and purification technologies and pursue new related products;

 pursue and develop new applications from the functional attributes of Burcon's proteins;

 fund Burcon's patent activities;

 fund the activities associated with Burcon's obligations under the ADM License and Production Agreement for the commercialization of Burcon's CLARISOY® soy protein;

 supporting ADM in connection with its commercialization of CLARISOY® soy protein;

 fund the activities associated with identifying, negotiating terms and securing a strategic alliance for the commercialization of Burcon's Peazazz® pea protein;

 fund the activities associated with efforts relating to identifying a strategic partner for the commercialization of Burcon's canola proteins and other proteins;

 fund the design, engineering and construction of an initial semi-works facility for the commercial production of Peazazz® pea protein;

 repay the Loan and the Note and the accrued interest thereon;

 pay the accrued interest due under the Convertible Debentures;

 fund the investment by Burcon in Merit Foods and Burcon's obligations under the Shareholders' Agreement;


- 17 -

 fund the activities associated with Burcon's obligations under the Merit License and Production Agreement, for the commercialization of Burcon's pea and canola proteins; 

 fund the activities associated with Burcon's obligations under the joint development agreement with Nestlé; and

 provide general working capital.

Pea

 Pea protein is increasing in popularity as a plant-based protein ingredient which can be used in a wide variety of food products.  One of the reasons is that pea protein is able to deliver functionality and protein nutrition to products without the issues of allergenicity and genetic modification that may be present with other proteins.  Pea proteins currently available in the market are sold for use in a variety of food products including: meat alternatives; snacks and cereals; diet products (high protein foods); gluten-free and vegetarian and vegan foods as well as in nutritional supplements such as meal replacement shakes. 

In November 2011, Burcon announced that it had developed a novel pea protein which it has branded as "Peazazz®".  Peazazz® is 100% soluble and transparent in low pH solutions with clean flavour characteristics.  It is heat stable permitting hot fill applications.  See "Description of the Business".

On January 29, 2013, Burcon announced that it had commenced building a Peazazz® semi-works production facility to produce Peazazz® pea protein at small commercial scale in Winnipeg, Manitoba to provide market development quantities to customers for product and market development activities.   

On June 25, 2013, Burcon announced that it had completed, on schedule, the construction of its new semi-works plant in Winnipeg for Peazazz®.  The Peazazz® semi-works plant utilizes commercial-scale equipment capable of producing the tonnage amounts required by food and beverage makers looking to conduct full-scale, real world market evaluations of Peazazz® in their consumer products. 

In July 2013, Burcon officially launched Peazazz® pea protein at the 2013 IFT Expo.  Burcon demonstrated two products: Peach Mango Rhythm, made from 30% real juice, with all natural flavors and containing five grams of Peazazz® pea protein per 250ml serving and Vanilla Jazz, a neutral pH milk-style beverage with a faint hint of vanilla flavoring, fortified with vitamins and minerals and five grams of Peazazz® pea protein per 250ml serving. 

On August 23, 2013, Burcon announced that the startup and commissioning of the Peazazz® pea protein semi-works plant had been completed, allowing it to begin producing sample quantities for shipment to interested parties who had signed material transfer agreements ("MTAs") with Burcon.  While the semi-works plant utilizes commercial-scale equipment, it is only used to produce the amounts of Peazazz® needed for targeted market development activities with certain prospective customers.  By functioning as a model for potential manufacturing partners to emulate, the plant can also ultimately shorten their time-to-market.  Burcon has entered into a number of MTAs with parties interested in Peazazz®.  Such parties include major food and beverage makers, suppliers and potential industry production and sales partners. During fiscal 2014 to fiscal 2019, Burcon shipped samples of Peazazz® pea protein to various key potential multi-national production and/or distribution partners and undertook applications work in response to requests from certain potential commercialization partners.   


- 18 -

On May 23, 2019, Burcon announced that it had signed the Shareholders Agreement with the JV Partners to form Merit Foods.  The business of Merit Foods is the commercial production, sales, marketing and distribution worldwide of Burcon's pea protein, pulse protein and canola protein products.  Concurrently with the signing of the Shareholders' Agreement, Burcon and Burcon-MB entered into the Merit License and Production Agreement pursuant to which Burcon and Burcon-MB have granted an exclusive, royalty-bearing, worldwide license to Merit Foods to use and exploit Burcon's pea, pulse and canola protein technologies to make, have made, use and market and sell Burcon's pea, pulse and canola proteins. 

On October 21, 2019, Burcon announced that it had received a GRAS (Generally Recognized As Safe) no-objection letter from the US Food and Drug Administration ("FDA") for its Peazazz® and Peazac® pea proteins.  Burcon had successfully obtained self-affirmed GRAS status for its Peazazz® and Peazac® pea protein products and had made its submission to the FDA for GRAS notification on June 15, 2018.  This "Letter of No Objection" is issued by the US FDA, after an extensive review of all of the scientific data submitted by Burcon, to confirm that the FDA has no questions or concerns regarding the safety of Burcon's pea protein ingredients.  Receipt of GRAS notification is a significant commercial milestone and is important for the acceptance and use of these proteins by global food and beverage companies.

On January 24, 2020, Burcon announced that Burcon, Merit Foods and Nestlé have entered into a joint development agreement for the development and use of Burcon's novel protein ingredients, including pea and canola proteins, into Nestlé's food and beverage products.  Nestlé is the largest food company in the world and the agreement is designed to provide Nestlé with access to Burcon's unique expertise and a new range of high-quality plant-based protein ingredients.  This collaboration with Nestlé is intended to be a long-term relationship where Burcon tailors its novel protein ingredients, supplied through Merit Food's state-of-the-art protein production facility, for use by Nestlé in nutritious and good tasting plant-based meat and dairy alternatives.  Since January 2020, Burcon has been collaborating with Nestlé scientists and food developers to tailor Burcon's pea and canola proteins for product development.


- 19 -

On May 4, 2020, Burcon announced that its joint venture company, Merit Foods is expanding production capacity at its state-of-the-art protein production facility currently under construction in Winnipeg, Manitoba.  Merit Foods is building a 94,000 square foot production facility to produce high-quality pea and canola proteins.  The facility is expected to be completed in Q4 2020.  Merit Foods' product portfolio currently consists of three product family offerings: pea protein, non-GMO canola protein, and MeritPro™, a unique lineup of nutritionally complete protein blends. Its entire portfolio aligns with a number of consumer label preferences, including allergen-free, gluten-free, non-dairy, non-GMO, and vegan. 

Canola

Burcon's technologies allow it to extract and purify three types of canola proteins from canola meal, a co-product (together with canola oil) of the canola seed crushing industry.  Burcon has branded these canola proteins under the trade names "Puratein®", "Supertein®" and "Nutratein®".

The goal of Burcon's research is to develop its patented and patent-pending processes to utilize inexpensive oilseed meals, such as canola meal, for the production of purified plant proteins that exhibit nutritional, functional or nutraceutical profiles.  Burcon expects that Puratein® canola protein, Supertein® canola protein and Nutratein® canola protein will participate and compete with soy, dairy, and egg proteins in the expanding global protein ingredient market, with potential uses in meat substitutes, dairy alternative beverages, prepared foods, nutritional supplements and personal care products.   

On May 23, 2019, Burcon announced that it had signed the Shareholders Agreement and the Merit License and Production Agreement.  On January 24, 2020, Burcon, Merit Foods and Nestlé entered into a joint development agreement for the development and use of Burcon's novel protein ingredients, including pea and canola proteins, into Nestlé's food and beverage products.  See "Material Contracts".     

Pea Protein/Canola Protein Blends

 Burcon's pea protein products can be combined with Burcon's canola protein products to provide proprietary protein blend products with excellent functional attributes and added nutritional value.  On their own, the individual pea and canola protein are limited in their content of certain essential amino acids.  However, the amino acid profiles of the pea and canola protein products are complementary, that is, the canola proteins are rich in essential amino acids that are limited in the pea proteins and the pea proteins are rich in essential amino acids that are limiting in the canola protein.  The resulting blends, marketed as Nutratein® blend products, are proprietary plant protein products providing improved protein nutrition. 


- 20 -

 On May 23, 2019, Burcon announced the development of the pea protein and canola protein blends Nutratein-PS™ and Nutratein-TZ™.  These blended products have exceptional functional characteristics and nutritional value.  Nutratein-PS™ is a blend of Peazazz® pea protein and Supertein® canola protein, having clean flavour and high solubility, intended for use in products such as dairy alternative beverages.  Nutratein-TZ™ is a blend of Peazac® pea protein and Puratein® canola protein, having functional properties that make it ideally suited for use in plant-based meat analogue products such as veggie-burgers or veggie-sausages.  As part of the Merit License and Production Agreement, Merit Foods will be responsible for the production, marketing and sales of Burcon's pea, canola and its proprietary Nutratein® protein blends.

Soy

Soy protein isolate is used as a functional ingredient or fortifier in a wide variety of food products including protein shakes, power bars, soups and sauces, meats and meat analogs, and breads and baked goods.  In addition to enhancing the protein content of foods, soy protein isolates are used by food manufacturers for their functional applications.  These applications include the ability to emulsify, whip, bind and add viscosity to foods.  See "Description of the Business".

Burcon has developed technologies to extract and purify soy protein from a variety of soy materials.  These technologies encompass various processes to produce a soy protein which Burcon has branded as "CLARISOY®".  A number of different processes are used to produce CLARISOY soy protein specific for certain applications ranging from soluble and transparent beverages with a pH of 4.0 and below to neutral beverages with a pH of 7.0 or higher.  CLARISOY® is specifically designed to enable beverage manufacturers to meet the demand for great-tasting, nutritionally enhanced beverages targeted to the ever-growing number of health and wellness minded consumers.  Potential applications for CLARISOY® include: sports nutrition beverages, citrus-based drinks, fruit-flavoured beverages, lemonades, powdered beverage mixes and in numerous non-beverage applications such as foods and nutritional products. 

 On March 4, 2011, Burcon, Burcon-MB and ADM entered into the ADM License and Production Agreement for the worldwide, exclusive production, marketing and sale by ADM of soy protein products using Burcon's CLARISOY® soy protein technology.  See "Material Contracts". 

 On June 18, 2012, Burcon announced that ADM had constructed and was operating a commercial-scale production plant in Decatur, Illinois to produce CLARISOY® soy proteins.  ADM conducted the first commercial sale of CLARISOY® soy protein by December 2012.


- 21 -

 Since the initial launch of CLARISOY® in 2012, ADM launched further extensions of the CLARISOY® product line at the Institute of Food Technologists Annual Meeting and Food Expo ("IFT Expo").  In addition, ADM showcased unique prototype products such as protein smoothies, non-dairy Greek yogurt, cold-brewed coffee and coffee creamer, where CLARISOY soy protein was either used as the sole protein source or the primary protein source in the product.

 These applications demonstrate how CLARISOY® is well-suited for adding protein, nutrition and functionality to everyday products, and how it excels particularly in beverage applications due to its clean favor and smooth mouthfeel.  These applications can help meet consumer demand for good-tasting, convenient products featuring plant-based protein and also provide solutions for customers looking to replace dairy protein for products that appeal to consumers who choose a vegan or other healthy lifestyles.  ADM's focus on dairy replacement using CLARISOY® not only provides a price-stable and sustainable ingredient for food and beverage manufacturers, but also addresses the large consumer base that is lactose intolerant or sensitive to dairy products.

 ADM has also launched an energy drink suitable for vegans made with CLARISOY®.  This product is available in the United States and European markets.

 ADM continues to market CLARISOY® as a versatile soy protein ingredient well-suited to boosting the nutritional and functional profile of many different products.  CLARISOY®, having clean flavor and high solubility, is exceptional in beverage products including ready-to-drink beverages.  Customers that are looking for plant-based protein ingredients to formulate vegan or non-dairy products will find CLARISOY® to be an attractive protein source.  Not only is CLARISOY® suitable for high protein fortification products such as meal replacements and sport nutrition smoothies but is also suitable for casual wellness products that require a bit of protein boost.

 On December 17, 2015, Burcon announced that it expected ADM's first full-scale commercial CLARISOY® production facility to be operational by mid-2016.  On November 8, 2016, Burcon announced that ADM had successfully commissioned the first full-scale CLARISOY® production facility.

 Since March 2013 to the date of this AIF, Burcon has been granted seventeen U.S. patents covering its soy protein composition and extraction and purification processes. 

Specialty Proteins and Phytochemical Extractions

 Burcon's extraction and purification technologies can also be used to produce specialty proteins such as flax and hemp proteins.  Burcon's core extraction and purification technology is versatile and can be adapted to process a range of oilseed and non-oilseed meals to produce high-value protein products for use in the food and beverage industries.


- 22 -

 The demand for plant proteins in the protein market continues to grow and as such, Burcon believes that there may be niche market opportunities for its specialty protein ingredients.  Burcon plans to explore these opportunities in the near future.

 In February 2018, Burcon applied for accreditation from Health Canada's Office of Controlled Substances to conduct research for the future commercial production of purified cannabinoid extracts.  Burcon received its research license from Health Canada on July 17, 2019.  Given its focus on other business initiatives, Burcon does not plan to conduct research in cannabinoid extracts in the coming fiscal year. 

DESCRIPTION OF THE BUSINESS

The protein ingredient industry continues to experience rapid growth, with plant proteins in particular experiencing high demand. This increase in demand for plant proteins is fuelled in part by scientific advances, changing demographics, consumer awareness of livestock's environmental impact, consumer concerns regarding animal welfare, and recent public sentiments in light of the COVID-19 pandemic, as well as by the public's changing perception of the safety of animal-based products.  External issues such as melamine tampering/contamination, mad cow disease, E. coli, swine flu, avian flu and the growing use of antibiotics in animal production, as well as demographic trends are all combining to produce significant demand for plant proteins.

Two major attributes are relevant to the commercial value of protein as an ingredient: functional value and nutritional value.

             Functional Value

Proteins possess a wide range of attributes essential to the structure and textural integrity of food products. These relevant properties include: solubility, viscosity, water-binding, gelation, cohesion, adhesion, elasticity, emulsification, foaming, whipping, fat-binding, film forming and flavour-enhancing qualities.

In weighing the commercial potential of any protein ingredient, functional utility is at least as important as nutritional value.  For example, although the nutritional value of wheat protein is comparatively low, (the Protein Digestibility Corrected Amino Acid Score ("PDCAAS") of whole wheat is 0.40, only wheat protein-called gluten-will make a traditional loaf of bread.  Thus, the functionality of wheat protein makes it a staple in the North American diet.  At the top end of the functional scale, egg white protein will whip, coagulate, and form films.  Such functional versatility makes egg white one of the most valuable food proteins.  Certain of Burcon's proteins can be made to mimic many of egg's functions, and in certain instances can outperform egg. 


- 23 -

             Nutritional Value

Proteins are organic compounds made up of carbon, hydrogen, oxygen and nitrogen. It is the presence of the nitrogen that sets proteins apart from other nutrients.  Nitrogen is essential to human life, but since we have no other source of nitrogen-unlike plants, we are unable to absorb it as a nutrient from the ground-one of the most important roles of dietary protein is to bring nitrogen into the body.

Proteins are made up of sub-units called amino acids. There are twenty dietary amino acids, typically subdivided into two categories: non-essential amino acids, which can be made within the body, and essential amino acids which must come from diet.

Amino acids supplied from dietary protein are needed for synthesis of body proteins in muscle, organs, bone and skin, and for synthesis of enzymes, certain hormones, antibodies and a host of bodily processes.

The essential amino acids are lysine, methionine + cysteine, threonine, tryptophan, leucine, isoleucine, valine, phenylalanine, arginine and histidine (adults do not require a dietary supply of arginine).

A diet deficient in one or more of the essential amino acids impairs growth in children, causes adults to lose muscle mass, and lowers the body's resistance to a variety of diseases. Extreme protein deficiency can be a cause of death. An adequate daily supply of high-quality protein is essential to optimal growth and health.

The nutritional supplements industry has seen rapid growth in the use of protein ingredients over the past ten years. Protein bars, once consumed only by endurance athletes, are now widely available and protein-rich meal-replacement products and dietary supplements have become supermarket staples and are sold in large quantities through all the major multi-level marketing companies. Protein supplements are also increasingly and successfully being promoted to the expanding market of geriatric consumers. Potential nutritional applications for protein isolates include power shakes, protein bars, protein powders and any other concentrated protein supplement.

Pea

Field pea, or Pisum sativum in Latin, is part of the legume family and was one of the earliest cultivated food crops.  A pea is most commonly the green or yellow small spherical seed inside a peapod that contains multiple peas.  The pea plant is grown in cool-weather conditions in many parts of the world, including Canada, Europe and temperate regions of Asia.


- 24 -

Peas are consumed as a vegetable worldwide for their high nutritional value and health benefits, being high in protein, fibre, starch, vitamins and minerals.  Peas are also not considered a major allergen. As part of the legume family, pea plants have the ability to lock in nitrogen from the atmosphere and store it in their root nodules. This nitrogen-fixation ability allows producers to use less fertilizer and replenish the soil with nitrogen, making peas a much desired sustainable crop.

In November 2011, Burcon announced that it had developed a novel pea protein which it has branded as "Peazazz®", its first technology platform to extract added-value proteins from a non-oilseed source. Burcon's technology extracts and purifies a novel pea protein from field peas. Both the nutritional and functional characteristics of pea protein allow for a host of great tasting food and beverage product applications as well as for use in nutritional supplements.

Pea protein is increasing in popularity as a plant-based protein ingredient which can be used in a wide variety of food products.  One of the reasons is that pea protein is able to deliver functionality and protein nutrition to products without the issues of allergenicity and genetic modification that may be present with other proteins.  Pea proteins currently available in the market are sold for use in a variety of food products including: snacks and cereals; diet products (high protein foods); gluten-free and vegetarian and vegan foods as well as in nutritional supplements such as meal replacement shakes.

 Peazazz®

Peazazz® pea protein is uniquely soluble and clean-tasting pea protein that is suitable for dairy alternative food and beverages.  Peazazz® has clean flavour characteristics and is well suited for use in low and neutral pH beverages as well as a variety of other healthy and great tasting food and beverage product applications.  Its valuable nutritional and functional characteristics make Peazazz® an attractive product to companies looking for an alternative plant protein ingredient.

Pea is a widely accepted and consumed vegetable, recognized for its nutritional value and health benefits.  Burcon has successfully extracted added-value proteins that contain essential amino acids into a white powder that can easily be incorporated into a variety of foods and beverages including dairy alternative products, dry-blended beverages, ready-to-drink beverages, protein bars and crisps, weight management and meal replacement products, and vegetarian and vegan foods. 


- 25 -

Burcon's Peazazz® pea protein can be produced from a non-GMO source and pea protein is not considered a major allergen.  Consumers are increasingly looking for clean-label and "free-from" products.  Burcon's Peazazz® pea protein is dairy-free, soy-free, gluten-free, allergen and GMO-free and does not require allergen labelling. 

Pea proteins currently available on the market are sold for use in a variety of food products including: snacks and cereals; high-protein weight management products; gluten-free and vegetarian and vegan foods.  Burcon is not aware of any pea protein isolate in the market that is clean-tasting with superior solubility like Peazazz®.  Burcon expects the introduction of Peazazz® pea protein to be able to gain a share of the pea protein market, as well as expand the pea protein market to include (what it previously could not) a broader range of product applications such as low pH beverages.

On January 29, 2013, Burcon announced that it had commenced building a Peazazz® semi-works production facility to produce Peazazz® pea protein at small commercial scale in Winnipeg, Manitoba to provide market development quantities to customers for product and market development activities. 

On June 25, 2013, Burcon announced that it had completed, on schedule, the construction of its new semi-works plant in Winnipeg for Peazazz®.  The Peazazz® semi-works plant utilizes commercial-scale equipment capable of producing the tonnage amounts required by food and beverage makers looking to conduct full-scale, real world market evaluations of Peazazz® in their consumer products.  The plant also supports Burcon's ongoing discussions with companies who are potential partners with Burcon for the production and marketing of Peazazz®.

In July 2013, Burcon officially launched Peazazz® pea protein at the 2013 IFT Expo.  Burcon demonstrated two products: Peach Mango Rhythm, made from 30% real juice, with all natural flavors and containing five grams of Peazazz® pea protein per 250ml serving and Vanilla Jazz, a neutral pH milk-style beverage with a faint hint of vanilla flavoring, fortified with vitamins and minerals and five grams of Peazazz® pea protein per 250ml serving. 

On August 23, 2013, Burcon announced that the start-up and commissioning of the Peazazz® pea protein semi-works plant had been completed, allowing it to begin producing sample quantities for shipment to interested parties who had signed MTAs with Burcon.  While the semi-works plant utilizes commercial-scale equipment, it has only been used to produce the amounts of Peazazz® needed for targeted market development activities with certain prospective customers.  By functioning as a model for potential manufacturing partners to emulate, the plant can also ultimately shorten their time-to-market.


- 26 -

Burcon has entered into a number of MTAs with parties interested in Peazazz®.  Such parties include major food and beverage makers, suppliers and potential industry production and sales partners. During fiscal 2014 to fiscal 2019, Burcon shipped samples of Peazazz® pea protein to various key potential multi-national production and/or distribution partners and undertook applications work in response to requests from certain potential commercialization partners.  On May 23, 2019, Burcon announced that it had signed the Shareholders Agreement and the Merit License and Production Agreement.  See "General Development of the Business".

 Peazac®

Peazac® pea protein is a co-product of the production of Peazazz® pea protein.  Extracted pea proteins are fractionated under conditions that give rise to two product streams, which are separately further processed to provide Peazazz® and Peazac®.  The properties of Peazac® differ from those of Peazazz®, including a lower protein content in Peazac®.  Recommended food applications for Peazac® include plant based meat analogue products, bar products, baked goods, vegan and vegetarian foods and gluten free foods.  Like Peazazz® pea protein, Peazac® pea protein is dairy-free, soy-free, gluten-free, GMO-free and does not require allergen labelling. 

 Pea Protein Production

Current production of pea protein products in the market involve the use of either a dry fractionation process or a combination of both dry and aqueous fractionation processes.  Mechanical separation from a dry fractionation process is used to produce pea protein flours and concentrates, which contain a lower protein content.  An aqueous fractionation process is used to produce pea protein isolates with higher protein content ideal for use in human food and beverage applications.  Current methods of production often result in a pea protein that retains its vegetable off-flavour, insoluble in solution and imparts undesirable color and aroma into food applications. Burcon has developed and filed applications to obtain patent protection for novel processes allowing for the production of uniquely soluble pea proteins with clean flavour characteristics suitable for various food and beverage applications.

Pursuant to the terms of the Merit License and Production Agreement (see "Material Contracts"), Burcon has licensed its Peazazz® pea protein and its canola protein technologies to Merit Foods, on an exclusive basis, to use, market and sell the products that use the pea and canola technologies.  Under the Merit Licence and Production Agreement, Merit Foods is the primary party responsible for the commercialization efforts for Burcon's pea and canola protein products, including:


- 27 -

 During the term of the license under the Merit License and Production Agreement, Burcon will continue to refine its protein extraction and purification technologies for pea and canola proteins in its Winnipeg Technical Centre. 

 On May 4, 2020, Burcon announced that Merit Foods is expanding production capacity at its state-of-the-art protein production facility currently under construction in Winnipeg, Manitoba.  Merit Foods is building a 94,000 square foot production facility to produce high-quality pea and canola proteins.  The facility is expected to be completed in Q4 2020. 

Canola

Canola is the North American name for the enhanced variation of rapeseed first developed and introduced in 1974 when a Canadian researcher bred a "double low" variety of rapeseed with reduced levels of the two negative elements naturally occurring in rapeseed: erucic acid and glucosinolates.  This type of rapeseed is known in Europe and parts of Asia as rapeseed or oilseed rape and has become the world's second largest oilseed crop. The growth of rapeseed as an international crop can be attributed to three factors: the ability to grow rapeseed in temperate climates; favourable production costs; and a beneficial fatty acid profile for the oil, which is high in monounsaturates.

Each canola plant produces yellow flowers which produce pods that are similar in shape to pea pods and about 1/5th the size.  Within the pods are tiny round seeds that are crushed to obtain canola oil.  After the oil is removed through processing at a canola crushing plant, the remainder of the seed (approximately 60% by weight) is canola meal.  Canola meal is the raw material from which Burcon intends to extract protein commercially to produce Puratein® canola protein, Supertein® canola protein and Nutratein® canola protein.  Canola meal is comprised of approximately 35% protein.  Canola meal is in abundant and relatively inexpensive supply and is sold almost exclusively as an animal feed ingredient; however, its protein value, even in feed applications, is limited by the presence of a large amount of fiber and other anti-nutritional factors naturally present in canola seed.  Burcon's extraction process separates the protein from the fiber and from most of the naturally occurring anti-nutritional factors.

In the past, numerous attempts have been made at finding an economically viable method to extract canola protein from canola meal.  There is a significant amount of scientific publications describing various methods to do so, most of which publications also underscore numerous reasons for the scientific interest in obtaining canola protein isolate, including, amongst others: a unique amino acid profile, rich in sulfur containing amino acids; an abundant source of protein; and two distinct protein fractions.  However, none of the existing technologies described in the scientific literature is commercially applied at present. Major drawbacks of the existing technologies, which often use alkaline extraction followed by isoelectric precipitation, include the insufficient purity of the canola protein isolate, unacceptable colour and taste of the canola protein products as well as the resulting protein's limitations regarding functionality.  Phenolics that are naturally present in canola oxidize readily in alkaline conditions causing dark coloration of the final protein product. 


- 28 -

Burcon's canola protein extraction process does not use harsh chemicals but rather is based primarily on making use of physical separation and purification techniques. At the core of Burcon's canola protein production process is a micelle formation step, which separates the two naturally occurring proteins in canola: napin and cruciferin.  Processing of these two fractions results in the cruciferin-rich canola protein isolate Puratein® canola protein and the napin-rich canola protein isolate Supertein® canola protein.  Burcon has also developed Nutratein® canola protein, which consists of a blend of the two fractions.

 Canola Protein

Potential nutritional applications for canola proteins include power shakes, protein bars, protein powders and any other concentrated protein supplement.

Based on the recommendations of the Joint Expert Consultation of the Food and Agricultural Organization ("FAO") and World Health Organization ("WHO") in 1989, the FDA and the FAO/WHO adopted in 1993 the PDCAAS as the preferred method for measuring the quality of a protein based on the amino acid requirements of humans.  The PDCAAS method for evaluating protein quality is based on the needs of humans.  The quality of a protein is based on the amino acid requirements of a 2 to 5 year old child, which is considered to be the most nutritionally demanding age group, other than infants.  After adjusting for digestibility, the protein quality rankings of a specific protein evaluated under the PDCAAS method are compared to a standard amino acid profile with the highest possible score being a 1.0.  A PDCAAS score of 1.0 means that, after digestion of the protein, it provides 100% or more of all the essential amino acids required.  Proteins with a PDCAAS of 1.0 include egg and cow's milk.

The PDCAAS scoring system has since been updated by the FAO/WHO/United Nations University ("UNU") in 2002, altering the reference amount of specific amino acids and also dividing the requirement by age groups of children 1-2 years and 3-10 years.  In the Report of a Joint FAO/WHO expert consultation on protein and amino acid requirements in human nutrition, the FAO/WHO/UNU came to the conclusion that previous reports considerably overestimated the protein requirements.  Despite the foregoing, the FDA has neither formally adopted the updated levels recommended in the 2002 report nor advised food companies to use these updated levels when calculating PDCAAS values.


- 29 -

Based on the PDCAAS method, the PDCAAS scores for Burcon's canola proteins are as follows:

Canola Protein

FAO/WHO 1989

mg/g protein

(2-5 years old)

FAO/WHO/UNU 2002

mg/g protein

(3-10 years old)

Puratein®

0.60

0.72

Supertein®

0.71

0.91

Nutratein®

0.90

1.00

Burcon's canola protein has a score in the range of 0.60 to 0.90 under the 1989 FAO/WHO pattern and a score in the range of 0.72 - 1.00 under the 2002 FAO/WHO/UNU pattern, suggesting that Burcon's canola protein is a good quality protein source. 

 Puratein® Canola Protein

Puratein® canola protein's key functionalities are emulsifying, gelling and binding.  Puratein® canola protein has potential in a wide variety of food types.

Puratein® canola protein is a canola protein isolate comprised mainly of globulin proteins. The functional properties of Puratein® canola protein include emulsification, gel formation, thickening, formation of heat-stable foams, and water- and ingredient-binding. Applications for Puratein® canola protein include dressings and sauces, meat substitutes, baked goods and protein bars.  Puratein® canola protein has good taste characteristics with no off-flavours.

 Supertein® Canola Protein

Supertein® canola protein is a highly soluble canola protein isolate comprised principally of albumin proteins. The functional properties of Supertein® canola protein include solubility, the ability to form transparent solutions, foaming and nutrition. Applications for Supertein® canola protein include beverages, confectionery, aerated desserts, and protein bars, among many others.  Supertein® canola protein has a slightly sweet taste with no off-flavours.

The exceptional cysteine content of canola protein (rapeseed protein) has long been of interest to nutritional scientists.  A potential link between canola protein's high cysteine content and disease prevention has been reported in a study in the British Journal of Nutrition entitled "Rapeseed protein inhibits the initiation of insulin resistance by a high-saturated fat, high-sucrose diet in rats" by Mariotti F., Hermier D., Sarrat C., Magné J., Fénart E., Evrard J., et al 2008 Nov; 100(5):984-91.  The study's aim was to determine whether rapeseed protein, described by the study's authors as "an emergent cysteine-rich protein" could inhibit the onset of the metabolic syndrome.  The main finding of the study "is that rapeseed protein substituted for milk protein inhibited the onset of insulin resistance in rats fed the high-saturated fat, high-sucrose diet".  The authors further noted that rapeseed protein mitigated certain factors associated with metabolic syndrome: "The study's result highlights the importance of the type of protein as a major component of diet quality, in terms of cardiovascular and diabetic risks."Supertein® canola protein is rich in sulfur-containing amino acids and particularly rich in cysteine.  The typical cysteine content of Burcon's Supertein® canola protein is nearly double that of whey protein, which is recognized for its high cysteine content. The findings in the study reported in the British Journal of Nutrition suggest that Supertein® may have potential applications in the prevention of metabolic syndrome.


- 30 -

Nutratein® Canola Protein

Nutratein® canola protein is comprised of a mixture of globulin and albumin proteins.  Nutratein® canola protein is a fine powder that has good solubility across a broad pH range.  Nutratein® canola protein has an excellent amino acid profile and its PDCAAS score makes it an excellent choice for use in nutritional supplements, meal replacement products, protein bars, plant-based meat-analogue products, high protein foods, baked goods and beverages.  Nutratein® canola protein is bland in taste with no off-flavours.

Pea Protein/Canola Protein Blends

 Burcon has developed proprietary blends of its pea protein products and canola protein products for applications where improved protein nutritional value is desired compared to the use of pea proteins alone or canola proteins alone.  In addition to their nutritional value, these blend products, marketed as Nutratein® blend products, have excellent functional attributes.  The blends are proprietary plant protein products providing improved protein nutrition that may be used as a convenient alternative to both high protein nutrition animal protein products and soy protein products.

 On May 23, 2019, Burcon announced the development of the pea protein and canola protein blends Nutratein-PS™ and Nutratein-TZ™.  These blended products have exceptional functional characteristics and nutritional value.  Nutratein-PS™ is a blend of Peazazz® pea protein and Supertein® canola protein, having clean flavour and high solubility, intended for use in products such as dairy alternative beverages.  Nutratein-TZ™ is a blend of Peazac® pea protein and Puratein® canola protein, having functional properties that make it ideally suited for use in plant-based meat analogue products such as veggie-burgers or veggie-sausages.


- 31 -

Soy

According to the Soyfoods Association of North America, the soybean was introduced to North America around the 1760s.  Today, soybeans are the largest oilseed crop in the world with Brazil being the largest producer of this crop, followed by the United States, Argentina and China. Soybeans are similar in size and colour to peas and are primarily cultivated for their oil and protein. Soybeans are the largest single source of edible oil and accounted for approximately 59%* of the world's total oilseed production in 2019. In addition to being a source of oil and protein, soybean meal is used in animal feed for the production of meat and eggs.  Soy flour is used in the commercial baking industry while soy hulls are processed to make breads, cereal and snacks. 

Each soybean is comprised of approximately 40% protein, 35% carbohydrate (including fiber), 20% oil, and 5% ash. 

 Soy Protein

Commercially sold soy protein is available in predominantly three forms: soy flour, soy concentrates and soy protein isolates.  After cracking and dehulling the soybean, soy processors roll them into flakes.  Oil from the soybean flakes is removed and then the flakes are dried.  The defatted flakes are then further processed into soy protein.

Soy protein isolate is the purest of the three forms of soy protein and contains over 90% protein, on a moisture free basis.  Soy protein isolates are relatively neutral in flavour and odour and are used primarily by the food industry.  Today, soy protein isolate is used in a variety of food applications, including as a protein replacement for dairy proteins in food or in products such as protein shakes, power bars, soups and sauces, meat analogs, breads and baked goods.  Soy protein isolates are desired by food manufacturers for their functional applications.  These applications include the ability to emulsify, whip, bind and add viscosity to foods. 

In addition to its functional attributes, soy protein isolate provides nutritional enhancement to foods.  Soy protein contains all the essential amino acids required for human nutrition.

Numerous studies have been conducted on the health benefits of soy protein.  In October 1999, the FDA approved a health claim for soy protein and its role in reducing the risk of coronary heart disease.  In March 2015, after a meta-analysis of scientific studies, Health Canada's Food Directorate concluded that scientific evidence exists to support a health claim about soy protein and blood cholesterol lowering. The evidence supports a direction of effect towards a reduction in total and LDL cholesterol levels when soy protein is consumed.


* Source: www.soystats.com


- 32 -

The quest for healthier lifestyles has led consumers to search for healthier alternatives to animal protein.  The FDA's and Health Canada's approval of a health claim for soy protein has fuelled soy protein's increasing popularity and general acceptance among consumers.  These factors, along with the desire by consumers for food producers to find eco-friendly ways to produce food for humans, are expected to sustain market demand for soy protein isolates.  Burcon intends to participate in this growing market through its CLARISOY® soy protein.

 CLARISOY®

In November 2008, Burcon announced that it had developed a soy protein which it branded as CLARISOY®. Burcon has developed technologies to extract and purify soy protein from a variety of soy materials.  These technologies encompass various processes to produce CLARISOY® soy protein.  A number of different processes are used to produce CLARISOY soy protein specific for certain applications ranging from soluble and transparent beverages with a pH of 4.0 and below to neutral beverages with a pH of 7.0 or higher.  CLARISOY® is specifically designed to enable beverage manufacturers to meet the demand for great-tasting, nutritionally enhanced beverages targeted to the ever-growing number of health and wellness minded consumers. 

ADM is currently marketing CLARISOY® as an economical, high-quality plant-based dairy alternative that provides greater cost stability and comparable nutrition.  Food and beverage manufacturers who are looking to manage cost and product margins should be able to rely on CLARISOY® soy protein as a reliable source of plant-based protein with uncompromising taste, nutrition and performance.  CLARISOY® soy protein is expected to be an ideal protein ingredient to replace or partially replace dairy protein in food, drinks and snacks without affecting taste.    Potential applications for CLARISOY® include: sports nutrition beverages, dairy alternative yogurts and cheeses, powdered beverage mixes, coffee creamers and in numerous other foods and nutritional products. 

Based on the PDCAAS method, Burcon's CLARISOY® soy protein has a score of 0.98 and 1.00 under the 1989 FAO/WHO pattern and the 2002 FAO/WHO/UNU pattern, respectively, suggesting that Burcon's CLARISOY® soy protein is a good quality protein source.   


- 33 -

 Soy Protein Production

Pursuant to the terms of the ADM License and Production Agreement (see "Material Contracts"), Burcon has licensed its CLARISOY® soy protein technology to ADM, on an exclusive basis, to use, market and sell the products (the "Soy Products") that use the CLARISOY® technology. 

During the term of the license under the ADM License and Production Agreement, Burcon will continue to refine its protein extraction and purification technology for soy protein in its Winnipeg Technical Centre. 

   On March 6, 2014, Burcon announced that it received written notice from ADM that ADM intends to expand to full-commercial scale production of CLARISOY® soy protein pursuant to the License and Production Agreement ("Full Commercial Production").    On November 8, 2016, Burcon announced that ADM had successfully commissioned the first full-scale CLARISOY® production facility.

Research and Development

Burcon has designed and built a semi-works production facility, complete with an analytical laboratory, for the development and production of proteins from various plant sources.  On January 29, 2013, Burcon announced that it had commenced building a Peazazz® semi-works production facility to produce Peazazz® pea protein at commercial scale in Winnipeg, Manitoba.    On June 25, 2013, Burcon announced that it had completed, on schedule, the construction of its new semi-works plant in Winnipeg for Peazazz®.  The Peazazz® semi-works plant utilizes commercial-scale equipment and is capable of producing the tonnage amounts required by food and beverage makers looking to conduct full-scale market evaluations of Peazazz® in their consumer products.  Start-up and commissioning of the plant was completed in August 2013.  During fiscal 2020, the semi-works plant continued to produce samples to support the commercialization of Burcon's pea and canola proteins by Merit Foods, as well as conduct work required to support Burcon's joint development agreement with Nestlé and Burcon's intellectual property portfolio.

Burcon has over 20 years of experience in developing high-quality vegetable protein ingredients and has successfully developed CLARISOY® soy protein and is developing Peazazz® and Peazac® pea proteins, three unique canola proteins, Supertein®, Puratein® and Nutratein® canola proteins and other specialty proteins such as flax and hemp.  After years of research on developing these products and the associated extraction technologies and in running large-scale pilot operations to a standard that meets Burcon's expectations of commercial quality, Burcon has amassed significant experience and know-how. 


- 34 -

Objectives

For fiscal 2021, Burcon's main objective will be to support Merit Foods to complete the construction of and then to commission and operate Merit Foods' state-of-the-art pea and canola protein production facility currently under construction in Winnipeg, while also supporting Merit Foods in market development activities for its protein products.

Burcon's activities will include:

 working with Merit Foods and Merit Foods' third-party suppliers to construct and commission phase one of Merit Foods' production facility, where Merit Foods will produce Burcon's pea and canola proteins;

 continuing to operate the semi-works facility to produce sample protein products to support the business of Merit Foods, including supplying food and beverage makers with commercial quantities sufficient for product development, consumer trials and in some cases, regional product launches;

 conducting further research to develop additional applications for Peazazz® and Peazac® pea protein Supertein®, Puratein® and Nutratein® canola proteins and blends into food products;

 continuing to file patent applications to protect the Peazazz® pea protein extraction process as well as the composition of Peazazz® pea protein and applications for Peazazz® pea protein into food products; and

 support Merit Foods in pursuing regulatory approval of Burcon's Supertein®, Puratein® and Nutratein® canola proteins in Canada and Europe.

In addition, Burcon will also:

 expand the production capacity of the semi-works facility to produce sample products in sufficient amounts for major food and beverage companies to conduct product development trials and limited product launches;

 implement a food safety program at its semi-works facility that meets or exceeds the safety requirements for food ingredients of major food and beverage companies;

 continue to refine its protein extraction and purification technologies, develop new technologies and related products;


- 35 -

 further strengthen and expand its core intellectual property portfolio;

 explore opportunities for acquiring or licensing into Burcon, novel technologies that will complement or enhance Burcon's intellectual property portfolio and business initiatives;

 pursue product development agreements with major food, beverage and nutritional product companies to develop improved or novel applications for Burcon's other specialty proteins into their products; and

 pursue activities to support the expansion of Burcon's investor base, particularly from the US investment community, by raising awareness about Burcon through various media channels, analyst coverage and investor relations.

Marketing Strategies

Burcon's Peazazz® and Peazac® pea proteins, Puratein®, Supertein® and Nutratein® canola proteins, Nutratein® pea protein/canola protein blend products and CLARISOY® soy protein are expected to compete with soy, whey, milk and egg proteins in the expanding global multi-billion dollar protein ingredient market.  Burcon's proteins are expected to specifically compete with whey protein isolates, casein/caseinates and dried egg-white as well as with existing traditional soy and pea proteins. 

Food Business News reported the following average prices for the major protein ingredients that Burcon expects its products to compete with: 

Whey protein isolate US $5.10 /pound1 CDN $15.75 /kg. 2
Casein/caseinates  US $3.95 /pound3  CDN $12.20 /kg. 2
Dried Egg-white US $4.95 /pound3 CDN $15.29 /kg. 2

Soy and pea protein prices are not readily available to the public.  However, through discussions with industry participants and market data research, Burcon management estimates that soy protein isolate and pea protein isolate prices are approximately as follows:

Soy protein isolate US $3.50 /pound CDN $10.81 /kg.2
Pea protein isolate US $4.20 /pound CDN $12.97 /kg. 2

Notes:

1. Price based on last available listing in Food Business News (November 22, 2011 edition).  There is no current available price listing for whey protein isolate (90% edible).


- 36 -

2. Conversion into Canadian dollars made by Burcon, based on Bank of Canada exchange rate of C$1.00 = US$0.7135 on May 22, 2020.

3. Prices based on the May 12, 2020 edition of Food Business News for the week ending May 8, 2020. 

Burcon expects Merit Foods to develop the sales and marketing strategies for Peazazz® and Peazac® pea proteins, Puratein®, Supertein® and Nutratein® canola proteins and Nutratein® pea protein/canola protein blend products.    Burcon expects the average selling price of Peazazz® pea protein to achieve an average price level that would equate to a premium over current pea pricing and at a discount to some animal-based proteins.  Burcon expects the cost to produce Peazazz® pea protein to be materially consistent with the cost to produce traditional pea protein isolates. 

Pursuant to the ADM License and Production Agreement, ADM has the sole discretion in developing the sales and marketing strategies for CLARISOY® soy protein. Given ADM's extensive experience in the sale and marketing of soy protein products, Burcon expects that CLARISOY® will be strategically priced amongst ADM's current product portfolio and other competing protein products in the global market.

Plant Protein

According to Markets and Markets, the overall plant protein ingredients market accounted for US$18.5 billion in 2019 and is expanding at a CAGR of 14% to reach a value of $40.6 billion by 2025. Protein is a macro-ingredient that has gained a strong consumer acceptance in food and beverage products.  Rising consumer demand for healthy and nutritious product offerings in addition to the increase in purchasing power are driving the growth of the protein ingredient market. 

Plant-based protein ingredients include soy, pea, rice, wheat, canola, flax, safflower, hemp and potato.  Soy protein continues to dominate the plant-based protein ingredients market.  However, Global Market Insights estimates that the pea protein ingredients market may see the highest gains in the coming years, with pea protein isolate registering a rate of 13% CAGR through 2026.

Plant proteins continue to experience significant sales growth in North America and Western Europe for a variety of reasons. Changing demographics is one reason for this trend as nutrition-conscious baby boomers become aware of the health benefits of protein in general and, more specifically, of the benefit of plant proteins over certain animal proteins. Food manufacturers in turn are motivated by simple economics to prefer inexpensive plant proteins over their more costly animal counterparts.

Health concerns caused by African swine flu, E. coli, Asian bird flu, mad cow disease and most recently, COVID-19 have provoked consumer concern that animal-based protein products may be unsafe. Consumers have begun to question the role of livestock agriculture in the spread of animal and human pandemics.  Moreover, as a result of African swine flu as well as supply chain issues directly resulting from COVID-19, the world is currently experiencing meat shortages, which has led to higher prices on many animal protein products.  Consumers faced with animal protein shortages may begin to explore plant-based protein options such as meat substitutes.  This shift in consumption behaviour could be significant and lasting well beyond the pandemic.  As a result, COVID-19 appears to be providing an unexpected boost to plant-based protein consumption.


- 37 -

Near-vegetarians, also called flexitarians, a growing group of consumers who choose meatless meals regularly but not exclusively, are also contributing to the trend favoring plant proteins. Responding to this new demographic, food manufacturers are taking advantage of the functional merits of plant proteins to create meat-free, high-protein foods.

While the demand for plant proteins is being driven by the health and wellness trend in the developed world, a possibly even larger force shaping the global protein ingredient industry is the growth of the middle-class consumer in the developing world.  During the past number of years, there has been a marked increase in demand for, and the price of, all protein ingredients.  The growth of the middle class in the BRIC countries (Brazil, Russia, India and China) has been noted by many observers as being the key factor in that demand increase. As consumers evolve from a subsistence living to earning incomes where - in their respective countries - they can be classified as middle class, they invariably spend a large portion of their new income on food. 

Casein and whey, the two major dairy protein ingredients, have experienced a decline in price in recent years due to surplus in the global supply.  This, in turn, has pressured major soy protein producers, led by Solae LLC, now DuPont, to lower the price of their soy proteins in order to compete with the dairy protein ingredient suppliers.  Dairy prices have since stabilized and the market is beginning to see an uptrend in prices as stronger global demand meets the supply surplus.

Wellness consumers are not only looking for products using plant-based ingredients but are also becoming more aware of the "what's in" and "what's not" trends in their food and beverage products.  The "free-from" trend is an extension of the health and wellness trend, where consumers are seeking out products which use ingredients that are, for example, free from major allergens, artificial flavours, genetically modified organisms (GMO) or pesticides and herbicides.  There are an increasing number of product launches with claims such as "dairy-free", "soy-free" and "gluten-free".  More often than not, consumers are now checking the nutrition label and ingredients list on a product before making a decision to buy it.


- 38 -

In addition to the health and wellness trend in the developed world and the expanding middle class in the developing world, plant proteins are gaining popularity from the recognition that they offer a more environmentally friendly alternative to animal derived proteins.  Consumers are considering the environmental footprint a product makes when making their purchase decisions.  Production of animal proteins is viewed as less "environmentally economic" when compared to the production of plant proteins.  Producers must feed plant protein to animals in order to produce animal proteins and animals are not efficient converters, pound for pound, of the proteins they consume.  There is also a growing awareness of the large amount of greenhouse gases generated globally through livestock production.  As a result of these factors, consumers are looking to food manufacturers to find more eco-friendly ways to produce food for humans. 

 Pea Protein

Rising consumer demand for non-GMO and non-allergenic plant-based proteins has put pea protein into the spotlight in recent years.  Pea protein is versatile and contains an excellent amino acid profile making it an ideal protein source for many product applications, including dairy alternative and meat substitute applications.  The global pea protein market is expected to reach US$1.4 billion by 2025, growing at a CAGR of 12.3%.

The following chart illustrates the annual global production of dried peas (in tonnes) from 2012 to 2018 as estimated by the FAO:

 

2012

2013

2014

2015

2016

2017

2018

Canada

3,340,800

3,960,800

3,810,100

3,200,700

4,835,900

4,112,200

3,580,700

United States

499,042

708,510

778,140

829,303

1,259,260

643,880

722,530

Western Europe

733,239

663,378

731,859

991,073

886,043

1,126,217

851,480

Asia

2,206,273

2,315,935

2,478,859

2,375,862

2,368,803

2,852,081

2,775,276

World

10,563,679

11,236,845

11,650,440

11,875,021

14,927,396

16,179,523

13,534,166

All figures in tonnes

Global production of dried peas in 2018 was estimated at 13.5 million tonnes, down 16.6% from 2017 with Canada being the largest producer in the world at 3.6 million tonnes.  A portion of peas are further processed into different components: proteins, fibres and starch.  The separation of pea components can be based on a dry-milling or an aqueous separation process and the use of organic solvents is not required.

Burcon management believes that a small fraction of the global production of dried peas is further processed into pea protein concentrates and pea protein isolates.  Major producers of pea protein have expanded their production capacity to meet the growing demand.  Current pea protein demand outweighs supply and has led to higher prices. The unique functionality of Burcon's Peazazz® pea protein and its clean flavor profile could be major factors in expanding and growing the vegetable protein market.


- 39 -

Canola Protein

The initial market for Puratein®,  Supertein® and Nutratein® canola proteins is anticipated to be food and nutrition processors that target: the baking industry; plant-based meat analogue manufacturers (E.g. veggie-burgers); beverage processors (non-dairy fortified drinks); sport nutrition manufacturers; and prepared foods manufacturers incorporating whole egg, dried egg white or certain dairy proteins.   

The overall strategic intent is to build Nutratein®, Puratein® and Supertein® canola proteins as global products.  Merit Foods is working with food and beverage manufacturers to establish the value of all three of Burcon's canola proteins in potential market applications.

Pea Protein/Canola Protein Blends

Burcon's proprietary pea protein/canola protein blend products are unique products that combine excellent functionality with improved nutritional value.  These products are a convenient replacement for high protein nutrition animal protein products (eg.  whey, casein, egg-white) and soy protein products and should allow the use of Burcon protein products in applications where the use of canola or pea protein product alone would be limited by their nutritional value.

 Soy Protein

Reports and Data estimated that in 2018, the global soy protein market was valued at US$9.7 billion and is projected to reach about US$16.6 billion by 2026, growing at a CAGR of 6.9%.  Despite the slowing growth of soy protein in new products, soy-based meat alternatives continue to dominate the market with 48% market share of the meat substitute market.  Soy protein in dairy replacement segments continue to grow at a CAGR of 7.8%. 

As discussed above, ADM has the sole discretion in developing the sales and marketing strategies for CLARISOY® soy protein pursuant to the License and Production Agreement. Given ADM's extensive experience in the sale and marketing of soy protein products, Burcon expects that CLARISOY® will be strategically priced amongst ADM's current product portfolio and other competing protein products in the global market.


- 40 -

Intellectual Property

 Patents

In October 1999, Burcon acquired the shares of Burcon-MB.  At the time of the acquisition, Burcon-MB held patents and applications covering the protein micellar mass process for extracting and producing a canola protein isolate.  Since the acquisition, Burcon has focused on developing its protein extraction and purification processes and seeking patent protection for its developments.  Through Burcon-MB, Burcon has filed patent applications in various countries over its inventions.  Burcon's patent applications can be grouped into three categories:

 applications to protect additional novel protein extraction and purification technologies;

 applications to protect the uses of Puratein®, Supertein® and Nutratein® canola proteins, CLARISOY® soy protein, Peazazz® pea protein, and other plant proteins, for example, as functional food and beverage ingredients; and

 applications to protect the "signature characteristics" of Puratein®, Supertein® and Nutratein® canola proteins, CLARISOY® soy protein, Peazazz® and Peazac® pea proteins and other plant proteins.

As of the date of this AIF, Burcon's patents and patent applications cover over 50 distinct inventions.  Burcon has filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  As at the date of this AIF, Burcon holds 287 issued patents in various countries, including patents covering composition of matter and a number of key processes and uses of Burcon's products as functional food and beverage ingredients, 70 of which have been issued in the U.S.  Burcon holds patents or has filed patent applications in: Australia, Brazil, Canada, China, Hong Kong, India, Japan, the European Union, Mexico, New Zealand, Russia, South Africa, South Korea and the United States.  Burcon currently has over 255 patent applications that are being reviewed by the patent offices in various countries, 43 of which are U.S. patent applications.

 Granted U.S. Patents

Burcon holds 70 issued patents in the United States relating to soy protein, canola protein, flax protein and pea protein.  Although the initial protein micellar mass canola protein isolate patents acquired from Burcon-MB expired in 2016 and 2017, Burcon holds patents covering improvements made by Burcon to the protein extraction and purification technologies.  These new inventions include:


- 41 -

Soy

Canola

 technologies for improving the quality of input meal prior to the purification and extraction process, to result in better protein quality and higher protein yield;

 process improvements to produce canola protein isolate efficiently and to obtain higher yields of canola protein isolate;

 processes for reducing phytic acid in the production of protein isolates from oilseed meals.  Phytic acid is a naturally occurring anti-nutritional component found in oilseed meals such as canola meal and soybean meal;

 protection covering important processing conditions for producing Supertein® canola protein as well as for the preparation of a highly refined Supertein® canola protein and product characteristics;

 protection covering the composition of the dominant species of protein in Burcon's Puratein® canola protein.  Puratein® is a cruciferin-rich canola protein isolate comprised principally of globulin proteins, allowing it to have unique functional qualities;

 protection covering the process for producing Nutratein® canola protein and the use of Nutratein® canola protein in food compositions; 

 processes to improve the final colour profile of Puratein® canola protein and Supertein® canola protein;

 applications for the uses of canola protein as a functional food and beverage ingredient;


- 42 -

 the use of canola protein as a flavour enhancer in a food product;

 alternative processes for producing canola protein isolates;

 protection covering the process for producing protein isolates using mustard seed as a starting material;

Pea

 pea protein product having signature characteristics, including properties in low pH solution;

 protection covering the processes for producing pea protein isolates having reduced astringency in low pH solutions; and

Flax

 processes for the production of flax protein isolates with unique protein profiles.

 Patent Strategy

Burcon believes that it has developed a dynamic patent portfolio by seeking protection for new technologies as well as further protecting current technologies.  In addition, Burcon has filed patent applications to cover alternative extraction technologies, which, in Burcon's opinion, would not be commercially viable.  Such filings have been made as part of Burcon's defensive strategy to gain as much protection in the protein extraction and purification space as possible.  Burcon will continue its research and development to further refine its processes and make new discoveries.  The Company will continue to file additional patent applications to protect these discoveries. 

In an effort to conserve cash resources, Burcon made the decision to abandon certain non-core canola patents and canola patent applications during fiscal year 2014 which it deemed to be non-essential or redundant for the purposes of achieving its strategic objectives by not paying annuities or maintenance payments when due. 

 Trade-marks

Burcon has obtained trade-mark registrations for "Nutratein" and "Supertein" in Canada, as well as "Puratein", "Peazazz", "Peazac" and the slogan "A New World in Protein" in Canada and the United States.  Burcon has filed for trade-mark protection for "Nutratein-PS" and Nutratein-TZ" in Canada. 


- 43 -

Burcon had previously obtained trademark registrations for "CLARISOY" in the United States and Canada.  In June 2011, Burcon and ADM entered into a trademark assignment and license agreement pursuant to which Burcon assigned its ownership of the CLARISOY® trademark to ADM.  In return, Burcon has obtained a worldwide, non-exclusive, royalty-free license to use the CLARISOY® trademark for corporate marketing and promotion of Burcon, conducting research or development of CLARISOY® soy protein products and compliance with the requirements of applicable law. Burcon also has the option to re-acquire the CLARISOY® trademark if the license under the ADM License and Production Agreement is terminated.

Burcon has granted Merit Foods a royalty-free non-exclusive license (the "Trademark License Agreement") to certain Burcon trademarks registered by Burcon in association with the products under the Merit License as long as the Merit License is exclusive.  Under the Trademark License Agreement, Merit Foods has granted Burcon a royalty-free non-exclusive license to use certain Merit Foods trademarks.  The term of the Trademark License Agreement will continue for so long as the Merit License is exclusive, provided that either party may terminate the Trademark License Agreement at any time for any reason with written notice to the other party of not less than ninety (90) days. 

Facilities

Burcon's head office is located at 1946 West Broadway, Vancouver, British Columbia, Canada in leased office space.  Through Burcon-MB, Burcon leases the premises where the Winnipeg Technical Centre is located at market rental rates.  These premises are located at 1388 Waller Avenue, Winnipeg, Manitoba, Canada.  The lease will expire on August 31, 2021.  The premises include a 10,333 square foot facility in a light industrial park.  Burcon owns the equipment in this facility which includes tanks of up to 20,000 litre capacity, membrane systems, centrifuges, filter presses, various dryers and laboratory analytical equipment.  Burcon operates exclusively and independently within these facilities under the immediate direction of its management.  Certain services such as laboratory testing and analysis which cannot be conducted internally are contracted out as necessary. 

 Personnel

As of March 31, 2020, Burcon-MB had 16 employees and/or contractors with varying degrees of technical expertise who perform the duties relating to the operation of the research laboratory and pilot plant in Winnipeg.  Additionally, as of March 31, 2020, Burcon had 5 employees and/or contractors responsible for accounting, legal, administration, corporate development, investor and public relations, legal and research and development activities who were predominantly located at Burcon's head office in Vancouver. 


- 44 -

 Competitive Conditions

ADM has licensed Burcon's soy protein technology and has commissioned its first full-scale CLARISOY® commercial production facility.  On May 23, 2019, Burcon announced that it had signed the Shareholders Agreement with the JV Partners to form Merit Foods.  The business of Merit Foods is the commercial production, sales, marketing and distribution worldwide of Burcon's pea protein, pulse protein and canola protein products.  Merit Foods has licensed Burcon's pea and canola protein technologies.  See "General Development of the Business". 

The protein ingredient market is a global industry dominated by a few relatively large participants.  Burcon recognizes that the selective use of alliances and partnerships can lower certain risks and can be the fastest and most profitable approach to maximizing revenues and cash flow.  With this understanding, Burcon entered into the ADM License and Production Agreement with ADM to commercialize Burcon's soy protein ingredients.  See "Material Contracts". 

ADM is a public company with annual revenues of approximately US$64.7 billion (fiscal 2019).  It is a multinational company that produces among other things, ethanol, high fructose corn syrup, soy flour, soy protein concentrate, soy protein isolate and other specialty ingredients.  It is currently one of the world's largest processor of oilseed crops. 

Burcon recognizes that, in addition to ADM, there are other large industry participants with significant resources that dominate the plant protein ingredient industry.  Two of the other major industry participants that sell plant protein ingredients to the food and beverage industries include Cargill Inc. ("Cargill") and DuPont. 

Cargill is the U.S.'s largest private company with annual revenues of US$113.5 billion (2019).  Cargill is an international producer, marketer, processor and distributor of agricultural, food, financial and industrial products and is one of the world's largest canola crushers. 

E.I. du Pont de Nemours and Company ("DuPont") (NYSE: DD), through its wholly-owned subsidiary DuPont Nutrition and Biosciences, is a world leader in soy-based proteins and specialty ingredients for the food, beverage, meat and nutritional products industries.  In June 2019, Dow Chemical and DuPont, after merging for two years, completed its dissolution forming three companies: Dow, DuPont and Corteva.  In December 2019, DuPont announced that its Nutrition and Biosciences ("N&B") business will be merging with International Flavors & Fragrances Inc. ("IFF")(NYSE: IFF)(Euronext Paris: IFF)(TASE: IFF) to form a global leader in high-value ingredients and solutions  for global Food & Beverage, Home & Personal Care and Health & Wellness markets, with estimated 2019 pro forma revenue of $11.2 billion and EBITDA of $2.6 billion, excluding synergies.  The new $45 billion company will be a major supplier of products including soy proteins, probiotics, enzymes and ingredients for creating scents and tastes for consumer products.  The new company will continue to be called IFF and based in New York. The merger is expected to complete by Q1 2021.


- 45 -

The pea protein industry outside of China is dominated by four major participants: Roquette Freres ("Roquette"), Cosucra Groupe Warcoing, Nutri-Pea Limited and Puris Foods.  Based in France, Roquette is a private company which produces more than 700 by-products from the starch extracted from corn, wheat, potatoes and peas.  It has grown to become the second largest producer of starch in Europe and fifth largest producer in the world.  Roquette is currently the largest participant in the pea protein industry.  In 2017, Roquette announced the construction of a $400 million pea protein facility in Portage la Prairie, Manitoba.  Construction was stalled for most of 2018 to include expansion plans and the completion date was pushed back from 2019 to 2020.  Now the near-$500 million pea protein facility, the largest in the world, is set to commission at the end of 2020 with an annual processing capacity of 125,000 tonnes of peas.  With the combined capacity of Roquette's pea protein plant in Vic-Sur-Aisne, France, Roquette will become the largest pea protein producer in the world.

Cosucra Groupe Warcoing is a Belgian group of independent companies dedicated to the development, production and promotion of natural ingredients from chicory and yellow pea.  Cosucra's line of products includes pea protein isolate, pea fibre, pea hull fibre and pea native starch. 

Puris Foods, formerly World Food Processing, is another participant in the pea protein industry.  Puris has been processing pulse crops in Iowa, US, since 1985 and has recently expanded capacity to include downstream production of pea protein products.  In January 2018, Cargill entered into a joint venture agreement with Puris, with an initial investment of $25 million to expand the capacity of Puris' Turtle Lake, Wisconsin production facility.  In August 2019, Cargill invested an additional $75 million to more than double the capacity of Puris' existing 200,000 square-foot pea protein facility in Dawson, Minnesota.  Puris Foods is the largest North American producer of pea protein.

Based in Manitoba, Canada, Nutri-Pea Limited is a privately-owned company specializing in the manufacture of food ingredients derived from Canadian yellow field peas.  Nutri-Pea extracts fibre, starch and protein products from yellow field peas.  In 2018, Nutri-Pea Limited was acquired by G.S. Dunn Limited, an Ontario-based supplier of dry milled mustard products.

Rising commodity prices have had a noticeable impact on the global aquaculture and livestock farming sectors in recent years, as through their direct impact on feed costs as well as on energy costs.  These rising input prices have in turn been one of the factors that has increased the cost to produce animal proteins (egg protein products as well as the dairy proteins, casein and whey).  Burcon anticipates that under commercial production levels, it will be able to produce its plant protein isolates at a cost level which will make them significantly competitive with animal proteins.


- 46 -

Burcon offers a value proposition for both the multibillion-dollar oilseed crushing industry which produces enormous volumes of canola meal and soybean meal that currently sell as relatively low-margin animal feed.  Burcon has the technology and know-how to add value to these oilseed meals by extracting unique and potentially valuable food proteins. The unique nutritional and functional characteristics of Puratein® canola protein, Supertein® canola protein, Nutratein® canola protein, CLARISOY® soy protein and Peazazz® pea protein and Nutratein® pea protein/canola protein blend products differentiate them from the existing plant-based proteins (predominantly soy) as well as from the existing animal based proteins (casein, whey and egg).  Burcon has also developed specialty proteins, including flax and hemp.  Burcon anticipates that all these unique attributes will make the proteins valuable to the food and beverage industry.

For the branded consumer product companies and food ingredient companies, the value proposition comes from both the novel properties of Burcon's proteins as well as the inherent first-mover advantage. Exclusivity through patent protection and the first-mover advantage could add significant value to Burcon's opportunity in an industry where first-movers dominate, and market share changes slowly. 

See also "Risk Factors".

 Environmental Matters

Burcon's extraction processes use no harsh chemicals and emit no noxious odours or significant waste products.  Biodegradable, natural and/or recyclable input materials, end-products and by-products are used and, therefore, are expected to present no significant environmental risk.  As such, Burcon does not foresee any financial and operational effects of environmental protection or requirements on the capital expenditures, earnings and the competitive position of Burcon in the current financial year or in the foreseeable future.

Burcon's processes, as demonstrated to date, are expected to work equally well on input materials from both genetically modified ("GM") and non-GM sources.

 Regulatory Approval For Marketing CLARISOY®

Food-grade soy protein isolate first became available on October 2, 1959 with the dedication of Central Soya's edible soy isolate, Promine D, production facility in Chicago. An edible soy isolate and edible spun soy fiber has also been available since 1960 from the Ralston Purina Company in St. Louis, where they had originally developed the technology.  In 1987, Protein Technologies, Inc. ("PTI") became the world's leading maker of isolated soy protein and was subsequently acquired by DuPont.


- 47 -

Soy protein isolate is a highly refined or purified form of soy protein with a minimum protein content of 90% on a moisture-free basis. It is made from defatted soy flour, processed to provide a product which has had most of the non-protein components, fats and carbohydrates removed. Because of this, it has a neutral flavour and will cause less gas due to bacterial flatulence.

Soy protein isolates are mainly used to improve the texture of meat products, but are also used to increase protein content, enhance flavour, and as an emulsifier.

Pure soy protein isolate is used mainly by the food industry. It is sometimes available in health stores or in the pharmacy section of the supermarket. It is usually found combined with other food ingredients.

In 1995, the New England Journal of Medicine (Vol. 333, No. 5) published a report from the University of Kentucky entitled, "Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids." It was financed by the PTI division of DuPont, The Solae Company, St. Louis. This meta-analysis concluded that soy protein is correlated with significant decreases in serum cholesterol, Low Density Lipoprotein LDL (bad) cholesterol and triglyceride concentrations. However, High Density Lipoprotein HDL (good) cholesterol did not increase. Soy phytoestrogens (isoflavones: genistein and daidzein) adsorbed onto the soy protein were suggested as the agent reducing serum cholesterol levels. On the basis of this research, PTI, in 1998, filed a petition with FDA for a health claim that soy protein may reduce cholesterol and the risk of heart disease.

In October 1999, the FDA approved a health claim for soy protein and its role in reducing the risk of coronary heart disease.  Food manufacturers may label foods containing soy protein by stating that "Diets low in saturated fat and cholesterol that include 25 grams of soy protein daily may reduce the risk of heart disease. One serving of (name of food) provides __ grams of soy protein."  One serving (1 cup or 240 mL) of soy milk, for instance, contains 6 or 7 grams of soy protein.

In March 2015, after a meta-analysis of scientific studies, Health Canada's Food Directorate concluded that scientific evidence exists to support a health claim about soy protein and blood cholesterol lowering. The evidence supports a direction of effect towards a reduction in total and LDL cholesterol levels when soy protein is consumed. Foods containing soy protein may state on its label, "[Serving size] of (brand name) [name of food] supplies/provides X% of the daily amount of soy protein shown to help reduce/lower cholesterol."  The daily amount referred to is 25 grams of soy protein.  For example, "150g of tofu supplies 70% of the daily amount of soy protein shown to help lower cholesterol".


- 48 -

While soy proteins and soy protein isolates themselves have not been granted GRAS status by the FDA, they are widely used in food and nutritional applications including infant formula.  As a result, Burcon does not anticipate any regulatory process for its CLARISOY® soy protein.  However, there can be no assurance that the FDA will not require companies producing and selling soy protein isolates to meet additional regulatory requirements in the future.

 Regulatory Approval For Marketing Peazazz® and Peazac®

Peas were one of the earliest cultivated food crops and have a long history of safe consumption in human foods.  They are widely accepted and consumed as a vegetable in our daily diets.  Although pea protein is a relatively new vegetable-based protein ingredient, it is commercially available and used by the food industry.

Despite peas and pea protein being widely accepted and consumed, Burcon has, in the process of discussions with potential strategic partners, been informed by certain major food and beverage manufacturers that they require all of their procured ingredients to be GRAS approved to ensure consistent quality and safety in their end products.  On October 21, 2019, Burcon announced that it had received a GRAS (Generally Recognized As Safe) no-objection letter from the US Food and Drug Administration ("FDA") for its Peazazz® and Peazac® pea proteins.  Burcon had successfully obtained self-affirmed GRAS status for its Peazazz® and Peazac® pea protein products and had made its submission to the FDA for GRAS notification on June 15, 2018.  This "Letter of No Objection" is issued by the US FDA, after an extensive review of all of the scientific data submitted by Burcon, to confirm that the FDA has no questions or concerns regarding the safety of Burcon's pea protein ingredients.  Receipt of GRAS notification is a significant commercial milestone and is important for the acceptance and use of these proteins by global food and beverage companies.

As part of the Merit License and Production Agreement, Merit Foods is responsible for the production, marketing and sales of Burcon's pea, canola and the proprietary Nutratein® protein blends.  Merit Foods will be responsible for obtaining regulatory approval, if needed, in the geographical locations where it intends to market and sell Burcon's pea and canola products.

 Obtaining Regulatory Approval For Marketing Puratein®, Supertein® and Nutratein® Canola Proteins

Canola meal is currently used as a protein ingredient in dairy, beef, swine and poultry rations and is recognized for its consistent quality and value.  Canola meal's nutritional value, even in animal feed applications, is limited by the presence of a large amount of fiber and other anti-nutritional factors such as glucosinolates. Glucosinolates are the sulphur compounds that give mustard its sharp taste.  Analysis of Puratein® canola protein, Supertein® canola protein and Nutratein® canola protein conducted by independent testing laboratories has indicated very low levels of glucosinolates.  Puratein®, Supertein® and Nutratein® canola proteins have numerous potential applications, primarily as a food ingredient and as a personal care product ingredient.  See "Description of the Business". 


- 49 -

As part of the Merit License and Production Agreement, Merit Foods is responsible for the production, marketing and sales of Burcon's pea, canola and the proprietary Nutratein® protein blends.  Merit Foods will be responsible for obtaining regulatory approval, if needed, in the geographical locations where it intends to market and sell Burcon's pea and canola products.

 United States

 Puratein® and Supertein® Canola Proteins

During fiscal 2008, Burcon, in conjunction with ADM, pursued regulatory recognition for Puratein® canola protein and Supertein® canola protein. 

A substance may be "generally recognized as safe" or "GRAS" as a food ingredient based on two principles:  it is a prior sanctioned substance, meaning that it has been used in food before 1958; or it is determined to be GRAS by scientific experts based on scientific procedures.  Accordingly, because canola meal (and canola protein contained therein) does not have a history of safe use in human foods, the determination that Puratein® canola protein and Supertein® canola protein are GRAS must be based on scientific procedures. 

Scientific studies were conducted during fiscal 2008 and based on those studies, Burcon and ADM prepared a dossier of data that included scientific information about canola, how canola is grown, handled and processed, Burcon's protein extraction process and finally, the intended uses of the proteins in foods and beverages.  A panel of qualified experts in the fields of food safety, toxicology, nutritional sciences, food allergies and pediatric nutrition reviewed the dossier to which it also had input and affirmed unanimously that the proteins are safe for their intended uses.  In October 2008, Burcon's Puratein® canola protein and Supertein® canola protein achieved self-affirmed GRAS status. 

Substances that are GRAS under conditions of their intended use are exempted from the usual Federal Food, Drug, and Cosmetic Act ("FFDCA") food additive tolerance requirements.

For a substance to be GRAS, the scientific data and information about the use of the substance must be widely known and there is a consensus among qualified experts that the data and information establish that the substance is safe under the conditions of its intended use. 


- 50 -

When a use of a substance does not qualify for the GRAS exemption, then the substance is considered to be a food additive under the FFDCA.  Use of the substance is subject to the premarket approval mandated by the FFDCA.  For a food additive, privately held data and information about the use of a substance are sent by the proponent to the FDA, which evaluates the data and information to determine whether the data and information establishes that the substance is safe under the conditions of its intended use.  If found unsafe, the FDA may take enforcement action to stop distribution of the food substance and foods containing it on the grounds that such foods are or contain an unlawful food additive.

A GRAS designation typically exists in one of three forms:

1. Self-affirmed. The manufacturer of the substance has performed all necessary research, including the formation of an expert panel to review safety concerns, and is prepared to use these findings to defend its product's GRAS status.

2. FDA-pending. The manufacturer has performed all the aforementioned due diligence, and submitted to the FDA for GRAS approval.

3. No comment. The FDA has reviewed a product's GRAS notification claim and responded with "no comment"; i.e., no further challenges on the product's GRAS status.

To enhance consumer acceptance of Puratein® canola protein and Supertein® canola protein, Burcon and ADM chose to pursue GRAS notification for Puratein® canola protein and Supertein® canola protein.  GRAS notification is a voluntary procedure whereby a company informs the FDA of its determination that the use of a substance is GRAS. 

During fiscal 2010, Burcon's scientists collaborated with ADM in the preparation and review of the manuscripts for the publication of the toxicology studies conducted in fiscal 2008 as part of the GRAS self-affirmation process.  On August 20, 2009 and November 3, 2009, Burcon announced the publication of the Puratein® and Supertein® toxicology studies, respectively, in peer-reviewed journals.  The publication of these scientific studies forms a significant part of the GRAS notification process. 

On January 19, 2010, Burcon announced that it had filed a formal notification in accordance with the FDA proposed regulation 62FR 18938, having determined, based on a review of the data referenced in the notification, that Burcon's Puratein® canola protein and Supertein® canola protein are GRAS for their intended use as an ingredient in a variety of food and beverage applications and in addition, that both substances are exempt from premarket approval requirements of the Food, Drug and Cosmetic Act (the "GRAS Notification").  In response to comments from the FDA, Burcon modified and resubmitted the GRAS Notification in February 2010.  In a letter dated April 1, 2010, the FDA formally acknowledged receipt of the GRAS Notification.


- 51 -

After the FDA acknowledges receipt of the GRAS notice, it then evaluates whether the submitted notice provides a sufficient basis for the GRAS determination and whether information in the notice or otherwise available to the FDA, raises issues that lead the FDA to question whether use of the substance is GRAS.  Following the evaluation and within 180 days, the FDA responds in one of 3 ways:

1. the FDA does not question the basis for the notifier's GRAS determination;

2. the FDA concludes that the notice does not provide a sufficient basis for a GRAS determination (for example, the notice does not include appropriate data and information, or because the available data and information raise questions about safety of the notified substance); or

3. the FDA has, at the notifier's request, ceased to evaluate the GRAS notice.

A substance is GRAS notified when, after reviewing the GRAS notification, the FDA responds with a no-objection letter if it is satisfied with the submission.

On August 30, 2010, Burcon announced that the FDA issued a no objection letter with respect to Puratein® and Supertein® canola protein.  This response indicates that the FDA has no objection to the conclusion that Puratein® and Supertein® are Generally Recognized as Safe (GRAS) among qualified experts for use alone or together as an ingredient in dairy products, grain products, fruit and vegetable juices and beverages, salad dressings, meal replacements and nutritional bars.

 Nutratein® Canola Protein

Burcon's Nutratein® canola protein production process results in a canola protein isolate that is rich in both of the two major storage proteins found in canola: napin and cruciferin.  Therefore, Nutratein® canola protein is a blended canola protein that consists of the napin-rich protein fraction (Supertein®) and the cruciferin-rich protein fraction (Puratein®) of canola.

 The FDA has issued a no objection letter with respect to Puratein® and Supertein® canola proteins.  This response indicates that the FDA has no objection to the conclusion that Puratein® and Supertein® are GRAS for their intended uses in human food.


- 52 -

 Burcon believes that, based on Puratein® and Supertein® being GRAS for their intended uses in human food, Nutratein® canola protein can also be affirmed as GRAS for its intended uses in human food applications. 

Europe

 Puratein®, Supertein®, and Nutratein® Canola Proteins

Where a new ingredient has not been used to a significant degree in human food in the EU market prior to May 1997, the ingredient is regarded as a novel food ingredient and would be regulated under the 2018 Regulation (EU) No 2015/2283 concerning Novel Foods and Novel Food Ingredients.

Under the 2018 Regulation (EU) No 2015/2283, the definition of a novel food includes a description of the following:

- food consisting of, isolated from or produced from plants or their parts, except when the food has a history of safe food use within the Union and is consisting of, isolated from or produced from a plant or a variety of the same species obtained by:

  Burcon believes that Puratein® canola protein, Supertein® canola protein and Nutratein® canola protein fall into this category of novel food and may require regulatory authorisation from the European Commission in a process described below.

Before a food business can place a novel food on the European Union market, it must first submit a novel food application online to obtain authorisation from the European Commission.  If the novel food is liable to have an effect on human health, the Commission will request the European Food Safety Authority (EFSA) to carry out a risk assessment.  EFSA will adopt its opinion in nine months from the date of receipt of a valid application from the Commission.  Within the seven months from the date of the publication of the EFSA's opinion, the Commission shall submit to the Standing Committee on Plants, Animals, Food and Feed a draft implementing act authorising the placing on the market of a novel food and updating the Union list. Once the act receives a favourable vote from the Standing Committee and is adopted and published by the Commission, the novel food can be lawfully placed on the European Union market.


- 53 -

Merit Foods will therefore be required to meet all requirements prescribed under the EU's novel foods regulation for marketing Puratein® canola protein, Supertein® canola protein and Nutratein® canola protein.  Merit Foods is investigating the process for obtaining regulatory authorization from the European Commission for its canola proteins.  However, there is no assurance that the European Commission will approve the product or will not require further testing.

Canada

Puratein®, Supertein® & Nutratein® Canola Proteins

The manufacture and sale of Puratein®, Supertein® and Nutratein® canola proteins is subject to compliance with regulatory regimes in Canada that require a manufacturer to demonstrate a product's safety as a food.

These activities are governed by the federal Food and Drugs Act and Regulations, which are administered by the Food Directorate, Health Products and Food Branch of Health Canada, a Canadian government agency.  The Food and Drug Regulations require a manufacturer to notify the Food Directorate in writing of its intention to sell or advertise for sale of a novel food.

In Canada, Burcon believes that each of Puratein®, Supertein® and Nutratein® canola protein is considered a "novel food", meaning a food that does not have a history of safe use in humans or that has been manufactured by a process that has not been previously applied to it and which causes it to undergo a major change.

The regulatory pathway to product acceptance requires a submission of a Safety Assessment Data Package to Health Canada that includes details such as novel extraction process, nutritional, toxicology and allergenicity considerations.  The package must also include specific information on the novel food's intended use and directions for its preparation, as well as the text of all labels to be used in connection with the novel food. 

The steps toward obtaining approval as a novel food include the following:

 preliminary consultation and meetings with Health Canada officials to review the characteristics and make-up of the product and obtain guidance on the Safety Assessment Data Package;


- 54 -

 toxicology tests conducted by recognized research and testing facilities to provide evidence of the safety of the product; and

 submission to Health Canada Food Directorate of a Novel Food Notification that includes a description of the product, its development and intended uses; details of the procedures for manufacturing; packaging and storing the product; information regarded expected levels of consumption; and results of the toxicology tests;

 safety assessment of the novel food by the relevant bureau of the Food Directorate and presented to the Food Rulings Committee for consideration; and

 Health Canada issues a no objection letter to the sale of novel food product as human food in Canada as specified in the notification.

Review of the Novel Food Notification by Health Canada will determine whether the toxicology test information is sufficient to establish safety of the product or whether any additional testing is required.  Merit Foods has begun the process for obtaining regulatory approval of Puratein®, Supertein® and Nutratein® canola proteins as novel foods in Canada.  However, there is no assurance that Health Canada will approve the product or will not require further testing.

 Regulatory Approval For Pea Protein/Canola Protein (Nutratein®) Products

Burcon believes that specific regulatory approval for the Nutratein® blend products is not required in jurisdictions where the individual components of the blend have already received regulatory approval. 

Risk Factors

 Patents and Proprietary Rights

Burcon's success will depend, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of others or having others infringe on its rights.  Burcon has filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  As at the date of this AIF, Burcon has been granted a total of 287 patents in various countries including patents covering composition of matter and a number of key processes for producing and using Burcon's soy, pea, canola and flax protein products as functional food and beverage ingredients.  Of those patents, 70 have been granted in the United States.  Countries in which Burcon holds issued patents or has filed patent applications are: Australia, Brazil, Canada, China, Hong Kong, India, Japan, the European Union, Mexico, New Zealand, Russia, South Africa, South Korea and the United States.  Currently, Burcon has over 255 patent applications that are being reviewed by the patent offices in those countries. 


- 55 -

The patent positions of food processing and manufacturing businesses, including Burcon's, are uncertain and involve complex legal and factual questions for which important legal issues are largely unresolved.  For example, the coverage claimed in a patent application can be significantly reduced before a patent is issued.  There can be no assurance that Burcon's pending patent applications will result in the issuance of patents, that Burcon will develop additional proprietary products that are patentable, that any patents issued to Burcon will provide it with adequate protection or any competitive advantages, that such patents will not be successfully challenged by any third parties or that the patents of others will not impede Burcon's ability to commercialize its technology.  Furthermore, there can be no assurance that others will not independently develop products or technologies similar to Burcon's or, if patents are issued to Burcon, design around any patented products developed by Burcon.

Publication of discoveries in the scientific or patent literature often lag behind actual discoveries.  As a consequence, Burcon cannot be certain that it was the first creator of inventions covered by issued patents or pending patent applications or that it was the first to file patent applications for such inventions.  Moreover, Burcon might have to participate in interference proceedings declared by the United States Patent and Trademark Office or other proceedings outside the United States, including oppositions, to determine priority of invention or patentability.  An unfavourable outcome in an interference or opposition proceeding could preclude Burcon from selling products using the technology or require Burcon to obtain license rights from prevailing third parties.  There is no guarantee that any prevailing party would offer Burcon a license or that Burcon could acquire any license made available to it on commercially acceptable terms.  There can be no assurance that the patents that Burcon has received or may be able to obtain in the future would be held valid or enforceable by a court or that a competitor's technology or product would be found to infringe such patents.

Part of Burcon's intellectual property is in the form of trade secrets and know-how and may not be protected by patents.  There can be no assurance that Burcon will be able to protect its trade secrets.  To help protect Burcon's rights, Burcon requires its employees, consultants, advisors and collaborators to enter into confidentiality agreements.  There can be no assurance that these agreements will provide meaningful protection for Burcon's trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure.

 Protection of Intellectual Property is Expensive

Burcon's future success and competitive position depends in part on its ability to obtain and maintain certain proprietary intellectual property rights used in its principal product candidates. Any such success may be achieved in part by prosecuting claims against others who it believes are infringing its rights and by defending claims of intellectual property infringement brought by its competitors and others.  Burcon's involvement in any such intellectual property litigation could result in significant expense incurred by Burcon, adversely affecting the development of product candidates or sales of such challenged product or intellectual property and diversion of efforts of Burcon's technical and management personnel, whether or not such litigation is resolved in Burcon's favour.  Some of Burcon's competitors may be able to sustain the costs of complex patent litigation more effectively than Burcon because they have substantially greater resources.  Uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Burcon's ability to continue its operations.  In the event of an adverse outcome as a defendant in any such litigation, Burcon may, among other things, be required to:


- 56 -

 pay substantial damages;

 cease the development, manufacture, use or sale of product candidates or products that infringe upon the intellectual property of others;

 expend significant resources to design around a patent or to develop or acquire non-infringing intellectual property;

 discontinue processes incorporating infringing technology; or

 obtain licenses to the infringing intellectual property.

No assurance can be provided that Burcon would be successful in such development or in the acquisition of non-infringing technology or that such licenses for such infringing technology would be available upon reasonable terms, if at all.  Any such development, acquisition or license could require the expenditure of substantial time and other resources and could have a material adverse effect on Burcon's business and financial results.  If Burcon does not obtain such licenses, it could encounter delays in the introduction of products or could find that the development, manufacture or sale of products requiring such licenses could be prohibited.

Should third parties file patent applications, or be issued patents claiming technology also claimed by Burcon in pending applications, Burcon may be required to participate in interference proceedings with the United States Patent and Trademark Office, or other proceedings outside the United States, including oppositions, to determine priority of invention or patentability, which could result in substantial cost to Burcon even if the eventual outcome were favourable to Burcon.


- 57 -

In an effort to conserve cash resources, Burcon decided to abandon certain non-core canola patents and canola patent applications during fiscal year 2014 which it deemed to be non-essential or redundant for the purposes of achieving its strategic objectives.  In addition, Burcon continues to review its portfolio of patent applications on an on-going basis to ensure that it is meeting its objectives.

 The Timeline for Development and Commercialization of New Food Products Can Be Long

Burcon acquired the initial canola protein extraction technology from Burcon-MB in October 1999.  Since then, it has conducted research and development on a number of plant proteins.  On June 18, 2012, Burcon announced that ADM has begun commercial production of CLARISOY® soy protein. On December 17, 2015, Burcon announced that it expects ADM's first full-scale commercial CLARISOY® production facility to be operational by mid-2016.  On November 8, 2016, Burcon announced that ADM had successfully commissioned the first full-scale CLARISOY® production facility.  However, there can be no assurance that ADM will be able to sell a sufficient amount of CLARISOY® to provide meaningful royalties to Burcon.  On May 23, 2019, Burcon entered into the Shareholders' Agreement with the JV Partners to form Merit Foods.  Although Burcon has entered into the Merit License and Production Agreement, Burcon has not commercialized any of its pea or canola products, and accordingly, has not begun to market or generate significant revenues from the commercialization of these products.  There can be no assurance that any of its products will: meet applicable food regulatory standards; obtain required regulatory approvals in countries where such approvals have yet to be sought; be capable of being produced in commercial quantities at reasonable costs; or be successfully marketed; or that the investment made in such potential products will be recouped through sales or related royalties.  With the exception of CLARISOY® soy protein, none of Burcon's potential products are commercially available as a food ingredient for human consumption.    The rising popularity of pea proteins has resulted in more companies entering the market to produce pea proteins that could compete with Burcon's pea proteins.  Even if Burcon commercializes a product or products, its business strategy may not be successful.

 Burcon Has a History of Net Losses and Negative Operating Cash Flow and May Never Achieve Profitability

Burcon has accumulated net losses of approximately $98.4 million from its date of incorporation through March 31, 2020.  On December 19, 2012, Burcon announced that it had been notified by ADM of the first commercial sale of CLARISOY® soy protein produced by ADM.  However, Burcon has reported minimal royalty revenue during fiscal 2013 to 2020.  Although Burcon expects to receive royalty payments from ADM pursuant to the ADM License and Production Agreement, the magnitude of future royalty payments cannot be ascertained at this time.  In the absence of a definitive time for when sales of products will be significant, Burcon expects its accumulated net losses will increase as it continues to commercialize its products, its research and development and its product application trials.  Although Merit Foods has commenced construction of the production facility for Burcon's pea and canola proteins, the construction may be delayed or may not be completed on time.  Therefore, it may be some time before product sales of pea and canola protein will occur.  Burcon expects to continue to incur substantial losses for the foreseeable future.  Burcon cannot predict if it will ever achieve profitability and, if it does, it may not be able to sustain or increase its profitability.


- 58 -

Burcon's ability to achieve and maintain profitability will depend on, among other things, the market's acceptance of any of its products that receive regulatory approval.  The commercial success of any of Burcon's products will depend on whether:

 they receive public and industry acceptance as a food ingredient and dietary supplement; and

 they may be sold at competitive prices or are able to obtain sufficient royalty revenue from licensing which adequately exceeds Burcon's production (or business) costs.

 Market Conditions

During fiscal year 2020, Burcon completed the 2019 Rights Offering, issued the Convertible Debentures and completed the 2020 Offering.  Burcon has sufficient funds to operate until September 2022, assuming the Guarantee is released and the LC is terminated within the next twelve months. See "Material Contracts".  It may need to raise capital beyond this date in order to meet its business objectives.  However, the inherent risk in investing in companies such as Burcon may make it difficult for the Company to obtain capital and financing for its operations.  There can be no assurance that additional financing will be available on acceptable terms, if at all.

 Financing Requirements

Since acquiring Burcon-MB on October 8, 1999, Burcon has raised gross proceeds of approximately $102.4 million from the sale or issuance of equity securities.  Developing Burcon's products and conducting product application trials is capital intensive.  As at the March 31, 2020 balance sheet date, Burcon had approximately $15.0 million in cash and cash equivalents, of which $6.5 million has been utilized to secure the LC issued in favour of EDC.  See "Material Contracts".  Assuming the Guarantee is released and the LC is terminated in the next twelve months, management estimates that these cash resources are sufficient to continue the current level of operations until September 2022. Although Merit Foods has commenced construction of the production facility for Burcon's pea and canola proteins, the construction may be delayed or may not be completed on time.  Therefore, it will be some time before product sales of pea and canola protein will occur and for Burcon to receive any royalty revenues.  If Burcon does not receive sufficient royalties from ADM under the ADM License and Production Agreement, Burcon may need to raise additional capital to fund its objectives and operations beyond this date.  Additional financing may not be available on acceptable terms, if at all.  If Burcon raises funds by issuing more equity securities, holders of common shares will experience dilution.  If Burcon is unable to raise additional funds when it needs them, it may be required to delay, reduce or eliminate some or all of its development programs and some or all of its product application trials.  Burcon may also be forced to license technologies to others that it would prefer to develop internally.


- 59 -

 Product and Market Related Risks

The long-term success of Puratein®, Supertein® and Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea protein and Nutratein® pea protein/canola protein blend products hinges upon market acceptance by food and feed ingredient manufacturers and suppliers in numerous product applications.  Although Burcon has formed Merit Foods with the JV Partners to commercialize Burcon's pea and canola proteins, the commercial products manufactured using Burcon's protein and extraction technologies must exhibit certain functional and nutritional characteristics to garner any market share in the industries that are targeted.  There can be no assurance that Burcon's products will meet industry standards.  Even though Puratein® , Supertein® and  Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be found to be functionally acceptable in product applications, there is no assurance that they will obtain market acceptance and within a reasonable time frame.  Burcon's products have only been produced in small scale batches, and the majority of food or feed ingredient manufacturers will require a substantial testing phase and demonstration of consistent delivery and production capabilities for commercialization.  Although Merit Foods has commenced construction of the planned production facility for Burcon's pea and canola proteins, the construction may be delayed or may not be completed on time.  Therefore, it will be some time before product sales of pea and canola protein will occur.  Until large batches of products can be supplied, market acceptance of Puratein®, Supertein®, and Nutratein® canola proteins, and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be delayed.

There are many large companies in the marketplace that manufacture and produce mature and well-known protein ingredients that have been used for many years.  These companies also possess far greater financial, marketing and human resources than Burcon.  Products such as dried egg white and soy protein isolate have been used in the food processing industry for years with successful results.  These protein ingredients are proven to be functional, technologically sound, readily available and reliable.  Burcon recognizes that it must devote resources and energy over a long period of time to develop these markets as they tend to be quite conservative.  Food companies rely on taste, appearance and health appeal to sell their products and they are unlikely to accept even a lower priced product without comparable or superior functionality.  Major companies in the food processing industry have invested hundreds of millions of dollars in brand and product development and will avoid ingredients or processes that may be of questionable or unproven benefit.


- 60 -

 Consumer Acceptance

There is a continuing public issue regarding food products derived from genetically modified organisms ("GMOs"). Genetic modification, where a plant's genetic makeup is altered by insertion, deletion or reversal of genes, often from an entirely different organism, should not be confused with traditional plant breeding techniques which have been used for generations to selectively breed plants with desirable traits. In fact, canola is a variation of rapeseed developed by Canadian plant breeders using traditional techniques.

The GMO debate centres on the issue of whether food products derived from GMOs pose potential health risks to consumers and/or the environment. Burcon's processes for extracting a protein isolate from canola meal and soy are equally effective with starting materials from either GM or non-GM sources and can also utilize oilseed meals other than canola or soy. Therefore, if Burcon chooses to use starting materials from a GMO source, the resultant protein isolate may be less acceptable to some consumers.

 Government Regulatory Approval

The approval, manufacture and sale of food ingredients in Canada, the United States and Europe, such as Burcon's products, are governed by regulatory regimes in those countries which require a manufacturer to be able to demonstrate a product's safety.  In order to obtain approval to market a product, a manufacturer may be required to undertake controlled research and testing, which will be subject to government review and approval.  There is a risk that government approval may not be received in a timely fashion or at all.  See "Obtaining Regulatory Approval for Marketing Puratein®, Supertein® and Nutratein® Canola Proteins".

 Rapid Technological Change

The food processing industry is subject to rapid and substantial technological change.  There can be no assurance that developments by others will not render Burcon's products or technology non-competitive or that Burcon will be able to keep pace with technological developments.


- 61 -

 Significant Competition

Technological competition among food industry participants is intense and is expected to increase.  Many competitors and potential competitors of Burcon have substantially greater product development capabilities and financial, scientific, marketing, and human resources than Burcon.  Other companies may succeed in developing products earlier than Burcon, obtaining regulatory approvals for such products more rapidly than Burcon or in developing products that are more effective than those proposed to be developed by Burcon.  While Burcon will seek to expand its technological capabilities in order to remain competitive, there can be no assurance that research and development by others will not render Burcon's technology or products obsolete or non-competitive.

 Lack of Commercial Manufacturing Experience

Burcon has not yet manufactured any products in substantial quantity.  To be successful, Burcon's products must be manufactured in commercial quantities in compliance with regulatory requirements and at acceptable cost.  Even though Merit Foods has commenced construction of a production facility for Burcon's pea and canola proteins, the construction may be delayed or may not be completed on time.  Although the JV Partners have experience in the protein production and sales industry, no assurance can be given that the JV Partners will be successful in producing and selling Burcon's pea and canola proteins.   

 Ability to Hire and Retain Key Personnel

Burcon is highly dependent on its senior management and scientific and technical personnel. The competition for qualified personnel in the food industry is intense, and Burcon relies heavily on its ability to attract and retain qualified managerial, scientific and technical personnel. In addition, Burcon's ability to manage growth effectively will require it to continue to implement and improve its management systems and to recruit and train new employees. There can be no assurance that Burcon will be able to attract and retain skilled and experienced personnel.

 Reliance on Key Personnel

Burcon is dependent on certain members of its management and the loss of the services of one or more of these individuals could adversely affect the Company.  Neither Burcon nor Burcon-MB has purchased key man insurance on behalf of any member of Burcon's and/or Burcon-MB's senior management.


- 62 -

 Product Liability

Food products involve an inherent risk of product liability claims and associated adverse publicity.  There can be no assurance that Burcon and/or Merit Foods will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities.  Such insurance is expensive and may not be available in the future on acceptable terms, or at all.  The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of Burcon's potential products.

 Nasdaq Listing

On June 8, 2017, the Company received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC ("NASDAQ") notifying the Company that it was not in compliance with Listing Rule 5450(b)(2), which requires the listed securities of the Company to maintain a minimum market value of US$50 million.  The Company had not met the requirement for a period of 30 consecutive business days prior to receipt of the NASDAQ letter.    On August 21, 2017, the Company received a second letter from NASDAQ notifying the Company that it was not in compliance with Listing Rule 5450(a)(1), which requires the listed securities of the Company to maintain a minimum bid price of US$1 per share.  The Company had not met the requirement for a period of 30 consecutive business days prior to receipt of the second NASDAQ letter.  The receipt of the two NASDAQ letters did not result in the immediate delisting of the Company's common shares from the NASDAQ Global Market.  The Company had a compliance period of 180 calendar days or until December 5, 2017 and February 19, 2018, to regain compliance with NASDAQ's minimum market value of listed securities requirement and minimum bid price requirement, respectively.  On December 6, 2017, the Company received notification from NASDAQ stating the Company did not meet the December 5, 2017 deadline to regain compliance with NASDAQ's minimum market value of listed securities requirement.  NASDAQ stated that the Company's common shares would be delisted from the NASDAQ Global Market at the opening of business on December 15, 2017 unless the Company submitted a request to appeal the determination to the NASDAQ hearing Panel (the "Panel") by December 13, 2017.  On the same day, the Company received a further letter from NASDAQ notifying the Company that it was not in compliance with Listing Rule 5450(b)(2)(C), which requires the listed securities of the Company to maintain a minimum market value of publicly held shares of US$15 million.  The Company had not met the requirement for a period of 30 consecutive business days prior to receipt of the second NASDAQ letter dated December 6, 2017.  The Company submitted an appeal to the Panel together with a plan for regaining compliance with the various continued listing requirements. 


- 63 -

On February 5, 2018 the Company received notification from the Panel granting the Panel's approval for the Company to transfer its listing for its common shares from the NASDAQ Global Market to The NASDAQ Capital Market ("NASDAQ Capital Market").  Trading on the Company's common shares on the NASDAQ Capital Market became effective on February 7, 2018.  The Panel subjected the continued listing of the Company's shares on the NASDAQ Capital Market to certain conditions, including closing its 2018 Rights Offering (defined below) and having shareholders' equity of over US$2.5 million on or before February 16, 2018.    Because the 2018 Rights Offering was not fully subscribed, the Company was required to provide additional submissions in support of its compliance plan.  On April 24, 2018, the Company withdrew its appeal of the delisting.  The board of directors of Burcon determined that it was in the overall best interest of the Company to withdraw the appeal of the delisting.  The decision was based on several factors, including the board's assessment of the probability of the Company regaining compliance with the continued listing requirements, an analysis of the benefits of continued listing weighed against the onerous regulatory burden and significant costs associated with maintaining the continued listing.  On April 27, 2018, the Company's common shares were suspended from trading on the NASDAQ Capital Market.    The Company filed a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934) with the United States Securities and Exchange Commission (the "SEC") on June 4, 2018 to delist the Company's common shares from the NASDAQ Capital Market and to deregister its common shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").  The delisting became effective on June 14, 2018 and the deregistration became effective ninety days from June 4, 2018.  On June 15, 2018, the Company filed a Form 15 with the SEC to suspend its reporting obligations under Section 15(d) of the Exchange Act.  The Company's reporting obligations with the SEC were suspended upon the filing of the Form 15 and shall remain suspended for as long as the Company continues to meet the criteria for such suspension on the first day of any subsequent fiscal year.    The common shares of Burcon are quoted for trading in the United States on the on the OTCQB Venture Market operated by OTC Markets Group, under the ticker "BUROF". 

  The delisting of Burcon's common shares from the Nasdaq Capital Market  could negatively impact Burcon because it: (i) could reduce the liquidity, and possibly the market price, of our common shares; (ii) could reduce the number of US investors willing to hold or acquire our common shares, which could negatively impact Burcon's ability to raise equity financing; and (iii) would limit Burcon's ability to use certain types of a registration statements in the United States to offer and sell freely tradable securities, thereby preventing the Company from accessing the US public capital markets.


- 64 -

 COVID-19 - Pandemic Risk

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  While economies began to slowly reopen starting in June 2020, governments have taken a phased approach and it is not expected that economies will fully return to its pre-COVID-19 state until a vaccine has been developed to treat the virus.  The duration and effects of the COVID-19 pandemic is unknown at this time.  Even though governments worldwide, including Canada have implemented significant monetary and fiscal relief programs designed to stabilize their economies, it is too early to predict the efficacy of such programs at this time.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  While the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations to date, it is not possible to predict how long the pandemic will last and whether the financial and business conditions of Burcon and Merit Foods will be impacted in future periods. 

DIVIDEND RECORD AND POLICY

There are no restrictions that could prevent Burcon from paying dividends provided that Burcon has retained earnings from which such dividends can be paid.  Burcon has not declared any dividends on its Common Shares.  The Company's directors have determined that dividends will not be paid until a number of years after it receives revenues from the commercial production of its products, and will only be paid if the directors believe that to do so would be in the best interests of the Company and its shareholders.

DESCRIPTION OF CAPITAL STRUCTURE

The authorized share capital of Burcon consists of an unlimited number of Common Shares without par value. Each holder of Common Shares is entitled to one vote in respect of each Common Share held by such holder at meetings of shareholders.  In the event of the liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary or any other distribution of its assets among its shareholders, the holders of Common shares will be entitled to receive the remaining property or assets of the Company available for distribution pro rata, in proportion to the number of Common Shares held.  As at June 29, 2020, 97,713,921 Common Shares were issued and outstanding. In addition, the Company has 4,507,606 outstanding incentive options to purchase Common Shares as at June 29, 2020.  The Company issued convertible debentures in the principal amount of $9.5 million on December 10, 2019.  The convertible debentures are convertible into Common Shares at $1.05 up to December 10, 2022.  As at June 29, 2020, $960,000 principal amount of convertible debentures had been converted into 914,283 Common Shares.  As part of the 2020 Offering, the Company issued warrants to purchase up to 4,229,286 Common Shares. 


- 65 -

MARKET FOR SECURITIES

The Common Shares have been listed and trade on the TSX under the symbol "BU" since June 18, 2009 and NASDAQ since October 27, 2011.  As disclosed above, the Company's Common Shares were delisted from the NASDAQ Capital Market effective June 14, 2018.  In February 2020, the Company's Common Shares began trading on the OTCQB Venture Market under the symbol "BUROF".  See "General Development of the Business".  Prior to their listing on the TSX, the Common Shares were listed and traded on the TSXV under the symbol "BU". The following table sets forth, for the periods indicated, the reported high and low closing prices and total volume of trading of the Common Shares on the TSX (Canadian dollars):

 

TORONTO STOCK EXCHANGE

Calendar Period

High*

(C$)

Low*

(C$)

Total Volume

April 2019

0.38

0.28

331,500

May 2019

1.87

0.35

15,033,100

June 2019

0.99

0.48

20,846,500

July 2019

1.47

0.64

32,582,600

August 2019

1.74

1.09

21,143,200

September 2019

1.98

1.26

14,313,300

October 2019

1.64

0.86

8,394,600

November 2019

1.13

0.73

5,525,100

December 2019

1.08

0.90

2,809,900

January 2020

1.98

0.92

15,815,800

February 2020

1.94

1.12

9,510,100

March 2020

1.38

0.60

10,578,300



Source: Yahoo Finance

* Includes intra-day highs and lows


- 66 -

PRIOR SALES

The Company issued the following common shares during the fiscal year ended March 31, 2020:

Number of common shares

Issue Price per common share

Date of Issue

Description of Issuance

66,667

$0.69

May 28, 2019

Common shares issued pursuant to exercise of options under the Company's Amended and Restated 2001 Share Option Plan.

75,000

$0.23

May 28, 2019

Common shares issued pursuant to exercise of options under the Company's Amended and Restated 2001 Share Option Plan.

 

44,083,203

$0.35

June 25, 2019

Common shares issued pursuant to a rights offering circular dated May 23, 2019.

30,000

$0.23

July 3, 2019

Common shares issued pursuant to exercise of options under the Company's Amended and Restated 2001 Share Option Plan.

1,333

$0.69

November 29, 2019

Common shares issued pursuant to exercise of options under the Company's Amended and Restated 2001 Share Option Plan.



- 67 -


1,182,099

$0.45

February 13, 2020

Exercise of compensation warrants issued to a guarantor for the standby commitment provided pursuant to the rights offering circular dated January 5, 2018.

7,419,800

$1.31*

February 19, 2020

Common shares issued pursuant to the short form prospectus dated February 12, 2020.

*Under the 2020 Offering, 7,419,800 Units were issued at $1.55 per Unit.  Each Unit consisted of one common shares and one-half share purchase warrant.  A value of $1.31 was attributed to the common share and $0.24 was attributed to each one-half warrant.

The following securities convertible into common shares were issued during the fiscal year ended March 31, 2020:

Convertible Debentures

Principal Amount

Conversion Price

Date of Issue

Description of Issuance

$9,500,000

$1.05

December 10, 2019

Unsecured convertible debentures bearing interest at 8.5% per annum convertible into common shares of the Company at the conversion price per share.

Options

Number of Options

Exercise Price

Date of Issue

Description of Issuance

757,000

$1.88

January 27, 2020

Options granted pursuant to the Company's Amended and Restated 2001 Share Option Plan.



- 68 -

Warrants

Number of Warrants

Exercise Price

Date of Issue

Description of Issuance

4,229,286

$2.00

February 19, 2020

Warrants issued pursuant to the short form prospectus dated February 12, 2020.

DIRECTORS AND OFFICERS

 Directors and Officers

The following chart sets out the name, province or state and country of residence of each director and officer of the Company, each such person's principal occupation during the past five years, the period of time each has served as a director or officer of the Company and the Common Shares beneficially owned or controlled by each of them as at June 29, 2020.  A biography of each director and officer, which includes a five year history of employment, follows under "Biographies of Directors and Officers".  The term of office of each director will expire at the conclusion of the Company's next annual meeting. 

Name, Position and Municipality of Residence

Principal Occupation During the Previous Five Years

Period as a Director of the Company

Common Shares Held

Options Held

Johann F. Tergesen, President, Chief Executive Officer British Columbia, Canada

President since September 2000 and Chief Executive Officer since January 2019 of Burcon; Chief Operating Officer of Burcon from September 2000 to January 2019

From November 3, 1998 to September 12, 2012

2,500,315** 

528,992



**As at June 29, 2020, Mr. Tergesen holds Convertible Debentures in the principal amount of $1,000,000 which is convertible into 952,380 Common Shares of the Company at $1.05.  See "General Development of the Business".


- 69 -


Name, Position and Municipality of Residence

Principal Occupation During the Previous Five Years

Period as a Director of the Company

Common Shares Held

Options Held

Rosanna Chau, Director,
Hong Kong, China

Director of certain subsidiaries of PT International Development Corporation Limited ("PT International") (formerly known as ITC Corporation Limited) (investment holding) until September 30, 2019; Deputy Chairman and Executive Director of PT International until December 28, 2017

Since November 3, 1998

850,022

175,844



- 70 -


David Lorne John Tyrrell,

Chairman of the Board and Director,

Alberta, Canada

Chairman of the Board of Burcon since January 2019; Director, Li Ka Shing Institute of Virology & Distinguished University Professor, University of Alberta since April 2010;  Glaxo SmithKline Chair in Virology, Department of Medical Microbiology and Immunology, University of Alberta since 2004; Chief Scientific Officer of KMT Hepatech (biotechnology company in Edmonton) from  2004 to 2017; Professor of Medical Microbiology & Immunology, University of Alberta since 1982; Distinguished university professor of the University of Alberta

Since December 1, 2009

500,923§**

215,844



§ 25,519 of these Shares are held by Kathleen Tyrrell (daughter) and 46,940 of these Shares are held by spouse, Lee Ann Tyrrell as at June 29, 2020.

** As at June 29, 2020, Dr. Tyrrell holds Convertible Debentures in the principal amount of $500,000 which is convertible into 476,190 Common Shares of the Company at $1.05.  See "General Development of the Business".


- 71 -


Alan Chan, Director,

Hong Kong, China

Executive Director of ITC Properties Group Ltd. ("ITC Properties") (property development and investment) since March 2010; Executive Director of PT International Development Corporation Ltd. ("PT International") (formerly ITC Corporation Limited) (investing holding) from March 2009 to March 2017;; Executive director of PYI from  November 2011 to July 2016; Non-executive director of PYI from July 2016 to April 2017

Since April 20, 2010

22,866,574††

270,844

J. Douglas Gilpin,

Director,

Alberta,

Canada

Consultant, providing corporate governance, corporate director and business advisory services; Retired KPMG from 1999-2020

Since September 1, 2011

NIL

235,844



†† Alan Chan's wholly-owned company, Firewood Elite Limited, held through its wholly-owned subsidiaries Large Scale Investments Limited and Great Intelligence Limited, 22,866,574 common shares of Burcon ("Common Shares"), representing 23.4% of the outstanding Common Shares of Burcon as at June 29, 2020. 


- 72 -


Peter H. Kappel,

Director,

British Columbia, Canada

 

Corporate Director

Since January 28, 2016

499,608‡‡‡§§§

132,502

David Ju,

Director,

British Columbia,

Canada

 

Real Estate Investment and Development

Since December 21, 2017

NIL

90,000

Calvin Chi Leung Ng,

Director,

Hong Kong,

China

Group Legal Counsel, ITC Properties Group Ltd. (property development and investment) from April 2017; Legal Counsel/Group Legal Counsel, PT International Development Corporation Limited (formerly known as ITC Corporation Limited) (investment holding) from September 2009 to March 2017

Since July 23, 2019

NIL

30,000



‡‡‡ 20,584 of these Common Shares are held by Philip Kappel (son) and 62,492 of these Common Shares are held by Stefanie Kappel (spouse) as at June 29, 2020.

§§§ As at June 29, 2020, Mr. Kappel holds, directly or indirectly, Convertible Debentures in the principal amount of $500,000 which is convertible into 476,190 Common Shares of the Company at $1.05.  See "General Development of the Business".


- 73 -


Jade Cheng,
Chief Financial Officer and Treasurer,
British Columbia, Canada

Chief Financial Officer and Treasurer of Burcon; Controller of Burcon Group Limited (investment company); Director and President of Burcon Group Limited since July 2007

n/a

455,362

447,727

Randy Willardsen, Senior Vice-President,
Process, California, United States of America

Senior Vice-President, Process of Burcon; President, Willardsen Consulting & Engineering, Inc. (agriculture and biotech industries consulting services)

n/a

764,016

502,659

Dorothy Law, Senior Vice-President, Legal, Corporate Secretary,
British Columbia,  Canada

Senior Vice-President, Legal of Burcon since September 2009; Corporate Secretary of Burcon since September 2000; Director, Secretary and Corporate Counsel of Burcon Group Limited (investment company)

From December 1998 to April 2010

587,004

459,727

Martin Schweizer,

Vice-President, Technical Development, Manitoba, Canada

Vice President, Technical Development of Burcon since September 2009

n/a

169,494

397,727

TOTAL SECURITIES

 

 

29,193,318

3,507,710



- 74 -

Committees

Burcon does not have an executive committee of its directors.  Burcon has an audit committee, a corporate governance committee and a nominating and compensation committee. The members of the audit committee consist of J. Douglas Gilpin, David Ju and Peter H. Kappel.  The members of the corporate governance committee consist of Lorne Tyrrell, J. Douglas Gilpin and Peter H. Kappel.  The members of the nominating and compensation committee consist of Peter H. Kappel, David Ju and Lorne Tyrrell. 

 Aggregate Ownership of Securities

As at June 29, 2020, directors and officers of Burcon as a group, beneficially owned, directly or indirectly, 29,193,318 or 29.9% of the issued and outstanding Common Shares of the Company.  As at June 29, 2020, directors and officers of Burcon and its subsidiaries held options to acquire an additional 3,507,710 Common Shares.

 Biographies of Directors and Officers

Johann F. Tergesen - President and Chief Executive Officer

Mr. Tergesen is a twenty-year veteran of the plant-based food industry.  He co-founded Burcon NutraScience Corporation in October 1999, and since that time has overseen Burcon's strategic and financing initiatives.  He has a life-long passion for the environment and deep knowledge of the plant-based economy, having led Burcon's market outreach as well as the Company's research and commercialization efforts for over two decades.  Prior to his role as president and CEO of Burcon, Mr. Tergesen was vice president and treasurer of BurCon Properties Limited, a real estate development and ownership company with assets in excess of $3 billion.  Mr. Tergesen has been with the Burcon group of companies since December of 1995.  Mr. Tergesen holds a B.A. in economics from the University of Winnipeg, an M.B.A. from McGill University, and is a member of the Chartered Professional Accountants of British Columbia.

Rosanna Chau - Director

Ms. Chau has over 39 years of experience in international corporate management, strategic investments and finance.  Throughout her career, she has served on the board of directors of twelve publicly-listed companies spanning multiple industries, including property, hotel, bio-tech, construction and building materials, pharmaceuticals, entertainment, and consumer electronic products, and geographical locations, including Hong Kong, Mainland China, Macau, the United States, Canada, Singapore, Australia and Europe.  Ms. Chau holds a Bachelor's Degree in Commerce at the University of Alberta and a Master's Degree in Commerce at the University of New South Wales and has been awarded the Certificate in Traditional Chinese Medicine: A Way to Health at the Chinese University of Hong Kong.  She has professional accounting qualifications and experience in different jurisdictions and is a fellow member of the Hong Kong Institute of Certified Public Accountants and the CPA Australia and a member of the Chartered Professional Accountants of British Columbia. 


- 75 -

David Lorne John Tyrrell - Director

D. Lorne Tyrrell is a distinguished professor in the Department of Medical Microbiology and Immunology at the University of Alberta.  Since 1986, he has focused his research on viral hepatitis.  Supported by Canadian Institute of Health Research and Glaxo Canada, Dr. Tyrrell's work on the development of antiviral therapy resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection - lamivudine - in 1998.  Dr. Tyrrell holds more than 60 international patents for his studies on viral hepatitis.  Dr. Tyrrell was Dean of the Faculty of Medicine and Dentistry from 1994 - 2004 at the University of Alberta and is currently the Chair of the Board of Directors of the Gairdner Foundation.  The Canada Gairdner International Awards recognizes excellence in medical science research globally.  Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation (2000), the FNG Starr Award of the Canadian Medical Association (2004), the Principal Award of the Manning Awards Foundation (2005) and the Queen Elizabeth II Diamond Jubilee Medal (2012).  Dr. Tyrrell was appointed Officer of the Order of Canada in 2002.  In April 2010, Dr. Tyrrell was appointed as the founding director of the Li Ka Shing Institute of Virology at the University of Alberta.  On April 28, 2011, Dr. Tyrrell was inducted to the Canadian Medical Hall of Fame.  In 2015, he was awarded the Canada Council for the Arts Killam Prize in Health Sciences.

Alan Chan - Director

Mr. Chan is an executive director of ITC Properties Group Limited ("ITC Properties").  At ITC Properties, Mr. Chan is involved with the investment and development of commercial, hospitality and residential projects.  In addition, he is the lead in developing new policies for green and sustainable practices throughout the group.  Prior to joining ITC Properties, Mr. Chan worked in the Investment Banking Division of Goldman Sachs Group with a focus on capital raising, mergers & acquisitions and strategic advisory for financial institutions in Greater China and Southeast Asia. Mr. Chan is a graduate of Duke University majoring in Political Science - International Relations and minoring in Philosophy and Economics. 

  J. Douglas Gilpin - Director

Douglas Gilpin, FCA, FCPA, ICD.D., retired from the partnership of KPMG LLP in 1999.  In 2008, Mr. Gilpin received a Life Service Award from The Institute of Chartered Accountants of Alberta in recognition of 40 years experience in delivering professional services to business and the community.  During his 18 years tenure as a partner in Advisory Services at KPMG he served as an audit engagement partner.  He was a member of the KPMG's National Quality Assurance, the National Financial Institutions and Insurance Groups and he was the Quality Assurance Partner for the Edmonton office for 10 years.  Mr. Gilpin has consulted on corporate governance, including compliance with the Sarbanes Oxley Act 404 and National Instrument 52-109 reporting for issuers listed on the Toronto Stock Exchange.  Mr. Gilpin has served as a director of Canada Health Infoway ("CHI"), Afexa Life Sciences Inc., Alberta Innovates (formerly Alberta Innovates Technology Futures) ("AITF") and on the Board of the Health Quality Council of Alberta ("HQCA").  He was the chair of the governance committee and a member of the audit committee of CHI, and was the Chair of the audit committee for each of AITF and HQCA.  He currently is a director and chair of the audit committee of The Institute of Health Economics.  Mr. Gilpin is executive chair of The Inspections Group Inc., a privately owned company that performs safety code inspection services, building, plumbing and gas and electrical inspections in compliance with the Safe Codes Act of Alberta.  Mr. Gilpin is a member of the Institute of Corporate Directors and received his ICD.D. designation from the Institute in 2011.  Mr. Gilpin was elected as Fellow of the Institute of Chartered Accountants of Alberta in 2012.


- 76 -

Peter H. Kappel - Director

Mr. Kappel is a former investment banker who now manages a private investment portfolio.  A former chartered accountant with KPMG in Vancouver and Frankfurt, he made the transition to investment banking with JP Morgan (New York/Frankfurt) after business school.  He also served in senior roles at Nomura, Dresdner Kleinwort Wasserstein, Calyon and DVB Bank in London.  In the latter three, he was the Managing Director in charge of their respective European Securitisation businesses.  He was responsible for many ground breaking transactions, a regular speaker at ABS conferences and a founding and former executive committee member of the European Securitisation Forum of the Bond Market Association.  He holds an MBA from the Institut Européen d'Administration des Affaires ("INSEAD"), a Bachelor of Arts (Honours) degree in Economics from the University of Victoria and received his Chartered Accountant designation through the Institute of Chartered Accountants of British Columbia.  Mr. Kappel is on the Board of Partnerships British Columbia, where he serves as Audit Committee Chair.  Mr. Kappel is on the board of directors of the British Columbia Lottery Corporation, where he serves as Board Chair.

David Ju - Director

Mr. Ju is a Vice President of Concord Pacific Group, a Canadian multi-industry investment group with a diverse portfolio of businesses in Canada, the United Kingdom and Hong Kong. Mr. Ju has extensive experience in financial services and large-scale real estate development projects in both the United States and Canada.  A Chartered Accountant by training, Mr. Ju was a former member of PricewaterhouseCoopers in Vancouver and New York, where he consulted on transactions, and advised on corporate governance and assurance matters, including compliance with the Sarbanes Oxley Act 404 for clients listed on both the Toronto Stock Exchange as well as the New York Stock Exchange.  Mr. Ju holds a Bachelor's Degree in Business Administration from Simon Fraser University and is a member of the Chartered Professional Accountants of British Columbia.


- 77 -

Calvin Chi Leung Ng - Director

Mr. Ng has over 21 years' experience of advising on and executing corporate and commercial transactions in law firm and private sectors.  During his professional career, Mr. Ng has been involved in various commercial projects, setting up and overseeing corporate governance and regulatory compliance mechanisms, and providing recommendations on business undertakings.  He is currently the Group Legal Counsel of ITC Properties Group Limited ("ITC Properties") and a director of certain subsidiaries of ITC Properties.  Mr. Ng holds a Bachelor's degree in Laws and a Postgraduate Certificate in Laws from The University of Hong Kong. He was admitted as a solicitor of the High Court of Hong Kong Special Administrative Region in 1999 and is a practising member of The Law Society of Hong Kong.

Jade Cheng - Chief Financial Officer and Treasurer

Ms. Cheng is a senior financial executive with over 25 years of experience.  She has been with Burcon since inception and is responsible for its financial management, reporting and compliance.  Prior to joining Burcon, Ms. Cheng held senior financial positions with a TSX-listed real estate development and ownership company and was a manager in Coopers & Lybrand's (now PricewaterhouseCoopers LLP) audit and assurance practice.  Ms. Cheng holds a B.A. (Economics) and M.B.A. from the University of British Columbia and is a member of the Chartered Professional Accountants of British Columbia.

Randy Willardsen - Senior Vice-President, Process

Mr. Willardsen has over 32 years of experience in the fields of membrane filtration and food, dairy and biotechnology processes.  Mr. Willardsen was the founder of Separation Technology, Inc., a leading supplier of membrane-based purification equipment and related services to the food industry with particular emphasis on dairy and beverage applications.  Mr. Willardsen was also co-founder of both Inprotech Corporation, a supplier of high quality whey proteins to the U.S. market, and BioPlex Nutrition, a nutritional supplement company focused on formulated protein supplements.  With BioPlex, he served as technical director, and oversaw manufacturing of all products until the company was sold in 1999.  Most recently, Mr. Willardsen founded Gallo Protein, a partnership with Joseph Gallo Farms to produce highly purified whey protein isolates.


- 78 -

Mr. Willardsen has worked with Burcon since April of 2001, and holds a Masters degree in Food Science and Nutrition from the University of Minnesota.

Dorothy Law - Senior Vice-President, Legal and Corporate Secretary

Ms. Law was a director of Burcon from December 1998 to April 2010.  Ms. Law joined the Burcon group of companies in August 1997 and acted as corporate counsel.  Prior thereto, she was an associate at the law firm of Lang Michener LLP (now McMillan LLP), practising primarily in the areas of securities, corporate and commercial law.  Ms. Law was called to the British Columbia Bar and admitted as a member of the Law Society of British Columbia in August 1996.  Ms. Law holds a Bachelor of Laws degree and a Bachelor of Commerce degree from the University of British Columbia.  Ms. Law was also admitted as a solicitor of the High Court of Hong Kong in May 1999.  She is a non-practising member of the Law Society of Hong Kong.

Martin Schweizer - Vice President, Technical Development

 Dr. Schweizer joined Burcon in May 2002 as a process-engineering specialist.  He relocated from Nancy, France, where he earned his doctorate at the Institut National Polytechnique de Lorraine, with an emphasis on the enzymatic hydrolysis of rapeseed proteins.  Prior to his Ph.D. work, Dr. Schweizer completed a chemical engineering degree (Dipl.-Ing) at the University of Karlsruhe, Germany, where he specialized in food process engineering and water technology.  He has over 20 years of experience in research and development and his main expertise lies in the fractionation and purification of biochemical compounds using current state of the art technology such as membrane filtration, liquid chromatography and various extraction technologies, both aqueous and solvent based.  Since January 2003, Dr. Schweizer has overseen Burcon's research and development efforts at its Winnipeg Technical Centre. 

 Cease Trade Orders, Bankruptcies, Penalties or Sanctions

Other than as set out below, none of the directors or executive officers:

a)  is, as at the date of the AIF, or was within 10 years before the date of the AIF, a director or chief executive officer or chief financial officer of any company (including Burcon) that:

i)  was the subject of an order (as defined in National Instrument 51-102F2) that was issued while the director or executive officer was acting in the capacity as director, chief executive officer or chief financial officer; or


- 79 -

ii)  was subject to an order that was issued after the director or executive officer ceased to be a director, chief executive officer, or chief financial officer, and which resulted from an event that occurred while that person was acting in the capacity as a director, chief executive officer, or chief financial officer.

Except as set out below, none of the directors, executive officers or a shareholder holding a sufficient number of securities of the Company to affect materially the control of the Company,

a)  is at the date hereof, or has been within 10 years before the date of this AIF, a director or executive officer of any company (including Burcon) that while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets;

b)  has, within the 10 years before this AIF, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director, executive officer or shareholder;

c) has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or

d) has been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.

Ms. Rosanna Chau was the Deputy Chairman and Executive Director of PT International (formerly ITC Corporation Limited ("ITC")), a company whose shares are listed on The Stock Exchange of Hong Kong Limited, up to December 28, 2017.  On November 15, 2005 the Securities and Futures Commission (the "SFC") of Hong Kong criticized the board of directors of ITC for breaching Rule 21.3 of the Code on Takeovers and Mergers (the "Takeovers Code") in respect of the dealing in the securities of Hanny Holdings Limited ("Hanny", now known as Master Glory Group Limited) by ITC during an offer period without the consent of the Executive Director of the Corporate Finance Division of the SFC.  Rule 21.3 of the Takeovers Code restricts share dealings and transactions by an offeror and parties acting in concert with it during securities exchange offers.  Hanny was involved in a securities exchange offer announced in April 2005.  Since ITC held over 20% of the shares of Hanny, it was presumed to be acting in concert with Hanny under the Takeovers Code.  Ms. Rosanna Chau was a director of ITC at that time.


- 80 -

 Conflicts of Interest

  As of the date of this AIF, Mr. Alan Chan is the beneficial owner, and one of the directors of two shareholders of Burcon, Large Scale and Great Intelligence Limited, which together own approximately 22,866,574 common shares or 23.4%of the issued and outstanding common shares of Burcon.  Ms. Rosanna Chau and Mr. Calvin Ng are also directors of Large Scale and Great Intelligence Limited.

In connection with the Note and the Loan as described in "General Development of the Business", Large Scale is a wholly-owned subsidiary of Firewood Elite Limited, a wholly-owned company of Mr. Alan Chan, who in turn is an insider and related party of Burcon. The issuance of the Note to Large Scale and the Loan from Large Scale (the "Transactions") are considered a "related party transaction" pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the following disclosure is provided in accordance with s. 5.2 thereof.

The material terms of the Transactions are summarized in the section "General Development of the Business". The purpose and business reason for the Transactions were to raise funds so that Burcon could continue to meet its working capital requirements and use the funds for the purposes described above. Firewood currently holds 22,866,574 Common Shares, representing approximately23.4% of the Common Shares outstanding as of June 29, 2020.  The Purchase Agreement, the issuance of the Note and the Loan was approved by the independent directors of the board of directors of Burcon, with Mr. Alan Chan and Ms. Rosanna Chau, abstaining from participating in the vote. Other than the Purchase Agreement, the Note and the Loan described above, Burcon has not entered into any agreement with an interested party or a joint actor with an interested party (as such terms are defined in MI 61-101) in connection with the Transaction.  Burcon relied on the exemption available under s. 5.7(a) of MI 61-101 from the formal valuation and minority shareholder approval requirement of MI 61-101.

Mr. Peter Kappel, Mr. Johann Tergesen and Dr. Lorne Tyrrell, insiders of Burcon, participated in the Convertible Debenture Offering in the principal amounts of $500,000, $1,000,000 and $500,000, respectively.  The Convertible Debenture Offering was approved by the directors of the board of directors of Burcon, with Mr. Kappel and Dr. Tyrrell, abstaining from participating in the vote

The issuance of Convertible Debentures to insiders under the Convertible Debenture Offering was considered a related party transaction under Multilateral Instrument 61-101. Burcon relied on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(a) of Multilateral Instrument 61-101 on the basis that the participation in the Convertible Debenture Offering by insiders did not exceed 25% of Burcon's market capitalization.


- 81 -

The Company rents its head office premises from and shares certain office equipment with Burcon Group Limited ("Burcon Group").  Jade Cheng and Dorothy Law, officers of the Company, are the officers and directors of Burcon Group.  Rosanna Chau and Calvin Ng, directors of Burcon, were directors of an indirect shareholder of Burcon Group until June 24, 2019. Ms. Chau, Ms. Cheng, Ms. Law and Mr. Ng do not have any shareholding interests in Burcon Group.  During fiscal 2020, Burcon paid $75,006 (2019 - $75,006) to Burcon Group for the rental charges. In addition, administrative services are contracted through a management agreement with Burcon Group.  For the year ended March 31, 2020, Burcon was charged $574 (2019 - $142) by Burcon Group for these services. From April 1, 2019 to March 31, 2020, professional services provided by Burcon to Burcon Group provided income to Burcon of $14,197 (2019 - $14,896).  These transactions, occurring in the normal course of operations, are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. 

Burcon has a Services Agreement with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services AgreementFor the period March 31, 2020, included in interest and other income is $464,780 (2019 - $nil) for technical services provided and sample production by the Company to Merit Foods, of which $110,594 was included in amounts receivable at March 31, 2020 (March 31, 2019 - $nil). See "Material Contracts".

TRANSFER AGENTS AND REGISTRARS

The Company's transfer agent and registrar for its Common Shares is Computershare Investors Services Inc. at its principal transfer offices in Vancouver, British Columbia and Toronto, Ontario.

MATERIAL CONTRACTS

Burcon is a party to the following material contracts, copies of which are available on SEDAR at www.sedar.com:             

Guarantees in connection with EDC financing of Merit Functional Foods Corporation

 On April 24, 2020, Burcon signed a guarantee in favour of Export Development Canada ("EDC") for each of EDC's senior loan facility and subordinate loan facility to Merit Foods (the "Guarantees") pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations of Merit Foods under the loan agreements between EDC and Merit Foods.  The aggregate maximum liability of Burcon under the Guarantees is limited to $4,000,000.  The Guarantees contain provisions dealing with when Burcon's guarantee may be reduced in the event that Merit Foods is able to obtain certain other government sources of funding, subject to certain conditions being met.


- 82 -

Loan Agreement with Merit Functional Foods Corporation

 On April 21, 2020 Burcon's wholly-owned subsidiary, Burcon NutraScience Holdings Corp. ("Burcon Holdings"), entered into a loan agreement (the "Loan Agreement") with Merit Foods pursuant to Burcon Holdings agreed to obtain a letter of credit ("LC") from HSBC Bank Canada in the amount of $6,500,000 with EDC as beneficiary.  In connection with the loan facilities from EDC by Merit Foods (see "General Development of the Business" above), Merit Foods must fulfill various obligations including, without limitation, establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility.  $6,500,000 of this amount is permitted to be funded by way of letter of credit.  To assist Merit Foods to fulfill this obligation, Burcon Holdings, through Burcon, obtained the LC from HSBC Bank Canada ("HSBC")ich is secured by a cash deposit of the same amount with HSBC.  The Loan Agreement was entered into by Burcon Holdings and Merit Foods to evidence the loan in the amount of $6,500,000 (the "Loan").  Under the terms of the Loan Agreement, Merit Foods acknowledges and agrees that it is indebted to Burcon Holdings for the Loan from the Advance Date and obligated to pay interest on the Loan.  The term (the "Term") of the Loan and the commitment by Burcon Holdings to maintain the LC will terminate no later than September 30, 2020, unless extended by mutual agreement in writing between Burcon Holdings and Merit Foods.  The principal amount of the Loan will bear interest at 5% per annum, compounded annually, and is payable by Merit Foods by way of a lump sum balloon payment at the end of the Term. 

Under terms of the Loan Agreement, Burcon Holdings has the option to contribute the amount of Loan as a capital contribution to Merit Foods in certain circumstances including if the other shareholders of Merit Foods are unable to deliver a letter of credit in favour of EDC for their entire pro rata share of the LC amount by September 30, 2020.  The Loan Agreement contains provisions dealing with the calculation of change of shareholding interest of Burcon Holdings and the other shareholders of Merit Foods in such circumstance.

If EDC draws on the LC prior to September 30, 2020 and each of the other shareholders of Merit Foods are unable to reimburse Burcon Holdings for such other shareholder's entire pro rata share of the amount of such draw within the time period set out in the Loan Agreement, then the draw amount will be deemed a capital contribution by Burcon Holdings and Burcon Holdings' shareholding interest in Merit Foods will be increased.  The Loan Agreement contains provisions dealing with the calculation of change of shareholding interest of Burcon Holdings and the other shareholders of Merit Foods in such circumstance. 


- 83 -

Unanimous Shareholders Agreement

On May 23, 2019, Burcon's wholly-owned subsidiary, Burcon NutraScience Holdings Corp., entered into a shareholders agreement (the "Shareholders Agreement") with RBT Holdco Ltd. ("RBT Holdco") and 10039406 Manitoba Ltd. ("Crew Holdco") (RBT Holdco and Crew Holdco together referred to as the "JV Partners")  to become shareholders of Merit Functional Foods Corporation (formerly Burcon Functional Foods Corporation) ("Merit Foods").  Currently, Burcon Holdings holds 40%, RBT Holdco holds 40% and Crew Holdco holds 20% of the issued and outstanding common shares of Merit Foods.  Ryan Bracken and Barry Tomiski each hold a 50% interest in RBT Holdco.  Crew Holdco is wholly-owned by Shaun Crew.  The business of Merit Foods is the commercial production, sales, marketing and distribution worldwide of Burcon's pea protein, pulse protein and canola protein products.  Pursuant to the Shareholders Agreement, the parties agreed that on or before July 2, 2019, Burcon Holdings and the JV Partners will make a capital contribution to Merit Foods by way of shareholder loans and/or subscription of shares in the aggregate of $10,000,000.  Burcon Holdings has agreed to make a capital contribution of $4,000,000 to Merit Foods (less certain deductions for certain expenses), while RBT Holdco and Crew Holdco have agreed to contribute $4,000,000 and $2,000,000, respectively (each an "Initial Capital Contribution").  In the event that any of Burcon Holdings, RBT Holdco or Crew Holdco fail to contribute its respective Initial Capital Contribution on or before July 2, 2019, then the Shareholders Agreement will automatically terminate. 

Provided that the Shareholders Agreement has not been previously terminated, the parties have agreed to make further contributions to Merit Foods on or before September 3, 2019 in the aggregate amount of $10,000,000.  Burcon Holdings has agreed to contribute a further $4,000,000 to Merit Foods, while RBT Holdco and Crew Holdco have agreed to contribute $4,000,000 and $2,000,000, respectively (each an "Additional Capital Contribution").  In the event that any of Burcon Holdings, RBT Holdco or Crew Holdco fail to contribute its respective Additional Capital Contribution (a "Capital Deficiency"), any shareholder under the Shareholders Agreement that has contributed its full proportionate share of the Additional Capital Contribution may make a further capital contribution in the amount of the Capital Deficiency and the proportionate ownership of each shareholder will be adjusted accordingly.  If Burcon Holdings only contributes its Initial Capital Contribution and not the Additional Capital Contribution while the remaining shareholders contribute their Initial Capital Contribution, Additional Capital Contribution and any Capital Deficiency, Burcon Holdings' ownership interest in Merit Foods will be reduced to 20%.


- 84 -

The Shareholders Agreement contains provisions to deal with the management of Merit Foods, and sets out matters requiring board of directors' approval or shareholder approval.  It also sets out the rights of the parties with respect to restrictions on transfers, transfers to third parties and what happens in the event of a takeover bid.

Merit Foods License and Production Agreement

 On May 23, 2019, Burcon and its wholly-owned subsidiary, Burcon NutraScience (MB) Corp. entered into entered into a license and production agreement with Merit Foods (the "Merit License and Production Agreement").  Under the Merit License and Production Agreement, Burcon has granted an exclusive, royalty-bearing, worldwide license (the "Merit License") to Merit Foods to use and exploit Burcon's pea, pulse and canola protein technologies to make, have made, use and market and sell Burcon's pea, pulse and canola proteins (the "Merit Licensed Products"). 

Merit Foods has agreed to develop, build and commission an initial production facility in the Province of Manitoba within a specified amount of time to manufacture the Merit Licensed Products (the "Flex Production Facility").  Merit Foods will also, within a time specified under the License Agreement, provide written notice (the "Notice") to Burcon to advise whether it will or will not increase its annual production capacity of the Products to develop, build and commission a full commercial scale production facility ("Full-Commercial Production Facility").  The License Agreement provides Burcon with the right to convert the exclusive license to a non-exclusive license under certain conditions. 

In consideration of the Merit License, Merit Foods will pay to Burcon running royalties based on the net revenue (as defined in the Merit License and Production Agreement) in relation to the sale of the Products which fall within the scope of the Burcon Technology.  Once a sale in the Flex Production Facility occurs, Merit Foods will pay to Burcon royalties based on a percentage of net revenue from the sale of Products.  If Merit Foods expands production to the Full-Commercial Production Facility the royalty rate will be reduced to a lower percentage rate.  The royalty rate may also be reduced if the exclusive license is converted to a non-exclusive license or if a certain Burcon patent does not grant within a specified time.

If the exclusive license is converted to a non-exclusive license, Burcon will be entitled to make, have made, use, market and sell Products on a non-exclusive basis and to grant any such rights to any other person.  Merit Foods will grant to Burcon an irrevocable, non-exclusive, royalty bearing license, with a right to sublicense, to use certain intellectual property developed by Merit Foods ("Merit Foods Improvements") to make, have made, use, market or sell the Products worldwide.    If the license is converted to a non-exclusive license and Burcon chooses to use the Merit Foods Improvements, the aggregate royalties payable by Burcon to Merit Foods in any year will not exceed the aggregate royalties payable by Merit Foods to Burcon in the same year. 


- 85 -

As long as the Merit License is exclusive, Burcon will be responsible for filing, prosecution and maintenance of Burcon patent rights in certain countries.  While the Merit License is exclusive, Merit Foods shall have the right to defend any action in which the validity of any Burcon patent right is raised in any jurisdiction.  If Merit Foods does not exercise such right, Burcon shall have the right but not the obligation to assume such defence.

The Merit License and Production Agreement has a term of the greater of twenty years and the last to expire of Burcon patents that are being used to produce products under the Merit License and Production Agreement.   

Services Agreement with Merit Foods

 On May 23, 2019, Burcon, Burcon-MB and Merit Foods entered into a services agreement (the "Services Agreement") pursuant to which Burcon and Burcon-MB will provide certain services (the "Services") to Merit Foods in support of Merit Foods' business.  The Services will commence on July 3, 2019 and the agreement will have an initial term ending on June 30, 2022.  Under the Services Agreement, Burcon and Burcon-MB will provide general management/administrative/technical services, research and analytical services and sample production services.  The Services will be charged to Merit Foods based on rates set out in the Services Agreement.

Loan Agreement with Large Scale Investments Limited

On November 13, 2018, Burcon announced that it entered into a loan agreement (the "Loan Agreement") pursuant to which Large Scale, at the time  and currently a wholly-owned subsidiary of Firewood, provided Burcon with an unsecured loan (the "Loan") of up to $1,000,000 (the "Initial Loan Amount") for a term of 180 days from December 5, 2018. 

On March 27, 2019, Burcon and Large Scale amended (the "Loan Amendment") the Loan Agreement, pursuant to which Large Scale agreed to increase the Initial Loan Amount to Burcon by $500,000 (together with the Initial Loan, the "Loan Amount").  See "General Development of the Business".


- 86 -

Standby Commitment Agreement with Allan Yap

 On January 5, 2018, Burcon entered into a standby commitment agreement with Allan Yap in connection with the 2018 Standby Commitment.  See "General Development of the Business".

Convertible Note Purchase Agreement with Large Scale Investments Limited

On April 7, 2016, Burcon announced that it had entered into the Purchase Agreement with Large Scale Investments Limited (the "Lender"), a wholly-owned subsidiary of PT International, pursuant to which it will issue the Note for the Principal Amount.  On May 21, 2019, the Company announced that Burcon and Large Scale amended the Note (the "Amendment") to extend the maturity date of the Note from May 11, 2019 to June 21, 2019.

Under the Note, Large Scale could convert the Principal Amount in whole or in part into common shares in the capital of Burcon at any time commencing on or after July 1, 2016 and up to and including the Maturity Date.  When issued, the conversion price of the Note was $4.01 per common share, which represented a premium of approximately 24% over the volume weighted average trading price of the common shares on the TSX for the 5 trading days immediately before April 7, 2016 (the "Conversion Price").  Burcon also had the right, before the Maturity Date, upon written notice to the Lender of not less than thirty (30) days, to prepay in cash all or any portion of the Principal Amount by paying to the Lender an amount equal to the Principal Amount to be prepaid multiplied by 110%.  At any time on or after July 1, 2016 and up to the end of such 30-day notice period, Large Scale had the right to convert the Principal Amount in full or in part, into common shares at the Conversion Price.  The Note was and any common shares issued upon the conversion of the Note would have be subject to a four month hold period under applicable Canadian securities laws.  Upon completion of the 2018 Rights Offering (as defined below), the Conversion Price of the Note was adjusted effective immediately after the 2018 Record Date (as defined below).  After the adjustment, the Conversion Price was reduced to $3.94 per common share. 

Funding by Large Scale and the issuance of the Note occurred on May 12, 2016.  The Note bore interest at a rate of 8% per annum, calculated daily, compounded monthly.  Interest accrued on the Principal Amount and was payable on the earlier of June 21, 2019, the occurrence of an event of default as set out in the Note, or voluntary prepayment by Burcon (the "Maturity Date"). 

The Amendment also provided Large Scale with a right to offset any amounts due to it under the Note against any obligations of Large Scale to pay for subscription proceeds of any rights offering that Burcon may conduct.  See "General Development of the Business".


- 87 -

 License and Production Agreement with ADM

On March 4, 2011, Burcon and Burcon's wholly-owned subsidiary, Burcon NutraScience (MB) Corp. (together referred to for this section only, as "Burcon") entered into a license and production agreement (the "ADM License and Production Agreement") with ADM.  Pursuant to the ADM License and Production Agreement, Burcon has granted to ADM an exclusive, royalty-bearing, worldwide license (the "License") to use and exploit Burcon's soy protein technology solely to make, have made, use, market and sell soy protein products (the "Soy Products") that use, incorporate or are derived from any Burcon technology.  ADM has agreed to use reasonable commercial efforts to design, build and commission an initial production facility (the "Semi-works Production Facility") within a specified amount of time after it receives permit approval from the US Environmental Protection Agency ("EPA Approval Date") to manufacture the Soy Products.  ADM will also, within a time specified under the ADM License and Production Agreement, provide written notice to Burcon to advise whether it will or will not increase its annual production capacity of the Products beyond the capacity of the Semi-works Production Facility ("Full Commercial Production").  The License and Production Agreement provides each party the right to convert the exclusive license to a non-exclusive license under certain conditions. 

In consideration of the License, ADM will pay to Burcon running royalties based on the net revenue (as defined in the License and Production Agreement) in relation to the sale of the Soy Products which fall within the scope of the Burcon Technology.  ADM will pay quarterly royalties (the "Pre-production Royalty") to Burcon from the EPA Approval Date until the first bona fide arms' length sale of Products manufactured in the Semi-works Production Facility.  Once such sale in the Semi-works Production Facility occurs, ADM will pay to Burcon royalties based on a percentage of net revenue from the sale of Products (the "Semi-works Production Royalty").  If ADM expands production to Full Commercial Production the royalty rate will be reduced to a lower percentage rate (the "Full Commercial Production Royalty").  The Full Commercial Production Royalty rate will be further reduced if ADM expands production and sale into certain geographic regions or if ADM achieves a pre-defined further expanded level of production capacity.  The Semi-works Production Royalty and the Full Commercial Production Royalty rates may also be reduced if the exclusive license is converted to a non-exclusive license or if certain Burcon patents do not grant within a specified time.

If the exclusive license is converted to a non-exclusive license, Burcon will be entitled to make, have made, use, market and sell the Soy Products on a non-exclusive basis and to grant any such rights to any other person.  ADM will grant to Burcon an irrevocable, non-exclusive, royalty bearing license, with a right to sublicense, to use ADM Improvements (as defined in the License and Production Agreement) to make, have made, use, market or sell the Soy Products worldwide.    If the license is converted to a non-exclusive license and Burcon chooses to use ADM improvements, the aggregate royalties payable by Burcon to ADM in any year will not exceed the aggregate royalties payable by ADM to Burcon in the same year. 


- 88 -

Under the ADM License and Production Agreement, Burcon will be responsible for filing, prosecution and maintenance of Burcon patent rights in certain countries.  Burcon will also be responsible for defending any action in which the validity of any Burcon patent right is raised in any jurisdiction. 

Royalties payable under the License will terminate on the later of the date of expiry of the last to expire of the Burcon Patent Rights (as defined in the License and Production Agreement) and twenty years from March 4, 2011.  Since March 4, 2011, Burcon has filed additional patent applications to seek important commercial protection for the production and use of CLARISOY®.  ADM has elected to include these applications to the License and, if granted could lengthen the royalty term under the License and Production Agreement to at least the year 2035.

INTERESTS OF EXPERTS

The Company's auditors are PricewaterhouseCoopers LLP, Chartered Professional Accountants, who have prepared an independent auditor's report dated June 29, 2020 in respect of the Company's consolidated financial statements as at March 31, 2020 and March 31, 2019 and for the years then ended.  PricewaterhouseCoopers LLP has advised that they are independent with respect to the Company within the meaning of the Chartered Professional Accountants of British Columbia code of Professional Conduct.

AUDIT COMMITTEE AND DISCLOSURE UNDER NATIONAL INSTRUMENT 52-110

Under National Instrument 52-110 ("NI 52-110"), Burcon is required to disclose in its AIF certain information concerning the composition of its audit committee and its auditor. The audit committee carries out the various responsibilities set forth in its charter, a copy of which is attached to this AIF as Schedule "A".

 Composition of the Audit Committee

The audit committee of Burcon is comprised of J. Douglas Gilpin, David Ju and Peter H. Kappel. Mr. Gilpin is the chair of the audit committee.  All members of the audit committee are financially literate.  Under NI 52-110, an individual is "financially literate" if he has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by Burcon's financial statements.  Mr. Gilpin was an audit engagement partner in Advisory Services at KPMG LLP (chartered accountants) for 18 years until 1999.  Mr. Kappel holds a Bachelor of Arts (Honours) degree in Economics from the University of Victoria and received his Chartered Accountant designation through the Institute of Chartered Accountants of British Columbia.  Mr. Kappel is on the Board of Partnerships British Columbia, where he serves as Audit Committee Chair.  Mr. Ju became a member of the audit committee on January 3, 2018.  Mr. Ju is a Chartered Accountant and is a member of the Chartered Professional accountants of British Columbia.  A member of the audit committee is "independent" if the member has no direct or indirect material relationship with Burcon, which could, in the view of Burcon's board of directors, reasonably interfere with the exercise of a member's independent judgement. All the members of the audit committee are independent.  The Board has determined that each of the audit committee members is independent, as that term is defined by NI-52-110. 


- 89 -

 Audit Committee Oversight

During the most recently completed financial year, all recommendations of the audit committee with respect to financial reporting and to nomination or compensation of Burcon's external auditor were adopted by the board of directors.

 Pre-Approval Policies and Procedures

The charter of the audit committee requires pre-approval of non-audit services provided by the external auditor of Burcon. The auditor was engaged to provide certain tax return review services during the years ended March 31, 2020 and 2019.  These services were pre-approved by the audit committee.

 External Auditor Service Fees

Fees billed by PricewaterhouseCoopers LLP ("PwC") to Burcon for professional services relating to the last two fiscal years are outlined in the following table.

Nature of Services

Fees billed by auditor for the fiscal year ended March 31, 2020

Fees billed by auditor for the fiscal year ended March 31, 2019

Audit Fees1

$56,500

$34,000

Audit-Related Fees2

$77,000

$39,000

Tax Fees3

$2,100

$1,700

All Other Fees4

Nil

Nil

Total

$135,600

$74,700



- 90 -

Notes:

(1) "Audit Fees" include the aggregate fees billed by PwC relating to the respective fiscal year.  Included in Fiscal 2019's Audit Fees is a credit of $15,000 received from Fiscal 2018's Audit Fees due to the suspension of the Company's U.S. reporting obligations.  In addition to the Audit Fees, the Company paid Scarrow & Donald LLP, auditors of Merit Foods, $9,650 to act as component auditor to perform certain specified audit procedures on Merit Food's financials statements to March 31, 2020.

(2) "Audit-Related Fees" include the aggregate fees billed for the respective fiscal year for assurance and related services by PwC that are not reported under "Audit Fees".    Of the $77,000 incurred in Fiscal 2020, $37,000 related to quarterly reviews of each of the Company's interim financial statements and $10,000 related to services rendered in connection with the 2019 Rights Offering and $30,000 related to services rendered in connection with the 2020 Offering. 

(3) "Tax Fees" include the aggregate fees billed for the respective fiscal year for professional services rendered by PwC for tax compliance and tax advice. 

(4) "All Other Fees" include the aggregate fees billed for the respective fiscal year for products and services provided by PwC, other than the services reported under "Audit Fees", "Audit-Related Fees" and "Tax Fees". 

ADDITIONAL INFORMATION

Additional information relating to Burcon can be found on the SEDAR website at www.sedar.com

Additional information, including directors' and officers' remuneration and indebtedness, principal holders of Burcon's securities and securities authorized for issuance under equity compensation plans, is contained in Burcon's Management Proxy Circular dated July 30, 2019 for its most recent annual meeting of shareholders that involved the election of directors.

Additional financial information is provided in Burcon's financial statements and MD&A for its most recently completed financial year ended March 31, 2020.


- 91 -

GLOSSARY

In this AIF, the following terms have the meanings set forth herein:

ADM

Archer-Daniels-Midland Company

   

10039406 Manitoba Ltd.

one of the JV Partners and is a company wholly-owned by Shaun Crew and his family

   

ADM License and Production Agreement

the license and production agreement dated March 4, 2011 made among Burcon, Burcon-MB and ADM

   

Affiliate

has the meaning set out in the Canada Business Corporations Act

   

albumin

refers generally to any protein with water solubility, which is moderately soluble in concentrated salt solutions, and experiences heat coagulation (protein denaturation).  Substances containing albumin, such as egg white, are called albuminoids

   

BMW

B.M.W. Canola Inc.

   

Board

the Board of Directors of the Company

   

Burcon or Company

Burcon NutraScience Corporation

   

Burcon Holdings

Burcon NutraScience Holdings Corp.

   

Burcon-MB

Burcon Nutrascience (MB) Corp. (formerly B.M.W. Canola Inc.)

   

CLARISOY®

the trade-marked brand name for Burcon's soy protein.  CLARISOY® is a trademark of ADM and is licensed to Burcon 

   

Common Share or Shares

a common share in the capital of the Company

   

EDC

Export Development Canada

   

erucic acid

fatty acids contained in canola, but not considered essential for human growth



- 92 -


FAO

the Food and Agricultural Organization

   

FDA

the United States Food and Drug Administration

   

Firewood

Firewood Elite Limited, a company wholly-owned by Alan Chan, a director of Burcon

   

globulin

this generic term encompasses a heterogeneous series of families of proteins, with larger molecules and less soluble in pure water than albumin.  Globular proteins, or spheroproteins are one of the two main protein classes, comprising "globe"-like proteins that are more or less soluble in aqueous solutions (where they form colloidal solutions)

   

glucosinolates

the sulphur compounds that give mustards their sharp taste

   

GM

genetically modified

   

GMO

genetically modified organism

   

GRAS

generally recognized as safe

   

Guarantee

guarantee by Burcon in favour of EDC  to guarantee all of the indebtedness, liabilities and obligations of Merit Foods under the loan agreements between EDC and Merit Foods in aggregate maximum liability of $4 million

   

ITC

ITC Corporation Limited (now PT International Development Corporation Limited)

   

JV Partners

RBT Holdco Ltd. and 10039406 Manitoba Ltd.

   

Large Scale

Large Scale Investments Limited

   

LC

letter of credit from HSBC Bank Canada in the amount of $6.5 million with EDC as beneificiary

   

Merit Foods

Merit Functional Foods Corporation (formerly Burcon Functional Foods Corporation)

   

Merit License and Production Agreement

the license and production agreement dated May 23, 2019 made among Burcon, Burcon-MB and Merit Foods

   

NASDAQ

Nasdaq Stock Market LLC



- 93 -


NASDAQ Global Market

The NASDAQ Global Market

   

NASDAQ Capital Market

The NASDAQ Capital Market

   

Nestlé

Société des Produits Nestlé, SA

   

Nutratein®

the trade-marked brand name for Burcon's blended cruciferin-rich and napin-rich canola proteins

   

Nutratein-PS™

the trade-marked brand name for Burcon's blend of Peazazz® pea protein and Supertein® canola protein

   

Nutratein-TZ™

the trade-marked brand name for Burcon's blend of Peazac® pea protein and Puratein® canola protein

   

PDCAAS

protein digestibility corrected amino acid score

   

Peazac®

the trade-marked brand name for one of Burcon's pea protein 

   

Peazazz®

the trade-marked brand name for Burcon's pea protein

   

PT International

PT International Development Corporation Limited (formerly ITC Corporation Limited)

   

Puratein®

the trade-marked brand name for Burcon's cruciferin-rich canola protein

   

RBT Holdco Ltd.

one of the JV Partners and is a company beneficially owned equally by Ryan Bracken and Barry Tomiski and their respective family

   

Shareholders Agreement

the shareholders agreement dated May 23, 2019 among Burcon Holdings, RBT Holdco Ltd. and 10039406 Manitoba Ltd.

   

Supertein®

the trade-marked brand name for Burcon's napin-rich canola protein 

   

TSX

Toronto Stock Exchange

   

TSXV

TSX Venture Exchange



- 94 -


US or United States

the United States of America

   

Winnipeg Technical Centre

the premises where Burcon's research laboratory and pilot plant operations are located



- 95 -

SCHEDULE "A"

BURCON NUTRASCIENCE CORPORATION ("BURCON")

AUDIT COMMITTEE CHARTER

General Functions, Authority and Role

The purpose of the audit committee is to oversee the accounting and financial reporting process of Burcon and the audits of its financial statements, and thereby assist the Board of Directors of Burcon in monitoring (1) the integrity of the financial statements of Burcon, (2) compliance by Burcon with legal and regulatory requirements related to financial reporting, (3) the performance of Burcon's external auditors, and (4) the performance of Burcon's internal controls and financial reporting process.

The audit committee has the power to conduct or authorize investigations into any matters within its scope of responsibilities, with full access to its auditors and its legal advisors and to all books, records, facilities and personnel of Burcon.  In connection with such investigations or otherwise in the course of fulfilling its responsibilities under this charter, the audit committee has the authority to independently retain special legal, accounting, or other consultants to advise it, and may request any officer or employee of Burcon, its independent legal counsel or independent auditor to attend a meeting of the audit committee or to meet with any members of, or consultants to, the audit committee.  Burcon shall provide appropriate funding, as determined by the audit committee, for payment of (i) compensation to the external auditor to prepare and issue an audit report or perform other audit, review or attest services for Burcon, (ii) compensation to any outside advisors employed by the audit committee, and (iii) ordinary administrative expenses of the audit committee that are necessary or appropriate in carrying out the audit committee's duties. 

Burcon's independent auditor is ultimately accountable to the audit committee, who, in its capacity as a committee of Burcon's board of directors, is directly responsible for appointing, retaining and determining the appropriate compensation of the external auditor.  The audit committee must also oversee the work of the external auditor engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for Burcon, including resolution of disagreements between management and the external auditor regarding financial reporting.  The external auditor must report directly to the audit committee.  In the course of fulfilling its specific responsibilities hereunder, the audit committee must maintain free and open communication between Burcon's external auditors, Board of Directors and Burcon management.  The responsibilities of a member of the audit committee are in addition to such member's duties as a member of the Board of Directors.


- 96 -

Membership

The audit committee of the board of directors of Burcon shall consist of a minimum of three directors.  Members of the audit committee shall be directors appointed by the board of directors and may be removed by the board of directors at its discretion. 

All members of the audit committee shall satisfy the independence and audit committee composition requirements of all applicable corporate and securities laws and stock exchange listing standards; provided, however, that one or more members may be non-independent within the meaning of all applicable regulations.

All members of the audit committee must be financially literate, i.e. have the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by Burcon's financial statements.  At least one member shall be a financial expert.

The members of the audit committee shall elect, amongst themselves, one member to act as chairperson on an annual basis.

Responsibilities

The audit committee is responsible for:

  • reviewing Burcon's interim and annual financial statements and management's discussion and analysis related thereto, and all annual and interim earnings press releases before they are publicly disclosed;
  • ensuring that adequate procedures are in place for the review of Burcon's public disclosure of financial information extracted or derived from Burcon's financial statements, other than management's discussion and analysis and annual and interim earnings press releases, and periodically reviewing and updating such procedures;
  • establishing procedures for the receipt, retention and treatment of complaints received by Burcon regarding accounting, internal accounting controls, or auditing matters;
  • establishing procedures for the confidential, anonymous submission by  employees of Burcon of concerns regarding questionable accounting or auditing matters;
  • reviewing and approving Burcon's hiring policies regarding partners, employees and former partners and employees of the present and former auditor of Burcon;
  • reviewing with management, Burcon's major financial risk exposures and the steps management has taken to monitor and control such exposures;
  • assessing risk areas and policies to manage risk;

- 97 -

  • overseeing the work of Burcon's external auditors engaged for the purpose of preparing or issuing an audit report or related work;
  • ensuring Burcon's external auditors report directly to the audit committee throughout the term of their appointment;
  • ensuring Burcon's external auditors provide a formal written statement delineating all relationships between the external auditor and Burcon, actively engaging in a dialogue with the external auditor with respect to any disclosed relationships or services that may impact the objectivity and independence of the external auditor and for taking, or recommending that Burcon's full board of directors take, appropriate action to oversee the independence of the external auditor;
  • pre-approving all non-audit services to be provided to Burcon or Burcon's subsidiaries by Burcon's external auditor;
  • recommending to Burcon's board of directors the external auditor to be nominated for the purpose of preparing or issuing an auditor's report (or any related work), as well as the compensation to be paid to the external auditor;
  • annually reviewing and reassessing the adequacy of this charter and recommend any proposed changes to the Board of Directors for approval;
  • reporting committee actions to the Board of Directors with such recommendations as the committee may deem appropriate; and
  • providing copies of meeting of the audit committee to the Board of Directors.

The audit committee does the following main things to discharge these responsibilities:

  • meeting with management and the external auditors at least two times per year;
  • meeting separately with each of management and the external auditors several times per year as required;
  • reviewing and approving the annual audit scope and the annual audit plan proposed by the auditors;
  • reviewing carefully and acting on all internal control points raised by the auditors in correspondence with management; and
  • discussing Burcon's compliance with tax and financial reporting rules as issues arise.


News Release

Burcon Announces Fiscal 2020 Results and Reviews Operations

Vancouver, British Columbia, June 29, 2020 - Burcon NutraScience Corporation (TSX: BU; OTCQB: BUROF), a global leader in developing functionally and nutritionally valuable plant-proteins, reported results for the year ended March 31, 2020. 

"Fiscal 2020 was truly a transformational year for Burcon," said Johann F. Tergesen, Burcon's president and chief executive officer, adding, "Coming out of the year, we have a strong balance sheet, we established the Merit Functional Foods joint venture and we partnered with Nestlé, the largest food and beverage company in the world.  Through the Merit Foods joint venture, we are well advanced in building a state-of-the-art production facility to produce our unique pea and canola proteins as well as our new protein blends.  The production facility, which is on track to be completed in Q4 2020, will be the only commercial facility in the world with the capability to produce non-GMO food grade canola proteins."

Fiscal 2020 Operational Highlights

The Company completed / announced the following significant developments:


Subsequent to the year-end, the Company announced the following significant developments:

Management Commentary

The past year was marked by a number of key developments in commercializing Burcon's technologies.  For over twenty years, Burcon has been developing technologies to produce novel plant-based protein ingredients for use in foods and beverages and the achievements of this past year confirm the economic value of that lengthy effort.  The establishment of the Merit Foods JV and entering into a collaboration with Nestlé are two such developments, while strengthening Burcon's balance sheet through three separate financing rounds is yet another key development.

During fiscal 2020, Burcon advanced the commercialization of its pea and canola technologies through the establishment of Merit Foods.  Merit Foods is building a 94,000 square foot production facility in Winnipeg, Manitoba to produce Burcon's high-quality pea and canola proteins. The state-of-the-art facility, which is scheduled to be completed in Q4 2020 will be the only commercial facility in the world with the capability to produce non-GMO food grade canola proteins. 

Burcon's team at the Winnipeg Technical Centre has supported Merit Foods during the past year through: assisting in the design and construction of the production facility; continued applications work on potential customer products; and sample production for food and beverage companies who have expressed an interest in Peazazz® and Peazac® or Burcon's canola proteins.

Burcon and Merit Foods entered into a joint development agreement with Nestlé, the largest food and beverage company in the world, to tailor Burcon's pea and canola proteins for use in Nestlé's plant-based food and beverage offerings.  The partnership between Nestlé and Burcon/Merit Foods is designed to provide Nestlé access to Burcon's unique expertise and a new range of high-quality plant-based protein ingredients. The collaboration is intended to be a long-term relationship whereby Burcon tailors its novel protein ingredients, produced in Merit Foods' state-of-the-art protein facility, for use by Nestlé in a range of nutritious and great-tasting plant-based meat and dairy alternatives.

Subsequent to the year-end, Burcon announced that Merit Foods secured a total of $95 million in debt financing in two separate transactions. 

The first was an $85 million debt financing package, provided by a syndicate of lenders including Export Development Canada, Farm Credit Canada and the Canadian Imperial Bank of Commerce.  To facilitate the debt financing package, Burcon provided a short-term letter of credit in the amount of $6.5 million, which will remain in place until no later than September 30, 2020, and Burcon also provided a $4 million guarantee of Merit Foods' debt obligations. 


The second was a $10 million financing in the form of a 10-year interest free loan from Agriculture and Agri-Food Canada (the "AIP Loan").  The interest free loan, repayable over 10 years, was approved under Agriculture and Agri-Food Canada's AgriInnovate Program.  As a result of Merit Foods obtaining this second debt financing, Burcon expects the $4 million guarantee Burcon previously provided to help facilitate Merit Food's $85 million debt financing package, will be released in stages over time as Merit Foods draws down on the $10 million AIP Loan.

In the coming year, Burcon will continue to assist Merit Foods with all aspects of the process to complete the construction and commissioning of the commercial production facility.  Burcon will also continue to conduct research on other plant-based protein opportunities and to undertake patenting activities.

Financial Results (in Canadian dollars)

Revenues totaled $31,000 for the year, as compared to $40,000 in the same year-ago period.  The nominal revenues reflect the company's development phase status as it transitions to the commercial stage. 

Net loss totaled $4.7 million or $0.06 per basic and diluted share for fiscal 2020, as compared to a net loss of $4.8 million or $0.11 per basic and diluted share in fiscal 2019.

Research and development expenses totaled $722,000 for the year, as compared to $1.7 million in fiscal 2019.  The Company began deferring canola and pea development expenses from the second quarter of this year and also recorded production costs for inventory.  This has contributed to a reduction of about $1.1 million of R&D costs. 

Intellectual property expenses decreased by $372,000, from $1.2 million in fiscal 2019 to $846,000 in fiscal 2020.  The Company also began deferring patent expenses for the pea and canola patent portfolios and this has contributed to $694,000 of the reduction.  Before the deferral, patent expenditures increased by $318,000 due to higher patenting activity in the pea and canola portfolios.   

General and administrative expenses increased to $504,000 over fiscal 2019.  About two-thirds of the decrease is attributed to higher stock-based compensation expense for options that had immediately vested, with the balance due to higher professional fees.   

At March 31, 2020, cash balances totaled $15.0 million compared to $489,000 at March 31, 2019.  In connection with Merit Foods' financing arrangements, Burcon has provided a $6.5 million letter of credit ("LC") in favour of the lenders, which is secured by a term deposit of the same amount.  The LC is expected to terminate no later than September 30, 2020.  In addition, Burcon has provided a guarantee of $4.0 million in connection with Merit Foods' financing arrangements.  The guarantee will be released in stages as Merit Foods draws down on the AIP loan.  Assuming the LC and the guarantee will be released in the short-term, management believes it has sufficient resources to fund its expected level of operations and working capital requirements to September 2022.  This estimate does not take into account potential proceeds from outstanding convertible securities or royalty revenues from its license agreements.


The company's complete financial statements, along with management's more detailed discussion and analysis, are available from the company's Investors section at www.burcon.ca or from www.sedar.com.

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements. CLARISOY is a trademark of Archer Daniels Midland Company.

Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca


www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM


BURCON NUTRASCIENCE CORPORATION

Consolidated Balance Sheets

As at March 31, 2020 and March 31, 2019

(Prepared in Canadian dollars)

    March 31, 2020
$
    March 31, 2019
$
 
ASSETS            
Current assets            
  Cash and cash equivalents   15,030,988     489,215  
  Amounts receivable   332,248     126,605  
  Inventory   132,142     -  
  Prepaid expenses   289,278     307,997  
    15,784,656     923,817  
             
Property and equipment   470,504     284,689  
Deferred development costs - net of accumulated amortization of $nil
(2019 - $nil)
  1,554,584     -  
Investment in and loan to Merit Functional Foods Corporation   12,204,538     -  
Goodwill   1,254,930     1,254,930  
             
    31,269,212     2,463,436  
             
LIABILITIES            
Current liabilities            
  Accounts payable and accrued liabilities   1,067,251     633,209  
  Short-term loan   -     1,250,000  
  Derivative liability   -     5,384  
  Convertible note   -     1,990,686  
  Deferred revenue   275,578     -  
  Accrued interest   249,310     564,251  
    1,592,139     4,443,530  
             
Convertible debentures   6,731,350     -  
             
    8,323,489     4,443,530  
SHAREHOLDERS' EQUITY            
Capital stock   98,046,103     73,361,133  
Contributed surplus   9,030,861     9,001,467  
Options   9,673,821     9,184,852  
Warrants   1,792,168     199,117  
Convertible debentures   2,762,927     -  
Deficit   (98,360,157 )   (93,726,663 )
             
    22,945,723     (1,980,094 )
             
    31,269,212     2,463,436  


BURCON NUTRASCIENCE CORPORATION

Consolidated Statements of Operations and Comprehensive Loss

Years ended March 31, 2020 and 2019

(Prepared in Canadian dollars)

    2020
$
    2019
$
 
             
REVENUE            
Royalty income   31,134     40,177  
             
EXPENSES            
Research and development   721,851     1,692,519  
Intellectual property   846,137     1,217,949  
General and administrative   2,186,273     1,681,882  
             
    3,754,261     4,592,350  
             
LOSS FROM OPERATIONS   (3,723,127 )   (4,552,173 )
             
INTEREST AND OTHER INCOME   247,918     77,177  
             
MANAGEMENT FEE INCOME   364,210     14,896  
             
SHARE OF LOSS IN MERIT FUNCTIONAL FOODS CORPORATION   (939,806 )   -  
             
INTEREST EXPENSE   (589,277 )   (324,259 )
             
FOREIGN EXCHANGE GAIN   2,153     6,982  
             
LOSS ON DISPOSAL OF EQUIPMENT   (949 )   -  
             
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITY   5,384     -  
             
LOSS AND COMPREHENSIVE LOSS FOR THE YEAR   (4,633,494 )   (4,777,377 )
             
BASIC AND DILUTED LOSS PER SHARE   (0.06 )   (0.11 )





 

July 03, 2020

510 Burrard St, 3rd Floor

 

Vancouver BC, V6C 3B9

 

www.computershare.com

To: All Canadian Securities Regulatory Authorities

 

   

Subject: BURCON NUTRASCIENCE CORPORATION

 

   

Dear Sir/Madam:

 

We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:

Meeting Type :

 

Annual General and Special Meeting

Record Date for Notice of Meeting :

 

July 30, 2020

 

Record Date for Voting (if applicable) :

 

July 30, 2020

 

Beneficial Ownership Determination Date :

 

July 30, 2020

 

Meeting Date :

 

September 17, 2020

 

Meeting Location (if available) :

 

Virtual meetng

 

Issuer sending proxy related materials directly to NOBO:

Yes

 

Issuer paying for delivery to OBO:

 

Yes

 

       

Notice and Access (NAA) Requirements:

 

 

 

NAA for Beneficial Holders

 

Yes

 

Beneficial Holders Stratification Criteria:

 

Not Applicable

 

NAA for Registered Holders

 

No

 

       

Voting Security Details:

 

 

 

Description

CUSIP Number

ISIN

COMMON SHARES

120831102

CA1208311029

Sincerely,

Computershare

Agent for BURCON NUTRASCIENCE CORPORATION



News Release

BURCON ANNOUNCES APPOINTMENT OF

DEBORA FANG TO ITS BOARD OF DIRECTORS

Vancouver, July 6, 2020 / - Burcon NutraScience Corporation ("Burcon") (TSX:BU, OTCQB:BUROF), a global technology leader in the development of plant-based proteins, is pleased to announce that Ms. Debora Fang has been appointed to its board of directors. 

Ms. Fang has 20 years' experience in the fast moving consumer goods industry, across mergers and acquisitions, strategy, finance and marketing roles for Unilever (London, UK), Danone (Paris, France and Amsterdam, Netherlands), Kraft Foods (Sao Paulo, Brazil) and as a consultant for Bain & Company (Los Angeles, USA).  While at Unilever as VP Mergers & Acquisitions, Ms. Fang was responsible for a range of acquisitions and disposals in the foods, ice cream and tea categories, leading multidisciplinary teams and covering a global scope.  She is now an independent advisor for private equity and strategic clients in the food arena as well as a private investor.  Ms. Fang holds an MBA from the Kellogg Graduate School of Management at Northwestern University in Chicago, USA and a Bachelor of Arts in Business from the University of Sao Paulo, Brazil.

Dr. Lorne Tyrrell, Chairman of Burcon's board of directors said, "I am very pleased to have Debora join our board of directors.  Her extensive experience and knowledge in the food industry will be valuable assets to Burcon now and in the future."

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward- looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca

www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



July 30, 2020

NOTICE RE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
OF BURCON NUTRASCIENCE CORPORATION

NOTICE-AND-ACCESS

Burcon NutraScience Corporation (the "Issuer," "us" or "we") will be holding its annual and special meeting (the "Meeting") of shareholders on Thursday, September 17, 2020 held virtually via live webcast. A notice of meeting and management information circular dated July 30, 2020 in respect of the Meeting (the "Notice of Meeting" and the "Circular") and the annual financial statements for the year ended March 31, 2020, along with the related management discussion & analysis (the "Financial Statements and MD&A") have been posted at www.burcon.ca and on the Issuer's profile on www.SEDAR.com.

The Meeting is being held to consider the matters in the Voting Instruction Form or Form of Proxy accompanying this Notice.

These matters are set out in detail under the headings "Election of Directors" on page 7,  "Appointment of Auditors" on page 13, ""Re-approval of Amended and Restated 2001 Share Option Plan"on page 13  and "Continuation under the Busines Corporations Act (British Columbia) on page 16 of the Circular.

You may vote in the manner indicated in the enclosed Voting Instruction Form or Form of Proxy, which includes voting via internet or telephone, or by completing and returning the enclosed Voting Instruction Form or Form of Proxy to Computershare Investor Services Inc. at the specified address not less than 48 hours (exclusive of non-business days) before the Meeting, or any adjournment or postponement of the Meeting, in order for your shares to be voted at the Meeting.

Please review the Circular prior to voting.

In lieu of mailing the Notice of Meeting and Circular and our Financial Statements and MD&A, we are using notice-and-access to provide an electronic copy of these documents to registered holders and beneficial owners of the Issuer's common shares by posting them on the websites noted above. Registered holders and beneficial owners who have previously provided standing instructions will receive a paper copy of the Notice of Meeting, Circular, Financial Statements and MD&A.

If you wish to obtain a paper copy of these documents or for more information regarding notice-and-access you may call us toll free at 1-888-408-7960 from Canada or the United States or 604-408-7960 if you are calling from another country.  You must call to request a paper copy by August 27, 2020 in order to receive a paper copy prior to 10:00 a.m. (Vancouver time) on September 17, 2020, which is the deadline for the submission of your voting instructions or form of proxy.



BURCON NUTRASCIENCE CORPORATION

Notice of Annual and Special Meeting of Shareholders

to be held on September 17, 2020

Management Proxy Circular


TABLE OF CONTENTS

LETTER TO SHAREHOLDERS 1
NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS 1
MANAGEMENT PROXY CIRCULAR 1
GENERAL PROXY INFORMATION 1
Who Can Vote 1
Obtaining a Paper Copy of Management Proxy Circular and Financial Statements 2
Attending the Virtual Only Meeting 2
How You Can Vote 3
Distribution of Meeting Materials to Beneficial Shareholders 5
Solicitation of Proxies 5
Appointment and Revocation of Proxies 5
Exercise of Discretion 6
Votes Necessary to Pass Resolutions 7
Majority Voting for Directors 7
MATTERS TO BE ACTED UPON AT THE MEETING 7
Election of Directors 7
Appointment of Auditors 13
Re-approval of Amended and Restated 2001 Share Option Plan 13
Continuation under the Business Corporations Act (British Columbia) 16
SECURITIES AUTHORISED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 24
CORPORATE GOVERNANCE DISCLOSURE 25
Board of Directors 25
Board Mandate and Ethical Business Conduct 26
Position Descriptions 27
Orientation and Continuing Education 28
Nomination of Directors and Compensation 28
Corporate Governance Committee 29
Assessment 29
Director Term Limits and Gender Diversity 30
Objectives for the year ending March 31, 2021 30
AUDIT COMMITTEE AND DISCLOSURE UNDER NATIONAL INSTRUMENT 52-110 31
STATEMENT OF EXECUTIVE COMPENSATION 31
Compensation Discussion and Analysis 31
Components of Executive Compensation 33
Performance Graph 35
Compensation of Executive Officers 37
Outstanding Option-Based and Share-Based Awards 38
Employment and Consulting Contracts with Named Executive Officers 40
Estimated Termination Payments 44
Compensation of Directors 45
Director Compensation Table 45
Outstanding Option-Based and Share-Based Awards 46
Executive Compensation-Related Fees 48
ADDITIONAL INFORMATION 48
Indebtedness of Directors and Executive Officers 48
Interest of Certain Persons in Matters to be Acted Upon 49
Interest of Informed Persons in Material Transactions 49
Requesting Documentation 49



DIRECTORS' APPROVAL 50
SCHEDULE "A"  AMENDED AND RESTATED 2001 SHARE OPTION PLAN A
SCHEDULE "B"  PROPOSED ARTICLES OF BURCON NUTRASCIENCE CORPORATION B
SCHEDULE "C"  SECTION 193 OF THE YUKON BUSINESS CORPORATIONS ACT C
SCHEDULE "D"  BOARD OF DIRECTORS' MANDATE D
SCHEDULE "E"  CODE OF BUSINESS ETHICS AND CONDUCT E


BURCON NUTRASCIENCE CORPORATION
1946 West Broadway
Vancouver, British Columbia V6J 1Z2
Telephone:  (604) 733-0896
Facsimile:  (604) 733-8821

LETTER TO SHAREHOLDERS

July 30, 2020

Dear Fellow Shareholders,

This past year has truly been a transformative one for Burcon.  We formed a joint venture to build and operate a state-of-the-art production facility to produce our pea and canola proteins, we entered into a collaboration agreement with Nestle and we completed over $36.0 million in financings. 

Through our new joint venture, Merit Functional Foods Corporation ("Merit Foods"), we are now in an excellent position to capitalize on the massive growth in demand for high quality plant-based foods.  Plant-based foods are now being widely recognized for the healthy alternative that they are: an option that is both "good for you and good for the planet". 

This past year saw plant-based food sales grow two times faster than their animal-based meat counterparts.  Driven by concerns over the health and safety of animal-based products, and compounded by pandemic related meat shortages, consumers are shifting their food preferences to plant-based alternatives. 

As Burcon's Chairman, I am proud to share the following significant achievements of the past year.

Merit Functional Foods Joint Venture

In May 2019, Burcon advanced the commercialization of its pea and canola technologies through the establishment of Merit Foods, a joint venture between Burcon and three veteran executives of the agri-foods industry.  Burcon holds a 40% equity interest in Merit Foods and also entered into a 20-year royalty-bearing license with Merit Foods for Burcon's pea and canola protein technologies.  Through the joint venture ownership interest and license agreement Burcon stands to earn a significant return on its investment.

Merit Foods is building a 94,000 square foot protein production facility in Winnipeg, Manitoba to produce, market and sell Burcon's unique pea and canola proteins, as well as new protein blends.  Merit Foods' state-of-the-art protein production facility is on schedule to be completed in Q4 2020 and will be the only commercial facility in the world with the capability to produce non-GMO food grade canola proteins.


2

In response to the overwhelming demand for its plant-based protein ingredients, Merit Foods has already chosen to expand the initially planned production capacity of its pea and canola protein production facility.  To undertake the capacity expansion, Merit Foods secured a debt financing package of $85 million from a syndicate of lenders including Export Development Canada, Farm Credit Canada and the Canadian Imperial Bank of Commerce.  In addition, Merit Foods received a $9.2 million non-repayable grant from Protein Industries Canada and in June 2020, Merit Foods secured an additional $10 million in the form of a 10-year interest-free loan from Agriculture and Agri-Food Canada.  We are pleased and encouraged by the valuable support Merit Foods has received from Canadian government agencies and institutions. 

Taking into account all sources, Merit Foods secured a combined total of over $100 million in debt, and non-repayable grants during the year.  This provides a significant amount of leverage against Burcon's investment into Merit Foods and the funds will allow Merit Foods to accelerate the growth of its business of supplying premium Canadian-grown pea and canola protein ingredients to global consumer product companies.

Joint Development Agreement with Nestle

During the year, Burcon also announced a joint development agreement with Nestle, the world's largest food and beverage company, which represented the culmination of two plus years of effort by our entire team.  The collaboration with Nestle is a testament to Burcon's position as a leader in developing plant-based proteins and further validates our unique high-quality plant protein ingredients.  Burcon has been working diligently with the highly motivated team at Nestle to develop and tailor our novel pea and canola protein ingredients for formulation into new and existing dairy alternative and meat substitute products.  We are excited to be working with such an impressive company as Nestle and we expect this collaboration to be a long-term relationship, developing nutritious and great-tasting plant-based products.

Financing

During fiscal 2020, Burcon raised over $36 million across three financing rounds.  The first of the three financing rounds was an over-subscribed rights offering of $15.4 million in June 2019, which demonstrated the unwavering support of our long-term shareholders, many of whom have been with Burcon since our inception.  Subsequently, in December 2019, we announced our intention to raise $4 million through a non-brokered private placement of convertible debentures, which we subsequently upscaled to $9.5 million due to the significant demand we received.  Lastly, Burcon closed an $11.5 million bought deal financing in February 2020 to carry us forward with our strongest balance sheet in over a decade, providing us with the flexibility to capitalize on key opportunities and to develop additional new novel plant-based protein ingredients.

Protection of Intellectual Property

Building on Burcon's extensive patent portfolio, Burcon was granted an important Peazazz pea protein patent during the year which covers certain valuable properties of Peazazz including its exceptional solubility and clarity in solution at low pH.  Our strategy to protect unique and distinctive attributes that differentiate Burcon's novel plant-based protein ingredients from competitors' proteins, provides Burcon and Merit Foods with a competitive advantage in key markets, including the rapidly-growing dairy alternative beverage market.  We believe the strength of our intellectual property provides a distinct advantage that will help us establish and gain market share in the burgeoning plant-based food market.


3

Also during the past year, the US Food and Drug Administration issued a Generally Recognized As Safe ("GRAS") no-objection letter for Burcon's Peazazz and Peazac pea proteins.  Achieving GRAS-Notified status is a major milestone and is critical for the acceptance and use of our pea proteins by US and global food and beverage companies. 

Support from our Board, team and shareholders

Burcon's Board worked closely with management over this very busy year, and I extend my sincere thanks to the Board for their continued diligence and dedication.  The addition of Debora Fang after year-end as a new Board member brings a welcome skill set, as well as exceptional experience in the food industry. 

I would like to acknowledge and thank our talented and innovative team for their tireless commitment to and belief in Burcon's vision.  Our achievements from this past year are a direct product of our team's efforts and contributions.  Lastly, I would also like to sincerely thank my fellow shareholders for their loyal support and faith in our company.  I look forward to the coming year with high expectations and great enthusiasm.

Yours truly,

"D. Lorne Tyrrell"

D. Lorne Tyrrell, OC AOE MD PhD

Chairman of the Board of Directors


BURCON NUTRASCIENCE CORPORATION
1946 West Broadway
Vancouver, British Columbia V6J 1Z2
Telephone:  (604) 733-0896
Facsimile:  (604) 733-8821

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

TO OUR SHAREHOLDERS:

 Burcon NutraScience Corporation's (the "Corporation" or "Burcon") Annual and Special Meeting (the "Meeting") will be held virtually on September 17, 2020, at 10:00 a.m. (Vancouver time) via live webcast. Registered shareholders and duly appointed proxyholders can attend the Meeting online at https://web.lumiagm.com/484863078 where they can participate, vote of submit questions during the Meeting's live webcast.  The Meeting will be conducted for the following purposes:

a) to receive the report of the directors;

b) to receive the audited consolidated financial statements of the Corporation for the fiscal year ended March 31, 2020, together with the report of the auditors thereon;

c) to elect directors for the ensuing year;

d) to appoint auditors and to authorize the directors to fix their remuneration;

e) to consider, and, if thought advisable, to pass an ordinary resolution to re-approve Burcon's share option plan as more particularly set out in the attached management proxy circular (the "Management Proxy Circular");

f) to consider, and, if thought advisable, to pass a special resolution to approve and have the Corporation continue into the Province of British Columbia (the "Continuance Resolution") pursuant to the Business Corporations Act (British Columbia), as amended (the "BCA") as more particularly set out in the attached Management Proxy Circular;

g) to transact such other business as may properly come before the Meeting or any adjournment of the Meeting; and

h) to consider any amendment to or variation of any matter identified in this Notice.

 Our Management Proxy Circular and form of proxy accompany this Notice.  The Management Proxy Circular contains details of matters to be considered at the Meeting. 


2

 If you are unable to attend the Meeting online and wish to ensure that your shares will be voted at the Meeting, you must complete, date, execute and deliver the accompanying form of proxy by fax at 1-866-249-7775 (within North America) or (416) 263-9524 (outside North America), by hand or by mail to Computershare Investor Services Inc. at Proxy Dept., 100 University Avenue, 8th Floor, Toronto, Ontario, M5J 2Y1, in accordance with the instructions set out in the form of proxy and in the Management Proxy Circular.

 If you plan to attend the Meeting online you must follow the instructions set out in the form of proxy and in the Management Proxy Circular to ensure that your shares will be voted at the Meeting.

 DATED at Vancouver, British Columbia on July 30, 2020.

BY ORDER OF THE BOARD OF DIRECTORS

"Johann F. Tergesen" 

Johann F. Tergesen

President and Chief Executive Officer


BURCON NUTRASCIENCE CORPORATION

1946 West Broadway
Vancouver, British Columbia V6J 1Z2
Telephone:  (604) 733-0896
Facsimile:  (604) 733-8821

MANAGEMENT PROXY CIRCULAR

as at July 30, 2020

 The board of directors (the "Board") of Burcon NutraScience Corporation (the "Corporation") is delivering this management proxy circular (the "Management Proxy Circular") to you in connection with the solicitation of proxies for use at the annual and special meeting of its shareholders (the "Meeting") to be held on September 17, 2020 at the time and place and for the purposes set forth in the accompanying Notice of Meeting.  In this Management Proxy Circular, unless the context otherwise requires, all references to "Burcon NutraScience Corporation", "Burcon", "we", "us" and "our" refer to Burcon NutraScience Corporation.

GENERAL PROXY INFORMATION

Who Can Vote

 Burcon is authorized to issue an unlimited number of common shares ("Common Shares") without nominal or par value.  As of July 30, 2020, we had outstanding 98,176,920 Common Shares.  Persons who on July 30, 2020 are recorded on our share register as holders of our Common Shares can vote at the Meeting.  Each Common Share has the right to one vote.

 To the knowledge of our directors and officers, as of July 30, 2020, the only person or corporation who beneficially owns, directly or indirectly, or exercises control or direction over, Common Shares carrying 10% or more of the voting rights attached to all outstanding Common Shares of Burcon is:

 

Number of Shares Held

Percentage of Voting Shares

Firewood Elite Limited ("Firewood") (a British Virgin Islands Company)

22,866,574*

23.3%

Note:

*  17,584,458 of these shares are held by Large Scale Investments Limited and 5,282,116 of these shares are held by Great Intelligence Limited, both of which are British Virgin Islands companies and direct wholly-owned subsidiaries of Firewood.  Firewood is wholly-owned by Mr. Alan Chan, a director of the Corporation.


2

Obtaining a Paper Copy of Management Proxy Circular and Financial Statements

In lieu of mailing the Notice of Meeting, Management Proxy Circular and our audited financial statements and management's discussion and analysis for the year ended March 31, 2020, the Corporation is using notice-and-access to provide an electronic copy of these documents to registered shareholders and beneficial shareholders of the Corporation's Common Shares by posting them on www.burcon.ca and on the Corporation's profile on www.SEDAR.com. 

If you wish to obtain a paper copy of these documents or for more information regarding notice-and-access, you may call us toll free at 1-888-408-7960 from Canada or the United States or 604-408-7960 if you are calling from another country.  You must call to request a paper copy by August 27, 2020 in order to receive a paper copy prior to the deadline for submission of your voting instructions or form of proxy.  If your request is received on or after the date of the Meeting, then the documents will be sent to you within ten calendar days of your request.  Burcon will provide a paper copy of the documents to any registered or beneficial shareholder upon request for a period of one year following the date of the filing of this Management Proxy Circular on www.SEDAR.com.

If you are a registered shareholder and have standing instructions to receive paper copies of these documents and would like to revoke them, you may call us toll free at 1-888-408-7960 from Canada or the United States or 604-408-7960 if you are calling from another country.

Attending the Virtual Only Meeting

The meeting will be hosted online by way of a live webcast. Shareholders will not be able to attend the meeting in person.  Shareholders and duly appointed proxyholders can attend the meeting online by going to https://web.lumiagm.com/484863078.

Shareholders who wish to appoint a third party proxyholder to represent them at the online meeting must submit their proxy or voting instruction form (as applicable) prior to registering their proxyholder.  Registering the proxyholder is an additional step once a shareholder has submitted their proxy/voting instruction form.  Failure to register a duly appointed proxyholder will result in the proxyholder not receiving a Username to participate in the meeting. To register a proxyholder, shareholders MUST visit http://www.computershare.com/burcon by 10am Vancouver time on September 15, 2020 and provide Computershare Trust Company of Canada / Computershare Investor Services Inc. ("Computershare") with their proxyholder's contact information, so that Computershare may provide the proxyholder with a Username via email.   


3

It is important that you are connected to the internet at all times during the meeting in order to vote when balloting commences.

In order to participate online, shareholders must have a valid 15-digit control number and proxyholders must have received an email from Computershare containing a Username. 

How You Can Vote

If you are a registered shareholder (i.e., your Common Shares are held in your name) you may vote your Common Shares either by attending the online Meeting or, if you do not plan to attend the online Meeting, by completing the accompanying form of proxy and following the delivery instructions contained in it and this Management Proxy Circular.

If you are a beneficial shareholder (i.e., your Common Shares are held in "street name" because they are registered in the name of a stockbroker or financial intermediary), you must follow the instructions on the voting instruction form ("VIF"), which is similar to a form of proxy, but is provided to you by your stock broker or financial intermediary.  If you do not follow the special procedures described by your broker or financial intermediary, you will not be entitled to vote.  If you are unsure as to how to follow these procedures, please contact your stockbroker.

A summary of the information shareholders will need to attend and vote at the online meeting is provided below. The meeting will begin at 10:00am Vancouver time on September 17, 2020.


4

Computershare
100 University Avenue

8th Floor

Toronto, Ontario

M5J 2Y1

Email:  uslegalproxy@computershare.com

Requests for registration must be labeled as "Legal Proxy" and be received no later than 10am Vancouver time on September 15, 2020.  You will receive a confirmation of your registration by email after we receive your registration materials. You may attend the Meeting and vote your shares at https://web.lumiagm.com/484863078  during the meeting.  Please note that you are required to register your appointment at http://www.computershare.com/burcon

If you are eligible to vote at the meeting, it is important that you are connected to the internet at all times during the meeting in order to vote when balloting commences. It is your responsibility to ensure connectivity for the duration of the meeting.

A registered shareholder of Common Shares, or a non- registered shareholder who has appointed themselves or a third party proxyholder to represent them at the Meeting, will appear on a list of shareholders prepared by Computershare, the transfer agent and registrar for the Meeting. To have their Common Shares voted at the Meeting, each registered shareholder or proxyholder will be required to enter their control number or Username provided by Computershare at https://web.lumiagm.com/484863078 prior to the start of the meeting. In order to vote, non-registered shareholders who appoint themselves as a proxyholder MUST register with Computershare at http://www.computershare.com/burcon after submitting their voting instruction form in order to receive a Username (please see the information under the headings "Appointment and Revocation of Proxies" below for details).


5

Distribution of Meeting Materials to Beneficial Shareholders

The Corporation has distributed copies of the notice-and-access notice and VIF to the depositories and intermediaries for onward distribution to beneficial shareholders. In addition, the notice-and-access notice and VIF may have been sent directly by the Corporation or its agent, rather than through an intermediary, to non-objecting beneficial owners under National Instrument 54-101 - Communication with Beneficial Owners of Securities of a Reporting Issuer ("NI 54-101"). Beneficial shareholders who have previously provided standing instructions will receive a paper copy of the Notice of Meeting, Management Proxy Circular, financial statements and related management discussion and analysis. If you are a non-objecting beneficial shareholder and the Corporation or its agent has sent these materials directly to you, your name and address and information about your holdings and securities have been obtained in accordance with the requirements of NI 54-101 from the intermediary holding on your behalf.  All costs of deliveries to beneficial shareholders will be borne by Burcon.

Solicitation of Proxies

The solicitation of proxies will be primarily by mail, but proxies may be solicited personally or by telephone by directors, officers and regular employees of Burcon.  All costs of this solicitation will be borne by Burcon.

Appointment and Revocation of Proxies

Registered Shareholders

The individuals named in the accompanying form of proxy are the President and Chief Executive Officer of Burcon and the Senior Vice President, Legal and Corporate Secretary of Burcon.  You may also appoint some other person, who need not be a shareholder, to represent you at the Meeting by following the instructions below under the heading "Third Party Proxyholder".  A proxy will not be valid unless the completed, signed and dated form of proxy is delivered to Computershare Investor Services Inc.  by fax at 1-866-249-7775 (within North America) or (416) 263-9524 (outside North America), by mail or by hand at its office at Proxy Dept., 100 University Avenue, 8th Floor, Toronto, Ontario, M5J 2Y1 not less than 48 hours (exclusive of non-business days) before the Meeting or any adjournment thereof at which the proxy is to be used.                A registered shareholder may revoke a proxy by

(a) providing a written notice of revocation to Computershare Investor Services Inc. by fax at 1-866-249-7775 (within North America) or (416) 263-9524 (outside North America), by mail or by hand at its office at Proxy Dept., 100 University Avenue, 8th Floor, Toronto, Ontario, M5J 2Y1 at any time up to and including the last business day that precedes the day of the Meeting or, if the Meeting is adjourned, that precedes the reconvening thereof,

(b) providing a written notice of revocation to Burcon at its head office which is located at 1946 West Broadway, Vancouver, British Columbia, V6J 1Z2 at any time up to and including the last business day that precedes the day of the Meeting or, if the Meeting is adjourned, that precedes the reconvening thereof,


6

(c) providing a written notice of revocation to the Chairman of the Meeting on the day of the Meeting and before any vote in respect of which the proxy to be used is taken that you are revoking your proxy and voting in person at the Meeting, or

(d) any other manner provided by law.

Your revocation of a proxy will not affect a matter on which any vote has already been taken.

Beneficial Shareholders

If you are a beneficial shareholder and wish to revoke your VIF, you should contact you stock broker or financial intermediary directly. 

Third Party Proxyholder

Shareholders who wish to appoint a third party proxyholder to represent them at the online meeting must submit their proxy or voting instruction form (if applicable) prior to registering your proxyholder.  Registering your proxyholder is an additional step once you have submitted your proxy or voting instruction form.  Failure to register the proxyholder will result in the proxyholder not receiving a Username to participate in the meeting. To register a proxyholder, shareholders MUST visit http://www.computershare.com/burcon by (day/time) and provide Computershare with their proxyholder's contact information, so that Computershare may provide the proxyholder with a Username via email.  Without a Username, proxyholders will not be able to vote at the meeting.

If a shareholder who has submitted a proxy attends the meeting via the webcast and has accepted the terms and conditions when entering the meeting online, any votes cast by such shareholder on a ballot will be counted and the submitted proxy will be disregarded.

Exercise of Discretion

The nominees named in the accompanying form of proxy will vote or withhold from voting the Common Shares represented by the proxy in accordance with your instructions on any ballot that may be called for and if you specify a choice with respect to any matter to be acted upon, the Common Shares will be voted accordingly.  The proxy grants the nominees the discretion to vote on

(a) each matter or group of matters identified in the proxy where you do not specify how you want to vote, except for the election of directors and the appointment of auditors,

(b) any amendment to or variation of any matter identified in the proxy, and

(c) any other matter that properly comes before the Meeting.

If on a particular matter to be voted on, you do not specify in your proxy the manner in which you want to vote, your Common Shares will be voted as recommended by management.


7

As of the date of this Management Proxy Circular, we know of no amendment, variation or other matter that may come before the Meeting, but if any amendment, variation or other matter properly comes before the Meeting each proxyholder named in the proxy can vote in accordance with their discretion.

Votes Necessary to Pass Resolutions

Burcon's by-laws provide that a quorum for the transaction of business at any shareholders' meeting is two persons present in person or by proxy representing 5% of the outstanding Common Shares entitled to vote at the Meeting.  A simple majority of affirmative votes cast at the Meeting is required to pass the resolutions other than the election of directors and appointment of auditor.  If there are more nominees for election as directors or appointment as Burcon's auditor than there are vacancies to fill, those nominees receiving the greatest number of votes will be elected or appointed, as the case may be, until all such vacancies have been filled.  If the number of nominees for election or appointment is equal to the number of vacancies to be filled all such nominees will be declared elected or appointed by acclamation.

Majority Voting for Directors

The Board has adopted a majority voting policy for the election of directors.  Pursuant to this policy, any nominee proposed for election as a director in an uncontested election who receives, from the shares voted at the meeting in person or by proxy, a greater number of shares withheld than shares voted in favour of his or her election, must promptly tender his or her resignation to the board of directors of the Corporation. The Board will promptly accept the resignation unless it is determined that there are extraordinary circumstances relating to the composition of the board or the voting results that should delay the acceptance of the resignation or justify rejecting it.  The Board will make its decision and reasons available to the public within 90 days of the annual meeting.

MATTERS TO BE ACTED UPON AT THE MEETING

Election of Directors

Burcon's Articles of Incorporation provide that the Board is to be comprised of a minimum of three directors and a maximum of ten directors.  The number of directors is fixed by the Board, and has been fixed at eight for the ensuing year.  The term of office of each of the present directors expires at the conclusion of the Meeting.  The persons named below will be presented for election at the Meeting as management's nominees and the persons named in the accompanying form of proxy intend to vote for the election of these nominees.  Management does not contemplate that any of these nominees will be unable to serve as a director; however, if for any reason any proposed nominee does not stand for election or is unable to serve as such, proxies in favour of management's designees will be voted for another nominee in its discretion unless the shareholder has specified in his proxy that his or her Common Shares are to be withheld from voting on the election of directors.  Each director elected will hold office until the conclusion of the next annual meeting of shareholders of Burcon or until his or her successor is elected or appointed, unless his or her office is earlier vacated in accordance with our by-laws or with the provisions of the Business Corporations Act (Yukon).


8

The following table sets out the names of the nominees for election as directors, the province and/or country in which each is ordinarily resident, all offices of Burcon now held by each of them, their principal occupations, the period of time for which each has been a director of Burcon, and the number of Common Shares of Burcon beneficially owned by each, directly or indirectly, or over which control or direction is exercised, as at July 30, 2020. A biography of each director, which includes a five year history of employment, follows under "Biographies of Directors". 

Name, Position and Country of Residence(1)

Principal Occupation During the Previous Five Years(1)

Period as a Director of the Corporation

Common Shares Held(1)

Rosanna Chau, Director,
Hong Kong, China

 

Director of certain subsidiaries of PT International Development Corporation Limited ("PT International") (formerly known as ITC Corporation Limited) (investment holding) until September 2019; Deputy Chairman and Executive Director of PT International until December 28, 2017

Since November 3, 1998

850,022

David Lorne John Tyrrell,

Chairman of the Board and Director,

Alberta, Canada

Chairman of the Board of Burcon since January 2019; Director, Li Ka Shing Institute of Virology & Distinguished University Professor, University of Alberta since April 2010; Glaxo SmithKline Chair in Virology, Department of Medical Microbiology and Immunology, University of Alberta since 2004; Chief Scientific Officer of KMT Hepatech (biotechnology company in Edmonton) from 2004 to 2017; Professor of Medical Microbiology & Immunology, University of Alberta since 1982

Since December 1, 2009

500,923(2)

Alan Chan,

Director,

Hong Kong, China

Executive director of ITC Properties Group Ltd. (property development and investment) since March 2010; Executive Director of PT International Development Corporation Limited  (formerly ITC Corporation Limited) (investment holding) from March 2009 to March 2017;  Executive director of PYI from November 2011 to July 2016; Non-executive director of PYI from July 2016 to April 2017

Since April 20, 2010

22,866,574(3)

J. Douglas Gilpin,

Director,

Alberta, Canada

Consultant, providing corporate governance, corporate director and business advisory services; Retired KPMG from 1999-2020

Since September 1, 2011

NIL



9


Name, Position and Country of Residence(1)

Principal Occupation During the Previous Five Years(1)

Period as a Director of the Corporation

Common Shares Held(1)

Peter H. Kappel

Director,

British Columbia, Canada

Corporate Director

Since January 28, 2016

499,608(4)

David Ju

Director,

British Columbia,

Canada

Real Estate Investment and Development

Since December 21, 2017

NIL

Calvin Chi Leung Ng

Director,

Hong Kong, China

Group Legal Counsel, ITC Properties Group Ltd. (property development and investment) from April 2017; Legal Counsel/Group Legal Counsel, PT International Development Corporation Limited (formerly known as ITC Corporation Limited) (investment holding) from September 2009 to March 2017

Since July 23, 2019

NIL

Debora S. Fang

Director,

London, United Kingdom

Independent advisor, F&F Advisory from 2018 to present; VP, M&A, Unilever from 2013 to 2018

 

Since July 6, 2020

NIL

(1) The information as to province, country of residence, principal occupation, and Common Shares beneficially owned has been furnished by the respective nominees.

(2) 25,519 of these Common Shares are held by Kathleen Tyrrell (daughter) and 46,940 of these Common Shares are held by spouse, Lee Ann Tyrrell.  As at July 30, 2020, Dr. Tyrrell holds convertible debentures in the principal amount of $500,000 which are convertible into 476,190 Common Shares at $1.05 per share.

(3) Alan Chan's wholly-owned company, Firewood Elite Limited, holds through its wholly-owned subsidiaries Large Scale Investments Limited and Great Intelligence Limited, 22,866,574 Common Shares, representing 23.3% of the outstanding Common Shares.

(4) 20,584 of these Common Shares are held by Philip Kappel (son) and 62,492 of these Common Shares are held by Stefanie Kappel (spouse).  As at July 30, 2020, Mr. Kappel holds convertible debentures in the principal amount of $500,000 which are convertible into 476,190 Common Shares at $1.05 per share.

Biographies of Directors

Rosanna Chau - Director

Ms. Chau has over 39 years of experience in international corporate management, strategic investments and finance.  Throughout her career, she has served on the board of directors of twelve publicly-listed companies spanning multiple industries, including property, hotel, bio-tech, construction and building materials, pharmaceuticals, entertainment, and consumer electronics products, and geographical locations, including Hong Kong, Mainland China, Macau, the United States, Canada, Singapore, Australia and Europe.  Ms. Chau holds a Bachelor's Degree in Commerce at the University of Alberta and a Master's Degree in Commerce at the University of New South Wales and has been awarded the Certificate in Traditional Chinese Medicine: A Way to Health at the Chinese University of Hong Kong.  She has professional accounting qualifications and experience in different jurisdictions and is a fellow member of the Hong Kong Institute of Certified Public Accountants and the CPA Australia and a member of the Chartered Professional Accountants of British Columbia. 


10

David Lorne John Tyrrell - Director

D. Lorne Tyrrell is a distinguished professor in the Department of Medical Microbiology and Immunology at the University of Alberta.  Since 1986, he has focused his research on viral hepatitis.  Supported by the Canadian Institute of Health Research and Glaxo Canada, Dr. Tyrrell's work on the development of antiviral therapy resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection - lamivudine - in 1998.  Dr. Tyrrell holds more than 60 international patents for his studies on viral hepatitis.  Dr. Tyrrell was Dean of the Faculty of Medicine and Dentistry from 1994 - 2004 at the University of Alberta and is currently the Chair of the Board of Directors of the Gairdner Foundation.  The Canada Gairdner International Awards recognizes excellence in medical science research globally.  Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation (2000), the FNG Starr Award of the Canadian Medical Association (2004), the Principal Award of the Manning Awards Foundation (2005) and the Queen Elizabeth II Diamond Jubilee Medal (2012).  Dr. Tyrrell was appointed Officer of the Order of Canada in 2002.  In April 2010, Dr. Tyrrell was appointed as the founding director of the Li Ka Shing Institute of Virology at the University of Alberta.  On April 28, 2011, Dr. Tyrrell was inducted to the Canadian Medical Hall of Fame.  In 2015, he was awarded the Canada Council for the Arts Killam Prize in Health Sciences. 

Alan Chan - Director

Mr. Chan is an executive director of ITC Properties Group Limited ("ITC Properties").  At ITC Properties, Mr. Chan is involved with the investment and development of commercial, hospitality and residential projects.  In addition, he is the lead in developing new policies for green and sustainable practices throughout the group.  Prior to joining ITC Properties, Mr. Chan worked in the Investment Banking Division of Goldman Sachs Group with a focus on capital raising, mergers & acquisitions and strategic advisory for financial institutions in Greater China and Southeast Asia. Mr. Chan is a graduate of Duke University majoring in Political Science - International Relations and minoring in Philosophy and Economics. 

J. Douglas Gilpin - Director

Douglas Gilpin, FCA, FCPA, ICD.D., retired from the partnership of KPMG LLP in 1999.  In 2008, Mr. Gilpin received a Life Service Award from The Institute of Chartered Accountants of Alberta in recognition of 40 years experience in delivering professional services to business and the community.  During his 18 years tenure as a partner in Advisory Services at KPMG he served as an audit engagement partner.  He was a member of the KPMG's National Quality Assurance, the National Financial Institutions and Insurance Groups and he was the Quality Assurance Partner for the Edmonton office for 10 years.  Mr. Gilpin has consulted on corporate governance, including compliance with the Sarbanes Oxley Act 404 and National Instrument 52-109 reporting for issuers listed on the Toronto Stock Exchange.  Mr. Gilpin has served as a director of Canada Health Infoway ("CHI"), Afexa Life Sciences Inc., Alberta Innovates (formerly Alberta Innovates Technology Futures) ("AITF") and the board of the Health Quality Council of Alberta ("HQCA").  He was the chair of the governance committee and a member of the audit committee of CHI, and was the Chair of the audit committee AITF and HQCA.  He currently is a director and chair of the audit committee of The Institute of Health Economics.  Mr. Gilpin is executive chair of The Inspections Group Inc., a privately owned company that performs safety code inspection services, building, plumbing and gas and electrical inspections in compliance with the Safe Codes Act of Alberta.  Mr. Gilpin is a member of the Institute of Corporate Directors and received his ICD.D designation from the Institute in 2011.  Mr. Gilpin was elected a Fellow of the Institute of Chartered Accountants of Alberta in 2012.


11

Peter H. Kappel - Director

Mr. Kappel is a former investment banker who now manages a private investment portfolio.  A former chartered accountant with KPMG in Vancouver and Frankfurt, he made the transition to investment banking with JP Morgan (New York/Frankfurt) after business school.  He also served in senior roles at Nomura, Dresdner Kleinwort Wasserstein, Calyon and DVB Bank in London.  In the latter three, he was the Managing Director in charge of their respective European Securitisation businesses.  He was responsible for many ground breaking transactions, a regular speaker at ABS conferences and a founding and former executive committee member of the European Securitisation Forum of the Bond Market Association.  He holds an MBA from the Institut Européen d'Administration des Affaires ("INSEAD"), a Bachelor of Arts (Honours) degree in Economics from the University of Victoria and received his Chartered Accountant designation through the Institute of Chartered Accountants of British Columbia.  Mr. Kappel is on the Board of Partnerships British Columbia, where he serves as Audit Committee Chair.  Mr. Kappel is on the board of directors of the British Columbia Lottery Corporation, where he serves as Board Chair.

David Ju - Director

Mr. Ju is a Vice President of Concord Pacific Group, a Canadian multi-industry investment group with a diverse portfolio of businesses in Canada, the United Kingdom and Hong Kong. Mr. Ju has extensive experience in financial services and large-scale real estate development projects in both the United States and Canada.  A Chartered Accountant by training, Mr. Ju was a former member of PricewaterhouseCoopers in Vancouver and New York, where he consulted on transactions, and advised on corporate governance and assurance matters, including compliance with the Sarbanes Oxley Act 404 for clients listed on both the Toronto Stock Exchange as well as the New York Stock Exchange.  Mr. Ju holds a Bachelor's Degree in Business Administration from Simon Fraser University and is a member of the Chartered Professional Accountants of British Columbia.

Calvin Chi Leung Ng - Director

Mr. Ng has over 21  years' experience of advising on and executing corporate and commercial transactions in law firm and private sectors.  During his professional career, Mr. Ng has been involved in various commercial projects, setting up and overseeing corporate governance and regulatory compliance mechanisms, and providing recommendations on business undertakings.  He is currently the Group Legal Counsel of ITC Properties Group Limited ("ITC Properties") and a director of certain subsidiaries of ITC Properties.  Mr. Ng holds a Bachelor's degree in Laws and a Postgraduate Certificate in Laws from The University of Hong Kong. He was admitted as a solicitor of the High Court of Hong Kong Special Administrative Region in 1999 and is a practising member of The Law Society of Hong Kong.


12

Debora S. Fang - Director

Mrs. Debora Fang has 20 years' experience in the Fast Moving Consumer Goods industry, across mergers and acquisitions, strategy, finance and marketing roles in Unilever (London, UK), Danone (Paris, France and Amsterdam, Netherlands), Kraft Foods (Sao Paulo, Brazil) and as a consultant for Bain & Company (Los Angeles, USA).  While at Unilever as VP Mergers & Acquisitions, Ms. Fang was responsible for a range of acquisitions and disposals in the Foods, Ice cream and Tea categories, leading multidisciplinary teams and covering a global scope. She is now an independent advisor for Private Equity and strategic clients in the Foods arena as well as a private investor. Ms. Fang holds an MBA from the Kellogg Graduate School of Management at Northwestern University in Chicago, USA and a Bachelor of Arts in Business from the University of Sao Paulo, Brazil.

Board Committees

Burcon does not have an executive committee of its directors.  Burcon has an audit committee, a corporate governance committee and a nominating and compensation committee. The members of the audit committee are Debora Fang, J. Douglas Gilpin, David Ju and Peter H. Kappel.  The members of the corporate governance committee are J. Douglas Gilpin, Peter Kappel and Lorne Tyrrell.  The members of the nominating and compensation committee are David Ju, Peter H. Kappel and Lorne Tyrrell.         

Cease Trade Orders, Bankruptcies, Penalties or Sanctions

Other than as set out below, none of the persons nominated for election as a director:

(a) is, as at the date of this Management Proxy Circular, or has been within 10 years before the date of this Management Proxy Circular, a director or chief executive officer or chief financial officer of any company (including Burcon) that:

(a) was subject to an order that was issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer; or

(b) was subject to an order that was issued after the proposed director ceased to be a director, chief executive officer, or chief financial officer, and which resulted from an event that occurred while that person was acting in the capacity as a director, chief executive officer, or chief financial officer;

(b) is at the date hereof, or has been within 10 years before the date of this Management Proxy Circular, a director or executive officer of any company (including Burcon) that while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets;


13

(c) has, within the 10 years before this Management Proxy Circular become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director;

(d) has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or

(e) has been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.

Ms. Rosanna Chau was the Deputy Chairman and Executive Director of PT International (formerly ITC Corporation Limited ("ITC")), a company whose shares are listed on The Stock Exchange of Hong Kong Limited, up to December 28, 2017.  On November 15, 2005 the Securities and Futures Commission (the "SFC") of Hong Kong criticized the board of directors of ITC for breaching Rule 21.3 of the Code on Takeovers and Mergers (the "Takeovers Code") in respect of the dealing in the securities of Hanny Holdings Limited ("Hanny"), (now known as Master Glory Group Limited) by ITC during an offer period without the consent of the Executive Director of the Corporate Finance Division of the SFC.  Rule 21.3 of the Takeovers Code restricts share dealings and transactions by an offeror and parties acting in concert with it during securities exchange offers.  Hanny was involved in a securities exchange offer announced in April 2005.  Since ITC held over 20% of the shares of Hanny, it was presumed to be acting in concert with Hanny under the Takeovers Code.  Ms. Rosanna Chau was a director of ITC at that time.

Appointment of Auditors

PricewaterhouseCoopers LLP, Chartered Professional Accountants ("PwC"), of Suite 700, 250 Howe Street, Vancouver, B.C., V6C 3S7 will be nominated at the Meeting for reappointment as auditor of Burcon at a remuneration to be fixed by the directors.  PwC has been Burcon's auditor since March l, 2001.

Re-approval of Amended and Restated 2001 Share Option Plan

At Burcon's annual and special meeting held on September 19, 2001, the shareholders of Burcon approved the terms of the 2001 Share Option Plan (the "Plan") under which directors, officers, employees, management company employees and consultants ("Service Providers") of Burcon may be granted options to acquire Common Shares of Burcon.  The principal purpose of the Plan is to encourage equity participation in Burcon by its Service Providers so that they have an interest in preserving and maximizing shareholder value in the longer term while enabling Burcon to attract and retain individuals with experience and ability and reward individuals for current and expected future performance.  The Plan had a fixed number of options that could be granted to Service Providers.  The Plan was amended in 2003, 2004, 2007 and 2009 to increase the number of Common Shares issuable under the Plan.  At Burcon's annual meeting on September 1, 2011, the shareholders of Burcon approved the amendment to the Plan to convert it from a fixed plan to a rolling plan (the "Amended and Restated Plan").  A rolling plan has a plan maximum expressed as a percentage of the total number of common shares outstanding on a non-diluted basis and all exercised, cancelled, expired or terminated options become available for future grant.  The Amended and Restated Plan permits the issuance of that number of options up to a maximum of 10% of the issued and outstanding Common Shares of Burcon from time to time.  As of the date hereof, Burcon has 98,176,920 Common Shares outstanding of which 10% is 9,817,692.


14

During the year ended March 31, 2013, the Board amended the Amended and Restated Plan to provide optionees with an alternative method to exercise stock options.  An optionee may elect to exercise an option using the cashless method, whereby the optionee receives the number of shares the value of which is equal to the amount by which the fair market value of the Common Shares exceeds the option exercise price.  The fair market value is determined by the weighted average trading price of the Common Shares during the five trading days preceding the date of exercise.

The TSX requires that rolling plans, such as the Amended and Restated Plan, be approved by a majority of directors and by shareholders every three years.  The Amended and Restated Plan was re-approved on the first 3 year anniversary by directors and shareholders on July 24, 2014 and September 10, 2014, respectively.  The Amended and Restated Plan was re-approved on the second 3 year anniversary by directors and shareholders on July 18, 2017 and September 7, 2017, respectively.  The next three year anniversary of the approval of the Amended and Restated Plan is September 7, 2020.  The Board unanimously re-approved the Amended and Restated Plan on July 23, 2020. The Board does not intend to grant any options under the Amended and Restated Plan after September 7, 2020 until re-approval by the Shareholders has been obtained at the Meeting.

The principal terms of the Amended and Restated Plan are summarized as follows: 

 The aggregate number of optioned shares that may be granted under the Amended and Restated Plan, shall not exceed 10% of the Common Shares then issued and outstanding on a non-diluted basis.  Any increase in the issued and outstanding Common Shares will result in an increase in the number optioned shares available under the Amended and Restated Plan and any exercise, conversion, redemption, expiry, termination, cancellation or surrender of options granted will make additional optioned shares available under the Amended and Restated Plan;

 The Board is responsible for the general administration of the Amended and Restated Plan and the proper execution of its provisions and its interpretation; 

 The Amended and Restated Plan contains limitations on option issuances.  The limitations are unless disinterested shareholder approval is obtained: (a) insiders cannot be granted awards under the Amended and Restated Plan or any other security based compensation plan to purchase more than 10% of the listed Common Shares within any 12 month period; and (b) the aggregate number of outstanding awards granted to insiders under the Amended and Restated Plan or any other security based compensation plan may not exceed 10% of the listed Common Shares at any time.  As of the date of this Management Proxy Circular the Corporation has no other security based compensation plans.


15

 Other than in the case of an optionee's death, where options become exercisable by the deceased optionee's lawful personal representatives, heirs or executors, all options granted under the Amended and Restated Plan continue to be non-assignable and non-transferable, however, the Amended and Restated Plan allows for a transfer to a Service Provider's registered retirement savings plan, registered retired income fund or tax-free savings account, or the equivalent thereof, established by or for the benefit of the optionee;

 A Service Provider who is no longer employed by Burcon, except in the case of death, retirement or the participant becoming totally disabled, has up to the lesser of 30 days after ceasing to be a Service Provider, and the expiration of the term applicable to such option, to exercise their options;

 In the case of an optionee's death, any vested option held on the date of death is exercisable by the optionee's lawful personal representatives, heirs or executors until the earlier of one year from death and the expiration of the option's term, while in the case where a Service Provider has retired, become totally disabled or died after ceasing to be a Service Provider, outstanding options whether vested or unvested can be exercised by the optionee, or if the optionee has died by their personal representatives, until the earlier of the option's expiry date and 90 days after the date of retiring, becoming totally disabled or death after ceasing to be a Service Provider;

 The exercise price of the options will be set by the Board at the time the options are allocated but cannot be less than the price per Burcon's common share traded on the TSX as at the closing on the last trading day before the date that the options are granted;

 The Board at their discretion has the power to determine the time, or times when options will be granted, vest and be exercisable and to determine when it is appropriate to accelerate when options otherwise subject to vesting may be exercised;

 The term of an option will not exceed 10 years from the date of grant, however, if the expiry date of any vested option falls during or within nine business days of a black-out period or other trading restriction imposed by Burcon, then the option's expiry date shall be automatically extended for ten business days following the date of the relevant black-out period or other trading restriction being lifted, terminated or removed;

 The Board has the ability to: (a) with shareholder approval by ordinary resolution make any amendment to any option commitment, option or the Amended or Restated Plan; and (b) without shareholder approval make any amendments: (i) of a clerical nature, (ii) to reflect regulatory requirements, (iii) to vesting provisions, (iv) to expiration dates as long as there is no extension past the original date of expiration, and (v) providing for a cashless exercise feature; and 

 The Amended and Restated Plan allows Burcon to satisfy its withholding obligations from any amount payable to a Service Provider that is an optionee as is required by law to be withheld or deducted upon an option exercise.


16

As at the date of this Management Proxy Circular, a total of 4,507,606 stock options are issued and outstanding under the Plan representing  approximately 4.59% of our issued and outstanding capital.  If re-approval of the Amended and Restated Plan by Shareholders is obtained, then 5,310,086 options will be available for grant under the Amended and Restated Plan representing approximately 5.41% of the issued and outstanding Common Shares as of the date hereof.

Shareholders are being asked to re-approve the Amended and Restated Plan attached as Schedule "A" to this Management Proxy Circular, by passing the following ordinary resolution:

"BE IT RESOLVED AS AN ORDINARY RESOLUTION THAT:

1. The Amended and Restated Plan, in the form approved by the Board and attached as Schedule "A" to the Corporation's Management Proxy Circular dated July 30, 2020, be and is hereby approved.

2. All unallocated options under the Amended and Restated Plan be and are hereby approved.

3. The Corporation have the ability to continue granting options under the Amended and Restated Plan until September 17, 2023, being the date which is three years from the date of the shareholders' meeting at which shareholders' approval is being sought.

4. Any one officer or director of the Corporation is authorized on behalf and in the name of the Corporation to execute all such documents and to take all such actions as may be necessary or desirable to implement and give effect to this resolution or any part thereof."

In order for this ordinary resolution to be passed, it requires the positive approval of a simple majority (greater than 50%) of the votes cast thereon at the Meeting.  The directors of the Corporation believe the passing of the foregoing ordinary resolution is in the best interests of the Corporation and recommend that shareholders of the Corporation vote in favour of the resolution.  The persons named as proxies in the enclosed Proxy intend to cast the votes represented by proxy in favour of the foregoing resolution unless the holder of Common Shares who has given such proxy has directed that the votes be otherwise cast.

Continuation under the Business Corporations Act (British Columbia)

The Corporation was incorporated under the Business Corporations Act (Yukon) (the "YBCA") on November 3, 1998 under the name "Burcon Capital Corp." and extra-provincially registered in British Columbia on February 5, 1999. The Board has determined that it would be more expedient and cost effective to have the Corporation continue into the Province of British Columbia (the "Continuance") pursuant to the Business Corporations Act (British Columbia), as amended (the "BCA"). Upon completion of the Continuance, the BCA will apply to the continued company to the same extent as if the Corporation had been incorporated under the BCA. Therefore, pursuant to the YBCA, shareholders of the Corporation will be asked to consider and, if thought advisable, to approve a special resolution (the "Continuance Resolution") authorizing the Board, in its sole discretion, to continue the Corporation out of the Yukon Territory and into the jurisdiction of the province of British Columbia under the BCA.


17

The Continuation Process

The process to effect the Continuance would proceed as follows:

1) Shareholders of the Corporation must authorize, by special resolution, the Continuance Resolution at the Meeting;

2) upon application by the Corporation, the Yukon Registrar will issue a Notice of Authorization to continue the Corporation into the other jurisdiction;

3) the Corporation will then file with the British Columbia Registrar of Companies (the "BC Registrar") a continuation application (a "Continuation Application") in the prescribed form setting out the name reserved for the continuing company, being the current name of the Corporation, "Burcon NutraScience Corporation", and a notice of articles (the "Notice of Articles") reflecting the information that will apply to the continuing company on its recognition;

4) the Corporation will also provide the BC Registrar with any records or information required regarding the standing of the continuing company in the foreign corporation's jurisdiction or required for authorization for the continuation from the foreign corporation's jurisdiction;

5) the BC Registrar will then authorize the proposed Continuance under the BCA and issue a Certificate of Continuance;

6) the Corporation will send the Yukon Registrar a certified copy of the Certificate or Continuance and the Yukon Registrar will file it and issue a Certificate of Discontinuance; and

7) on the date shown on its Certificate of Continuance, the Corporation becomes a corporation governed by the BCA, as if it had been incorporated under the BCA, and the Corporation will cease to be a YBCA corporation.

Under the BCA, the charter documents of the Corporation will consist of a Notice of Articles, which sets forth the name of the corporation and the amount and type of authorized capital, and articles (the "Articles"), which will govern the management of the continuing company following the Continuance. A Continuation Application with the Notice of Articles will be filed with the BC Registrar and the Articles will be filed only with the continuing company's records office.

The Continuance and the adoption of the Notice of Articles and Articles will not result in any substantive changes to the constitution, powers or management of the Corporation, except as otherwise described herein. A copy of the Articles is attached to this Management Proxy Circular in Schedule "B".

The following is a summary comparison of the provisions of the BCA and the YBCA which pertain to the rights of shareholders. This summary is not intended to be exhaustive and shareholders should consult their legal advisors regarding all of the implications of the Continuance. The comparison set forth below is based on the BCA as at the date hereof. The BCA may be subject to amendments before the Continuance is finalized, therefore, the comparison set forth below may in certain circumstances prove inaccurate. The Corporation has no obligation to update shareholders about any amendments to the BCA.


18

Sale of a Corporation's Undertaking

The YBCA permits directors of a corporation to approve a sale, lease or exchange of all or substantially all of the property of the Corporation, if: (i) the Corporation is authorized to do so in its articles or a unanimous shareholder agreement, (ii) the Corporation does so in the ordinary course of business, or (iii) the Corporation obtains shareholder approval via special resolution. Under the YBCA, special resolutions require a "special majority" which is at least two-thirds of the votes cast unless otherwise specified in the Articles. Each Common Share carries the right to vote in respect of a sale, lease or exchange of all or substantially all of the property of the Corporation whether or not it otherwise carries the right to vote. Holders of shares of a class or series can vote separately only if that class or series is affected by the sale, lease or exchange in a manner different from the shares of another class or series.

Under the BCA, the directors of a corporation may dispose of all or substantially all of the business or undertaking of the corporation only if it is in the ordinary course of the Corporation's business or with shareholder approval authorized by special resolution. Like the YBCA, the BCA also requires special resolutions to be approved by a "special majority". However, under the BCA, "a special majority" means the majority specified in a corporation's articles of at least two-thirds (66.67%), and not more than three-quarters (75%), of the votes cast by those shareholders voting in person or by proxy at a general meeting of the Corporation.

The proposed Articles specify that the majority of the votes required for the Corporation to pass a special resolution at a meeting of shareholders will be two-thirds (66.67%) of the votes cast on the resolution.

Amendments to the Charter Documents of a Corporation

Substantive changes to the corporate charter of a corporation under the YBCA, such as a change in the name of a corporation, an alteration of the restrictions, if any, on the business of the corporation, or changes to the authorized capital structure of the corporation, generally require approval by a special resolution passed by not less than two-thirds (66.67%) of the votes cast by the shareholders voting on the resolution. Where the rights of the holders of a class or series of shares would be affected differently by the alteration than those of the holders of other classes or series of shares, the alteration must be approved by a special resolution passed by not less than two-thirds (66.67%) of the votes cast by the holders of the shares of such class or series.

Changes to the articles of a corporation under the BCA will be firstly governed by the resolutions specified by the BCA for the type of change being proposed. If the BCA does not specify the type of resolution for the change, then the change will be implemented by the type of resolution specified in the articles. If the articles are also silent, the BCA provides that changes can be effected by special resolution. The proposed Articles for the Corporation specify that if both the BCA and the Articles are silent on the type of resolution required to effect a particular change, the Corporation may approve the change via ordinary resolution.


19

Many alterations of the articles of a corporation, including changes of the corporate name, can be approved solely by a directors' resolution under the BCA if provided for in the articles. Alteration of the special rights and restrictions attached to issued shares requires, in addition to any resolution provided for by the articles, consent by a special resolution of the holders of the class or series of shares affected. A proposed amalgamation or continuation of a corporation out of the jurisdiction requires a special resolution as described above.

The proposed Articles specify that, subject to the BCA, the Corporation may effect a corporate name change, subdivide or consolidate all or any of its issued or unissued shares, or alter the number of directors via directors' resolutions. The proposed Articles also state that other changes to the Articles may be made through ordinary resolutions, including: creating or eliminating additional classes of shares, increasing or reducing the maximum number of shares, subdividing or consolidating its shares, modifying the par value of any approved shares with par value, and renaming any of its shares.

Rights of Dissent and Appraisal

The BCA provides that shareholders, including beneficial holders, who dissent to certain actions being taken by a corporation may exercise a right of dissent and require the corporation to purchase the shares held by such shareholder at the fair value of such shares. The dissent right is applicable where a corporation proposes to, among other things:

(a) continue out of the jurisdiction;

(b) sell the whole or substantially the whole of the corporation's undertaking or business;

(c) enter into a statutory amalgamation other than with an affiliated corporation; and

(d) amend its articles to add, change or remove any restriction on the business or businesses that the company may carry on.

The YBCA contains a similar dissent remedy, however, the remedy is only available to registered shareholders, not beneficial shareholders, and the specific procedure for exercising this remedy is different than that contained in the BCA.

Oppression Remedies

Under the YBCA a shareholder, former shareholder, director, former director, officer, former officer of a corporation or any of its affiliates, or any other person who, in the discretion of a court, is a proper person to seek an oppression remedy may apply to a court for an order granting the remedy. Such an order is sought to rectify the matters complained of where in respect of a corporation or any of its affiliates, any act or omission of the corporation or its affiliates effects a result, the business or affairs of the corporation or its affiliates are or have been exercised in a manner that is oppressive or unfairly prejudicial to, or that unfairly disregards the interest of, any security holder, creditor, director or officer.

Under the BCA, a shareholder of a corporation, including a beneficial shareholder, and any other person the court considers to be appropriate, has the right to apply to court on the grounds that the corporation is acting or proposes to act in a way that is prejudicial or oppressive to the shareholder. On such an application the court may make such order as it sees fit including an order to prohibit any act proposed by the corporation.


20

Shareholder Derivative Actions

Under the BCA, a shareholder, including a beneficial shareholder or a director of a corporation, and any other person deemed "appropriate" by the court, may, with leave of the court, bring an action in the name and on behalf of the corporation to enforce an obligation owed to the corporation that could be enforced by the corporation itself or to obtain damages for any breach of such an obligation. An applicant may also, with leave of the court, defend a legal proceeding brought against a corporation.

A broader right to bring a derivative action is contained in the YBCA and this right extends to shareholders, former shareholders, directors, former directors, officers or former officers of a corporation or its affiliates, and any person who, in the discretion of the court, is a proper person to make an application to court to bring a derivative action.

In addition, the YBCA permits derivative actions to be commenced in the name and on behalf of a corporation or any of its subsidiaries.

Requisition of Meetings

The YBCA permits the holders of not less than 5% of the issued shares that carry the right to vote at a meeting sought to be held to require the directors to call and hold a meeting of the shareholders of the corporation for the purposes stated in the requisition. If the directors do not call a meeting within 21 days of receiving the requisition, any shareholder who signed the requisition may call the meeting.

The BCA provides that one or more shareholders of a corporation holding not less than 5% of the issued voting shares of the corporation may give notice to the directors requiring them to call and hold a general meeting which must be held not more than four months after the date of the requisition.

Form of Proxy and Information Circular

Both the YBCA and BCA require a corporation to send notice of a general meeting to each shareholder entitled to attend the meeting, and subject to statute and the articles of the corporation, a shareholder has one vote in respect of each share held by that shareholder and is entitled to vote in person or by proxy. In any event, the Corporation is and will continue to be a reporting issuer, therefore, National Instruments 51-102 and 54-101 will continue to apply with respect to the solicitation of shareholder proxies and communications with beneficial shareholders.

Place of Meetings

The YBCA provides that meetings of shareholders may be held outside the Yukon as designated by the directors, unless the articles, bylaws or a unanimous shareholder agreement provide otherwise. Under the BCA, a general meeting of the shareholders of a corporation must be held in British Columbia unless: (i) the location outside British Columbia is provided for in the articles; (ii) the articles do not restrict the corporation from approving a location outside British Columbia for the holding of the general meeting and the location for the meeting is (A) approved by the resolution required by the articles for that purpose, or (B) if no resolution is required for that purpose by the articles, approved by ordinary resolution of the shareholders; or (iii) the location for the meeting is approved in writing by the BC Registrar before the meeting is held.


21

The proposed Articles provide that general meetings of shareholders may be held at such time and at such place, either in or outside British Columbia, as may be determined by the Board.

Directors

The YBCA provides that a distributing corporation must have at least three directors, at least two of whom must not be officers or employees of the corporation or its affiliates. The YBCA does not have any residence requirements for its directors.

The BCA provides that a public corporation must have at least three directors and also does not have any residency requirements.

Shareholder Approval of Continuance

Accordingly, the shareholders of the Corporation will be asked to consider, and if thought advisable, approve the following special resolution, being the Continuance Resolution relating to the Continuance:

"BE IT RESOLVED AS A SPECIAL RESOLUTION THAT:

1. the Corporation make application to the Yukon Registrar of Corporations for approval to file a Continuation Application with the British Columbia Registrar of Companies continuing the Corporation as if it had been incorporated under the laws of the province of British Columbia and make application to the Yukon Registrar of Corporations for a Certificate of Discontinuance;

2. subject to the issuance by the British Columbia Registrar of Companies of the Certificate of Continuance, and without affecting the validity of the Corporation and the existence of the Corporation by or under its articles and by-laws and any act done thereunder, effective upon issuance of the Certificate of Continuance, the Corporation adopt the Notice of Articles and the Articles substantially in the form presented at the Meeting in substitution for the existing articles and by-laws of the Corporation and all amendments to the existing articles and by-laws of the Corporation reflected therein are adopted;

3. the board of directors of the Corporation may, without further notice or approval of the shareholders of the Corporation, decide not to proceed with the Continuance or otherwise give effect to this Continuance Resolution, at any time prior to the Continuance becoming effective; and


22

4. any one or more of the directors or officers of the Corporation be authorized and directed to perform all such acts, deeds and things and execute and file all instruments and documents necessary or desirable to give effect to the true intent of this resolution."

In order for this special resolution to be passed, it requires the positive approval of a special majority (greater than 66.67%) of the votes cast thereon at the Meeting. The directors of the Corporation believe the Continuance is in the best interest of the Corporation and recommend that shareholders of the Corporation vote IN FAVOR of the resolution. The persons named as proxies in the enclosed Proxy intend to cast the votes represented by proxy in favour of the foregoing resolution unless the holder of Common Shares who has given such proxy has directed that the votes be otherwise cast.

Right of Dissent with Respect to Continuance

Shareholders are entitled to the dissent rights set out in Section 193 of the YBCA and to be paid the fair value of their Common Shares if such shareholder dissents to the Continuance and the Continuance becomes effective.

Neither a vote against the Continuance Resolution, nor an abstention or the execution or exercise of a proxy vote against the Continuance Resolution will constitute notice of dissent, but a shareholder need not vote against the Continuance Resolution in order to object. A shareholder must dissent with respect to all Common Shares either held personally by him or her or on behalf of any one beneficial owner and which are registered in one name. A brief summary of the provisions of Section 193 of the YBCA is set out below.

Persons who are beneficial owners of Common Shares registered in the name of a broker, custodian, nominee or other intermediary who wish to dissent should be aware that under the YBCA, ONLY A REGISTERED SHAREHOLDER IS ENTITLED TO DISSENT. A shareholder who beneficially owns Common Shares but is not the registered holder thereof should contact the registered holder for assistance.

In order to dissent, a shareholder (a "Dissenting Shareholder") must send to the Corporation in the manner set forth below, a written notice of objection (an "Objection Notice") to the Continuance Resolution. On the action approved by the Continuance Resolution becoming effective, the making of an agreement between the Corporation and the Dissenting Shareholder as to the payment to be made for the Dissenting Shareholder's shares or the pronouncement of an order by the Court, whichever first occurs, the Dissenting Shareholder ceases to have any rights as a shareholder other than the right to be paid the fair value of his or her Common Shares in an amount agreed to by the Corporation and the Dissenting Shareholder or in the amount of the judgment, as the case may be. The fair value of the Common Shares shall be determined as of the close of business on the last business day before the day on which the Continuance Resolution was adopted. Until any one of such events occurs, the Dissenting Shareholder may withdraw his or her dissent or the Corporation may rescind the Continuance Resolution and in either event, the proceedings shall be discontinued.

If the Continuance is approved, a Dissenting Shareholder who sent an Objection Notice, or the Corporation, may apply to the Court to fix the fair value of the Common Shares held by the Dissenting Shareholder. Upon such an application, the Court shall make an order fixing the fair value of those Common Shares, giving judgment in that amount against the Corporation in favour of the Dissenting Shareholder(s) and fixing the time by which the Corporation must pay that amount each of the Dissenting Shareholders. If such an application is made by a Dissenting Shareholder, the Corporation shall, unless the Court otherwise orders, send to each Dissenting Shareholder a written offer (the "Offer to Purchase") to pay to the Dissenting Shareholder. The Offer to Purchase shall contain an amount considered by the directors of the Corporation to be the fair value of the subject Common Shares, together with a statement showing how the fair value of the subject Common Shares was determined.


23

Every Offer to Purchase shall be on the same terms. At any time before the Court pronounces an order fixing the fair value of the Dissenting Shareholder's Common Shares, a Dissenting Shareholder may make an agreement with the Corporation for the purchase of his or her Common Shares, in the amount of the Offer to Purchase, or otherwise. The Offer to Purchase shall be sent to each Dissenting Shareholder within 10 days of the Corporation being served with a copy of the originating notice. Any order of the Court may also contain directions in relation to the payment to the Dissenting Shareholder of all or part of the sum offered by the Corporation for the Common Shares, the deposit of the share certificates representing the Common Shares, and other matters.

The Corporation may not be permitted to make a payment to a Dissenting Shareholder due to there being reasonable grounds for believing that the Corporation is or would after the payment be unable to pay its liabilities as they become due, or the realizable value of the Corporation's assets would thereby be less than the aggregate of its liabilities. In that case, the Corporation shall, within ten days after the pronouncement of an order, or the making of an agreement between the Dissenting Shareholder and the Corporation as to the payment to be made for his or her Common Shares, notify each Dissenting Shareholder that it is lawfully unable to pay such Dissenting Shareholders for their Common Shares.

Notwithstanding that a judgment has been given in favour of a Dissenting Shareholder by the Court, if the Corporation is not permitted to make a payment to a Dissenting Shareholder for the reasons stated in the previous paragraph, the Dissenting Shareholder by written notice delivered to the Corporation within 30 days after receiving the notice, as set forth in the previous paragraph, may withdraw his or her Objection Notice. In that case, the Corporation is deemed to consent to the withdrawal and the Dissenting Shareholder is reinstated to his or her full rights as a shareholder, failing which he retains his or her status as a claimant against the Corporation to be paid as soon as it is lawfully able to do so or, in a liquidation, to be ranked subordinate to the rights of creditors of the Corporation but in priority to its shareholders.

In order to be effective, a written Objection Notice must be received by the Corporation at 1946 West Broadway, Vancouver, British Columbia, V6J 1Z2, Attention: Senior Vice-President, Legal and Corporate Secretary or by the Chairman of the Meeting, prior to the commencement or recommencement thereof.

The foregoing summary does not purport to provide a comprehensive statement of the procedures to be followed by a Dissenting Shareholder who seeks payment of the fair value of his or her Common Shares. Section 193 of the YBCA requires strict adherence to the procedures established therein and failure to do so may result in the loss of all dissenters' rights. Accordingly, each shareholder who might desire to exercise the dissenters' rights should carefully consider and comply with the provisions of the section and consult such shareholders' legal advisor.


24

See Schedule "C" attached to this Management Proxy Circular for the full text of section 193 of the YBCA.

SECURITIES AUTHORISED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

EQUITY COMPENSATION PLAN INFORMATION AS AT MARCH 31, 2020

Plan Category

Number of securities to be issued upon exercise of outstanding options, warrants and rights
(a)

Weighted-average exercise price of outstanding options, warrants and rights

(b)

Number of securities remaining available for future issuance under equity compensation plans [excluding securities reflected in column (a)]

(c)

Equity compensation plans approved by Securityholders

4,507,606

3.32

5,172,357

Equity compensation plans not approved by Securityholders

Nil

N/A

Nil

Total

4,507,606

3.32

5,172,357

The numbers in the above chart are as at March 31, 2020.  As at the date of this Management Proxy Circular, a total of 4,507,606 stock options are issued and outstanding under the Amended and Restated Plan (as defined below) representing approximately 4.59% of our issued and outstanding capital.  Of the total options outstanding, 3,507,710 options are granted to insiders representing approximately 3.57% of our outstanding capital.  Currently, 5,310,086 options are available for grant under the Amended and Restated Plan representing approximately 5.41% of the issued and outstanding Common Shares as of the date hereof. 

Burn Rate of the Amended and Restated Plan

The chart below sets out the burn rate of the Amended and Restated Plan for the three most recently completed fiscal years ended March 31, 2020, March 31, 2019 and March 31, 2017.  The annual burn rate is expressed as a percentage by dividing the number options granted under the Amended and Restated Plan during the applicable fiscal year by the weighted average number of common shares outstanding for the applicable fiscal year. 


25


Fiscal Year

Number of Stock Options Granted

Weighted Average Number of Common Shares

Stock Option Burn Rate

2020

757,000

78,935,751

0.96%

2019

680,000

43,941,536

1.55%

2018

452,000

38,614,504

1.17%

CORPORATE GOVERNANCE DISCLOSURE

Under National Instrument 58-101 - Disclosure of Corporate Governance Practices ("NI 58-101") Burcon is required to disclose its corporate governance practices in its Management Proxy Circular.  National Policy 58-201 - Corporate Governance Guidelines ("NP 58-201") sets out corporate governance guidelines for public companies.  The Board and management of Burcon believe that good corporate governance practices are integral to the overall success of the Corporation and to protect shareholders' interests.  During the past fiscal year, Burcon continued to maintain corporate governance practices that are in line with the guidelines established in NP 58-201.     

Board of Directors

Burcon's Board currently consists of eight directors.  The size of the Board and its composition are reviewed annually by the nominating and compensation committee.  The Board believes that its composition reflects a good mix of individuals with varying backgrounds and experience in the fields of business, finance and science and will be conducive to facilitate a diversity of perspectives in the overall management of the Corporation. Of the eight nominees proposed for election at the Meeting, five of the directors are considered independent within the meaning of the term "independent" set out in NI 58-101.  The independent directors currently on the Board are Debora Fang, J. Douglas Gilpin, David Ju, Peter H. Kappel and D. Lorne Tyrrell.  Alan Chan, through his wholly-owned company, Firewood Elite Limited ("Firewood") owns, directly or indirectly, approximately 23.3% of Burcon's issued and outstanding Common Shares.  Rosanna Chau and Calvin Chi Leung Ng are directors of certain subsidiaries of Firewood.  Mr. Chan, Ms. Chau and Mr. Ng are not considered to be independent.   

The Corporation is a not a venture issuer pursuant to NP 58-201.  The Board currently consists of eight directors, a majority of which are independent.  If the eight nominees proposed for election at the Meeting are all elected, the Board will consist of a majority of independent directors.  During the preceding year, independent directors actively participated in board meetings and had direct communication with management on key business issues to ensure independent supervision over management.

Directorships

The following table sets out the relationships of Burcon's directors with other reporting issuers.

Director

Reporting Issuer or the Equivalent in a Jurisdiction or a Foreign Jurisdiction

Alan Chan

Executive Director, ITC Properties Group Limited



26

Independent Director Meetings

During the fiscal year, the independent directors of the Board held an in-camera session at the end of each regularly scheduled Board meeting if they deemed such session to be necessary. Four in-camera sessions were held following Board meetings during the fiscal year.  Non-management directors were invited to attend such sessions. Given that the committees of the Board are comprised solely of independent directors, the Board believes that committee meetings also provide another suitable forum for independent directors to have open and candid discussions among them about various issues.  Committee members have the discretion to conduct in-camera sessions at the end of committee meeting.  Each of the audit committee and nominating and compensation committee held two in-camera sessions during the fiscal year while the corporate governance committee held one in-camera session at the end of the committee's meetings during the fiscal year. 

Chairman

The Chairman of the Board is D. Lorne Tyrrell who was appointed since January 15, 2019.  Dr. Tyrrell facilitates discussions among all directors during meetings and acts as liaison between the Board and management.  He also communicates with management regularly and receives input from directors of the Board to set the agenda for Board meetings. 

Summary of Attendance of Directors

The table below sets out the attendance by the directors at meetings during the fiscal year ended March 31, 2020.

Director(1)

Board of
Directors

Audit
Committee

Nominating and
Compensation
Committee

Corporate
Governance
Committee

 

14 meetings

5 meetings

3 meetings

3 meetings

Alan Chan

10/14

N/A

N/A

N/A

Rosanna Chau

14/14

N/A

N/A

N/A

David Lorne John Tyrrell

14/14

N/A

3/3

3/3

J. Douglas Gilpin

14/14

5/5

N/A

3/3

Peter H. Kappel

14/14

5/5

3/3

3/3

David Ju

9/14

5/5

2/3

N/A

Calvin Chi Leung Ng(2)

10/14

N/A

N/A

N/A

(1) Mrs. Debora Fang was appointed to the board of directors on July 6, 2020.  Therefore, she does not appear in the above table.

(2) Mr. Calvin Chi Leung Ng was appointed to the board of directors on July 23, 2019. 

Board Mandate and Ethical Business Conduct

The Board is responsible for the stewardship of the Corporation and for the supervision of the management of the business and affairs of the Corporation.  The Board actively participates in assessing significant decisions proposed by management. On April 14, 2010, the Board adopted a written mandate defining its responsibilities, a copy of which is attached to this Management Proxy Circular as Schedule "D". 


27

Since October 2005, the Board has adopted a Code of Business Ethics and Conduct (the "Code"), a copy of which is attached to this Management Proxy Circular as Schedule "E".  The Code was amended in February 2011, August 2011 and September 2012.  All directors, officers and employees of Burcon and its subsidiary, Burcon NutraScience (MB) Corp. have read and agreed to abide by the Code and are required to confirm, on an annual basis, that they have reviewed the Code.  The Board had previously delegated to the audit committee the authority to monitor compliance with the Code and report any non-compliance to the Board at quarterly intervals. In February 2011, the Board transferred that authority to the corporate governance committee.  The corporate governance committee has established procedures to allow directors, officers and employees to report breaches of the Code or any illegal or unethical behaviour anonymously to the chair of the corporate governance committee.    No waivers or implicit waivers from a provision of the Code have been granted to any directors, officers or employees since its inception.  Shareholders may obtain a copy of the Code by written request to Burcon at 1946 West Broadway, Vancouver, British Columbia, V6J 1Z2, Attn.: Corporate Secretary.

In December 2011, the Board implemented a whistleblower reporting program.  Under the program, Burcon established a confidential and anonymous procedure for reporting claims of unethical and illegal behaviour or concerns regarding questionable accounting and audit matters.  On an annual basis, all employees are reminded about the whistleblower reporting program and procedures on how to make a report.  Burcon engaged a third party to receive the reports and direct them to the chair of the audit committee of the Board.  The whistleblower reporting program is tested by management every quarter and reviewed by the members of the audit committee.  To date, no reports of unethical or illegal behaviour or concerns have been received by the Corporation under this program.

Position Descriptions

In February 2013, the Board adopted written position descriptions for the Chairman of the Board and the chair of each committee.  The Board believes that having position descriptions in place will further assist the respective chairs in fulfilling their duties.

During his tenure as Chief Executive Officer, the Board had not developed a position description for Allan Yap who acted as Chief Executive Officer of the Corporation until his resignation in January 2019.  Dr. Yap was responsible for the overall strategic management of Burcon.  Under the direction of Dr. Yap, the duties relating to Burcon's day-to-day operations were delegated to Johann F. Tergesen.    When Dr. Yap resigned from the Board and his position as Chief Executive Officer, the Board appointed Mr. Tergesen to succeed him, given his experience with the Corporation.  Mr. Tergesen's duties as the Corporation's President and Chief Operating Officer are outlined in his employment agreement with Burcon dated June 21, 2011.  His employment terms did not change upon his appointment as Chief Executive Officer.    See "Employment and Consulting Contracts with Named Executive Officers".  Mr. Tergesen is charged with fulfilling the Corporation's objectives. The Board believes that he is sufficiently skilled through his business experience to manage and provide direction to Burcon's management to achieve these objectives.


28

Orientation and Continuing Education

New directors of Burcon are provided with orientation materials containing information on Burcon's business, technology, financial information and the roles and responsibilities of directors.  Directors are also updated on new developments in the business by management presentations at Board meetings and through regular management reports in between Board meetings.  Finally, directors are regularly informed about changes in legal or regulatory requirements applicable to the Corporation.

Each committee of the Board has, with the input of committee members, developed and implemented a charter.  The charter is reviewed by the applicable committee on an annual basis.  Committee members are guided by its charter when fulfilling their roles.  Committee members are also updated by management on legal or regulatory requirements specific to the committee's area of focus.  The Corporation's auditors and outside consultants also provide committee members with updates on emerging accounting, auditing, compensation and regulatory developments. 

Nomination of Directors and Compensation

Burcon has a nominating and compensation committee comprised of David Ju, Peter H. Kappel and Lorne Tyrrell.  All of the directors of the nominating and compensation committee are independent.  Mr. Kappel is the chair of the nominating and compensation committee.  The nominating and compensation committee has adopted a written charter to assist committee members in fulfilling their roles.  The duties and responsibilities of the nominating and compensation committee are:

  All members of the Board are encouraged to recommend individuals they believe are suitable to serve on the Board of the Corporation. When reviewing the suitability of prospective director nominees for Burcon's Board, the nominating and compensation committee will review the candidate's education, background and any business experience that may be relevant for Burcon. 

After Dr. Allan Yap's resignation from the Board in January 2019, the nominating and compensation committee did not immediately fill the vacancy of the Board.  During the first half of calendar 2019, the Corporation was focused on its business objectives, including securing a strategic partner for its pea and canola protein extraction and purification technologies.  As such, the Board and management focused their attention of these matters.


29

Following the execution of the unanimous shareholders agreement to form Merit Functional Foods Corporation with certain strategic partners and the closing of the Corporation's rights offering in late June 2019, the Board decided to fill the vacancy left by Dr. Yap's departure from the Board.  Certain candidates were considered by the nominating and compensation committee members and after due consideration, the nominating and compensation committee recommended Mr. Calvin Chi Leung Ng for appointment to the Board.  Mr. Ng was appointed to the Board on July 23, 2019. 

Although the board is comprised of a group of individuals with a wealth of experience in various facets of business across many industries, the nominating and compensation committee continued to review the composition of the board during the fiscal year and identified the need to add a candidate with experience in the food industry to the Board.  After a detailed search and interviews with certain candidates, the nominating and compensation committee recommended Mrs. Debora Fang for appointment to the Board.  The recommendation was accepted and on July 6, 2020, Mrs. Fang as appointed as a director.  Mrs. Fang's extensive experience in food industry will be an asset to the Corporation's business.

During fiscal year 2012, directors of the nominating and compensation committee began the process of reviewing the executive compensation program.  During the process, the nominating and compensation committee developed a compensation and performance management review program for executive officers and employees.  The program was finalized in fiscal year 2013 and the Board adopted and implemented the compensation and performance management review program in February 2013.  Performance reviews of executive officers and employees of the Corporation and it subsidiaries are conducted annually by their supervisor.  Although the nominating and compensation committee began the process of reviewing the director compensation program during fiscal 2012, no new director compensation program has been implemented given the current pre-revenue stage of development of the Corporation.  The annual retainer and meeting fees for directors remained unchanged during the year ended March 31, 2020. Each non-management director is paid an annual retainer of $7,500 and a fee of $750 per meeting for attendance at each Board or committee meeting.  The non-management director annual retainer and per meeting fee has remained the same since 2004. For more information, refer to the section "Statement of Executive Compensation". 

Corporate Governance Committee

Burcon has a corporate governance committee comprised of J. Douglas Gilpin, Peter Kappel and Lorne Tyrrell.  All of the directors of the corporate governance committee are independent.  Dr. Tyrrell is the chair of the corporate governance committee.  The corporate governance committee has adopted a written charter to assist committee members in fulfilling their roles.  The corporate governance committee is responsible for all matters relating to the governance of the Corporation and for reporting and making recommendations to the board of directors regarding such matters. 

Assessment

The Board meets at least once per quarter to assess the developments of Burcon's business and management recommendations.  The Corporation undertook numerous corporate transactions during the fiscal year, which resulted in the Board holding 14 board meetings. These meetings were beneficial to both the board members and management and facilitated healthy discussions in the strategic planning process and execution of key decisions  of the Corporation during the fiscal year. The Board has a formal self-assessment process in place and an assessment is conducted every two year, with the most recent assessment performed during the fiscal year 2020.  The results of the self-assessments were reviewed by the Board and each of the board committees and reported to the Board. 


30

Director Term Limits and Gender Diversity

In 2014, NI 58-101 was amended to require TSX-listed companies to disclose their practices relating to representation of women on boards of directors and in executive officer positions and on mechanisms of board renewal.  The corporate governance committee reviewed these amendments but did not view that the Board needed to develop policies regarding gender diversity or board renewal given the current stage of development of Burcon.  The Board accepted this recommendation.    The Board believes that at this stage, the Board is adequately populated with directors possessing varying skills and experience that are sufficient to competently manage the affairs of the Corporation.  Therefore, the Board does not believe in limiting the skills available to the Corporation by imposing a term limit for the directors.  The Board believes that it will be appropriate to review this practice when the Corporation evolves into the revenue-generating phase.

Although the Corporation does not have a written policy with regard to gender diversity, the Board believes that female participation currently on the Board and at the senior management level is suitable for the size and complexity of issues facing Burcon.  Recognizing that gender diversity is important, the nominating and compensation committee recommended the appointment of Mrs. Debora Fang to the Board.  On July 6, 2020, the Board appointed Mrs. Fang to the Burcon's Board.  Currently, two of eight of the directors on the Board are female, representing 25% of the members.  Two of six senior officers of the Corporation are female, representing 33% of senior management.  The Corporation does not have a target regarding women on the board or in executive positions.  Going forward, the nominating and compensation committee will continue to review gender diversity in light of Burcon's current stage of development, while also considering factors such as skills, experience, qualifications and character when assessing whether a potential candidate is suitable for the Board as well as senior management positions. 

Objectives for the year ending March 31, 2021

The Board believes that it has continued to make good progress during the fiscal year to further improve its corporate governance practices to meet the guidelines set out in NI 58-101 and NP 58-201.  Burcon believes that some of the guidelines may not be suitable for the Corporation given its current stage of development.  In July 2020, the corporate governance committee engaged Hugessen Consulting in Toronto to conduct a review of the Corporation's corporate governance policies and procedures with a view to further improve its corporate governance practices.  Upon completion of its work, Hugessen Consulting will present its findings to the nominating and compensation committee for further review and recommendation to the Board. 


31

AUDIT COMMITTEE AND DISCLOSURE UNDER
NATIONAL INSTRUMENT 52-110

Under National Instrument 52-110 ("NI 52-110"), Burcon is required to disclose in its Management Proxy Circular certain information concerning the composition of its audit committee and its auditor. The required disclosure can be found on pages 88-90 of Burcon's Annual Information Form ("AIF") dated June 29, 2020.  The audit committee charter is set out in Schedule "A" of the AIF.  A copy of the AIF can be found on the SEDAR website at www.sedar.com.  Shareholders may obtain a copy of the AIF by written request to Burcon at 1946 West Broadway, Vancouver British Columbia, V6J 1Z2, Attn: Corporate Secretary.     

STATEMENT OF EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

Nominating and Compensation Committee

Burcon has a nominating and compensation committee comprised of the following directors:  David Ju, Peter H. Kappel and Lorne Tyrrell.  Mr. Kappel is the chair of the nominating and compensation committee.  See "Biographies of Directors".  All of the directors on the nominating and compensation committee are independent.  The Board believes that the members of the nominating and compensation committee are sufficiently skilled to perform their duties. 

The Board believes that Burcon's nominating and compensation committee members possess the educational and practical experience to enable the committee to make decisions on the suitability of the Corporation's compensation policies and practices, including experience in the following areas:

The purpose of the nominating and compensation committee is to carry out the Board's overall responsibility to review and approve the Corporation's employee and management compensation policies and practices, incentive compensation plans (cash and equity-based short and long term incentive plans), the amount and form of compensation of the executive officers of the Corporation, all appointments of employees as executive officers, all director nominations to the board and succession plans for directors and executive officers of the Corporation. 

The nominating and compensation committee makes recommendations to the Board with respect to executive compensation. 


32

Fiscal Year 2020 Highlights

During fiscal year 2020, Burcon achieved key business goals and objectives, including: 

 The establishment of Merit Functional Foods Corporation ("Merit Foods") a joint venture partnership with three veterans of the agri-foods industry to build and operate a plant protein production facility;

 Made equity contributions totalling $13.0 million to Merit Foods for a 40% equity stake in the joint venture;

 Announced Burcon's new novel and proprietary Nutratein-PS™, and Nutratein-TZ™ pea and canola protein blends.  These new plant-protein blends have exceptional functional characteristics, low allergenicity, and a nutritional value exceeding those of the standard pea proteins available on the market today;

 Entered into a 20-year exclusive, royalty-bearing license agreement with Merit Foods for Burcon's pea and canola protein technologies;

 Completed a $15.4 million rights offering that was 37% over-subscribed (60,572,585 total shares subscribed-for);

 Entered into a joint development agreement with Nestlé to tailor Burcon and Merit Foods' plant-based proteins for use in Nestlé's food and beverage applications;

 Issued $9.5 million of convertible debentures;

 Merit Foods was granted funding of $9.2 million from Protein Industries Canada; and

 Completed a $11.5 million bought deal equity offering; and

 Received acknowledgment from US Food and Drug Administration of Burcon's GRAS (Generally Recognized as Safe) notification for Peazazz® and Peazac®.

Subsequent to the year-end, the Company announced the following significant developments:

 Merit Foods secured $85 million of financing from a consortium of lenders including Export Development Canada and Farm Credit Canada; and

 Merit Foods secured additional debt financing of $10 million, in the form of a 10-year interest free loan from Agri-Food Canada's AgriInnovate Program.

Compensation Program

Historically, the Corporation did not have a formal compensation program given the size and number of employees of the Corporation.  The Corporation's compensation program is intended to attract, retain and motivate highly qualified executive officers, while at the same time promoting a greater alignment of interests between such executive officers and the Corporation's shareholders. The Corporation's compensation program is designed to compensate the Named Executive Officers for their contributions to the Corporation and is based, to a large extent, on the achievement of goals set by the Corporation. The Corporation's Board strives to be competitive with the overall market for compensation.


33

During the year ended March 31, 2012, the Corporation's Nominating and Compensation Committee (the "Committee") reviewed the Corporation's compensation practices with the goal of developing a formal compensation and performance management review program for executive officers and employees. The Committee's goal was to develop a compensation program to compensate employees based on certain general performance management criteria.

In January 2012, the Corporation engaged York HR Solutions Inc. ("York Solutions") of Maple Ridge, British Columbia, to develop a formal compensation and performance management program for the Corporation (the "Program"). York Solutions' mandate was to work with the Committee to:

 develop and document the compensation philosophy and strategy;

 design a compensation structure;

 develop performance measures and standards;

 develop a set of core competencies consisting of behaviours that employees should possess in the performance of goals;

 develop feedback methods, processes and documentation;

 develop and document a bonus plan clearly linked to corporate objectives;

 develop a communication plan for rollout of the Program; and

 assist with implementation and training of employees and managers.

The Committee worked with York Solutions to finalize the Program during fiscal year 2013.  In February 2013, the Program was formally approved by the Board.  The Corporation has implemented and followed the guidelines set out in the Program for determining compensation for executives and employees of Burcon. 

Components of Executive Compensation

The Corporation's Program is comprised of a combination of base salary, incentive stock options and bonuses.

Given the Corporation's stage of development, the Board has deferred the implementation of the bonus component of the Program until the Corporation has reached positive cash flows.  The Board believes that the two elements of base salary and incentive stock options as compensation are appropriate to compensate the Corporation's executives in light of the Corporation's current stage of development. The Board reviews these elements individually and comprehensively to ensure alignment with the Corporation's strategic goals and objectives and the Corporation's overall compensation objectives. In the process of developing the components, the Board has, through the nominating and compensation committee, considered the implications of risks associated with its compensation policies. The Board believes that the risks are mitigated to a certain degree given the approach it has taken in the past on executive compensation. With respect to the salary component of the executive compensation, the Board has strived to be competitive in order to attract, retain and motivate executives. Options granted to employees under the incentive stock option plan generally do not vest immediately upon grant but vest over a three year period. The Board believes that using a vesting schedule encourages employee loyalty, aligns employee and company interests and reduces certain risks that may be associated with granting stock options that vest immediately upon grant.


34

The Corporation does not have a specific policy with respect to NEOs (as defined below) and directors purchasing financial instruments designed to hedge or offset a decrease in market value of equity securities of the Corporation.

Base Salary

Johann F. Tergesen Chief Executive Offer, Jade Cheng, Chief Financial Officer, Randy Willardsen, Senior Vice President, Process, Dorothy Law, Senior Vice President, Legal and Corporate Secretary and Martin Schweizer, Vice President, Technical Development  are the "Named Executive Officers" ("NEO") of Burcon. 

The primary element of the Corporation's compensation program is base salary.  The Corporation's view is that a competitive base salary is a necessary element for attracting and retaining qualified executive officers. 

  During the year ended March 31, 2011, the Committee negotiated with each of Mr. Tergesen, Ms. Cheng and Ms. Law to determine their salaries. Following the negotiations, formal employment agreements were entered into with Mr. Tergesen in June 2011 and Ms. Cheng and Ms. Law in March 2011.  Mr. Willardsen is a consultant of Burcon and has a consulting agreement with Burcon (entered into in 2007 as amended).  Mr. Willardsen was paid a monthly fee until July 2019, when his consulting agreement was amended to provide for payment on an hourly basis.  Dr. Martin Schweizer has been employed by Burcon's wholly-owned subsidiary, Burcon NutraScience (MB) Corp. since March 2002 and is paid an annual salary.  See "Employment and Consulting Contracts with Named Executive Officers".

The amount payable to an NEO as base salary is determined primarily by the number of years of experience of the NEO, as well as negotiations with the NEO, and recommendations of the Committee based on its view of general market conditions.  As noted above, the Committee engaged York Solutions in 2012 to develop the Program. As part of its engagement, York Solutions conducted a salary survey based on overall market data (rather than company specific data) derived from a number of published surveys, including:


35

The findings supported the salary being paid to Ms. Cheng and Ms. Law.  In an effort to conserve cash, the Committee did not recommend any adjustment to the salaries of Mr. Tergesen, Ms. Cheng or Ms. Law from 2011 to 2015.  During fiscal year 2016, the salaries of Ms. Cheng and Ms. Law were adjusted.    No adjustments were made to the salaries of Mr. Tergesen, Ms. Cheng and Ms. Law during fiscal years 2018 to 2020. 

Mr. Willardsen's consulting agreement was amended on July 31, 2019 to provide for payment of his services by the hour, rather than a fixed monthly fee.  Dr. Schweizer's salary has been adjusted over the term of his employment based on his experience with the Corporation and general market conditions. 

Incentive Stock Options

The second element of the Corporation's compensation program is incentive stock options. At the Corporation' annual and special meeting held on September 19, 2001, the shareholders approved the terms of the Plan under which directors, officers, employees and consultants of the Corporation may be granted options to acquire Common Shares of the Corporation. The Plan was amended in 2003, 2004, 2007 and 2009 to, among other amendments, increase the number of Common Shares issuable under the Plan. In 2011, the Corporation's shareholders approved an amendment to the Plan to convert it from a fixed plan to a rolling plan.  The Amended and Restated Plan was further amended during the year ended March 31, 2013 to provide for a cashless exercise method.  For further details on the Amended and Restated Plan see "Securities Authorized for Issuance Under Equity Compensation Plans".

The options granted to executive officers and other employees are granted by the Board, based on the recommendations of the Committee. The Board reviews the Committee's recommendations regarding grants of options based on contributions and performance during the year. In determining option grants, the Board also takes into account previous grants to the grantees and attempts to compensate for any deficiencies in the cash component in the NEO's salary vis-a-vis competitive market rates. The Program developed by York Solutions also contains an allocation formula for determining stock option grants based on the cash salary of the individual.  Although the formula contemplates the value of the option grant to be approximately 33% of the individual's annualized salary, the Board has the discretion to adjust the amount allocated under this formula based on the individual's seniority, level of management within the Corporation and the Corporation's overriding goal of retaining key talent within Burcon.  During the year ended March 31, 2020, the Committee recommended to the Board the grant of options based on the formula set out in the Program and consideration of the discretionary factors such as contributions by the individual to the Corporation's developments, previous option grants that are out-of-the money and the lack of salary adjustments for certain employees for a number of years. 

Performance Graph

The following graph shows the total cumulative return over five years for a shareholder of Burcon on an investment of $100 compared to the S&P/TSX composite index.


36


 

2015

2016

2017

2018

2019

2020

Burcon NutraScience

100.00

111.00

69.67

17.33

12.33

30.67

S&P/TSX Composite

100.00

90.55

104.33

103.12

108.05

89.78

From 2015 to 2016, Burcon's share price increased by 11% while the S&P/TSX composite decreased by 9.5%.  In 2017, Burcon's share price dropped 37% trending the opposite of the S&P/TSX composite index which went up by 15%.  Burcon's share price continued its downward trend, dropping 75% in 2018 and 29% in 2019.  Comparatively, the S&P/TSX composite index dropped 1% in 2018 and increased 5% in 2019.  In 2020, Burcon's share price made a significant recovery and went up by 149%, while the S&P/TSX composite declined by 17%.

The trend shown in the above graph does not necessarily correspond to the Corporation's compensation to its Named Executive Officers for the period ended March 31, 2020 or for any prior fiscal periods.  The trading price of the Corporation's Common Shares is subject to fluctuation based on several factors, many of which are outside the control of Burcon.  These include market perception of the Corporation's ability to achieve business goals, trading volume in the Corporation's Common Shares, changes in general conditions in the economy and the financial markets or other general developments in the animal or plant protein industry that affect the Corporation or its competitors.  In determining compensation, the Board strives to be competitive in order to attract, retain and motivate executives, provide incentives for executives and key employees to work towards achieving business goals and objectives as well as to ensure that the interests of management of Burcon and Burcon's shareholders are aligned.


37

Compensation of Executive Officers

Summary Compensation Table

Johann Tergesen, President and Chief Executive Officer and Jade Cheng, Chief Financial Officer , Randy Willardsen, Senior Vice President, Process, Dorothy Law, Senior Vice President Legal and Corporate Secretary and Martin Schweizer, Vice President, Technical Development are the "Named Executive Officers" of Burcon for the purposes of the following disclosure, which is required for all reporting issuers, as set out in securities legislation.  The following table provides a summary of the total compensation paid to the Named Executive Officers during Burcon's three most recently completed fiscal years ended March 31, 2020, March 31, 2019 and March 31, 2018.


SUMMARY COMPENSATION TABLE

Name and Principal Position

Year

Salary
($)

Share-based awards

($)

Option-based awards
($)

Non-equity incentive plan compensation

($)

Pension value

($)

All other compensation

($)

Total compensation

($)

 

 

 

 

 

Annual incentive plans

Long term incentive plans

 

 

 

Johann F. Tergesen
President and Chief
Executive Officer

2020

2019

2018

275,000

275,000

275,000

Nil

Nil

Nil

94,034(1)

10,746(1)

19,024(1)

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil

Nil

369,034

285,746

294,024

Jade Cheng
Chief Financial Officer

2020

2019

2018

177,000

177,000

177,000

Nil

Nil
Nil

94,034(1)

8,792(1)

15,565(1)

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil

Nil

271,034

185,792

192,565

Randy Willardsen

SVP, Process

2020

2019

2018

220,711

123,066

123,066

Nil

Nil
Nil

67,167(1)

10,746(1)

19,024(1)

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil
Nil

287,878

133,812

142,090

Dorothy Law

SVP, Legal and Corporate Secretary

2020

2019

2018

129,800

129,800

129,800

Nil

Nil
Nil

94,034(1)

8,792(1)

15,565(1)

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil
Nil

223,834

138,592

145,365

Martin Schweizer

VP, Technical Development

2020

2019

2018

150,833

125,000

125,000

Nil

Nil
Nil

67,167(1)

11,723(1)

15,565(1)

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil
Nil

Nil

Nil
Nil

218,000

136,723

140,565



38

Notes:

(1) In determining the fair value of the option awards, the Black-Scholes option pricing model was used and was calculated in accordance with IFRS 2, Share-based payment, with the following assumptions:              

Assumptions

2020

2019

2018

Risk-free interest rate:

1.30%

1.83%

1.96%

Dividend rate:

0%

0%

0%

Expected forfeitures:

7.67%

8.06%

8.44%

Expected volatility in the market price of shares:

75.70%

73.65%

61.13%

Expected life:

7.5 years

7.5 years

7.5 years

Fair value per option:

$1.34

$0.16

$0.43

Outstanding Option-Based and Share-Based Awards

The following table sets forth, for each Named Executive Officer, all of the option-based and share-based grants and awards outstanding on March 31, 2020.

 

Option-based Awards

Share Based Awards

 

 

 

 

 

 

 

Name

Number of

Option

Option

Value of

Number of

Market or

 

securities

Exercise

Expiration

unexercised

shares or

payout value

 

underlying

Price

Date

in-the-

units of

of share-

 

unexercised

($)

mm/dd/yyyy

money

shares that

based

 

options

 

 

options(1)

have not

awards that

 

(#)

 

 

($)

vested

have not

 

 

 

 

 

(#)

vested

 

 

 

 

 

 

($)

Johann F. Tergesen

125,000

9.60

12/17/2019(2)

0

Nil

Nil

President and Chief

24,000

4.16

10/29/2022(3)

0

 

 

Executive Officer

44,353

2.48

12/04/2023(4)

0

 

 

 

67,201

2.86

11/10/2024(5)

0

 

 

 

54,247

2.33

11/12/2025(6)

0

 

 

 

48,858

2.66

12/15/2026(7)

0

 

 

 

29,333

0.69

1/3/2028(8)

6,747

 

 

 

66,000

0.23

2/19/2029(9)

45,540

 

 

 

70,000

1.88

1/27/2030(10)

0

 

 

Jade Cheng

110,000

9.60

12/17/2019(2)

0

Nil

Nil

Chief Financial

18,000

4.16

10/29/2022(3)

0

 

 

Officer

35,482

2.48

12/04/2023(4)

0

 

 

 

53,761

2.86

11/10/2024(5)

0

 

 

 

43,398

2.33

11/12/2025(6)

0

 

 

 

39,086

2.66

12/15/2026(7)

0

 

 

 

24,000

0.69

1/3/2028(8)

5,520

 

 

 

54,000

0.23

2/19/2029(9)

37,260

 

 

 

70,000

1.88

1/27/2030(10)

0

 

 

Randy Willardsen

110,000

9.60

12/17/2019(2)

0

Nil

Nil

SVP, Process

18,000

4.16

10/29/2022(3)

0

 

 

 

44,353

2.48

12/04/2023(4)

0

 

 

 

67,201

2.86

11/10/2024(5)

0

 

 

 

54,247

2.33

11/12/2025(6)

0

 

 

 

48,858

2.66

12/15/2026(7)

0

 

 

 

44,000

0.69

1/3/2028(8)

10,120

 

 

 

66,000

0.23

2/19/2029(9)

45,540

 

 

 

50,000

1.88

1/27/2030(10)

0

 

 

 



39


 

Option-based Awards

Share Based Awards

 

 

 

 

 

 

 

Name

Number of

Option

Option

Value of

Number of

Market or

 

securities

Exercise

Expiration

unexercised

shares or

payout value

 

underlying

Price

Date

in-the-

units of

of share-

 

unexercised

($)

mm/dd/yyyy

money

shares that

based

 

options

 

 

options(1)

have not

awards that

 

(#)

 

 

($)

vested

have not

 

 

 

 

 

(#)

vested

 

 

 

 

 

 

($)

Dorothy Law

110,000

9.60

12/17/2019(2)

0

Nil

Nil

SVP, Legal and

18,000

4.16

10/29/2022(3)

0

 

 

Corporate Secretary

35,482

2.48

12/04/2023(4)

0

 

 

 

53,761

2.86

11/10/2024(5)

0

 

 

 

43,398

2.33

11/12/2025(6)

0

 

 

 

39,086

2.66

12/15/2026(7)

0

 

 

 

36,000

0.69

1/3/2028(8)

8,280

 

 

 

54,000

0.23

2/19/2029(9)

37,260

 

 

 

70,000

1.88

1/27/2030(10)

0

 

 

Martin Schweizer

50,000

9.60

12/17/2019(2)

0

Nil

Nil

VP, Technical

18,000

4.16

10/29/2022(3)

0

 

 

Development

35,482

2.48

12/04/2023(4)

0

 

 

 

53,761

2.86

11/10/2024(5)

0

 

 

 

43,398

2.33

11/12/2025(6)

0

 

 

 

39,086

2.66

12/15/2026(7)

0

 

 

 

36,000

0.69

1/3/2028(8)

8,280

 

 

 

72,000

0.23

2/19/2029(9)

49,680

 

 

 

50,000

1.88

1/27/2030(10)

0

 

 


Notes:

(1) Based on the March 31, 2020 closing price of $0.92 per share on the TSX.

(2) These options vested as to 1/3 on each of August 17, 2010, April 17, 2011 and December 17, 2011. Because the expiry date of these options fell within an internal trading blackout period, the expiry has been extended until the trading blackout is lifted.  As at July 30, 2020, the trading blackout remains in place. Pursuant to the terms of the Amended and Restate Plan, the expiry date of these options will be extended until ten business days following the lifting of the trading blackout.

(3) These options vested as to 1/3 on each of October 29, 2013, October 29, 2014 and October 29, 2015.

(4) These options vested as to 1/3 on each of December 4, 2014, December 4, 2015 and December 4, 2016.

(5) These options vested as to 1/3 on November 10, 2015, November 10, 2016 and November 10, 2017.

(6) These options vested as to 1/3 on November 12, 2016, November 12, 2017 and November 12, 2018.

(7) These options vested as to 1/3 on each of December 15, 2017, December 15, 2018 and December 15, 2019.

(8)  These options vested as to 1/3 on each of January 3, 2019 and January 3, 2020 and will vest as to 1/3 on January 3, 2021.

(9) These options vested as to 1/3 on February 19, 2020 and will vest as to 1/3 on each of February 19, 2021 and February 19, 2022, respectively.

(10) These options vest as to 1/3 on each of January 27, 2021, January 27, 2022 and January 27, 2023, respectively.

Value Vested or Earned during Fiscal Year Ended March 31, 2020

The following table sets forth, for each Named Executive Officer, the value vested for all outstanding option-based and share-based awards and the value earned for all non-equity incentive plan compensation during the twelve month period ended March 31, 2020.


40


Name

Option-based awards - Value vested during the year(1)
($)

Share-based awards - Value vested during the year
($)

Non-equity incentive plan compensation - Value earned during the year
($)

Johann F. Tergesen

35,420(2)

Nil

Nil

Jade Cheng

28,980(2)

Nil

Nil

Randy Willardsen

35,420(2)

Nil

Nil

Dorothy Law

28,980(2)

Nil

Nil

Martin Schweizer

37,560(2)

Nil

Nil

Notes:

(1) See the "Outstanding Option Based and Share Based Awards" table for NEOs (above) for more information on the options awarded to NEOs.

(2) Based on the December 13, 2019 of $1.05 per share on the TSX (given no trading on December 15, 2019), the closing price on January 3, 2020 of $0.96 per share on the TSX and the closing price on February 19, 2020 of $1.66 per share on the TSX.

Employment and Consulting Contracts with Named Executive Officers

Burcon has entered into employment agreements with the following Named Executive Officers below:

Johann F. Tergesen

Mr. Tergesen is the Corporation's President and Chief Executive Officer and has been an employee of Burcon since September 1, 2001.  However, no written employment agreement had been entered into between Burcon and Mr. Tergesen until June 21, 2011 when the Corporation entered into a written employment agreement with Mr. Tergesen to formalize the terms of his employment.  Mr. Tergesen was the Chief Operating Officer of the Corporation from September 2000 until January 15, 2019.  When Mr. Allan Yap resigned from his position of Chief Executive Officer, Mr. Tergesen was appointed as Chief Executive Officer on the same date.  Under the terms of Mr. Tergesen's employment agreement, Mr. Tergesen is entitled to an annual base salary, and, at the discretion of Corporation, participation in the Corporation's incentive program, including, but not limited to, any bonus, share option, share purchase, share bonus or financial assistance program or plan and participation in the benefits plan available to senior staff from time to time.

Although Mr. Tergesen's employment agreement commenced on June 21, 2011, the Board agreed to apply Mr. Tergesen's salary retroactively to May 2010, which was the time at which the nominating and compensation committee first began its review and negotiation of the terms of employment with Mr. Tergesen.  The retroactive salary amount paid for the period from May 1, 2010 to March 31, 2011 totalled to $73,333.  Total compensation paid to Mr. Tergesen during fiscal 2020, 2019 and 2018 is disclosed in the Summary Compensation Table.  During fiscal year 2017, Mr. Tergesen's employment terms were temporarily amended, resulting in a decrease in his base salary.

Mr. Tergesen's employment agreement has an indefinite term and may be terminated by Mr. Tergesen at any time by providing two months' notice in writing to the Corporation.  In the event that the Corporation terminates Mr. Tergesen's employment without cause, Mr. Tergesen is entitled to payment of salary and any amounts owing to him under any applicable incentive program earned up to and including the last day of employment and (a) notice of termination or salary in lieu thereof equal to 18 months' salary, plus one month of additional salary for each year of continuous employment with the Corporation from the effective date of his employment agreement up to a maximum of 24 months (the "Notice Period"), (b) continuation of coverage of British Columbia medical services plan and extended health and dental coverage where such continuation of coverage is permitted by the terms of the benefits plan during the Notice Period or until Mr. Tergesen obtains alternative employment, whichever is earlier; and (c) where the terms of the Corporation's applicable share option plan permits an optionee to do so, Mr. Tergesen shall be deemed to be a "Service Provider" as that term is defined in the Corporation's share option plan until the last day of the Notice Period and he will be permitted to exercise any options he may hold during that time period. 


41

Mr. Tergesen's employment agreement contains provisions with respect to non-competition and non-solicitation during the term of the employment agreement and for a period of 12 months following the termination of his employment for any reason.

In the event of a change of control, Mr. Tergesen may elect to terminate his employment agreement.  If he does so, then the Corporation will pay a severance payment of salary equal to 18 months plus one additional month's salary per year of continuous service with the Corporation from the effective date of the employment agreement up to a maximum of 24 months' salary. Pursuant to the Corporation's Amended and Restated 2001 Share Option Plan, a change of control is an "Accelerated Vesting Event".  If an Accelerated Vesting Event occurs and TSX approval is obtained, Mr. Tergesen will be entitled to exercise each option held by him at any time on or before the expiry date of such option, provided that the Accelerated Vesting Event must have occurred on or before the last day on which Mr. Tergesen worked for Burcon.

Jade Cheng

Ms. Cheng entered into an employment agreement with the Corporation on March 1, 2011.  Prior thereto, Ms. Cheng had been providing her services as the Corporation's Chief Financial Officer pursuant to the management services agreement between the Corporation and Burcon Group Limited.    The terms of Ms. Cheng's employment agreement are similar to those of Mr. Tergesen's agreement.  Under the terms of Ms. Cheng's employment agreement, Ms. Cheng is entitled to an annual base salary, and, at the discretion of the Corporation, participation in the Corporation's incentive program, including, but not limited to, any bonus, share option, share purchase, share bonus or financial assistance program or plan and participation in the benefits plan available to senior staff from time to time.

Although Ms. Cheng's employment agreement commenced on March 1, 2011, the Board agreed to apply Ms. Cheng's salary retroactively to May 2010, which was the time at which the nominating and compensation committee first began its review and negotiation of the terms of employment with Ms. Cheng.  The retroactive salary component of $52,500 was paid to Ms. Cheng in March, 2011.  Ms. Cheng's salary was adjusted in fiscal 2016.  Total compensation paid to Ms. Cheng during fiscal 2020, 2019 and 2018 is disclosed in the Summary Compensation Table.

Ms. Cheng's employment agreement has an indefinite term and may be terminated by Ms. Cheng at any time by providing two months' notice in writing to the Corporation.  In the event that the Corporation terminates Ms. Cheng's employment without cause, Ms. Cheng is entitled to payment of salary and any amounts owing to her under any applicable incentive program earned up to and including the last day of employment and (a) notice of termination or salary in lieu thereof equal to 18 months' salary, plus one month of additional salary for each year of continuous employment with the Corporation from the effective date of her employment agreement up to a maximum of 24 months (the "Notice Period"), (b) continuation of coverage of British Columbia medical services plan and extended health and dental coverage where such continuation of coverage is permitted by the terms of the benefits plan during the Notice Period or until Ms. Cheng obtains alternative employment, whichever is earlier; and (c) where the terms of the Corporation's applicable share option plan permits an optionee to do so, Ms. Cheng shall be deemed to be a "Service Provider" as that term is defined in the Corporation's share option plan until the last day of the Notice Period and she will be permitted to exercise any options she may hold during that time period.


42

Ms. Cheng's employment agreement contains provisions with respect to non-competition and non-solicitation during the term of the employment agreement and for a period of 12 months following the termination of her employment for any reason.

In the event of a change of control, Ms. Cheng may elect to terminate her employment agreement.  If she does so, then the Corporation will pay a severance payment of salary equal to 18 months plus one additional month salary per year of continuous service with the Corporation from the effective date of the employment agreement up to a maximum of 24 month's salary.  Pursuant to the Corporation's Amended and Restated 2001 Share Option Plan, a change of control is an "Accelerated Vesting Event".  If an Accelerated Vesting Event occurs and TSX approval is obtained, Ms. Cheng will be entitled to exercise each option held by her at any time on or before the expiry date of such option, provided that the Accelerated Vesting Event must have occurred on or before the last day on which Ms. Cheng worked for Burcon.

Randy Willardsen

Mr. Randy Willardsen is a consultant of Burcon.  The following is a summary of the terms of his consulting contract with the Corporation.

Mr. Willardsen was initially engaged as a consultant of Burcon in April 1999 to evaluate the commercial viability of the canola protein extraction and purification process (the "Process") of B.M.W. Canola Inc. ("BMW").  Burcon acquired BMW in October 1999 and changed BMW's name to Burcon NutraScience (MB) Corp.  ("Burcon-MB").  By an agreement dated November 30, 2001, Burcon engaged Mr. Willardsen as a consultant to assist with the commercialization of the Process.  He was appointed as Senior Vice President, Process of the Corporation on November 30, 2001.  Mr. Willardsen and the Corporation entered into a new Management Consulting Agreement (the "Consulting Agreement") on December 19, 2007, which was amended on December 15, 2008, May 4, 2011 and July 31, 2019. 

The Consulting Agreement had an initial term of 18 months, but automatically renews for successive one year periods unless either the Consultant or the Corporation terminates the Consulting Agreement 30 days prior to the end of the term.  The initial fee paid to Mr. Willardsen was US$6,500 per month.  In May 2011, the fee was increased to US$8,000 per month.  Mr. Willardsen will devote up to 20 hours per week to perform the services set out under the Consulting Agreement.  After the formation of Merit Functional Foods Corporation ("Merit Foods") by Burcon and the other shareholders of Merit Foods, Burcon and Merit Foods entered into a services agreement pursuant to which Burcon and Burcon-MB will provide services to Merit Foods in connection with the commercialization efforts of Merit Foods of Burcon's pea and canola protein technologies.  As a result, Mr. Willardsen increased the time he spent performing the services.  In order to compensate Mr. Willardsen for the increased amount of time spent, Burcon and Mr. Willardsen entered into an amendment to the Consulting Agreement dated July 31, 2019, pursuant to which he would paid at a rate of US$100 per hour rather than a monthly fee. 


43

The Consulting Agreement may be terminated by either party to the agreement with written notice to the other party of not less than 30 days.  The Consulting Agreement does not provide for payment in the event of a change of control.

Dorothy K.T. Law

Ms. Law entered into an employment agreement with the Corporation on March 1, 2011.  Prior thereto, Ms. Law had been providing her services as the Corporation's Senior Vice President, Legal and Corporate Secretary pursuant to the management services agreement between the Corporation and Burcon Group Limited.  The terms of Ms. Law's employment agreement are similar to those of Mr. Tergesen's and Ms. Cheng's agreements.  Under the terms of Ms. Law's employment agreement, Ms. Law is entitled to an annual base salary, and, at the discretion of the Corporation, participation in the Corporation's incentive program, including, but not limited to, any bonus, share option, share purchase, share bonus or financial assistance program or plan and participation in the benefits plan available to senior staff from time to time.

Although Ms. Law's employment agreement commenced on March 1, 2011, the Board agreed to apply Ms. Law's salary retroactively to May 2010, which was the time at which the nominating and compensation committee first began its review and negotiation of the terms of employment with Ms. Law.  The retroactive salary component of $40,917 was paid to Ms. Law in March, 2011.  Ms. Law's salary was adjusted in fiscal 2016.  Total compensation paid to Ms. Law during fiscal 2020, 2019 and 2018 is disclosed in the Summary Compensation Table.

Ms. Law's employment agreement has an indefinite term and may be terminated by Ms. Law at any time by providing two months' notice in writing to the Corporation.  In the event that the Corporation terminates Ms. Law's employment without cause, Ms. Law is entitled to payment of salary and any amounts owing to her under any applicable incentive program earned up to and including the last day of employment and (a) notice of termination or salary in lieu thereof equal to 18 months' salary, plus one month of additional salary for each year of continuous employment with the Corporation from the effective date of her employment agreement up to a maximum of 24 months (the "Notice Period"), (b) continuation of coverage of British Columbia medical services plan and extended health and dental coverage where such continuation of coverage is permitted by the terms of the benefits plan during the Notice Period or until Ms. Law obtains alternative employment, whichever is earlier; and (c) where the terms of the Corporation's applicable share option plan permits an optionee to do so, Ms. Law shall be deemed to be a "Service Provider" as that term is defined in the Corporation's share option plan until the last day of the Notice Period and she will be permitted to exercise any options she may hold during that time period.


44

Ms. Law's employment agreement contains provisions with respect to non-competition and non-solicitation during the term of the employment agreement and for a period of 12 months following the termination of her employment for any reason.

In the event of a change of control, Ms. Law may elect to terminate her employment agreement.  If she does so, then the Corporation will pay a severance payment of salary equal to 18 months plus one additional month salary per year of continuous service with the Corporation from the effective date of the employment agreement up to a maximum of 24 month's salary.  Pursuant to the Corporation's Amended and Restated 2001 Share Option Plan, a change of control is an "Accelerated Vesting Event".  If an Accelerated Vesting Event occurs and TSX approval is obtained, Ms. Law will be entitled to exercise each option held by her at any time on or before the expiry date of such option, provided that the Accelerated Vesting Event must have occurred on or before the last day on which Ms. Law worked for Burcon.

Martin Schweizer

Dr. Schweizer entered into an employment agreement with Burcon-MB on March 21, 2002 and commenced his employment in May 2002 as a process engineering specialist.  Since January 2003, Dr. Schweizer has overseen Burcon's research and development efforts at its Winnipeg Technical Centre.  Dr. Schweizer was appointed as the Corporation's Vice President, Technical Development in September 2009. 

Dr. Schweizer's employment agreement has an indefinite term and may be terminated by Dr. Schweizer at any time by providing one months' notice in writing to the Corporation.  In the event that the Corporation terminates Dr. Schweizer's employment without cause, Dr. Schweizer is entitled to notice required by legislation or payment in lieu of notice or a combination of notice and payment under the employment agreement.

Dr. Schweizer's employment agreement contains provisions with respect to non-competition and non-solicitation during the term of the employment agreement and for a period of 12 months following the termination of his employment for any reason.  Dr. Schweizer's employment agreement does not provide for payment in the event of a change of control.

Estimated Termination Payments

The table below reflects amounts payable to the Named Executive Officers, assuming their employment was terminated on March 31, 2020 either without cause or upon change of control of the Corporation.

Name

Termination Other than for Cause ($)

Continued Benefits

($)

Termination Upon Change of Control

($)

Johann F. Tergesen

550,000

8,482

550,000

Jade Cheng

354,000

8,482

354,000

Randy Willardsen

See Note 1 below

Nil

See Note 1 below

Dorothy Law

259,600

8,482

259,600

Martin Schweizer

24,000

624

24,000

Note:

(1) Mr. Willardsen is paid on an hourly basis.  If his agreement is terminated without cause, then the Corporation will provide written notice to Mr. Willardsen of not less than 30 days and pay what is due and owing during the notice period.


45

Compensation of Directors

Burcon does not have a formal compensation program for its directors.  Each non-management director of Burcon is paid an annual retainer of $7,500 ("Annual Retainer") and $750 for attendance at each committee or Board meeting.  The non-management director annual retainer and per meeting fee has remained the same since 2004.  For the financial year ended March 31, 2020, Burcon paid $45,000 in Annual Retainer fees and an aggregate of $134,250 to non-management directors for attendance at committee and Board meetings during the year.  During the year ended March 31, 2020, the non-management directors of Burcon included Alan Chan, Rosanna Chau, J. Douglas Gilpin, David Ju, Peter H. Kappel, David Lorne John Tyrrell and Calvin Chi Leung Ng.

In January 2012, the Corporation engaged Koenig & Associates Inc.  ("Koenig") of Saskatoon, Saskatchewan, to conduct a board remuneration survey for Burcon.  The objective of conducting the Board remuneration survey for Burcon was to determine whether the Board members are fairly compensated.  The review was also conducted to determine the degree of comparability of the Board to the board structure of similar organizations.  Although Koenig has completed its survey, the nominating and compensation committee deferred its review of director compensation during fiscal year 2020 in light of the Corporation's current stage of development and financial resources.

Director Compensation Table

During the most recently completed fiscal year ended March 31, 2020, each non-management director of Burcon received total compensation for services provided to Burcon in his or her capacity as director as follows:

Name(1)

Fees earned(2)(3)

 

($)

Share-based awards
($)

Option-based awards
($)

Non-equity incentive plan compensation
($)

Pension value

($)

All other compen-
sation
($)

Total compen-
sation
($)

Alan Chan

15,750

Nil

41,465(4)

Nil

Nil

Nil

57,215

Rosanna Chau

18,750

Nil

41,465(4)

Nil

Nil

Nil

60,215

J. Douglas Gilpin

24,000

Nil

55,286(4)

Nil

Nil

Nil

79,286

David Ju

19,500

Nil

41,465(4)

Nil

Nil

Nil

60,965

Peter H. Kappel

21,000

Nil

96,751(4)

Nil

Nil

Nil

117,751

David Lorne John Tyrrell

23,250

Nil

69,108(4)

Nil

Nil

Nil

92,358

Calvin Chi Leung Ng

12,000

Nil

41,465(4)

Nil

Nil

Nil

53,465

Notes:

(1) Mrs. Debora Fang was appointed to the board of directors of the Corporation on July 6, 2020, which was after the year end date of March 31, 2020.  Therefore, she does not appear on the above table.

(2) Each non-management director is paid a fee of $750 per meeting for attendance at each Board or committee meeting.

(3) Each non-management director is paid an annual retainer of $7,500.  See "Director Compensation".


46

(4) In determining the fair value of the option awards, the Black-Scholes option pricing model was used and was calculated in accordance with IFRS 2, Share-based payment, with the following assumptions:              

Assumptions (weighted average)

2020

Risk-free interest rate:

1.30%

Dividend rate:

0%

Expected forfeitures:

7.67%

Expected volatility in the market price of shares:

74.1%

Expected life:

8.5 years

Fair value per option:

$1.38

Outstanding Option-Based and Share-Based Awards

The following table sets forth, for each non-management director, all of the option-based and share-based grants and awards outstanding on March 31, 2020.

 

Option-based Awards

Share Based Awards

Name(1)

Number of

Option

Option

Value of

Number of

Market or

 

securities

Exercise

Expiration Date

unexercised

shares or

payout

 

underlying

Price

mm/dd/yyyy

in-the-

units of

value of

 

unexercised

($)

 

money

shares that

share-based

 

options

 

 

options(2)

have not

awards that

 

(#)

 

 

($)

vested

have not

 

 

 

 

 

(#)

vested

 

 

 

 

 

 

($)

Alan Chan

40,000

8.65

04/20/2020(3)

0

N/A

N/A

 

25,000

8.65

04/20/2020(4)

0

 

 

 

20,000

8.05

11/16/2021(5)

0

 

 

 

20,000

4.16

10/29/2022(6)

0

 

 

 

20,000

2.48

12/04/2023(7)

0

 

 

 

20,000

2.86

11/10/2024(8)

0

 

 

 

24,462

2.33

11/12/2025(9)

0

 

 

 

21,382

2.66

12/15/2026(10)

0

 

 

 

20,000

0.69

1/3/2028(11)

4,600

 

 

 

30,000

0.23

2/19/2029(15)

20,700

 

 

 

30,000

1.88

1/27/2030(16)

0

 

 

Rosanna

20,000

9.60

12/17/2019(12)

0

N/A

N/A

Chau

20,000

8.05

11/16/2021(5)

0

 

 

 

20,000

4.16

10/29/2022(6)

0

 

 

 

20,000

2.48

12/04/2023(7)

0

 

 

 

20,000

2.86

11/10/2024(8)

0

 

 

 

24,462

2.33

11/12/2025(9)

0

 

 

 

21,382

2.66

12/15/2026(10)

0

 

 

 

20,000

0.69

1/3/2028(11)

4,600

 

 

 

30,000

1.88

1/27/2030(16)

0

 

 

 



47


 

 Option-based Awards

Share Based Awards

Name(1)

Number of

Option

Option

Value of

Number of

Market or

 

securities

Exercise

Expiration Date

unexercised

shares or

payout

 

underlying

Price

mm/dd/yyyy

in-the-

units of

value of

 

unexercised

($)

 

money

shares that

share-based

 

options

 

 

options(2)

have not

awards that

 

(#)

 

 

($)

vested

have not

 

 

 

 

 

(#)

vested

 

 

 

 

 

 

($)

J. Douglas

40,000

6.78

09/22/2021(13)

0

N/A

N/A

Gilpin

20,000

4.16

10/29/2022(6)

0

 

 

 

20,000

2.48

12/04/2023(7)

0

 

 

 

20,000

2.86

11/10/2024(8)

0

 

 

 

24,462

2.33

11/12/2025(9)

0

 

 

 

21,382

2.66

12/15/2026(10)

0

 

 

 

20,000

0.69

1/3/2028(11)

4,600

 

 

 

30,000

0.23

2/19/2029(15)

20,700

 

 

 

40,000

1.88

1/27/2030(16)

0

 

 

David Ju

30,000

0.69

1/3/2028(11)

6,900

N/A

N/A

 

30,000

0.23

2/19/2029(15)

20,700

 

 

 

30,000

1.88

1/27/2030(16)

0

 

 

Peter H.

41,120

2.76

2/22/2026(14)

0

N/A

N/A

Kappel

21,382

2.66

12/15/2026(10)

0

 

 

 

70,000

1.88

1/27/2030(16)

0

 

 

David Lorne

40,000

9.60

12/17/2019(12)

0

N/A

N/A

John Tyrrell

20,000

8.05

11/16/2021(5)

0

 

 

 

20,000

4.16

10/29/2022(6)

0

 

 

 

20,000

2.48

12/04/2023(7)

0

 

 

 

20,000

2.86

11/10/2024(8)

0

 

 

 

24,462

2.33

11/12/2025(9)

0

 

 

 

21,382

2.66

12/15/2026(10)

0

 

 

 

20,000

0.69

1/3/2028(11)

4,600

 

 

 

30,000

0.23

2/19/2029(15)

20,700

 

 

 

40,000

1.88

1/27/2030(16)

0

 

 

Calvin Chi

30,000

1.88

1/27/2030(16)

0

N/A

N/A

Leung Ng

 

 

 

 

 

 


Notes:

(1) Mrs. Debora Fang was appointed to the board of directors of the Corporation on July 6, 2020, which was after the year end date of March 31, 2020.  Therefore, she does not appear on the above table.

(2) Based on the March 31, 2020 closing price of $0.92 per share on the TSX.

(3) These options all vested on April 20, 2010.  Because the expiry date of these options fell within an internal trading blackout period, the expiry has been extended until the trading blackout is lifted.  As at July 30, 2020, the trading blackout remains in place. Pursuant to the terms of the Amended and Restate Plan, the expiry date of these options will be extended until ten business days following the lifting of the trading blackout.

(4) These options vested as to 1/3 on April 20, 2011, April 20, 2012 and April 20, 2013, respectively. The expiry date of these options has been extended due to an internal trading blackout being in place.

(5) These options all vested on November 16, 2011.

(6) These options all vested on October 29, 2012.

(7) These options all vested on December 4, 2013.

(8) These options all vested on November 10, 2014.

(9) These options all vested on November 12, 2015. 

(10) These options all vested on December 15, 2016.

(11) These options all vested on January 3, 2018.

(12) These options all vested on December 17, 2009. Because the expiry date of these options fell within an internal trading blackout period, the expiry has been extended until the trading blackout is lifted.  As at July 30, 2020, the trading blackout remains in place. Pursuant to the terms of the Amended and Restate Plan, the expiry date of these options will be extended until ten business days following the lifting of the trading blackout.


48

(13) These options all vested on September 22, 2011.

(14) These options all vested on February 22, 2016.

(15) These options all vested on February 19, 2019.

(16) These options all vested on January 27, 2020.

Value Vested or Earned during Fiscal Year Ended March 31, 2020

The following table sets forth, for each non-management director, the value vested for all outstanding option-based and share-based awards and the value earned for all non-equity incentive plan compensation during the twelve month period ended March 31, 2020.

Name(1)

Option-based awards - Value vested during the year(2)
($)

Share-based awards - Value vested during the year
($)

Non-equity incentive plan compensation - Value earned during the year
($)

Alan Chan

0(3)

N/A

N/A

Rosanna Chau

0(3)

N/A

N/A

J. Douglas Gilpin

0(3)

N/A

N/A

Peter H. Kappel

0(3)

N/A

N/A

David Lorne John Tyrrell

0(3)

N/A

N/A

David Ju

0(3)

N/A

N/A

Calvin Chi Leung Ng

0(3)

N/A

N/A

Notes:

(1) Mrs. Debora Fang was appointed to the board of directors of the Corporation on July 6, 2020, which was after the year end date of March 31, 2020.  Therefore, she does not appear on the above table.

(2) See the "Outstanding Option-Based and Share-Based Awards" table for directors (above) for more information on the options awarded to directors.

(3) Based on the January 27, 2020 closing price of $1.71 per share on the TSX.

Executive Compensation-Related Fees

No fees were billed by any consultant or advisors for services related to determining compensation for the Corporation's directors and executive officers and employees for the two years ended March 31, 2020 and March 31, 2019.  No compensation consultants or advisors have been engaged since the Corporation's most recently completed financial year to assist the Board or the Committee in determining compensation for any of the Corporation's directors or officers.

ADDITIONAL INFORMATION

Indebtedness of Directors and Executive Officers

None of the directors or executive officers of Burcon or any subsidiary thereof, or any associate or affiliate of any of them, is or has been indebted to Burcon or its subsidiaries, or to another entity where any indebtedness is the subject of a guarantee, support agreement, letter of credit or other similar arrangement or understanding provided by Burcon or any of its subsidiaries.


49

Interest of Certain Persons in Matters to be Acted Upon

Other than as set forth in this Management Proxy Circular, no person who has been a director or executive officer of Burcon at any time since the beginning of the last fiscal year, nor any individual proposed to be a director or officer of Burcon, nor any associate or affiliate of any of the foregoing, has any material interest, directly or indirectly, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Meeting, other than the election of directors.

Interest of Informed Persons in Material Transactions

Through his wholly-owned company, Firewood, Mr. Alan Chan, a director of Burcon, owns directly or indirectly, approximately 23.3% of the issued and outstanding Common Shares of Burcon.  Firewood's wholly-owned subsidiary, Large Scale Investments Limited ("Large Scale") entered into a loan agreement dated November 13, 2018 with the Corporation pursuant to which Large Scale provided Burcon with an unsecured loan of up to $1,000,000 for a term of 180 days from December 5, 2018.  On March 27, 2019, Large Scale and Burcon amended the Loan Agreement (the "Loan Amendment") pursuant to which Large Scale agreed to increase the loan amount to Burcon by $500,000 (together with the initial $1,000,000 amount referred to as the "Loan Amount").  In connection with the rights offering of the Corporation completed in June 2019, Large Scale offset the Loan Amount against its obligations to pay for subscription funds under the offering.  Mr. Chan is a director of Large Scale.  Ms. Rosanna Chau and Mr. Calvin Chi Leung Ng, directors of Burcon, are also directors of Large Scale.  For further information on the Loan Agreement and the Loan Amendment, refer to pages 9-10 of Burcon's Annual Information Form ("AIF") dated June 29, 2020.  A copy of the AIF can be found on the SEDAR website at www.sedar.com.  Shareholders may obtain a copy of the AIF by written request to Burcon at 1946 West Broadway, Vancouver British Columbia, V6J 1Z2, Attn: Corporate Secretary. 

On December 10, 2019, Burcon issued convertible debentures in the aggregate principal amount of $9,500,000.  Each convertible debenture consists of $1,000 principal amount, and bears interest at a rate of 8.5% per annum, payable semi-annually in arrears and is unsecured.  The principal amount outstanding under the convertible debentures and all accrued and unpaid interest thereon will be payable in cash thirty-six (36) months from the date of issuance of the convertible debentures.  Mr. Johann Tergesen, Mr. Peter Kappel and Dr. Lorne Tyrrell, insiders of Burcon, subscribed for convertible debentures in the principal amount of $1,000,000, $500,000 and $500,000, respectively.  For further information on the convertible debentures, refer to pages 13-14 of Burcon's AIF dated June 29, 2020.

To the knowledge of Burcon's management, no other insider or nominee for election as a director of Burcon, or any associate or affiliate of any such persons, had any interest in any material transaction during the year ended March 31, 2020, or has any interest in any proposed transaction that has materially affected or would materially affect Burcon or any of its subsidiaries.

Requesting Documentation

Additional information relating to Burcon can be found on the SEDAR website at www.SEDAR.com. Shareholders may obtain copies of Burcon's financial statements and management's discussion and analysis ("MD&A") by written request to Burcon at 1946 West Broadway, Vancouver, British Columbia, V6J 1Z2, Attn.: Corporate Secretary.  Financial information is provided in Burcon's comparative financial statements and MD&A for its most recently completed financial year.


50

DIRECTORS' APPROVAL

The contents of this Management Proxy Circular and its distribution to shareholders have been approved by the Board of Burcon.

DATED at Vancouver, British Columbia, as of the 30th day of July, 2020.

BY ORDER OF THE BOARD OF DIRECTORS

"Johann F. Tergesen"

Johann F. Tergesen
President and Chief Executive Officer


Schedule "A"

AMENDED AND RESTATED 2001 SHARE OPTION PLAN

 

 

 

A


 

 

 

BURCON NUTRASCIENCE CORPORATION

 

AMENDED AND RESTATED

2001 SHARE OPTION PLAN

 

 

Dated for Reference September 19, 2001

 

and Amended
on September 17, 2003, September 14, 2004, September 5, 2007, September 3, 2009, September 1, 2011 and August 15, 2012

 

 

 


TABLE OF CONTENTS

PART 1
DEFINITIONS AND INTERPRETATION
 
1.1 Definitions 1
PART 2
SHARE OPTION PLAN
 
2.1 Maximum Plan Shares 5
2.2 Eligibility 5
2.3 Option Commitment 5
2.4 Powers of the Board 5
2.5 Limitations on Issue 7
PART 3
TERMS AND CONDITIONS OF OPTIONS
 
3.1 Option Exercise Price 7
3.2 Term of Option and Blackout Extension 7
3.3 Accelerated Vesting Event 7
3.4 Optionee Ceasing to be Director, Employee or Service Provider 8
3.5 Non Assignable 8
3.6 Adjustment of the Number of Optioned Shares 8
PART 4
COMMITMENT AND EXERCISE PROCEDURES
 
4.1 Option Commitment 10
4.2 Manner of Exercise 10
4.3 Delivery of Certificate and Hold Period 10
4.4 Withholding Tax 10
4.5 Alternative Method for Stock Option Exercise 11
4.6 Conditions 12
PART 5
GENERAL
 
5.1 No Rights as Shareholder 13
5.2 No Fettering of Directors' Discretion 13
5.3 Employment and Services 13
5.4 No Representation or Warranty 13
5.5 Applicable Law 13
5.6 Interpretation 13
5.7 Suspension, Amendment or Termination of Plan 14
5.8 Limitations 14
5.9 Powers of Board Survive Termination 15


BURCON NUTRASCIENCE CORPORATION

AMENDED AND RESTATED

2001 SHARE OPTION PLAN

 

Dated for Reference September 19, 2001
and
Amended on September 17, 2003, September 14, 2004, September 5, 2007,
September 3, 2009, September 1, 2011 and August 15, 2012

 

PART 1
DEFINITIONS AND INTERPRETATION

1.1 Definitions

In this Plan

Accelerated Vesting Event means the occurrence of any one of:

(a) a take-over bid as defined in the Securities Act (British Columbia) is made for Common Shares or Convertible Securities which, if successful would result (assuming the conversion, exchange or exercise of the Convertible Securities, if any, that are the subject of the take-over bid) in any person or persons acting jointly or in concert (as such phrase is defined in the Securities Act (British Columbia)) or persons associated or affiliated with such person or persons within the meaning of the Business Corporations Act (Yukon) beneficially, directly or indirectly, owning shares that would, notwithstanding any agreement to the contrary, entitle the holders thereof for the first time to cast at least 50% of the votes attaching to all shares in the capital of Burcon that may be cast to elect Directors,

(b) the acquisition or continuing ownership by any person or persons acting jointly or in concert (as such phrase is defined in the Securities Act (British Columbia)), directly or indirectly, of Common Shares or of Convertible Securities, which, when added to all other securities of Burcon at the time held by such person or persons, or persons associated or affiliated with such person or persons within the meaning of the Business Corporations Act (Yukon) (collectively, the "Acquirors"), and assuming the conversion, exchange or exercise of Convertible Securities beneficially owned by the Acquirors, results in the Acquirors beneficially owning shares that would, notwithstanding any agreement to the contrary, entitle the holders thereof for the first time to cast at least 50% of the votes attaching to all shares in the capital of Burcon that may be cast to elect Directors,


2

(c) the sale, lease, exchange or other disposition of all or substantially all of Burcon's assets, or

(d) an amalgamation, merger, arrangement or other business combination (a "Business Combination") involving Burcon that results in the securityholders of the parties to the Business Combination other than Burcon owning, directly or indirectly, shares of the continuing entity that entitle the holders thereof to cast at least 50% of the votes attaching to all shares in the capital of the continuing entity that may be cast to elect Directors;

Associate has the meaning assigned by the Securities Act;

Board means the board of directors of Burcon or any committee thereof duly empowered or authorized to grant options under this Plan;

Burcon means Burcon NutraScience Corporation and includes, unless the context otherwise requires, all of its subsidiaries or affiliates and successors according to law;

Business Day means any day other than a Saturday, Sunday or statutory holiday in Vancouver, British Columbia, Canada;

Common Shares means common shares without par value in the capital of Burcon providing such class is listed on the TSX;

Consultant means an individual (or a company wholly-owned by individuals) who:

(a) provides ongoing consulting, managerial, technical, professional or like services to Burcon under a written contract other than services provided in relation to a distribution;

(b) possesses technical, business or management expertise of value to Burcon;

(c) spends a significant amount of time and attention on the business and affairs of Burcon; and

(d) has a relationship with Burcon that enables the individual to be knowledgeable about the business and affairs of Burcon;

Convertible Securities means securities convertible into, exchangeable for or representing the right to acquire Common Shares;


3

Directors means the directors of Burcon from time to time elected or appointed;

Disinterested Shareholders' Approval means approval by a majority of the votes cast by all Burcon's shareholders at a duly constituted shareholders' meeting, excluding votes attached to shares beneficially owned by Service Providers who are insiders;

Effective Date for an Option means the date of grant thereof by the Board whether or not the grant is subject to any Regulatory Approval;

Employee means:

(e) an individual who is considered an employee under the Income Tax Act (Canada) (i.e. for whom income tax, employment insurance and CPP deductions must be made at source);

(f) an individual who works full-time for Burcon providing services normally provided by an employee and who is subject to the same control and direction by the Company over the details and methods of work as an employee of Burcon, but for whom income tax deductions are not made at source; or

(g) an individual who works for Burcon on a continuing and regular basis for a minimum amount of time per week (the number of hours having been disclosed to the TSX) providing services normally provided by an employee and who is subject to the same control and direction by Burcon over the details and methods of work as an employee of Burcon, but for whom income tax deductions need not be made at source;

Expiry Date means the day on which an Option expires as specified in the Option Commitment therefor or in accordance with the terms of this Plan;

Listed Shares means the number of Common Shares of Burcon that have been accepted for listing on the TSX but excluding dilutive Convertible Securities not yet converted into Listed Shares;

Management Company Employee means an individual employed by another individual or a corporation providing management services to Burcon which are required for the ongoing successful operation of the business enterprise of Burcon, but excluding a corporation or individual engaged primarily in Investor Relations Activities;

Market Price means the price per Burcon's Common Share traded on the TSX as at closing on the last trading day before the date that the Option is granted;

Officer means a duly appointed officer of Burcon;

Option means the right to purchase Common Shares granted hereunder to a Service Provider;


4

Option Commitment means the notice of grant of an Option delivered by Burcon hereunder to a Service Provider and substantially in the form of Schedule A hereto;

Option Exercise Price means the amount payable per Common Share on the exercise of an Option, as determined in accordance with the terms hereof;

Optionee means a Service Provider to whom an Option is granted by Burcon under the Plan;

Optioned Shares means the Common Shares issuable pursuant to an exercise of Options;

Participant means a Service Provider that is an Optionee;

Plan means this amended and restated share option plan, the terms of which are set out herein or as may be amended;

Plan Shares means the total number of Common Shares reserved for issuance as Optioned Shares under the Plan as provided in §2.1;

Regulatory Approval means the approval of the TSX and any other securities regulatory agency that may have lawful jurisdiction over any Options to a particular Optionee;

Retired means

(h) with respect to an Officer or Employee, the retirement of the Officer or Employee within the meaning of the Canada Pension Plan, after attainment of age 65, and

(i) with respect to a Director, cessation of office as a Director, other than by reason of death, after attainment of age 70;

Securities Act means the Securities Act, R.S.B.C. 1996, [c. 418], as amended from time to time;

Service Provider means an individual who is a Director, Officer, Employee, Management Company Employee or Consultant, but also includes a company, of which 100% of the share capital is beneficially owned by one or more individual Service Providers;

Totally Disabled, with respect to an Employee or Officer, means that, solely because of disease or injury the Employee or Officer is deemed by a qualified physician selected by Burcon to be unable to work at any occupation which the Employee or Officer is reasonably qualified to perform and, with respect to a Director, means that, solely because of disease or injury, the Director is deemed by a qualified physician selected by Burcon to be unable to carry out his or her responsibilities on the Board;

TSX Company Manual means the rules and policies of the TSX as amended from time to time; and

TSX means the Toronto Stock Exchange and any successor thereto.


5

PART 2
SHARE OPTION PLAN

2.1 Maximum Plan Shares

The aggregate number of Optioned Shares reserved for issuance under this Plan, shall not exceed 10% of the Common Shares then issued and outstanding (on a non-diluted basis).  For greater certainty, any increase in the issued and outstanding Common Shares will result in an increase in the number of Optioned Shares available under this Plan and any exercise, conversion, redemption, expiry, termination, cancellation or surrender of Options granted under this Plan will make additional Optioned Shares available under this Plan.

Any Options issued as at the date hereof shall be counted towards the 10% maximum under this Plan.

2.2 Eligibility

Options to purchase Common Shares may be granted hereunder to Service Providers from time to time by the Board.

2.3 Option Commitment

Subject to specific variations approved by the Board, all terms and conditions set out herein will be deemed to be incorporated into and form part of an Option Commitment made hereunder.

2.4 Powers of the Board

The Board will be responsible for the general administration of the Plan and the proper execution of its provisions, the interpretation of the Plan and the determination of all questions arising hereunder. Without limiting the generality of the foregoing, the Board has the power to:

(a) allot Common Shares for issuance in connection with Options granted under the Plan;

(b) grant Options hereunder;

(c) delegate all or such portion of its powers hereunder as it may determine to one or more committees of the Board, either indefinitely or for such period of time as it may specify, and thereafter each such committee may exercise the powers and discharge the duties of the Board in respect of the Plan so delegated to the same extent as the Board is hereby authorized so to do;


6

(d) interpret and construe this Plan and any Option Commitment and to determine all questions arising out of this Plan and any Option Commitment, and any such interpretation, construction or determination made by the Board will be final, binding and conclusive for all purposes;

(e) determine to which Service Provider Options are granted and to grant Options;

(f) determine the number of Optioned Shares covered by each Option;

(g) determine the Option Exercise Price for each Option;

(h) determine the time or times when Options will be granted, vest and be exerciseable and to determine when it is appropriate to accelerate when Options otherwise subject to vesting may be exercised;

(i) determine if the Optioned Shares that are subject to an Option will be subject to any restrictions or repurchase rights upon the exercise of such Option including, where applicable, the endorsement of a legend on any certificate representing Optioned Shares acquired on the exercise of any Option to the effect that such Optioned Shares may not be offered, sold or delivered except in compliance with the applicable securities laws and regulations of Canada or any other country and if any rights or restrictions exist they will be described in the applicable Option Commitment;

(j) determine the expiration date for each Option;

(k) prescribe the form of the instruments relating to the grant, exercise and other terms of Options;

(l) enter into an Option Commitment evidencing each Option which will incorporate such terms as the Board in its discretion deems consistent with this Plan;

(m) take such steps and require such documentation from Service Providers which in its opinion are necessary or desirable to ensure compliance with the rules and regulations of the TSX and all applicable laws;

(n) adopt such modifications, procedures and subplans as may be necessary or desirable to comply with the provisions of the laws of Canada and other countries in which Burcon or its Affiliates may operate to ensure the viability and maximization of the benefits from the Options granted to Optionees residing in such countries and to meet the objectives of this Plan; and

(o) determine such other matters as provided for herein.


7

2.5 Limitations on Issue

Subject to the other provisions hereof, the following restrictions on issuances of Options are applicable under the Plan:

(a) unless Disinterested Shareholders' Approval has been obtained, insiders cannot be granted awards under this or any other security based compensation plan to purchase more than 10% of the issued and outstanding Listed Shares within any 12 month period;

(b) unless Disinterested Shareholders' Approval has been obtained, the aggregate number of outstanding awards granted under this or any other security based compensation plan to insiders may not exceed 10% of the issued and outstanding Listed Shares at any time; and

(c) the number of Optioned Shares granted under the Plan cannot exceed the number of Plan Shares.

PART 3
TERMS AND CONDITIONS OF OPTIONS

3.1 Option Exercise Price

The Option Exercise Price per Optioned Share will be set by the Board at the time the Options are allocated under the Plan, and cannot be less than the Market Price of the Common Shares at the time the Options are granted.

3.2 Term of Option and Blackout Extension

Each Option Commitment shall have the following terms:

(a) the term of an Option will not exceed 10 years from the Effective Date thereof; and

(b) notwithstanding any other provision hereof, if the Expiry Date of any vested Option held by an Optionee falls during or within nine Business Days following the end of a black-out period or other trading restriction imposed by Burcon, then the Expiry Date of such Option shall be automatically extended to the date that is ten (10) Business Days following the date of the relevant black-out period or other trading restriction being lifted, terminated or removed.  Notwithstanding any provision of this Plan, the ten Business Day period referred to in this §3.2(b) may not be extended by the Board.

3.3 Accelerated Vesting Event

If an Accelerated Vesting Event occurs and TSX approval is obtained, each Option held by an Optionee may be exercised by the Optionee at any time or from time to time on or before the Expiry Date of the Option, provided that with respect to an Option held by an Officer or Employee the Accelerated Vesting Event must have occurred on or before the last day on which the Officer or Employee worked for Burcon.


8

3.4 Optionee Ceasing to be Director, Employee or Service Provider

No Option may be exercised after the Service Provider has left the employ/office or has been advised his services are no longer required or his service contract has expired, except as follows:

(a) in the case of the death of an Optionee, any vested Option held by him at the date of death shall become exercisable by the Optionee's lawful personal representatives, heirs or executors until the earlier of: (i) one year after the date of death; and (ii) the expiration of the term otherwise applicable to such Option;

(b) subject to §3.4(c), if an Optionee ceases to be a Service Provider, any vested Option held by such Optionee at the date of ceasing to be a Service Provider, may be exercised until the earlier of: (i) 30 days following the date on which such Optionee ceases to be so employed or to provide services to Burcon; and (ii) the expiration of the term otherwise applicable to such Option; and

(c) an Option that would otherwise so cease to be exercisable by reason that at the time of cessation ("the particular time") the Optionee has Retired or has become Totally Disabled, may be exercised by the Optionee or, if the Optionee dies after the particular time, by the personal representatives of the Optionee, from time to time no later than the earlier of: (i) the Expiry Date of the Option; and (ii) 90 days after the particular time, as to a total number of shares not exceeding the number of Optioned Shares as to which the Optionee did not exercise the Option before the particular time, including Optioned Shares as to which the Optionee was at the particular time not yet entitled to exercise the Option.

3.5 Non Assignable

Subject to §3.4(a) or §3.4(c), or as permitted by applicable regulatory authorities in connection with a transfer to a registered retirement savings plan, registered retirement income fund or tax-free savings account, or the equivalent thereof, established by or for the Optionee or under which the Optionee is the beneficiary, all Options shall be exercisable only by the Optionee to whom they are granted and shall not be assignable or transferable.

3.6 Adjustment of the Number of Optioned Shares

The number of Common Shares subject to an Option will be subject to adjustment in the events and in the following manner:

(a) in the event of a subdivision of Common Shares as constituted on the date hereof, at any time while an Option is outstanding, into a greater number of Common Shares, Burcon will thereafter deliver at the time of purchase of Optioned Shares hereunder, in addition to the number of Optioned Shares in respect of which the right to purchase is then being exercised, such additional number of Common Shares as result from the subdivision without an Optionee making any additional payment or giving any other consideration therefor;


9

(b) in the event of a consolidation of the Common Shares as constituted on the date hereof, at any time while an Option is outstanding, into a lesser number of Common Shares, Burcon will thereafter deliver and an Optionee will accept, at the time of purchase of Optioned Shares hereunder, in lieu of the number of Optioned Shares in respect of which the right to purchase is then being exercised, the lesser number of Common Shares as result from the consolidation;

(c) in the event of any change of the Common Shares as constituted on the date hereof, at any time while an Option is outstanding, Burcon will thereafter deliver at the time of purchase of Optioned Shares hereunder the number of shares of the appropriate class resulting from the said change as an Optionee would have been entitled to receive in respect of the number of Common Shares so purchased had the right to purchase been exercised before such change;

(d) in the event of a capital reorganization, reclassification or change of outstanding equity shares (other than a change in the par value thereof) of Burcon, a consolidation, merger or amalgamation of Burcon with or into any other company or a sale of the property of Burcon as or substantially as an entirety at any time while an Option is outstanding, an Optionee will thereafter have the right to purchase and receive, in lieu of the Optioned Shares immediately theretofore purchasable and receivable upon the exercise of the Option, the kind and amount of shares and other securities and property receivable upon such capital reorganization, reclassification, change, consolidation, merger, amalgamation or sale which the holder of a number of Common Shares equal to the number of Optioned Shares immediately theretofore purchasable and receivable upon the exercise of the Option would have received as a result thereof. The subdivision or consolidation of Common Shares at any time outstanding (whether with or without par value) will not be deemed to be a capital reorganization or a reclassification of the capital of Burcon for the purposes of this §3.6(d);

(e) an adjustment will take effect at the time of the event giving rise to the adjustment provided for in this Section are cumulative;

(f) Burcon will not be required to issue fractional shares in satisfaction of its obligations hereunder. Any fractional interest in a Common Share that would, except for the provisions of this §3.6(f), be deliverable upon the exercise of an Option will be cancelled and not be deliverable by Burcon; and

(g) if any questions arise at any time with respect to the Option Exercise Price or number of Optioned Shares deliverable upon exercise of an Option in any of the events set out in this §3.6, such questions will be conclusively determined by Burcon's auditors, or, if they decline to so act, any other firm of Chartered Accountants, in Vancouver, British Columbia (or in the city of Burcon's principal executive office) that Burcon may designate and who will have access to all appropriate records and such determination will be binding upon Burcon and all Optionees.


10

PART 4
COMMITMENT AND EXERCISE PROCEDURES

4.1 Option Commitment

Upon grant of an Option hereunder, the secretary or other authorized officer of Burcon will deliver to the Optionee an Option Commitment detailing the terms of his or her Option and upon such delivery the Service Provider will be a Participant in the Plan and have the right to purchase the Optioned Shares at the Option Exercise Price set out therein subject to the terms and conditions hereof.

4.2 Manner of Exercise

An Optionee who wishes to exercise his Option may do so by delivering

(a) a written notice to Burcon specifying the number of Optioned Shares being acquired pursuant to the Option;

(b) wire transfer or a certified cheque payable to Burcon for the aggregate Option Exercise Price for the Optioned Shares being acquired; and

(c) if required by Burcon, the amount necessary to satisfy any applicable tax withholding or remittance obligations under applicable law.

4.3 Delivery of Certificate and Hold Period

Not later than five days after receipt of the notice of exercise described in §4.2 and payment in full for the Optioned Shares being acquired, Burcon will direct its transfer agent to issue a certificate to the Optionee for the appropriate number of Optioned Shares. The certificate issued will bear a legend stipulating that the Optioned Shares are subject to a four month hold period from the date of the Option Commitment or such longer term if required by applicable law.

4.4 Withholding Tax

(a) Burcon may withhold from any amount payable to a Participant, either under the Plan or otherwise, such amounts as are required by law to be withheld or deducted as a consequence of his or her exercise of Options or other participation in this Plan ("Withholding Obligations"). Burcon shall have the right, in its discretion, to satisfy any Withholding Obligations by:


11

(i) selling or causing to be sold, on behalf of any Participant, such number of Optioned Shares issued to the Participant on the exercise of Options as is sufficient to fund the Withholding Obligations;

(ii) retaining the amount necessary to satisfy the Withholding Obligations from any amount which would otherwise be delivered, provided or paid to the Participant by Burcon, whether under this Plan or otherwise;

(iii) requiring the Participant, as a condition of exercise under §4.2 or §4.5 to (i) remit the amount of any such Withholding Obligations to Burcon in advance; (ii) reimburse Burcon for any such Withholding Obligations; or (iii) cause a broker who sells Optioned Shares acquired by the Participant on behalf of the Participant to withhold from the proceeds realized from such sale the amount required to satisfy any such Withholding Obligations and to remit such amount directly to Burcon; and/or

(iv) making such other arrangements as Burcon may reasonably require.

(b) The sale of Optioned Shares by Burcon, or by a broker engaged by Burcon (the "Broker"), under clause (a) above will be made on the exchange on which the Common Shares are then listed for trading. The Participant consents to such sale and grants to the Company an irrevocable power of attorney to effect the sale of such Optioned Shares on his or her behalf and acknowledges and agrees that: (i) the number of Optioned Shares sold shall, at a minimum, be sufficient to fund with Withholding Obligations net of all selling costs, which costs are the responsibility of the Participant and which the Participant hereby authorizes to be deducted from the proceeds of such sale; (ii) in effecting the sale of any such Optioned Shares, the Company or the Broker will exercise its sole judgement as to the timing and the manner of sale and will not be obligated to seek or obtain a minimum price; and (iii) neither the Company nor the Broker will be liable for any loss arising out of any sale of such Optioned Shares including any loss relating to the pricing,  manner or timing of such sales or any delay in transferring any Optioned Shares to a Participant or otherwise.  The Participant further acknowledges that the sale price of Optioned Shares will fluctuate with the market price of Burcon's Common Shares and no assurance can be given that any particular price will be received upon any sale.

4.5 Alternative Method for Stock Option Exercise

(a) A Participant may, in lieu of exercising an Option in accordance with §4.2 elect to surrender such Option to the Corporation in consideration for an amount from the Corporation equal to the amount by which (i) the fair market value of the Common Shares under such Option, exceeds (ii) the aggregate Option Exercise Price in respect of such Option (the "In-the-Money-Amount").  The Corporation shall satisfy payment of the In-the-Money Amount by: (i) pursuant to §4.4 (a) (iii) (i), requiring the Participant to remit the amount of any such Withholding Obligation to Burcon in advance and remitting such amount to the relevant taxation authority (the "Remittance Amount"), and (ii) delivering to the Participant, at the sole discretion of the Corporation, either (a) cash in an amount equal to the amount by which the In-the-Money Amount exceeds the Remittance Amount, or (b) such number of Common Shares (rounded down to the nearest whole number) having a fair market value equal to the amount by which the In-the-Money Amount exceeds the Remittance Amount.  For these purposes, the fair market value of a Common Share shall be determined with reference to the weighted average trading price of a Common Share on the relevant Stock Exchange during the five trading days preceding the date of surrender, but if the Common Shares are not listed and posted for trading at the relevant time, shall be the fair value of the Common Shares as determined by the Board acting in good faith.


12

(b) No fractional Common Shares will be issued upon a Participant making an election pursuant to §4.5 (a). If the number of Common Shares to be issued to the Participant in the event of such an election would otherwise include a fraction of a Common Share, the Corporation will pay a cash amount to such Participant equal to: (i) the fraction of a Common Share otherwise issuable, multiplied by (ii) the fair market value of a Common Share calculated in accordance with §4.5 (a).

(c) The number of Optioned Shares underlying an Option that is surrendered pursuant to §4.5 (a) shall be deducted from the total number of Optioned Shares reserved pursuant to the Plan.

4.6 Conditions

Notwithstanding any of the provisions contained in this Plan or in any Option Commitment, the Company's obligation to issue Optioned Shares to a Participant pursuant to the exercise of an Option will be subject to, if applicable:

(a) completion of such registration or other qualification of such Optioned Shares or obtaining approval of such governmental authority as Burcon will determine to be necessary or advisable in connection with the authorization, issuance or sale thereof;

(b) the receipt from the Participant of such representations, agreements and undertakings, including as to future dealings in such Optioned Shares, as the Company or its counsel determines to be necessary or advisable in order to safeguard against the violation of the securities laws of any jurisdiction; and

(c) compliance with all applicable laws, and all rules and requirements of any stock exchange upon which the Common Shares of Burcon may be listed.

The Participant agrees to fully cooperate with Burcon in doing all such things, including executing and delivering all such agreements, undertakings or other documents or furnishing all such information as is reasonably necessary to facilitate compliance by Burcon with such laws, rules and requirements, including all tax withholding and remittance obligations.


13

PART 5
GENERAL

5.1 No Rights as Shareholder

Nothing herein or otherwise shall be construed so as to confer on any Optionee any rights as a shareholder of Burcon with respect to any Optioned Shares reserved for the purpose of any Option.

5.2 No Fettering of Directors' Discretion

Nothing contained in this Plan will restrict or limit or be deemed to restrict or limit the right or power of the Board in connection with any allotment and issuance of Common Shares which are not allotted and issued under this Plan including, without limitation, with respect to other compensation arrangements.

5.3 Employment and Services

Nothing contained in this Plan will confer upon or imply in favour of any Optionee any right with respect to office, employment or provision of services with Burcon, or interfere in any way with the right of Burcon to lawfully terminate the Optionee's office, employment or service at any time pursuant to the arrangements pertaining to same. Participation in the Plan by an Optionee will be voluntary.

5.4 No Representation or Warranty

Burcon makes no representation or warranty as to the future market value of Common Shares issued in accordance with the provisions of the Plan or to the effect of the Income Tax Act (Canada) or any other taxing statute governing the Options or the Common Shares issuable thereunder or the tax consequences to a Service Provider. Compliance with applicable securities laws as to the disclosure and resale obligations of each Participant is the responsibility of such Participant and not Burcon.

5.5 Applicable Law

The Plan and any Option or Option Commitment granted will be governed, construed and administered in accordance with the laws of the Province of British Columbia and the laws of Canada applicable therein.

5.6 Interpretation

References herein to any gender include all genders and to the plural includes the singular and vice versa.  The division of this Plan into Sections and Articles and the insertion of headings are for convenience of reference only and will not affect the construction or interpretation of this Plan.


14

5.7 Suspension, Amendment or Termination of Plan

The Board will have the right at any time to suspend or terminate this Plan and, subject to §5.8, may:

(a) with approval of shareholders of Burcon by ordinary resolution make any amendment to any Option Commitment, Option or the Plan; and

(b) without approval of shareholders of Burcon make any amendments (other than those amendments specified in §5.8 which require shareholder approval or any amendment to §5.7 and §5.8) to the Plan, any Option or any Option Commitment, including without limitation the following amendments:

(i) amendments of a clerical nature, including but not limited to the correction of grammatical or typographical errors or clarification of terms;

(ii) amendments to reflect any requirements of any regulatory authorities to which Burcon is subject, including the TSX;

(iii) amendments to vesting provisions contained in any Option Commitment, Options or the Plan;

(iv) amendments to the expiry of Options that do not entail an extension past the original date of expiration; and

(v) amendments which provide a cashless exercise feature to an Option or the Plan that provides for the full deduction of the number of underlying Optioned Shares from the total number of Optioned Shares reserved pursuant to the Plan.

Notwithstanding the foregoing, all procedures and necessary approvals required under the applicable rules and regulations of all regulatory authorities to which Burcon is subject shall be complied with and obtained in connection with any such suspension, termination or amendment to the Plan or amendments to any Option Commitment.

5.8 Limitations

In exercising its rights pursuant to §5.7, the Board will not have the right to:

(a) reduce the Exercise Price per Common Share under any Option or cancel any Option and replace such Option with a lower Exercise Price per Common Share under such replacement Option, without the prior approval of shareholders, except as permitted pursuant to §3.6; or

(b) affect in a manner that is adverse or prejudicial to, or that impairs, the benefits and rights of any Participant under any Option previously granted under this Plan (except: (a) with the consent of such Participant; (b) as permitted pursuant to §3.6; or (c) for the purpose of complying with the requirements of any regulatory authorities to which Burcon is subject, including the TSX).


15

5.9 Powers of Board Survive Termination

The full powers of the Board as provided for in this Plan will survive the termination of this Plan until all Options have been exercised in full or have otherwise expired.


16

SCHEDULE A

SHARE OPTION PLAN

OPTION COMMITMENT

Notice is hereby given that, effective this day of (the "Effective Date") BURCON NUTRASCIENCE CORPORATION (the "Corporation") has granted to (the "Service Provider") , an Option to acquire Common Shares ("Optioned Shares") up to 5:00 p.m. Vancouver Time on the day of (the "Expiry Date") at a Option Exercise Price of Cdn$per share.

The grant of the Option evidenced hereby is made on and subject to the vesting provisions and other terms and conditions of the Plan, which are incorporated by reference herein. The number of Optioned Shares will be adjusted if and to the extent required in accordance with §3.6 of the Plan.

To exercise your Option, deliver a written notice specifying the number of Optioned Shares you wish to acquire, together with evidence of a wire transfer or a certified cheque payable to Burcon for the aggregate Option Exercise Price, to Burcon. A certificate for the Optioned Shares so acquired will be issued by the transfer agent as soon as practicable thereafter and will bear a minimum four month non-transferability legend from the date of this Option Commitment.

Burcon and the Service Provider understand that the Service Provider under the terms and conditions of the Plan is a bonafide Service Provider of Burcon, entitled to receive Options.

 

 

BURCON NUTRASCIENCE CORPORATION

By:

 

 

Name:

 

Title:

 

 

 

 

 

 



Schedule "B"

PROPOSED ARTICLES OF BURCON NUTRASCIENCE CORPORATION

 

 

 

B



Incorporation Number 

 

ARTICLES

OF

BURCON NUTRASCIENCE CORPORATION

PROVINCE OF BRITISH COLUMBIA

BUSINESS CORPORATIONS ACT


TABLE OF CONTENTS

ARTICLE 1
INTERPRETATION

Section 1.1 Definitions 1
Section 1.2 BCA and Interpretation Act Definitions Applicable 2
Section 1.3 Conflicts or Inconsistencies 2
ARTICLE 2
SHARES AND SHARE CERTIFICATES
 
Section 2.1 Authorized Share Structure 2
Section 2.2 Form of Share Certificate 2
Section 2.3 Shareholder Entitled to Certificate or Acknowledgement 2
Section 2.4 Delivery by Mail 2
Section 2.5 Replacement of Worn Out or Defaced Certificate or Acknowledgement 2
Section 2.6 Replacement of Lost, Destroyed or Wrongfully Taken Certificate 3
Section 2.7 Recovery of New Share Certificate 3
Section 2.8 Splitting Share Certificates 3
Section 2.9 Certificate Fee 3
Section 2.10 Recognition of Trusts 3
ARTICLE 3
ISSUE OF SHARES
 
Section 3.1 Board Authorized 4
Section 3.2 Commissions and Discounts 4
Section 3.3 Brokerage 4
Section 3.4 Conditions of Issue 4
Section 3.5 Share Purchase Warrants and Rights 4
ARTICLE 4
SHARE REGISTERS
 
Section 4.1 Central Securities Register 4
Section 4.2 Closing Register 5
ARTICLE 5
SHARE TRANSFERS
 
Section 5.1 Registering Transfers 5
Section 5.2 Waivers of Requirements for Transfer 5
Section 5.3 Form of Instrument of Transfer 5
Section 5.4 Transferor Remains Shareholder 5
Section 5.5 Signing of Instrument of Transfer 6
Section 5.6 Enquiry as to Title Not Required 6
Section 5.7 Transfer Fee 6
ARTICLE 6
TRANSMISSION OF SHARES
 
Section 6.1 Legal Personal Representative Recognized on Death 6
Section 6.2 Rights of Legal Personal Representative 6

(i)



ARTICLE 7
ACQUISITION OF COMPANY'S SHARES
 
Section 7.1 Company Authorized to Purchase or Otherwise Acquire Shares 7
Section 7.2 No Purchase, Redemption or Other Acquisition When Insolvent 7
Section 7.3 Sale and Voting of Purchased, Redeemed or Otherwise Acquired Shares 7
ARTICLE 8
BORROWING POWERS
 
Section 8.1 Borrowing Powers 7
ARTICLE 9
ALTERATIONS
 
Section 9.1 Alteration of Authorized Share Structure 7
Section 9.2 Special Rights or Restrictions 8
Section 9.3 No Interference with Class or Series Rights without Consent 8
Section 9.4 Change of Name 9
Section 9.5 Other Alterations 9
ARTICLE 10
MEETINGS OF SHAREHOLDERS
 
Section 10.1 Annual General Meetings 9
Section 10.2 Resolution Instead of Annual General Meeting 9
Section 10.3 Calling of Meetings of Shareholders 9
Section 10.4 Electronic Meetings 9
Section 10.5 Notice for Meetings of Shareholders 9
Section 10.6 Record Date for Notice 10
Section 10.7 Record Date for Voting 10
Section 10.8 Failure to Give Notice and Waiver of Notice 10
Section 10.9 Notice of Special Business at Meetings of Shareholders 10
Section 10.10 Class Meetings and Series Meetings of Shareholders 10
Section 10.11 Notice of Dissent Rights 11
Section 10.12 Advance Notice Provisions 11
ARTICLE 11
PROCEEDINGS AT MEETINGS OF SHAREHOLDERS
 
Section 11.1 Special Business 14
Section 11.2 Special Majority 15
Section 11.3 Quorum 15
Section 11.4 Persons Entitled to Attend Meeting 15
Section 11.5 Requirement of Quorum 15
Section 11.6 Lack of Quorum 15
Section 11.7 Lack of Quorum at Succeeding Meeting 15
Section 11.8 Chair 16
Section 11.9 Selection of Alternate Chair 16
Section 11.10 Adjournments 16
Section 11.11 Notice of Adjourned Meeting 16
Section 11.12 Electronic Voting 16
Section 11.13 Decisions by Show of Hands or Poll 16
Section 11.14 Declaration of Result 16
Section 11.15 Motion Need Not be Seconded 17
Section 11.16 Casting Vote 17
Section 11.17 Manner of Taking Poll 17

(ii)



Section 11.18 Demand for Poll on Adjournment 17
Section 11.19 Chair Must Resolve Dispute 17
Section 11.20 Casting of Votes 17
Section 11.21 No Demand for Poll on Election of Chair 17
Section 11.22 Demand for Poll Not to Prevent Continuance of Meeting 17
Section 11.23 Retention of Ballots and Proxies 17
ARTICLE 12
VOTES OF SHAREHOLDERS
 
Section 12.1 Number of Votes by Shareholder or by Shares 18
Section 12.2 Votes of Persons in Representative Capacity 18
Section 12.3 Votes by Joint Holders 18
Section 12.4 Legal Personal Representatives as Joint Shareholders 18
Section 12.5 Representative of a Corporate Shareholder 18
Section 12.6 When Proxy Holder Need Not Be Shareholder 19
Section 12.7 When Proxy Provisions Do Not Apply to the Company 19
Section 12.8 Appointment of Proxy Holders 19
Section 12.9 Alternate Proxy Holders 19
Section 12.10 Deposit of Proxy 19
Section 12.11 Validity of Proxy Vote 20
Section 12.12 Form of Proxy 20
Section 12.13 Revocation of Proxy 20
Section 12.14 Revocation of Proxy Must Be Signed 21
Section 12.15 Chair May Determine Validity of Proxy. 21
Section 12.16 Production of Evidence of Authority to Vote 21
ARTICLE 13
DIRECTORS
 
Section 13.1 Number of Directors 21
Section 13.2 Change in Number of Directors 21
Section 13.3 Board's Acts Valid Despite Vacancy 22
Section 13.4 Qualifications of Directors 22
Section 13.5 Remuneration of Directors 22
Section 13.6 Reimbursement of Expenses of Directors 22
Section 13.7 Special Remuneration for Directors 22
Section 13.8 Gratuity, Pension or Allowance on Retirement of Director 22
ARTICLE 14
ELECTION AND REMOVAL OF DIRECTORS
 
Section 14.1 Election at Annual General Meeting 22
Section 14.2 Consent to be a Director 22
Section 14.3 Failure to Elect or Appoint Directors 23
Section 14.4 Places of Retiring Directors Not Filled 23
Section 14.5 Board May Fill Casual Vacancies 23
Section 14.6 Remaining Directors' Power to Act 23
Section 14.7 Shareholders May Fill Vacancies 23
Section 14.8 Additional Directors 24
Section 14.9 Ceasing to be a Director 24
Section 14.10 Removal of Director by Shareholders 24
Section 14.11 Removal of Director by Directors 24

(iii)



ARTICLE 15
ALTERNATE DIRECTORS
 
Section 15.1 Application 24
Section 15.2 Appointment of Alternate Director 24
Section 15.3 Notice of Meetings 25
Section 15.4 Alternate for More Than One Director Attending Meetings 25
Section 15.5 Consent Resolutions 25
Section 15.6 Alternate Director Not an Agent 25
Section 15.7 Revocation of Appointment of Alternate Director 25
Section 15.8 Ceasing to be an Alternate Director 25
Section 15.9 Remuneration and Expenses of Alternate Director 26
ARTICLE 16
POWERS AND DUTIES OF THE BOARD
 
Section 16.1 Powers of Management 26
Section 16.2 Appointment of Attorney of Company 26
ARTICLE 17
INTERESTS OF DIRECTORS AND OFFICERS
 
Section 17.1 Obligation to Account for Profits 26
Section 17.2 Restrictions on Voting by Reason of Interest 26
Section 17.3 Interested Director Counted in Quorum 26
Section 17.4 Disclosure of Conflict of Interest or Property 26
Section 17.5 Director Holding Other Office in the Company 27
Section 17.6 No Disqualification 27
Section 17.7 Professional Services by Director or Officer 27
Section 17.8 Director or Officer in Other Corporations 27
ARTICLE 18
PROCEEDINGS OF THE BOARD
 
Section 18.1 Meetings of the Board 27
Section 18.2 Voting at Meetings 27
Section 18.3 Chair of Meetings 27
Section 18.4 Meetings by Telephone or Other Communications Medium 28
Section 18.5 Calling of Meetings 28
Section 18.6 Notice of Meetings 28
Section 18.7 When Notice Not Required 28
Section 18.8 Meeting Valid Despite Failure to Give Notice 28
Section 18.9 Waiver of Notice of Meetings 28
Section 18.10 Quorum 29
Section 18.11 Validity of Acts Where Appointment Defective 29
Section 18.12 Consent Resolutions in Writing 29
ARTICLE 19
EXECUTIVE AND OTHER COMMITTEES
 
Section 19.1 Appointment and Powers of Executive Committee 29
Section 19.2 Appointment and Powers of Other Committees 29
Section 19.3 Obligations of Committees 30
Section 19.4 Powers of Board 30
Section 19.5 Committee Meetings 30

(iv)



ARTICLE 20
OFFICERS
 
Section 20.1 Board May Appoint Officers 31
Section 20.2 Functions, Duties and Powers of Officers 31
Section 20.3 Qualifications 31
Section 20.4 Remuneration and Terms of Appointment 31
ARTICLE 21
INDEMNIFICATION
 
Section 21.1 Definitions 31
Section 21.2 Mandatory Indemnification of Eligible Parties 32
Section 21.3 Permitted Indemnification 32
Section 21.4 Non-Compliance with BCA 32
Section 21.5 Company May Purchase Insurance 32
ARTICLE 22
DIVIDENDS
 
Section 22.1 Payment of Dividends Subject to Special Rights 32
Section 22.2 Declaration of Dividends 32
Section 22.3 No Notice Required 32
Section 22.4 Record Date 33
Section 22.5 Manner of Paying Dividend 33
Section 22.6 Settlement of Difficulties 33
Section 22.7 When Dividend Payable 33
Section 22.8 Dividends to be Paid in Accordance with Number of Shares 33
Section 22.9 Receipt by Joint Shareholders 33
Section 22.10 Dividend Bears No Interest 33
Section 22.11 Fractional Dividends 33
Section 22.12 Payment of Dividends 33
Section 22.13 Capitalization of Retained Earnings or Surplus 34
Section 22.14 Unclaimed Dividends 34
ARTICLE 23
ACCOUNTING RECORDS AND AUDITOR
 
Section 23.1 Recording of Financial Affairs 34
Section 23.2 Inspection of Accounting Records 34
Section 23.3 Remuneration of Auditor 34
ARTICLE 24
NOTICES
 
Section 24.1 Method of Giving Notice 34
Section 24.2 Deemed Receipt 35
Section 24.3 Certificate of Sending 35
Section 24.4 Notice to Joint Shareholders 35
Section 24.5 Notice to Legal Personal Representatives and Trustees 36
Section 24.6 Undelivered Notices 36
ARTICLE 25
SEAL
 
Section 25.1 Who May Attest Seal 36
Section 25.2 Sealing Copies 36

(v)



Section 25.3 Mechanical Reproduction of Seal 36
ARTICLE 26
PROHIBITIONS
 
Section 26.1 Definitions 37
Section 26.2 Application 37
Section 26.3 Consent Required for Transfer of Shares or Transfer Restricted Securities 37

(vi)



Incorporation Number 

 

ARTICLES

BURCON NUTRASCIENCE CORPORATION

(the "Company")

ARTICLE 1
INTERPRETATION

Section 1.1 Definitions

In these Articles, unless the context otherwise requires:

(1) "appropriate person" has the meaning assigned in the Securities Transfer Act;

(2) "board of directors" and "board" mean the board of directors or sole director of the Company for the time being;

(3) "BCA" means the Business Corporations Act (British Columbia) from time to time in force and all amendments thereto and includes all regulations and amendments thereto made pursuant to that Act;

(4) "director" means a person who is a director of the Company for the time being;

(5) "directors' resolution" means a resolution of the board of directors passed at a meeting of the board or consented to by the directors in accordance with Section 140 of the BCA and Section 18.12;

(6) "Interpretation Act" means the Interpretation Act (British Columbia) from time to time in force and all amendments thereto and includes all regulations and amendments thereto made pursuant to that Act;

(7) "legal personal representative" means the personal or other legal representative of a shareholder or other person, as the context requires;

(8) "protected purchaser" has the meaning assigned in the Securities Transfer Act;

(9) "registered address" of a shareholder means the shareholder's address as recorded in the central securities register;

(10) "seal" means the seal of the Company, if any;

(11) "Securities Act" means the Securities Act (British Columbia) from time to time in force and all amendments thereto and includes all regulations and amendments thereto made pursuant to that Act;

(12) "securities legislation" means statutes concerning the regulation of securities markets and trading in securities and the regulations, rules, forms and schedules under those statutes, all as amended from time to time, and the blanket rulings and orders, as amended from time to time, issued by the securities commissions or similar regulatory authorities appointed under or pursuant to those statutes; "Canadian securities legislation" means the securities legislation in any province or territory of Canada and includes the Securities Act; and "U.S. securities legislation" means the securities legislation in the federal jurisdiction of the United States and in any state of the United States and includes the Securities Act of 1933 and the Securities Exchange Act of 1934;


(13) "Securities Transfer Act" means the Securities Transfer Act (British Columbia) from time to time in force and all amendments thereto and includes all regulations and amendments thereto made pursuant to that Act; and

(14) "special business" has the meaning set out in Section 11.1.

Section 1.2 BCA and Interpretation Act Definitions Applicable

The definitions in the BCA and the definitions and rules of construction in the Interpretation Act, with the necessary changes, so far as applicable, and unless the context requires otherwise, apply to these Articles as if they were an enactment.

Section 1.3 Conflicts or Inconsistencies

If there is a conflict between a definition in the BCA and a definition or rule in the Interpretation Act relating to a term used in these Articles, the definition in the BCA will prevail in relation to the use of the term in these Articles. If there is a conflict or inconsistency between these Articles and the BCA, the BCA will prevail.

ARTICLE 2
SHARES AND SHARE CERTIFICATES

Section 2.1 Authorized Share Structure

The authorized share structure of the Company consists of shares of the class or classes and series, if any, described in the Notice of Articles of the Company.

Section 2.2 Form of Share Certificate

Each share certificate issued by the Company must comply with, and be signed as required by, the BCA.

Section 2.3 Shareholder Entitled to Certificate or Acknowledgement

Unless the shares of which the shareholder is the registered owner are uncertificated shares within the meaning of the BCA, each shareholder is entitled, without charge, to (a) one share certificate representing the shares of each class or series of shares registered in the shareholder's name or (b) a non-transferable written acknowledgement of the shareholder's right to obtain such a share certificate, provided that in respect of a share held jointly by several persons, the Company is not bound to issue more than one share certificate or acknowledgement and delivery of a share certificate or an acknowledgement to one of several joint shareholders or to a duly authorized agent of one of the joint shareholders will be sufficient delivery to all.

Section 2.4 Delivery by Mail

Any share certificate or non-transferable written acknowledgement of a shareholder's right to obtain a share certificate may be sent to the shareholder by mail at the shareholder's registered address and neither the Company nor any director, officer or agent of the Company is liable for any loss to the shareholder because the share certificate or acknowledgement is lost in the mail or stolen.

Section 2.5 Replacement of Worn Out or Defaced Certificate or Acknowledgement

If the Company is satisfied that a share certificate or a non-transferable written acknowledgement of the shareholder's right to obtain a share certificate is worn out or defaced, it must, on production to it of the share certificate or acknowledgement, as the case may be, and on such other terms, if any, as it thinks fit:


(1) order the share certificate or acknowledgement, as the case may be, to be cancelled; and

(2) issue a replacement share certificate or acknowledgement, as the case may be.

Section 2.6 Replacement of Lost, Destroyed or Wrongfully Taken Certificate

If a person entitled to a share certificate claims that the share certificate has been lost, destroyed or wrongfully taken, the Company must issue a new share certificate, if that person:

(1) so requests before the Company has notice that the share certificate has been acquired by a protected purchaser;

(2) provides the Company with an indemnity bond sufficient in the Company's judgement to protect the Company from any loss that the Company may suffer by issuing a new certificate; and

(3) satisfies any other reasonable requirements imposed by the Company.

A person entitled to a share certificate may not assert against the Company a claim for a new share certificate where a share certificate has been lost, apparently destroyed or wrongfully taken if that person fails to notify the Company of that fact within a reasonable time after that person has notice of it and the Company registers a transfer of the shares represented by the certificate before receiving a notice of the loss, apparent destruction or wrongful taking of the share certificate.

Section 2.7 Recovery of New Share Certificate

If, after the issue of a new share certificate, a protected purchaser of the original share certificate presents the original share certificate for the registration of transfer, then in addition to any rights under any indemnity bond, the Company may recover the new share certificate from a person to whom it was issued or any person taking under that person other than a protected purchaser.

Section 2.8 Splitting Share Certificates

If a shareholder surrenders a share certificate to the Company with a written request that the Company issue in the shareholder's name two or more share certificates, each representing a specified number of shares and in the aggregate representing the same number of shares as represented by the share certificate so surrendered, the Company must cancel the surrendered share certificate and issue replacement share certificates in accordance with that request.

Section 2.9 Certificate Fee

There must be paid to the Company, in relation to the issue of any share certificate under Section 2.5, Section 2.6, or Section 2.8, the amount, if any and which must not exceed the amount prescribed under the BCA, determined by the board.

Section 2.10 Recognition of Trusts

Except as required by law or statute or these Articles, no person will be recognized by the Company as holding any share upon any trust, and the Company is not bound by or compelled in any way to recognize (even when having notice thereof) any equitable, contingent, future or partial interest in any share or fraction of a share or (except as required by law or statute or these Articles or as ordered by a court of competent jurisdiction) any other rights in respect of any share except an absolute right to the entirety thereof in the shareholder.


ARTICLE 3
ISSUE OF SHARES

Section 3.1 Board Authorized

Subject to the BCA and the rights, if any, of the holders of issued shares of the Company, the Company may issue, allot, sell or otherwise dispose of the unissued shares, and issued shares held by the Company, at the times, to the persons, including directors, in the manner, on the terms and conditions and for the issue prices (including any premium at which shares with par value may be issued) that the board may determine. The issue price for a share with par value must be equal to or greater than the par value of the share.

Section 3.2 Commissions and Discounts

The Company may at any time pay a reasonable commission or allow a reasonable discount to any person in consideration of that person purchasing or agreeing to purchase shares of the Company from the Company or any other person or procuring or agreeing to procure purchasers for shares of the Company.

Section 3.3 Brokerage

The Company may pay such brokerage fee or other consideration as may be lawful for or in connection with the sale or placement of its securities.

Section 3.4 Conditions of Issue

Except as provided for by the BCA, no share may be issued until it is fully paid.  A share is fully paid when:

(1) consideration is provided to the Company for the issue of the share by one or more of the following:

(a) past services performed for the Company;

(b) property;

(c) money; and

(2) the value of the consideration received by the Company equals or exceeds the issue price set for the share under Section 3.1.

Section 3.5 Share Purchase Warrants and Rights

Subject to the BCA, the Company may issue share purchase warrants, options and rights upon such terms and conditions as the board determines, which share purchase warrants, options and rights may be issued alone or in conjunction with debentures, debenture stock, bonds, shares or any other securities issued or created by the Company from time to time.

ARTICLE 4
SHARE REGISTERS

Section 4.1 Central Securities Register

As required by and subject to the BCA, the Company must maintain a central securities register, which may be kept in electronic form. The board may, subject to the BCA, appoint an agent to maintain the central securities register. The board may also appoint one or more agents, including the agent which keeps the central securities register, as transfer agent for its shares or any class or series of its shares, as the case may be, and the same or another agent as registrar for its shares or such class or series of its shares, as the case may be. The board may terminate such appointment of any agent at any time and may appoint another agent in its place.


Section 4.2 Closing Register

The Company must not at any time close its central securities register.

ARTICLE 5
SHARE TRANSFERS

Section 5.1 Registering Transfers

Subject to Article 26, the BCA and the Securities Transfer Act, the Company must register a transfer of a share of the Company if either:

(1) the Company or the transfer agent or registrar for the class or series of shares to be transferred has received:

(a) in the case where the Company has issued a share certificate in respect of the share to be transferred, that share certificate and a written instrument of transfer (which may be on a separate document or endorsed on the share certificate) made by the shareholder or other appropriate person or by an agent who has actual authority to act on behalf of that person;

(b) in the case of a share that is not represented by a share certificate (including an uncertificated share within the meaning of the BCA and including the case where the Company has issued a non-transferable written acknowledgement of the shareholder's right to obtain a share certificate in respect of the share to be transferred), a written instrument of transfer, made by the shareholder or other appropriate person or by an agent who has actual authority to act on behalf of that person; and

(c) such other evidence, if any, as the Company or the transfer agent or registrar for the class or series of shares to be transferred may require to prove the title of the transferor or the transferor's right to transfer the share, that the written instrument of transfer is genuine and authorized and that the transfer is rightful or to a protected purchaser; or

(2) all the preconditions for a transfer of a share under the Securities Transfer Act have been met and the Company is required under the Securities Transfer Act to register the transfer.

Section 5.2 Waivers of Requirements for Transfer

The Company may waive any of the requirements set out in Section 5.1(1) and any of the preconditions referred to in Section 5.1(2).

Section 5.3 Form of Instrument of Transfer

The instrument of transfer in respect of any share of the Company must be either in the form, if any, on the back of the Company's share certificates or in any other form satisfactory to the Company or the transfer agent for the class or series of shares to be transferred.

Section 5.4 Transferor Remains Shareholder

Except to the extent that the BCA otherwise provides, the transferor of shares is deemed to remain the holder of the shares until the name of the transferee is entered in a securities register of the Company in respect of the transfer.


Section 5.5 Signing of Instrument of Transfer

If a shareholder or other appropriate person or an agent who has actual authority to act on behalf of that person, signs an instrument of transfer in respect of shares registered in the name of the shareholder, the signed instrument of transfer constitutes a complete and sufficient authority to the Company and its directors, officers and agents to register the number of shares specified in the instrument of transfer or specified in any other manner, or, if no number is specified but share certificates are deposited with the instrument of transfer, all the shares represented by such share certificates:

(1) in the name of the person named as transferee in that instrument of transfer; or

(2) if no person is named as transferee in that instrument of transfer, in the name of the person on whose behalf the instrument is deposited for the purpose of having the transfer registered.

Section 5.6 Enquiry as to Title Not Required

Neither the Company nor any director, officer or agent of the Company is bound to inquire into the title of the person named in the instrument of transfer as transferee or, if no person is named as transferee in the instrument of transfer, of the person on whose behalf the instrument is deposited for the purpose of having the transfer registered or is liable for any claim related to registering the transfer by the shareholder or by any intermediate owner or holder of the shares, of any interest in the shares, of any share certificate representing such shares or of any written acknowledgement of a right to obtain a share certificate for such shares.

Section 5.7 Transfer Fee

Subject to the applicable rules of any stock exchange on which the shares of the Company may be listed, there must be paid to the Company, in relation to the registration of any transfer, the amount, if any, determined by the board.

ARTICLE 6
TRANSMISSION OF SHARES

Section 6.1 Legal Personal Representative Recognized on Death

In the case of the death of a shareholder, the legal personal representative of the shareholder, or in the case of shares registered in the shareholder's name and the name of another person in joint tenancy, the surviving joint holder, will be the only person recognized by the Company as having any title to the shareholder's interest in the shares. Before recognizing a person as a legal personal representative of a shareholder, the board may require the original grant of probate or letters of administration or a court certified copy of them or the original or a court certified or authenticated copy of the grant of representation, will, order or other instrument or other evidence of the death under which title to the shares or securities is claimed to vest.

Section 6.2 Rights of Legal Personal Representative

The legal personal representative of a shareholder has the rights, privileges and obligations that attach to the shares held by the shareholder, including the right to transfer the shares in accordance with these Articles and applicable securities legislation, if appropriate evidence of appointment or incumbency within the meaning of the Securities Transfer Act has been deposited with the Company. This Section 6.2 does not apply in the case of the death of a shareholder with respect to shares registered in the shareholder's name and the name of another person in joint tenancy.


ARTICLE 7
ACQUISITION OF COMPANY'S SHARES

Section 7.1 Company Authorized to Purchase or Otherwise Acquire Shares

Subject to Section 7.2, the special rights or restrictions attached to the shares of any class or series of shares, the BCA and applicable securities legislation, the Company may, if authorized by the board, purchase or otherwise acquire any of its shares at the price and upon the terms determined by the board.

Section 7.2 No Purchase, Redemption or Other Acquisition When Insolvent

The Company must not make a payment or provide any other consideration to purchase, redeem or otherwise acquire any of its shares if there are reasonable grounds for believing that:

(1) the Company is insolvent; or

(2) making the payment or providing the consideration would render the Company insolvent.

Section 7.3 Sale and Voting of Purchased, Redeemed or Otherwise Acquired Shares

If the Company retains a share redeemed, purchased or otherwise acquired by it, the Company may sell, gift or otherwise dispose of the share, but, while such share is held by the Company, it:

(1) is not entitled to vote the share at a meeting of its shareholders;

(2) must not pay a dividend in respect of the share; and

(3) must not make any other distribution in respect of the share.

ARTICLE 8
BORROWING POWERS

Section 8.1 Borrowing Powers

The Company, if authorized by the board, may:

(1) borrow money in the manner and amount, on the security, from the sources and on the terms and conditions that the board considers appropriate;

(2) issue bonds, debentures and other debt obligations either outright or as security for any liability or obligation of the Company or any other person and at such discounts or premiums and on such other terms as the board considers appropriate;

(3) guarantee the repayment of money by any other person or the performance of any obligation of any other person; and

(4) mortgage, charge, whether by way of specific or floating charge, grant a security interest in, or give other security on, the whole or any part of the present and future assets and undertaking of the Company.

ARTICLE 9
ALTERATIONS

Section 9.1 Alteration of Authorized Share Structure

Subject to Section 9.2, the special rights or restrictions attached to the shares of any class or series of shares and the BCA, the Company may:


(1) by ordinary resolution;

(a) create one or more classes or series of shares or, if none of the shares of a class or series of shares are allotted or issued, eliminate that class or series of shares;

(b) increase, reduce or eliminate the maximum number of shares that the Company is authorized to issue out of any class or series of shares or establish a maximum number of shares that the Company is authorized to issue out of any class or series of shares for which no maximum is established;

(c) subdivide or consolidate all or any of its unissued, or fully paid issued, shares;

(d) if the Company is authorized to issue shares of a class of shares with par value:

(i) decrease the par value of those shares; or

(ii) if none of the shares of that class of shares are allotted or issued, increase the par value of those shares;

(e) change all or any of its unissued, or fully paid issued, shares with par value into shares without par value or any of its unissued shares without par value into shares with par value;

(f) alter the identifying name of any of its shares; or

(g) otherwise alter its shares or authorized share structure when required or permitted to do so by the BCA;

and, if applicable, alter its Notice of Articles and, if applicable, its Articles, accordingly; or

(2) by directors' resolution, subdivide or consolidate all or any of its unissued, or fully paid issued, shares and if applicable, alter its Notice of Articles and, if applicable, its Articles accordingly.

Section 9.2 Special Rights or Restrictions

Subject to the special rights or restrictions attached to the shares of any class or series of shares and the BCA, the Company may by ordinary resolution:

(1) create special rights or restrictions for, and attach those special rights or restrictions to, the shares of any class or series of shares, whether or not any or all of those shares have been issued; or

(2) vary or delete any special rights or restrictions attached to the shares of any class or series of shares, whether or not any or all of those shares have been issued;

and alter its Articles and Notice of Articles accordingly.

Section 9.3 No Interference with Class or Series Rights without Consent

A right or special right attached to issued shares must not be prejudiced or interfered with under the BCA, the Notice of Articles or these Articles unless the holders of shares of the class or series of shares to which the right or special right is attached consent by a special separate resolution of the holders of such class or series of shares.


Section 9.4 Change of Name

The Company may by directors' resolution or ordinary resolution authorize an alteration to its Notice of Articles in order to change its name.

Section 9.5 Other Alterations

If the BCA does not specify the type of resolution and these Articles do not specify another type of resolution, the Company may by ordinary resolution alter these Articles.

ARTICLE 10
MEETINGS OF SHAREHOLDERS

Section 10.1 Annual General Meetings

Unless an annual general meeting is deferred or waived in accordance with the BCA, the Company must hold its first annual general meeting within 18 months after the date on which it was incorporated or otherwise recognized, and after that must hold an annual general meeting at least once in each calendar year and not more than 15 months after the last annual reference date at such time and place, either in or outside British Columbia, as may be determined by the board.

Section 10.2 Resolution Instead of Annual General Meeting

If all the shareholders who are entitled to vote at an annual general meeting consent by a unanimous resolution to all of the business that is required to be transacted at that annual general meeting, the annual general meeting is deemed to have been held on the date of the unanimous resolution. The shareholders must, in any unanimous resolution passed under this Section 10.2, select as the Company's annual reference date a date that would be appropriate for the holding of the applicable annual general meeting.

Section 10.3 Calling of Meetings of Shareholders

The board may, at any time, call a meeting of shareholders, to be held at such time and at such place, either in or outside British Columbia, as may be determined by the board.

Section 10.4 Electronic Meetings

The board may determine that a meeting of shareholders shall be held entirely by means of telephone, electronic or other communications facilities that permit all participants to communicate with each other during the meeting. A meeting of shareholders may also be held at which some, but not necessarily all, persons entitled to attend may participate by means of such communications facilities, if the board determines to make them available. A person participating in a meeting by such means is deemed to be present at the meeting.

Section 10.5 Notice for Meetings of Shareholders

The Company must send notice of the date, time and location of any meeting of shareholders (including, without limitation, any notice specifying the intention to propose a resolution as an exceptional resolution, a special resolution or a special separate resolution, and any notice to consider approving an amalgamation into a foreign jurisdiction, an arrangement or the adoption of an amalgamation agreement, and any notice of a general meeting, class meeting or series meeting), in the manner provided in these Articles, or in such other manner, if any, as may be prescribed by ordinary resolution (whether previous notice of the resolution has been given or not), to each shareholder entitled to attend the meeting, to each director and to the auditor of the Company, unless these Articles otherwise provide, at least the following number of days before the meeting:

(1) if and for so long as the Company is a public company, 21 days;

(2) otherwise, 10 days.


Section 10.6 Record Date for Notice

The board may set a date as the record date for the purpose of determining shareholders entitled to notice of any meeting of shareholders.  The record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general meeting requisitioned by shareholders under the BCA, by more than four months. The record date must not precede the date on which the meeting is held by fewer than:

(1) if and for so long as the Company is a public company, 21 days;

(2) otherwise, 10 days.

If no record date is set, the record date is 5 p.m. on the day immediately preceding the first date on which the notice is sent or, if no notice is sent, the beginning of the meeting.

Section 10.7 Record Date for Voting

The board may set a date as the record date for the purpose of determining shareholders entitled to vote at any meeting of shareholders. The record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general meeting requisitioned by shareholders under the BCA, by more than four months.  If no record date is set, the record date is 5 p.m. on the day immediately preceding the first date on which the notice is sent or, if no notice is sent, the beginning of the meeting.

Section 10.8 Failure to Give Notice and Waiver of Notice

The accidental omission to send notice of any meeting of shareholders to, or the non-receipt of any notice by, any of the persons entitled to notice does not invalidate any proceedings at that meeting. Any person entitled to notice of a meeting of shareholders may, in writing or otherwise, waive that entitlement or agree to reduce the period of that notice.  Attendance of a person at a meeting of shareholders is a waiver of entitlement to notice of the meeting unless that person attends the meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called.

Section 10.9 Notice of Special Business at Meetings of Shareholders

If a meeting of shareholders is to consider special business within the meaning of Section 11.1, the notice of meeting must:

(1) state the general nature of the special business; and

(2) if the special business includes considering, approving, ratifying, adopting or authorizing any document or the signing of or giving of effect to any document, have attached to it a copy of the document or state that a copy of the document will be available for inspection by shareholders:

(a) at the Company's records office, or at such other reasonably accessible location in British Columbia as is specified in the notice; and

(b) during statutory business hours on any one or more specified days before the day set for the holding of the meeting.

Section 10.10 Class Meetings and Series Meetings of Shareholders

Unless otherwise specified in these Articles, the provisions of these Articles relating to a meeting of shareholders will apply with the necessary changes and so far as they are applicable, to a class meeting or series meeting of shareholders holding a particular class or series of shares.


Section 10.11 Notice of Dissent Rights

The Company must send to each of its shareholders, whether or not their shares carry the right to vote, a notice of any meeting of shareholders at which a resolution entitling shareholders to dissent is to be considered specifying the date of the meeting and containing a statement advising of the right to send a notice of dissent together with a copy of the proposed resolution at least the following number of days before the meeting:

(1) if and for so long as the Company is a public company, 21 days;

(2) otherwise, 10 days.

Section 10.12 Advance Notice Provisions

(1) Nomination of Directors

Subject only to the BCA and these Articles, only persons who are nominated in accordance with the procedures set out in this Section 10.12 shall be eligible for election as directors to the board of directors of the Company. Nominations of persons for election to the board may only be made at an annual meeting of shareholders, or at a special meeting of shareholders called for any purpose at which the election of directors is a matter specified in the notice of meeting, as follows:

(a) by or at the direction of the board or an authorized officer of the Company, including pursuant to a notice of meeting;

(b) by or at the direction or request of one or more shareholders pursuant to a valid proposal made in accordance with the provisions of the BCA or a valid requisition of shareholders made in accordance with the provisions of the BCA; or

(c) by any person entitled to vote at such meeting (a "Nominating Shareholder"), who:

(i) is, at the close of business on the date of giving notice provided for in this Section 10.12 and on the record date for notice of such meeting, either entered in the securities register of the Company as a holder of one or more shares carrying the right to vote at such meeting or who beneficially owns shares that are entitled to be voted at such meeting and provides evidence of such beneficial ownership to the Company; and

(ii) has given timely notice in proper written form as set forth in this Section 10.12.

(2) Exclusive Means

For the avoidance of doubt, this Section 10.12 shall be the exclusive means for any person to bring nominations for election to the board before any annual or special meeting of shareholders of the Company.

(3) Timely Notice

In order for a nomination made by a Nominating Shareholder to be timely notice (a "Timely Notice"), the Nominating Shareholder's notice must be received by the corporate secretary of the Company at the principal executive offices or registered office of the Company:

(a) in the case of an annual meeting of shareholders (including an annual and special meeting), not later than 5:00 p.m. (Vancouver time) on the 30th day before the date of the meeting; provided, however, if the first public announcement made by the Company of the date of the meeting (each such date being the "Notice Date") is less than 50 days before the meeting date, notice by the Nominating Shareholder may be given not later than the close of business on the 10th day following the Notice Date; and


(b) in the case of a special meeting (which is not also an annual meeting) of shareholders called for any purpose which includes the election of directors to the board, not later than the close of business on the 15th day following the Notice Date;

provided that, in either instance, if notice-and-access (as defined in National Instrument 54-101 - Communication with Beneficial Owners of Securities of a Reporting Issuer) is used for delivery of proxy related materials in respect of a meeting described in Section 10.12(3)(a) or Section 10.12(3)(b), and the Notice Date in respect of the meeting is not less than 50 days before the date of the applicable meeting, the notice must be received not later than the close of business on the 40th day before the date of the applicable meeting.

(4) Proper Form of Notice

To be in proper written form, a Nominating Shareholder's notice to the corporate secretary must comply with all the provisions of this Section 10.12 and disclose or include, as applicable:

(a) as to each person whom the Nominating Shareholder proposes to nominate for election as a director (a "Proposed Nominee"):

(i) the name, age, business and residential address of the Proposed Nominee;

(ii) the principal occupation/business or employment of the Proposed Nominee, both presently and for the past five years;

(iii) the number of securities of each class of securities of the Company or any of its subsidiaries beneficially owned, or controlled or directed, directly or indirectly, by the Proposed Nominee, as of the record date for the meeting of shareholders (if such date shall then have been made publicly available and shall have occurred) and as of the date of such notice;

(iv) full particulars of any relationships, agreements, arrangements or understandings (including financial, compensation or indemnity related) between the Proposed Nominee and the Nominating Shareholder, or any affiliates or associates of, or any person or entity acting jointly or in concert with, the Proposed Nominee or the Nominating Shareholder;

(v) any other information that would be required to be disclosed in a dissident proxy circular or other filings required to be made in connection with the solicitation of proxies for election of directors pursuant to the BCA or applicable securities law; and

(vi) a written consent of each Proposed Nominee to being named as nominee and certifying that such Proposed Nominee is not disqualified from acting as director under the provisions of subsection 124(2) of the BCA; and

(b) as to each Nominating Shareholder giving the notice, and each beneficial owner, if any, on whose behalf the nomination is made:

(i) their name, business and residential address;


(ii) the number of securities of the Company or any of its subsidiaries beneficially owned, or controlled or directed, directly or indirectly, by the Nominating Shareholder or any other person with whom the Nominating Shareholder is acting jointly or in concert with respect to the Company or any of its securities, as of the record date for the meeting of shareholders (if such date shall then have been made publicly available and shall have occurred) and as of the date of such notice;

(iii) their interests in, or rights or obligations associated with, any agreement, arrangement or understanding, the purpose or effect of which is to alter, directly or indirectly, the person's economic interest in a security of the Company or the person's economic exposure to the Company;

(iv) any relationships, agreements or arrangements, including financial, compensation and indemnity related relationships, agreements or arrangements, between the Nominating Shareholder or any affiliates or associates of, or any person or entity acting jointly or in concert with, the Nominating Shareholder and any Proposed Nominee;

(v) full particulars of any proxy, contract, relationship arrangement, agreement or understanding pursuant to which such person, or any of its affiliates or associates, or any person acting jointly or in concert with such person, has any interests, rights or obligations relating to the voting of any securities of the Company or the nomination of directors to the board;

(vi) a representation that the Nominating Shareholder is a holder of record of securities of the Company, or a beneficial owner, entitled to vote at such meeting, and intends to appear in person or by proxy at the meeting to propose such nomination;

(vii) a representation as to whether such person intends to deliver a proxy circular and/or form of proxy to any shareholder of the Company in connection with such nomination or otherwise solicit proxies or votes from shareholders of the Company in support of such nomination; and

(viii) any other information relating to such person that would be required to be included in a dissident proxy circular or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to the Business Corporations Act or as required by applicable securities law.

Reference to "Nominating Shareholder" in this Section 10.12(4) shall be deemed to refer to each shareholder that nominated or seeks to nominate a person for election as director in the case of a nomination proposal where more than one shareholder is involved in making the nomination proposal.

(5) Currency of Nominee Information

All information to be provided in a Timely Notice pursuant to this Section 10.12 shall be provided as of the date of such notice. The Nominating Shareholder shall provide the Company with an update to such information forthwith so that it is true and correct in all material respects as of the date that is 10 business days before the date of the meeting, or any adjournment or postponement thereof.


(6) Delivery of Information

Notwithstanding Article 24 of these Articles, any notice, or other document or information required to be given to the corporate secretary pursuant to this Section 10.12 may only be given by personal delivery or courier (but not by fax or email) to the corporate secretary at the address of the principal executive offices or registered office of the Company and shall be deemed to have been given and made on the date of delivery if it is a business day and the delivery was made prior to 5:00 p.m. (Vancouver time) and otherwise on the next business day.

(7) Defective Nomination Determination

The chair of any meeting of shareholders of the Company shall have the power to determine whether any proposed nomination is made in accordance with the provisions of this Section 10.12, and if any proposed nomination is not in compliance with such provisions, must as soon as practicable following receipt of such nomination and prior to the meeting declare that such defective nomination shall not be considered at any meeting of shareholders.

(8) Failure to Appear

Despite any other provision of this Section 10.12, if the Nominating Shareholder (or a qualified representative of the Nominating Shareholder) does not appear at the meeting of shareholders of the Company to present the nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such nomination may have been received by the Company.

(9) Waiver

The board may, in its sole discretion, waive any requirement in this Section 10.12.

(10) Definitions

For the purposes of this Section 10.12, "public announcement" means disclosure in a press release disseminated by the Company through a national news service in Canada, or in a document filed by the Company for public access under its profile on the System of Electronic Document Analysis and Retrieval at www.sedar.com.

ARTICLE 11
PROCEEDINGS AT MEETINGS OF SHAREHOLDERS

Section 11.1 Special Business

At a meeting of shareholders, the following business is special business:

(1) at a meeting of shareholders that is not an annual general meeting, all business is special business except business relating to the conduct of or voting at the meeting;

(2) at an annual general meeting, all business is special business except for the following:

(a) business relating to the conduct of or voting at the meeting;

(b) consideration of any financial statements of the Company presented to the meeting;

(c) consideration of any reports of the board or auditor;

(d) the setting or changing of the number of directors;

(e) the election or appointment of directors;


(f) the appointment of an auditor;

(g) the setting of the remuneration of an auditor;

(h) business arising out of a report of the board not requiring the passing of a special resolution or an exceptional resolution;

(i) any non-binding advisory vote; and

(j) any other business which, under these Articles or the BCA, may be transacted at a meeting of shareholders without prior notice of the business being given to the shareholders.

Section 11.2 Special Majority

The majority of votes required for the Company to pass a special resolution at a general meeting of shareholders is two-thirds of the votes cast on the resolution.

Section 11.3 Quorum

Subject to the special rights or restrictions attached to the shares of any class or series of shares, a quorum for the transaction of business at a meeting of shareholders is present if shareholders who, in the aggregate, hold at least 5% of the issued shares entitled to be voted at the meeting are present in person or represented by proxy, irrespective of the number of persons actually present at the meeting.

Section 11.4 Persons Entitled to Attend Meeting

In addition to those persons who are entitled to vote at a meeting of shareholders, the only other persons entitled to be present at the meeting are the directors, the officers, any lawyer for the Company, the auditor of the Company, any persons invited to be present at the meeting by the board or by the chair of the meeting and any other persons who, although not entitled to vote, are entitled or required under the BCA or these Articles to be present at the meeting; but if any of those persons does attend the meeting, that person is not to be counted in the quorum and is not entitled to vote at the meeting unless that person is a shareholder or proxy holder entitled to vote at the meeting.

Section 11.5 Requirement of Quorum

No business, other than the election of a chair of the meeting and the adjournment of the meeting, may be transacted at any meeting of shareholders unless a quorum of shareholders entitled to vote is present at the commencement of the meeting, but such quorum need not be present throughout the meeting.

Section 11.6 Lack of Quorum

If, within one-half hour from the time set for holding a meeting of shareholders, a quorum is not present:

(1) in the case of a general meeting requisitioned by shareholders, the meeting is dissolved, and

(2) in the case of any other meeting of shareholders, the meeting stands adjourned to the same day in the next week at the same time and place.

Section 11.7 Lack of Quorum at Succeeding Meeting

If, at the meeting to which the meeting referred to in Section 11.6(2) was adjourned, a quorum is not present within one-half hour from the time set for holding the meeting, the person or persons present and being, or representing by proxy, one or more shareholders entitled to attend and vote at the meeting constitute a quorum.


Section 11.8 Chair

The following individual is entitled to preside as chair at a meeting of shareholders:

(1) the chair of the board, if any; or

(2) if the chair of the board is absent or unwilling to act as chair of the meeting, the president, if any.

Section 11.9 Selection of Alternate Chair

If, at any meeting of shareholders, there is no chair of the board or president present within 15 minutes after the time set for holding the meeting, or if the chair of the board and the president are unwilling to act as chair of the meeting, or if the chair of the board and the president have advised the secretary, if any, or any director present at the meeting, that they will not be present at the meeting, the directors present must choose one of their number to be chair of the meeting.  If all of the directors present decline to take the chair or fail to so choose or if no director is present, the shareholders entitled to vote at the meeting who are present in person or by proxy may choose any person present at the meeting to chair the meeting.

Section 11.10 Adjournments

The chair of a meeting of shareholders may, and if so directed by the meeting must, adjourn the meeting from time to time and from place to place, but no business may be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place.

Section 11.11 Notice of Adjourned Meeting

It is not necessary to give any notice of an adjourned meeting of shareholders or of the business to be transacted at an adjourned meeting of shareholders except that, when a meeting is adjourned for 30 days or more, notice of the adjourned meeting must be given as in the case of the original meeting.

Section 11.12 Electronic Voting

Any vote at a meeting of shareholders may be held entirely or partially by means of telephonic, electronic or other communications facilities if the directors determine to make them available whether or not persons entitled to attend participate in the meeting by means of telephonic, electronic or other communications facilities.

Section 11.13 Decisions by Show of Hands or Poll

Subject to the BCA, every motion put to a vote at a meeting of shareholders will be decided on a show of hands or the functional equivalent of a show of hands by means of telephonic, electronic or other communications facilities, unless a poll, before or on the declaration of the result of the vote by show of hands (or its functional equivalent), is directed by the chair or demanded by any shareholder entitled to vote who is present in person or by proxy.

Section 11.14 Declaration of Result

The chair of a meeting of shareholders must declare to the meeting the decision on every question in accordance with the result of the show of hands (or its functional equivalent) or the poll, as the case may be, and that decision must be entered in the minutes of the meeting. A declaration of the chair that a resolution is carried by the necessary majority or is defeated is, unless a poll is directed by the chair or demanded under Section 11.13, conclusive evidence without proof of the number or proportion of the votes recorded in favour of or against the resolution.


Section 11.15 Motion Need Not be Seconded

No motion proposed at a meeting of shareholders need be seconded unless the chair of the meeting rules otherwise, and the chair of any meeting of shareholders is entitled to propose or second a motion.

Section 11.16 Casting Vote

In the case of an equality of votes, the chair of a meeting of shareholders does not, either on a show of hands or on a poll, have a second or casting vote in addition to the vote or votes to which the chair may be entitled as a shareholder.

Section 11.17 Manner of Taking Poll

Subject to Section 11.18, if a poll is duly demanded at a meeting of shareholders:

(1) the poll must be taken:

(a) at the meeting, or within seven days after the date of the meeting, as the chair of the meeting directs; and

(b) in the manner, at the time and at the place that the chair of the meeting directs;

(2) the result of the poll is deemed to be the decision of the meeting at which the poll is demanded; and

(3) the demand for the poll may be withdrawn by the person who demanded it.

Section 11.18 Demand for Poll on Adjournment

A poll demanded at a meeting of shareholders on a question of adjournment must be taken immediately at the meeting.

Section 11.19 Chair Must Resolve Dispute

In the case of any dispute as to the admission or rejection of a vote given on a poll, the chair of the meeting must determine the dispute, and his or her determination made in good faith is final and conclusive.

Section 11.20 Casting of Votes

On a poll, a shareholder entitled to more than one vote need not cast all the votes in the same way.

Section 11.21 No Demand for Poll on Election of Chair

No poll may be demanded in respect of the vote by which a chair of a meeting of shareholders is elected.

Section 11.22 Demand for Poll Not to Prevent Continuance of Meeting

The demand for a poll at a meeting of shareholders does not, unless the chair of the meeting so rules, prevent the continuation of the meeting for the transaction of any business other than the question on which a poll has been demanded.

Section 11.23 Retention of Ballots and Proxies

The Company must, for at least three months after a meeting of shareholders, keep each ballot cast on a poll and each proxy voted at the meeting, and, during that period, make them available for inspection during normal business hours by any shareholder or proxyholder entitled to vote at the meeting. At the end of such three month period, the Company may destroy such ballots and proxies.


ARTICLE 12
VOTES OF SHAREHOLDERS

Section 12.1 Number of Votes by Shareholder or by Shares

Subject to any special rights or restrictions attached to any shares and to the restrictions imposed on joint shareholders under Section 12.3:

(1) on a vote by show of hands (or its functional equivalent), every person present who is a shareholder or proxy holder and entitled to vote on the matter has one vote; and

(2) on a poll, every shareholder entitled to vote on the matter has one vote in respect of each share entitled to be voted on the matter and held by that shareholder and may exercise that vote either in person or by proxy.

Section 12.2 Votes of Persons in Representative Capacity

A person who is not a shareholder may vote at a meeting of shareholders, whether on a show of hands or on a poll, and may appoint a proxy holder to act at the meeting, if, before doing so, the person satisfies the chair of the meeting, or the board, that the person is a legal personal representative or a trustee in bankruptcy for a shareholder who is entitled to vote at the meeting.

Section 12.3 Votes by Joint Holders

If there are joint shareholders registered in respect of any share:

(1) any one of the joint shareholders may vote at any meeting of shareholders, personally or by proxy, in respect of the share as if that joint shareholder were solely entitled to it; or

(2) if more than one of the joint shareholders is present at any meeting of shareholders, personally or by proxy, and more than one of them votes in respect of that share, then only the vote of the joint shareholder present whose name stands first on the central securities register in respect of the share will be counted.

Section 12.4 Legal Personal Representatives as Joint Shareholders

Two or more legal personal representatives of a shareholder in whose sole name any share is registered are, for the purposes of Section 12.3, deemed to be joint shareholders registered in respect of that share.

Section 12.5 Representative of a Corporate Shareholder

If a corporation that is not a subsidiary of the Company is a shareholder, that corporation may appoint a person to act as its representative at any meeting of shareholders of the Company, and:

(1) for that purpose, the instrument appointing a representative must be received:

(a) at the registered office of the Company or at any other place specified, in the notice calling the meeting, for the receipt of proxies, at least the number of business days specified in the notice for the receipt of proxies, or if no number of days is specified, two business days before the day set for the holding of the meeting or any adjourned meeting; or

(b) at the meeting or any adjourned meeting, by the chair of the meeting or adjourned meeting or by a person designated by the chair of the meeting or adjourned meeting;

(2) if a representative is appointed under this Section 12.5:


(a) the representative is entitled to exercise in respect of and at that meeting the same rights on behalf of the corporation that the representative represents as that corporation could exercise if it were a shareholder who is an individual, including, without limitation, the right to appoint a proxy holder; and

(b) the representative, if present at the meeting, is to be counted for the purpose of forming a quorum and is deemed to be a shareholder present in person at the meeting.

Evidence of the appointment of any such representative may be sent to the Company by written instrument, fax or any other method of transmitting legibly recorded messages.

Section 12.6 When Proxy Holder Need Not Be Shareholder

A person must not be appointed as a proxy holder unless the person is a shareholder, although a person who is not a shareholder may be appointed as a proxy holder if:

(1) the person appointing the proxy holder is a corporation or a representative of a corporation appointed under Section 12.5;

(2) the Company has at the time of the meeting for which the proxy holder is to be appointed only one shareholder entitled to vote at the meeting;

(3) the shareholders present in person or by proxy at and entitled to vote at the meeting for which the proxy holder is to be appointed, by a resolution on which the proxy holder is not entitled to vote but in respect of which the proxy holder is to be counted in the quorum, permit the proxy holder to attend and vote at the meeting; or

(4) the Company is a public company.

Section 12.7 When Proxy Provisions Do Not Apply to the Company

If and for so long as the Company is a public company, Section 12.8 to Section 12.16 apply only insofar as they are not inconsistent with any Canadian securities legislation applicable to the Company, any U.S. securities legislation applicable to the Company or any rules of an exchange on which securities of the Company are listed.

Section 12.8 Appointment of Proxy Holders

Every shareholder of the Company, including a corporation that is a shareholder but not a subsidiary of the Company, entitled to vote at a meeting of shareholders may, by proxy, appoint one or more proxy holders to attend and act at the meeting in the manner, to the extent and with the powers conferred by the proxy. The instructing of proxy holders may be carried out by means of telephonic, electronic or other communications facility in addition to or in substitution for instructing proxy holders by mail.

Section 12.9 Alternate Proxy Holders

A shareholder may appoint one or more alternate proxy holders to act in the place of an absent proxy holder.

Section 12.10 Deposit of Proxy

Subject to Section 12.13 and Section 12.15, a proxy for a meeting of shareholders must:

(1) be received at the registered office of the Company or at any other place specified, in the notice calling the meeting, for the receipt of proxies, at least the number of business days specified in the notice, or if no number of days is specified, two business days before the day set for the holding of the meeting or any adjourned meeting; or


(2) unless the notice provides otherwise, be received, at the meeting or any adjourned meeting, by the chair of the meeting or adjourned meeting or by a person designated by the chair of the meeting or adjourned meeting.

A proxy may be sent to the Company by written instrument, fax or any other method of transmitting legibly recorded messages or by using such available telephone or internet voting services as may be approved by the board.

Section 12.11 Validity of Proxy Vote

A vote given in accordance with the terms of a proxy is valid notwithstanding the death or incapacity of the shareholder giving the proxy and despite the revocation of the proxy or the revocation of the authority under which the proxy is given, unless notice in writing of that death, incapacity or revocation is received:

(1) at the registered office of the Company, at any time up to and including the last business day before the day set for the holding of the meeting or any adjourned meeting at which the proxy is to be used; or

(2) at the meeting or any adjourned meeting, by the chair of the meeting or adjourned meeting, before any vote in respect of which the proxy has been given has been taken.

Section 12.12 Form of Proxy

A proxy, whether for a specified meeting or otherwise, must be either in the following form or in any other form approved by the board or the chair of the meeting:

[name of company]

(the "Company")

The undersigned, being a shareholder of the Company, hereby appoints [name] or, failing that person, [name], as proxy holder for the undersigned to attend, act and vote for and on behalf of the undersigned at the meeting of shareholders of the Company to be held on [month, day, year] and at any adjournment of that meeting.

Number of shares in respect of which this proxy is given (if no number is specified, then this proxy is given in respect of all shares registered in the name of the undersigned): _________________________________

____________________________
Signed [month, day, year]

____________________________
[Signature of shareholder]

____________________________
[Name of shareholder - printed]

Section 12.13 Revocation of Proxy

Subject to Section 12.14 and Section 12.15, every proxy may be revoked by an instrument in writing that is received:

(1) at the registered office of the Company at any time up to and including the last business day before the day set for the holding of the meeting or any adjourned meeting at which the proxy is to be used; or


(2) at the meeting or any adjourned meeting, by the chair of the meeting or adjourned meeting, before any vote in respect of which the proxy has been given has been taken.

Section 12.14 Revocation of Proxy Must Be Signed

An instrument referred to in Section 12.13 must be signed as follows:

(1) if the shareholder for whom the proxy holder is appointed is an individual, the instrument must be signed by the shareholder or his or her legal personal representative or trustee in bankruptcy; or

(2) if the shareholder for whom the proxy holder is appointed is a corporation, the instrument must be signed by the corporation or by a representative appointed for the corporation under Section 12.5.

Section 12.15 Chair May Determine Validity of Proxy.

The chair of any meeting of shareholders may, at his or her sole discretion, determine whether or not a proxy deposited for use at the meeting, which may not strictly comply with the requirements of this Article 12 as to form, execution, accompanying documentation, time of filing or otherwise, shall be valid for use at the meeting, and any such determination made in good faith shall be final, conclusive and binding upon the meeting.

Section 12.16 Production of Evidence of Authority to Vote

The board or the chair of any meeting of shareholders may, but need not, at any time (including before, at or subsequent to the meeting), inquire into the authority of any person to vote at the meeting and may, but need not, demand from that person production of evidence for the purposes of determining a person's share ownership as at the relevant record date and the authority to vote.

ARTICLE 13
DIRECTORS

Section 13.1 Number of Directors

(1) The number of directors is the number determined from time to time by directors' resolution.

(2) If the number of directors has not been determined as provided in paragraph (1), the number of directors is equal to the number of directors designated as directors in the Notice of Articles that applied when the Company was recognized under the BCA or the number of directors holding office immediately following the most recent election or appointment of directors, whether at an annual or special general meeting of the shareholders, by a consent resolution of shareholders, or by the directors pursuant to Section 14.4, Section 14.5 or Section 14.8.

(3) Notwithstanding paragraph (2), the minimum number of directors is one or, if the company is a public company, three.

Section 13.2 Change in Number of Directors

If the number of directors is set under Section 13.1(1):

(1) the shareholders may elect or appoint the directors needed to fill any vacancies in the board of directors up to that number; and

(2) if the shareholders do not elect or appoint the directors needed to fill any vacancies in the board of directors up to that number at the first meeting of shareholders following the setting of that number, then the board, subject to Section 14.8, may appoint, or the shareholders may elect or appoint, directors to fill those vacancies.


No decrease in the number of directors will shorten the term of an incumbent director.

Section 13.3 Board's Acts Valid Despite Vacancy

An act or proceeding of the board is not invalid merely because fewer than the number of directors set or otherwise required under these Articles is in office.

Section 13.4 Qualifications of Directors

A director is not required to hold a share of the Company as qualification for his or her office but must be qualified as required by the BCA to become, act or continue to act as a director.

Section 13.5 Remuneration of Directors

The directors are entitled to the remuneration for acting as directors, if any, as the board may from time to time determine. If the board so decides, the remuneration of the directors, if any, will be determined by the shareholders. That remuneration may be in addition to any salary or other remuneration paid to any officer or employee of the Company as such, who is also a director.

Section 13.6 Reimbursement of Expenses of Directors

The Company must reimburse each director for the reasonable expenses that he or she may incur in and about the business of the Company.

Section 13.7 Special Remuneration for Directors

If any director performs any professional or other services for the Company that in the opinion of the board are outside the ordinary duties of a director, or if any director is otherwise specially occupied in or about the Company's business, he or she may be paid remuneration fixed by the board, or, at the option of that director, fixed by ordinary resolution, and such remuneration may be either in addition to, or in substitution for, any other remuneration that he or she may be entitled to receive.

Section 13.8 Gratuity, Pension or Allowance on Retirement of Director

Unless otherwise determined by ordinary resolution, the board on behalf of the Company may pay a gratuity or pension or allowance on retirement to any director who has held any salaried office or place of profit with the Company or to his or her spouse or dependants and may make contributions to any fund and pay premiums for the purchase or provision of any such gratuity, pension or allowance.

ARTICLE 14
ELECTION AND REMOVAL OF DIRECTORS

Section 14.1 Election at Annual General Meeting

At every annual general meeting and in every unanimous resolution contemplated by Section 10.2:

(1) the shareholders entitled to vote at the annual general meeting for the election of directors must elect, or in the unanimous resolution appoint, a board of directors consisting of the number of directors for the time being set under these Articles; and

(2) all the directors cease to hold office immediately before the election or appointment of directors under paragraph (1) but are eligible for re-election or re-appointment.

Section 14.2 Consent to be a Director

No election, appointment or designation of an individual as a director is valid unless:

(1) that individual consents to be a director in the manner provided for in the BCA;


(2) that individual is elected or appointed at a meeting at which the individual is present and the individual does not refuse, at the meeting, to be a director; or

(3) with respect to first directors, the designation is otherwise valid under the BCA.

Section 14.3 Failure to Elect or Appoint Directors

If:

(1) the Company fails to hold an annual general meeting, and all the shareholders who are entitled to vote at an annual general meeting fail to pass the unanimous resolution contemplated by Section 10.2, on or before the date by which the annual general meeting is required to be held under the BCA; or

(2) the shareholders fail, at the annual general meeting or in the unanimous resolution contemplated by Section 10.2, to elect or appoint any directors;

then each director then in office continues to hold office until the earlier of:

(3) when his or her successor is elected or appointed; and

(4) when he or she otherwise ceases to hold office under the BCA or these Articles.

Section 14.4 Places of Retiring Directors Not Filled

If, at any meeting of shareholders at which there should be an election of directors, the places of any of the retiring directors are not filled by that election, those retiring directors who are not re-elected and who are asked by the newly elected directors to continue in office will, if willing to do so, continue in office to complete the number of directors for the time being set pursuant to these Articles until further new directors are elected at a meeting of shareholders convened for that purpose.

Section 14.5 Board May Fill Casual Vacancies

Any casual vacancy occurring in the board of directors may be filled by the remaining directors. For greater certainty, the appointment of a director to fill a casual vacancy as contemplated by this section is not the appointment of an additional director for the purposes of Section 14.8.

Section 14.6 Remaining Directors' Power to Act

The board may act notwithstanding any vacancy in the board of directors, but if the Company has fewer directors in office than the number set pursuant to these Articles as the quorum of directors, the board may only act for the purpose of:

(1) appointing directors up to that number; or

(2) calling a meeting of shareholders for the purpose of filling any vacancies on the board of directors or, subject to the BCA, for any other purpose.

Section 14.7 Shareholders May Fill Vacancies

If the Company has no directors or fewer directors in office than the number set pursuant to these Articles as the quorum of directors, the shareholders may elect or appoint directors to fill any vacancies on the board of directors.


Section 14.8 Additional Directors

Notwithstanding Section 13.1 and Section 13.2, between annual general meetings or unanimous resolutions contemplated by Section 10.2, the board may appoint one or more additional directors, but the number of additional directors appointed under this Section 14.8 must not at any time exceed:

(1) one-third of the number of first directors, if, at the time of the appointments, one or more of the first directors have not yet completed their first term of office; or

(2) in any other case, one-third of the number of the current directors who were elected or appointed as directors other than under this Section 14.8.

Any director so appointed ceases to hold office immediately before the next election or appointment of directors under Section 14.1(1), but is eligible for re-election or re-appointment.

Section 14.9 Ceasing to be a Director

A director ceases to be a director when:

(1) the term of office of the director expires;

(2) the director dies;

(3) the director resigns as a director by notice in writing provided to the Company or a lawyer for the Company; or

(4) the director is removed from office pursuant to Section 14.10 or Section 14.11.

Section 14.10 Removal of Director by Shareholders

The Company may remove any director before the expiration of his or her term of office by special resolution. In that event, the shareholders may elect, or appoint by ordinary resolution, a director to fill the resulting vacancy. If the shareholders do not elect or appoint a director to fill the resulting vacancy contemporaneously with the removal, then the board may appoint or the shareholders may elect, or appoint by ordinary resolution, a director to fill that vacancy.

Section 14.11 Removal of Director by Directors

The board may remove any director before the expiration of his or her term of office if the director is convicted of an indictable offence, or if the director ceases to be qualified to act as a director of a company in accordance with the BCA and does not promptly resign, and the board may appoint a director to fill the resulting vacancy.

ARTICLE 15
ALTERNATE DIRECTORS

Section 15.1 Application

The provisions of this Article 15 do not apply to the Company and its directors if and for so long as it is a public company.

Section 15.2 Appointment of Alternate Director

Any director (an "appointor") may by notice in writing received by the Company appoint any person (an "appointee") who is qualified to act as a director to be his or her alternate to act in his or her place at meetings of the board or committees of the board at which the appointor is not present unless (in the case of an appointee who is not a director) the board  has reasonably disapproved the appointment of such person as an alternate director and has given notice to that effect to his or her appointor within a reasonable time after the notice of appointment is received by the Company.


Section 15.3 Notice of Meetings

Every alternate director so appointed is entitled to notice of meetings of the board and of committees of the board of which his or her appointor is a member and to attend and vote as a director at any such meetings at which his or her appointor is not present.

Section 15.4 Alternate for More Than One Director Attending Meetings

A person may be appointed as an alternate director by more than one director, and an alternate director:

(1) will be counted in determining the quorum for a meeting of the board once for each of his or her appointors and, in the case of an appointee who is also a director, once more in that capacity;

(2) has a separate vote at a meeting of the board for each of his or her appointors and, in the case of an appointee who is also a director, an additional vote in that capacity;

(3) will be counted in determining the quorum for a meeting of a committee of the board once for each of his or her appointors who is a member of that committee and, in the case of an appointee who is also a member of that committee as a director, once more in that capacity; and

(4) has a separate vote at a meeting of a committee of the board for each of his or her appointors who is a member of that committee and, in the case of an appointee who is also a member of that committee as a director, an additional vote in that capacity.

Section 15.5 Consent Resolutions

Every alternate director, if authorized by the notice appointing him or her, may sign in place of his or her appointor any resolutions to be consented to in writing.

Section 15.6 Alternate Director Not an Agent

Every alternate director is deemed not to be the agent of his or her appointor.

Section 15.7 Revocation of Appointment of Alternate Director

An appointor may at any time, by notice in writing received by the Company, revoke the appointment of an alternate director appointed by him or her.

Section 15.8 Ceasing to be an Alternate Director

The appointment of an alternate director ceases when:

(1) his or her appointor ceases to be a director and is not promptly re-elected or re-appointed;

(2) the alternate director dies;

(3) the alternate director resigns as an alternate director by notice in writing provided to the Company or a lawyer for the Company;

(4) the alternate director ceases to be qualified to act as a director; or

(5) his or her appointor revokes the appointment of the alternate director.


Section 15.9 Remuneration and Expenses of Alternate Director

The Company may reimburse an alternate director for the reasonable expenses that would be properly reimbursed if he or she were a director, and the alternate director is entitled to receive from the Company such proportion, if any, of the remuneration otherwise payable to the appointor as the appointor may from time to time direct.

ARTICLE 16
POWERS AND DUTIES OF THE BOARD

Section 16.1 Powers of Management

The board must, subject to the BCA and these Articles, manage or supervise the management of the business and affairs of the Company and has the authority to exercise all such powers of the Company as are not, by the BCA or by these Articles, required to be exercised by the shareholders of the Company.

Section 16.2 Appointment of Attorney of Company

The board may from time to time, by power of attorney or other instrument, under seal if so required by law, appoint any person to be the attorney of the Company for such purposes, and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the directors under these Articles and excepting the power to fill vacancies in the board of directors, to remove a director, to change the membership of, or fill vacancies in, any committee of the board, to appoint or remove officers appointed by the board and to declare dividends) and for such period, and with such remuneration and subject to such conditions as the board may think fit. Any such power of attorney may contain such provisions for the protection or convenience of persons dealing with such attorney as the board thinks fit. Any such attorney may be authorized by the board to sub-delegate all or any of the powers, authorities and discretions for the time being vested in him or her.

ARTICLE 17
INTERESTS OF DIRECTORS AND OFFICERS

Section 17.1 Obligation to Account for Profits

A director or senior officer who holds a disclosable interest (as that term is used in the BCA) in a contract or transaction into which the Company has entered or proposes to enter is liable to account to the Company for any profit that accrues to the director or senior officer under or as a result of the contract or transaction only if and to the extent provided in the BCA.

Section 17.2 Restrictions on Voting by Reason of Interest

A director who holds a disclosable interest in a contract or transaction into which the Company has entered or proposes to enter is not entitled to vote on any directors' resolution to approve that contract or transaction, unless all the directors have a disclosable interest in that contract or transaction, in which case any or all of those directors may vote on such resolution.

Section 17.3 Interested Director Counted in Quorum

A director who holds a disclosable interest in a contract or transaction into which the Company has entered or proposes to enter and who is present at the meeting of the board at which the contract or transaction is considered for approval may be counted in the quorum at the meeting whether or not the director votes on any or all of the resolutions considered at the meeting.

Section 17.4 Disclosure of Conflict of Interest or Property

A director or senior officer who holds any office or possesses any property, right or interest that could result, directly or indirectly, in the creation of a duty or interest that materially conflicts with that individual's duty or interest as a director or senior officer, must disclose the nature and extent of the conflict as required by the BCA.


Section 17.5 Director Holding Other Office in the Company

A director may hold any office or place of profit with the Company, other than the office of auditor of the Company, in addition to his or her office of director for the period and on the terms (as to remuneration or otherwise) that the board may determine.

Section 17.6 No Disqualification

No director or intended director is disqualified by his or her office from contracting with the Company either with regard to the holding of any office or place of profit the director holds with the Company or as vendor, purchaser or otherwise, and no contract or transaction entered into by or on behalf of the Company in which a director is in any way interested is liable to be voided for that reason.

Section 17.7 Professional Services by Director or Officer

Subject to the BCA, a director or officer, or any person in which a director or officer has an interest, may act in a professional capacity for the Company, except as auditor of the Company, and the director or officer or such person is entitled to remuneration for professional services as if that director or officer were not a director or officer.

Section 17.8 Director or Officer in Other Corporations

A director or officer may be or become a director, officer or employee of, or otherwise interested in, any person in which the Company may be interested as a shareholder or otherwise, and, subject to the BCA, the director or officer is not accountable to the Company for any remuneration or other benefits received by him or her as director, officer or employee of, or from his or her interest in, such other person.

ARTICLE 18
PROCEEDINGS OF THE BOARD

Section 18.1 Meetings of the Board

The board may meet for the conduct of business, adjourn and otherwise regulate its meetings as the board thinks fit, and meetings of the board held at regular intervals may be held at the place, at the time and on the notice, if any, as the board may from time to time determine.

Section 18.2 Voting at Meetings

Questions arising at any meeting of the board are to be decided by a majority of votes and, in the case of an equality of votes, the chair of the meeting does not have a second or casting vote.

Section 18.3 Chair of Meetings

The following individual is entitled to preside as chair at a meeting of the board:

(1) the chair of the board, if any;

(2) in the absence of the chair of the board, the president, if any, if the president is a director; or

(3) any other director chosen by the directors present if:

(a) neither the chair of the board nor the president, if a director, is present at the meeting within 15 minutes after the time set for holding the meeting;


(b) neither the chair of the board nor the president, if a director, is willing to chair the meeting; or

(c) the chair of the board and the president, if a director, have advised the secretary, if any, or any other director, that they will not be present at the meeting.

Section 18.4 Meetings by Telephone or Other Communications Medium

A director may participate in a meeting of the board or of any committee of the board:

(1) in person;

(2) by telephone; or

(3) with the consent of all directors who wish to participate in the meeting, by other communications medium;

if all directors participating in the meeting, whether in person, or by telephone or other communications medium, are able to communicate with each other.  A director who participates in a meeting in a manner contemplated by this Section 18.4 is deemed for all purposes of the BCA and these Articles to be present at the meeting and to have agreed to participate in that manner.

Section 18.5 Calling of Meetings

A director may, and the secretary or an assistant secretary of the Company, if any, on the request of a director must, call a meeting of the board at any time.

Section 18.6 Notice of Meetings

Other than for meetings held at regular intervals as determined by the board pursuant to Section 18.1 or as provided in Section 18.7, reasonable notice of each meeting of the board, specifying the place, day and time of that meeting must be given to each of the directors and the alternate directors by any method set out in Section 24.1 or orally or by telephone conversation with that director.

Section 18.7 When Notice Not Required

It is not necessary to give notice of a meeting of the board to a director or an alternate director if:

(1) the meeting is to be held immediately following a meeting of shareholders at which that director was elected or appointed, or is the meeting of the board at which that director is appointed; or

(2) the director or alternate director, as the case may be, has waived notice of the meeting.

Section 18.8 Meeting Valid Despite Failure to Give Notice

The accidental omission to give notice of any meeting of the board to, or the non-receipt of any notice by, any director or alternate director, does not invalidate any proceedings at that meeting.

Section 18.9 Waiver of Notice of Meetings

Any director or alternate director may send to the Company a document signed by him or her waiving notice of any past, present or future meeting or meetings of the board and may at any time withdraw that waiver with respect to meetings held after that withdrawal. After sending a waiver with respect to all future meetings and until that waiver is withdrawn, no notice of any meeting of the board need be given to that director or, unless the director otherwise requires by notice in writing to the Company, to his or her alternate director, and all meetings of the board so held are deemed not to be improperly called or constituted by reason of notice not having been given to such director or alternate director.


Attendance of a director or alternate director at a meeting of the board is a waiver of notice of the meeting, unless that director or alternate director attends the meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called.

Section 18.10 Quorum

The quorum necessary for the transaction of the business at a meeting of the board may be set by the board and, if not so set, is deemed to be set at a majority of the number of directors then in office.  If the number of directors is set at one, the quorum is deemed to be set at one director, and that director may constitute a meeting.

Section 18.11 Validity of Acts Where Appointment Defective

Subject to the BCA, an act of a director or officer is not invalid merely because of an irregularity in the election or appointment or a defect in the qualification of that director or officer.

Section 18.12 Consent Resolutions in Writing

A resolution of the board or of any committee of the board may be passed without a meeting:

(1) in all cases, if each of the directors entitled to vote on the resolution consents to it in writing; or

(2) in the case of a resolution to approve a contract or transaction in respect of which a director has disclosed that he or she has or may have a disclosable interest, if each of the other directors who have not made such a disclosure consents in writing to the resolution.

A consent in writing under this Section 18.12 may be by any written instrument, fax, e-mail or any other method of transmitting legibly recorded messages in which the consent of the director is evidenced, whether or not the signature of the director is included in the record.  A consent in writing may be in two or more counterparts which together are deemed to constitute one consent in writing.  A resolution of the board or of any committee of the board passed in accordance with this Section 18.12 is effective on the date stated in the consent in writing or on the latest date stated on any counterpart and is deemed to be a proceeding at a meeting of the board or of the committee of the board and to be as valid and effective as if it had been passed at a meeting of the board or of the committee of the board that satisfies all the requirements of the BCA and all the requirements of these Articles relating to meetings of the board or of a committee of the board.

ARTICLE 19
EXECUTIVE AND OTHER COMMITTEES

Section 19.1 Appointment and Powers of Executive Committee

The board may, by resolution, appoint an executive committee consisting of the director or directors that they consider appropriate, and during the intervals between meetings of the board all of the board's powers are delegated to the executive committee, except:

(1) the power to fill vacancies in the board of directors;

(2) the power to remove a director;

(3) the power to change the membership of, or fill vacancies in, any committee of the board; and

(4) such other powers, if any, as may be set out in the resolution or any subsequent directors' resolution.

Section 19.2 Appointment and Powers of Other Committees

The board may, by resolution:


(1) appoint one or more committees (other than the executive committee) consisting of the director or directors that they consider appropriate;

(2) delegate to a committee appointed under paragraph (1) any of the board's powers, except:

(a) the power to fill vacancies in the board of directors;

(b) the power to remove a director;

(c) the power to change the membership of, or fill vacancies in, any committee of the board; and

(d) the power to appoint or remove officers appointed by the board; and

(3) make any delegation referred to in paragraph (2) subject to the conditions set out in the resolution or any subsequent directors' resolution.

Section 19.3 Obligations of Committees

Any committee appointed under Section 19.1 or Section 19.2, in the exercise of the powers delegated to it, must:

(1) conform to any rules that may from time to time be imposed on it by the board; and

(2) report every act or thing done in exercise of those powers at such times as the board may require.

Section 19.4 Powers of Board

The board may, at any time, with respect to a committee appointed under Section 19.1 or Section 19.2:

(1) revoke or alter the authority given to the committee, or override a decision made by the committee, except as to acts done before such revocation, alteration or overriding;

(2) terminate the appointment of, or change the membership of, the committee; and

(3) fill vacancies in the committee.

Section 19.5 Committee Meetings

Subject to Section 19.3(1) and unless the board otherwise provides in the resolution appointing the committee or in any subsequent resolution, with respect to a committee appointed under Section 19.1 or Section 19.2:

(1) the committee may meet and adjourn as it thinks proper;

(2) the committee may elect a chair of its meetings but, if no chair of a meeting is elected, or if at a meeting the chair of the meeting is not present within 15 minutes after the time set for holding the meeting, the directors present who are members of the committee may choose one of their number to chair the meeting;

(3) a majority of the members of the committee constitutes a quorum of the committee; and

(4) questions arising at any meeting of the committee are determined by a majority of votes of the members present, and in the case of an equality of votes, the chair of the meeting does not have a second or casting vote.


ARTICLE 20
OFFICERS

Section 20.1 Board May Appoint Officers

The board may, from time to time, appoint such officers, if any, as the board determines and the board may, at any time, terminate any such appointment.

Section 20.2 Functions, Duties and Powers of Officers

The board may, for each officer:

(1) determine the functions and duties of the officer;

(2) delegate to the officer any of the powers exercisable by the board on such terms and conditions and with such restrictions as the board thinks fit; and

(3) revoke, withdraw, alter or vary all or any of the functions, duties and powers of the officer.

Section 20.3 Qualifications

No officer may be appointed unless that officer is qualified in accordance with the BCA. One person may hold more than one position as an officer of the Company. Any person appointed as the chair of the board must be a director. Any other officer need not be a director.

Section 20.4 Remuneration and Terms of Appointment

All appointments of officers are to be made on the terms and conditions and at the remuneration (whether by way of salary, fee, commission, participation in profits or otherwise) that the board thinks fit and are subject to termination at the pleasure of the board, and an officer may in addition to such remuneration be entitled to receive, after he or she ceases to hold such office or leaves the employment of the Company, a pension or gratuity.

ARTICLE 21
INDEMNIFICATION

Section 21.1 Definitions

In this Article 21:

(1) "eligible penalty" means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding;

(2) "eligible proceeding" means a legal proceeding or investigative action, whether current, threatened, pending or completed, in which a director, former director, alternate director, officer or former officer of the Company (each, an "eligible party") or any of the heirs and legal personal representatives of the eligible party, by reason of the eligible party being or having been a director or alternate director or officer of the Company:

(a) is or may be joined as a party; or

(b) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding;

(3) "expenses" has the meaning set out in the BCA; and

(4) "officer" means a person appointed by the board as an officer of the Company.


Section 21.2 Mandatory Indemnification of Eligible Parties

Subject to the BCA, the Company must indemnify an eligible party and his or her heirs and legal personal representatives against all eligible penalties to which such person is or may be liable, and the Company must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding.  Each director, alternate director and officer is deemed to have contracted with the Company on the terms of the indemnity contained in this Section 21.2.

Section 21.3 Permitted Indemnification

Notwithstanding Section 21.2 and subject to any restrictions in the BCA, the Company may indemnify any person including directors, officers, employees, agents and representatives of the Company.

Section 21.4 Non-Compliance with BCA

The failure of a director, alternate director or officer of the Company to comply with the BCA or these Articles or, if applicable, any former Articles, does not invalidate any indemnity to which he or she is entitled under this Article 21.

Section 21.5 Company May Purchase Insurance

The Company may purchase and maintain insurance for the benefit of any person (or his or her heirs or legal personal representatives) who:

(1) is or was a director, alternate director, officer, employee or agent of the Company;

(2) is or was a director, alternate director, officer, employee or agent of a corporation at a time when the corporation is or was an affiliate of the Company;

(3) at the request of the Company, is or was a director, alternate director, officer, employee or agent of a corporation or of a partnership, trust, joint venture or other unincorporated entity;

(4) at the request of the Company, holds or held a position equivalent to that of a director, alternate director or officer of a partnership, trust, joint venture or other unincorporated entity;

against any liability incurred by him or her as such director, alternate director, officer, employee or agent or person who holds or held such equivalent position.

ARTICLE 22
DIVIDENDS

Section 22.1 Payment of Dividends Subject to Special Rights

The provisions of this Article 22 are subject to the rights, if any, of shareholders holding shares with special rights as to dividends.

Section 22.2 Declaration of Dividends

Subject to the BCA, the board may from time to time declare and authorize payment of such dividends as it may consider appropriate.

Section 22.3 No Notice Required

The board need not give notice to any shareholder of any declaration under Section 22.2.


Section 22.4 Record Date

The board may set a date as the record date for the purpose of determining shareholders entitled to receive payment of a dividend. The record date must not precede the date on which the dividend is to be paid by more than two months. If no record date is set, the record date is 5 p.m. on the date on which the board passes the resolution declaring the dividend.

Section 22.5 Manner of Paying Dividend

A resolution declaring a dividend may direct payment of the dividend wholly or partly in money or by the distribution of specific assets or of fully paid shares or of bonds, debentures or other securities of the Company or any other corporation, or in any one or more of those ways.

Section 22.6 Settlement of Difficulties

If any difficulty arises in regard to a distribution under Section 22.5, the board may settle the difficulty as it deems advisable, and, in particular, may:

(1) set the value for distribution of specific assets;

(2) determine that money in substitution for all or any part of the specific assets to which any shareholders are entitled may be paid to any shareholders on the basis of the value so fixed in order to adjust the rights of all parties; and

(3) vest any such specific assets in trustees for the persons entitled to the dividend.

Section 22.7 When Dividend Payable

Any dividend may be made payable on such date as is fixed by the board.

Section 22.8 Dividends to be Paid in Accordance with Number of Shares

All dividends on shares of any class or series of shares must be declared and paid according to the number of such shares held.

Section 22.9 Receipt by Joint Shareholders

If several persons are joint shareholders of any share, any one of them may give an effective receipt for any dividend, bonus or other money payable in respect of the share.

Section 22.10 Dividend Bears No Interest

No dividend bears interest against the Company.

Section 22.11 Fractional Dividends

If a dividend to which a shareholder is entitled includes a fraction of the smallest monetary unit of the currency of the dividend, that fraction may be disregarded in making payment of the dividend and that payment represents full payment of the dividend.

Section 22.12 Payment of Dividends

Any dividend or other distribution payable in respect of shares will be paid by cheque or by electronic means or by such other method as the directors may determine.  The payment will be made to or to the order of each registered holder of shares in respect of which the payment is to be made.  Cheques will be sent to the registered address of the shareholder, unless the shareholder otherwise directs.  In the case of joint holders, the payment will be made to the order of all such joint holders and, if applicable, sent to them at the registered address of the joint shareholder who is first named on the central securities register, unless such joint holders otherwise direct.  The sending of the cheque or the sending of the payment by electronic means or the sending of the payment by a method determined by the directors in an amount equal to the dividend or other distribution to be paid less any tax that the Company is required to withhold will satisfy and discharge the liability for the payment, unless payment is not made upon presentation, if applicable, or the amount of tax so deducted is not paid to the appropriate taxing authority.


Section 22.13 Capitalization of Retained Earnings or Surplus

Notwithstanding anything contained in these Articles, the board may from time to time capitalize any retained earnings or surplus of the Company and may from time to time issue, as fully paid, shares or any bonds, debentures or other securities of the Company as a dividend representing the retained earnings or surplus so capitalized or any part thereof.

Section 22.14 Unclaimed Dividends

Any dividend unclaimed after a period of six years from the date on which the same has been declared to be payable shall be forfeited and shall revert to the Company. The Company shall not be liable to any person in respect of any dividend which is forfeited to the Company or delivered to any public official pursuant to any applicable abandoned property, escheat or similar law.

ARTICLE 23
ACCOUNTING RECORDS AND AUDITOR

Section 23.1 Recording of Financial Affairs

The board must cause adequate accounting records to be kept to record properly the financial affairs and condition of the Company and to comply with the BCA.

Section 23.2 Inspection of Accounting Records

Unless the board determines otherwise, or unless otherwise determined by ordinary resolution, no shareholder of the Company is entitled to inspect or obtain a copy of any accounting records of the Company.

Section 23.3 Remuneration of Auditor

The board may set the remuneration of the auditor of the Company.

ARTICLE 24
NOTICES

Section 24.1 Method of Giving Notice

Unless the BCA or these Articles provide otherwise, a notice, statement, report or other record required or permitted by the BCA or these Articles to be sent by or to a person may be sent by any one of the following methods:

(1) mail addressed to the person at the applicable address for that person as follows:

(a) for a record mailed to a shareholder, the shareholder's registered address;

(b) for a record mailed to a director or officer, the prescribed address for mailing shown for the director or officer in the records kept by the Company or the mailing address provided by the recipient for the sending of that record or records of that class;

(c) in any other case, the mailing address of the intended recipient;

(2) delivery at the applicable address for that person as follows, addressed to the person:


(a) for a record delivered to a shareholder, the shareholder's registered address;

(b) for a record delivered to a director or officer, the prescribed address for delivery shown for the director or officer in the records kept by the Company or the delivery address provided by the recipient for the sending of that record or records of that class;

(c) in any other case, the delivery address of the intended recipient;

(3) unless the intended recipient is the auditor of the Company, sending the record by fax to the fax number provided by the intended recipient for the sending of that record or records of that class;

(4) unless the intended recipient is the auditor of the Company, sending the record by e-mail to the e-mail address provided by the intended recipient for the sending of that record or records of that class;

(5) physical delivery to the intended recipient;

(6) creating and providing a record posted on or made available through a general accessible electronic source and providing written notice by any of the foregoing methods as to the availability of such record; or

(7) as otherwise permitted by applicable securities legislation.

Section 24.2 Deemed Receipt

A notice, statement, report or other record that is:

(1) mailed to a person by ordinary mail to the applicable address for that person referred to in Section 24.1 is deemed to be received by the person to whom it was mailed on the day, Saturdays, Sundays and holidays excepted, following the date of mailing;

(2) faxed to a person to the fax number provided by that person referred to in Section 24.1 is deemed to be received by the person to whom it was faxed on the day it was faxed;

(3) e-mailed to a person to the e-mail address provided by that person referred to in Section 24.1 is deemed to be received by the person to whom it was e-mailed on the day it was e-mailed; and

(4) delivered in accordance with Section 24.1(6), is deemed to be received by the person on the day such written notice is sent.

Section 24.3 Certificate of Sending

A certificate signed by the secretary, if any, or other officer of the Company or of any other corporation acting in that capacity on behalf of the Company stating that a notice, statement, report or other record was sent in accordance with Section 24.1 is conclusive evidence of that fact.

Section 24.4 Notice to Joint Shareholders

A notice, statement, report or other record may be provided by the Company to the joint shareholders of a share by providing such record to the joint shareholder first named in the central securities register in respect of the share.


Section 24.5 Notice to Legal Personal Representatives and Trustees

A notice, statement, report or other record may be provided by the Company to the persons entitled to a share in consequence of the death, bankruptcy or incapacity of a shareholder by:

(1) mailing the record, addressed to them:

(a) by name, by the title of the legal personal representative of the deceased or incapacitated shareholder, by the title of trustee of the bankrupt shareholder or by any similar description; and

(b) at the address, if any, supplied to the Company for that purpose by the persons claiming to be so entitled; or

(2) if an address referred to in paragraph (1)(b) has not been supplied to the Company, by giving the notice in a manner in which it might have been given if the death, bankruptcy or incapacity had not occurred.

Section 24.6 Undelivered Notices

If, on two consecutive occasions, a notice, statement, report or other record is sent to a shareholder pursuant to Section 24.1 and on each of those occasions any such record is returned because the shareholder cannot be located, the Company shall not be required to send any further records to the shareholder until the shareholder informs the Company in writing of his or her new address.

ARTICLE 25
SEAL

Section 25.1 Who May Attest Seal

Except as provided in Section 25.2 and Section 25.3, the Company's seal, if any, must not be impressed on any record except when that impression is attested by the signatures of:

(1) any two directors;

(2) any officer, together with any director;

(3) if the Company only has one director, that director; or

(4) any one or more directors or officers or persons as may be determined by the board.

Section 25.2 Sealing Copies

For the purpose of certifying under seal a certificate of incumbency of the directors or officers of the Company or a true copy of any resolution or other document, despite Section 25.1, the impression of the seal may be attested by the signature of any director or officer or the signature of any other person as may be determined by the board.

Section 25.3 Mechanical Reproduction of Seal

The board may authorize the seal to be impressed by third parties on share certificates or bonds, debentures or other securities of the Company as the board may determine appropriate from time to time. To enable the seal to be impressed on any share certificates or bonds, debentures or other securities of the Company, whether in definitive or interim form, on which facsimiles of any of the signatures of the directors or officers of the Company are, in accordance with the BCA or these Articles, printed or otherwise mechanically reproduced, there may be delivered to the person employed to engrave, lithograph or print such definitive or interim share certificates or bonds, debentures or other securities one or more unmounted dies reproducing the seal and such persons as are authorized under Section 25.1 to attest the Company's seal may in writing authorize such person to cause the seal to be impressed on such definitive or interim share certificates or bonds, debentures or other securities by the use of such dies. Share certificates or bonds, debentures or other securities to which the seal has been so impressed are for all purposes deemed to be under and to bear the seal impressed on them.


ARTICLE 26
PROHIBITIONS

Section 26.1 Definitions

In this Article 26:

(1) "security" has the meaning assigned in the Securities Act;

(2) "transfer restricted security" means

(a) a share of the Company;

(b) a security of the Company convertible into shares of the Company; or

(c) any other security of the Company which must be subject to restrictions on transfer in order for the Company to satisfy the requirement for restrictions on transfer under the "private issuer" exemption of Canadian securities legislation or under any other exemption from prospectus or registration requirements of Canadian securities legislation similar in scope and purpose to the "private issuer" exemption.

Section 26.2 Application

Section 26.3 does not apply to the Company if and for so long as it is a public company.

Section 26.3 Consent Required for Transfer of Shares or Transfer Restricted Securities

No share or other transfer restricted security may be sold, transferred or otherwise disposed of without the consent of the board and the board is not required to give any reason for refusing to consent to any such sale, transfer or other disposition.

Dated September 25, 2020.

 

signature and full name of one of the directors pursuant to s. 302(1)(c) of the business corporations act (british columbia)

 

 

_______________________________
David Lorne John Tyrrell

Director




Schedule "C"

SECTION 193 OF THE YUKON BUSINESS CORPORATIONS ACT

 

 

 

C


SECTION 193 OF THE YUKON BUSINESS CORPORATIONS ACT

Shareholder's right to dissent 193

(1)  Subject to sections 194 and 243, a holder of shares of any class of a corporation may dissent if the corporation resolves to 

(a) amend its articles under section 175 or 176 to add, change or remove any provisions restricting or constraining the issue or transfer of shares of that class;

(b) amend its articles under section 175 to add, change or remove any restrictions on the business or businesses that the corporation may carry on;

(c) amalgamate with another body corporate, otherwise than under section 186;

(d) be continued under the laws of another jurisdiction under section 191; or

(e) sell, lease or exchange all or substantially all its property under paragraph 192(1)(c).

(2)   A holder of shares of any class or series of shares entitled to vote under section 178 may dissent if the corporation resolves to amend its articles in a manner described in that section.

(3) In addition to any other right, but subject to subsection (20), a shareholder entitled to dissent under this section and who complies with this section is entitled to be paid by the corporation the fair value of the shares in respect of which the shareholder dissents, determined as of the close of business on the last business day before the day on which the resolution from which the shareholder dissents was adopted.

(4) A dissenting shareholder may only claim under this section with respect to all the shares of a class held by the dissenting shareholder or on behalf of any one beneficial owner and registered in the name of the dissenting shareholder.

(5) A dissenting shareholder shall send to the corporation a written objection to a resolution referred to in subsection (1) or (2) 

(a) at or before any meeting of shareholders at which the resolution is to be voted on; or

(b) if the corporation did not send notice to the shareholder of the purpose of the meeting or of the shareholder's right to dissent, within a reasonable time after learning that the resolution was adopted and of the right to dissent.

(5.1) The execution or exercise of a proxy does not constitute a written objection for the purposes of subsection (5).

(6) An application may be made to the Supreme Court after the adoption of a resolution referred to in subsection (1) or (2), 

(a) by the corporation; or

(b) subject to subsection (6.1), by a shareholder if an objection under subsection (5) has been sent by the shareholder to the corporation,

to set the fair value in accordance with subsection (3) of the shares of a shareholder who dissents under this section.

(6.1) A shareholder who has sent an objection under subsection (5) ceases to be a dissenting shareholder and is not entitled to make an application under subsection (6) or to claim under this section if


(a) the shareholder votes, in person or by proxy, in favour of the resolution referred to in subsection (1) or (2); or

(b) the shareholder withdraws the objection by written notice to the corporation.

(7) If an application is made under subsection (6), the corporation shall, unless the Supreme Court otherwise orders, send to each dissenting shareholder a written offer to pay an amount considered by the directors to be the fair value of the shares to that shareholder.

(8) Unless the Supreme Court otherwise orders, an offer referred to in subsection (7) shall be sent to each dissenting shareholder

(a) at least 10 days before the date on which the application is returnable, if the corporation is the applicant; or

(b) within 10 days after the corporation is served with a copy of the originating notice, if a shareholder is the applicant.

(9) Every offer made under subsection (7) shall

(a) be made on the same terms; and

(b) contain or be accompanied by a statement showing how the fair value was determined.

(10) A dissenting shareholder may make an agreement with the corporation for the purchase of that shareholder's shares by the corporation, in the amount of the corporation's offer under subsection (7) or otherwise, at any time before the Supreme Court pronounces an order setting the fair value of the shares.

(11) A dissenting shareholder

(a) is not required to give security for costs in respect of an application under subsection (6); and

(b) except in special circumstances shall not be required to pay the costs of the application or appraisal.

(12) In connection with an application under subsection (6), the Supreme Court may give directions for

(a) joining as parties all dissenting shareholders whose shares have not been purchased by the corporation and for the representation of dissenting shareholders who, in the opinion of the Supreme Court, are in need of representation;

(b) the trial of issues and interlocutory matters, including pleadings and examinations for discovery;

(c) the payment to the shareholder of all or part of the sum offered by the corporation for the shares;

(d) the deposit of the share certificates with the Supreme Court or with the corporation or its transfer agent;

(e) the appointment and payment of independent appraisers, and the procedures to be followed by them;

(f) the service of documents; and

(g) the burden of proof on the parties.

(13) On an application under subsection (6), the Supreme Court shall make an order


(a) setting the fair value of the shares in accordance with subsection (3) of all dissenting shareholders who are parties to the application;

(b) giving judgment in that amount against the corporation and in favour of each of those dissenting shareholders; and

(c) setting the time within which the corporation must pay that amount to a shareholder.

(14) On

(a) the action approved by the resolution from which the shareholder dissents becoming effective;

(b) the making of an agreement under subsection (10) between the corporation and the dissenting shareholder as to the payment to be made by the corporation for that shareholder's shares, whether by the acceptance of the corporation's offer under subsection (7) or otherwise; or

(c) the pronouncement of an order under subsection (13), whichever first occurs, the shareholder ceases to have any rights as a shareholder other than the right to be paid the fair value of the shares in the amount agreed to between the corporation and the shareholder or in the amount of the judgment, as the case may be.

(15) Paragraph (14)(a) does not apply to a shareholder referred to in paragraph (5)(b).

(16) Until one of the events mentioned in subsection (14) occurs,

(a) the shareholder may withdraw the dissent; or

(b) the corporation may rescind the resolution, and in either event proceedings under this section shall be discontinued.

(17) The Supreme Court may in its discretion allow a reasonable rate of interest on the amount payable to each dissenting shareholder, from the date on which the shareholder ceases to have any rights as a shareholder because of subsection (14) until the date of payment.

(18) If subsection (20) applies, the corporation shall, within 10 days after 

(a) the pronouncement of an order under subsection (13); or

(b) the making of an agreement between the shareholder and the corporation as to the payment to be made for the shares, notify each dissenting shareholder that it is unable lawfully to pay dissenting shareholders for their shares.

(19) Even though a judgment has been given in favour of a dissenting shareholder under paragraph (13)(b), if subsection (20) applies, the dissenting shareholder, by written notice delivered to the corporation within 30 days after receiving the notice under subsection (18), may withdraw the notice of objection, in which case the corporation is deemed to consent to the withdrawal and the shareholder is reinstated to having full rights as a shareholder, failing which the shareholder retains a status as a claimant against the corporation, to be paid as soon as the corporation is lawfully able to do so or, in a liquidation, to be ranked subordinate to the rights of creditors of the corporation but in priority to its shareholders.


(20)  A corporation shall not make a payment to a dissenting shareholder under this section if there are reasonable grounds for believing that

(a) the corporation is or would after the payment be unable to pay its liabilities as they become due; or

(b) the realizable value of the corporation's assets would thereby be less than the aggregate of its liabilities.

(21) Upon application by a corporation that proposes to take any of the actions referred to in subsection (1) or (2), the Supreme Court may, if satisfied that the proposed action is not in all the circumstances one that should give rise to the rights arising under subsection (3), by order declare that those rights will not arise upon the taking of the proposed action, and the order may be subject to compliance with such terms and conditions as the Supreme Court thinks fit. S.Y. 2010, c.8, s. 126; S.Y. 2002, c.20, s. 193


Schedule "D"

BOARD OF DIRECTORS' MANDATE

 

 

D


BOARD OF DIRECTORS' MANDATE

PURPOSE

1. The Board of Directors (the "Board") of Burcon NutraScience Corporation (the "Corporation") is responsible for the overall stewardship of the Corporation and for managing and supervising the management of the Corporation.  The Board shall at all times act in the best interests of the Corporation.

RESPONSIBILTIES

2. The Board discharges its responsibilities for supervising the management of the business and affairs of the Corporation by delegating the day-to-day management of the Corporation to senior officers.  In discharging its responsibility, the Board should, among other things:

(a) to the extent feasible, satisfy itself as to the integrity of the chief executive officer (the "CEO") and other executive officers and that the CEO and other executive officers create a culture of integrity throughout the organization;

(b) adopt a strategic planning process and approve, on at least an annual basis, a strategic plan which takes into account, among other things, the opportunities and risks of the Corporation's business;

(c) ensure that the business of the Corporation is conducted in compliance with applicable laws and regulations;

(d) identify the principal risks of the Corporation's business, and ensure the implementation of appropriate systems to manage these risks;

(e) plan for senior management succession, including the appointment, training and monitoring of senior management's performance;

(f) require senior management to develop and maintain a strategy to communicate effectively with its security holders, investment analysts and the public generally and to accommodate and address feedback from security holders;

(g) require management to maintain internal control and management information systems and, through Board committees or otherwise, to monitor these systems as it considers fit; and

(h) through the Corporation's Corporate Governance Committee, develop the Corporation's approach to corporate governance, including developing a set of corporate governance principles and guidelines that are applicable to the Corporation.


ORGANIZATION OF THE BOARD

3. The organization of the Board shall comply with applicable corporate and securities laws.

4. Appointments to the Board will be reviewed on an annual basis.  The Nominating and Compensation Committee, in consultation with the CEO, is responsible for identifying and recommending new nominees with appropriate skills to the Board.

5. The Board will report to the shareholders of the Corporation.

6. The Board may:

(a) appoint one or more committees of the Board, however designated, and delegate to any such committee any of the powers of the Board, except those which are not permitted under applicable corporate and securities laws;

(b) appoint a Chairman of the Board and prescribe his or her powers and duties;

(c) appoint a Lead Director of the Board and prescribe his or her powers and duties;

(d) appoint a Chief Executive Officer and prescribe his or her powers and duties;

(e) appoint a President and other officers of the Corporation and prescribe their powers and duties.

MEETINGS, MEETING PREPARATION AND ATTENDANCE

7. The Board will meet as required, but at least once per quarter.

8. The independent directors will meet as required, without the non-independent directors and members of management, but at least once per quarter.

9. In connection with each meeting of the Board and each meeting of a committee of the Board of which a director is a member, each director will:

(a) review the materials provided to the directors in connection with the meeting and be prepared for the meeting; and

(b) attend each meeting, in person or by telephone conference, to the extent practicable.

MANAGEMENT OF BOARD AFFAIRS

10. The Board will:


(a) Develop a process for the orientation and education of new members of the Board;

(b) Support continuing education opportunities for all member of the Board;

(c) Assess the participation, contributions and effectiveness of the Chairman and individual board members on a biennial basis;

(d) Monitor the effectiveness of the Board and its committees and the actions of the Board  as viewed by the individual directors and senior management;

(e) Establish the committees of the Board it deems necessary to assist it in the fulfillment of its mandate; and

(f) Disclose on an annual basis, the mandate, composition of the Board and its committees.


Schedule "E"

CODE OF BUSINESS ETHICS AND CONDUCT

 

 

E


CODE OF BUSINESS ETHICS AND CONDUCT

1. Purpose and Application

Burcon NutraScience Corporation (the "Corporation") is committed to maintaining high standards of integrity and accountability in conducting its business while at the same time seeking to grow its business and value.  This code of business ethics and conduct (the "Code") provides a framework of guidelines and principles to govern and encourage ethical and professional behaviour in conducting our business.

This Code applies to all directors, officers and employees of the Corporation and its subsidiaries ("representatives"). The guidelines set out in this Code may be further supplemented by specific corporate, divisional or departmental policies.  As with all guidelines or principles, you are expected to use your own judgement and discretion, having regard to these standards, to determine the best course of action for any specific situation.  If you are unsure about a particular situation or course of action, please speak to the Chief Executive Officer or Chief Operating Officer of the Corporation.

The Code sets forth such standards as are reasonably designed to deter wrongdoing and to promote: honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; full, fair, accurate, timely, and understandable disclosure in the reports and documents that the Corporation files with, or submits to, securities regulatory authorities and in other public communications made by the Corporation; compliance with applicable governmental laws, rules and regulations; the prompt internal reporting of violations of the Code to an appropriate person or persons identified in the Code; and accountability for adherence to the Code.


2. Conflicts of Interest

It is our policy to ensure the Corporation's best interests are paramount in all of our dealings with customers, suppliers, contractors, competitors, existing and potential business partners and other representatives and are conducted in a manner that avoids any actual or potential conflicts of interest.

In general, a conflict of interest exists where a representative's personal interests interfere with his or her ability to act in the best interests of the Corporation. Conflicts of interests may exist in any situation where your ability to act objectively, or in the best interests of the Corporation, are influenced.  These include the receipt of improper personal benefits by you or your family and friends, as a result of your position with the Corporation.

Full and timely disclosure of any actual or potential conflict of interest is very strongly encouraged.  Proper disclosure provides an opportunity to obtain advice from the appropriate level of management and to resolve actual or potential conflicts of interests in a timely and effective manner.  Employees should promptly disclose to their supervisor any material transaction or relationship that reasonably could be expected to give rise to a potential or actual conflict of interest.  Directors and officers shall disclose any potential conflicts of interest in writing to the board of directors for review in accordance with applicable law.



3. Protection and Use of the Corporation's Assets and Opportunities

All representatives are responsible for protecting the Corporation's assets from improper use including fraud, theft and misappropriation.  It is the Corporation's policy to protect its assets and promote their efficient use for legitimate business purposes.  This requires proper documentation (which is timely, accurate and complete) and appropriate use of discretion.  Corporation assets should not be wasted through carelessness or neglect nor appropriated for improper personal use. Proper discretion and restraint should always govern the personal use of the Corporation's assets.


4. Corporate Opportunities

The benefit of any business venture, opportunity or potential opportunity resulting from your employment with the Corporation should not be appropriated for any improper personal advantage.  As employees, officers and directors, a duty is owed to the Corporation to advance its legitimate interests when the opportunity to do so arises.


5. Confidentiality of Corporate Information

Information is a key asset of the Corporation.  It is our policy to ensure that the Corporation's proprietary and confidential information, including information that has been entrusted to the Corporation by others, is adequately safeguarded.  All confidential information, including information about the Corporation's business, suppliers, intellectual property, opportunities, products, customers, assets and competitors, should be duly protected from advertent or inadvertent disclosure.  Confidential information should be marked or identified as being confidential whenever practicable and should be disclosed only when properly authorized or required by law or stock exchange requirements.


6. Fair Dealing with Other People and Organizations

All business dealings undertaken on behalf of the Corporation should be conducted in a manner that preserves our integrity and reputation.  It is the Corporation's policy to seek to avoid misrepresentations of material facts, manipulation, concealment, abuse of confidential information or any other illegal practices in dealing with the Corporation's security holders, customers, suppliers, competitors and employees.


7. Complying with the Law

The Corporation strives to ensure that its business is conducted in all material respects in accordance with all applicable laws, stock exchange rules and securities regulations.  This includes compliance with applicable antitrust/competition, privacy, labour, human rights, environmental and securities laws in all material respects. 

Specifically, it is also our policy to seek to comply with all applicable securities laws and regulations to ensure that material information that is not generally available to the public ("inside information") is disclosed in accordance with law.  This includes implementation of policies and procedures, as set out in our Insider Trading Policy, to protect against the improper use or disclosure of inside information, including the improper trading of securities while in possession of inside information.

Applicable securities laws require the Corporation to disclose certain information in various reports and documents that the Corporation must file or submit to securities regulatory authorities.  In addition, from time to time, the Corporation makes other public communications, such as issuing press releases.  The Corporation has a responsibility to provide full, fair, accurate, timely and understandable disclosure in reports and documents filed with or submitted to securities regulatory authorities and in other public communications.

8. Reporting of Illegal or Unethical Behaviour

The Corporation strives to foster a business environment that promotes integrity and deters unethical or illegal behaviour.  It is our responsibility to monitor and to ensure compliance with the guidelines set out in this Code, including compliance in all material respects, with all applicable financial reporting and accounting requirements applicable to the Corporation.  Concerns or complaints in this regard may be reported by anonymous submission to the Chair of the Corporate Governance Committee of the Board of Directors in connection with unethical or illegal behaviour, including questionable accounting, internal accounting controls or auditing matters involving the Corporation.


9. Compliance

It is the role of the Board of Directors to monitor compliance with the Code.  Disciplinary measures may be taken against any representative who authorizes, directs, approves or participates in any violation of a provision of this Code.  These measures will depend upon the circumstances of the violation and may range from formal sanction or reprimand to dismissal from employment.  Consideration will be given to whether or not a violation was intentional, as well as to the level of good faith shown by a representative in reporting the violation or in cooperating with any resulting investigation or corrective action.  In addition, persons who violate the law during the course of their employment are subject to criminal and civil penalties, as well as payment of civil damages to the Corporation or third parties.  A Director or officer who violates this Code may be asked to resign or may not be nominated for re-election.


The terms of this Code are not intended to give rise to civil liability on the part of the Corporation, its directors or officers, shareholders, security holders, customers, suppliers, competitors, employees or other persons, or to any other liability whatsoever.

10. Currency of Code

This Code of Business Ethics and Conduct was approved by the Board of Directors on October 26, 2005 and amended on February 24, 2011, August 30, 2011 and September 12, 2012.  The Board of Directors may amend the Code from time to time.
__________________________________________________________________________

I acknowledge that I have read and understand the Code of Business Conduct and Ethics of Burcon NutraScience Corporation and agree to conduct myself in accordance with the Code.

Name:___________________________________________

Signature:__________________________________

Date:_______________________________________




 
 


 

 




 
 


 
 


News Release

Burcon Agrees to Terminate Clarisoy License Agreement with ADM

Vancouver, August 10, 2020 / - Burcon NutraScience Corporation ("Burcon") (TSX:BU, OTCQB:BUROF), a global technology leader in the development of plant-based proteins, announced today that Burcon and ADM have agreed to terminate the license and production agreement dated March 4, 2011 made among Burcon, Burcon NutraScience (MB) Corp. and ADM  for CLARISOY™ soy protein effective August 7th, 2020. 

As part of the agreement to terminate the exclusive license, the CLARISOY trademark will revert back to Burcon. Additionally, Burcon and ADM are discussing opportunities for Burcon to acquire certain processing equipment from ADM's CLARISOY™ processing facility. Burcon will provide additional updates on its plans for CLARISOY™ in the future.

Unique to any other soy proteins on the market, CLARISOY™ soy proteins offer exceptionally high solubility, clean flavor and complete protein nutrition for low pH and neutral pH beverage systems.

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements. CLARISOY is a trademark of Archer Daniels Midland Company.


Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca

www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



 

 

Burcon NutraScience Corporation

 

Condensed Consolidated Interim Financial Statements

Three months ended June 30, 2020 and 2019

(Unaudited)

(Prepared in Canadian dollars)


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Balance Sheets

(Unaudited)

As at June 30, 2020 and March 31, 2020

(Prepared in Canadian dollars)

    June 30, 2020
$
    March 31, 2020
$
 
             
ASSETS            
             
Current assets            
  Cash and cash equivalents   6,623,340     15,030,988  
  Restricted cash (note 4)   6,500,000     -  
  Amounts receivable (notes 3 and 10)   306,862     332,248  
  Inventory   192,477     132,142  
  Prepaid expenses   75,124     289,278  
    13,697,803     15,784,656  
             
Property and equipment   965,972     470,504  
Deferred development costs - net of accumulated amortization of $nil (2020 - $nil)   2,074,776     1,554,584  
Investment in and loan to Merit Functional Foods Corporation (note 3)   11,896,172     12,204,538  
Goodwill   1,254,930     1,254,930  
             
    29,889,653     31,269,212  
             
LIABILITIES            
Current liabilities            
  Accounts payable and accrued liabilities (note 10)   954,417     1,067,251  
  Deferred revenue   275,578     275,578  
  Accrued interest (notes 4 and 5)   41,650     249,310  
    1,271,645     1,592,139  
             
Lease liability   59,377     -  
Convertible debentures (note 4)   6,222,911     6,731,350  
             
    7,553,933     8,323,489  
             
SHAREHOLDERS' EQUITY (note 6)            
Capital stock   99,016,713     98,046,103  
Contributed surplus   9,030,861     9,030,861  
Options   9,773,109     9,673,821  
Warrants   1,792,168     1,792,168  
Convertible debentures (note 4)   2,483,726     2,762,927  
Deficit   (99,760,857 )   (98,360,157 )
    22,335,720     22,945,723  
             
    29,889,653     31,269,212  

Subsequent events (note 14)

Approved by the Audit Committee of the Board of Directors

"Douglas Gilpin"   "Peter H. Kappel"
Director   Director

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss

(Unaudited)

For the three months ended June 30, 2020 and 2019

(Prepared in Canadian dollars)

    2020
$
    2019
$
 
             
REVENUE            
Royalty income (note 1(b))   8,515     15,636  
             
EXPENSES            
Research and development (note 7)   100,489     356,130  
Intellectual property   138,774     361,260  
General and administrative (note 8)   656,951     397,077  
             
    896,214     1,114,467  
             
LOSS FROM OPERATIONS   (887,699 )   (1,098,831 )
             
INTEREST AND OTHER INCOME (notes 3 and 10)   149,560     6,057  
             
MANAGEMENT FEE INCOME   109,316     5,218  
             
WARRANT VALUATION ADJUSTMENT (notes 6(a) and 10)   -     (85,421 )
             
SHARE OF LOSS IN MERIT FUNCTIONAL FOODS CORP. (note 3)   (382,176 )   (46,762 )
             
INTEREST EXPENSE (notes 4 and 5)   (388,023 )   (117,258 )
             
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITY (note 4)   -     5,384  
             
FOREIGN EXCHANGE LOSS   (1,678 )   (367 )
             
LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD   (1,400,700 )   (1,331,980 )
             
BASIC AND DILUTED LOSS PER SHARE (note 9)   (0.01 )   (0.03 )

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity

(Unaudited)

For the three months ended June 30, 2020 and 2019

(Prepared in Canadian dollars)

    Number of
fully paid
common
shares 
    Capital
stock
$
    Contributed
surplus
$
    Options
$
    Warrants
$
    Convertible
debentures

$ 
    Deficit
$
    Total
shareholders'
equity
$
 
                                                 
Balance - March 31, 2019   43,941,536     73,361,133     9,001,467     9,184,852     199,117     -     (93,726,663 )   (1,980,094 )
                                                 
Loss and comprehensive loss for the year   -     -     -     -     -           (1,331,980 )   (1,331,980 )
Shares issued   44,083,203     15,429,121     -     -     -     -     -     15,429,121  
Issue costs   -     (144,691 )   -     -     -     -     -     (144,691 )
Options exercised   141,667     104,984     -     (41,734 )   -     -     -     63,250  
Warrant valuation adjustment   -     -     -     -     85,421     -     -     85,421  
Stock-based compensation expense   -     -     -     35,080     -     -     -     35,080  
                                                 
Balance - June 30, 2019   88,166,406     88,750,547     9,001,467     9,178,198     284,538     -     (95,058,643 )   12,156,107  
                                                 
Balance, March 31, 2020   96,799,638     98,046,103     9,030,861     9,673,821     1,792,168     2,762,927     (98,360,157 )   22,945,723  
Loss and comprehensive loss for the year   -     -     -     -     -     -     (1,400,700 )   (1,400,700 )
Shares issued   914,283     970,610     -     -     -     (279,201 )   -     691,409  
Stock-based compensation expense   -     -     -     99,288     -     -     -     99,288  
                                                 
Balance - June 30, 2020   97,713,921     99,016,713     9,030,861     9,773,109     1,792,168     2,483,726     (99,760,857 )   22,335,720  

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Cash Flows

(Unaudited)

For the three months ended June 30, 2020 and 2019

(Prepared in Canadian dollars)

 
 
  2020
$
    2019
$
 
             
CASH FLOWS FROM OPERATING ACTIVITIES            
Loss for the period   (1,400,700 )   (1,331,980 )
Items not affecting cash            
Amortization of property and equipment   22,145     14,543  
Unrealized foreign exchange loss   1,068     98  
Interest accretion   (73,810 )   -  
Interest expense   182,969     -  
Share of loss in Merit Functional Foods Corporation   382,176     46,762  
Change in fair value of derivative liability   -     (5,384 )
Warrant valuation adjustment   -     85,421  
Stock-based compensation expense   63,790     35,080  
             
    (822,362 )   (1,155,460 )
Changes in non-cash working capital items            
Amounts receivable   25,386     (230,121 )
Inventory   (60,335 )   (46,351 )
Prepaid expenses   214,154     260,408  
Accounts payable and accrued liabilities   162,714     16,915  
Accrued interest   (207,660 )   (564,251 )
             
    (688,103 )   (1,718,860 )
             
CASH FLOWS FROM INVESTING ACTIVITIES            
Investment in Merit Functional Foods Corporation   -     (4,000,001 )
Restricted term deposit   (6,500,000 )   -  
Development costs deferred   (464,906 )   -  
Acquisition of property and equipment   (581,193 )   (162 )
    (7,546,099 )   (4,000,163 )
             
CASH FLOWS FROM FINANCING ACTIVITIES            
Issue of capital stock   -     15,492,371  
Share issue costs   (231,755 )   (38,844 )
Lease liability   59,377     -  
Proceeds from short-term loan   -     250,000  
Repayment of convertible note   -     (1,990,687 )
Repayment of short-term loan   -     (1,500,000 )
    (172,378 )   12,212,840  
             
FOREIGN EXCHANGE LOSS ON CASH AND CASH  EQUIVALENTS   (1,068 )   (98 )
             
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (8,407,648 )   6,493,719  
             
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD   15,030,988     489,215  
             
CASH AND CASH EQUIVALENTS - END OF PERIOD   6,623,340     6,982,934  
             
INTEREST RECEIVED   6,694     2,807  

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

1. Nature of operations

Burcon NutraScience Corporation ("Burcon" or the "Company") is an incorporated entity headquartered in Vancouver, British Columbia, Canada.

Burcon is a research and development company that has developed plant protein extraction and purification technology in the field of functional, renewable plant proteins.  The Company has an extensive portfolio of composition, application and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. 

a) Peazazz®, Peazac®, Puratein®, Supertein® and Nutratein®

Burcon has developed novel pea proteins that it has branded Peazazz® and Peazac®.  In 2017, Peazazz® and Peazac® pea proteins achieved US self-affirmed GRAS ("Generally Recognized As Safe") status, and the US Food and Drug Administration ("US-FDA") formally acknowledged receipt of Burcon's GRAS notification for Peazazz® and Peazac® in October 2019.

Burcon has developed three canola protein products, Puratein®, Supertein® and Nutratein®.  In 2008, Puratein® and Supertein® achieved US self-affirmed GRAS status, and the US-FDA formally acknowledged receipt of Burcon's GRAS notification for Puratein® and Supertein® in 2010.

On May 23, 2019, Burcon, entered into a shareholders' agreement with two other entities to become shareholders of Merit Functional Foods Corporation ("Merit Foods"), to build a new commercial production facility in Western Canada to produce its pea and canola protein  products.  See note 3 for further details.

On May 23, 2019, Burcon entered into a license agreement with Merit Foods granting Merit Foods an exclusive, royalty-bearing, worldwide license to use and exploit Burcon's pea, pulse, and canola protein technologies required to produce, market and sell Burcon's pea, pulse and canola proteins (collectively the "Products").  See note 3 for further details.

b) CLARISOY®

Burcon had entered into a license and production agreement (the "Soy Agreement") on March 4, 2011 with Archer Daniels Midland Company ("ADM") to license its CLARISOY® technology to ADM on an exclusive basis to produce market and sell CLARISOY® soy protein worldwide.  Subsequent to the quarter-end, Burcon announced that it and ADM have agreed to terminate the Soy Agreement, effective August 7, 2020.  As part of the agreement to terminate the exclusive license, the CLARISOY trademark reverted back to Burcon on the effective date. 

c) COVID-19

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  To-date, the COVID-19 pandemic has not had significant adverse effect on Burcon's business.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

2. Significant accounting policies

Basis of presentation

These condensed consolidated interim financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") applicable to the preparation of interim financial statements, including International Accounting Standards ("IAS") 34, Interim Financial Reporting, and interpretations issued by the IFRS Interpretations Committee ("IFRIC") on a basis consistent with those accounting policies  followed in the most recent annual consolidated financial statements, except for the new accounting standards adopted in the current year, as discussed below.  These condensed consolidated financial statements do not include all of the information required for full annual financial statements and were approved and authorized for issue by the Audit Committee of the Board of Directors on August 12, 2020.

The condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated annual financial statements for the year ended March 31, 2020. 

Principles of consolidation

These condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries, Burcon NutraScience (MB) Corp. ("Burcon-MB") and Burcon NutraScience Holdings Corp. ("Burcon Holdings").  A subsidiary is an entity in which the Company has control, directly or indirectly.  Under IFRS 10, an investor controls an investee if and only if the investor has power over the investee, exposure, or rights, to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect the amount of the investor's returns.  All material intercompany transactions and balances have been eliminated on consolidation.

Details of the Company's subsidiary at June 30, 2020 are as follows:

 

 

Place of

incorporation

 

Interest

%

 

Principal activity

 

 

 

 

 

 

 

Burcon NutraScience (MB) Corp.

 

Manitoba, Canada

 

100

 

Research and development

Burcon NutraScience Holdings Corp.

 

Canada

 

100

 

Investment holding



BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

3. Investment in and loan to Merit Functional Foods Corporation

On May 23, 2019, Burcon, through a new wholly-owned subsidiary incorporated on May 22, 2019, Burcon Holdings, entered into a shareholders' agreement (the "Shareholders' Agreement") with two other entities to become shareholders of Merit Foods, to build and own a new commercial production facility in Western Canada to produce, sell, market and distribute Burcon's Peazazz® and Peazac® pea proteins, Burcon's Puratein®, Supertein® and Nutratein® canola proteins, as well as Burcon's new pea and canola protein blends that it has branded Nutratein-PS and Nutratein-TZ

Burcon Holdings holds 40% of the issued and outstanding shares of Merit Foods, and the two other parties hold 40% and 20%, respectively.  Each shareholder made its respective capital loan advances in June, September, December 2019 and February 2020 by way of shareholder loans totalling $32.5 million (the "Merit Shareholder Loans").

Summary financial position for Merit Foods as at June 30, 2020

    As at June
30, 2020
    As at March
31, 2020
 
    $     $  
             
Current assets   14,168,841     5,828,739  
Non-current assets   64,080,071     36,056,689  
Current liabilities   14,023,948     11,369,931  
Non-current liabilities   41,318,631     6,653,724  

Summary financial results for Merit Foods

    Three
months
ended June
30, 2020
    Period ended
June 30, 2019
 
    $     $  
             
Total revenue   538,544     -  
Loss and comprehensive loss for the period   (955,440 )   (116,906 )

As at June 30, 2020, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)


    Investment in
Share capital

$
    Capital
Contribution

$
    Loan
receivable

$
    Total net
investment

$
 
                         
From inception to December 31, 2019   1     -     11,000,000     11,000,001  
Modification to loan terms         8,871,512     (8,871,512 )   -  
Capital loan advance, February 2020   -     1,613,002     386,998     2,000,000  
Share of loss in Merit Foods   -     (939,806 )   -     (939,806 )
Interest accretion   -     -     144,343     144,343  
                         
Net Investment in Merit Foods, March 31, 2020   1     9,544,708     2,659,829     12,204,538  
                         
Share of loss in Merit Foods   -     (382,176 )   -     (382,176 )
Interest accretion   -     -     73,810     73,810  
                         
Net Investment in Merit Foods, June 30, 2020   1     9,162,532     2,733,639     11,896,172  

From inception to December 2019, the Merit Shareholder Loans were recorded as loan receivable.  In December 2019, the terms of the Merit Shareholder Loans were finalized.  The loans are non-interest bearing, unsecured, subordinated to Merit Foods' other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder's loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts.  As a result, Burcon recalculated the fair value at that date, resulting in a reduction of the fair value of the loan receivable that was transferred to a capital contribution account.  Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest.  The Company has recorded interest accretion of $73,809 (2019 - $nil) for the three months ended June 30, 2020.

On May 23, 2019, Burcon entered into a license agreement (the "License Agreement") with Merit Foods granting Merit Foods an exclusive, royalty-bearing, worldwide license to use and exploit Burcon's Products.  Under the terms of the License Agreement, Merit Foods will have the exclusive rights across all geographic regions and all product uses for Burcon's pulse protein (including pea) and canola protein technologies (the "License").  Burcon will receive running royalties on the net revenue (as defined in the License Agreement) from the sales of the Products by Merit Foods.  Burcon is responsible for the technology transfer to Merit Foods, and is providing assistance, under a services agreement, to support the design, construction and commissioning of the commercial protein production facility.

Merit Foods has agreed to develop, build and commission an initial production facility within a specified amount of time to manufacture the Products.  Merit Foods will also, within a specified time period, provide written notice to Burcon to advise whether it will or will not increase its annual production capacity of the Products to develop, build and commission a full commercial scale production facility (the "Full Commercial Production Facility").  If Merit Foods expands production to the Full Commercial Production Facility, the royalty rate will reduce to a lower percentage rate.  The royalty rate may also reduce if the exclusive license is converted to a non-exclusive license or if a certain Burcon patent does not grant within a specified time.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

The License Agreement has a term of the greater of twenty years and the last to expire of Burcon patents that are being used to produce products under the License Agreement.  The License Agreement provides Burcon with the right to convert the exclusive license to a non-exclusive license under certain conditions.  As long as the License is exclusive, Burcon will be responsible for the filing, prosecution and maintenance of Burcon patent rights in certain countries. 

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  For the three months ended June 30, 2020, included in management fee income is $104,600 (2019 - $960) for services provided and $77,048 of samples sold to Merit Foods, of which $58,367 was included in amounts receivable at June 30, 2020 (March 31, 2020 - $110,594).

Merit Foods also provides certain technical and consulting services to Burcon.  For the three months ended June 30, 2020, Burcon recorded professional fee expense of $10,000 (2019 - $nil), of which $3,280 was included in accounts payable and accrued liabilities as at June 30, 2020.

In May 2020, Burcon announced that Merit Foods has secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada ("EDC"), Farm Credit Canada and the Canadian Imperial Bank of Commerce.  Merit Foods' shareholders, including Burcon Holdings, were required to pledge their shares in Merit Foods as security under the loan facilities from EDC.  In connection with the loan facilities from EDC, Merit Foods must fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility.  $6.5 million of this amount is permitted to be funded by way of a letter of credit ("LC").  To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada ("HSBC") in April 2020, which is secured by a term deposit with HSBC in the same amount. 

In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the "Merit Loan Agreement") with Merit Foods in the amount of $6.5 million (the "Merit Loan").  The Merit Loan and the commitment by Burcon Holdings to maintain the LC will terminate no later than September 30, 2020, unless extended by mutual agreement.  The Merit Loan bears interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term.  Under the Merit Loan Agreement, Burcon Holdings has the option to contribute the amount of the Merit Loan as a capital contribution to Merit Foods in certain circumstances including if the other shareholders of Merit Foods are unable to deliver a letter of credit in favour of EDC for their entire pro rata share of the LC amount by September 30, 2020.  If EDC draws on the LC prior to September 30, 2020 and each of the other shareholders of Merit Foods are unable to reimburse Burcon Holdings for such other shareholder's entire pro rata share of the amount of such draw within the time period set out in the Merit Loan Agreement, then the draw amount will be deemed a capital contribution by Burcon Holdings and its shareholding interest in Merit Foods will be increased.  During the period ended June 30, 2020, Burcon recorded interest income of $67,671 (2019 - $nil) related to the Merit Loan, which was included in amounts receivable as at June 30, 2020 (March 31, 2020 - $nil).


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

In addition, Burcon has provided a guarantee in favour of EDC's senior loan facility and subordinate loan facility to Merit Foods (the "Guarantees"), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC and Merit Foods.  The aggregate maximum liability of Burcon under the Guarantees is limited to $4.0 million.  On June 22, 2020, Burcon announced that Merit Foods secured additional debt financing of $10 million in the form of a 10-year interest free loan from Agriculture and Agri-Food Canada (the "AIP Loan").  It is expected that Burcon's portion of the Guarantees will be released in stages over time as Merit Foods draws down on the $10 million AIP Loan.

Burcon Holdings and the other Merit Foods shareholders have also provided a guarantee for the AIP Loan (the "AIP Guarantee").  The obligations of the AIP Guarantee are joint and several.  However, Burcon Holdings and the other Merit Foods shareholders (the "AIP Guarantors") have entered into a reciprocal indemnity agreement (the "Indemnity Agreement').  Under the Indemnity Agreement, if any AIP Guarantor (each, a "Paying Guarantor") is required to make payment under the AIP Guarantee and any other AIP Guarantor (each, a "Contributing Guarantor") has not made a corresponding payment equal to its share based on its shareholdings in Merit Foods ("Contributive Share"), such Contributing Guarantor(s) shall pay the Paying Guarantor such amounts so that, after payment, all obligations and liabilities under the AIP Guarantee will have been borne by the AIP Guarantors in their respective shareholding percentage in Merit Foods.

4. Convertible debentures and convertible note

Convertible debentures

On December 10, 2019, the Company issued convertible debentures (the "Debentures") through a non-brokered private placement for an aggregate principal amount of $9.5 million.  Certain directors and an officer of the Company subscribed for Debentures totalling $2 million in principal amount.  Each Debenture consists of $1,000 principal amount, bears interest at a rate of 8.5% per annum, payable semi-annually in arrears and is unsecured.  The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon will be payable in cash on December 10, 2022.  The Debentures will be convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share.  Burcon has the right, at its sole discretion, to force the conversion of the Debentures if the shares trade at or above $2.15 for a period of 14 consecutive trading days.  The Company incurred issue costs of $228,432, of which $156,600 were finder's fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders. 

The Debentures are a level 3 financial liability with an embedded conversion feature.  As a result, the debt and equity components were bifurcated, and the instrument valued to par at the issuance date.  The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option.  From the date of issuance, the liability component is accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive loss.  The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641.  The residual amount of $2,762,927 was recognized within equity as the value of the conversion option.  For the three months ended June 30, 2020, the Company recorded interest expense of $375,324 (2019 - $nil).


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

For the three months ended June 30, 2020, an aggregate of $960,000 in principal amount of Debentures was converted for 914,283 common shares.  Subsequent to the quarter-end, an additional $644,500 in principal amount of Debentures were converted for 613,808 common shares.

Convertible note

The Company had a convertible note (the "Note") with Large Scale Investments Limited ("Large Scale'), a wholly owned subsidiary of Firewood Elite Limited ("Firewood"), for the principal amount of $2.0 million (the "Principal Amount").  Firewood, a related party of Burcon that has significant influence over the Company, is wholly owned by Mr. Alan Chan, a director of the Company.

The Note bore interest at 8% per annum, compounded monthly.  The Principal Amount and accrued interest were payable on the earlier of May 12, 2019, the occurrence of an event of default as set out in the Note (the "Maturity Date"), or voluntary prepayment by the Company.  Under the Note, Large Scale could convert the Principal Amount in whole or in part at $4.01 per share into common shares of the Company commencing on or after July 1, 2016 and up to and including the Maturity Date.  Pursuant to the terms of the Note, the conversion price was adjusted upon completion of Burcon's rights offering that completed in 2016 to $3.99 per share and further adjusted upon the completion of Burcon's 2018 Rights Offering (note 6(a)) to $3.94 per share. 

Burcon had the right, before the Maturity Date, upon written notice to Large Scale of not less than thirty days, to prepay in cash all or any portion of the Principal Amount by paying to Large Scale an amount equal to the Principal Amount to be prepaid multiplied by 110%.  The payment of the Principal Amount and all accrued and unpaid interest thereon were subordinated in right of payment to any amount owing in respect of secured indebtedness of the Company.   

On May 21, 2019, the Company and Large Scale amended (the "Amendment") the Note's Maturity Date to June 21, 2019.  The Amendment also provided Large Scale with the right to offset any amounts due to it under the Note against any obligations of Large Scale to pay for subscription proceeds of any rights offering that Burcon may conduct.

In connection with the 2019 Rights Offering (note 6(a)), Large Scale exercised its right to offset the amounts due under the Note against its obligations to pay for subscription proceeds under the 2019 Rights Offering.  The offset was completed on June 25, 2019.  The total amount offset under the Note included the principal amount and accrued interest of $2,565,022.

The conversion option was recorded as a derivative liability (note 12).  Under the terms of the Note, there are certain conditions where the conversion price may be adjusted.  Therefore, in accordance with IFRS, an obligation to issue shares for a price that is not fixed must be classified as a derivative liability and measured at fair value, with changes recognized in change in fair value of conversion option in the consolidated statement of operations and comprehensive loss.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

The conversion and prepayment options were recorded as a net derivative liability and measured at fair value, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss.  The fair value of the conversion and prepayment options was estimated based on a methodology for pricing convertible bonds using the Partial Differential Equation Method, with the following initial assumptions:  expected volatility of 63%; expected dividend per share of $nil; risk-free rate of 0.60%, entity-specific credit spread, and expected life of 3 years.  The assumptions as at March 31, 2019 were as follows:  expected volatility of 99%, expected dividend per share of $nil; risk-free rate of 1.63%, initial entity-specific credit spread adjusted by the movement in the option adjusted spread of the Canada High Yield Index, and expected life of 1.1 years.  The initial fair value of the net derivative liability was estimated as $189,705 as at the issue date of the Note.  As at March 31, 2019, the fair value of the net derivative liability was estimated to be $5,384.  Upon the offset by Large Scale of its obligations to pay for subscription proceeds under the 2019 Rights Offering, the net derivative liability was expensed in the first quarter of fiscal 2020 as financing expense.

5. Short-term loan

On November 13, 2018, the Company entered into a loan agreement with Large Scale to provide Burcon with an unsecured loan for up to $1.0 million (the "Loan").  On March 27, 2019, Burcon and Large Scale amended the loan (the "Loan Amendment") to increase the principal amount available to $1.5 million.  The Loan Amendment provided the Lender with the right to offset any amount due to it under the Note against any obligations of the Lender to pay for subscription proceeds of any rights offering that Burcon may conduct.  During the three months ended June 30, 2019, the Company drew down $250,000 to the maximum principal amount available under the Loan. 

The Loan bore interest at 18% per annum on the amount drawn, and 3% per annum on the undrawn portion.  Burcon paid Large Scale a commitment fee of 1%, or $15,000, on the principal amount available under the Loan.  The amounts drawn on the Loan and the accrued interest was payable on the earlier of June 3, 2019, the occurrence of an event of default as set out in the Loan, or voluntary prepayment by the Company.   

In connection with the 2019 Rights Offering (note 6(a)), Large Scale exercised its right to offset the amounts due under the Loan against its obligations to pay for subscription proceeds under the 2019 Rights Offering.  The offset was completed on June 25, 2019 for $1,436,629 against the principal amount.  The balance of the principal amount of $63,371 and accrued interest of $107,173 was repaid to Large Scale in cash on June 28, 2019.

6. Shareholders' equity

a) Capital stock

Authorized

Unlimited number of common shares without par value


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Equity Offering

On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the "Units") at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the "Offering") and net proceeds of $10.3 million.

Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant").  Each Warrant is exercisable to acquire one common share (a "Warrant Share") until February 19, 2022 at an exercise price of $2.00 per Warrant Share.  The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model and has been included in Warrants.  At June 30, 2020, all of the Warrants were outstanding.  Subsequent to June 30, 2020, Warrants were exercised for 79,500 common shares of the Company.

The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents' Warrants) entitling the agents to purchase up to 519,386 common shares.  Each Agent's Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022.  The fair value of the Agents' Warrants was estimated at $249,305 using the Black-Scholes pricing model and has been included in Warrants.  At June 30, 2020, all of the Agents' Warrants were outstanding.

In addition to the Agents' Warrants, the Company incurred total issue costs of $1.2 million related to the Offering.

2019 Rights Offering

On June 25, 2019, the Company completed a rights offering (the "2019 Rights Offering") for 44,083,203 common shares at $0.35 per common share for gross proceeds of $15,429,121, and net proceeds of $15,284,430.  Burcon issued to each shareholder as of the record date of May 30, 2019 one transferrable right (the "2019 Rights") for each common share held by such shareholder.  Every 2019 Right entitled the holder thereof to purchase one common share in the Company at a price of $0.35 per common share. 

The Company's directors, officers and persons controlling over 10% of the common shares of the Company agreed to exercise at least all of the 2019 Rights they were issued in connection with the 2019 Rights Offering for 14,306,740 common shares, representing 32.5% of the 2019 Rights Offering.

Of the net proceeds of the 2019 Rights Offering, $2,565,022 were used to repay the Note and accrued interest to Large Scale (note 4) and $1,607,183 has been used to repay the Loan and accrued interest to Large Scale (note 5). 

2018 Rights Offering

On February 13, 2018, the Company completed a rights offering (the "2018 Rights Offering") for 6,114,361 common shares at $0.57 per common share for gross proceeds of $3,485,186, and net proceeds of $3.4 million.  As consideration for providing a standby guarantee to purchase such common shares that were available to be purchased that would have resulted in a minimum of 4,728,397 common shares being issued under the 2018 Rights Offering, Dr. Allan Yap ("Dr. Yap"), the Company's former Chairman and Chief Executive Officer, received share purchase warrants ("Standby Warrants") to acquire up to 1,182,099 common shares at an exercise price of $0.69 per common share that would be exercisable up to February 13, 2020.  Pursuant to the terms of the Standby Warrants, the exercise price was adjusted upon completion of the 2019 Rights Offering from $0.69 per share to $0.45 per share.  Burcon recorded a warrant valuation adjustment of $85,420 during the first quarter of fiscal 2020.  The Standby Warrants were exercised during fiscal 2020.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

b) Contributed surplus

Contributed surplus comprises the value ascribed to expired warrants and options and forfeited vested options, previously categorized in either warrants or options, as applicable, within shareholders' equity. 

c) Options

The Company has a stock option plan in which all directors, officers, employees and consultants of the Company and its subsidiary are eligible to participate.

At June 30, 2020, 4,507,606 (March 31, 2020 - 4,507,606) options to purchase common stock are outstanding from the stock option plan.  These options, when vested under the terms of the plan, are exercisable at prices ranging between $0.23 and $9.60 per common share.  An additional 5,263,786 (March 31, 2020 - 5,172,357) options may be granted in future years under this plan.  Unless otherwise determined by the board of directors, the options have a term of 10 years from the date of grant.  The vesting terms are determined at the discretion of the board of directors at the time of grant.  All grants are recognized using graded vesting, with each vesting tranche being valued separately, and the fair value of each tranche recognized over its respective vesting period.

    Three months ended June 30, 2020     Year ended March 31, 2020  
                         
    Number of
options
 
    Weighted
average
exercise
price

$
    Number of
options
 
    Weighted
average
exercise
price

$
 
                         
Outstanding - Beginning of period   4,507,606     3.32     3,953,739     3.46  
                         
Granted   -     -     757,000     1.88  
Exercised   -     -     (173,000 )   0.41  
Cancelled   -     -     (30,133 )   1.96  
                         
Outstanding - End of period   4,507,606     3.32     4,507,606     3.32  


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

The following table summarizes information about stock options outstanding and exercisable at June 30, 2020:

    Options outstanding     Options exercisable  
Range of
exercise prices


$
  Number
outstanding
at June 30,
2020
    Weighted
average
remaining
contractual
life

(years)
    Weighted
average
exercise
price

$
    Number
exercisable
at June 30,
2020
    Weighted
average
exercise
price

$
 
                               
0.23 - 0.69   926,333     8.20     0.41     508,992     0.46  
1.88 - 4.16   2,763,773     5.99     2.54     2,286,773     .68  
6.78 - 9.60   817,500     0.16     9.27     817,500     9.27  
                               
    4,507,606     5.39     3.32     3,613,265     3.86  

The fair value of each option is estimated as at the date of grant or other measurement date using the Black-Scholes option pricing model and the following weighted average assumptions:

  Three months
ended
June 30,
2020
Year ended
March 31,
2020
     
Dividend yield N/A 0.0%
Expected volatility N/A 75.1%
Risk-free interest rate N/A 1.3%
Expected forfeitures N/A 7.7%
Expected average option term (years) N/A 7.9

The expected volatility and expected forfeitures are based on historical volatility and forfeitures. The risk-free rate of return is the yield on a zero-coupon Canadian treasury bill of a term consistent with the expected average option term. The expected average option term is the average expected period to exercise, based on the historical activity patterns for each individually vesting tranche.

There were no options granted during the three months ended June 30, 2020.  The weighted average fair value of the options granted during the year ended March 31, 2020 was $1.36 per option.

Included in research and development expenses (salaries and benefits) is $nil (2019 - $18,938) (note 7) of stock-based compensation and included in general and administrative expenses (salaries and benefits) is $49,375 (2019 - $16,142) (note 8) of stock-based compensation.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

7. Research and development

          Three months
ended June 30,
 
    2020     2019  
    $     $  
Salaries and benefits   87,577     249,856  
Laboratory operation   5,562     56,797  
Rent   5,394     19,344  
Amortization of property and equipment   1,956     12,562  
Analyses and testing   -     13,382  
Travel and meals   -     4,189  
    100,489     356,130  

8. General and administrative

          Three months
ended June 30,
 
    2020     2019  
    $     $  
             
Salaries and benefits   459,605     226,503  
Professional fees   92,428     66,684  
Office supplies and services   43,033     41,136  
Investor relations   34,718     21,706  
Other   13,311     19,905  
Financing expense   9,907     3,131  
Transfer agent and filling fees   3,926     3,448  
Travel and meals   23     14,564  
    656,951     397,077  


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

9. Basic and diluted loss per share

The following table sets forth the computation of basic and diluted loss per share:

    2020
$
    2019
$
 
             
Loss for the period, being loss attributable to common  shareholders - basic and diluted   (1,400,700 )   (1,331,980 )
             
Weighted average common shares - basic and diluted   97,175,670     46,901,051  
             
Basic and diluted loss per share   (0.01 )   (0.03 )

For the three months ended June 30, 2020 and 2019, the Company excluded all potential common share equivalents from the diluted loss per share calculation as they were anti-dilutive.

10. Related party transactions

The Company engaged an entity that is related by virtue of common officers for the following related party transactions:

Included in general and administrative expenses (office supplies and services) for the three months ended June 30, 2020 is $4,584 (2019 - $18,752) for office space rental.

For the three months ended June 30, 2020, included in general and administrative expenses (management fees) are $648 (2019 - $458), for services provided to the Company.  At June 30, 2020, $186 (March 31, 2020 - $11) of this amount is included in accounts payable and accrued liabilities.  For the three months ended June 30, 2020, included in interest and other income is $4,716 (2019 - $4,258) for management services provided by the Company.  At June 30, 2020, $451 (March 31, 2020 - $1,785), of this amount is included in amounts receivable. 

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  Merit Foods also provides certain technical and consulting services to Burcon.  See note 3 for details.

In connection with the LC, Burcon Holdings entered the Merit Loan Agreement with Merit Foods in the amount of $6.5 million.  During the period ended June 30, 2020, Burcon recorded interest income of $67,671 (2019 - $nil) related to the Merit Loan, which was included in amounts receivable as at June 30, 2020 (March 31, 2020 - $nil).

Certain directors and an officer subscribed for $2.0 million of the Debentures.  During the quarter, the Company made convertible debenture interest payments of $85,000, in aggregate, to these directors and officer.

Burcon had the Loan and Note with Large Scale, a company that is wholly owned by Firewood.  For the three months ended June 30, 2019, included in interest expense is $56,502 related to the Note and $60,756 related to the Loan. 


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Upon completion of the 2019 Rights Offering, the exercise price for the share purchase warrants issued to Dr. Yap was adjusted from $0.69 per share to $0.45 per share.  The Company recorded $85,421 as a warrant valuation adjustment for the first quarter of fiscal 2020.

11. Key management compensation

Key management includes the Company's CEO.  Remuneration of directors and key management personnel comprises:

    2020
$
    2019
$
 
             
Short-term benefits   162,159     94,526  
Option-based awards   14,534     4,162  
             
    176,693     98,688  

Short-term benefits comprise salaries, director fees and employment benefits.

Option-based awards represent the cost to the group of senior management and directors' participation in the incentive stock option plan, as measured by the fair value of instruments granted accounted for in accordance with IFRS 2, Share-based Payment.  For details of these plans refer to note 6 to these condensed consolidated interim financial statements.

12. Financial instruments

Credit risk

The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable.  The Company's cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks.  The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks.

Interest rate risk

All of the Company's financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, short-term deposits that earn interest at fixed interest rates, and the Loan to Merit Foods that bears interest at a fixed interest rate.  Burcon's cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk.  For the three months ended June 30, 2020, the weighted average interest rate earned on the Company's cash and cash equivalents was 0.21% per annum (2019 - 1.82% per annum).  The impact of a 1% strengthening or weakening of interest rates on the Company's cash and cash equivalents at June 30, 2020 is estimated to be a $131,000 increase or decrease in interest income per year.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Liquidity risk

The Company manages liquidity risk through the management of its capital structure (note 13). It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations. The Company's estimated minimum contractual undiscounted cash flow requirement for its financial liabilities at June 30, 2020 is $9,871,022, of which $1,271,645 is within the next 12 months. 

Fair value

The fair value of the Company's short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and accrued interest approximates their carrying values due to the short-term maturities of these financial instruments.

The fair value of the Merit loan approximates the carrying value as at June 30, 2020 given the risk profile of Merit Foods has not changed substantially since the issue date of the Merit loan.

The carrying values and fair values of financial instruments, by class, are as follows as at June 30, 2020 and March 31, 2020: 

 
As at June 30, 2020
                       
    At fair value
through
profit or loss
    Financial
assets at
amortized
cost
    Financial
liabilities at
amortized
cost
    Fair value  
Financial assets   $     $     $     $  
Cash and cash equivalents   -     6,623,340     -     6,623,340  
Restricted cash   -     6,500,000     -     6,500,000  
Amounts receivable
Loan to Merit Foods
  -
-
    306,862
2,733,639
    -
-
    306,862
2,733,639
 
Total   -     16,163,841     -     16,163,841  
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     954,417     954,417  
Accrued interest   -     -     41,650     41,650  
Deferred revenue   -     -     275,578     275,578  
Lease liability   -     -     59,377     59,377  
Convertible debentures   -     -     6,222,911     6,222,911  
Total   -     -     7,553,933     7,553,933  


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)


As at March 31, 2020                         
                         
    At fair value
through profit
or loss
    Financial
assets at
amortized
cost
    Financial
liabilities at
amortized
cost
    Fair value  
Financial assets   $     $     $     $  
Cash and cash equivalents   -     15,030,988     -     15,030,988  
Amounts receivable   -     332,248     -     332,248  
Loan to Merit Foods   -     2,659,830     -     2,659,830  
Total   -     18,023,066     -     18,023,066  
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,067,251     1,067,251  
Accrued interest   -     -     249,310     249,310  
Deferred revenue   -     -     275,578     275,578  
Convertible debentures   -     -     6,731,350     6,731,350  
Total   -     -     8,323,489     8,323,489  
                         

Currency risk

In June 2020, the Company entered into certain forward U.S. dollar purchase contracts to hedge its estimated exposure to currency fluctuations for its U.S. denominated liabilities.  As at June 30, 2020 and March 31, 2020, the Company is exposed to currency risk for the following assets and liabilities denominated in U.S. dollars:

    June 30, 2020     March 31, 2020  
U.S. Dollars             
Cash and cash equivalents $ 19,113   $ 21,819  
Amounts receivable   6,144     2,528  
Accounts payable and accrued liabilities   (374 )   (40,556 )
Net exposure $ 24,883   $ (16,209 )
             
Canadian dollar equivalent  $ 33,910   $ (22,996 )


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Based on the above net exposure at June 30, 2020, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $3,000 (March 31, 2020 - $2,000) in the Company's loss from operations.

13. Capital disclosures

The Company considers its capital to be its shareholders' equity.

The Company manages its capital structure to have sufficient resources available to meet day-to-day operating requirements, continue as a going concern and fund its research and development program.  The Company is dependent on non-operating sources of cash, primarily from issuing equity and debt, to fund its operations and research development programs.  The Company monitors its capital and the expected cash flows required to achieve its business objectives to determine its future financing needs. It seeks additional capital when deemed appropriate, but there is no assurance that it will be able to secure the necessary capital when required. 

The Company is not subject to externally imposed capital requirements and there has been no change with respect to the overall capital risk management strategy during the three months ended June 30, 2020.

14. Subsequent events

Subsequent to June 30, 2020:

a) An aggregate of $644,500 in principal amount of convertible debentures were converted for 613,808 common shares;

b) Warrants were exercised for 79,500 common shares at $2.00 per share.

c) Burcon and ADM terminated the Soy Agreement, effective August 7, 2020.

 



MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

 

(All amounts following are expressed in Canadian dollars unless otherwise indicated.)

This Management's Discussion and Analysis ("MD&A") has been prepared as at August 14, 2020 to provide a meaningful understanding of Burcon NutraScience Corporation's ("Burcon" or the "Company") operations, performance, and financial condition for the three months ended June 30, 2020.  The following information should be read in conjunction with the Company's unaudited condensed consolidated interim financial statements and accompanying notes for the periods ended June 30, 2020 and 2019, which are prepared in accordance with International Accounting Standards (IAS) 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB), as well as the audited consolidated annual financial statements for the year ended March 31, 2020.  We have prepared this MD&A with reference to National Instrument 51-102 "Continuous Disclosure Obligations" of the Canadian Securities Administrators.  Additional information relating to Burcon, including the Company's Annual Information Form ("AIF"), is available on SEDAR at www.sedar.com

FORWARD-LOOKING STATEMENTS

This MD&A contains certain "forward-looking statements" and "forward-looking information" as defined under applicable Canadian and U.S. securities laws (collectively, "forward-looking statements").  All statements, other than statements of historical fact, are forward-looking statements.  When used in this MD&A the words "estimate", "project", "believe", "anticipate", "intend", "expect", "plan", "predict", "may", "should", "will", or the negatives of these words or other variations thereof and comparable terminology are intended to identify forward-looking statements.  The forward-looking statements pertain to, among other things:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

The forward-looking statements are based on a number of key expectations and assumptions made by management of the Company, including, but not limited to:

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on such forward-looking statements.  The forward-looking statements reflect the Company's current views with respect to future events based on currently available information and are inherently subject to risks and uncertainties.  Many factors, both known and unknown could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements contained in this MD&A, including, but not limited to:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected.  The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Although the Company has attempted to identify important factors that could cause actual results to differ materially from forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated, described or intended.  The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect changes in assumptions or the occurrence of anticipated or unanticipated events, except as required by law.

The Company qualifies all the forward-looking statements contained in this MD&A by the foregoing cautionary statements.

OVERVIEW OF THE COMPANY AND ITS BUSINESS

Since 1999, Burcon has developed an extensive portfolio of composition, application, and process patents originating from our core protein extraction and purification technology.  Our technology cover novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation ("Merit Foods") was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a commercial production facility in Manitoba, Canada where it will produce, under license, Burcon's novel pea and canola protein ingredients.  Our environmentally friendly and sustainable technologies have been developed at our own research facility led by our team of highly specialized scientists and engineers.  Our patent portfolio currently consists of 287 issued patents worldwide, including 70 issued U.S. patents, and in excess of 250 additional patent applications, 43 of which are U.S. patent applications.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

NEW PROTEIN BLENDS

On May 23, 2019, Burcon introduced its new pea protein and canola protein blends:  Nutratein-PS and Nutratein-TZ.  These new protein blends have exceptional functional characteristics, low allergenicity, and a nutritional value that exceed those of the standard pea proteins available on the market today.

Canola is grown for its highly prized oil, with heart-healthy properties and renowned culinary qualities.  Up until now, after the pressing the oil from canola, the residual meal has predominantly been sold as animal feed.  Burcon's technology unlocks the protein from canola meal for human consumption in the form of highly purified protein ingredients with exceptional functional properties and unique nutritional value.  Burcon extracts and purifies two distinctly different canola protein fractions branded under the names Puratein® and Supertein®, both of which achieved US self-affirmed GRAS ("Generally Recognized As Safe") status in 2008, and the US Food and Drug Administration ("US-FDA") formally acknowledged receipt of Burcon's GRAS notification for Puratein® and Supertein® in 2010.

Field peas offer important advantages to consumers, and to farmers as their production is environmentally friendly while being a good source of protein, with numerous applications in dairy-free foods, vegetarian foods, meat analogues, sports and slimming foods, senior nutrition and clinical nutrition products.  Burcon's Peazazz® pea protein has exceptionally clean flavour characteristics and is well-suited for use in beverages, dairy alternative products, meal replacements and meat analogues, as well as a variety of other healthy and great tasting food and beverage product applications.  Burcon successfully obtained self-affirmed GRAS status for its Peazazz® and Peazac® pea protein products in 2017 and the US-FDA formally acknowledged receipt of Burcon's GRAS notification for Peazazz® and Peazac® in October 2019.

While pea is a good source of protein, its nutritional value falls below that of animal protein such as dairy protein or egg protein, due to its low levels of the amino acids, methionine, and cysteine.  In contrast, Burcon's canola protein is uniquely rich in these same amino acids.  By blending Burcon's pea and canola proteins, Burcon can offer plant protein ingredients with a nutritional value equaling or exceeding that of animal proteins like dairy and egg. 

The method accepted by the US-FDA, Food and Agriculture Organization and the World Health Organization for evaluating the nutritional qualify of a protein is referred to the Protein Digestibility Corrected Amino Acid Score ("PDCAAS"), with the highest possible score being 1.0.  The protein in cow's milk and eggs are examples of proteins with a PDCAAS of 1.0.  Peas have a PDCAAS score of less than 0.8; however, Burcon's blends of pea and canola protein have PDCAAS of 1.0, equaling the gold standard of dairy protein.

Burcon's blend of its Peazazz® pea protein and Supertein® canola protein, branded as Nutratein-PS, has a clean flavour profile with high solubility, making it suitable for fortifying dairy-alternative beverages such as almond milk, or to formulate a stand-alone beverage with a nutritional value consistent with cow's milk.  Burcon's blend of its Peazac® pea protein, and Supertein® canola protein, has been branded Nutratein-TZ, which has functional properties that are ideally suited in the formulation of plant-based meat products such as veggie burgers, or veggie sausages.  Both Nutratein products are over 90% pure protein.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

MERIT FUNCTIONAL FOODS CORPORATION

On May 23, 2019, Burcon, through its newly-formed wholly-owned subsidiary, Burcon NutraScience Holdings Corp. ("Burcon Holdings"), entered into a shareholders agreement (the "Shareholders Agreement") with RBT Holdco Ltd. ("RBT Holdco") and 10039406 Manitoba Ltd. ("Crew Holdco") (RBT Holdco and Crew Holdco together referred to as the "Partners") to become shareholders of Merit Functional Foods Corporation ("Merit Foods").  The business of Merit Foods is the commercial production, sales, marketing and distribution worldwide of Burcon's pea protein, pulse protein and canola protein products.  Merit Foods is currently building and commissioning an initial protein production facility (the "Flex Production Facility") in Western Canada. 

Burcon Holdings holds 40%, RBT Holdco holds 40% and Crew Holdco holds 20% of the issued and outstanding shares of Merit Foods.  Each of Ryan Bracken and Barry Tomiski (and their respective family) beneficially owns a 50% interest in RBT Holdco.  Crew Holdco is wholly owned by Shaun Crew and his family.  Messrs. Bracken, Tomiski and Crew are veterans of the agri-foods industry, most notably demonstrated by the rapid growth and successful sale of Hemp Oil Canada Inc. ("HOCI").  Originally founded by Mr. Crew in 1998, HOCI grew to become the world's largest producer and processor of bulk hemp foods products and ingredients.  Messrs. Bracken, Tomiski and Crew's association with HOCI ended with the recent acquisition of FHF Holdings Ltd. (the parent company of Manitoba Harvest Hemp Foods including HOCI) by Tilray Inc. 

Under the Shareholders Agreement, Burcon Holdings may agree to provide additional capital to Merit Foods, either as an equity contribution or as a shareholder loan, to finance budget increases and/or scope changes in the development, construction and commission of the Flex Production Facility, but is not obligated to do so.  Burcon Holdings may agree to provide additional support to Merit Foods in connection with such financing.  Support may come in the form of additional capital contributions by way of a further equity contribution or as a shareholder loan, a limited recourse guarantee or otherwise. 

On May 23, 2019, Burcon entered into a license and production agreement (the "License Agreement') with Merit Foods to license the technology required to produce, market and sell Burcon's pulse protein ingredients, including Peazazz® and Peazac® pea proteins and Burcon's canola proteins, Supertein®, Puratein® and Nutratein® (collectively the "Products").  Under the terms of the License Agreement, Merit Foods has the exclusive rights over Burcon's pulse proteins (including pea) and canola protein technologies across all geographic regions and all product uses (the "License").  Burcon will receive running royalties on the net revenue (as defined in the License Agreement) from the sales of the Products by Merit Foods.  Burcon will be responsible for the technology transfer to Merit Foods and is also providing assistance, under a services agreement, to support the design, construction and commissioning of the commercial protein production facility.

Under the License Agreement, Merit Foods is to develop, build and commission an initial production facility in Western Canada within a specified amount of time to manufacture the Products.  Merit Foods will also, within a specified time period, provide written notice to Burcon to advise whether it will or will not increase its annual production capacity of the Products to develop, build and commission a full commercial scale production facility (the "Full Commercial Production Facility").  If Merit Foods expands production to the Full Commercial Production Facility, the royalty rate will be reduced to a lower percentage rate.  The royalty rate may also be reduced if the exclusive license is converted to a non-exclusive license or if a certain Burcon patent does not grant within a specified time.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

The License Agreement has a term of the greater of twenty years and the last to expire of Burcon patents that are being used to produce products under the License Agreement.  The License Agreement provides Burcon with the right to convert the exclusive license to a non-exclusive license under certain conditions.  As long as the License is exclusive, Burcon is responsible for the filing, prosecution and maintenance of Burcon patent rights in certain countries. 

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement. 

In accordance with the Shareholders Agreement, Burcon Holdings and the Partners made their capital loan advances (the "Initial Capital Loan Advances") in June 2019 by way of shareholder loans to Merit Foods in the aggregate of $10.0 million.  Burcon Holdings and the Partners made further loan advances to Merit Foods in the amounts of $10.0 million in September 2019, $7.5 million in December 2019 and $5.0 million in February 2020 (the "Additional Capital Loan Advances") (the Initial Capital Loan Advances and the Additional Capital Loan Advances, together referred to as the "Merit Shareholder Loans").  To-date, all the shareholders of Merit Foods have contributed an aggregate of $32.5 million into Merit Foods.

As at June 30, 2020, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans. 

(in thousands of dollars):

    Investment in
Share capital

    Capital
Contribution

    Loan receivable
    Total net
investment

 
                         
At inception to December 31, 2019   -     -     11,000     11,000  
Modification to loan terms   -     8,872     (8,872 )   -  
Capital loan advance, February 2020   -     1,613     387     2,000  
Share of loss in Merit foods   -     (940 )   -     (940 )
Interest accretion   -     -     145     145  
                         
Net Investment in Merit Foods, March 31, 2020   -     9,545     2,660     12,205  
Share of loss in Merit foods   -     (382 )   -     (382 )
Interest accretion   -     -     73     73  
                         
Net Investment in Merit Foods, June 30, 2020   -     9,163     2,733     11,896  

On inception, the Merit Shareholder Loans were recorded as a loan receivable.  In December 2019, the terms of the Merit Shareholder Loans were finalized.  They are non-interest bearing, unsecured, subordinated to Merit Foods' other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder's loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts.  As a result, Burcon recalculated the fair value at this date, resulting in a reduction of the fair value was been transferred to a capital contribution account.  Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest.  For the three months ended June 30, 2020, Burcon has recorded interest accretion of $73,810 (2019 - $nil).


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

During the second fiscal quarter of fiscal 2020, Merit Foods completed the purchase of the land, on which the Flex Production Facility is being constructed.  In May 2020, Merit Foods announced that it is expanding the production capacity of the Flex Production Facility currently under construction in Winnipeg, Manitoba.  The design changes of the facility will facilitate future production capacity expansions and the larger footprint of the Flex Production Facility will enable Merit Foods to economically scale the throughput as compared to the initial capacity.  Merit Foods is building a 94,000 square foot production facility to produce the Products and the Flex Production Facility is expected to be completed in the fourth calendar quarter of 2020.  Merit Foods believes it will be the only commercial facility in the world with the capability to produce food grade non-GMO canola proteins. 

On January 10, 2020, Merit Foods announced it has received a co-investment from Protein Industries Canada ("PIC") to help facilitate the rapid growth of Merit Foods.  PIC is an industry-led, not-for-profit organization committed to positioning Canada as a global source of high-quality plant protein ingredients.  It is one of Canada's five innovation superclusters, which are government-initiated efforts to significantly boost Canada's job market, GDP, research and innovations.

In May 2020, Burcon announced that Merit Foods has secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada ("EDC"), Farm Credit Canada ("FCC") and the Canadian Imperial Bank of Commerce.  Merit Foods' shareholders, including Burcon Holdings, were required to pledge their shares in Merit Foods as security under the loan facilities from EDC.  In connection with the loan facilities from EDC, Merit Foods must fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility.  $6.5 million of this amount is permitted to be funded by way of a letter of credit ("LC").  To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada ("HSBC") in April 2020, which is secured by a term deposit with HSBC in the same amount.  In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the "Merit Loan Agreement") with Merit Foods in the amount of $6.5 million (the "Merit Loan").  The Merit Loan and the commitment by Burcon Holdings to maintain the LC will terminate no later than September 30, 2020, unless extended by mutual agreement.  The Merit Loan bears interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term.  Under the Merit Loan Agreement, Burcon Holdings has the option to contribute the amount of the Merit Loan as a capital contribution to Merit Foods in certain circumstances including if the other shareholders of Merit Foods are unable to deliver a letter of credit in favour of EDC for their entire pro rata share of the LC amount by September 30, 2020.  If EDC draws on the LC prior to September 30, 2020 and each of the other shareholders of Merit Foods are unable to reimburse Burcon Holdings for such other shareholder's entire pro rata share of the amount of such draw within the time period set out in the Merit Loan Agreement, then the draw amount will be deemed a capital contribution by Burcon Holdings and Burcon Holding's shareholding interest in Merit Foods will be increased. 

In addition, Burcon has provided a guarantee in favour of EDC's senior loan facility and subordinate loan facility to Merit Foods (the "Guarantees"), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC and Merit Foods.  The aggregate maximum liability of Burcon under the Guarantees is limited to $4.0 million.  The Guarantees contain provisions dealing with when Burcon's guarantee may be reduced in the event that Merit Foods is able to obtain certain other government sources of funding, subject to certain conditions being met. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

In June 2020, Burcon announced that Merit Foods has secured additional debt financing of $10 million in the form of a 10-year interest-free loan from Agriculture and Agri-Food Canada's Agrilnnovate Program ("AIP").  Merit has now secured a total of $99.2 million financing package from the Government of Canada that includes the financing noted above from EDC, FCC, AIP and PIC.  It is expected that Burcon's portion of the Guarantees will be released in stages over time as Merit Foods draws down on the $10 million AIP Loan.

Burcon Holdings and the other Merit Foods shareholders have also provided a guarantee for the AIP Loan (the "AIP Guarantee").  The obligations of the AIP Guarantee are joint and several.  However, Burcon Holdings and the other Merit Foods shareholders (the "AIP Guarantors") have entered into a reciprocal indemnity agreement (the "Indemnity Agreement').  Under the Indemnity Agreement, if any AIP Guarantor (each, a "Paying Guarantor") is required to make payment under the AIP Guarantee and any other AIP Guarantor (each, a "Contributing Guarantor") has not made a corresponding payment equal to its share based on its shareholdings in Merit Foods ("Contributive Share"), such Contributing Guarantor(s) shall pay the Paying Guarantor such amounts so that, after payment, all obligations and liabilities under the AIP Guarantee will have been borne by the AIP Guarantors in their respective shareholding percentage in Merit Foods.

As noted above, Burcon has a 40% investment in Merit Functional Foods Corporation.  There is no contingent issuance of securities by the equity investee that might significantly affect Burcon's share of profit or loss.  The following is the summarized financial information of the investee:

Summary financial information of Merit Foods

(Unaudited, in thousands of dollars)

    June 30, 2020     March 31, 2020  
             
Total assets   78,249     41,885  
Total liabilities   55,343     18,024  

    Three months ended
June 30, 2020
    Period ended
June 30, 20191 
 
             
Total revenue   539     -  
Loss and comprehensive loss for the period   (955 )   (117 )

Merit Foods has placed purchase orders for long lead-time processing equipment that will be incorporated into the Flex Production Facility and initiated collaboration discussions with several strategic food and beverage companies.  In addition, Merit Foods has added key hires and is well into the process of building out its management team.  Merit's management, together with Burcon's technical and engineering team in Winnipeg, plus third-party engineers and consultants, are working on the development of the Flex Production Facility.

______________________________________
1Merit Foods was incorporated on May 15, 2019.  As a result, information in this table represents certain financial information of Merit Foods from the date of its incorporation to June 30, 2019.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

NESTLE COLLABORATION

On January 24, 2020, the Company announced that Burcon, Nestlé and Merit Foods have entered into a joint development agreement to tailor Burcon and Merit's plant-based proteins for use in Nestlé food and beverage applications.  The joint agreement commences what is intended to be a long-term relationship among the parties covering ongoing innovation and the future supply of Burcon and Merit's plant-based proteins from the Flex Production Facility.  The partnership combines Nestlé's expertise in the development, production and commercialization of plant-based foods and beverages with Burcon's proprietary plant protein extraction and purification technology, while leveraging Merit Foods' plant protein production capabilities.  The aim of the joint development is to tailor the functionality of Burcon and Merit's plant proteins, to be supplied from Merit's Flex Production Facility, for use by Nestlé in plant-based meat and dairy alternatives.  The Winnipeg Technical Centre has been working with Nestlé's scientists and food developers to tailor Burcon's pea and canola proteins for product development.

CONVERTIBLE DEBENTURES

On December 10, 2019, the Company issued convertible debentures (the "Debentures") through a non-brokered private placement for an aggregate principal amount of $9.5 million.  Certain directors and an officer of the Company subscribed for Debentures totaling $2 million in principal amount.  Each Debenture consists of $1,000 principal amount, bears interest at a rate of 8.5% per annum, payable semi-annually in arrears and be unsecured.  The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon will be payable in cash on December 10, 2022.  The Debentures will be convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share.  Burcon will have the right, at its sole discretion, to force the conversion of the Debentures if the shares trade at or above $2.15 for a period of 14 consecutive trading days.  The Company incurred issue costs of $228,432, of which $156,600 were finder's fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders. 

The Debentures are a level 3 financial liability with an embedded conversion feature.  As a result, the debt and equity components were bifurcated and the instrument valued to par at the issuance date.  The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option.  From the date of issuance, the liability component is accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive loss.  The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641.  The residual amount of $2,762,927 was recognized within equity as the value of the conversion option.  For the three months ended June 30, 2020, the Company recorded interest expense of $375,324 (2019 - $nil).

For the three months ended June 30, 2020, an aggregate of $960,000 in principal amount of Debentures was converted for 914,283 common shares.  Subsequent to the quarter-end, an additional $644,500 in principal amount of Debentures were converted for 613,808 common shares.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

The Company utilized a portion of the net proceeds from the Debentures to make further Additional Capital Loan Advances to Merit Foods of $3.0 million in December 2019 and $2.0 million in February 2020.

EQUITY OFFERING

On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the "Units") at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the "Offering") and net proceeds of $10.3 million.

Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant").  Each Warrant is exercisable to acquire one common share (a "Warrant Share") until February 19, 2022 at an exercise price of $2.00 per Warrant Share.  The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model and has been included in Warrants.  All Warrants were outstanding as at March 31, 2020.  Subsequent to the quarter-end, Warrants were exercised for 79,500 common shares.

The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents' Warrants) entitling the agents to purchase up to 519,386 common shares.  Each Agent's Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022.  The fair value of the Agents' Warrants was estimated at $249,305 using the Black-Scholes pricing model and has been included in Warrants.  All Agents' Warrants were outstanding as at  June 30, 2020.

In addition to the Agents' Warrants, the Company incurred total issue costs of $1.2 million related to the Offering.

The Company is using the net proceeds of the Offering and the balance of the net proceeds from the Debentures for further development of its extraction and purification technologies and pursue new related products, pursue and develop new applications from functional attributes of Burcon's proteins and carry out research on protein extraction from various plant sources.  Burcon will also continue work to tailor its plant-based proteins for use in Nestlé food and beverage applications.  Burcon also intends to use the net proceeds to maintain, further strengthen and expand the Company's intellectual property portfolio.  Burcon is obligated to prosecute and maintain its pea and canola patent portfolios under its License Agreement with Merit foods.  Additionally, Burcon intends to continue to file additional patent applications to protect discoveries arising from its research and development activities.  Burcon also intends to use the net proceeds for expansion initiatives and to provide for general working capital.   

RIGHTS OFFERINGS

2019 Rights Offering

On June 25, 2019, the Company completed a rights offering (the "2019 Rights Offering") for 44,083,203 common shares at $0.35 per common share for gross proceeds of $15,429,121 and net proceeds of $15.3 million.  Burcon issued to each shareholder as of the record date of May 30, 2019 one transferrable right (the "2019 Rights") for each common share held by such shareholder.  Every 2019 Right entitled the holder thereof to purchase one common share in the Company at a price of $0.35 per common share. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

The Company's directors, officers and persons controlling over 10% of the common shares of the Company, (collectively, the "Insiders") agreed to exercise at least all of the 2019 Rights they were issued in connection with the 2019 Rights Offering for 14,306,740 common shares, representing 32.5% of the 2019 Rights Offering.

Of the net proceeds of the 2019 Rights Offering, $2,565,022 has been used to repay the convertible note and accrued interest to Large Scale and $1,607,183 has been used to repay the Loan and accrued interest to Large Scale.  Burcon also made its Initial Capital Loan Advance of $4.0 million to Merit Foods in June 2019 and its Additional Capital Loan Advance of $4.0 million to Merit Foods in September 2019.

2018 Rights Offering

On February 13, 2018, the Company completed a rights offering (the "2018 Rights Offering") for 6,114,361 common shares at $0.57 per common share for gross proceeds of $3,485,186, and net proceeds of $3.4 million.  As consideration for providing a standby guarantee to purchase such common shares that were available to be purchased that would have resulted in a minimum of 4,728,397 common shares being issued under the 2018 Rights Offering, Dr. Allan Yap ("Dr. Yap"), the Company's former Chairman and Chief Executive Officer, received share purchase warrants ("Standby Warrants") to acquire up to 1,182,099 common shares at an exercise price of $0.69 per common share that were exercisable up to February 13, 2020.  Pursuant to the terms of the Standby Warrants, the exercise price was adjusted upon completion of the 2019 Rights Offering from $0.69 per share to $0.45 per share.  Burcon recorded a warrant valuation adjustment of $85,421 during the first quarter of fiscal 2020.  The Standby Warrants were fully exercised during fiscal 2020.

CONVERTIBLE NOTE

The Company had a convertible note (the "Note") with Large Scale Investments Limited ("Large Scale'), a wholly owned subsidiary of Firewood Elite Limited ("Firewood"), for the principal amount of $2.0 million (the "Principal Amount").  Firewood, through its shareholdings in Large Scale and Great Intelligence Limited ("Great Intelligence"), has significant influence over the Company, and is wholly owned by Mr. Alan Chan, a director of the Company.

The Note bore interest at 8% per annum, compounded monthly.  The Principal Amount and accrued interest were payable on the earlier of May 12, 2019, the occurrence of an event of default as set out in the Note (the "Maturity Date"), or voluntary prepayment by the Company.  Under the Note, Large Scale could convert the Principal Amount in whole or in part at $4.01 per share into common shares of the Company commencing on or after July 1, 2016 and up to and including the Maturity Date.  Pursuant to the terms of the Note, the conversion price was adjusted upon completion of Burcon's rights offering that completed in 2016 to $3.99 per share and further adjusted upon the completion of Burcon's 2018 Rights Offering to $3.94 per share. 

Burcon had the right, before the Maturity Date, upon written notice to Large Scale of not less than thirty days, to prepay in cash all or any portion of the Principal Amount by paying to Large Scale an amount equal to the Principal Amount to be prepaid multiplied by 110%.  The payment of the Principal Amount and all accrued and unpaid interest thereon would be subordinated in right of payment to any amount owing in respect of secured indebtedness of the Company.   

On May 21, 2019, the Company and Large Scale amended (the "Amendment") the Note's Maturity Date to June 21, 2019.  The Amendment also provided Large Scale with the right to offset any amounts due to it under the Note against any obligations of Large Scale to pay for subscription proceeds of any rights offering that Burcon may conduct.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

In connection with the 2019 Rights Offering, Large Scale exercised its right to offset the amounts due under the Note against its obligations to pay for subscription proceeds under the 2019 Rights Offering.  The offset was completed on June 25, 2019.  The total amount offset under the Note included the principal amount and accrued interest of $2,565,022.

The conversion option was recorded as a derivative liability.  Under the terms of the Note, there are certain conditions where the conversion price may be adjusted.  Therefore, in accordance with International Financial Reporting Standards ("IFRS"), an obligation to issue shares for a price that is not fixed must be classified as a derivative liability and measured at fair value, with changes recognized in change in fair value of conversion option in the consolidated statement of operations and comprehensive loss.

The conversion and prepayment options were recorded as a net derivative liability and measured at fair value, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss.  The fair value of the conversion and prepayment options was estimated based on a methodology for pricing convertible bonds using the Partial Differential Equation Method, with the following initial assumptions:  expected volatility of 63%; expected dividend per share of nil; risk-free rate of 0.60%, entity-specific credit spread, and expected life of 3 years.  The assumptions as at March 31, 2019 were as follows:  expected volatility of 99%, expected dividend per share of nil; risk-free rate of 1.63%, initial entity-specific credit spread adjusted by the movement in the option adjusted spread of the Canada High Yield Index, and expected life of 1.1 years.  The initial fair value of the net derivative liability was estimated as $189,705 as at the issue date of the Note.  As at March 31, 2019, the fair value of the net derivative liability was estimated to be $5,384.  Upon the offset by Large Scale of its obligations to pay for subscription proceeds under the 2019 Rights Offering, the net derivative liability was expensed as financing expense during the first quarter of fiscal 2020.

SHORT-TERM LOAN

On November 13, 2018, the Company entered into a loan agreement with Large Scale to provide Burcon with an unsecured loan for up to $1.0 million (the "Short-term Loan").  On March 27, 2019, Burcon and Large Scale amended the loan (the "Loan Amendment") to increase the principal amount available to $1.5 million.  The Loan Amendment provided the Lender with the right to offset any amount due to it under the Note against any obligations of the Lender to pay for subscription proceeds of any rights offering that Burcon may conduct.  During the three months ended June 30, 2019, the Company drew down $250,000 to the maximum principal amount available under the Loan. 

The Short-term Loan bore interest at 18% per annum on the amount drawn, and 3% per annum on the undrawn portion.  Burcon paid Large Scale a commitment fee of 1%, or $15,000, on the principal amount available under the Short-term Loan.  The amounts drawn on the Short-term Loan and the accrued interest was payable on the earlier of June 3, 2019, the occurrence of an event of default as set out in the Short-term Loan, or voluntary prepayment by the Company.   

In connection with the 2019 Rights Offering, Large Scale exercised its right to offset the amounts due under the Short-term Loan against its obligations to pay for subscription proceeds under the 2019 Rights Offering.  The offset was completed on June 25, 2019 for $1,436,629 against the principal amount.  The balance of the balance of the principal amount of $63,371and accrued interest of $107,173 was repaid to Large Scale in cash on June 28, 2019.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

COVID-19

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  To-date, the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations or Merit Foods' construction progress.

NEW DIRECTOR APPOINTMENTS

On July 6, 2020, Burcon appointed Ms. Debora Fang as a director to its board of directors.  Ms. Fang has 20 years' of experience in the consumer goods industry, across mergers and acquisitions, strategy, and marketing roles for Unilver (London, UK), Danone (Paris, France and Amsterdam, Netherlands), Kraft Foods (Sao Paulo, Brazil) and as a consultant for Bain & Company (Los Angeles, USA).  She is now an independent advisor for private equity and strategic clients in the food arena as well as a private investor.

In July 2019, Burcon appointed Mr. Calvin Chi Leung Ng as a director to its board of directors.  Mr. Ng is a director or Large Scale and Great Intelligence.  Mr. Ng is the group legal counsel for ITC Properties Limited, a real estate property development and investment company.  Mr. Ng has over 20 years' experience of advising on and executing corporate and commercial transactions in law firms and private sectors. 

CLARISOY®

Burcon had entered into a license and production agreement (the "Soy Agreement") on March 4, 2011 with Archer Daniels Midland Company ("ADM") to license its CLARISOY® technology to ADM on an exclusive basis to produce market and sell CLARISOY® soy protein worldwide.  Subsequent to the quarter-end, Burcon announced that it and ADM have agreed to terminate the Soy Agreement, effective August 7, 2020.  As part of the agreement to terminate the exclusive license, the CLARISOY trademark reverted back to Burcon on the effective date.  In addition, Burcon and ADM are discussing opportunities for Burcon to acquire certain processing equipment for ADM's CLARISOY® processing facility. 

Burcon has not received any significant royalty revenues from ADM's sales of CLARISOY®.  For the three months June 30, 2020, Burcon recorded royalty revenues of $8,515 (2019 - $15,636). 

Burcon will provide additional updates on its plans for CLARISOY® in the future.

Other

During fiscal 2018, Burcon applied for accreditation from Health Canada's Office of Controlled Substances to conduct research for the future commercial production of purified cannabinoid extracts.  Burcon subsequently modified its intentions regarding potential cannabis research opportunities to focus instead on cannabis protein extraction and intends to pursue partnering opportunities with growers and suppliers of hemp and cannabis input materials accordingly.  The Company was issued a research license under the Cannabis Act by Health Canada in June 2019.  Given its focus on other business initiatives, Burcon does not plan to conduct research in cannabinoid extracts this fiscal year.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

Burcon continued work to further the development of a new plant-based protein process, as well as limited research work on protein extraction from various plant sources to explore potential new commercial and patenting opportunities.  Burcon's extraction and purification technologies are versatile and may be adapted to process a range of oilseed and non-oilseed meals to produce specialty proteins, such as flax and hemp.  The demand for plant-based proteins continues to grow and Burcon believes there may be niche market opportunities for its specialty protein ingredients. 

INTELLECTUAL PROPERTY

Burcon's patent strategy is to seek protection for new technologies as well as further protecting current technologies.  Over the years, Burcon has filed patent applications in various countries over its inventions.  Burcon's patent applications can be grouped into three categories:

Burcon continued the maintenance and prosecution of its patent applications during the quarter ended June 30, 2020. 

Burcon currently holds 70 U.S. issued patents over its canola, soy, pea and flax protein processing technologies and canola and soy protein isolate applications, as well as canola and soy patents covering composition of matter.  In addition, Burcon has a further 43 patent applications currently filed with the U.S. Patent and Trademark Office.

As of the date of this MD&A, Burcon's patents and patent applications cover over 50 distinct inventions.  Burcon has also filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  Together with patents issued in other countries, Burcon now holds a total of 287 issued patents covering inventions that include the 70 granted U.S. patents.  Currently, Burcon has over 250 additional patent applications that are being reviewed by the respective patent offices in various countries.

RESULTS OF OPERATIONS

As at June 30, 2020, Burcon has not yet generated any significant revenues from its technology.  For the three months ended June 30, 2020, the Company recorded a loss of $1,400,700 ($0.01 per share), as compared to $1,331,980 ($0.03 per share) for the same period last year.  Included in the loss amounts are the following non-cash items:  interest accretion of $73,810 (2019 - $nil), stock-based compensation expense of $63,790 (2019 - $35,080), interest expense of $182,969 (2019 - $nil), share of loss in Merit Foods of $382,176 (2019 - $46,762), amortization of property and equipment of $22,145 (2019 - $14,543), unrealized foreign exchange loss of $1,068 (2019 - $98), warrant valuation adjustment of $nil (2019 - $85,421), and change in fair value of convertible note derivative liability of $nil (2019 - $5,384). 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

The following provides a comparative analysis of significant changes in major expenditures items.

Research and development expenses

Components of research and development ("R&D") expenditures are as follows:

(in thousands of dollars) 

    2020     2019  
Salaries and benefits   88     250  
Laboratory operation   6     57  
Rent   5     19  
Amortization of property and equipment   2     13  
Analyses and testing   -     13  
Travel and meals   -     4  
    101     356  

Effective July 1, 2019, the Company determined that it had met all the criteria of deferring development costs ("DDC") with respect to its pea and canola proteins and has been deferring its expenditures relating to pea and canola to deferred development costs.  For the three months ended June 30, 2020, Burcon  deferred approximately $275,000 of R&D costs.  Under the Services Agreement with Merit Foods, Burcon also has been producing inventory saleable to Merit Foods' potential customers for product evaluation.  This has contributed to about $153,000 R&D costs that have been allocated to inventory production.  Before the cost deferral and allocation to inventory production, total R&D costs increased by about $128,000.  The increase is due primarily to increases in salaries and benefits. 

Intellectual property expenses

(in thousands of dollars)

    2020     2019  
Patent fees and expenses   139     360  
Trademark    -     1  
    139     361  

As noted in the R&D section, the Company began deferring costs related to its pea and canola technology in the second quarter of fiscal y2020 including related patent fees and expenses.  During the three months ended June 30, 2020, Burcon deferred about $232,000 of patent fees and expenses for its pea and canola patent portfolio to deferred development costs.  Before the cost deferral, patent fees and expenses remained relatively unchanged from the same quarter last year. 

Burcon's patent strategy is to seek protection for new technologies as well as further protecting current technologies.  Over the years, Burcon believes it has developed a dynamic and extensive patent portfolio and has filed patent applications in various countries over its inventions.  From inception, Burcon has expended $20.1 million on patent legal fees and disbursements to strengthen its patent portfolio in various countries of the world and file patent applications for new inventions.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

General and administrative ("G&A") expenses

(in thousands of dollars) 

    2020     2019  
Salaries and benefits   460     226  
Professional fees   92     67  
Office supplies and services   43     41  
Investor relations   35     22  
Other   13     20  
Financing expense   10     3  
Transfer agent and filing fees   4     3  
Travel and meals   -     15  
    657     397  

Salaries and benefits

Included in salaries and benefits is stock-based compensation expense of approximately $49,000 (2019 -$16,000).  The higher expense incurred in the current quarter of last year is due to options granted in the fourth quarter of fiscal 2020 that had a higher valuation.

The cash portion of salaries and benefits increased by $200,000.  The increase is due mainly to bonuses of $130,000 approved during the quarter for fiscal 2020, and salary increases effected at the beginning of this quarter.  Directors' fees also increased by $17,000, due to more meetings held this quarter, as well as  the addition of a director in July 2019.

Professional fees

Professional fees increased by about $25,000 over the same period last year.  The increase was due primarily to an increase of $51,000 in legal fees incurred for Merit Foods' financing and other matters.  The increase was offset by a decrease of $25,000 in consulting costs due to the write-off during the first quarter of fiscal 2020 of engineering consulting costs incurred in previous years that have been determined not to be usable for the Flex Production Facility. 

Investor relations

Investor relations expenses increased by $13,000 over the same period last year, due mainly to higher U.S. investor relations consulting fees.

LIQUIDITY AND FINANCIAL POSITION

At June 30, 2020, the Company had cash and cash equivalents of $6.6 million.  As noted above, $6.5 million has been invested in a restricted term deposit to secure the $6.5 million LC issued in favour of the EDC.  The LC and the related security are expected to be terminated no later than September 30, 2020, unless extended by mutual agreement between Burcon Holdings and Merit Foods.  In addition, Burcon has issued a Guarantee for a maximum amount of $4.0 million in favour of EDC for its loan facilities with Merit Foods.  The Guarantee may be reduced in the event that Merit Foods is able to obtain certain other government sources of funding.  With the announcement of the $10 million AIP Loan, it is expected that Burcon's portion of the Guarantees will be released in stages over time as Merit Foods draws down on the AIP Loan.  Assuming the LC terminates by September 30, 2020, Burcon's guarantee with the EDC is released within the next 12 months and Burcon Holdings is not required to make payment under the AIP Guarantee, management estimates the cash resources to be sufficient to fund its operations to September 2022.  The estimated date excludes proceeds from outstanding convertible securities and royalty revenues from its License Agreement.  If Burcon does not receive sufficient royalties from its license agreements, Burcon will require additional capital beyond this date to meet its business objectives, although there is no assurance that additional financing will be available on acceptable terms, if at all.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

The net cash used in operations during the three months ended June 30, 2020 was $688,000, as compared to $1,719,000 last year.  The decrease in the net cash used in operations of $1,031,000 is mainly attributed to changes in non-cash working capital items that contributed to $698,000 of the decrease, higher management fee income of $104,000, interest and other income of $144,000, R&D expenses and intellectual property expenses of $595,000 that were capitalized to deferred development costs or allocated to inventory production, offset by higher R&D expenses of $79,000, G&A expenses of $162,000, intellectual property expenses of $11,000, interest expense of $258,000, and a decrease in royalty income of $7,000.   

At June 30, 2020, Burcon had working capital of $5.9 million (March 31, 2020 - $14.2 million).  As at June 30, 2020, Burcon was not committed to significant capital expenditures.  Burcon may incur up to $500,000 in additional capital expenditures if modifications or further upgrades are required to the Winnipeg Technical Centre ("WTC").  Burcon is continuing to limit the prosecution of certain patent applications and defer the maintenance fees for certain non-core patent applications.  This does not affect the strength of Burcon's patent portfolio.  Burcon expects to expend up to $1.1 million in patent expenditures for the balance of this fiscal year.  With the termination of the ADM license and production agreement, Burcon will further review its soy patent portfolio for possible reductions in patent fees and disbursements.

FINANCIAL INSTRUMENTS

The Company's financial instruments are its cash and cash equivalents, amounts receivable, loan to Merit Foods, and accounts payable and accrued liabilities, accrued interest, deferred revenue, and convertible debentures.

Credit risk

The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable.  The Company's cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks.  The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks.

Interest rate risk

All of the Company's financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, short-term deposits that earn interest at fixed interest rates, and the Loan to Merit Foods that bears interest at a fixed interest rate.  Burcon's cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk.  For the three months ended June 30, 2020, the weighted average interest rate earned on the Company's cash and cash equivalents was 0.21% per annum (2019 - 1.82% per annum).  The impact of a 1% strengthening or weakening of interest rates on the Company's cash and cash equivalents at June 30, 2020 is estimated to be a $131,000 increase or decrease in interest income per year.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

Liquidity risk

The Company manages liquidity risk through the management of its capital structure.  It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations.  The Company's estimated minimum contractual undiscounted cash flow requirements for its financial liabilities as at June 30, 2020 is $9,871,022, of which $1,271,645 is due within the next 12 months. 

Fair value

The fair value of the Company's short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and accrued interest approximates their carrying values due to the short-term maturities of these financial instruments.

The fair value of the Merit Loan approximates the carrying value as at June 30, 2020 given the risk profile of Merit Foods has not changed substantially since the issue date of the Merit Loan.

The carrying values and fair values of financial instruments, by class, are as follows as at June 30, 2020 and March 31, 2020:

(in thousands of dollars)

As at June 30, 2020                        
    At fair
value
through
profit or
loss
    Financial
assets at
amortized
cost
    Financial
liabilities at
amortized
cost
    Fair value  
                         
Financial assets                        
Cash and cash equivalents   -     6,623     -     6,623  
Restricted cash   -     6,500     -     6,500  
Amounts receivable   -     307     -     307  
Loan to Merit Foods   -     2,734     -     2,734  
Total   -     16,164     -     16,164  
                         
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     954     954  
Accrued interest   -     -     42     42  
Deferred revenue   -     -     276     276  
Lease liability   -     -     59     59  
Convertible debentures   -     -     6,223     6,223  
Total   -     -     7,554     7,554  


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019


As at March 31, 2020                        
    At fair
value
through
profit or
loss
    Financial
assets at
amortized
cost
    Financial
liabilities at
amortized
cost
    Fair value  
                         
Financial assets                        
Cash and cash equivalents   -     15,031     -     15,031  
Amounts receivable   -     332     -     332  
Loan to Merit Foods   -     2,660     -     2,660  
Total   -     18,023     -     18,023  
                         
Financial liabilities                        
Accounts payable and accrued  liabilities   -     -     1,067     1,067  
Accrued interest   -     -     249     249  
Deferred revenue   -     -     276     276  
Convertible debentures   -     -     6,731     6,731  
Total   -     -     8,323     8,323  

Currency risk

In June 2020, the Company entered into certain forward U.S. dollar purchase contracts to hedge its estimated exposure to currency fluctuations for its U.S. denominated liabilities.  As at June 30, 2020 and March 31, 2020, the Company is exposed to currency risk for the following assets and liabilities denominated in U.S. dollars:

    June 30, 2020     March 31, 2020  
U.S. Dollars (in thousands)            
Cash and cash equivalents   19     22  
Amounts receivable   6     3  
Accounts payable and accrued liabilities   -     (41 )
Net exposure   25     (16 )
             
Canadian dollar equivalent (in thousands)   34     (23 )

Based on the above net exposure at June 30, 2020, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $3,000 (March 31, 2020 - $2,000) in the Company's loss from operations.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

OUTSTANDING SHARE DATA

As at June 30, 2020, Burcon had 97,713,921 common shares outstanding, 4,507,606 stock options outstanding exercisable at a weighted average exercise price of $3.32 per share, 4,229,286 share purchase warrants that were convertible to an equal number of common shares at an exercise price of $2.00 per share, and convertible debentures that were convertible to 8,133,333 common shares. 

As at the date of this MD&A, Burcon has 98,407,229 common shares outstanding, and 4,507,606 stock options that are convertible to an equal number of shares at a weighted average exercise price of $3.32 per share, 4,149,786 share purchase warrants that are convertible to an equal number of common shares at an exercise price of $2.00 per share, and convertible debentures that are convertible to 7,519,523 common shares. 

QUARTERLY FINANCIAL DATA

(Derived from unaudited interim financial statements.  All figures in thousands of dollars, except per-share amounts)

    Three months ended  
    June 30,     March 31,     December 31,     September 30,  
    2020     2020     2019     2019  
Revenue, foreign exchange gain, interest and other income, management fee income   267     268     221     172  
Loss for the period   (1,401 )   (1,121 )   (788 )   (697 )
Basic and diluted loss per share   (0.01 )   (0.01 )   (0.01 )   (0.01 )

 

    Three months ended  
    June 30,     March 31,     December 31,     September 30,  
    2019     2019     2018     2018  
Revenue, foreign exchange gain, interest and other income   27     105     34     15  
Loss for the period   (1,332 )   (1,245 )   (1,155 )   (1,301 )
Basic and diluted loss per share   (0.03 )   (0.03 )   (0.03 )   (0.03 )

Included in the first quarter of fiscal 2020 is a gain of $5,000 for the change in the fair value of the derivative liability related to the Note.  Included in the losses of the current quarter, the first, second, third and fourth quarters of fiscal 2020, and the second and third and fourth quarter of fiscal 2019 are $64,000, $33,000, $17,000, $12,000, $424,000, $65,000, $60,000, and $60,000, respectively, of stock-based compensation expense. 

Included in the current quarter of this fiscal year, the second and fourth quarter of fiscal 2019 are foreign exchange losses of $1,000, $5,000 and $6,000, respectively.  Included in the fourth quarter of fiscal 2020, the third quarter of fiscal 2019 are foreign exchange gains of $3,000, $12,000, respectively.  Included in the first quarter of fiscal 2020 is a valuation adjustment of $85,000 from the change in exercise price of the warrants issued under the 2018 Rights Offering.  Included in the second quarter of fiscal 2019 is non-cash financing expense of $145,000 related to the difference between the fair value of the standby warrants issued and the derivative liability pursuant to the 2018 Rights Offering.     


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

RELATED PARTY TRANSACTIONS

Burcon engaged Burcon Group Limited, a company that is related by virtue of common directors, for the following related party transactions:

Included in general and administrative expenses (office supplies and services and other expenses) for the three months ended June 30, 2020 is $4,584 (2019 - $18,752) for office space rental. 

For the three months ended June 30, 2020, included in general and administrative expenses (management fees) is $648 (2019 - $458) for administrative services provided.  At June 30, 2020, $186 (March 31, 2020 - $11) of this amount is included in accounts payable and accrued liabilities.  For the three months ended June 30, 2020, included in interest and other income is $4,716 (2019 - $4,258) for legal and accounting services provided by the Company.  At June 30, 2020, $451 (March 31, 2020- $1,785) of this amount is included in amounts receivable.   

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  For the three months ended June 30, 2020, included in interest and other income is $104,600 (2019 - $960) for services provided and $77,048 of samples sold to Merit Foods, of which $61,259 was included in amounts receivable at June 30, 2020 (March 31, 2020 - $110,594). 

Merit Foods also provides certain technical and consulting services to Burcon.  For the three months ended June 30, 2020, Burcon recorded professional fee expense of $10,000 (2019 - $nil), of which $3,280 was included in accounts payable and accrued liabilities as at June 30, 2020.

In connection with the LC, Burcon Holdings entered the Merit Loan Agreement with Merit Foods in the amount of $6.5 million.  During the period ended June 30, 2020, Burcon recorded interest income of $67,671 (2019 - $nil) related to the Merit Loan, which was included in amounts receivable as at June 30, 2020 (March 31, 2020 - $nil).

Certain directors and an officer subscribed for $2.0 million of the Debentures.  During the quarter, the Company made convertible debenture interest payments of $85,000, in aggregate, to these directors and officer.

Burcon had the Loan and Note with Large Scale, a company that is wholly owned by Firewood.  For the three months ended June 30, 2019, included in interest expense is $56,502 related to the Note and $60,756 related to the Loan. 

Upon completion of the 2019 Rights Offering, the exercise price for the share purchase warrants issued to Dr. Yap was adjusted from $0.69 per share to $0.45 per share.  The Company recorded $85,421 as a warrant valuation adjustment for the first quarter of fiscal 2020.

CRITICAL ACCOUNTING ESTIMATES

The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34, Interim Financial Reporting, as issued by the International Accounting Standard Board (IASB) on a basis consistent with those accounting policies followed in the most recent annual consolidated financial statements, except as discussed below. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

The preparation of condensed consolidated interim financial statements in accordance with IFRS requires management to apply judgment when making estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, the reported amount of expenses during the reporting period, and disclosures made in the accompanying notes to the financial statements.  Actual results could differ from those estimates.

The significant areas where management's judgment is applied are in determining the fair value of stock-based compensation, derivative liability, whether all criteria for deferring development costs are met, the point at which amortization of development costs commences, the expense allocation to deferred development costs and the recoverable amount of goodwill, and the discount rate used to fair value the loans receivable from Merit Functional Foods following their modification and determining the loan and equity components of the Debentures.

NEWLY ADOPTED ACCOUNTING STANDARDS

Effective April 1, 2019, the Company has adopted IFRS 16, - Leases, which requires, among other things, leases to recognize leases traditionally recorded as operating leases in the same manner as a financing lease. 

The Company applied IFRS 16 on a modified retrospective basis and it did not have a significant impact on the consolidated financial statements.

OTCQB LISTING

On February 10, 2020, the Company's common shares were listed on the OTCQB Venture Market under the ticker "BUROF".

DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING

The Chief Executive Officer and Chief Financial Officer, as well as other executives, have designed disclosure controls and procedures ("DC&P"), or have caused them to be designed under their supervision, to provide reasonable assurance that material information relating to the Company has been made known to them. 

These officers are also responsible for designing and maintaining internal controls over financial reporting ("ICFR") or have caused them to be designed under their supervision, to provide reasonable assurance regarding the reliability of the Company's ICFR. 

There have been no significant changes in the DC&P and ICFR that occurred during the three months ended June 30, 2020 that could have materially affected, or are reasonably likely to materially affect, such controls. 

RISKS AND UNCERTAINTIES

The Company is subject to a number of risks and uncertainties that can significantly affect its financial condition and future operations.  Key risks are outlined below.  In addition, a detailed explanation of the risk factors which we face is provided in our AIF for the year ended March 31, 2020 under the section titled "Risk Factors", which is incorporated by reference herein.  The AIF is available at www.sedar.com


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

Patents and proprietary rights - Burcon's success will depend, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of others or having others infringe on its rights.  Burcon has filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  As at the date of this MD&A, Burcon has been granted a total of 287 patents in various countries covering a number of key processes and uses of Burcon's soy, pea, canola and flax protein products as functional food and beverage ingredients.  Of those patents, 70 have been granted in the United States.  Although Burcon expends significant resources and efforts to patent its discoveries and innovations, there can be no assurance that our patent applications will result in the issuance of patents, or any patents issued to Burcon will provide it with adequate protection or any competitive advantages, or that such patents will not be successfully challenged by third parties.  Burcon cannot be assured that competitors will not independently develop products similar to the Company's products or manufacture products designed to circumvent the exclusive patent rights granted to the Company.  Further, Burcon may need to incur significant expenditures in prosecuting claims against others whom it believes are infringing on its rights and by defending claims of intellectual property infringement brought by its competitors and others.

Development and commercialization - The long-term success of Puratein®, Supertein® and Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea protein  and Nutratein® pea protein/canola protein blend products hinges upon market acceptance by food and feed ingredient manufacturers and suppliers in numerous product applications.  Although Burcon has formed Merit Foods with the Partners to commercialize Burcon's pea and canola proteins, the commercial products manufactured using Burcon's protein and extraction technologies must exhibit certain functional and nutritional characteristics to garner any market share in the industries that are targeted.  There can be no assurance that Burcon's products will meet industry standards.  Even though Puratein®, Supertein® and  Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be found to be functionally acceptable in product applications, there is no assurance that they will obtain market acceptance and within a reasonable time frame.  Burcon's products have only been produced in small scale batches, and the majority of food or feed ingredient manufacturers will require a substantial testing phase and demonstration of consistent delivery and production capabilities for commercialization.  Although Merit Foods has commenced construction of the planned production facility for Burcon's pea and canola proteins, the construction may be delayed or may not be completed on time.  Therefore, it will be some time before product sales of pea and canola protein will occur.  Until large batches of products can be supplied, market acceptance of Puratein®, Supertein®, and Nutratein® canola proteins, and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be delayed.

There are many large companies in the marketplace that manufacture and produce mature and well-known protein ingredients that have been used for many years.  These companies also possess far greater financial, marketing and human resources than Burcon.  Products such as dried egg white and soy protein isolate have been used in the food processing industry for years with successful results.  These protein ingredients are proven to be functional, technologically sound, readily available and reliable.

History of operating losses and financing requirements- Burcon has accumulated net losses of approximately $99.8 million from its date of incorporation through June 30, 2020.  While Merit Foods' Flex Production Facility is under construction for the production of Burcon's pea and canola proteins, it will be some time before product sales of pea and canola protein will occur.  There is no assurance that the production facility will be built on time or within budget or that Burcon will be able to make the transition to commercial production.  Burcon cannot predict if it will ever achieve profitability and, if it does, it may not be able to sustain or increase its profitability.  In the absence of a definitive time for when sales of products will be significant, Burcon expects such losses to increase as it continues to commercialize its products, its research and development and product and its product application trials.  Burcon expects to continue to incur substantial losses for the foreseeable future.  The commercial success of any of Burcon's products will depend on whether they receive public and industry acceptance as a food ingredient and dietary supplement, and whether they may be sold at competitive prices or are able to obtain sufficient royalty revenue from licensing, which adequately exceeds Burcon's production or business costs.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

Developing Burcon's products and conducting product application trials is capital intensive.  Since acquiring its subsidiary in October 1999, Burcon has raised gross proceeds of approximately $102.5 million from the sale or issuance of equity securities and $9.5 million from the issuance of convertible debentures.  As at June 30, 2020, Burcon had approximately $6.6 million in cash and cash equivalents and restricted cash of $6.5 million.  Burcon believes that it has sufficient capital to fund the current level of operations through September 2022.  Although Burcon has sufficient funds to operate until September 2022, it will need to raise additional capital on acceptable terms in order for the Company to meet its business objectives and fund its operations. 

COVID-19 - Pandemic Risk - The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  While economies began to slowly reopen starting in June 2020, governments have taken a phased approach and it is not expected that economies will fully return to its pre-COVID-19 state until a vaccine has been developed to treat the virus.  The duration and effects of the COVID-19 pandemic are unknown at this time.  Even though governments worldwide, including Canada have implemented significant monetary and fiscal relief programs designed to stabilize their economies, it is too early to predict the efficacy of such programs at this time.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  While the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations to date, it is not possible to predict how long the pandemic will last and whether the financial and business conditions of Burcon and Merit Foods will be impacted in future periods. 

OUTLOOK

For the balance of this fiscal year, Burcon's primary objective is to support Merit Foods to build and commission the pea protein and canola protein production facility and to support market development activities for its protein products, which will include: 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three months ended June 30, 2020 and 2019

In addition, Burcon will also:

 



Burcon NutraScience Corporation

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, Jade Cheng, Chief Financial Officer of Burcon NutraScience Corporation, certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Burcon NutraScience Corporation (the "issuer") for the interim period ended June 30, 2020.

2.  No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a)  designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b)  designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework:  The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Internal Control - Integrated Framework (2013) issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design:  N/A.

1


5.3 Limitation on scope of design:  N/A.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on April 1, 2020 and ended on June 30, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date:  August 14, 2020

"Jade Cheng"

______________________

Jade Cheng

Chief Financial Officer

2



Burcon NutraScience Corporation

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, Johann F. Tergesen, Chief Executive Officer of Burcon NutraScience Corporation, certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Burcon NutraScience Corporation (the "issuer") for the interim period ended June 30, 2020.

2.  No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a)  designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b)  designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework:  The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Internal Control - Integrated Framework (2013) issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design:  N/A.

1


5.3 Limitation on scope of design:  N/A.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on April 1, 2020 and ended on June 30, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date:  August 14, 2020

"Johann F. Tergesen"

______________________

Johann F. Tergesen

Chief Executive Officer

2



 

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

Burcon NutraScience Corporation ("Burcon")

1946 West Broadway

Vancouver, British Columbia, Canada

V6J 1Z2

Item 2: Date of Material Change

August 7, 2020.

Item 3: News Release

A news release with respect to the material change described herein was disseminated on  August 10, 2020 through Newsfile Corp.

Item 4: Summary of Material Change

On August 10, 2020 Burcon announced that Burcon and Archer Daniels Midland Company ("ADM") have agreed to terminate the license and production agreement dated March 4, 2011 made among Burcon, Burcon NutraScience (MB) Corp. and ADM  for CLARISOY™ soy protein effective August 7, 2020. 

As part of the agreement to terminate the exclusive license, the CLARISOY™ trademark will revert back to Burcon.  Additionally, Burcon and ADM are discussing opportunities for Burcon to acquire certain processing equipment from ADM's CLARISOY™ processing facility. 

Item 5.1:  Full Description of Material Change

On March 4, 2011, Burcon and Burcon's wholly-owned subsidiary, Burcon NutraScience (MB) Corp. (together referred to for this section only, as "Burcon") entered into a license and production agreement (the "License and Production Agreement") with ADM.  Pursuant to the ADM License and Production Agreement, Burcon granted ADM an exclusive, royalty-bearing, worldwide license (the "License") to use and exploit Burcon's soy protein technology solely to make, have made, use, market and sell soy protein products  that use, incorporate or are derived from any Burcon technology.  ADM agreed to use reasonable commercial efforts to design, build and commission an initial production facility (the "Semi-works Production Facility") within a specified amount of time also, within a time specified under the ADM License and Production Agreement, provide written notice to Burcon to advise whether it will or will not increase its annual production capacity of the Products beyond the capacity of the Semi-works Production Facility ("Full Commercial Production").  The License and Production Agreement provided each party the right to convert the exclusive license to a non-exclusive license under certain conditions and set out the royalties payable under the License during the term of the agreement.


2

On June 18, 2012, Burcon announced that ADM had constructed and was operating the Semi-works Production Facility in Decatur, Illinois to produce CLARISOY™ soy proteins.  ADM conducted the first commercial sale of CLARISOY™ soy protein by December 2012.

On March 6, 2014, Burcon announced that it received written notice from ADM that ADM intended to expand to Full Commercial Production.  On November 8, 2016, Burcon announced that ADM had successfully commissioned the first full-scale CLARISOY™ production facility.

On August 10, 2020 Burcon announced that Burcon and ADM have agreed to terminate the License and Production Agreement effective August 7, 2020. 

As part of the agreement to terminate the exclusive license, the CLARISOY™ trademark will revert back to Burcon.  Burcon will pay ADM an agreed upon percentage of the aggregate direct third party costs paid by ADM in connection with the marketing, trademark prosecution, and trademark maintenance of the CLARISOY™ trademark. Within 30 days of such payment to ADM, ADM will assign the CLARISOY™ trademark to Burcon.

Burcon and ADM are discussing opportunities for Burcon to acquire certain processing equipment from ADM's CLARISOY™ processing facility. 

Item 5.2: Disclosure for Restructuring Transactions

Not applicable.

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

This material change report is not being filed on a confidential basis.

Item 7: Omitted Information

Not applicable.

Item 8: Executive Officer

Johann F. Tergesen, President and Chief Executive Officer

Telephone: (604) 733-0896 Ext. 15

Email: jtergesen@burcon.ca

Item 9: Date of Report

August 17, 2020.

 
























TERMINATION OF LICENSE AND PRODUCTION AGREEMENT

This Termination of License and Production Agreement is made as of the 7th day of August, 2020 by Burcon Nutrascience Corporation, a Territory of Yukon corporation, having its principal place of business 1946 West Broadway, Vancouver, British Columbia, V6J 1Z2, and Burcon Nutrascience (MB) Corp., a Manitoba corporation, having its principal place of business 1946 West Broadway, Vancouver, British Columbia, V6J 1Z2,  (referred to collectively as "Burcon") and Archer-Daniels-Midland Company, a Delaware corporation, having a place of business at 4666 Faries Parkway, Decatur, Illinois, 62526 ("ADM"). Each of Burcon and ADM may be referred to as a Party, and collectively as the Parties.

WHEREAS, the Parties entered into a License and Development Agreement effective as of March 4, 2011, which has subsequently been amended ("License Agreement");

WHEREAS, the Parties entered into a Trademark Assignment and License effective as of June 22, 2011 ("Trademark Assignment"); and

WHEREAS, the Parties desires to mutually terminate the License and Production Agreement pursuant to Section 8.3(b) of the License Agreement, effective as of August 7, 2020.

Therefore the Parties agree:

    1. Pursuant to Section 8.3(b) of the License Agreement, the Parties agree to terminate the License Agreement as of August 7, 2020 ("the Termination Date").

    2. Burcon and ADM acknowledge that the Notice provisions of Section 11.11 of the License Agreement are deemed satisfied upon the signature of the Parties to this Termination of License and Production Agreement and Acknowledgement of Receipt.

      3. The Parties agree to comply with Section 8.4, Consequences of Termination of Agreement, of the License Agreement.

    4. Pursuant to Section 5(c) of the Trademark Assignment, Burcon agrees to pay ADM [commercially sensitive information redacted]% of the aggregate direct third party costs paid by ADM in connection with the marketing, trademark prosecution, and trademark maintenance of the CLARISOY Trademarks. Within 30 days of such payment to ADM, ADM agrees to assign the CLARISOY Trademarks to Burcon.


5. This Termination of License and Production Agreement and Acknowledgement of Receipt may be executed in counterparts and by facsimile and each such counterpart shall be deemed an original.

The parties have caused this Termination of License and Production Agreement and Acknowledgement of Receipt to be executed by their duly authorized representatives below.

BURCON NUTRASCIENCE CORPORATION

 "Johann F. Tergesen"

Per:__________________________________

Name: Johann F. Tergesen

Title: President & CEO

BURCON NUTRASCIENCE (MB) CORP.

 "Johann F. Tergesen"

Per:__________________________________

Name: Johann F. Tergesen

Title: President

ARCHER-DANIELS-MIDLAND COMPANY

 "Mike Zora"

Per:__________________________________

Name: Mike Zora

Title: Vice President



News Release

Burcon JV Company, Merit Functional Foods, Partners with

Bunge to Bring Pea and Canola Protein to Market

Vancouver, August 27, 2020 - Burcon NutraScience Corporation ("Burcon") (TSX:BU, OTCQB:BUROF), a global technology leader in the development of plant-based proteins, is pleased to announce that its joint venture company, Merit Functional Foods Corporation ("Merit Foods" or "Merit") has received a $30 million investment from a new equity partner, Bunge Limited (NYSE: BG) ("Bunge"), a leading international agribusiness and food company. The partnership will expedite Merit's construction of its state-of-the-art plant-based protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients. It will be the only commercial-scale facility capable of producing food-grade canola protein in the world. Construction is well underway, and the plant is on track to be fully operational by December 2020.

In addition to purchasing equity directly from Merit, Bunge purchased additional shares and debt from existing Merit shareholders who are Burcon's joint venture partners. As a result of these transactions, Bunge is a 25% shareholder in Merit, and Burcon is now Merit Foods largest shareholder owning 33.3% of the plant-based protein producer.

"Burcon is thrilled to have Bunge as an equity partner in Merit Foods," said Johann F. Tergesen, Burcon's president and chief executive officer, adding: "This secures the future for Merit, which will benefit greatly from Bunge's large canola origination footprint and multinational platform.  With this transaction, Burcon is aligned with a leader in the global food ingredients industry, expanding Merit's reach to new customers and consumers in Canada, North America and worldwide." 

The demand for plant-based foods and beverages including dairy and meat alternatives is rapidly increasing. Merit's product portfolio of pea and canola protein ingredients supports the growing need for highly functional and taste-forward plant-based applications. As one of the leading processors of canola in Canada, Bunge has strong origination expertise and will supply Merit with certain critical inputs. Bunge's experience in selling canola-based products will complement Merit's patented processing technology.

"We're excited to have a global partner like Bunge recognize our mission and assist us in accelerating our plans and path to launch," Merit's Co-CEO Ryan Bracken said. "Bunge also holds a deep knowledge of international commodity markets which will help reinforce our canola business globally."

As part of the transactions announced today, Bunge, Burcon and Merit's other shareholders have agreed to certain contractual rights, including a right, but not an obligation, of Burcon, in certain circumstances, to participate in a sale of all but not less than all of its shares in Merit, and that in certain circumstances, Merit will have the right to buyout from Burcon the May 2019 license and production agreement for an amount representing the discounted future royalties over the life of the license agreement. 


About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

About Merit Functional Foods

Established in 2019, Merit Functional Foods is committed to exceeding expectations for plant-based protein, providing the market with the highest quality protein ingredients and blends that offer unmatched purity, exceptional taste, and excellent solubility. Merit is building a state-of-the-art production facility in Winnipeg, where it will produce a portfolio of pea and canola protein ingredients with exceptional functional and nutritional values. For more information, visit meritfoods.com.

About Bunge

Bunge (www.bunge.com, NYSE: BG) is a world leader in sourcing, processing and supplying oilseed and grain products and ingredients. Founded in 1818, Bunge's expansive network feeds and fuels a growing world, creating sustainable products and opportunities for more than 70,000 farmers and the consumers they serve across the globe. The company is headquartered in St. Louis, Missouri and has almost 25,000 employees worldwide who stand behind more than 350 port terminals, oilseed processing plants, grain facilities, and food and ingredient production and packaging facilities around the world.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca

www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



News Release

Burcon Provides Business Update and Notice to

Convertible Debenture Holders

Vancouver, September 2, 2020 / - Burcon NutraScience Corporation ("Burcon") (TSX:BU, OTCQB:BUROF), a global technology leader in the development of plant-based proteins, is pleased to provide further updates with respect to its activities and announces the forced conversion of its outstanding convertible debentures.

Consumers today are looking for great taste, simple labels and alternative sources of plant-based protein that they can feel good about, and that includes feeling good about the environmental impact of their food purchase decisions.  Beyond its pea and canola proteins, which Burcon has exclusively licensed to Merit Foods, Burcon has a pipeline of additional technologies to produce alternative plant-based protein ingredients with valuable functional and nutritional attributes making Burcon ideally positioned to further exploit today's market opportunity. 

Burcon has developed technologies and holds patents and or patent applications for high purity hemp protein, sunflower seed protein, flax protein and more, all of which show promise for application in products ranging from meat alternatives to nutritional supplements.  Burcon's pipeline of additional plant-based proteins, which are non-GMO, can be certified organic, and are allergen-friendly, and as such they check all the boxes consumers are looking for in label-friendly products.

"With Merit Foods secured and strengthened through the addition of Bunge as an equity partner, Burcon now has the luxury of focusing our team of scientists and engineers - at Burcon's Winnipeg-based technical center - to exploit our pipeline of additional alternative plant-based proteins." said Johann F. Tergesen, Burcon's president and chief executive officer, adding, "For over twenty years, Burcon's vision has been to be the recognized global leader in the development of novel high-purity plant-based proteins."

As part of the investment by Bunge Limited into Merit Functional Foods, announced by Burcon on August 27, 2020, Export Development Canada ("EDC") and Farm Credit Canada ("FCC") have now released the $4 million guarantee originally provided by Burcon  to EDC and FCC in connection with the $85 million financing package EDC, FCC and the Canadian Imperial Bank of Commerce provided to Merit.   

EDC also released and returned to Burcon a letter of credit from HSBC Bank Canada in the amount of $6.5 million that Burcon had provided to EDC, as beneficiary, to secure Merit Food's obligations under its loan facilities with EDC. 

In addition to the foregoing updates, Burcon is providing notice to its holders of convertible debentures issued on December 10, 2019.  Burcon completed a non-brokered private placement of unsecured convertible debentures (the "Convertible Debentures") to raise gross proceeds of $9.5 million in December 2019.  Under the terms of the Convertible Debentures, Burcon has the right to force the conversion of the Convertible Debentures into common shares of the Corporation (the "Common Shares") if the Common Shares have traded at or above $2.15 on the Toronto Stock Exchange (the "TSX") for a period of fourteen (14) consecutive trading days.  Between August 12, 2020 to August 31, 2020, Burcon's Common Shares traded at or above $2.15 on the TSX for fourteen consecutive days.  The Convertible Debentures will be converted into Common Shares at a conversion price of $1.05 per Common Share, being a rate of 952.38 Common Shares for each $1,000 principal amount of the Convertible Debentures. No fractional interest in Common Shares will be issued. The number of Common Shares issued to each holder will be rounded down to the nearest whole number. A formal notice will be sent to Convertible Debenture holders setting out the details of the conversion date and the procedures for conversion. 


About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.

Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca

www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM




FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

Burcon NutraScience Corporation ("Burcon")

1946 West Broadway

Vancouver, British Columbia, Canada

V6J 1Z2

Item 2: Date of Material Change

August 27, 2020.

Item 3: News Release

A news release with respect to the material change described herein was disseminated on August 27, 2020 through Newsfile Corp.

Item 4: Summary of Material Change

On August 27, 2020, Burcon announced that its joint venture company, Merit Functional Foods Corporation ("Merit") received a $30 million investment (the "Investment") from a new equity partner, Bunge Limited.  As a result of the Investment and certain related transactions, Tirem Holdings Inc. ("Bunge"), an indirect wholly-owned subsidiary of Bunge Limited, now owns a 25% equity interest in Merit, Burcon now owns a 33.33% equity interest in Merit and the other existing shareholders of Merit (the "Other Shareholders") now own, collectively, the remaining 41.67% equity interests of Merit.

In connection with the Investment: (i) Burcon, Bunge and the Other Shareholders entered into an amended and restated unanimous shareholders agreement dated August 27, 2020; and (ii) Burcon and its wholly-owned subsidiary, Burcon NutraScience (MB) Corp. ("Burcon-MB") entered into an amended and restated license and production agreement with Merit (the "Amended and Restated License Agreement") dated August 27, 2020. 

Following the completion of the Investment, Export Development Canada ("EDC") and Farm Credit Canada ("FCC") released the $4 million guarantee provided by Burcon to EDC and FCC in connection with the $85 million financing package that EDC, FCC and the Canadian Imperial Bank of Commerce provided to Merit, which was announced by Burcon on May 4, 2020.  In addition, EDC also returned the $6.5 million letter of credit provided by Burcon to EDC, which was put in place to facilitate the financing. 

Item 5.1:  Full Description of Material Change

Investment

On August 27, 2020 Merit received a $30 million investment from Bunge.  The Investment was completed by way of a subscription by Bunge for shares from treasury and the advancement of shareholder loans by Bunge. Concurrently with the Investment, Bunge purchased additional shares and debt from the Other Shareholders.  As a result of the foregoing, Bunge now owns a 25% equity interest in Merit, Burcon now owns a 33.33% equity interest in Merit and the Other Shareholders now own, collectively, the remaining 41.67% equity interest in Merit.


2

Amended and Restated Shareholders Agreement

On August 27, 2020, Burcon's wholly-owned subsidiary, Burcon NutraScience Holdings Corp. ("Burcon Holdings"), entered into an amended and restated unanimous shareholders agreement (the "Amended and Restated Shareholders Agreement") with Bunge, the Other Shareholders, Tirem Holdings Limited Partnership and Burcon. Among other things, the Amended and Restated Shareholders Agreements sets out the respective rights and obligations of the shareholders of Merit in respect of Merit, the shares owned by the shareholders and the management and conduct of the business of Merit, including matters requiring board of directors' approval or shareholder approval and the rights of the parties with respect to restrictions on transfers and transfers to third parties.

The Amended and Restated Shareholders Agreement amends and restates the original shareholders agreement (the "Original Shareholders Agreement") dated May 23, 2019 by and between Burcon Holdings and the other Merit shareholders.  The terms of the Original Shareholders Agreement were described in Burcon's material change report dated June 3, 2019, a copy of which has been filed on www.sedar.com.

Under the Amended and Restated Shareholders Agreement, Bunge has the right to acquire the balance of the Merit shares owned by the Other Shareholders through a call option (the "Call Option").  The Amended and Restated Shareholders Agreement sets out the terms and conditions of the Call Option, including the circumstances under which the Call Option will vest and become exercisable. The principal intended trigger for the vesting of the Call Option is based on the completion, commissioning and demonstrated growth of Merit's canola and pea protein production facility in Winnipeg, Manitoba.  If and when Bunge exercises the Call Option to acquire the Merit shares owned by the Other Shareholders, Burcon Holdings then has the right, but not the obligation, to sell all, but not less than all, of its interest in Merit to Bunge at the equivalent valuation.

If Bunge exercises its Call Option to buy out the Other Shareholders, and thereby acquires majority ownership of Merit, certain terms of the Amended and Restated Shareholders Agreement will come into effect, which changes are designed to align the interests of Bunge and Burcon.  Such terms include, among other matters, that on the closing of the Call Option, Bunge will provide financing to Merit on terms that are materially similar to those of Merit's existing third party financing arrangements.  Merit will use the proceeds from the financing to repay existing third party financing arrangements.  Future financings will be provided to Merit by Bunge from time to time, provided that the terms are no less favorable to Merit than what could be obtained in a comparable arm's length transaction.

Bunge has agreed that it will not produce and sell pea and canola proteins exceeding certain specified purity thresholds for a certain time period set out in the Amended and Restated Shareholders Agreement.


3

Amended and Restated License Agreement

Concurrently with the signing of the Amended and Restated Shareholders Agreement, Burcon and Burcon-MB entered into the Amended and Restated License Agreement.  The Amended and Restated License Agreement amends and restates the original license and production agreement (the "Original License Agreement") dated May 23, 2019 between the parties, pursuant to which Burcon granted an exclusive, royalty-bearing, worldwide license to Merit to use and exploit Burcon's pea, pulse and canola protein technologies to make, have made, use and market and sell Burcon's pea, pulse and canola proteins.  The terms of the Original License Agreement were described in Burcon's material change report dated June 3, 2019, a copy of has been filed on www.sedar.com.

Under the Amended License Agreement the parties have agreed among other things, that if Bunge exercises its Call Option to buyout the Other Shareholders under the Amended and Restated Shareholders Agreement, Merit will have an option to convert (the "Conversion") the license granted under the Amended License Agreement into an exclusive, royalty-bearing, worldwide license to Merit over Burcon's pea, pulse and canola protein technologies for an amount representing the discounted future royalties that would otherwise be payable to Burcon over the life of the license agreement.  Upon the Conversion, Merit will assume all the responsibilities and costs relating to filing, prosecution and maintenance of Burcon patent rights.

The Amended and Restated License Agreement modifies certain conditions under which Burcon may convert the exclusive license granted to Merit to a non-exclusive license.  In one instance, if Merit produces a certain amount of products that are not products licensed by Burcon, Burcon has the right to convert the exclusive license to a non-exclusive license.  In such circumstance, Merit may elect to retain exclusivity by paying royalties based on the net revenues derived from the sale of such other products. 

EDC/FCC Release of Guarantee and Letter of Credit

In connection with the Investment and following the deposit by Merit of $10 million of the proceeds of the Investment into a designated account, EDC and FCC have released the $4 million guarantee provided by Burcon to EDC and FCC in connection with the $85 million financing package EDC, FCC and the Canadian Imperial Bank of Commerce provided to Merit.  Burcon signed the released guarantees in favour of each of EDC and FCC on April 24, 2020, pursuant to which Burcon agreed to guarantee all the indebtedness, liabilities and obligations of Merit under the loan agreements between EDC, FCC and Merit.  The Other Shareholders also provided similar guarantees up to an aggregate maximum liability of $6 million, which were also released. 

EDC also released and returned to Burcon a letter of credit from HSBC Bank Canada in the amount of $6.5 million that Burcon Holdings had provided to EDC, as beneficiary, to secure Merit's obligations under its loan facilities with EDC. 

Item 5.2: Disclosure for Restructuring Transactions

Not applicable.


4

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

This material change report is not being filed on a confidential basis.

Item 7: Omitted Information

Not applicable.

Item 8: Executive Officer

Johann F. Tergesen, President and Chief Executive Officer

Telephone: (604) 733-0896 Ext. 15

Email: jtergesen@burcon.ca

Item 9: Date of Report

September 4, 2020




EXECUTION VERSION

[personal information redacted] ("Party A")

and

[personal information redacted] ("Party B")

and

BURCON NUTRASCIENCE HOLDINGS CORP.

and

TIREM HOLDINGS INC.

and

MERIT FUNCTIONAL FOODS CORPORATION
(formerly Burcon Functional Foods Corporation)

[commercially sensitive information redacted]

[personal information redacted ("Party C")

and

[personal information redacted ("Party D")

and

[personal information redacted ("Party E")

and

[personal information redacted ("Party F")

and

TIREM HOLDINGS LIMITED PARTNERSHIP

and

BURCON NUTRASCIENCE CORPORATION

AMENDED AND RESTATED
UNANIMOUS SHAREHOLDERS AGREEMENT

August 27, 2020


TABLE OF CONTENTS

Page

ARTICLE 1 INTERPRETATION 2
   
1.1 Defined Terms. 2
1.2 Gender and Number. 10
1.3 Headings, etc. 10
1.4 Currency. 10
1.5 Certain Phrases, etc. 10
1.6 Accounting Terms. 10
1.7 Statutory References. 11
1.8 References to this Agreement. 11
1.9 Schedules. 11
1.10 Fully Diluted Basis. 11
1.11 Waiver of Rights under the Original Shareholders Agreement. 11
   
ARTICLE 2 IMPLEMENTATION OF AGREEMENT AND TERM 11
   
2.1 Actions in Accordance with Agreement. 11
2.2 Conflicts. 11
2.3 Corporation Consent. 11
2.4 Share Certificates. 11
2.5 Term of Agreement. 12
2.6 Agreement to be Bound. 12
2.7 Deemed Consent under Articles. 12
   
ARTICLE 3 DIRECTORS AND SHAREHOLDERS 12
   
3.1 Directors of the Corporation. 12
3.2 Directors' Meetings/Decisions of Directors. 13
3.3 Exercise of Authority. 14
3.4 Indemnity for Directors. 14
3.5 Insurance. 14
3.6 Remuneration of Directors 14
3.7 Board Committees 14
3.8 Shareholder Meetings. 14
3.9 Subsidiaries. 15
   
ARTICLE 4 BUSINESS AND MANAGEMENT OF THE CORPORATION 15
   
4.1 Business of the Corporation. 15
4.2 Management of the Corporation. 15
4.3 Shareholder Approvals. 17
4.4 Annual Business Plan and Financial Statements. 22
4.5 Compliance with Policies 22
4.6 Indemnifications for Shareholder Guarantees of Corporation Debt. 23
   
ARTICLE 5 CAPITAL OF THE CORPORATION 23
   
5.1 Initial Capital 23
5.2 Bunge Pre-emptive Rights 23

-i-


TABLE OF CONTENTS
(continued)

Page

5.3 Pre-emptive Right Regarding Additional Securities and Debt. 24
   
ARTICLE 6 RESTRICTIONS ON TRANSFER 26
   
6.1 Restrictions on Transfer by Shareholders. 26
6.2 Permitted Transfers by Shareholders. 26
6.3 Encumbering of Shares. 27
   
ARTICLE 7 TRANSFERS TO THIRD PARTIES; RIGHT OF FIRST OFFER 27
   
7.1 Right of First Offer. 27
7.2 Third Party Sale. 28
7.3 Right of First Refusal 28
7.4 Piggy-Back Rights. 29
7.5 Carry Along / Tag Along Provisions 30
7.6 Third Party Sale Provisions 31
   
ARTICLE 8 TRIGGERING EVENTS 31
   
8.1 Triggering Events. 31
8.2 Irrevocable Option to Purchase Shares and Shareholder Loans. 32
8.3 Purchase Price for Triggered Securities. 32
8.4 Closing. 33
8.5 No Sale. 33
8.6 Restrictions on Rights. 34
   
ARTICLE 9 PROCEDURE FOR SALE OF SHARES 34
   
9.1 Closing Procedures. 34
9.2 Approvals. 35
9.3 Multiple Purchasers and Vendors. 35
9.4 Irrevocable Power of Attorney. 35
9.5 Continuing Obligations. 35
   
ARTICLE 10 BUNGE CALL OPTION 35
   
10.1 Grant of Call Option 35
10.2 Calculation of Call Option Price 36
10.3 Vesting of Call Option 36
10.4 Call Option Expiry 36
10.5 Exercise of Call Option 36
10.6 Pre-Vesting Call Option 37
10.7 BurconCo Piggy-Back Option 37
   
ARTICLE 11 REPRESENTATIONS AND WARRANTIES/COVENANTS/INDEMNITY 39
   
11.1 Representations and Warranties of the Shareholders. 39
11.2 Indemnification. 40
11.3 Survival 41
11.4 Most Favoured Customer 41

-ii-


TABLE OF CONTENTS
(continued)

Page

ARTICLE 12 CONFIDENTIALITY 42
   
12.1 Confidentiality Obligation. 42
12.2 Confidentiality Exceptions. 42
12.3 Ownership of Confidential Information. 42
   
ARTICLE 13 NON-COMPETITION/NON-SOLICITATION 43
   
13.1 Non-Competition. 43
13.2 Non-Competition - BurconCo. 43
13.3 Non-Competition - Bunge. 44
13.4 Non Solicitation - Restricted Party. 44
13.5 Non Solicitation - BurconCo and Bunge. 45
13.6 Acknowledgement. 45
   
ARTICLE 14 SHAREHOLDER GUARANTEES 45
   
14.1 Shareholder Obligations 45
   
ARTICLE 15 DISPUTE RESOLUTION 46
   
15.1 Resolving Disputes 46
   
ARTICLE 16 MISCELLANEOUS 47
   
16.1 Notices. 47
16.2 Time of the Essence. 48
16.3 Announcements. 49
16.4 Third Party Beneficiaries. 49
16.5 No Agency or Partnership. 49
16.6 Expenses. 49
16.7 Amendments. 50
16.8 Waiver. 50
16.9 Entire Agreement. 50
16.10 Successors and Assigns. 50
16.11 Severability. 50
16.12 Governing Law. 50
16.13 Counterparts. 51
16.14 English Language. 51
   
SCHEDULE A SHARE OWNERSHIP - CORPORATION 1
   
SCHEDULE B SHAREHOLDER LOANS 1
   
SCHEDULE C [COMMERCIALLY SENSITIVE INFORMATION REDACTED] 1
   
SCHEDULE D AUTHORIZED AND ISSUED CAPITAL OF EACH OF THE SHAREHOLDERS 1
   
SCHEDULE E DISTRIBUTION POLICY 1

-iii-


AMENDED AND RESTATED UNANIMOUS SHAREHOLDERS AGREEMENT

THIS AMENDED AND RESTATED UNANIMOUS SHAREHOLDERS AGREEMENT dated as of August 27, 2020 among [personal information redacted] Party A, [personal information redacted] Party B, Burcon NutraScience Holdings Corp., ("BurconCo"), Tirem Holdings Inc. ("Bunge"), Merit Functional Foods Corporation (the "Corporation") and, with respect to Articles 3, 6 and 14 only, [personal information redacted] Party C, [personal information redacted] Party D, [personal information redacted] Party E, [personal information redacted] Party F, Tirem Holdings Limited Partnership, by its general partner Tirem Holdings GP Inc., and Burcon NutraScience Corporation.

WHEREAS:

A. [personal information redacted] Party A, [personal information redacted]Party B, BurconCo and the Corporation are parties to a shareholders' agreement dated as of May 23, 2019 (the "Original Shareholders Agreement");

B. the Original Shareholders Agreement was executed and delivered by each of the Corporation, [personal information redacted] Party A, [personal information redacted] Party B and BurconCo on May 23, 2019 (the "Original Commencement Date"), which date was, for the purposes of the Original Shareholders Agreement, the "Commencement Date";

C. concurrently with the Original Commencement Date, each of [personal information redacted] Party A, [personal information redacted] Party B and BurconCo (i)  subscribed for Class A Common Shares at price per share of $[commercially sensitive information redacted], and (ii) made certain shareholder loans in favour of the Corporation, which transactions constituted their respective Initial Capital Contributions (as defined in the Original Shareholders Agreement) and which consisted of, in the case of (A) [personal information redacted] Party A , [commercially sensitive information redacted], (B) [personal information redacted] Party B, [commercially sensitive information redacted, and (C) BurconCo, 400 Class A Common Shares and a shareholder loan in the amount of $[commercially sensitive information redacted]

D. on the Original Commencement Date, BurconCo was fully reimbursed for those expenses incurred in providing the Services (as defined in the Services Agreement) and neither BurconCo nor Burcon (as defined in the Services Agreements) has any further claims for reimbursement relating to the Services under Section 2.2(d) or 6.2 of the Services Agreement;

E. on September 3, 2019, each of [personal information redacted] Party A, [personal information redacted] Party B, and BurconCo made an additional shareholder loan to the Corporation, consisting of, in the case of (i) [personal information redacted] Party A, [commercially sensitive information redacted], (ii) BurconCo, an additional shareholder loan in the amount of $[commercially sensitive information redacted], and (iii) [personal information redacted] Party B, [commercially sensitive information redacted], which contributions represented payment in full of the each such party's September Capital Contribution (as defined in the Original Shareholders Agreement);

F. during the period from November 12, 2019 to December 12, 2019, each of [personal information redacted] Party A, [personal information redacted] Party B, and BurconCo made an additional shareholder loan to the Corporation, consisting of, in the case of (i) [personal information redacted] Party A, [commercially sensitive information redacted], (ii) BurconCo, an additional shareholder loan in the amount of $[commercially sensitive information redacted], and (iii) [personal information redacted] Party B,[commercially sensitive information redacted];


- 2 -

G. on February 3, 2020, each of [personal information redacted] Party A, [personal information redacted] Party B, and BurconCo made an additional shareholder loan to the Corporation, consisting of, in the case of (i) [personal information redacted] Party A, [commercially sensitive information redacted], (ii) BurconCo, an additional shareholder loan in the amount of $[commercially sensitive information redacted], and (iii) [personal information redacted] Party B, [commercially sensitive information redacted];

H. immediately prior to the execution of this Agreement, the Corporation filed articles of amendment to create the Class B Common Shares and Class C Common Shares (each as defined herein);

I. concurrent with the execution of this Agreement, the Corporation and certain of the Shareholders completed an investment transaction with Bunge under the Purchase Agreement, pursuant to which Bunge [commercially sensitive information redacted];

J. as of the date hereof, the authorized capital of the Corporation consists of an unlimited number of Class A Common Shares, an unlimited number of Class B Common Shares (non-voting) and an unlimited number of Class C Common Shares;

K. the undersigned Shareholders are the registered and beneficial owners of those Shares set out opposite their respective names in Schedule A attached to this Agreement, which Shares are all of the issued and outstanding share capital of the Corporation;

L. the undersigned Shareholders have made those Shareholder Loans set out opposite their respective names in Schedule B hereto, which loans are all of the loans and other Debt owed by the Corporation to the Shareholders; and

M. the Shareholders and the Corporation wish to amend and restate the Original Shareholders Agreement and to enter into this Agreement to establish (or re-establish as the case may be) their respective rights and obligations in respect of the Corporation, the Shares owned by the Shareholders, the management and conduct of the business of the Corporation and various matters hereinafter set forth.

In consideration of the above recitals and the mutual agreements contained in this Agreement (the receipt and adequacy of which are acknowledged), the Parties agree as follows:

ARTICLE 1
INTERPRETATION

1.1 Defined Terms.

As used in this Agreement, the following terms have the following meanings:

"Act" means the Canada Business Corporations Act.

"Affiliate" means, with respect to any Person (i) any other Person of which the securities or other ownership interests representing 50% or more of the equity or 50% or more of the ordinary voting power or 50% or more of the general partnership interests are, at the time such determination is being made, owned, Controlled or held, directly or indirectly, by such Person, or (ii) any other Person which, at the time such determination is being made, is Controlling, Controlled by or under common Control with, such Person.


- 3 -

"Agreement" means this amended and restated unanimous shareholders agreement and all schedules attached to it as it may be amended, modified, restated, replaced or supplemented from time to time in accordance with this Agreement.

"Annual Budget" means the operating and capital expenditure budget prepared by senior management and presented to the Board for approval pursuant to Section 4.4.

"Arm's Length" has the meaning given to it in the Income Tax Act (Canada) and the jurisprudence issued in respect thereof.

"Articles" means the articles of the Corporation (as "articles" are defined by the Act).

"ASPE" has the meaning specified in Section 1.6.

"Associate" has the meaning given to it in the Act.

"Authorization" means, with respect to a Person, any order, permit, approval, consent, waiver, licence or similar authorization of any governmental or other regulatory entity having jurisdiction over the Person.

"Board" means the board of Directors of the Corporation appointed or elected pursuant to this Agreement.

"Board Committee" has the meaning specified in Section 3.7.

"Bunge Offer Period" has the meaning specified in Section 5.2(2).

"Bunge Offering Notice" has the meaning specified in Section 5.2(1).

"Bunge Subscription Notice" has the meaning specified in Section 5.2(2).

"Burcon Restricted Party" has the meaning specified in Section 13.2.

"Business" has the meaning specified in Section 4.1.

"Business Day" means any day of the year, other than a Saturday, Sunday or day on which Canadian chartered banks are closed for business in Vancouver, British Columbia or Winnipeg, Manitoba.

"By-laws" means the by-laws of the Corporation (as "by-laws" are defined by the Act).

"Call Granting Shareholders" has the meaning specified in Section 10.1.

"Call Option" has the meaning specified in Section 10.1.

"Call Option Exercise Notice" has the meaning specified in Section 10.5.

"Call Option Expiry Time" has the meaning specified in Section 10.4.

"Call Option Phase 2 Trigger" has the meaning specified in Section 10.3.

"Call Option Piggy-Back Notice" has the meaning specified in Section 10.6.

"Call Option Premium" means[commercially sensitive information redacted].


- 4 -

"Call Option Price" has the meaning specified in Section 10.2.

"Call Option Securities" has the meaning specified in Section 10.1.

"Call Option Vesting Date" has the meaning specified in Section 10.3.

"Cash Based Merit Model" means that financial model attached hereto as Schedule C.

"Claim" has the meaning specified in Section 11.2.

"Class A Common Shares" means the class A common shares in the capital of the Corporation.

"Class B Common Shares" means the class B common shares (non-voting) in the capital of the Corporation.

"Class C Common Shares" means the class C common shares in the capital of the Corporation.

"Closing Date" with respect to a Sale Transaction has the meaning specified in Section 7.1(5), or Section 8.4, as the case may be.

"Commencement Date" means the first date on which this Agreement has been executed and delivered by each of the Corporation, [personal information redacted] Party A, [personal information redacted] Party B, BurconCo and Bunge, being the date first referenced as the date of this Agreement.

"Commercial Operation Date" means the date on which the Project Technical Consultant certifies that the Corporation has achieved steady plant operation over 15 days for pea and canola feedstock (it being understood that each day involves a 20 hour continuous run followed by 4 hours clean and maintenance) as follows: [commercially sensitive information redacted].

"Contract" means any agreement, contract, licence, undertaking, engagement or commitment of any nature, written or oral.

"Control" means (a) when applied to the relationship between a Person and a corporation, the beneficial ownership by that Person and/or by Persons not dealing at Arm's Length with such Person at the relevant time of shares of that corporation carrying the greater of (i) a majority of the voting rights ordinarily exercisable at meetings of shareholders of that corporation and (ii) the percentage of voting rights ordinarily exercisable at meetings of shareholders of that corporation that are sufficient to elect a majority of the directors, and (iii) in the case of either of [personal information redacted] Party A or [personal information redacted] Party B, the percentage of participating equity of the holders of such equity being not less than 51% of the aggregate participating equity of [personal information redacted] Party A or [personal information redacted] Party B, respectively, and (b) when applied to the relationship between a Person and a partnership or joint venture, means either the beneficial ownership by that Person and/or by Persons not dealing at Arm's Length with such Person at the relevant time of more than 50% of the ownership interests of the partnership or joint venture in circumstances where it can reasonably be expected that that Person and/or by Persons not dealing at Arm's Length with such Person directs the affairs of the partnership or joint venture, or that such Person and/or by Persons not dealing at Arm's Length with such Person otherwise directs the affairs of the partnership or joint venture as a result of being the general partner or managing partner of the partnership, or the manager of the joint venture; and the words "Controlled", "Controlling" and similar words have corresponding meanings.


- 5 -

"Corporation" means Merit Functional Foods Corporation, a federal corporation having its head office in Winnipeg, Manitoba, and any successor corporation resulting from any amalgamation, merger, arrangement or other corporate reorganization.

"Current Assets" means the sum of all cash, accounts receivable, investment tax credits receivable, sales tax receivable, inventory, prepaid expenses and deposits, and other assets that are classified as "Current Assets" of the Corporation on the relevant date, determined without reference to that cash or cash equivalents of the Corporation otherwise captured by the variable "E" of Section 10.2 on the applicable date.

"Current Liabilities" means the sum of all accounts payable and accrued liabilities that are classified as "Current Liabilities" of the of the Corporation on the relevant date, determined without reference to that Debt of the Corporation otherwise captured by the variable "C" of Section 10.2 on the applicable date.

"Debt" means in respect of a Person, (i) all indebtedness of the Person for borrowed money, (ii) all indebtedness of the Person for the deferred purchase price of property or services represented by a note, bond, debenture or other evidence of debt, (iii) all indebtedness created or arising under any hire purchase agreement, conditional sale agreement or other title retention agreement or arrangement with respect to property acquired by the Person, (iv) all current liabilities of the Person represented by a note, bond, debenture or other evidence of debt, (v) all obligations under leases which have been or should be, in accordance with ASPE, recorded as capital leases in respect of which the Person is liable as lessee, (vi) all obligations of a Person upon which interest charges are customarily paid, and (vii) any indebtedness, liabilities or obligations of the Corporation under foreign currency or commodity hedging contracts and/or interest rate swap agreements together with all accrued interest, prepayment penalties, make-whole payment, breakage fees, or similar amounts payable upon the repayment of any of the foregoing.

"Directors" means the Persons who are elected or appointed as directors of the Corporation in accordance with this Agreement.

"Dispute" has the meaning specified in Section 15.1.

"Distribution Policy" means the policy of the Corporation attached hereto as Schedule E and effective the date hereof, and which shall govern the making of any distributions to the Shareholders made by the Corporation.

"Employee Incentive Plan" means that employee incentive stock option plan, made effective as of October 1, 2019, providing for the issuance of Class B Common Shares constituting up to 10% of the total Shares (calculated on a fully diluted basis) to key employees, directors and management of the Corporation or any Subsidiaries.

"Governmental Entity" means any domestic or foreign government, whether federal, provincial, state, territorial, local, regional, municipal or other political jurisdiction, and any agency or authority instrumentality, court, tribunal, board, commission, bureau, arbitrator, arbitration tribunal or other tribunal, or any quasi-governmental or other entity, insofar as it exercises a legislative, judicial, regulatory, administrative, expropriation or taxing power or function of or pertaining to government.

"Guaranteed Obligations" has the meaning specified in Section 14.1.

"Income Tax Act" means the "Income Tax Act" (Canada) as may be amended or replaced by similar legislation from time to time.


- 6 -

"Indemnified Party" has the meaning specified in Section 11.2(1).

"Indemnifying Party" has the meaning specified in Section 11.2(1).

"Laws" means applicable (i) laws, constitutions, treaties, statutes, codes, ordinances, principles of common and civil law and equity, orders, decrees, rules, regulations and municipal by-laws, whether domestic, foreign or international, (ii) judicial, arbitral, administrative, ministerial, departmental and regulatory judgments, orders, writs, injunctions, decisions, rulings, decrees and awards of any Governmental Entity, and (iii) policies, practices and guidelines of, or Contracts with, any Governmental Entity, which, although not actually having the force of law, are considered by such Governmental Entity as requiring compliance as if having the force of law, in each case binding on or affecting the Person, or the assets of the Person, referred to in the context in which such word is used.

"License Agreement" means the amended and restated license agreement between Burcon NutraScience Corporation, Burcon NutraScience (MB) Corp. and the Corporation dated the date hereof, as the same may be amended or amended and restated from time to time. 

"Limitation Period" has the meaning specified in Section 13.1.

"Normalized and Annualized EBITDA" means the net income of the Corporation from Phase 1 for the immediately preceding four (4) month period, before taking account of payments of interest, taxes and without deduction for depreciation or amortization, all determined in accordance with ASPE applied on a consistent basis, annualized and normalized to remove the effects of items of a non-recurring or extraordinary nature and the effects of seasonality and to account for the expected net earnings from any new, recurring booked sales commitments for high margin protein products while assuming all other low margin co-products are sold at then current market rates, in respect of which the Corporation has entered into a binding supply contract (the "New Commitments"), the satisfaction of which requires the use of any Phase 1 capacity that was unused or unallocated on the date that the Call Option is exercised, less allowances for bad accounts and appropriate discounts for uncertainty of the future commitments, and provided that: (i) additions to the net income of the Corporation in respect of New Commitments shall be made only in respect of that portion of such New Commitments which require the use of any Phase 1 capacity that was unused or unallocated on the date that the Call Option is exercised; and (ii) the aggregate of the used and or allocated Phase 1 capacity on the date that the Call Option is exercised together with the additional capacity that is deemed to be used in order to fulfill the New Commitments, shall in no instance exceed the full Phase 1 production capacity for high purity protein ingredients and blends based on the then known actual production capacity, in all cases, without double counting.

"Normalized EBITDA" means the Normalized and Annualized EBITDA determined with reference to the net income of the Corporation for the immediately preceding month and without being annualized.

"Notice" has the meaning specified in Section 16.1.

"Notice of Claim" has the meaning specified in Section 11.2(2).

"Offer" has the meaning specified in Section 7.1(1).

"Offer Acceptance Notice" has the meaning specified in Section 7.1(3).

"Offer Period" has the meaning specified in Section 5.3(3) for the purposes of Article 5 and Section 7.1(2) for the purposes of Article 7.


- 7 -

"Offered Securities" has the meaning specified in Section 5.3(2).

"Offering Notice" has the meaning specified in Section 5.3(2).

"Option Notice" has the meaning specified in Section 8.2(3).

"Option Period" has the meaning specified in Section 8.2(3).

"Ordinary Resolution" means a resolution of the Voting Shareholders (i) passed at a duly-called meeting of the Voting Shareholders by an affirmative vote of the Voting Shareholders holding more than 50% of the voting rights attached to all of the issued and outstanding Voting Shares (voting together as a single class), or (ii) signed by all of the Voting Shareholders.

"Parties" means the Corporation and the Shareholders.

"Permitted Transferee" has the meaning specified in Section 6.2(1).

"Person" means an individual, partnership, limited partnership, limited liability partnership, corporation, limited liability company, unlimited liability company, joint stock company, trust, unincorporated association, joint venture, governmental, regulatory or other entity, and pronouns have a similarly extended meaning.

"Phase 1" means the initial two spray dryer lines and related production processes for the initial production line at the Plant.

"Phase 2" means the third and fourth spray dryer lines and related production processes to be installed at the Plant.

"Piggy-Back Notice" has the meaning specified in Section 7.3(1).

"Plant" means the approximately [commercially sensitive information redacted] pea, pulse and canola protein extraction facility having a civic address of 400 Goldenrod Drive, Winnipeg, Manitoba.

"Pre-Vesting Call Option" has the meaning specified in Section 10.6.

"Pre-Vesting Call Option Price" has the meaning specified in Section 10.6.

"Products" has the meaning specified in Section 11.4.

"Project Technical Consultant" means[commercially sensitive information redacted] or such other firm having the requisite skill and expertise to determine the Plant's Commercial Operation Date, in each case as determined by Bunge in consultation with the Corporation.

"Proportionate Interest" means at any time with respect to a Shareholder, the Shareholders' rateable ownership of Shares expressed as a percentage, which percentage is determined by dividing the number of Shares owned by the Shareholder by the total number of Shares owned all Shareholders, except with respect to (i) Article 7, in which case the denominator shall be the total number of Shares owned by the non-Selling Shareholders, and (ii) the variable "G" in Section 10.2, in which case the denominator shall be the total number of Shares on a fully-diluted basis, assuming the exercise of all of the Shares issuable under the Employee Incentive Plan.

"Proposed Financing" has the meaning specified in Section 5.2(1).


- 8 -

"Purchase Agreement" means the purchase and sale agreement dated the date hereof made among, the Corporation, Bunge,[personal information redacted] Party A,  Party B, Party C, Party D, Party E and Party F.

"Purchased Shares" means the Shares being Transferred pursuant to a Sale Transaction.

"Purchaser" means any Person or Persons purchasing or otherwise acquiring Shares pursuant to a Sale Transaction.

"Related Person" has the meaning specified in Section 4.5.

"Remaining Shareholders" has the meaning specified in Section 8.2(1).

"Restricted Party" has the meaning specified in Section 13.1

"Sale Shares" has the meaning specified in Section 7.1(1).

"Sale Transaction" means any transaction of purchase and sale defined in Section 7.1(5) or Section 8.4, as the case may be.

"Securities" means, other than the Shares or the Shareholder Loans, other shares in the capital of the Corporation and any rights, warrants, options or other instruments entitling the holder, whether or not on a contingency, to acquire from the Corporation, any of the foregoing, and any instruments convertible or exchangeable, whether or not on a contingency, into any of the foregoing, and "Security" shall mean one such security.

"Selling Shareholder" has the meaning specified in Section 7.1(1).

"Services Agreement" means the services agreement between BurconCo, Burcon NutraScience Corporation, Burcon NutraScience (MB) Corp. and the Corporation dated as of May 23, 2019, as the same may be amended or amended and restated form time to time.

"Shareholder Guarantors" means, (i) with respect to [personal information redacted] Party A, each of [personal information redacted] Party C. and [personal information redacted] Party D, (ii) with respect to [personal information redacted] Party B, [personal information redacted] Party E and [personal information redacted] Party F, (iii) with respect to BurconCo, Burcon NutraScience Corporation, and (iv) with respect to Bunge, Tirem Holdings Limited Partnership.

"Shareholder Loan" means those loans made by each of the Shareholders to the Corporation, in such amounts as may be amended from time to time, and which are, as of the Commencement Date, as set out in Schedule B hereto, and which for clarity does not include any debt or similar financing provided to the Corporation by Bunge pursuant to Section 10.8(2).

"Shareholders" means, as of the Commencement Date, [personal information redacted] Party A, [personal information redacted] Party B, BurconCo and Bunge and thereafter, any other Person who acquires Shares in accordance with this Agreement.

"Shares" means collectively the Class A Common Shares, the Class B Common Shares and the Class C Common Shares of the Corporation, and includes (i) any securities into which such shares may be converted, reclassified, re-designated, subdivided, consolidated or otherwise changed, (ii) any securities of the Corporation or of any other Person received by the holders of such shares as a result of any merger, amalgamation, reorganization, arrangement or other similar transaction involving the Corporation, (iii) any securities of the Corporation which are received by any one or more Persons as a stock dividend or distribution on or in respect of such shares, and (iv) any security, other instrument or right that is exercisable, exchangeable or convertible into, or evidences the right to acquire, any shares of the Corporation or any of the other above securities.


- 9 -

"Special Resolution" means a resolution of the Voting Shareholders (i) passed at a duly-called meeting of the Voting Shareholders by an affirmative vote of the Voting Shareholders holding at least 76% of the voting rights attached to all of the issued and outstanding Voting Shares (voting together as a single class) or (ii) signed by all of the Voting Shareholders.

"Spouse" means, in relation to any Person who is an individual, any individual to whom that first mentioned individual is married and for the purposes hereof also includes any individual with whom the first mentioned individual is living in a conjugal relationship outside marriage.

"Subscription Notice" has the meaning specified in Section 5.3(3).

"Subsidiary" means any direct or indirect subsidiary of the Corporation (as "subsidiary" is determined in the Act) and "Subsidiaries" means all such direct or indirect subsidiaries of the Corporation.

"Supply Agreement" means the proposed agreement for the supply of canola between Bunge and the Corporation, pursuant to which Bunge shall be the primary supplier to the Corporation of canola for processing in the Plant.

"Third Party" has the meaning specified in Section 7.3(1).

"Time of Closing" means 1:00 p.m. (Winnipeg time) or such other time on the Closing Date as the parties to the applicable Sale Transaction agree.

"Transfer" includes, in relation to securities (including Securities), any sale, exchange, transfer, assignment, gift, mortgage, pledge, encumbrance, hypothecation, alienation, transmission or a transaction, whether voluntary, involuntary or by operation of law by which the legal or beneficial ownership or a security interest or other interest (including, without limitation, the right to vote) in, the securities passes from one Person to another, or to the same Person in a different capacity, whether or not for value, other than an involuntary transmission of the securities of a deceased or incompetent holder to the legal personal representative of such holder (or from such legal personal representative to the beneficiaries of the estate of the deceased holder) for so long as the securities continue to be held by the legal personal representative of such Shareholder, and "Transferred", "Transferor" and "Transferee" and similar expressions have corresponding meanings.

"Triggered Securities" has the meaning specified in Section 8.2(1).

"Triggered Securities Price" has the meaning specified in Section 8.3.

"Triggered Shareholder" has the meaning specified in Section 8.2(1).

"Triggering Event" has the meaning specified in Section 8.1(1).

"Triggering Option" has the meaning specified in Section 8.2(1).

"Valuator" has the meaning specified in Section 8.3(2).


- 10 -

"Vendor" means any Person or Persons selling or otherwise disposing of Shares pursuant to a Sale Transaction.

"Voting Shareholders" means a Shareholder owning Voting Shares.

"Voting Shares" means the issued and outstanding Shares of the Corporation with voting rights attached thereto in accordance with the rights attributed thereto pursuant to the Articles and shall, as of the date of this Agreement, mean the issued and outstanding Class A Common Shares and Class C Common Shares.

"Working Capital" means Current Assets less Current Liabilities.

"Working Capital Modifier" means the difference when Working Capital Target is subtracted from the Working Capital.

"Working Capital Target" means the normalised and adjusted simple average of the Working Capital on the 10th, 20th and last Business Day in each of the months to which reference is had in determining the Normalized and Annualized EBITDA when calculating the Call Option Price.

1.2 Gender and Number.

Any reference in this Agreement to gender includes all genders. Words importing the singular number only include the plural and vice versa.

1.3 Headings, etc.

The provision of a Table of Contents, the division of this Agreement into Articles and Sections and the insertion of headings are for convenient reference only and do not affect its interpretation.

1.4 Currency.

All references in this Agreement to dollars or to "$" are expressed in Canadian currency unless otherwise specifically indicated.

1.5 Certain Phrases, etc.

In this Agreement, (i) the words "including", "includes" and "include" mean "including (or includes or include) without limitation", and (ii) the words "the aggregate of", "the total of", "the sum of", or a phrase of similar meaning means "the aggregate (or total or sum), without duplication, of". Unless otherwise specified, the expressions "Article", "Section" and other subdivision followed by a number mean and refer to the specified Article, Section or other subdivision of the Agreement.

1.6 Accounting Terms.

All accounting terms not specifically defined in this Agreement are to be interpreted in accordance with the accounting standards for private enterprises in Canada ("ASPE") from time to time including, for the avoidance of doubt, the standards prescribed in Part II of the CPA Canada Handbook - Accounting, (Accounting Standards for Private Enterprises), using those policies that most closing approximate IFRS standards, as any such standards may be amended, restated or replaced from time to time.


- 11 -

1.7 Statutory References.

Except as otherwise provided in this Agreement, any reference in this Agreement to a statute refers to such statute and all rules and regulations made under it as they may have been or may from time to time be amended, re-enacted or replaced.

1.8 References to this Agreement.

Whereas each of the License Agreement and the Service Agreement refer to certain provisions of the Original Shareholders Agreement, the Parties agree and acknowledge that, except to the extent that such references by their nature relate to obligations to be satisfied prior to the Commencement Date, such references shall be read as references to this Agreement and shall be interpreted hereunder and thereunder mutatis mutandi as though that was the case. 

1.9 Schedules.

The schedules attached to this Agreement form an integral part of it for all purposes of it.

1.10 Waiver of Rights under the Original Shareholders Agreement.

By executing and delivering this Agreements, each of [personal information redacted] Party A, [personal information redacted] Party B and BurconCo acknowledge and agree that they have consented to the Transfer to and subscription for Shares by Bunge and the associated transactions relating to the Shareholder Loans and further confirm that they have waived any rights (whether pre-emptive, piggy-back, drag-along or otherwise) that they may have had under the terms of the Original Shareholders Agreement with respect to such Transfers and related transactions.

ARTICLE 2
IMPLEMENTATION OF AGREEMENT AND TERM

2.1 Actions in Accordance with Agreement.

This Agreement will come into effect on the Commencement Date. Upon and from the Commencement Date, each Shareholder will vote its Shares to give effect to this Agreement whether at a meeting of the Shareholders or by written resolution of the Shareholders.

2.2 Conflicts.

In the event of any conflict between the provisions of this Agreement and the provisions of the Articles or By-laws, the provisions of this Agreement prevail to the extent permitted by law. Each of the Shareholders will take such steps and proceedings as may be required to amend the Articles and By-laws to resolve any conflicts in favour of this Agreement.

2.3 Corporation Consent.

The Corporation consents to this Agreement and agrees to be governed by and act in accordance with its terms.

2.4 Share Certificates.

In addition to any legends required by applicable securities laws, all certificates representing Shares must bear the following legend:


- 12 -

"The shares represented by this certificate are subject to a unanimous shareholders agreement dated as of August ___, 2020 between the Corporation and its shareholders, as may be amended from time to time, and such shares may not be pledged, sold or otherwise transferred except in accordance with the terms of that agreement. Any transfer made in contravention of such restrictions is null and void. A copy of the agreement is on file at the registered office of the Corporation and available for inspection on request and without charge."

2.5 Term of Agreement.

(1) Subject to Section 2.5(2), this Agreement terminates on the earlier of:

(a) the date on which one Person (which for this purpose includes a Person and that Person's Affiliate) acquires all of the issued and outstanding Shares in compliance with this Agreement; and

(b) the date on which this Agreement is terminated by written agreement of the Voting Shareholders.

(2) The obligations and rights of the Parties in Article 12 and Article 13 continue in full force and effect after termination of this Agreement. Even if this Agreement is terminated, each Party is responsible for paying all amounts owing by it under this Agreement prior to the date of termination, including any amounts owing for Shares purchased under this Agreement and, except in the case of the License Agreement which shall continue in full force and effect in accordance with its terms after termination of this Agreement, the Parties shall cooperate in good faith to effect an orderly wind-down and termination of their or their respective Affiliates' relationship among one and other, including those contemplated in the Services Agreement and the Supply Agreement.

2.6 Agreement to be Bound.

Each Person who becomes a Shareholder must concurrently with becoming a Shareholder execute and deliver to the Corporation a counterpart copy of this Agreement or a written attornment agreement in form and substance satisfactory to the Corporation, agreeing to be bound by this Agreement.

2.7 Deemed Consent under Articles.

Each of the Parties (i) consents to a Transfer of Shares made in accordance with this Agreement, and (ii) agrees that this consent satisfies any restriction on the transfer of the Shares contained in the Articles or By-laws and that no further consent is required for any such Transfer other than as expressly set out herein.

ARTICLE 3
DIRECTORS AND SHAREHOLDERS

3.1 Directors of the Corporation.

(1) Notwithstanding anything contained in the Articles or By-laws, the Board will be comprised of, and the Voting Shareholders shall exercise their rights as Voting Shareholders to elect, and shall cause the Board to be comprised of a minimum of three (3) Directors and maximum of eight (8) Directors, all of whom shall be individuals who are not disqualified under the Act to act as Directors. The Board shall initially be comprised of seven (7) Directors but may be increased to the extent required to permit the election of such nominees as are prescribed under Section 3.1(2).


- 13 -

(2) Each Voting Shareholder is entitled to nominate and have elected one Director for each complete 12.5% of the total number of issued and outstanding Voting Shares held by such Shareholder, provided that in all instances Bunge shall be entitled to nominate not less than one Director which Director shall in no circumstances be required to be a Canadian resident.

(3) The [personal information redacted] Party A nominees shall initially be [personal information redacted]and [personal information redacted], BurconCo's nominees shall initially be [personal information redacted]and [personal information redacted], Bunge's nominees shall initially be [personal information redacted] and [personal information redacted] and [personal information redacted] Party B's nominee shall initially be [personal information redacted].

(4) If a nominee Director of any Shareholder resigns or is removed, for any reason, the vacancy will be filled by the election or appointment of a Director nominated by the Voting Shareholder, provided the Voting Shareholder is still entitled to do so. If a replacement Director is not elected or appointed within 10 days because the Shareholder has failed to nominate a replacement, the Directors then in office are entitled to transact business and exercise all of the powers and functions of the Directors.

(5) If a Voting Shareholder disposes of all of its Voting Shares under this Agreement (except to a Permitted Transferee pursuant to Section 6.2), the Voting Shareholder's nominee Directors must resign or be removed. The new holder of the applicable Voting Shares will be entitled to the right to nominate Directors as set out in Section 3.1(2).

(6) No amount is payable by the Corporation, by way of salary, bonus or otherwise to any Director for acting as a Director. Each Director is entitled to be reimbursed for reasonable out-of-pocket expenses incurred in attending Directors' meetings, committee meetings, and shareholders' meetings and in performing other duties of the Directors.

3.2 Directors' Meetings/Decisions of Directors.

(1) Directors' meetings will be held at least once a calendar quarter unless all Directors agree otherwise.

(2) At least 48 hours' prior written notice of any Directors' meeting must be given unless all of the Directors are present or those who are absent waive notice. Directors shall be considered present at a meeting in person if they participate by way of telephone, video conference or similar equipment that allows them to hear and be heard by all of the other Directors present at the meeting. A Director is not considered present at a meeting where that Director attends the meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called.

(3) The quorum for a meeting of the Directors is three, of which one must be a nominee of Bunge and one must be a nominee of BurconCo. Despite the prior sentence, if proper notice of a Directors' meeting is given, specifying the purpose of, or the business to be transacted at, the meeting, and a quorum of Directors is not present, a second Directors' meeting may be held on 48 hours written notice to transact the business specified in the original notice. Subject to the Act, any Directors present at the second meeting constitute a quorum and the business specified in the original notice may be transacted by a majority vote of those Directors in attendance at the second meeting.

(4) In order to be effective, a decision of the Board must be approved either by a resolution passed by:


- 14 -

(a) the affirmative vote of not less than a majority of the Directors present at a meeting of the Board duly called and constituted and, if applicable, the any chairman of the Board shall not have a casting vote; or

(b) an instrument signed by all of the Directors.

3.3 Exercise of Authority.

Unless otherwise expressly required in this Agreement, all decisions, approvals, determinations and consents of the Directors or the Shareholders required by this Agreement may be decided, approved, determined or consented to by a majority of the votes cast at a Directors' meeting or Shareholders' meeting or by written resolution signed by all of the Directors or Shareholders, as the case may be.

3.4 Indemnity for Directors.

In addition to any existing provisions which may be contained in the Articles, the Corporation shall, to the fullest extent possible, indemnify any Director or officer of the Corporation and any former Director (whether appointed pursuant to this Agreement or pursuant to the Original Shareholders Agreement)  or officer of the Corporation that acted in such capacity at any time following the date of this Agreement, or any Person who acts or has acted at the Corporation's request as a director or officer of any Subsidiary at any time following the date of this Agreement, and his or her heirs and other personal representatives in accordance with the provisions of the Act. Nothing in this Section 3.4 shall limit the right of any Person entitled to claim any indemnity apart from the provisions of this Section 3.4. The Corporation will indemnify any Director to the fullest extent permitted by the Act. Nothing in this Agreement limits the right of any Director to claim indemnity apart from the provisions of this Agreement, if the Director is entitled to such indemnity.

3.5 Insurance.

The Corporation will use reasonable commercial efforts to purchase and maintain insurance for the benefit of the Directors and officers of the Corporation against such liabilities, in such amounts and on such terms as the Directors determine and as are permitted by law.

3.6 Remuneration of Directors

All Directors shall be reimbursed for reasonable out-of-pocket third party expenses incurred with respect to acting as a Director, including out-of-pocket expenses incurred in attending Directors' meetings.

3.7 Board Committees

In the event that any committee of the Board is formed (each, a "Board Committee"), each such Board Committee shall be comprised of no more than four (4) Directors with each Shareholder being entitled to appoint one individual as a member of such Board Committee; provided however, that no Shareholder may appoint as a member of the Audit Committee of the Board any individual who is an employee or officer of the Corporation or any Subsidiary.

3.8 Shareholder Meetings.

Meetings of Shareholders may be called by the Board or a Voting Shareholder holding at least 5% of the issued Voting Shares upon not less than 5 Business Days' written notice to the other Voting Shareholder(s) and the Corporation. Voting Shareholders or their representatives shall be considered present at a meeting in person if they participate by way of telephone, video conference or similar equipment that allows them to hear and be heard by all of the other Voting Shareholders present at the meeting. The quorum for a Shareholders' meeting is two Voting Shareholders of which one must be Bunge and one of which must be BurconCo, present in person or represented by proxy and holding at least 51% of the Voting Shares entitled to vote at the meeting. Despite the previous sentence, if proper notice of a Shareholders' meeting is given, and a quorum of Voting Shareholders is not present, a second Shareholders' meeting may be held on 48 hours written notice to transact the business specified in the original notice. Subject to the Act, any Voting Shareholders present at the second meeting constitute a quorum and the business specified in the original notice may be transacted by a majority vote of Voting Shares represented at the second meeting.


- 15 -

3.9 Subsidiaries.

The board of directors of any Subsidiary shall consist of the same individuals as acting as Directors and the provisions set forth in Section 3.2 through Section 3.6 shall apply to such Subsidiaries, mutatis mutandis, and the boards of the directors thereof and, so far as the laws of the jurisdiction of incorporation of such Subsidiaries allow, such provisions shall constitute a unanimous shareholder agreement in respect of such Subsidiary.

ARTICLE 4
BUSINESS AND MANAGEMENT OF THE CORPORATION

4.1 Business of the Corporation.

(1) The business of the Corporation is the commercial production, sales, marketing and distribution worldwide of pea protein, pulse protein and canola protein, by-products from the processing of such products and such other products from time to time as the Board may agree by resolution to produce, and includes without limitation, the construction of the Plant (the "Business").

4.2 Management of the Corporation.

(1) Subject to Section 4.3, the Directors will manage, or supervise the management of, the business and affairs of the Corporation in accordance with this Agreement, the Act and the By-laws, including without limitation, by passage of resolutions of the Board in accordance with Section 3.2 and this Section 4.2. Without limiting the generality of the foregoing, the following matters will be determined by the Board (subject to any additional approval requirements provided for under this Agreement):

(a) Declaring or paying any dividend or other distribution on or in respect of any Shares or other securities of the Corporation provided it is consistent with the Annual Budget prepared in accordance with Section 4.4 and the Distribution Policy. 

(b) Paying or distributing amounts out of any stated capital account, reducing any stated capital account, distributing any surplus or earnings, or returning any capital provided it is consistent with the Annual Budget prepared in accordance with Section 4.4 and the Distribution Policy.

(c) Creating, assuming or incurring any liability or obligation of any nature which assures or guarantees in any way the payment or performance (or payment of damages in the event of non-performance) of any Debt or other liability or obligation of any Person other than the Corporation itself which is not specifically set out in the then current Annual Budget as approved by the Directors pursuant to Section 4.4.


- 16 -

(d) Making an expenditure which is not consistent with the then current Annual Budget for the subject matter of such expenditure or which had been expressly designated by the Directors or Shareholders as requiring specific Board approval.

(e) Licensing or sublicensing any intellectual property of the Corporation, other than as contemplated by the License Agreement.

(f) Any amendments, modification or material supplements to the License Agreement.

(g) Any amendments, modification or material supplements to the Services Agreement.

(h) Any decision of the Corporation to commence any action, suit or claim against a third party with respect to infringement or potential infringement of any of the intellectual property licensed to the Corporation by Burcon NutraScience (MB) Corp. pursuant to the License Agreement.

(i) Any material branding decisions in connection with the Business.

(j) Approving the annual financial statements.

(k) Changing the financial year end of the Corporation.

(l) (i) Acknowledging the insolvency of the Corporation or the inability of the Corporation to pay its debts as they become due, (ii) making an assignment for the benefit of the creditors of the Corporation, (iii) appointing or allowing the appointment of any receiver, receiver-manager, trustee, liquidator or other Person acting in a similar capacity, (iv) instituting any proceeding seeking to have the Corporation adjudicated a bankrupt or insolvent, or (v) taking any action or instituting any proceeding for the purpose of, or leading to, the liquidation, dissolution, winding-up, reorganization, arrangement, adjustment, protection, relief or composition of the Corporation or its debts under any Law relating to bankruptcy, insolvency, reorganization or relief of debtors.

(m) (i) Commencing any action, suit or proceeding, (ii) compromising or settling any action, suit, proceeding, (iii) compromising or settling any material administrative proceeding or investigation, or (iv) submitting to binding arbitration, except pursuant to Article 15.

(n) Entering into any transaction with a Person related to a Shareholder (as determined under the Income Tax Act) or an Affiliate of the Corporation.

(o) Making or entering into any Contract or amending, modifying, restoring, replacing or supplementing any Contract which the Corporation is a party to, where such Contract or amendment or modification thereto is not within the expenditure level as set out in the Annual Budget for the subject matter of the Contract.

(p) The hiring or termination of either a Chief Executive Officer or Chief Financial Officer of the Corporation, or any other Person in a "C-suite" senior management position with the Corporation, and the terms of compensation and benefits for each.

(q) The hiring or engagement of any employee or independent contractor, respectively, where the annual compensation paid to such employee or independent contractor is $125,000 or more.


- 17 -

(r) The entry into or termination of any lease for premises of the Corporation including any lease for premises used for full production, semi-works or additional plants.

(s) Making any loan or advance to any Person unless such loan or advance has been set out in the then current Annual Budget as approved pursuant the terms of this Agreement.

(t) Changing materially the Business or taking any action which may lead to or result in such change, including expansion of any product line other than pea protein or canola protein, or entering into any transaction out of the ordinary course of that Business.

(u) Purchasing, selling, leasing, licensing or otherwise acquiring or disposing of any property or assets out of the ordinary course of business, or making any commitment to do so.

(2) Any nominee Directors may at any time request information regarding operational strategies, as well as in respect of functional areas of operation by contacting either the Corporation's Chief Financial Officer or either Chief Executive Officer. The Parties agree that those matters identified by any nominee Director as required discussion at the Board level will be added to the agenda for the next ensuing Board meeting for discussion by all of the Directors.

4.3 Shareholder Approvals.

(1) In addition to any other approval required by Law, the Corporation may not make a decision about, take action on or implement any of the following without a resolution of the Directors at a duly constituted meeting in accordance with Section 3.2 and the approval of Voting Shareholders by Ordinary Resolution:

(a) Repaying any Debt owing by the Corporation to any Shareholder, or any Associate or Affiliate of a Shareholder or making any loan to a Shareholder or any Associate or Affiliate of a Shareholder other than as specifically contemplated in the then current Annual Budget.

(b) Granting or permitting to exist any liens or other encumbrances on the assets of the Corporation other than (i) liens for taxes, assessments or governmental charges or levies on property not yet due and delinquent, (ii) easements, encroachments and other minor imperfections of title which do not, individually or in the aggregate, materially detract from the value of or impair the use or marketability of any real property, and (iii) liens charging property of the Corporation (other than accounts receivable or inventory), which are granted by the Corporation or which arise by operation of Law concurrently with and for the purpose of the acquisition of such property where the lien extends only to the property acquired and its proceeds.

(c) Making or filing any material tax election.

(2) Unless and until such time as the Call Option has been exercised by Bunge, in addition to any other approval required by Law, the Corporation may not make a decision about, take action on or implement any of the following without a resolution of the Directors at a duly constituted meeting in accordance with Section 3.2 and the approval of Voting Shareholders by Special Resolution:

(a) Approving any Transfer of Shares by any Shareholder, except in accordance with this Agreement.

(b) Changing the authorized capital of the Corporation, changing the number of issued and outstanding securities (for greater clarity, except as contemplated by Section 5.2) or increasing or reducing the capitalization of the Corporation, by way of split, conversion, exchange of securities or otherwise.


- 18 -

(c) Amending, replacing, superseding the Articles or amending, revoking or enacting By-laws, except to resolve any conflict in favour of this Agreement.

(d) Allotting, reserving, setting aside or issuing any Shares or other securities of the Corporation or issuing or granting any rights, warrants or options to purchase, acquire or otherwise obtain any unissued Shares or other securities of the Corporation other than in accordance with Section 5.2, Section 5.3 or on the exercise of the options existing on the date hereof that have been issued pursuant to the Employee Incentive Plan.

(e) Purchasing, redeeming or acquiring any Shares or other securities of the Corporation, except as expressly permitted by this Agreement and the Articles.

(f) The distribution of profits, assets or reserves by the Corporation (including the repayment or redemption of any Shareholders Loans or any amendment to the terms thereof, including the institution of the accrual of interest), except if such distribution is made: (i) to the Shareholders in proportion to their respective Proportionate Interest; (ii) pursuant to Section 4.3(3)(k); or (iii) in accordance with  the Distribution Policy.

(g) The decision to increase the number of Directors in accordance with the terms of this Agreement, except to the extent required to permit the election of such nominees as are prescribed under Section 3.1(2).

(h) The appointment or removal of any Director or officer of the Corporation, save for an appointment or removal made in accordance with this Agreement.

(i) Delegating any power, right or duty of the Directors other than to a duly appointed Board Committee.

(j) Any material change (including cessation, discontinuance, dissolution, and winding-up of the Corporation, in whole or in part) in the nature of the Business, or in the case of an entity acquired after the date of this Agreement, in the nature of its Business as at the date of such acquisition, including for greater certainty (i) acknowledging the insolvency of the Corporation or the inability of the Corporation to pay its debts as they become due, (ii) making an assignment for the benefit of the creditors of the Corporation, (iii) appointing or allowing the appointment of any receiver, receiver-manager, trustee, liquidator or other Person acting in a similar capacity, (iv) instituting any proceeding seeking to have the Corporation adjudicated a bankrupt or insolvent, or (v) taking any action or instituting any proceeding for the purpose of, or leading to, the liquidation, dissolution, winding-up, reorganization, arrangement, adjustment, protection, relief or composition of the Corporation or its debts under any Law relating to bankruptcy, insolvency, reorganization or relief of debtors;  provided that, in the case where a Shareholder is the creditor in respect of which creditor protections are being sought, such Shareholder's holdings shall not be included in either the numerator or the denominator of the Shares when calculating the percentage of Shares held by the Voting Shareholders considering the resolution.

(k) The entry into, termination or variation of any contract or arrangement between the Corporation and the Directors, officers or Shareholders (or a connected Person of such a Person) or an entity in which such Directors, officers or Shareholders are otherwise interested including the variation of the remuneration or other benefits under such contract or arrangement, the waiver of any breach of such contract or arrangement, the making of any bonus payment or the provision of any benefit by the Corporation to or to the order of a Shareholder, Director or officer of the Corporation or to a connected Person, other than the making of a payment or the provision of a benefit pursuant to and in accordance with: (i) an employment agreement; (ii) the License Agreement; (iii) the Supply Agreement; (iv)  the Services Agreement; or (v) as otherwise contemplated by this Agreement.


- 19 -

(l) Selling, transferring, leasing, licensing, sub-licencing, exchanging or otherwise disposing of all or substantially all of the assets of the Corporation (or any material asset or right), or granting any right, option or privilege to do so.

(m) Amalgamating, merging or entering into an arrangement or other corporate reorganization involving the Corporation or the continuance of the Corporation into any other jurisdiction.

(n) The incorporation of a new subsidiary or undertaking of the Corporation or the acquisition (however effected) by the Corporation of an interest in any shares in the capital of an entity, or in any instrument convertible into the share capital of an entity or the acquisition of any other interest in a company, business, undertaking or concern, including the acquisition of any share or marketable security which is traded on a recognized investment exchange or any other public securities market.

(o) Amending the Employee Incentive Plan or adopting or amending any other similar plan for the benefit of employees, Directors or officers of the Corporation.

(p) Amending, modifying, terminating, revoking, replacing or superseding the Distribution Policy;

(q) The approval of the Annual Budget and any alteration to an Annual Budget for the relevant financial year or the taking of steps which are materially inconsistent with the then current Annual Budget (whether on an aggregate basis or with respect to any individual line item).

(r) Following the Call Option Vesting Date, any capital expenditure of the Corporation which is greater than (i) $1,500,000 (exclusive of tax) in respect of any individual item of capital expenditure, or (ii) $1,500,000 (exclusive of tax) in aggregate in any twelve month period and which is not provided for in the approved Annual Budget for the relevant financial year, treating the entering into by the Corporation of any lease, license or similar obligation as capital expenditure of an amount equal to the rental and other payments payable by the Corporation as a result of that obligation.

(s) The entry into/or termination of or withdrawal from by the Corporation any partnership, consortium or joint venture arrangement with any person.

(t) Creating, assuming or incurring any Debt not approved as part of the then current Annual Budget, except customary trade credit taken in the ordinary and normal course of business.

(u) The lending of money or granting of credit by the Corporation except customary trade credit given in the ordinary and normal course of business.


- 20 -

(v) Any determination of whether the Corporation should expand to Phase 2, full-scale commercial production or otherwise beyond the initial full-scale production facility, including the determination of financing for such expansion.

(w) Appointing, changing or removing the auditors of the Corporation. 

(3) In the event that Bunge has exercised the Call Option, Section 4.3(2) shall cease to apply, and thereafter, in addition to any other approval required by Law, the Corporation may not make a decision about, take action on or implement any of the following without a resolution of the Directors at a duly constituted meeting in accordance with Section 3.2 and the approval of Voting Shareholders by Special Resolution:

(a) Approving any Transfer of Shares by any Shareholder, except in accordance with this Agreement.

(b) Changing the authorized capital of the Corporation, changing the number of issued and outstanding securities (for greater clarity, except as contemplated by Section 5.2) or, to the extent that such action shall have an adverse impact on the Shareholders, or any of them, increasing or reducing the capitalization of the Corporation, by way of split, conversion, exchange of securities or otherwise.

(c) Amending, replacing, superseding the Articles or amending, revoking or enacting By-laws, except to resolve any conflict in favour of this Agreement.

(d) Allotting, reserving, setting aside or issuing any Shares or other securities of the Corporation or issuing or granting any rights, warrants or options to purchase, acquire or otherwise obtain any unissued Shares or other securities of the Corporation other than in accordance with Section 5.3 or on the exercise of the options existing on the date hereof that have been issued pursuant to the Employee Incentive Plan.

(e) To the extent that such action shall have an adverse impact on the Shareholders, or any of them, purchasing, redeeming or acquiring any Shares or other securities of the Corporation, except as expressly permitted by this Agreement, the Articles or as permitted in the Distribution Policy.

(f) The distribution of profits, assets or reserves by the Corporation (including the repayment or redemption of any Shareholders Loans or any amendment to the terms thereof, including the institution of the accrual of interest), except if such distribution is made: (i) to the Shareholders in proportion to their respective Proportionate Interest; (ii) pursuant to Section 4.3(3)(k); or (iii) in accordance with  the Distribution Policy.

(g) The decision to increase the number of Directors in accordance with the terms of this Agreement, except to the extent required to permit the election of such nominees as are prescribed under Section 3.1(2).

(h) Delegating any power, right or duty of the Directors other than to a duly appointed Board Committee.

(i) Any material change (including cessation, discontinuance, dissolution, and winding-up of the Corporation, in whole or in part) in the nature of the Business, including for greater certainty (i) acknowledging the insolvency of the Corporation or the inability of the Corporation to pay its debts as they become due, (ii) making an assignment for the benefit of the creditors of the Corporation, (iii) appointing or allowing the appointment of any receiver, receiver-manager, trustee, liquidator or other Person acting in a similar capacity, (iv) instituting any proceeding seeking to have the Corporation adjudicated a bankrupt or insolvent, or (v) taking any action or instituting any proceeding for the purpose of, or leading to, the liquidation, dissolution, winding-up, reorganization, arrangement, adjustment, protection, relief or composition of the Corporation or its debts under any Law relating to bankruptcy, insolvency, reorganization or relief of debtors, provided that, in the case where a Shareholder is the creditor in respect of which creditor protections are being sought, such Shareholder's holdings shall not be included in either the numerator or the denominator of the Shares when calculating the percentage of Shares held by the Voting Shareholders considering the resolution.


- 21 -

(j) Subject to Section 10.8, entering into or allowing the Corporation to enter into, any agreement with, make any financial accommodation for, or otherwise enter into any transaction with, directly or indirectly, a Director, officer or Shareholder (or a connected Person of such a Person), as applicable, having in the aggregate, an annual value of equal to or greater than $1,000,000, and in each case, except:

(i) in the ordinary course of, and pursuant to the reasonable requirements of, business and provided that Bunge and its Affiliates will not allocate corporate overhead costs to the Corporation except in accordance with the services agreement described in Section 4.3(3)(j)(ii):

(A) at prices and on terms not less favourable to the Corporation than could be obtained in a comparable arm's length transaction; or

(B) at prices and on terms that Bunge has obtained (or agreed to) in an arm's length transaction in the ordinary course of business, and that is not at prices or on terms less favourable to Bunge or its Affiliate, as applicable, than could be obtained in a comparable arm's length transaction; or

(ii) services provided by Bunge or any of its Affiliates to the Corporation pursuant to a services agreement that has been approved by the Voting Shareholders by Special Resolution; or

(iii) the entering into of any sublicense of the License Agreement in accordance with the terms thereof.

(k) Selling, transferring, leasing, licensing, sub-licensing, exchanging or otherwise disposing of all or substantially all of the assets of the Corporation or any asset or right of the Corporation in respect of which more than 50% of the Corporation's gross revenue is derived, or granting any right, option or privilege to do so, unless the proceeds of such sale consists solely of:

(i) immediately available cash (subject only to customary hold backs and earn out);

(ii) freely tradable, non-assessable equity stock listed in on major stock exchange in Canada, the United States or the United Kingdom, or

(iii) a combination of (i) and (ii),


- 22 -

and, in each case, all or substantially all of the net proceeds to (and received by) the Corporation are distributed to the Shareholders in proportion to their respective Proportionate Interest.

(l) Amalgamating, merging or entering into an arrangement or other corporate reorganization involving the Corporation or the continuance of the Corporation into any other jurisdiction, to the extent that such action shall have an adverse impact on the Shareholders, or any of them.

(m) Adopting any shareholder incentive plan, or similar plan for the benefit of employees, Directors or officers of the Corporation, the effect of which would include the dilution of any Shareholder's equity interest in the Corporation.

(n) Amending, modifying, terminating, revoking, replacing or superseding the Distribution Policy.

(o) Appointing as auditors of the Corporation any firm other than that firm (or the local affiliate) employed by Bunge Limited as its auditors.

4.4 Annual Business Plan and Financial Statements.

(1) The Directors will cause management to prepare and submit the Annual Budget and an annual business plan to the Board at least 15 days prior to the beginning of each fiscal year, which shall include, among other things, the level of detail and materiality for inclusion as well as material contract planning and strategy implementation, provided that, the parties agree, the Cash Based Merit Model shall act as the Annual Budget for the Corporation's 2020 fiscal year. Senior management will be instructed to prepare each Annual Budget in accordance with such detail, it being intended that such Annual Budget will be a detailed document to instruct senior management on execution for the year to which such Annual Budget applies.

(2) The Directors will cause management of the Corporation to prepare and submit to the Voting Shareholders internally generated quarterly financial statements within 45 days of each fiscal quarter end and audited financial statements within 90 days of each fiscal year end, all prepared in accordance with ASPE.

(3) The Directors will cause management to prepare and submit to the Voting Shareholders monthly management reports that shall include, without limitation, monthly revenue reports, monthly reports on production capacity and throughput, monthly net consolidated profits and losses, cash flow and the net financial debt position of the Corporation and an estimate of the Corporation's Normalized EBITDA for the relevant month (which shall not be determinative for the purpose of calculating Normalized and Annualized EBITDA), which shall include management's analysis of the actual results during the period compared to the Annual Budget and management's expectations for the then current financial year.

(4) Notwithstanding the requirement that financial statements of the Corporation be prepared in accordance with ASPE, where there are options for different policies to apply in accordance with ASPE, the Corporation will endeavour to use that policy that most approximates IFRS standards.

4.5 Compliance with Policies

Each of the Shareholders covenants and agrees, and where applicable will cause its nominees to the Board to: (i) comply with the Distribution Policy; and (ii) promptly following the date hereof, adopt and thereafter comply with, a code of conduct that is materially similar to the Code of Conduct that is in effect for Bunge Limited.


- 23 -

4.6 Shareholder and Director Voting

Subject to Section 4.7 hereunder, in any vote of the Shareholders as provided for in this Agreement and as otherwise contemplated by applicable Law, such Shareholder will vote on its own behalf and will not enter into, whether in writing or otherwise, any form of voting agreement, voting trust or similar undertaking or understanding with respect to any such matter. Each Shareholder shall direct their nominees to the Board to ensure that such nominees will vote in accordance with their fiduciary duties as directors, and shall not enter into, or engage in, any agreement, undertaking or understanding to vote on matters with another nominee in compliance with such agreement, undertaking or understanding.

4.7 Statutory Voting Rights

Whenever Shareholders holding Shares of the Corporation that are not Voting Shares, if any, are entitled to exercise any voting rights, including without restriction any right to vote conferred on the holder of a non-voting share by the provisions of the Act notwithstanding the provisions of the Corporation's Articles and other constating documents, such Shareholders will vote each Share that he or she is entitled to vote in the same manner as the majority of the Voting Shareholders of the Corporation are voted. Each Shareholder holding Shares that are not Voting Shares covenants to do all things necessary to carry out the provisions of this paragraph according to its true intent. Without restricting the generality of the foregoing, each Shareholder holding Shares that are not Voting Shares hereby irrevocably appoints the Secretary of the Corporation for the time being as his or her attorney with full power to do all things necessary to implement the provisions of this paragraph.

ARTICLE 5
CAPITAL OF THE CORPORATION

5.1 Initial Capital

As of the Commencement Date, each Shareholder is the registered and beneficial owner of that number of Shares set out opposite their name in Schedule A and has made available to the Corporation those Shareholder Loans set out opposite their name in Schedule B.

5.2 Bunge Pre-emptive Rights

(1) During the period from the Commencement Date up to the Commercial Operation Date (the "Bunge Pre-emptive Period"), in the event that the Corporation wishes to obtain financing whether through the issuance of Shares or other securities of the Corporation or through the entering into of any loan or financing arrangement in whatever form or manner (each, a "Proposed Financing") the Corporation will give notice to Bunge (a "Bunge Offering Notice") of such Proposed Financing, which Bunge Offering Notice must specify (i) the net proceeds that the Corporation intends to raise as a result of the Proposed Financing, (ii) the proposed terms of the Proposed Financing, and (iii) the contemplated closing date in respect of the Proposed Financing, which may not be earlier than 30 days from the date the Bunge Offering Notice is delivered unless a shorter date is agreed to by Bunge. The pre-emptive rights described in this Section 5.2 shall expire upon the earlier to occur of:  (a) the end of the Bunge Pre-emptive Period and (b) the subscription by Bunge of the maximum number of [commercially sensitive information redacted] Class C Common Shares, as set out in clause (4) below. Notwithstanding the foregoing: (a) in the event that a Proposed Financing consists of government or Crown corporation government funding including programs providing subsidies, incentives, rebates or forgivable or deferred loans, offered at better than market terms or on terms that are not less favourable in any material respect than the then current market terms, and that is provided on terms that would not result in the aspects of the Proposed Financing that are provided on better than market terms or on terms that are not less favourable in any material respect than the then current market terms ceasing to be available on the exercise by Bunge of the Bunge Call Option, the Corporation shall be entitled to proceed with such other Proposed Financing and shall be required to provide to Bunge the Bunge Offering Notice solely for information purposes; and (b) in the event that a Proposed Financing is intended solely for the purpose of a value-added initiative which is not contemplated by or required to complete Phase 1, then the Corporation shall be entitled to proceed with such Proposed Financing and shall be required to provide to Bunge the Bunge Offering Notice solely for information purposes.


- 24 -

(2) During the Bunge Pre-emptive Period, Bunge may, at its sole and absolute discretion, direct that, in lieu of undertaking the Proposed Financing, the Corporation undertake a financing that consists of a treasury issuance of Class C Common Shares to Bunge, by delivering an irrevocable and unconditional subscription notice to the Corporation (the "Bunge Subscription Notice") within 15 days from the date the Bunge Offering Notice is delivered (the "Bunge Offer Period").

(3) Each Bunge Subscription Notice shall set out Bunge's intention to subscribe for that number of Class C Common Shares as is equal to (x) the net proceeds to the Corporation of the applicable Proposed Financing, rounded up to the nearest whole number divisible by [commercially sensitive information redacted] without remainder; divided by, (y) [commercially sensitive information redacted], at a subscription price per share that is equal to $[commercially sensitive information redacted].

(4) The maximum aggregate number of Class C Common Shares that Bunge shall be entitled to subscribe for under this Section 5.2 shall be limited to [commercially sensitive information redacted] Class C Common Shares, representing an aggregate subscription of $[commercially sensitive information redacted].

(5) On delivery of the Bunge Subscription Notice the Corporation will accept the subscription for the applicable number of Class C Common Shares and the Bunge Subscription Notice will constitute a binding agreement by Bunge to subscribe for and purchase and by the Corporation to issue and sell to Bunge, on the terms and conditions contained in the Bunge Offering Notice, the applicable Class C Common Shares.

(6) If Bunge elects not to deliver a Bunge Subscription Notice within the relevant Bunge Offer Period then, subject to any other provisions of this Agreement, including without limitation Section 5.3, the Corporation shall be entitled to proceed with Proposed Financing on the terms set forth in the Bunge Offering Notice.

(7) The obligation of the Corporation to issue any Class C Common Shares to Bunge pursuant to this Section 5.2 is subject to and conditional on the issuance of such securities being exempt from all registration and prospectus requirements under applicable securities laws.

5.3 Pre-emptive Right Regarding Additional Securities.

(1) Except as the Voting Shareholders may otherwise unanimously approve and subject to Bunge's rights set forth in Section 5.2 during the Bunge Pre-emptive Period, any issuance of Shares or other securities of the Corporation, except pursuant to the Employee Incentive Plan, is subject to this Section 5.3.

(2) The Corporation must give notice to the Voting Shareholders (an "Offering Notice") each time an offering of Shares or other Securities of the Corporation is subject to Section 5.3. The Offering Notice must specify the terms and conditions of the offering, which for greater certainty shall be the same for each Voting Shareholder, including (i) the total number of Shares or other securities of the Corporation which are being offered (the "Offered Securities"), (ii) the rights, privileges, restrictions, terms and conditions of the Offered Securities, (iii) the consideration for such Offered Securities, and (iv) the closing date which may not be earlier than 30 days from the date the Offering Notice is delivered.


- 25 -

(3) Each Voting Shareholder may subscribe for its Proportionate Interest of the Offered Securities by delivering an irrevocable and unconditional subscription notice to the Corporation (the "Subscription Notice") within 15 days from the date the Offering Notice is delivered (the "Offer Period"). A subscribing Voting Shareholder may also specify in its Subscription Notice the percentage, if any, of the remaining Offered Securities that the Voting Shareholder is prepared to acquire, which Offered Securities are available because one or more Voting Shareholders did not subscribe for its Proportionate Interest.

(4) If a Voting Shareholder fails to deliver a Subscription Notice within the Offer Period, then any right of the Voting Shareholder to subscribe for any of the Offered Securities is extinguished. Subject to Section 5.3(6), the Offered Securities will be allotted to those Voting Shareholders subscribing for them in accordance with Section 5.3(5).

(5) If the number or amount of Offered Securities that the Voting Shareholders subscribe for and are prepared to acquire is equal to or greater than the total number or amount of Offered Securities:

(a) each Voting Shareholder who has subscribed for Offered Securities will be allotted and will purchase or advance that Voting Shareholder's Proportionate Interest of the Offered Securities; and

(b) if there are any Offered Securities remaining, each Voting Shareholder that wants to acquire any of the remaining Offered Securities will also be allotted and will purchase or advance:

number or amount of Offered Securities that are not already allotted to Voting Shareholders

X

percentage of remaining Offered Securities the Voting Shareholder is prepared to acquire as indicated in its Subscription Notice

X

100%

 

 

total percentage of remaining Offered Securities that all Voting Shareholders are prepared to acquire as indicated in their Subscription Notices

where the calculations above result in a fraction of an Offered Security being allotted to a Voting Shareholder, the number or amount of Offered Securities allotted to that Voting Shareholder will be increased or decreased, with 0.5 of an Offered Security being increased, to the nearest whole number of Offered Securities

(6) If the number or amount of Offered Securities that the Voting Shareholders subscribe for and are prepared to acquire is less than the total number of Offered Securities, those Offered Securities not subscribed for may then be offered and upon subscription allotted to any other Persons during the 90 day period following the expiry of the Offer Period. Any such allotment and issuance must be at the same or higher price and otherwise on the same terms and conditions as contained in the Offering Notice. If any of the Offered Securities are not issued within the 90 day period, the Corporation must, before allotting and issuing them to any Person, again comply with Article 4 and this Section 5.3.


- 26 -

(7) If the Offered Securities are allotted to Voting Shareholders under Section 5.3(5) the Corporation will accept the subscriptions for their allotted number or amount of Offered Securities by notifying each Voting Shareholder who subscribed for Offered Securities of the number or amount of Offered Securities allotted to that Voting Shareholder. Subject to Section 5.3(8), once accepted, each Subscription Notice constitutes a binding agreement by the Voting Shareholder to subscribe for and purchase or advance, and by the Corporation to issue and sell to that Voting Shareholder, on the terms and conditions contained in the Offering Notice, the number or amount of Offered Securities allotted to the Voting Shareholder.

(8) The obligation of the Corporation to issue any Offered Securities to a Voting Shareholder is subject to and conditional on the issuance of such securities being exempt from all registration and prospectus requirements under applicable securities laws.

ARTICLE 6
RESTRICTIONS ON TRANSFER

6.1 Restrictions on Transfer by Shareholders.

(1) No Shareholder may Transfer any Shares or Shareholder Loans except as expressly permitted by this Agreement or as otherwise consented to by the Parties hereto, and for greater clarity, no Class B Common Shares may be Transferred except as expressly permitted by the Articles and By-laws and with the unanimous consent of holders of the Class A Common Shares and the Class C Common Shares.

(2) Any purported Transfer of Shares in violation of this Agreement is void to the maximum extent permitted by Law. To the maximum extent permitted by Law, the Corporation will not permit such a purported Transfer to be recorded on the share register of the Corporation maintained for the Shares.

(3) Any Transfer of securities of a Shareholder (the "Shareholder Securities") other than to an Affiliate of such holder of Shareholder Securities which results in a change of Control of such Shareholder shall be deemed to be a Transfer hereunder and any such purported Transfer of Shareholder Securities in violation of this Section 6.1(3) shall be void; provided however, that such a Transfer shall not be deemed to be a change of Control if (i) in the case of [personal information redacted] Party A, [commercially sensitive information redacted], (ii) in the case of Bunge, Bunge Limited continues to Control Bunge, and (iii) in the case of BurconCo, Burcon NutraScience Corporation continues to Control BurconCo.

(4) To the maximum extent permitted by applicable law, from the date of any purported Transfer of Shares or Shareholder Securities in violation of this Agreement, all rights attaching to such Shareholder's Shares and all rights attaching to any other Shares of the Shareholders involved with the purported Transfer are suspended and are inoperative and the provisions of Section 8.6 will be in effect until the purported Transfer is rescinded. Without limiting the generality of the foregoing, during time such Shareholder's Shares may not be voted and no dividends or other distributions may be paid or made on such Shares. These rights are in addition to and not in lieu of any other remedies.

6.2 Permitted Transfers by Shareholders.

(1) Subject to this Section 6.2 each Shareholder is entitled to Transfer all but not less than all of its Shares (together with any and all Shareholder Loans owned by it) to an Affiliate (in each case, a "Permitted Transferee"). A Shareholder must give prior written notice to the Corporation and the other Shareholders of any such Transfer.

(2) No proposed Transfer to a Permitted Transferee is effective until the Permitted Transferee complies with Section 2.6. No Transfer to an Affiliate will relieve a transferring Shareholder from its obligations and liability under this Agreement, and the transferring Shareholder will be liable for the performance of the Permitted Transferees obligations under this Agreement and will cause the Permitted Transferee to remain a Permitted Transferee for as long as it has any registered or beneficial interest in the Shares.


- 27 -

(3) If a transferee Affiliate under this Section 6.2 ceases to be a Permitted Transferee of the transferring Shareholder, then such cessation, in each case, shall be deemed to be a Transfer and, without limiting the generality of the foregoing, shall be deemed to be a Transfer in violation of this Agreement pursuant to Section 6.1 such that all rights attaching to such Shares and all rights attaching to any other Shares of the Shareholders and their Affiliates involved with the purported Transfer are suspended and are inoperative until the purported Transfer is rescinded.

6.3 Encumbering of Shares.

No Shareholder may grant a lien on or otherwise encumber any of its Shares in any way whatsoever without the prior written consent of all of the other Shareholders, which consent may be unreasonably or arbitrarily withheld.

6.4 Concurrent Transfer of Shareholder Loans.

For the abundance of clarity, the Parties agree that no Voting Shareholder may Transfer any of the Voting Shares held by it unless, in connection with such Transfer, the Voting Shareholder concurrently Transfers to the relevant purchaser an equivalent portion of the Shareholders Loans owned by such selling Voting Shareholders.

ARTICLE 7
TRANSFERS TO THIRD PARTIES; RIGHT OF FIRST OFFER

7.1 Right of First Offer.

(1) If, at any time after the Call Option Expiry Time, any one or more Voting Shareholders (the "Selling Shareholder") desires to commence negotiations for the sale and Transfer of its Shares and Shareholder Loans to any Person that is not a Permitted Transferee, the Selling Shareholder must first offer its Shares and Shareholders' Loans to the other Voting Shareholders (the "Offer") in accordance with this Section 7.1. The Offer must be for all but not less than all of the Shares and Shareholders' Loans owned by the Selling Shareholder (the "Sale Shares") and the entire consideration for such Shares and Shareholders' Loans must be payable in cash on the Closing Date. The Offer must be made by notice in writing and specify the consideration per Sale Share. The Offer is not revocable except with the unanimous consent of all Voting Shareholders.

(2) A Voting Shareholder receiving an Offer from a Selling Shareholder shall have the right to purchase that portion of the Sale Shares which is equivalent to its Proportionate Interest, and shall have 30 days following the date of delivery or deemed delivery of the Offer (the "Offer Period"), to deliver to the Selling Shareholder, and the Corporation, an acceptance of the Offer (an "Offer Acceptance Notice"). Such Offer Acceptance Notice shall specify the maximum amount of the Sale Shares that such Voting Shareholder is prepared to purchase. If a Voting Shareholder fails to deliver an Offer Acceptance Notice within the Offer Period, then any right of the Voting Shareholder to acquire any of the Sale Shares is extinguished.

(3) If the aggregate number of Sale Shares that the Voting Shareholders accept the Offer for and are prepared to acquire is less than the total number of Sale Shares, the rights of the Voting Shareholders to acquire any of the Sale Shares are extinguished, none of the Sale Shares will be allotted to any of the Voting Shareholders and Section 7.2 will apply. If the aggregate number of Sale Shares that the Voting Shareholders accept the Offer for and are prepared to acquire is greater than the total number of Sale Shares, the Voting Shareholders shall acquire the Sale Shares in proportion to their respective Proportionate Interest.


- 28 -

(4) If the Sale Shares are allotted to Voting Shareholders under Section 7.1(3), the Selling Shareholder will notify each Voting Shareholder who accepted the Offer of the number of Sale Shares allotted to that Voting Shareholder. Each Offer Acceptance Notice constitutes a binding agreement by the Voting Shareholder to purchase and the Selling Shareholder to sell to the Voting Shareholder, the number of Sale Shares allotted to the Voting Shareholder, on and subject to the terms of the Offer and 8.6(d).

(5) The completion of any transaction of purchase and sale contemplated by this Section 7.1 (a "Sale Transaction") will take place on the Closing Date in accordance with and subject to 8.6(d). "Closing Date" means (i) the date which is 90 days after the expiry of the Offer Period, (ii) unless all filings, notices and Authorizations necessary to complete the Sale Transaction have not been made, given or obtained by that date in which case the closing date will be extended for up to 45 days in order to make, give or obtain the filings, notices and Authorizations, or (iii) such earlier or later date as the parties to the Sale Transaction agree in writing.

7.2 Third Party Sale.

(1) If the number of Sale Shares that the Voting Shareholders accept the Offer for and are prepared to acquire is less than the total number of Sale Shares, during the 90 day period following the expiry of the Offer Period, the Selling Shareholder is entitled to Transfer all but not less than all of the Sale Shares to any other Persons, subject to Section 7.3. The consideration for the Sale Shares in any such transaction must not be less than that amount contained in the Offer and there must be no collateral or other agreements or understandings applicable to the Transfer that reduces the consideration for the Sale Shares to below that contained in the Offer.

(2) If the Selling Shareholder does not Transfer the Sale Shares, or the transaction contemplated by the binding agreement is not completed within the 90 day period, then any future dispositions by the Selling Shareholder will once again be subject to Section 7.1.

(3) The right of first offer set out in Section 7.1 shall be subject to the piggy-back rights set out in Section 7.3.

7.3 Right of First Refusal

(1) If, at any time after the Call Option Expiry Time, a Voting Shareholder (for the purposes of this Section 7.3, such Voting Shareholder, the "Accepting Shareholder") receives and is prepared to accept a bona fide offer (the "Third Party Offer") from any arm's length third Person (for the purposes of this Section 7.3, the "Third Party") to purchase all but not less than all of its Shares and Shareholders' Loans owned by the Accepting Shareholder (for the purposes of this Section 7.3, such Shares and Shareholder Loans, the "ROFR Shares"), the Accepting Shareholder must as promptly as reasonable possible give notice of the proposed Third Party Offer (a "ROFR Notice") to the other Voting Shareholders. The ROFR Notice must (i) be by notice in writing, (ii) specify the consideration per ROFR Share payable by the Third Party, (iii) be accompanied by a copy of the terms and conditions applicable to the Third Party Offer, and (iv) specify the proposed completion date for the Third Party Offer.

(2) A Voting Shareholder receiving a ROFR Notice from an Accepting Shareholder shall have the right to purchase that portion of the ROFR Shares which is equivalent to its Proportionate Interest, and shall have 30 days following the date of delivery of the ROFR Notice (the "ROFR Period"), to deliver to the Accepting Shareholder, and the Corporation, a notice accepting the terms set out in the ROFR Notice (a "ROFR Acceptance Notice"). Such ROFR Acceptance Notice shall specify the maximum amount of the ROFR Shares that such Voting Shareholder is prepared to purchase and constitutes a binding agreement by the Voting Shareholder to purchase and the Accepting Shareholder to sell to the Shareholder, the number of ROFR Shares allotted to the Voting Shareholder, on and subject to the terms of the Offer and 8.6(d). If a Voting Shareholder fails to deliver a ROFR Acceptance Notice within the ROFR Period, then any right of the Voting Shareholder to acquire any of the ROFR Shares is extinguished. 


- 29 -

(3) If the aggregate number of ROFR Shares in respect of which ROFR Acceptance Notices are delivered is:

(a) equal to or greater than the total number of ROFR Shares, the Voting Shareholders shall acquire the ROFR Shares in proportion to their respective Proportionate Interest and Section 7.3(4) shall apply; or

(b) less than the total number of ROFR Shares, the rights of the Voting Shareholders to acquire any of the ROFR Shares are extinguished, none of the ROFR Shares will be allotted to any of the Voting Shareholders and Section 7.3(5) shall apply. 

(4) Subject to Section 7.3(3)(a): 

(a) the Accepting Shareholder will promptly notify each Voting Shareholder who delivered a ROFR Acceptance Notice of the number of ROFR Shares allotted to that Voting Shareholder; and

(b) the completion of any transaction of purchase and sale contemplated by this Section 7.4 (a "ROFR Sale Transaction") will take place on the ROFR Closing Date in accordance with and subject to 8.6(d). "ROFR Closing Date" means (i) the date which is 90 days after the expiry of the ROFR Period, (ii) unless all filings, notices and Authorizations necessary to complete the ROFR Sale Transaction have not been made, given or obtained by that date in which case the closing date will be extended for up to 45 days in order to make, give or obtain the filings, notices and Authorizations, or (iii) such earlier or later date as the parties to the ROFR Sale Transaction agree in writing.

(5) Subject to Section 7.3(3)(b), if the number of ROFR Shares in respect of which ROFR Acceptance Notices are delivered is less than the total number of ROFR Shares, then:

(a) during the 90 day period following the expiry of the ROFR Period, the Accepting Shareholder is entitled to Transfer all but not less than all of the ROFR Shares to Third Party in accordance with the terms set out in the ROFR Notice;

(b) if transaction contemplated by the ROFR Notice is not completed within the 90 day period, then any future dispositions by the Accepting Shareholder will once again be subject to this Section 7.3; and

(c) such transfer shall be subject to the piggy-back rights set out in Section 7.4(1).

7.4 Piggy-Back Rights.

(1) If a Voting Shareholder (for the purposes of this Section 7.4, such Shareholder(s), the "Vendor Shareholder") receives and is prepared to accept a bona fide offer (the "Piggy-Back Offer") from any arm's length third Person (for the purposes of this Section 7.4, the "Permitted Third Party") to purchase all but not less than all of the Shares and Shareholders' Loans owned by the Vendor Shareholder (for the purposes of this Section 7.4, such Shares and Shareholder Loans, the "Piggy-Back Shares") which it is entitled to accept pursuant to either Section 7.1(3) or 7.3(5), the Vendor Shareholder must give notice of the proposed Piggy-Back Offer (a "Piggy-Back Notice") to the other Shareholders. The Piggy-Back Notice must (i) be by notice in writing, (ii) specify the consideration per Piggy-Back Share payable by the Permitted Third Party, (iii) be accompanied by a copy of the terms and conditions applicable to the Piggy-Back Offer, (iv) specify the proposed completion date for the Piggy-Back Offer and (v) be delivered at least 30 days prior to such proposed completion date. Each of the other Shareholders has the right to require the Permitted Third Party to purchase all but not less than all of the Shares held by it on the same terms and conditions as the Vendor Shareholder proposes to accept. This right may be exercised by delivering an irrevocable and unconditional notice in writing to the Vendor Shareholder and the Permitted Third Party (the "Piggy-Back Acceptance Notice") within a period of five days from the date the Piggy-Back Notice is delivered.


- 30 -

(2) If any Shareholder gives a Piggy-Back Acceptance Notice within the specified time period, the Vendor Shareholder may not sell any of its Shares to the Permitted Third Party unless the Permitted Third Party also purchases from the Shareholders giving Piggy-Back Notices those Shares (and Shareholder Loans) subject the Piggy-Back Notice, at the time of completion of, and on the same terms and conditions applicable to, the Piggy-Back Offer by the Selling Shareholder.

7.5 Carry Along / Tag Along Provisions

(1) Subject to Section 7.5(2), in which case, Section 7.5(2) shall apply and this Section 7.5(1) shall not apply, in the case of a purchase in respect of which the purchaser is one of the Voting Shareholders, if each of the Voting Shareholders (or in the case of a purchase by a Voting Shareholder, each of the Voting Shareholders other than the Voting Shareholder who is the purchasing Shareholder) agree to sell all but not less than all of their Shares and Shareholder Loans pursuant to any, or any combination, of Sections 7.2, 7.3 or 7.4 the Voting Shareholders shall have the right to require that the remaining Shareholders sell all of their Class B Common Shares and Shareholder Loans to the same party acquiring the Shares to be sold by the Voting Shareholders (the "Buyer"). Such right may be exercised by notice in writing delivered to the other Shareholders at least 5 days prior to the closing of the transaction(s) contemplated by Section 7.2, 7.3 or 7.4. Each Shareholder receiving such a notice shall be obligated to sell all of its Class B Shares and Shareholder Loans to the Buyer for the same price and consideration and on the same terms as the Class A Common Shares, Class B Common Shares, and/or Shareholder Loans as applicable (including with respect to the price, consideration and time and method of completion).

(2) In the event of exercise of the Call Option by Bunge pursuant to Article 10 hereunder (and whether or not BurconCo has exercised its options pursuant to Section 10.7), Bunge shall have the right, by giving notice in writing to the holders of Class B Common Shares and securities exercisable or convertible into Class B Common Shares (the "Relevant Parties") no more than one hundred and fifty (150) days following the date of the sale and transfer of the Call Option Securities, to require that the Relevant Parties (i) exercise all, but not less than all, of the securities held by them that are exercisable or convertible into Class B Common Shares, and (ii) sell all, but not less than all, of their Class B Common Shares and Shareholder Loans, if any, to Bunge at a price that is determined in the same manner as the price paid (or payable) by Bunge to the Call Granting Shareholders in respect of their respective Call Option Securities. 

(3) In the event of exercise of the Call Option by Bunge pursuant to Article 10 hereunder (and whether or not BurconCo has exercised its options pursuant to Section 10.7), each of the Relevant Parties shall have the right, by giving notice in writing to Bunge no more than one hundred and fifty (150) days following the date of the sale and transfer of the Call Option Securities, to require that Bunge purchase all, but not less than all, of such Shareholders' Class B Common Shares and Shareholder Loans, if any, to Bunge at a price that is determined in the same manner as the price paid (or payable) by Bunge to the Call Granting Shareholders in respect of their respective Call Option Securities. 


- 31 -

(4) Closing of sale and purchase of the Class B Common Shares (and Shareholder Loans) pursuant to either or both of Section 7.5(2) and 7.5(3) shall take place on the date that is six (6) months following the date of the completion of the sale and transfer of the Call Option Securities, or such earlier date as Bunge may determine in its sole discretion, and payment of the purchase price payable by Bunge to such Shareholders shall be payable in full in cash on the closing date, provided that, in connection with the exercise or conversion of any securities held by Relevant Parties that are exercisable or convertible into Class B Common Shares, the Relevant Parties may direct that Bunge deliver the applicable portion of the purchase price otherwise payable to them to the Corporation in satisfaction of the exercise price payable by such Relevant Parties to the Corporation on the exercise of the relevant securities.

7.6 Third Party Sale Provisions

(1) A Transfer of Shares under Section 7.2, 7.3, 7.4 or 7.5 is not permitted and the Corporation will not register any such Transfer on the share register maintained for the Shares unless (i) Section 2.6 is complied with and (ii) all debt owing to the Corporation by each Shareholder proposing to Transfer their Shares to the Third Party has been repaid or assumed and transferred to the Third Party.

(2) The Parties acknowledge that the completion of any Transfer of Shares to the Third Party is subject to all filings, notices and Authorizations necessary to complete the Transfer being made, given or obtained. The time for completion of the Transfer will be extended for up to 45 days if necessary for such purposes.

ARTICLE 8
TRIGGERING EVENTS

8.1 Triggering Events.

(1) The following circumstances are each a "Triggering Event":

(a) a Shareholder (i) acknowledges that he or it is insolvent or unable to pay his or its debts as they become due, (ii) makes an assignment for the benefit of his creditors, (iii) appoints or allows the appointment of any receiver, receiver-manager, trustee, liquidator or other Person acting in a similar capacity, (iv) institutes any proceeding seeking to have he or it adjudicated a bankrupt or insolvent, or (v) takes subject to any action or institutes any proceeding for the purpose of, or leading to, the liquidation, dissolution, winding-up, reorganization, arrangement, adjustment, protection, relief or composition of such Shareholder or its debts under any law relating to bankruptcy, insolvency, reorganization or relief of debtors;

(b) the initiation of proceedings or other actions through which a Shareholder may be adjudicated bankrupt or insolvent, or may be liquidated, dissolved, wound-up, or reorganized, or granted relief or protection under any Law relating to bankruptcy, insolvency, liquidation, reorganization, moratorium or relief of debtors, including under the Companies' Creditors Arrangement Act (Canada) and the Bankruptcy and Insolvency Act (Canada), or other similar applicable laws;

(c) the initiation of proceedings or other actions which would result in the seizure of Shares for payment or satisfaction of any judgement or order of a Court;


- 32 -

(d) the granting or exercise of any security interest in respect of any Shares or the placing of any lien or other encumbrance on any Shares (other than security granted to a lender to the Corporation where all Shares are subject to a security interest);

(e) commencement of any application or proceeding by a Spouse or former Spouse or dependent of a Person who is a Shareholder or directly or indirectly Controls a Shareholder to determine the entitlement of that Spouse, former Spouse or dependent to Shares held by such Shareholder, unless evidence reasonably satisfactory to the other Shareholders is provided to confirm that the financial claims of that Spouse, former Spouse or dependent can be settled without in any way, directly or indirectly, affecting, encumbering or resulting in the Transfer of Shares to or in favour of that Spouse, former Spouse or dependent; or

(f) a Shareholder transfers his Shares to any Person other than a Permitted Transferee unless in accordance with Section 6.2.

(2) For the purposes of this Article 8, the term Shareholder includes any executor, administrator, guardian, committee, liquidator, receiver, trustee or other legal representative or Person empowered at law to dispose of the property of the Shareholder.

(3) A Shareholder must give notice to the Corporation promptly following the occurrence of a Triggering Event.

8.2 Irrevocable Option to Purchase Shares and Shareholder Loans.

(1) Where a Triggering Event occurs with respect to a Shareholder (the "Triggered Shareholder") such Triggered Shareholder hereby grants to the other Shareholders that are Voting Shareholders (the "Remaining Shareholders") an irrevocable option (the "Triggering Option"), for so long as the Triggered Shareholder is a Shareholder, to purchase the Shares held by Triggered Shareholder together with all Shareholder Loans owing to the Triggered Shareholder (collectively, and including any Shareholder Loans, the "Triggered Securities") on and subject to the terms of this Section 8.2.

(2) The Corporation will notify the Remaining Shareholders as soon as the Board becomes aware of a Triggering Event.

(3) The Remaining Shareholders may exercise the Triggering Option to purchase all of the Triggered Securities by delivering an irrevocable and unconditional notice to the Corporation and to the Triggered Shareholder (the "Option Notice") within 30 days from the date notice of the Triggering Event is delivered by the Corporation (the "Option Period").

(4) If the Remaining Shareholders are unable or unwilling to exercise the Triggering Option to acquire all of the Triggered Securities, the Remaining Shareholders will notify the Corporation and the Corporation shall have the right to repurchase the Triggered Securities on the same terms as set out in this Article 8.

8.3 Purchase Price for Triggered Securities.

(1) The purchase price (the "Triggered Securities Price") for the Triggered Securities shall be equal to 90% of the fair market value of such Shares (and Shareholders' Loans) as determined in accordance with this Section 8.3.

(2) Upon receiving notice of or becoming aware of a Triggering Event, the Corporation, the Triggered Shareholder and the Remaining Shareholders will negotiate expeditiously and in good faith to arrive at a mutually agreeable fair market value for the Triggered Securities. If the Corporation, the Triggered Shareholder and the Remaining Shareholders cannot agree, the fair market value of the Triggered Securities will be determined by the Valuator. The "Valuator" means an independent valuator, appointed by the unanimous approval of the Voting Shareholders, and failing such appointment will be such other independent valuation, accounting or investment banking firm selected by the Corporation's auditors. The costs and expenses of the Valuator will be paid by the Corporation.


- 33 -

(3) The Valuator will determine the fair market value of the Triggered Securities as at the date of the Corporation's most recent fiscal year end, based upon the EBITDA of the Corporation for the preceding 12 months prior to the Triggering Event, as quickly as practicable after the date of its selection, having regard to the factors identified below. The Valuator may also have regard to any representations that the Triggered Shareholder or any Remaining Shareholder may wish to make. The Valuator will deliver its report concerning the fair market value of the Triggered Securities to the Corporation, the Triggered Shareholder and each of the Remaining Shareholders and the fair market value set out in that report will be conclusive and binding. In making such determination, the Valuator is considered to be acting as an expert and not an arbitrator.

(4) As used in this Section, "fair market value" means the price per Share that would have been received if all of the issued and outstanding Shares were sold in a single transaction in an open and unrestricted market between prudent parties, acting at arm's length and under no compulsion to act, and having reasonable knowledge of all relevant facts without any discount for a minority interest or premium for a majority interest.

8.4 Closing.

The completion of any transaction of purchase and sale contemplated by this Article 8 (a "Sale Transaction") will take place on the Closing Date in accordance with and subject to Article 9. "Closing Date" means:

(a) the later of:

(i) the date which is 90 days after the relevant Triggering Event; and

(ii) the date which is 30 days after the Triggered Securities Price is finally determined in accordance with Section 8.3;

(b) unless all filings, notices and Authorizations necessary to complete the Sale Transaction have not been made, given or obtained by that later date in which case the closing date will be extended for up to 45 days in order to make, give or obtain the filings, notices and Authorizations; or

(c) such earlier or later date as the parties to the Sale Transaction may agree in writing.

8.5 No Sale.

Notwithstanding any designation of the Corporation as Purchaser under Section 8.2, the Corporation may not complete any Sale Transaction contemplated by this Section 8.5 if, at the Time of Closing, the Sale Transaction is prohibited by the Act or otherwise by law. If the Corporation is prohibited from completing a Sale Transaction contemplated by this Section 8.5, the Triggered Shareholder and its Permitted Transferees may retain the Triggered Securities that the Corporation could not acquire.


- 34 -

8.6 Restrictions on Rights.

Upon the occurrence of a Triggering Event giving rise to a Triggering Option pursuant to Section 8.2, the Triggered Shareholder:

(a) has no right to nominate any Directors under Section 3.1;

(b) is not required nor entitled to approve the matters contemplated under Section 4.3 except as required by Law, which, for greater certainty, means that the Remaining Shareholders shall have the right to approve matters contemplated under Section 4.3 and the percentages required to pass an Ordinary Resolution or a Special Resolution will be determined based on the aggregate number of Shares held by such Remaining Shareholders without reference to the Triggered Securities;

(c) has no right to subscribe for any Offered Securities under Section 5.3; and

(d) has no right to Transfer Shares under Section 6.2.

ARTICLE 9
PROCEDURE FOR SALE OF SHARES

9.1 Closing Procedures.

(1) The completion of a Sale Transaction, a ROFR Sale Transaction, or a sale and transfer of the Call Option Securities pursuant to Article 10 (in each case, including any sales and transfers pursuant to Section 7.4 or 7.5 arising in connection therewith) will take place at the offices of Taylor McCaffrey LLP in Winnipeg, Manitoba, at the Time of Closing on the Closing Date or at such other place, on such other date and at such other time as the parties to the Sale Transaction, the ROFR Sale Transaction, or the transaction in respect of the sale and transfer of the Call Option Securities, as applicable, may agree to in writing.

(2) At the closing of the Sale Transaction:

(a) The Vendor will (i) assign and transfer title and deliver actual possession of the Purchased Shares and all Shareholder Loans to the Purchaser free and clear of all liens and encumbrances, other than those contained in the Corporation's articles and this Agreement and (ii) endorse the Share certificates representing the Purchased Shares for transfer to the Purchaser;

(b) The Vendor will provide the Purchaser with evidence that the Vendor is not a non-resident of Canada within the meaning of the Income Tax Act (Canada) or provide the Purchaser with a certificate pursuant to subsection 116(2) of the Income Tax Act (Canada) with a certificate limit in an amount not less than the Triggered Securities Price; 

(c) All guarantees, indemnities, covenants and security made or granted by the Vendor to secure any debt, liability or obligation of the Corporation (i) will be cancelled, or (ii) the Purchaser will indemnify and save harmless each of the Vendor against all losses, liabilities, claims, damages or expenses which may be paid, suffered or incurred with respect to the guarantees, indemnities, covenants or security;

(d) Subject to Section 9.1(2)(e), the Purchaser will pay or satisfy the purchase price for the Purchased Shares by delivering to the Vendor a certified cheque, bank draft or wire transfer of immediately available funds in the full amount of the purchase price for the Purchased Shares; and


- 35 -

(e) All debt owing by the Vendor to the Corporation will be repaid or assumed and transferred to the Purchaser. If the Vendor fails to repay the debt and it is not transferred to the Purchaser, the Purchaser will pay the amount of the debt from the Triggered Securities Price and the amount of the purchase price payable to the Vendor will be reduced accordingly.

9.2 Approvals.

The Parties acknowledge that the completion of any Sale Transaction is subject to (i) all filings, notices and Authorizations necessary to complete the Sale Transaction being made, given or obtained and (ii) the Sale Transaction not resulting in the violation of any applicable law.

9.3 Multiple Purchasers and Vendors.

For greater certainty, the Parties acknowledge and agree that where a Sale Transaction involves more than one Purchaser or more than one Vendor, each Purchaser and each Vendor in such Sale Transaction is only liable for its own representations, warranties, covenants, conditions and agreements. No Vendor or Purchaser is jointly liable with any other Vendor or Purchaser for the representations, warranties, covenants, conditions and agreements of any other Purchaser or Vendor.

9.4 Irrevocable Power of Attorney.

Each Shareholder irrevocably constitutes and appoints each other Shareholder that is a Voting Shareholder as the true and lawful attorney of the Shareholder for the purposes set out in this Section 9.4. As the attorney of the Shareholder, the appointed Shareholder has the power to act for and in the name of the Shareholder, with full power of substitution, to execute and deliver such documents, instruments or agreements, (including all transfers, share certificates, resignations and releases) and do all acts and things necessary to complete any Sale Transaction under which the Shareholder is the Vendor and the attorney is the Purchaser.

This power of attorney is irrevocable, is coupled with an interest, has been given for valuable consideration (the receipt and adequacy of which is acknowledged) and survives, and does not terminate upon, the legal or mental incapacity, death, bankruptcy, dissolution, winding-up or insolvency of the Shareholder. This power of attorney extends to and is binding upon the Shareholder's successors and permitted assigns. This power of attorney supersedes any prior delegation of authority that conflicts with it.

9.5 Continuing Obligations.

If a Shareholder Transfers all of its Shares, the obligations of the Shareholder under Article 12 continue in full force and effect.

ARTICLE 10
BUNGE CALL OPTION

10.1 Grant of Call Option

Each of [personal information redacted] Party A and [personal information redacted] Party B (the "Call Granting Shareholders") hereby grant to Bunge the option (the "Call Option") to purchase all, but not less than all, of the Shares (and Shareholder Loans) held by them on the date the Call Option is exercised (collectively, the "Call Option Securities") at a purchase price equal to the Call Option Price until the Call Option Expiry Time.


- 36 -

10.2 Calculation of Call Option Price

The purchase price payable by Bunge to each respective Call Granting Shareholders in respect of their respective Call Option Securities (the "Call Option Price") shall be that amount as is determined by the following formula:

[commercially sensitive information redacted]

10.3 Vesting of Call Option

(1) The Call Option shall vest and become exercisable on the first to occur of:

(a) the date on which the Call Granting Shareholders elect to cause the vesting of the Call Option by delivering a notice in writing to Bunge, with a copy for information purposes delivered to each of the Corporation and BurconCo;

(b) the first to occur of the date on which: (i) the Directors and Voting Shareholders authorize and approve the Corporation's Phase 2 expansion of its facility to full commercial production capacity; or (ii) the Corporation commences material physical construction, renovations or installations at or to the Plant in connection with its Phase 2 expansion of its facility to full commercial production capacity (in either case, a "Call Option Phase 2 Trigger");

(c) [commercially sensitive information redacted],

(the "Call Option Vesting Date").

(2) If an event, the cause of which is beyond the control of the Parties, including but not limited to acts of God, states of emergency caused by a global pandemic, war, strikes, labor disputes, embargoes, government orders (including lock-downs, shelter in place and similar orders), fires, floods or other similar force majeure events, that prevents the operation of, or the sale of Product from, the Plant (each, a "Force Majeure Event") occurs after the Call Option Vesting Date or prior to the Call Option Vesting Date and is continuing on the Call Option Vesting Date, the Call Option Expiry Time shall be extended for a time period equal to the length of the delay caused by the Force Majeure Event and for so long as such Force Majeure Event continues Bunge shall be prohibited from exercising the Call Option. 

10.4 Call Option Expiry

Subject to the provisions hereof, Bunge shall have the right to exercise the Call Option at any time prior to 5:00 pm Winnipeg time on the date that is nine months following the later of (i) the Call Option Vesting Date, or (ii) the date on which the Call Option Price is finally determined in accordance with Section 15.1(4) (in either event, the "Call Option Expiry Time"). At and from the Call Option Expiry Time, the Call Option shall forthwith expire and terminate and be of no force and effect whatsoever.

10.5 Exercise of Call Option

(1) The Call Option shall be exercisable by Bunge by delivering a notice (the "Call Option Exercise Notice") in writing to each of the Call Granting Shareholders and BurconCo, which Call Option Exercise Notice shall, within fifteen (15) Business Days, be followed by payment by Bunge by way of wire transfer to the Corporation, in its capacity as paying agent acting for and on behalf of the Call Granting Shareholders, for the full Call Option Price payable to each of the Call Granting Shareholders (in each case, net of any applicable withholding tax), provided that (i) in the event of a Dispute as to the Call Option Price, no payment is required to be made until the date that is fifteen (15) Business Days following the date that the Call Option Price is finally determined in accordance with Section 15.1(4), (ii) in the event that the exercise of the Call Option is subject to the approval or consent of any Governmental Entity, including without limitation, under the Investment Canada Act, no payment is required to be made until the date that is fifteen (15) Business Days following the date that such approval or consent is provided or received, and (iii) in the event that the Call Option Price determined in accordance with Section 15.1(4) is an amount that is greater than 110% of the Call Option Price: (A) contained in the initial Call Option Exercise Notice; or (B) that would be payable had the Call Option Exercise Notice been delivered on the date that the Call Option Price is determined in accordance with Section 15.1(4) as a result of the positive actions, negligence or neglect of the Call Granting Shareholders with respect to the operation of the Business (and for clarity, without reference to normal fluctuations in the performance of the Business that occur notwithstanding the due care and attention of the Call Granting Shareholders), Bunge shall have the option, at its sole discretion, to rescind the Call Option Exercise Notice.


- 37 -

(2) Concurrent with payment by Bunge of the Call Option Price, the Call Granting Shareholders shall (i) each direct the Corporation, and provide the Corporation with whatever documentation may be requested by the Corporation in connection with processing the transfer of the Call Option Securities to Bunge, to deliver to Bunge (A) a share certificate in the name of Bunge representing the Shares so purchased by Bunge, and (B) any documentation required in order to transfer the benefit of the applicable Shareholder Loan to Bunge, and (ii) be deemed to make those representations and warranties as are contained in Article 11.1 as of such date.

10.6 Pre-Vesting Call Option

Notwithstanding the provisions of Sections 10.2 through 10.5 hereof inclusive, Bunge shall have an additional option (the "Pre-Vesting Call Option") to purchase all, but not less than all, of the Shares (and Shareholder Loans) held by the Call Granting Shareholders at any time prior to the Call Vesting Date by delivering a notice (the "Pre-Vesting Call Option Exercise Notice") in writing to each of the Call Granting Shareholders and BurconCo, which Pre-Vesting Call Option Exercise Notice shall, within fifteen (15) Business Days, be followed by payment by Bunge by way of wire transfer to the Corporation, in its capacity as paying agent acting for and on behalf of the Call Granting Shareholders, for the full Pre-Vesting Call Option Price payable to each of the Call Granting Shareholders (in each case, net of any applicable withholding tax).  For the purposes of this Section 10.6, the "Pre-Vesting Call Option Price" shall mean an amount determined pursuant to Section 10.2, [commercially sensitive information redacted].  For greater certainty, the right to exercise the Call Option pursuant to this Section 10.6 shall terminate immediately upon the occurrence of the Call Vesting Date.

10.7 BurconCo Piggy-Back Option

(1) On receipt of the Call Option Exercise Notice or the Pre-Vesting Call Option Exercise Notice, as the case may be, BurconCo has the right to require that Bunge purchase all, but not less than all, of the Shares (and Shareholder Loans) held by it on the same terms and conditions (including with respect to pricing and the timing of sale) as are applicable to the purchase of the Call Option Securities acquired on exercise of the Call Option. This right may be exercised by BurconCo delivering an irrevocable and unconditional notice in writing to Bunge (the "Call Option Piggy-Back Notice") within a period of ten (10) Business Days from the first to occur of: (i) the 90th day following closing of the Call Option Exercise; and (ii) the date the License Conversion Notice (as defined in the License Agreement) is delivered.


- 38 -

(2) If BurconCo delivers the Call Option Piggy-Back Notice within the specified time period, then no Call Granting Shareholder may sell and Bunge may not purchase, any of the Call Option Securities unless Bunge also purchases from BurconCo all of the Shares (and Shareholder Loans) held by it, at the time of completion of, and on the same terms and conditions applicable to, the purchase and sale of the Call Option Securities.

10.8 Impact on Debt Financings

(1) On closing of the Call Option Exercise, Bunge shall enter into financing transactions with the Corporation, such that Bunge shall provide to the Corporation loans, having, in the aggregate, terms that are materially similar to those of the Corporation's then existing third party financing arrangements (which for clarity shall exclude customary supplier, trade and other day-to-day credit as well as any Shareholder Loans then outstanding), the proceeds of which shall be applied to satisfy in full such existing third party financing arrangements and to ensure the discharge of any and all mortgages, liens, charges, pledges, encumbrances, security interests or adverse claims against the Corporation in respect thereof, provided that Bunge will pay all additional fees, costs and expenses incurred in connection with the election to prepay the Corporation's then existing third party financing arrangements (and excluding, for clarity, any prepayment fees, costs and expenses resulting otherwise than from a voluntary election to prepay such obligation(s) or any costs that would otherwise have been payable whether immediately or with the passage of time).

(2) From and after the closing of the Call Option Exercise, the Corporation shall not enter into any financing arrangements or other debt obligations (including the provision of any guarantee) (which for clarity shall exclude customary supplier, trade and other day-to-day credit) or allow for any mortgage, lien, charge, pledge, encumbrance, security interest or adverse claim against to the Corporation except as such financing arrangements as may be provided by Bunge from time to time on terms no less favourable to the Corporation than could be obtained in a comparable arm's length transaction, and provided that the Corporation shall not enter into any financing arrangement or other debt obligation with Bunge that would result in the Corporation having a debt (without reference to the Shareholder Loans) to equity (inclusive of the value of the Shareholder Loans) ratio greater than [commercially sensitive information redacted] and any mortgages, liens, charges, pledges, encumbrances, security interests or adverse claims against the Corporation in respect thereof. 

(3) Concurrent with or prior to the Closing of the Call Option Exercise, each of the Voting Shareholders shall enter into an amending agreement with respect to their respective Shareholder Loans, pursuant to which the terms of each Shareholder Loan will be amended such that, unless otherwise satisfied in full prior to their maturity date pursuant to payments made in accordance with the Distribution Policy (or otherwise): (i) the obligation to repay such Shareholder Loan, in whole or in part, will be limited to payments from free cash flow from operations made on all of the Shareholder Loans on a pari passu basis at maturity; (ii) any amount of the Shareholder Loans that remain unpaid at their maturity date shall remain outstanding in respect of such unpaid portion (including any accrued or to be accrued interest thereon) until paid from free cash flow from operations, through payments made on all of the Shareholder Loans on a pari passu basis; and (iii) any failure of Merit to satisfy in full any Shareholder Loan on its maturity date, and the continuing term of such Shareholder Loan, or portion thereof, in accordance with (ii) shall not be an event of default under the Shareholder Loans.


- 39 -

ARTICLE 11
REPRESENTATIONS AND WARRANTIES/COVENANTS/INDEMNITY

11.1 Representations and Warranties of the Shareholders.

Each Shareholder represents and warrants as follows and acknowledges and confirms that the other Parties are relying on such representations and warranties in entering into this Agreement:

(a) such Shareholder is the legal and beneficial owner of those Shares as set out opposite such Shareholder's name in Schedule A;

(b) the truth and accuracy of those statements contained in Recitals A through H, J, K and L;

(c) except as expressly contemplated or permitted by the terms of this Agreement, none of the Securities held by such Shareholder are subject to any mortgage, lien, charge, pledge, encumbrance, security interest or adverse claim and that, except as expressly set out in this Agreement, no Person has any rights to become an owner, holder or possessor of any of such Securities or of the certificates representing the same;

(d) such Shareholder has duly executed and delivered this Agreement and it constitutes a valid and binding obligation enforceable in accordance with its terms, subject to the usual exceptions as to bankruptcy and the availability of equitable remedies;

(e) such Shareholder is not a non-resident of Canada within the meaning of the Income Tax Act and, if such Shareholder is a partnership, is a "Canadian partnership" within the meaning of the Income Tax Act;

(f) where such Shareholder is not an individual:

(i) it has been duly incorporated, organized or formed, as applicable, and is validly existing, under the laws of its jurisdiction of incorporation, organization or formation;

(ii) it has the corporate power and capacity to own its assets and to enter into and perform its obligations under this Agreement;

(iii) the execution and delivery of this Agreement has been duly authorized by all necessary corporate action on its part;

(iv) the execution, delivery and performance of this Agreement does not and will not contravene the provisions of its notice of articles, articles, by-laws, limited partnership agreement, deed of trust, or other constating or organizational documents or the documents by which it was created or established;

(v) the authorized and issued capital of each of the Shareholders is set out in Schedule D including the registered and beneficial holders of all such issued shares;

(vi) except as expressly contemplated or permitted by the terms of this Agreement, none of securities of any Shareholder are subject to any mortgage, lien, charge, pledge, encumbrance, security interest or adverse claim and, except as expressly set out in this Agreement, no Person has any rights to become an owner, holder or possessor of any of such securities or of the certificates representing the same;


- 40 -

(g) the execution, delivery and performance of this Agreement does not and will not: contravene the provisions of any indenture, agreement or other instrument to which the Shareholder is a party or by which the Shareholder may be bound; result in the imposition of any mortgage, lien, charge, pledge, encumbrance, security interest or adverse claim upon any of the assets of such Shareholder; or give any Governmental Entity or other person the right to challenge any of the transactions contemplated by this Agreement or to exercise any remedy or obtain any relief under any Laws; and

(h) the Shareholder is not a party to any voting trust, proxy or other agreement or understanding with respect to the voting of any of the Shares in the Corporation other than as expressly set forth in this Agreement.

11.2 Indemnification.

(1) Each Shareholder (together, and each of them, the "Indemnifying Party") agrees that it will defend, indemnify and save harmless each of the other Shareholders (and their Permitted Transferees) and the Corporation (either or both the "Indemnified Party") from, against and in respect of, any damage, obligation, loss, damage, judgment, cost, penalty, or other cost or expense (including, without limitation, reasonable legal fees and disbursements and accountant's fees, costs, and expenses reasonably incurred in defending against any litigation or claim, action, suit, proceeding, or demand (in any such case a "Claim")) sustained, incurred, or suffered by the Indemnified Party, either directly or indirectly, arising out of or resulting from the performance (or not) of the Indemnifying Party's obligations hereunder or as a consequence of a breach by the Indemnifying Party of any restrictive covenant in an agreement to which it is a party, precluding such Party from entering into this Agreement, and including where applicable, the use by the Corporation of any information that is alleged to be in breach of confidentiality obligations of the Indemnifying Party to any Person.

(2) In the event the Indemnified Party becomes aware of any Claim the Indemnified Party will promptly give written notice thereof to the Indemnifying Party (a "Notice of Claim"). Such Notice of Claim will specify with reasonable particularity (to the extent that the information is available), (i) the factual basis for the Claim, and (ii) the amount the Indemnified Party is seeking to be paid by the Indemnifying Party. A failure to give a Notice of Claim promptly as provided in this Section 11.2 will not affect the rights or obligations of the Indemnified Party except and only to the extent that, as a result of such failure, the Indemnifying Party entitled to receive such Notice of Claim was directly prejudiced as a result of such failure.

(3) The Indemnifying Party will have the right, at the expense of the Indemnifying Party, to participate in or assume control of the negotiation, settlement or defence of a Claim provided that they have first provided sufficient evidence to the Indemnified Party that the Indemnifying Party has the resources to conduct such negotiation, settlement, or defense of such Claim and to fulfill its indemnification obligations hereunder. If the Indemnifying Party elects to assume such control, the Indemnified Party will have the right to participate in the negotiation, settlement or defense of such Claim and to retain counsel to act on its behalf, provided that the fees and disbursements of such counsel will be paid by the Indemnified Party unless the Indemnifying Party consents to the retention of such counsel or unless the named parties to any action or proceeding include both the Indemnifying Party and the Indemnified Party and, based on the reasonable advice of outside counsel, representation of both the Indemnifying Party and the Indemnified Party by the same counsel would be inappropriate due to the actual or probable conflicting interests between them (such as the availability of different defenses).


- 41 -

(4) Notwithstanding the foregoing provisions of this Section 11.2 the Indemnified Party will have the sole and exclusive right to participate in or assume control of the negotiation, settlement or defense of a Claim if the Claim seeks any injunctive or other relief (other than monetary damages) against the Indemnified Party, in which case, the Indemnifying Party will have the right to participate in the negotiations, settlement or defense of such Claim and to retain counsel to act on its behalf and at its expense.

(5) Whether or not the Indemnifying Party assumes control of the negotiation, settlement, or defense of any Claim, the Indemnified Party will not settle or pay any Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld, conditioned, or delayed. The Indemnified Party and the Indemnifying Party will consult and co-operate fully with each other on a timely basis with respect to the Claim, and will keep each other fully advised with respect thereto (including supplying copies of all relevant documentation promptly as it becomes available). The Indemnified Party will make available to the Indemnifying Party or its representatives, on a timely basis, all documents, records and other materials in the possession of the Indemnified Party that are reasonably required by the Indemnifying Party for its use in connection herewith, all at the cost and expense of the Indemnifying Party.

11.3 Survival

The representations, warranties and covenants of the Parties contained in this Article survive the execution and delivery of this Agreement and continue in full force and effect with respect to each Party until it ceases to be bound by the provisions of this Agreement. Section 11.2 will survive and continue in full force and effect after the termination of this Agreement.

11.4 Most Favoured Customer

(1) The Corporation acknowledges and agrees that for so long as Bunge is a direct or indirect Voting Shareholder, Bunge, or an Affiliate thereof, shall have the right, but not the obligation, to purchase, from time to time, any amount of any products produced by Merit (the "Products") from the Corporation as it so desires at the lowest price paid by, and on terms otherwise no less favourable to Bunge than given to, any other Person for such Products (exclusive of taxes, duties, transportation and freight) during in the twelve (12) months immediately preceding the date on which Bunge, or an Affiliate thereof, announces its intention to complete such a purchase by way of the delivery, from time to time, of a written purchase order (each, a "Purchase Order") to the Corporation, provided that such twelve (12) month period shall only include one crop year. Each Purchase Order shall be delivered no less than thirty (30) days prior to the requested delivery and in accordance with Section 16.1.

(2) If at any time for so long as Bunge is a direct or indirect Voting Shareholder, the Corporation agrees to be paid by a Person a lower price for Products (exclusive of taxes, duties, transportation and freight) than that paid by, or otherwise agrees to the sale of Products on terms that are more favourable to the purchaser than those offered to, Bunge, or an Affiliate thereof, for the same Products in the six (6) months immediately preceding the payment by such other Person, the Corporation will promptly notify Bunge in accordance with Section 16.1, with such notice to set out each affected Product and the applicable lower price or improved terms agreed to with such other Person (each, a "Price Notice"). Upon receipt of a Price Notice by Bunge, and for the 12 month period immediately following such receipt, Bunge, or an Affiliate thereof, will be entitled to pay, and will only pay, the lower price paid by such other Person for the corresponding Products should Bunge, or an Affiliate thereof, elect to exercise its right to purchase Products at such lower price pursuant to this Section11.4.

(3) Should a dispute arise between Bunge and the Corporation relating to the value of any lowest price for Products, or the value of the lower price paid for Products set out in a Price Notice, the dispute resolution provisions set out in Article 15 shall apply.


- 42 -

ARTICLE 12
CONFIDENTIALITY

12.1 Confidentiality Obligation.

Each Shareholder and their respective directors, officers and shareholders, will keep all Confidential Information confidential and will not disclose any Confidential Information to any Person or use any Confidential Information except in connection with the operation by the Corporation of the Business or as otherwise permitted by this Agreement or under the Licence Agreement. Where information is determined by management to be competitively sensitive and/or highly confidential in nature, the Corporation or disclosing Shareholder shall notify the other Shareholders and their nominee Directors of the nature of such information prior to disclosure so that the parties may take steps to prevent receipt of such Confidential Information, including the withholding or redacting of such information. For clarity, the Corporation shall in no case be obliged to disclose any Confidential Information to Bunge or any of its officers, directors, employees or advisors prior to the exercise by Bunge of the Call Option or Pre-Vesting Call Option, where such disclosure contains, in the opinion of management of the Corporation acting reasonably, identifiable competitively sensitive information. 

A Shareholder may disclose Confidential Information to its directors, officers, employees and advisors but only to the extent that they need to know the Confidential Information, they have been informed of the confidential nature of the Confidential Information and they agree to be bound by and act in accordance with this Section. Each Shareholder will notify the Corporation as soon as practicable of the identity of each director, officer, employee and advisor to whom any Confidential Information has been disclosed. "Confidential Information" means all information relating to the business, operations, assets, liabilities, plans, prospects and other affairs of the Corporation and the other Shareholders, in whatever form, but does not include any information that (i) is or becomes generally available to and known by the public (other than as a result of its disclosure directly or indirectly by a Shareholder, its directors, officers, employees or advisors in violation of this Agreement), (ii) is or becomes available to the Shareholder, its directors, officers, employees or advisors from a source other than the Corporation, the other Shareholders or their directors, officers, employees or advisors, provided that such source, to the best of the Shareholder's knowledge was not and is not bound by a confidentiality agreement regarding such information, or otherwise prohibited from disclosing such information to the Shareholder, its directors, officers, employees or advisors by a legal, contractual or fiduciary obligation, (iii) was already known by or in the possession of the Shareholder, its directors, officers, employees or advisors as established by documentary evidence before being disclosed by or on behalf of the Corporation or the other Shareholders pursuant to this Agreement, or (iv) has been or is independently developed by the Shareholder, its directors, officers, employees or advisors as established by documentary evidence without violating any of its obligations under this Agreement or use of or reference to, in whole or in part, any of the Confidential Information.

12.2 Confidentiality Exceptions.

The restrictions set out in Section 12.1 do not apply to Confidential Information or any part of it that (i) is required to be disclosed by applicable law, or (ii) is permitted in writing to be disclosed by the Person who owns such Confidential Information.

12.3 Ownership of Confidential Information.

To the extent that any Confidential Information is owned by a Party it will remain the exclusive property of that Party. Nothing in this Agreement or in the disclosure of any Confidential Information will confer any interest in the Confidential Information on a receiving party.


- 43 -

ARTICLE 13
NON-COMPETITION/NON-SOLICITATION

13.1 Non-Competition.

Each Shareholder, other than Bunge and BurconCo, (for the purposes of this Article 13, each such Shareholder, other than Bunge and BurconCo, a "Restricted Party"), covenants in favour of the Corporation and each Subsidiary of the Corporation that for so long as he or it is a direct or indirect Shareholder of the Corporation and for a period of eighteen (18) months after the date on which the Restricted Party ceases to be a direct or indirect Shareholder in the Corporation, or such longer period as the Restricted Party may agree in writing with the Corporation (the "Limitation Period"), the Restricted Party shall not, without the prior written consent of each of the other Shareholders, either alone or in partnership or jointly or in conjunction with any Person or Persons, whether as principal, agent, partner, co-venturer, shareholder, investor, creditor, director, officer, employee, advisor, consultant or in any other capacity whatsoever, directly or indirectly:

(a) carry on, manage, organize, participate in, promote, advertise for, be engaged or interested in, or concerned with, any undertaking or business;

(b) have any financial or other interest (including without limitation, an interest by way of royalty or other compensation arrangements) in, or in respect of, the business or undertaking of any Person; or

(c) advise, lend money to, guarantee the debts or obligations of, or permit his or her name or any part thereof to be used or employed by any Person engaged or concerned with or interested in any business,

carried on within Canada, the United States of America, the United Kingdom and the European Union as each are currently constituted (the "Territory") which is the same or substantially similar to, or which competes with, all or any material part of the Business, as it is carried on in such jurisdictions during the Limitation Period, provided, however, that this Article 13 shall not be construed as preventing a Restricted Party from owning, directly or indirectly not more than 2% of the issued and outstanding securities of a corporation or other entity which is a competing business, provided that such securities are traded on a recognized exchange or in the over-the-counter market.

13.2 Non-Competition - BurconCo.

Provided that the license granted to the Corporation by BurconCo (or Affiliate thereof) under the Licence Agreement is and remains an exclusive licence, each of BurconCo and its Affiliates (for the purposes of this Article 13, each a "Burcon Restricted Party"), covenants in favour of the Corporation, each Subsidiary and each other Shareholder, that for so long as such license continues to be exclusive under the terms of the Licence Agreement and for the Limitation Period, the Burcon Restricted Party shall not, without the prior written consent of the Corporation, either alone or in partnership or jointly or in conjunction with any Person or Persons, whether as principal, agent, partner, co-venturer, shareholder, investor, creditor, director, officer, employee, advisor, consultant or in any other capacity whatsoever, directly or indirectly:

(a) carry on, manage, organize, participate in, promote, advertise for, be engaged or interested in, or concerned with, any undertaking or business;


- 44 -

(b) have any financial or other interest (including without limitation, an interest by way of royalty or other compensation arrangements) in, or in respect of, the business or undertaking of any Person; or

(c) advise, lend money to, guarantee the debts or obligations of, or permit his or her name or any part thereof to be used or employed by any Person engaged or concerned with or interested in any business,

carried on within the Territory which is the same or substantially similar to, or which competes with, all or any material part of the business of manufacturing, distributing, producing, selling or licensing any intellectual property in respect of, Products as defined in the License Agreement, as such business is carried on in such jurisdictions during the Limitation Period, provided, however, that this Article 13 shall not be construed as preventing a Burcon Restricted Party from owning, directly or indirectly not more than 2% of the issued and outstanding securities of a corporation or other entity which is a competing business, provided that such securities are traded on a recognized exchange or in the over-the-counter market. For greater certainty, if the license contemplated under the License Agreement at any time becomes a non-exclusive grant of license under the terms of the License Agreement, this clause will no longer be of any force or effect. For further clarity, the Shareholders and each of them acknowledge that BurconCo is in the plant protein business and nothing in this Section 13.2 shall prevent, limit or lessen BurconCo's continued operation of its plant protein business other than with respect to the Products. If there is any conflict between this Section 13.2 and the License Agreement, the License Agreement shall prevail.

13.3 Non-Competition - Bunge.

Each of Bunge and its Affiliates (for the purposes of this Article 13, each a "Bunge Restricted Party"), covenants in favour of the Corporation, and each Subsidiary and each other Shareholder, that for the Limitation Period, the Bunge Restricted Party shall not, without the prior written consent of each of the other Voting Shareholders, engage in the manufacture and subsequent sale (which terms are to be read collectively and not individually) of pea or canola protein products having a protein content greater than [commercially sensitive information redacted].  The Parties acknowledge that Bunge and its Affiliates are in the food processing business and the provisions of this Section 13.3 are not intended to limit or lessen Bunge's and its Affiliates' ability to: (i) purchase from a third party pea or canola protein products having a protein content greater than [commercially sensitive information redacted] for resale; or (ii) manufacture pea or canola protein products having a protein content greater than [commercially sensitive information redacted], provided that such proteins are only sold or distributed by Bunge or its Affiliates in a blended protein having a protein content equal to or less than [commercially sensitive information redacted]. For the purposes of this Section 13.3, the protein content of a protein product shall be determined on a dry basis and measured by multiplying the nitrogen content by a conversion factor of 6.25, where the nitrogen content is determined by a combustion method or by a Kjeldahl method.

13.4 Non Solicitation - Restricted Party.

Each Restricted Party (as defined in Section 13.1) covenants in favour of the Corporation and each Subsidiary of the Corporation that during the applicable Limitation Period neither he, nor it shall, without the prior written consent of the Corporation, either alone or in partnership or jointly or in conjunction with any Person or Persons, whether as principal, agent, partner, co-venturer, shareholder, investor, creditor, director, officer, employee, advisor, consultant or in any other capacity whatsoever, directly or indirectly:

(a) contact any customer, advance prospect, supplier, dealer, agent, distributor or other Person in the habit of dealing with the Corporation (or any Subsidiary) or the Business for the purpose of interfering with, or encouraging them to alter or terminate their business relationships with the Corporation (or any Subsidiary), or for the purpose of otherwise soliciting any business for a competing business from such Person;


- 45 -

(b) contact, for the purpose of solicitation other than at the request of the Corporation(or any Subsidiary), any Person that is a supplier, dealer, agent or distributor of the Corporation (or any Subsidiary) for the purpose of attempting to obtain a franchise, distribution or other arrangement with such Person in respect of the Territory; or

(c) make offers or invitations of employment or retention as a consultant to, or hire, retain, solicit, interfere with, entice away, or otherwise attempt to obtain the withdrawal or encourage the resignation or retirement of, any employee, consultant or advisor of the Corporation (or any Subsidiary).

13.5 Non Solicitation - BurconCo and Bunge.

Each of Bunge and BurconCo covenant, severally and not jointly and severally, in favour of the Corporation and each Subsidiary of the Corporation, each in respect of itself only and without reference to one and other, that for so long as it is a direct or indirect Shareholder of the Corporation and for a period of eighteen (18) months after the date on which it ceases to be a direct or indirect Shareholder in the Corporation, it shall not, without the prior written consent of the Corporation, either alone or in partnership or jointly or in conjunction with any Person or Persons, whether as principal, agent, partner, co-venturer, shareholder, investor, creditor, director, officer, employee, advisor, consultant or in any other capacity whatsoever, directly or indirectly make offers or invitations of employment or retention as a consultant to, or hire, retain, solicit, interfere with, entice away, or otherwise attempt to obtain the withdrawal or encourage the resignation or retirement of, any employee, consultant (acting in an employment like capacity) or exclusive advisor of the Corporation(or any Subsidiary), unless such individual responds to a general advertisement for a position not specifically aimed at the employees of the Corporation. In the case of Bunge, this covenant shall extend to [commercially sensitive information redacted], each of which provides consulting services to BurconCo and its Affiliates, and any employees and consultants (acting in an employment like capacity) of BurconCo, Burcon NutraScience Corporation and Burcon NutraScience (MB) Holdings Corp. known to Bunge to be employees or consultants (acting in an employment like capacity) thereof.

13.6 Acknowledgement.

Each Restricted Party, Burcon Restricted Party and Bunge Restricted Party acknowledges that:

(a) he, she or it is agreeing to the provisions of Article 13 in his, her or its capacity as a direct or indirect Shareholder of the Corporation; and

(b) the subsections of Section 13.1 and Section 13.2 constitute separate and independent restrictions and that the duration, extent and application of each restriction are no greater than is reasonable and necessary to protect the interests of the Corporation, each Subsidiary and the Shareholders.

ARTICLE 14
SHAREHOLDER GUARANTEES

14.1 Shareholder Obligations

(1) Each of the Shareholder Guarantors, with respect only to the obligations of the relevant Shareholder in respect of which they are a Shareholder Guarantor (i) unconditionally and irrevocably guarantee the performance by that Shareholder in respect of whom they are acting as a Shareholder Guarantor of their obligations contained in this Agreement (the "Guaranteed Obligations"), and (ii) acknowledge that there is joint and several liability between the such Shareholder Guarantor and the Shareholder in respect of whom they are acting as a Shareholder Guarantor. The liability of the Shareholder Guarantors by reason of this Section 14.1 is primary (and not a collection guarantee), and neither the Corporation nor the other Shareholders shall be required to make any demand on the relevant Shareholder for performance of the Guaranteed Obligations, nor to exhaust any legal, contractual or equitable remedies against such Shareholder prior to proceeding against the applicable Shareholder Guarantor. Each Shareholder Guarantor acknowledges that the benefit of the guarantee contained in this Section 14.1 is for the exclusive benefit of the Corporation and the other Shareholders, any of which in their sole and absolute discretion may claim under this guarantee or decline to claim under this guarantee with respect to the Guaranteed Obligations.


- 46 -

(2) The obligations of Shareholder Guarantors are absolute and unconditional, and will not be affected by, and will continue notwithstanding (i) any limitation of status or power or other circumstance relating to the relevant Shareholder whose obligations they have guaranteed including any bankruptcy, insolvency, winding-up, dissolution, liquidation, restructuring or other creditors' proceedings involving or affecting such entity, or (ii) any change in the ownership, control, name, assets or capital structure of the relevant Shareholder whose obligations they have guaranteed or any reorganization, amalgamation or other change in the existence thereof.

ARTICLE 15
DISPUTE RESOLUTION

15.1 Resolving Disputes

(1) Upon being notified by a Shareholder that there exists a dispute in connection with this Agreement (including its interpretation or application and further including the determination of the value of any of the variables used in computing the Call Option Price pursuant to Section 10.2) (a "Dispute"), the Shareholders agree to meet or hold a telephone conference together within ten (10) days of such notification and to attempt to address and resolve the Dispute to the satisfaction of all of the Shareholders within 30 days. The Shareholders agree to devote good faith efforts to resolve the Dispute which is the subject of the notification contemplated in this Article 15.

(2) In the event that a Dispute cannot be resolved within the time set out in Section 15.1, the Dispute shall be resolved by arbitration proceedings commenced by any party to the Dispute by any party giving written notice to the other Shareholders and the Corporation specifying the matter to be arbitrated and requesting an arbitration thereof. The Shareholders shall endeavour to agree upon the arbitrator. In the event that they are unable to agree upon an arbitrator within ten days after delivery of the notice of arbitration, each party to the Dispute shall appoint an arbitrator, and those arbitrators so appointed shall thereupon meet and select an arbitrator and the arbitrator so selected shall be the arbitrator to hear and arbitrate the Dispute. For the purposes of a Dispute governed by Section 15.1(4) the arbitrator(s) selected pursuant to this Section 15.1(2) shall be one of KPMG LLP, Ernst & Young LLP, Grant Thornton LLP, PricewaterhouseCoopers or MNP LLP (provided that such firm, in order to be qualified to act as an arbitrator with respect to any particular dispute, shall be, and shall be required to certify itself as, independent from all of the parties thereto) and such party shall be engaged for the purpose of an expedited review and on terms requiring that they provide an EBITDA Report (as defined below) as soon as is reasonably practicable.

(3) The arbitrator appointed in accordance with Section 15.1 shall govern the arbitration in accordance with the provisions and shall use his or her reasonable best efforts to render a written decision within sixty (60) days after the date on which the arbitrator was appointed, a copy of which will forthwith be delivered to each Shareholder and the Corporation. The decision of the arbitrator shall be final and binding on the parties involved in the Dispute and shall not be subject to appeal, but shall not be binding as a precedent with respect to any subsequent Disputes between any of the Shareholders hereunder. The cost of the arbitration will be borne by the Shareholders as the arbitrator determines and in the absence of such determination equally between the specific parties to the arbitration.


- 47 -

(4) Notwithstanding anything to the contrary contained in this Article 15, should the Dispute relate to the quantum of the Normalized and Annualized EBITDA for the purpose of determining the variable "B" in Section 10.2, the arbitrator shall allow Bunge on the one hand and the Call Granting Shareholders, acting together, on the other hand, to present their respective positions regarding the Dispute (provided that, for greater certainty, such presentations are limited to those matters subject to the Dispute not otherwise resolved pursuant to Section 15.1(1)) and each of Bunge and the Call Granting Shareholders shall have the right to present additional documents, materials and other information, and make an oral presentation to the arbitrator, regarding such dispute and the arbitrator shall consider such additional documents, materials and other information and such oral presentation. Any such other documents, materials or other information shall be copied to each of Bunge and the Call Granting Shareholders and each of Bunge and the Call Granting Shareholders shall be entitled to attend any such oral presentation. While the arbitrator is making its determination hereunder, the Parties shall not communicate with the arbitrator on the subject matter of its review, except by joint conference call, joint meeting or letter with copies simultaneously delivered to the other Parties. The arbitrator shall determine, based solely on such documents, materials, other information and presentations from Bunge and the Call Granting Shareholders and not by independent review, only those issues specifically presented to it that are still in dispute and shall render a written report (the "EBITDA Report") to Bunge and the Call Granting Shareholders in which the arbitrator shall, after considering all matters specifically presented to it that are still in dispute, determine what adjustments, if any, should be made to the quantum of the Normalized and Annualized EBITDA. The EBITDA Report shall set forth, in reasonable detail, the arbitrator's determination with respect to each of those items or amounts specifically presented to it that are still in dispute, and the revisions, if any, to be made to the Normalized and Annualized EBITDA, together with supporting calculations, and the parties shall make such revisions to the Normalized and Annualized EBITDA. In resolving any disputed item, the arbitrator (i) shall limit its review to matters specifically presented to it that are still in dispute at the time that the arbitrator is retained by Bunge and the Call Granting Shareholders, and (ii) shall not assign a value to any item higher than the highest value for such item claimed by either Bunge and the Call Granting Shareholders or lower than the lowest value for such item claimed by either Bunge and the Call Granting Shareholders. This Section 15.1(4) shall be the sole avenue available for any of the Parties to pursue a Dispute with respect to the quantum of the Normalized and Annualized EBITDA, notwithstanding the rights to pursue a Dispute under to this Section 15.1(4) accrue only to Bunge and the Call Granting Shareholders. 

(5) Any arbitration hereunder will take place in the City of Winnipeg, Manitoba unless the parties to the Dispute otherwise agree.

(6) Notwithstanding that a Dispute (or arbitration in respect of an unresolved Dispute) is ongoing, the Shareholders shall continue to perform all of their obligations under this Agreement, other than such obligations that are the subject matter of the Dispute, in order to ensure the uninterrupted and efficient conduct of the Business.

ARTICLE 16
MISCELLANEOUS

16.1 Notices.

Any notice, direction or other communication given regarding the matters contemplated by this Agreement (each a "Notice") must be in writing, sent by personal delivery, courier or electronic mail and addressed:


- 48 -

(a) to [personal information redacted] Party A at:

[personal information redacted]

(b) to [personal information redacted] Party B at:

[personal information redacted]

(c) to BurconCo at:

Burcon NutraScience Holdings Corp.

c/o Burcon NutraScience Corporation at:

1946 West Broadway

Vancouver, British Columbia

V6J 1Z2 CANADA

Attention: Dorothy Law

[personal information redacted]

(d) to Bunge at:

Bunge North America, Inc.

1391 Timberlake Manor Parkway

Chesterfield, Missouri 63017

Attention: Kaleb Belzer

[personal information redacted]

(e) to the Corporation at:

Merit Functional Foods Corporation

1601 C Silver Avenue

Winnipeg, MB R3J 4A1

Attention: Co-Chief Executive Officers

[personal information redacted]

with a copy to each of the Shareholders.

A Notice is deemed to be given and received (i) if sent by personal delivery or courier, on the date of delivery if it is a Business Day and the delivery was made prior to 4:00 p.m. (local time in place of receipt) and otherwise on the next Business Day, or (ii) if sent by electronic mail, on the Business Day on which such electronic mail was sent, and otherwise on the next Business Day. A Party may change its address for service from time to time by providing a Notice in accordance with the foregoing. Any subsequent Notice must be sent to the Party at its changed address. Any element of a Party's address that is not specifically changed in a Notice will be assumed not to be changed. Any Person who shall hereafter become a Shareholder and a party to and bound by this Agreement shall provide its address for service at the time such Person becomes a Shareholder in the same manner as required for providing a Notice of a change of address set out above.

16.2 Time of the Essence.

Time is of the essence in this Agreement.


- 49 -

16.3 Announcements.

No press release, public statement or announcement or other public disclosure with respect to this Agreement or the transactions contemplated in this Agreement may be made except with the prior written consent and joint approval of the Voting Shareholders, acting reasonably, or if required by applicable Law or a governmental or other regulatory entity. Where such disclosure is required by applicable Law or a governmental or other regulatory entity, the Party required to make the disclosure will consult with the other Voting Shareholders regarding the nature and scope of such required disclosure and will use its commercially reasonable efforts to obtain the approval of the other Voting Shareholders as to the form, nature and extent of the disclosure. The consent from such Voting Shareholders shall be granted to the other within 72 hours of the request being made. Where an announcement, statement or issuance of a press release is time sensitive, the Party seeking consent may request that the consent be granted by the other Voting Shareholders within 24 hours. In such circumstance, the request for consent must be in writing and followed up by telephone. The foregoing shall not preclude BurconCo and Burcon NutraScience Corporation from providing their shareholders with regular updates on the progress of the commercialization efforts of the Corporation, provided that (i) such updates shall not contain Confidential Information or information of a competitive nature with respect to the Corporation or, provided that BurconCo has provided notice to Bunge of the information to be disclosed and has been advised by Bunge in writing that disclosure of such information will not result in Bunge: (A) being in violation of applicable securities laws; or (B) being required to make any filing or public disclosure or statement in order to remain in compliance with applicable securities laws (in the case of Bunge advising that the circumstances in (A) or (B) will occur, BurconCo, Burcon NutraScience Corporation and Bunge shall expeditiously and meaningfully collaborate to amend such update to the minimum requirement necessary to avoid the results referenced in (A) and (B)); (ii) BurconCo and Burcon NutraScience Corporation shall use all commercially reasonable efforts to give prior oral or written notice to the other Voting Shareholders and reasonable opportunity to review or comment on the disclosure; and (iii) if such prior notice is not possible, to give such notice immediately following the making of such disclosure or filing.

16.4 Third Party Beneficiaries.

The Parties intend that this Agreement will not benefit or create any right or cause of action in favour of any Person, other than the Parties and except as contemplated under Section 11.2. No Person, other than the Parties, is entitled to rely on the provisions of this Agreement in any action, suit, proceeding, hearing or other forum. The Parties reserve their right to vary or rescind the rights at any time and in any way whatsoever, if any, granted by or under this Agreement to any Person who is not a Party, without notice to or consent of that Person.

16.5 No Agency or Partnership.

Nothing contained in this Agreement makes or constitutes any Party, or any of its directors, officers or employees, the trustee, fiduciary, representative, agent, principal, partner, joint venturer, employer, employee of any other Party. It is understood that no Party has the capacity to make commitments of any kind or incur obligations or liabilities binding upon any other Party.

16.6 Expenses.

Except the cost of any Valuator or arbitrator appointed pursuant to Article 16 or as otherwise expressly provided in this Agreement, each Party will pay for its own costs and expenses incurred in connection with this Agreement and the transactions contemplated by it. The fees and expenses referred to in this Section are those which are incurred in connection with the negotiation, preparation, execution and performance of this Agreement, and the transactions contemplated by this Agreement, including the fees and expenses of legal counsel, investment advisers and accountants.


- 50 -

16.7 Amendments.

This Agreement may only be amended, supplemented or otherwise modified by written agreement signed by all of the Voting Shareholders, or where such amendment, supplement or modification of this Agreement would amend, supplement or otherwise modify Articles 3, 6 and 14, by written agreement signed by all of the Parties other than the Corporation.

16.8 Waiver.

No waiver of any of the provisions of this Agreement will constitute a waiver of any other provision (whether or not similar). No waiver will be binding unless executed in writing by the Party to be bound by the waiver. A Party's failure or delay in exercising any right under this Agreement will not operate as a waiver of that right. A single or partial exercise of any right will not preclude a Party from any other or further exercise of that right or the exercise of any other right.

16.9 Entire Agreement.

This Agreement constitutes the entire agreement between the Parties with respect to the matters contemplated by this Agreement and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties related to such matters. There are no representations, warranties, covenants, conditions or other agreements, express or implied, collateral, statutory or otherwise, between the Parties in connection with the subject matter of this Agreement, except as specifically set forth in this Agreement. The Parties have not relied and are not relying on any other information, discussion or understanding in entering into this Agreement.

16.10 Successors and Assigns.

(1) This Agreement becomes effective only when executed by all of the Parties. After that time, it is binding on and enures to the benefit of the Parties and their respective heirs, administrators, executors, legal representatives, successors and permitted assigns.

(2) Except as otherwise provided in this Agreement, neither this Agreement nor any of the rights or obligations under this Agreement are assignable or transferable by any Party without the prior written consent of the other Parties.

16.11 Severability.

If any provision of this Agreement is determined to be illegal, invalid or unenforceable, by an arbitrator or any court of competent jurisdiction from which no appeal exists or is taken, that provision will be severed from this Agreement and the remaining provisions will remain in full force and effect.

16.12 Governing Law.

This Agreement is governed by, and will be interpreted and construed in accordance with, the laws of the Province of Manitoba and the federal laws of Canada applicable therein.


- 51 -

16.13 Counterparts.

This Agreement may be executed in any number of counterparts, each of which is deemed to be an original, and such counterparts together constitute one and the same instrument. Transmission of an executed signature page by facsimile, email or other electronic means is as effective as a manually executed counterpart of this Agreement.

16.14 English Language.

The Parties have agreed that this Agreement as well as any document or instrument relating to it be drawn up in English only but without prejudice to any such document or instrument which may from time to time be drawn up in French only or in both French and English. Les parties aux presentes ont convenu que la presente Convention ainsi que tous autres actes ou documents s'y rattachant soient rediges en anglais seulement mais sans prejudice a tous tels actes ou documents qui pourraient a l'occasion etre rediges en francais seulement ou a la fois en anglais et en francais.

[Signature Page Follows]


- 52 -

IN WITNESS WHEREOF the Parties have executed this Unanimous Shareholders' Agreement.

 

MERIT FUNCTIONAL FOODS CORPORATION

 

 

 

By:

"Ryan Bracken" (signed)

 

 

Name:  Ryan Bracken

 

 

Title:  President & Co-CEO

 

 

 

TIREM HOLDINGS INC.

 

 

 

By:

"Greg Billhartz" (signed)

 

 

Name:  Greg Billhartz

 

 

Title:  Vice President

 


 

BURCON NUTRASCIENCE HOLDINGS CORP.

 

 

 

By:

"Johann Tergesen" (signed)

 

 

 

Name:  Johann Tergesen"

 

 

Title:  President

 

 


 

BURCON NUTRASCIENCE CORPORATION

 

 

 

By:

"Johann Tergesen" (signed)

 

 

 

Name:  Johann Tergesen

 

 

Title: President & Chief Executive Officer

 

"Lorne Tyrrell" (signed)

 

By:

 

 

 

Name:  Lorne Tyrrell

 

 

Title:  Director and Chairman



- 53 -


 

TIREM HOLDINGS LIMITED PARTNERSHIP, by its general partner,
TIREM HOLDINGS GP INC.

 

 

By:

"Greg Billhartz" (signed)

 

 

Name: Greg Billhartz

 

 

Title:  Vice President

 

 

 

[personal information redacted]  Party A

 

 

 

By:

Signed by signatory for Party A

 

 

 

Name: [personal information redacted]

 

 

Title:

 

 

 

[personal information redacted] Party B

 

 

 

By:

Signed by signatory for Party B

 

 

Name: [personal information redacted]

 

 

Title:


 

[personal information redacted] Party C

 

 

 

By:

Signed by signatory Party C

 

 

Name: [personal information redacted]

 

 

Title:


 

[personal information redacted] Party D

 

 

 

By:

Signed by signatory for Party D

 

 

Name: [personal information redacted]

 

 

Title:



- 54 -


 

[personal information redacted] Party E

 

 

 

By:

Signed by Signatory for Party E

 

 

Name:  [personal information redacted]

 

 

Title:

 

 

 

)

)

 

Signed by Party F

[personal information redacted]

)

)

[personal information redacted] Party F

     


SCHEDULE A
SHARE OWNERSHIP - CORPORATION

Name

Number & Class of Shares

Voting %

     

[personal information redacted] Party A

[commercially sensitive information redacted]

(27.75%)

     

BurconCo

[commercially sensitive information redacted]

(33.33%)

     

[personal information redacted] Party B

[commercially sensitive information redacted]

(13.92%)

     

[commercially sensitive information redacted]

[commercially sensitive information redacted]

(25%)



SCHEDULE B
SHAREHOLDER LOANS

Shareholder   Principal Amount  
[personal information redacted] Party A $ 10,822,500  
BurconCo $ 13,000,000  
[personal information redacted] Party B $ 5,427,500  
[commercially sensitive information redacted] $ 9,750,000  
Total $ 39,000,000  


SCHEDULE C
[COMMERCIALLY SENSITIVE  INFORMATION REDACTED]


SCHEDULE D
AUTHORIZED AND ISSUED CAPITAL OF EACH OF THE SHAREHOLDERS

BurconCo:

Unlimited number of Common Shares

100 issued and outstanding, registered in the name of and beneficially held by Burcon NutraScience Corporation

[personal information redacted]


- 2 -

SCHEDULE E
DISTRIBUTION POLICY

DISTRIBUTION POLICY OF

MERIT FUNCTIONAL FOODS CORPORATION

(the "Corporation")

Dated August  , 2020

In this Distribution Policy, the following capitalized terms shall have the following meanings: "Annual Budget" has the meaning given to it in the Shareholders' Agreement.

"Articles" has the meaning given to it in the Shareholders' Agreement.

"ASPE" has the meaning given to it in the Shareholders' Agreement.

"Board" has the meaning given to it in the Shareholders' Agreement.

"Commercial Operation Date" has the meaning given to it in each of the EDC Loan Agreement and the FCC Credit Agreement.

"EDC Loan Agreement" means the loan agreement dated as of April 24, 2020 between the Corporation, as borrower, and Export Development Canada, as senior lender and as subordinated lender, as it may be amended, modified, restated, replaced or supplemented from time to time.

"FCC Credit Agreement" means the credit agreement dated as of April 24, 2020 between, inter alia, the Corporation, as borrower, and Farm Credit Canada, as lender, as it may be amended, modified, restated, replaced or supplemented from time to time.

"Free Cash Flow" means for any period in which such amount is a positive amount, that amount as is equal to, (i) the consolidated net income (or net deficit) of the Corporation and its subsidiaries, as determined in accordance with ASPE, to the extent that, where such income is domiciled outside of Canada, such income is capable of being re-domiciled into Canada in manner and at a cost that is, in the determination of the Board, reasonable, appropriate and in the best interests of the Corporation; plus (ii) expenses for amortization charged, accrued or otherwise allocated against such net income; plus (iii) expenses for depreciation charged, accrued or otherwise allocated against such net income; minus (iv) payments of interest and principal on indebtedness paid or accrued during such period or otherwise payable on the applicable payment date; minus (v) payments in respect of capital expenditures contemplated in the Annual Budget; minus (vi) payments in respect of expected, known or contingent payments that are determined by the Board to be likely to crystallise, the expectation, knowledge or likelihood of crystallization of which arose as a result of emergency, unforeseen circumstances or otherwise after the date of the then current Annual Budget (and which includes extraordinary expenses); minus (vii) such reserve amount as the Board determines is appropriate in the circumstances, in each case without duplication.

"Permitted Distribution Contributions" has the meaning given to it in each of the EDC Loan Agreement and the FCC Credit Agreement.

"Primary Lenders" means, collectively, Export Development Canada and Farm Credit Canada, and each of their respective successors and assigns.

"Shareholders" has the meaning given to it in the Shareholders' Agreement.


"Shareholders' Agreement" means the amended and restated unanimous shareholders agreement of the Corporation and all schedules attached to it as it may be amended, modified, restated, replaced or supplemented from time to time.

"Voting Shareholders" has the meaning given to it in the Shareholders' Agreement.

The Corporation recognizes that the Shareholders wish to receive regular cash distributions in accordance with the provisions below. This policy will be administered with that goal in mind.

Effective from and after the Commercial Operation Date, the Corporation shall implement and abide by the following policy regarding the distribution of profits, assets or reserves by the Corporation, including the declaration and payment of cash dividends.

1. Subject to applicable law and the Articles of the Corporation, and subject to compliance with the Permitted Distribution Conditions, including all notice requirements in connection therewith, the Corporation shall distribute to the Shareholders, in respect of each fiscal year of the Corporation, an aggregate amount equivalent to at least fifty percent (50%) of the Free Cash Flow for such fiscal year.

2. Subject to applicable law and the Articles of the Corporation, and subject to compliance with the Permitted Distribution Conditions, including all notice requirements in connection therewith, an estimate of one half of such annual distribution referred to in paragraph 1 shall be made within 30 days of the last day of the first 6 month period in each fiscal year of the Corporation based upon the estimated Free Cash Flow for such fiscal year relying and based upon the interim financial statements of the Corporation to the end of such 6 month period. Within 15 days of the date of the Corporation's final audited financial statements, the balance of the annual distribution referred to in paragraph 1 shall be made, provided that such distribution shall take into account, and be adjusted for, any overpayment or underpayment in respect of the previous distribution, and shall be based upon the final audited financial statements of the Corporation for such fiscal year and to the extent that there remains a balance owing to the Corporation in respect of an overpayment, each Shareholder shall, within 20 days of the Corporation providing notice to such Shareholder of the over payment, deliver to the Corporation funds in an amount equal to its proportionate share of such overpayment, in full and complete satisfaction of such outstanding amount.

3. Notwithstanding anything to the contrary herein, if the payment of any distributions in accordance with this Distribution Policy on any given payment date would be contrary to any provisions of applicable law, the Shareholders' Agreement, the Permitted Distribution Conditions or any other obligation of the Corporation contained in a document approved by the Board, the Corporation shall distribute on the applicable payment date such lesser amount as is the maximum amount of such distribution as would not then be contrary to any of the foregoing restrictions.

4. This Distribution Policy shall remain in force as long as Burcon NutraScience Holdings Corp. holds shares of the Corporation, except as expressly modified or repealed by written agreement signed by all of the Voting Shareholders.




BURCON NUTRASCIENCE CORPORATION

- and -

BURCON NUTRASCIENCE (MB) CORP.

- and -

MERIT FUNCTIONAL FOODS CORPORATION

AMENDED AND RESTATED
LICENSE AND PRODUCTION AGREEMENT


TABLE OF CONTENTS

SECTION PAGE 
   
ARTICLE 1 INTERPRETATION - 1 - 

 
Section 1.1 Definitions - 1 - 
Section 1.2 Interpretation - 8 - 
Section 1.3 Fair Market Value - 9 - 
   
ARTICLE 2 COMMERCIALIZATION AND PRODUCTION - 10 - 


Section 2.1 Development, Construction and Commission of Production Facilities - 10 - 
Section 2.2 Burcon Assistance - 10 - 
Section 2.3 Flex Production Facility - 11 - 
Section 2.4 Notice to Achieve Full Commercial Production - 12 - 
Section 2.5 Full-commercial Production Facility - 12 - 
Section 2.6 Covenant to Commercialize - 12 - 
Section 2.7 Samples - 13 - 
Section 2.8 Manufacturing Quality - 13 - 
Section 2.9 Limitation of Use - 13 - 
   
ARTICLE 3 INTELLECTUAL PROPERTY OWNERSHIP AND LICENSE GRANT - 13 - 

 
Section 3.1 Ownership of Burcon Technology - 13 - 
Section 3.2 Ownership of Corporation Technology - 14 - 
Section 3.3 Disclosure of Corporation Technology - 14 - 
Section 3.4 Exclusive License Grant - 14 - 
Section 3.5 Conversion to Non-Exclusive License - 15 - 
Section 3.6 Relief from Non-Exclusivity - 15 - 
Section 3.7 Terms of Non-Exclusive License - 16 - 
Section 3.8 Corporation's License to Burcon - 16 - 
Section 3.9 Burcon Improvements - 16 - 
Section 3.10 Trade-mark Option - 17 - 
Section 3.11 Condition of Grant of Sublicense - 17 - 
   
ARTICLE 4 LICENSE FEES AND ROYALTIES - 17 - 

 
Section 4.1 Royalties - 17 - 
Section 4.2 License Rates - 18 - 
Section 4.3 Corporation Royalty - 19 - 
Section 4.4 Limit on the Corporation Royalty - 19 - 
Section 4.5 Withholding Taxes - 19 - 
   
ARTICLE 5 INFORMATION RIGHTS, REPORTS AND AUDIT - 20 - 

 
Section 5.1 Access and Inspection Rights - 20 - 
Section 5.2 Reporting Obligations During Development, Construction and Commissioning of Production Facilities              - 20 - 
Section 5.3 Reports on Production and Sales Estimates - 21 - 
Section 5.4 Reports on Royalties - 22 - 
Section 5.5 Records and Audit - 22 - 
Section 5.6 Burcon Annual Audit - 23 - 
Section 5.7 Process Audit - 23 - 
Section 5.8 Record Keeping - 24 - 
Section 5.9 Right To Audit - 24 - 
Section 5.10 Equivalent Corporation Rights - 24 - 
   
ARTICLE 6 INFRINGEMENT, DEFENCE AND PATENT PROSECUTION - 24 - 

ii



Section 6.1 Infringement - 24 - 
Section 6.2 Patent Prosecution - 26 - 
Section 6.3 Defence of Actions - 27 - 
Section 6.4 Exclusive Remedies - 27 - 
   
ARTICLE 7 GOVERNANCE AND DISPUTE RESOLUTION - 28 - 

 
Section 7.1 Technology Commercialization Committee - 28 - 
Section 7.2 Dispute Resolution - 28 - 
Section 7.3 Arbitration - 29 - 
Section 7.4 Other Remedies - 30 - 
   
ARTICLE 8 CONFIDENTIALITY - 30 - 

 
Section 8.1 Confidentiality - 30 - 
Section 8.2 Permitted Disclosure - 31 - 
Section 8.3 Return of Confidential Information - 32 - 
Section 8.4 Existing Confidentiality Agreement - 32 - 
Section 8.5 Remedies - 32 - 
   
ARTICLE 9 TERM AND TERMINATION - 33 - 

 
Section 9.1 Term - 33 - 
Section 9.2 Termination of Royalty Obligations - 33 - 
Section 9.3 Termination of Agreement - 33 - 
Section 9.4 Consequences of Termination of Agreement - 34 - 
   
ARTICLE 10 REPRESENTATIONS, WARRANTIES AND COVENANTS - 35 - 

 
Section 10.1 Representations and Warranties by Burcon - 35 - 
Section 10.2 Representations and Warranties by the Corporation - 37 - 
Section 10.3 Corporation Covenant to Comply with Laws - 37 - 
Section 10.4 No Other Warranties - 38 - 
Section 10.5 Limitation of Liability - Food Safety Standards - 38 - 
Section 10.6 Non-Solicitation - 38 - 
Section 10.7 Indemnities for Representations and Warranties - 38 - 
   
ARTICLE 11 INDEMNIFICATION AND INSURANCE - 39 - 

 
Section 11.1 Indemnification by the Corporation - 39 - 
Section 11.2 Indemnification by Burcon - 39 - 
   
ARTICLE 12 GENERAL - 40 - 

 
Section 12.1 Time; Force Majeure - 40 - 
Section 12.2 Elimination of Force Majeure Event - 40 - 
Section 12.3 Severability - 40 - 
Section 12.4 Governing Law - 40 - 
Section 12.5 Entire Agreement - 41 - 
Section 12.6 Amendment and Waiver - 41 - 
Section 12.7 Relationship of the Parties - 41 - 
Section 12.8 Public Notices - 41 - 
Section 12.9 Notices - 42 - 
Section 12.10 Assignability - 43 - 
Section 12.11 Further Assurances - 43 - 
Section 12.12 Anti-Corruption - 43 - 
Section 12.13 Counterparts - 44 - 

SCHEDULE A -  BURCON PATENT RIGHTS

iii


AMENDED AND RESTATED LICENSE AND PRODUCTION AGREEMENT

This Agreement is made as of August 27, 2020, by and between:

BURCON NUTRASCIENCE CORPORATION, a company incorporated under the laws of the Territory of Yukon

- and -

BURCON NUTRASCIENCE (MB) CORP., a wholly-owned subsidiary of Burcon Nutrascience Corporation, incorporated under the laws of Manitoba

(Burcon Nutrascience Corporation and Burcon Nutrascience (MB) Corp. to be referred to collectively herein as "Burcon")

- and -

MERIT FUNCTIONAL FOODS CORPORATION (formerly Burcon Functional Foods Corporation), a company incorporated under the laws of Canada (the "Corporation")

WHEREAS Burcon has expertise and know-how in the discovery, characterization and development of canola, pea, pulse, hemp and flax protein products and is the owner of intellectual property rights with respect thereto;

WHEREAS the Corporation will have certain capabilities, production facilities and personnel that would allow for the commercial production of canola, pea and all pulse protein products using the Burcon Patent Rights and Burcon Technology;

WHEREAS the Parties entered into a license and production agreement dated May 23, 2019 (the "Original License Agreement"), pursuant to which the Corporation obtained an exclusive license to use the Burcon Patent Rights and Burcon Technology to make, have made, use, market and sell canola, pea and all pulse protein products;

WHEREAS the Parties wish to amend and restate the Original License Agreement in its entirety as set out herein, effective as of the date hereof.

NOW THEREFORE in consideration of the premises and the terms and conditions contained in this Agreement and other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged), the Parties agree as follows:

ARTICLE 1
INTERPRETATION

Section 1.1 Definitions

In this Agreement, the following terms have the meaning ascribed to them:


"Affiliate" means, with respect to any Person (a) any other Person of which the securities or other ownership interests representing fifty per cent (50%) or more of the equity or fifty per cent (50%) or more of the ordinary voting power or fifty per cent (50%) or more of the general partnership interests are, at the time such determination is being made, owned, Controlled or held, directly or indirectly, by such Person; or (b) any other Person which, at the time such determination is being made, is Controlling, Controlled by or under common Control with, such Person.  As used in this Agreement, the term "Control," whether used as a noun or verb, refers to the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

"Applicable Laws" means all statutes, by-laws, regulations, ordinances, orders and requirements of governmental or other public authorities having jurisdiction, and all amendments thereto, at any time and from time to time in force.

"Arm's Length" has the meaning given to it in the Income Tax Act (Canada) and the jurisprudence issued in respect thereof.

"Blended Product" means a product that consists of a blend of two or more Products, but does not contain any ingredients other than Products. 

"Burcon Improvements" has the meaning ascribed to it in Section 3.9 (Burcon Improvements).

"Burcon Indemnitees" has the meaning ascribed to it in Section 11.1 (Indemnification by the Corporation).

"Burcon Patent Rights" means the patents and patent applications in any jurisdiction owned by Burcon and claiming the Products or processes for producing and/or using the Products, including but not limited to those patents issuing from the patent applications listed on Schedule A or the priority applications thereof, together with all rights and interests in and to issued patents and pending patent applications in any jurisdiction, including, but not limited to, all provisional applications, substitutions, continuations, continuations-in-part, patents of addition, improvement patents, divisions and renewals, all letters patent granted thereon, and all reissues, confirmations, counterparts, reexaminations and extensions thereof, but shall not include any abandoned or lapsed patents or abandoned or lapsed patent applications.

"Burcon Technology" means all inventions, innovations, improvements, discoveries, works, designs or technical developments owned, licensed, controlled, conceived, reduced to practice, discovered or developed by Burcon and concerning canola, pea and all pulse protein products, whether patentable or not, Confidential Information (including trade secrets), copyright, methods, processes, techniques, concepts, ideas, information, data, materials, Burcon's know-how, industrial design or any other property right or any applications therefor, and including all information and tangible items of a scientific or technical nature in any form or medium and all information or records relating thereto, in any and all relevant jurisdictions, and expressly including the Burcon Patent Rights.  For purposes of clarification it is understood and agreed that Burcon Technology does not include any information or technology that is in the Corporation's possession before Burcon's disclosure to the Corporation of the Burcon Technology as evidenced by competent proof, including the Corporation's and/or Burcon's written records prior to the date of disclosure; or that is independently developed before the Effective Date by the Corporation or its Affiliates without the use, directly or indirectly, of the Burcon Technology as evidenced by competent proof, including Burcon's, the Corporation's or their respective Affiliates' (as the case may be in) written records prior to the date of disclosure; or that is received by the Corporation from a third party who is (i) not privy to this Agreement, (ii) not in violation of the confidential relationship created under this Agreement, or (iii) not then prohibited from disclosing such information to the Corporation under any legal, contractual or fiduciary obligation to Burcon; or that is freely available for use in the public domain.


"Business Day" means a day other than a Saturday, Sunday or statutory holiday in Canada.

"Call Option Closing Date" means the date upon which Bunge (as such term is defined in the Shareholders' Agreement) has purchased the Call Option Securities in accordance with the Shareholders' Agreement.

"Call Option Expiry Time" has the meaning ascribed to it in the Shareholders' Agreement.

"Call Option Securities" has the meaning ascribed to it in the Shareholders' Agreement.

"Claim" means any claim, demand, loss, award, judgment, settlement, fine, penalty, liability, damage, cost, expense, action, suit or proceeding including, but not limited to, reasonable investigatory fees, legal fees and disbursements, expert witness fees and court costs at both trial and appellate levels.

"Commission" means the testing of the production equipment in the Flex Production Facility (and/or the Full-commercial Production Facility or other production facility, if applicable), which, when tested, functions according to its design objectives or specifications and, for the Flex Production Facility (and/or the Full-commercial Production Facility, if applicable), is able to produce the quantity of Products required under this Agreement.

"Confidential Information" means any and all confidential information of any kind concerning a Party (a "Provider") or its Affiliates that is disclosed to, made available to, comes into the possession of, or of which the other Party (a "Recipient") is made aware, whether disclosed orally, visually, in writing or in any tangible or electronic form or media, and including, but not limited to, research and development, technology, trade secrets, know-how, proprietary information (whether or not reduced to writing), inventions, (whether or not patentable), patent applications, licenses, discoveries, techniques, methods, ideas, concepts, data, engineering and manufacturing information, procedures, specifications, diagrams, drawings, schematics, and any and all other technical, commercial, scientific and other data, processes, documents, or other information or physical object (including, without limitation, the Burcon Technology, the Burcon Improvements, the Corporation Technology and the Corporation Improvements), Samples of Product furnished pursuant to Section 2.7  (Samples), marketing data, agreements between any Party and a third party, license applications, and business plans and projections of any Party, and including, without limitation, confidential information of any third party which is disclosed to a Provider and is in turn disclosed to a Recipient or learned by the Recipient through visual or other inspection.


"Construction" means the construction of the Flex Production Facility (and/or the Full-commercial Production Facility, or other production facility, if applicable), including preparatory work and any necessary demolition of existing buildings or improvements, completion of engineering works on the site of the facility and surrounding vicinity, and the selection, procurement, and installation of production equipment in the Flex Production Facility (and/or the Full-commercial Production Facility, or other production facility, if applicable) in order for such facility to be Commissioned.

"Corporation Improvements" has the meaning ascribed to it in Section 3.3 (Disclosure of the Corporation Technology).

"Corporation Improvements License" has the meaning ascribed to it in Section 3.8 (Corporation's License to Burcon).

"Corporation Indemnitees" has the meaning ascribed to it in Section 11.2 (Indemnification by Burcon).

"Corporation Patent Improvements" means the Corporation Improvements which are in the form of patents or which are patentable.

"Corporation Royalty" has the meaning ascribed to it in Section 4.3 (Corporation Royalty).

"Corporation Technology" means all inventions, innovations, improvements, discoveries, works, designs or technical developments owned, licensed, controlled, conceived, reduced to practice, discovered or developed by the Corporation and concerning canola, pea and all pulse protein products, including any products or any processes relating to or applications for the commercialization of canola, pea and all pulse protein products, whether patentable or not, Confidential Information (including trade secrets), copyright, methods, processes, techniques, concepts, ideas, information, data, materials, know-how, industrial design or any other property right or any applications therefor and including all information and tangible items of a scientific or technical nature in any form or medium and all information or records relating thereto, in any and all relevant jurisdictions.


"Develop" means to manage, coordinate and administer all architectural, engineering, design, procurement, legal, and other services and acts relating to the Construction and Commissioning of the Flex Production Facility (and the Full-commercial Production Facility, or any other production facility, if applicable), and/or a portion thereof, including as may be required in connection with the:

(a) lease or purchase of land for the facility;

(b) planning and design of the facility;

(c) procurement, installation and testing of all fixtures and equipment for the facility;

(a) issuance of all required permits and authorizations, including any permit(s) issued by applicable authorities to permit occupancy of the facility (or portion thereof) and production of the Products; and

(b) entering into all necessary or desirable contracts with third parties in connection with the foregoing.

"Effective Date" means July 2, 2019.

"Event of Force Majeure" has the meaning ascribed to it in Section 12.1 (Time; Force Majeure).

"Excess Production" has the meaning ascribed to it in Section 3.5(1)(c).

"Exclusive License" has the meaning ascribed to it in Section 3.4 (Exclusive License Grant) and as the same may be amended and converted pursuant to Section 4.2(3).

"Fair Market Value" has the meaning ascribed to it in Section 1.3 (Fair Market Value).

"Flex Production Facility" has the meaning ascribed to it in Section 2.1(a) (Development, Construction and Commission of Production Facilities).

"Flex Production Facility Plans" has the meaning ascribed to it in Section 2.3(1) (Flex Production Facility).

"Flex Production Royalty" has the meaning ascribed to it in Section 4.2 (License Rates).

"Full-commercial Election Notice" has the meaning ascribed to it in Section 2.4(1)(b) (Corporation Notice to Achieve Commercial Production).


"Full-commercial Production" has the meaning ascribed to it in Section 2.4 (Notice to Achieve Commercial Production).

"Full-commercial Production Capacity" has the meaning ascribed to it in Section 2.4 (Notice to Achieve Commercial Production).

"Full-commercial Production Facility" has the meaning ascribed to it in Section 2.1(b) (Development, Construction and Commission of Production Facilities).

"Full-commercial Production Facility Plans" has the meaning ascribed to it in Section 2.5(a) (Full-commercial Production Facility).

"Full Commercial Production Royalty" has the meaning ascribed to it in Section 4.2 (License Rates).

"License" means the Exclusive License and the Non-Exclusive License.

"License Conversion Notice" has the meaning ascribed to it in Section 4.2(3).

"Net Revenue" means all revenue, consideration, receipts or other moneys recorded from the following sales (determined in accordance with generally accepted accounting principles) of Products and Blended Products:

(a) sales of Products or Blended Products by the Corporation or an Affiliate of the Corporation to any Person including Sublicensees (excluding sales between the Corporation and the Corporation's Affiliates);

(b) sales of Products or Blended Products by Sublicensees to any Person (excluding sales to the Corporation or an Affiliate of the Corporation) where such Sublicensee has been granted a sublicense to manufacture and sell Products and the Sublicensee did not purchase such Products, Blended Products or Products to produce such Blended Products from the Corporation or an Affiliate of the Corporation;

PLUS:

(c) the Fair Market Value of all Products and Blended Products contained in any Value Added Products that are (i) sold by the Corporation or an Affiliate of the Corporation to any Person including Sublicensees (but excluding sales between the Corporation and the Corporation's Affiliates); or (ii) sold by Sublicensees to any Person (excluding sales to the Corporation or an Affiliate of the Corporation) where such Sublicensee has been granted a sublicense to manufacture and sell Products and the Sublicensee did not purchase the Products included in such Value Added Products from the Corporation or an Affiliate of the Corporation,

but in no case including any amounts representing:


(d) any taxes, tariffs or import/export duties imposed and paid upon particular sales;

(e) credits, allowances, discounts and rebates to, and charge backs from the account of, customers for spoiled, damaged, out-dated, rejected or returned Products, Blended Products or Value Added Products;

(f) any brokerage & sales commissions paid to third party agencies for sale of Products, Blended Products or Value Added Products

(g) discounts and rebates to customers attributable solely to the marketing, sale and distribution of the Products, Blended Products or Value Added Products; or

(h) (to the extent included in the invoiced sales price) actual freight and insurance costs incurred in transporting Product, Blended Product or Value Added Product in final form to such customers.

"Non-Exclusive License" has the meaning ascribed to it in Section 3.5 (Conversion to Non-Exclusive License) and as the same may be amended and converted pursuant to Section 4.2(3).

"Operations" means every kind of work done, or activity performed by or on behalf of the Corporation in respect of the Development, Construction and Commissioning of the Flex Production Facility and the Full-commercial Production Facility, and operating such facilities, including, without limitation, the production of Products (including test and Sample production); sales and shipping of Products; and further including the management and administration necessary to conduct the work or activity aforesaid.

"Original License Agreement" means the license and production agreement dated May 23, 2019 by and between Burcon and the Corporation.

"Parties" means Burcon and the Corporation, and "Party" means either of them.

"Person" means any individual, sole proprietorship, partnership, unincorporated association, unincorporated syndicate, unincorporated organization, joint venture, trust, body corporate, governmental authority, governmental agency or political subdivision thereof, or a natural person in such person's capacity as trustee, executor, administrator or other legal representative.

"Pre-Full Commercial Production Royalty" has the meaning ascribed to it in Section 4.2 (License Rates).

"Product" means a canola, pea or pulse protein product (including any derivative thereof) that uses, incorporates or is derived from any Burcon Technology (but for greater certainty, excludes a Value Added Product), including without limitation, Peazazz® and Peazac™ pea protein isolates and Supertein®, Puratein® and Nutratein® canola protein isolates.


"Quarter" means a calendar quarter, i.e. January through March, April through June, July through September and October through December; provided, however, that Quarter shall include any shorter period at the commencement of the Agreement from the Effective Date through the closer of March, June, September or December, and shall include any shorter period at the termination or expiration of the Agreement from the closer of January, April, July or October through the date of such termination or expiration.

"Royalties" has the meaning ascribed to it in Section 4.1 (Royalties) and includes the Flex Production Royalty, the Pre-Full Commercial Production Royalty and the Full Commercial Production Royalty.

"Shareholders' Agreement" means the amended and restated unanimous shareholders' agreement dated as of the date hereof among the Corporation, Burcon or its Affiliate and the Corporation's other shareholders.

"Specified Patent" means United States patent application number [commercially sensitive information redacted] (or any continuations, continuation-in-part or divisional applications thereof).

"Sublicensee" means any entity to which the Corporation has granted a sublicense to any Burcon Technology or Burcon Patent Rights, whether express or implied.

"taxes" means all taxes, levies, imposts, deductions, charges or withholdings and all related liabilities imposed by any country (or any political subdivision or taxing authority of it), including any interest, additions to tax or penalties applicable thereto.

"Technology Commercialization Committee" has the meaning ascribed to it in Section 7.1 (Technology Commercialization Committee).

"Tonne" means a metric ton or 1,000 kilograms.

"Value Added Product" means a product that contains both (a) Products or Blended Products and (b) ingredients which are not Products or Blended Products. 

Section 1.2 Interpretation

In this Agreement, except as otherwise expressly provided or unless the context otherwise requires:

(a) "this Agreement" means this Amended and Restated License and Production Agreement, including the Schedules hereto, as from time to time supplemented or amended by one or more agreements entered into pursuant to the applicable provisions hereof;


(b) the headings in this Agreement are inserted for convenience only and do not form a part of this Agreement and are not intended to interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof;

(c) the word "including", when following any general statement or term, is not to be construed as limiting the general statement or term to the specific items or matters set forth or to similar items or matters, but rather as permitting the general statement or term to refer to all other items or matters that could reasonably fall within its broadest possible scope;

(d) all accounting terms not otherwise defined herein have the meanings assigned to them, and all calculations to be made hereunder are to be made in accordance with International Financial Reporting Standards applied on a consistent basis;

(e) a reference to a statute includes all regulations made thereunder, all amendments to the statute or regulations in force from time to time and any statute or regulation that supplements or supersedes such statute or regulations;

(f) a reference to an entity includes any successor to or permitted assigns of that entity;

(g) words importing the masculine gender include the feminine or neuter, words in the singular include the plural, words importing a corporate entity include individuals, and vice versa;

(h) a reference to "approval" "authorization" or "consent" means written approval, authorization or consent;

(i) except as otherwise expressly provided, a reference to currency herein means Canadian dollars and all amounts payable hereunder will be paid in Canadian dollars or in the equivalent other currency calculated at the relevant time; and

(j) any currency conversion required under this Agreement will be converted at the exchange rate for the day on which such conversion is required.

Section 1.3 Fair Market Value

For the purposes of this Agreement, "Fair Market Value" means the price that would have been received if a Product or Blended Product (or other ingredient or product, as applicable) was sold in an open and unrestricted market between parties acting at Arm's Length and under no compulsion to act.  Whenever a determination of Fair Market Value is required in relation to a specific Product or Blended Product under this Agreement, it will be based on the weighted average selling price of the Product or Blended Product over the immediately preceding Quarter; or if there were no sales of a given Product or Blended Product over the immediately preceding Quarter, then the lowest list price defined by the Corporation's wholesale pricelist for a specified volume; and if there is no such list price, then Fair Market Value will be determined by agreement of the Parties, acting reasonably (or failing such agreement, by an independent valuator appointed by the parties).


ARTICLE 2
COMMERCIALIZATION AND PRODUCTION

Section 2.1 Development, Construction and Commission of Production Facilities

Subject to the terms and conditions set forth in this Agreement, the Corporation will, on a timely basis, at its expense:

(a) Develop, Construct and Commission an initial production facility located in the Province of Manitoba to manufacture and sell Products and Blended Products, with a minimum annual production capacity capable of manufacturing [commercially sensitive information redacted]  of pea and/or pulse proteins (the "Flex Production Facility") using the Burcon Technology; and

(b) if the Corporation provides a Full-commercial Election Notice to Burcon, Develop, Construct and Commission a full commercial scale production facility (the "Full-commercial Production Facility") to manufacture and sell Products, Blended Products and Value Added Product, with a minimum annual production capacity capable of manufacturing at least twice the actual annual production capacity of the Flex Production Facility of pea and/or pulse proteins which shall not be less than [commercially sensitive information redacted]  or such other capacity as mutually agreed to by both parties (the "Full-commercial Production Capacity").  [commercially sensitive information redacted]

Section 2.2 Burcon Assistance 

(1) Burcon will make available its personnel with relevant knowledge of the Burcon Technology to consult with the Corporation throughout the Development, Construction and Commissioning of the Flex Production Facility and, if applicable, the Full-commercial Production Facility, and will use reasonable commercial efforts to facilitate knowledge transfer regarding the Burcon Technology and to answer questions and provide input regarding the design and functional specifications of such production facilities.  Burcon and the Corporation have entered into a services agreement dated as of May 23, 2019 and any fees charged for services offered by one Party to the other Party will be governed by the terms and conditions of such services agreement. 

(2) Without limiting the generality of the foregoing, to facilitate transfer of knowledge about the Burcon Technology to the Corporation, Burcon will use reasonable commercial efforts to:


(a) participate in workshops, meetings, and "hands-on" activities where requested by the Corporation;

(b) explain any relevant standards and production process procedures to the Corporation where requested by the Corporation;

(c) provide training to the Corporation's personnel in current production procedures for the Products at a time or times mutually agreeable to the Parties; and

(d) provide comments on the Flex Production Facility Plans, and if applicable, the Full-commercial Production Facility Plans.

(3) For greater certainty, nothing in this Section 2.2 will require Burcon to pay any portion of the cost of the Development, Construction and Commissioning of either the Flex Production Facility or the Full-commercial Production Facility.

Section 2.3 Flex Production Facility

(1) The Corporation will complete the engineering and design plans for the Flex Production Facility (the "Flex Production Facility Plans"), at its expense, on or before the date that is [commercially sensitive information redacted]  months from the Effective Date. Burcon will provide such reasonable assistance necessary to assist the Corporation in completing the Flex Production Facility Plans. 

(2) Immediately after the Effective Date, at its expense, the Corporation will, in good faith, allocate resources and use reasonable commercial efforts to pursue all necessary permits and regulatory approvals for the design and construction of the Flex Production Facility and for the manufacture of the Products and Blended Products at such facility (the "Flex Production Permits").  The Corporation will be responsible for determining, in consultation with its professional advisors, what permits and regulatory approvals will be necessary.

(3) The Corporation will complete the Construction of the Flex Production Facility as soon as reasonably possible, but in any event no later than [commercially sensitive information redacted] months after the Effective Date, provided that if the Corporation has acted in good faith to obtain the Flex Production Permits in a timely manner, Burcon will grant the Corporation an extension of up to [commercially sensitive information redacted]  months if the Flex Production Permits have not been obtained within [commercially sensitive information redacted] months after the Effective Date, solely for the purpose of allowing the Corporation to finalize and obtain the Flex Production Permits.  If such an extension is granted, the Corporation will complete the Construction of the Flex Production Facility no later than [commercially sensitive information redacted]  months after the Effective Date.

(4) The Corporation will, within [commercially sensitive information redacted]  months from the date of Construction of the Flex Production Facility and at its expense, complete a preliminary feasibility study, which shall include preliminary engineering, design and estimates of capital cost requirements for a Full-commercial Production Facility.


Section 2.4 Notice to Achieve Full Commercial Production

(1) The Corporation will, within [commercially sensitive information redacted] months from the date of the Construction of the Flex Production Facility, by written notice to Burcon, either advise that:

(a) it does not intend to increase its annual production capacity of pea and/or pulse protein products using the Burcon Technology beyond the capacity of the Flex Production Facility; or

(b) it will expand its annual production capacity up to the Full-commercial Production Capacity amount ("Full-commercial Production") for the commercial manufacture of pea and/or pulse protein products using the Burcon Technology and Blended Products based on pea and/or pulse protein products using the Burcon Technology (and in which case, the written notice will be referred to as the "Full-commercial Election Notice").   

(2) If the Corporation provides a Full-commercial Election Notice to Burcon, it will describe:

[commercially sensitive information redacted].

Section 2.5 Full-commercial Production Facility

If the Corporation provides a Full-commercial Election Notice to Burcon:

(a) the Corporation will complete the engineering and design plans for the Full-commercial Production Facility (the "Full-commercial Production Facility Plans"), at its expense, within [commercially sensitive information redacted]  months after the date that the Corporation provided the Full-commercial Election Notice to Burcon; and

(b) the Corporation will complete the Construction and Commissioning of the Full-commercial Production Facility as soon as reasonably possible, but in any event no later than [commercially sensitive information redacted]  months after the date of the Full-commercial Election Notice.

Section 2.6 Covenant to Commercialize

The Corporation covenants that it will use commercially reasonable efforts, taking into account supply, demand, market conditions and prices of competing products, to diligently exploit, commercialize, produce, market, develop applications for, and sell Products and Blended Products to existing and new customers in a competitive manner.


Section 2.7 Samples

Burcon will, at the Corporation's request, furnish, in such quantities and at such times as agreed between the Parties, acting reasonably, samples of Product produced at Burcon's pilot plant for testing and evaluation.  the Corporation will reimburse Burcon for the costs associated with the production of such samples including variable, fixed and out-of-pocket costs.  The Corporation will, upon Burcon's request, furnish, in such quantities and at such times as are agreed between the Parties, acting reasonably, samples of Products developed by the Corporation for evaluation.  Subject to Section 8.1(1)(g), the Corporation may also elect to provide samples of Products produced by either Party ("Samples") to third parties for screening and evaluation of their potential commercial utility and value.  The Corporation shall provide a report to Burcon setting out the details of any samples provided to third parties pursuant to this Section 2.7 including the quantities supplied (broken down by party) and the applications for which the samples were provided.

Section 2.8 Manufacturing Quality

The Corporation will manufacture all Products for sale in a manner consistent with good manufacturing practises and applicable standards, and in compliance with all Applicable Laws.

Section 2.9 Limitation of Use

Burcon acknowledges that the Development, Construction and Commissioning targets provided for in Section 2.3, Section 2.4 and Section 2.5 are targets only, the sole and exclusive use of which, and reference to, shall be in determining whether Burcon has the right to exercise its option set out in Section 3.5(1), and in no instance shall such targets be viewed as obligations, covenants, representations, warrants, or otherwise give rise to a claim of breach of this Agreement or any other cause of action by Burcon as against the Corporation.

ARTICLE 3
INTELLECTUAL PROPERTY OWNERSHIP AND LICENSE GRANT

Section 3.1 Ownership of Burcon Technology

All Burcon Technology and Burcon Improvements shall remain the exclusive property of Burcon and, except as expressly granted herein, the Corporation shall not acquire any right, title or interest in and to the Burcon Technology or Burcon Improvements.  The Corporation shall not directly or indirectly question, attack, contest or in any manner impugn (nor assist any other Person in any of the foregoing) the validity, enforceability, registration or Burcon's ownership of, or right to use, any Burcon Technology or Burcon Improvements, in whole or in part.  Except as expressly provided herein, Burcon shall, in its sole discretion, decide how to protect any Burcon Technology or Burcon Improvements.


Section 3.2 Ownership of Corporation Technology

All Corporation Technology and Corporation Improvements shall remain the exclusive property of the Corporation and, except as expressly granted herein, Burcon shall not acquire any right, title or interest in and to the Corporation Technology or the Corporation Improvements.  Burcon shall not directly or indirectly question, attack, contest or in any manner impugn (nor assist any other Person in any of the foregoing) the validity, enforceability, registration or the Corporation's ownership of, or right to use, any Corporation Technology or Corporation Improvements, in whole or in part.  The Corporation shall, in its sole discretion, decide how to protect any the Corporation Technology or the Corporation Improvements and, if required, Burcon shall use commercially reasonable efforts to assist and cooperate or provide any consent necessary to secure such protection.  Notwithstanding the foregoing and, for the avoidance of doubt, all Corporation Improvements relating to any products other than the Products arising from the Effective Date until the Flex Production Facility has been Commissioned shall be owned by Burcon and the Corporation will use commercially reasonable efforts to promptly assign such ownership to Burcon.

Section 3.3 Disclosure of Corporation Technology

The Corporation agrees that it will promptly disclose to Burcon all Corporation Technology invented, conceived, made, developed, discovered or created by or on behalf of any of the Corporation, its Affiliates that use or have access to the Burcon Technology or its Sublicensees that are desirable or necessary for the research, development, manufacture or sale of the Products or any other products (the "Corporation Improvements"). 

Section 3.4 Exclusive License Grant

Subject to the provisions of this Agreement, Burcon hereby grants to the Corporation an exclusive, royalty-bearing, worldwide license to use and exploit the Burcon Technology (including know-how and trade secrets) solely to make, have made, use, market and sell Products and Blended Products, together with the right to grant sublicenses, as part of the sale of the Products and Blended Products to a purchaser of the same to use, market or sell the Products and Blended Products without the consent of Burcon (the "Exclusive License").  Apart from the sale of Products and Blended Products, the Corporation may sublicense the Burcon Technology (including know-how and trade secrets) only upon mutual agreement between the Parties.  [commercially sensitive information redacted]  Except for the foregoing, Burcon covenants that, during the term of the Exclusive License, it shall not directly or indirectly grant other licences to the Burcon Technology or grant to any other Person any right, license or privilege to make, have made, market, use or sell Products or Blended Products.  Burcon covenants that, during the term of the Exclusive License, it shall not make, have made, market, or sell Products or Blended Products, provided that nothing herein shall be construed or interpreted in any way as limiting Burcon's right to conduct or continue research or development in any manner whatsoever, whether concerning canola, pea, pulse, hemp and flax products or otherwise.


Section 3.5 Conversion to Non-Exclusive License

(1) Burcon shall be entitled, at its option, to convert the Exclusive License to a non-exclusive license, on the terms set forth in Section 3.7 (the "Non-Exclusive License") if:

(2) [commercially sensitive information redacted] Burcon may exercise the option set forth in Section 3.5(1) immediately and without further action by notice in writing to the Corporation:

(a) at any time after the Call Option Expiry Time and provided that the Call Option Closing Date has not occurred, if any of the matters described in Section 3.5(1)(a), Section 3.5(1)(b) or Section 3.5(1)(c) occur; or

(b) at any time after the Call Option Closing Date, if the matters described in Section 3.5(1)(c) occur after the Call Option Closing Date,

and upon the delivery of such notice to the Corporation, the Exclusive License will be converted into the Non-Exclusive License.

(3) If the Exclusive License is converted into the Non-Exclusive License, Burcon shall thereafter be entitled to make, have made, use, market and sell Products and Blended Products on a non-exclusive basis, and to grant any such rights to any other Person (including any non-exclusive licenses or sublicenses of any related Burcon Technology or Burcon Improvements), provided that any such arrangements will be subject to, and will contain an explicit acknowledgment of the Corporation's right to, at its option, amend the Licence to be an exclusive licence in the manner described in Section 4.2(3), at which moment all rights of any party that are in conflict with the Corporation's rights under the License shall immediately terminate. Notwithstanding the foregoing, (i) Burcon reserves the right to use and exploit the Burcon Technology (including know-how and trade secrets) solely to make, have made, use, market and sell Products and Blended Products in connection with [commercially sensitive information redacted], and (ii) nothing herein shall be construed or interpreted in any way as limiting Burcon's right to conduct or continue research or development in any manner whatsoever, whether concerning canola, pea, pulse, hemp and flax products or otherwise.

Section 3.6 Relief from Non-Exclusivity

If Burcon exercises the option set forth in Section 3.5(1)(c), then the Corporation may either:

(1) accept the non-exclusivity of the License as set out in Section 3.5; or

(2) [commercially sensitive information redacted].


Section 3.7 Terms of Non-Exclusive License

(1) Subject to Section 3.6(2), under the Non-Exclusive License, the Corporation will have a non-exclusive, royalty-bearing (at the applicable Royalty rate), worldwide license to use and exploit the Burcon Technology (including know-how and trade secrets) solely to make, have made, use, market and sell Products and Blended Products, together with the right to grant sublicenses, as part of the sale of Products and Blended Products, to a purchaser of such products to use, market or sell such products without the consent of Burcon.

(2) [commercially sensitive information redacted].

Section 3.8 Corporation's License to Burcon

If the Exclusive License is converted into the Non-Exclusive License, the Corporation shall grant to Burcon an irrevocable, non-exclusive, royalty bearing license, with a right to sublicense, to use the Corporation Patent Improvements to make, have made, use, market or sell any Products worldwide (the "Corporation Improvements License").

Section 3.9 Burcon Improvements

(1) Burcon covenants and agrees that it will promptly and fully disclose to the Corporation all Burcon Technology invented, conceived, made, developed, discovered or created by or on behalf of Burcon during the term of the License relating to the Products, including any Burcon Technology that Burcon may acquire, license or otherwise gain control of after the Effective Date (subject, in the case of any Burcon Improvements licensed by Burcon from a third party, to any bona fide restrictions imposed by such third party) (the "Burcon Improvements"), in accordance with the provisions hereof. 

(2) At the Corporation's option, each Burcon Improvement disclosed to the Corporation will (subject, in the case of any Burcon Improvements licensed by Burcon from a third party, to any bona fide restrictions imposed by such third party) also be licensed to the Corporation under terms of the Exclusive License or the Non-Exclusive License, whichever is in effect from time to time, and the following provisions will apply:

(a) Burcon shall notify the Corporation in writing of its development or discovery of any Burcon Improvements either upon the filing of a provisional patent in respect of the Burcon Improvement if Burcon deems the discovery patentable, or, within sixty (60) days of Burcon's decision not to file a patent in respect of the Burcon Improvement;

(b) Upon notification by Burcon, the Corporation shall have a period of sixty (60) days to consider whether it wishes to license the Burcon Improvement, and shall provide notice to Burcon within such sixty (60) day period of its decision;


(c) If the Corporation wishes to license the Burcon Improvement, it shall be deemed to be included in the definition of Burcon Patent Rights and/or Burcon Technology licensed to the Corporation on the terms of the Exclusive License or the Non-Exclusive License, whichever is in effect from time to time; and

(d) If the Corporation does not elect to license the Burcon Improvement, or fails to provide Burcon with notice within such sixty (60) day period:

(i) the Burcon Improvement will be deemed to be carved out and excluded from the definitions of Burcon Technology and Burcon Patent Rights hereunder; and

(ii) Burcon shall have the right to exploit the Burcon Improvement or license the Burcon Improvement to any Person without any further obligation to the Corporation hereunder provided such exploitation does not breach any provision of this Agreement, including but not limited to Section 3.4.

Section 3.10 Trade-mark Option

Provided that the Exclusive License is in effect, the Corporation shall have an option to obtain a royalty-free license to any Burcon trade-mark registered by Burcon in association with the Products, on terms and conditions mutually agreeable to the Parties and the term of such license shall be the same as the term of the Exclusive License.  The trademark license shall provide that during the term of the license, the Corporation shall be responsible for paying all maintenance fees associated with the maintenance of the licensed trade-marks for the Products.

Section 3.11 Condition of Grant of Sublicense

Any grant of a sublicense by the Corporation will be subject to the Sublicensee agreeing in such sublicense to be bound by the provisions of this Agreement.  The Corporation will remain liable to Burcon for the actions, omissions and performance of all its Sublicensees.

ARTICLE 4
LICENSE FEES AND ROYALTIES

Section 4.1 Royalties

In consideration of the License, the Corporation shall pay to Burcon running royalties based on Net Revenue at the applicable royalty rate specified in Section 4.2 (the "Royalties"), the applicable royalty rate being the rate in effect when the Net Revenue is generated.  Payment of the Royalties by the Corporation shall be accompanied by all applicable taxes associated with the Royalties.  Royalties shall be payable within thirty (30)  days after the last day of each Quarter in Canadian dollars payable to the order of "Burcon NutraScience (MB) Corp." by wire transfer to a bank account or accounts designated by Burcon.


Section 4.2 License Rates

(1) Subject to Section 4.2(2), the applicable royalty rate for the License will be as follows:

(a) [commercially sensitive information redacted], until the applicable royalty rate is reduced pursuant to Section 4.2(1)(b) or Section 4.2(1)(c) or Section 4.2(1)(d) (the "Flex Production Royalty");

(b) [commercially sensitive information redacted], from and after the date that the Corporation has provided a Full-commercial Election Notice to Burcon, until the applicable royalty rate is reduced pursuant to Section 4.2(1)(c) or Section 4.2(1)(d) (the "Pre-Full Commercial Production Royalty"); 

(c) [commercially sensitive information redacted] upon completion of the Construction and Commissioning of the Full-commercial Production Facility (the "Full Commercial Production Royalty"); and

(d) [commercially sensitive information redacted] if, and beginning after, Burcon elects to convert the Exclusive License to the Non-Exclusive License, provided that the Corporation does not expand its annual production capacity in relation to the Products and Blended Products beyond the aggregate annual production capacity reached by the Corporation at the time Burcon provides the notice to the Corporation set out in Section 3.5(2).

(2) The Flex Production Royalty, the Pre-Full Commercial Production Royalty and the Full Commercial Production Royalty, in so far as such royalty relates to pea products, will be reduced by [commercially sensitive information redacted]  if the Specified Patent does not issue within [commercially sensitive information redacted]  years after the Effective Date, provided that the Flex Production Royalty, the Pre-Full Commercial Production Royalty and the Full Commercial Production Royalty will, on a going forward basis, revert to their original levels after the Specified Patent is issued thereafter.

(3) Notwithstanding the foregoing, the Corporation may elect, at any time during the ninety (90) days following the Call Option Closing Date, by delivering a notice (the "License Conversion Notice") in writing to Burcon and payment by, or on behalf of, the Corporation by way of wire transfer to Burcon of [commercially sensitive information redacted]  to convert and amend the License, following which the License shall, automatically and without further act or action on the part of any party, be amended to be an exclusive, royalty-free, sub-licensable (without limit or conditionality), perpetual and non-terminable, worldwide license to use and exploit the Burcon Technology (including know-how and trade secrets) to make, have made, use, market and sell canola, pea and pulse protein products, including without limitation the Products and Blended Products (whether as standalone products or as a constituent part of Value Added Products).


(4) On the conversion and amendment of the Licence pursuant to Section 4.2(3), each of Article 2, Section 3.3, Section 3.5, Section 3.6, Section 3.7, Section 3.8, Section 3.9, Section 3.11, Section 4.1, Section 4.2(1), Section 4.2(2), Section 4.3, Section 4.4, Article 5, Section 7.1, Section 9.4(1)(b) and Section 9.4(1)(c) shall cease to have any force and effect.  Provided that for clarity the exercise of the option contained in Section 4.2(3) shall in no way serve to terminate or otherwise limit the non-competition obligations of the Bunge Restricted Parties (as such term is defined in the Shareholders' Agreement) contained in Section 13.3 of the Shareholders' Agreement.

Section 4.3 Corporation Royalty

(1) In consideration of the license granted by the Corporation to Burcon in Section 3.8, Burcon shall, subject to Section 4.4, pay to the Corporation running royalties based on the Net Revenue relating to the sale by Burcon or its Sublicensees of Products that use, incorporate or are derived from the Corporation Patent Improvements at a rate of [commercially sensitive information redacted]  (the "Corporation Royalty").  Payment of the Corporation Royalty by Burcon shall be accompanied by all applicable taxes associated with the Corporation Royalty.

(2) For the purposes of this provision the definition of "Net Revenue" in Section 1.1 will be deemed to be read as if all references to the Corporation were references to Burcon, and vice-versa.

Section 4.4 Limit on the Corporation Royalty

In no calendar year while the License is in effect will the aggregate Royalties in respect of that year payable by Burcon to the Corporation pursuant to Section 4.3 exceed the aggregate Royalties payable by the Corporation to Burcon under the License in respect of the same year. 

Section 4.5 Withholding Taxes

(1) Unless otherwise mutually agreed to between the parties, all Royalty payments and the Corporation Royalty payments under this Agreement will be made free and clear of and without deduction or withholding for any and all taxes, unless such taxes are required by Applicable Law to be deducted or withheld.  If the paying Party is required by Applicable Law to deduct or withhold any such taxes from or in respect of any amount payable under this Agreement (i) the amount payable shall be increased as may be necessary so that after making all required deductions or withholdings (including deductions or withholdings applicable to any additional amounts paid under this Section 4.5(1)), the party entitled to receive a royalty payment receives an amount equal to the amount it would have received if no such deduction or withholding had been made, (ii) the paying Party will make such deductions or withholdings, and (iii) the paying Party will promptly pay the full amount deducted or withheld to the relevant taxation authority in accordance with Applicable Law.


ARTICLE 5
INFORMATION RIGHTS, REPORTS AND AUDIT

Section 5.1 Access and Inspection Rights

(1) At all reasonable times, the Corporation will provide the representatives of Burcon with access to, and the right to inspect and copy all production records, sublicenses, agreements, plans, designs, accounting and financial books and records and other business records and information relating to the Corporation's performance of its obligations under this Agreement. 

(2) The Corporation will allow representatives of Burcon, at Burcon's sole risk and expense and subject to reasonable safety regulations, to inspect the Flex Production Facility and the Full-commercial Production Facility and any other production facilities at which the Products or Value Added Products are or will be produced (before, during and after Construction and Commissioning of such facilities and during operations thereafter) at all reasonable times so long as the inspecting representatives do not unreasonably interfere with the Corporation's operations.  However, nothing in this Section will allow Burcon to audit or inspect any of the Corporation's facilities that do not use the Burcon Technology.

Section 5.2 Reporting Obligations During Development, Construction and Commissioning of Production Facilities

(1) Budgets.

(a) The Corporation will prepare and submit to Burcon a detailed budget for the Development, Construction and Commissioning of the Flex Production Facility, and if applicable, the Full-commercial Production Facility, within ninety (90) days of the Effective Date, with respect to the Flex Production Facility, and within ninety (90) days of the date that the Corporation provides a Full-commercial Election Notice to Burcon, with respect to the Full-commercial Production Facility.

(b) The Corporation will provide to Burcon any updated budgets in relation to the Flex Production Facility and Full-commercial Production Facility within 30 days of the date that the same are prepared internally by the Corporation during the term, and at a minimum will provide an updated budget to Burcon within thirty (30) days of the end of each Quarter during the Development, Construction and Commissioning of the Flex Production Facility, and if applicable, the Full-commercial Production Facility.

(2) Periodic Reports.

(a) During Development, Construction and Commissioning of the Flex Production Facility, and if applicable, the Full-commercial Production Facility, the Corporation will prepare and submit the following reports to the Technology Commercialization Committee:


(i)  Quarterly reports to be delivered within thirty (30) days of the end of each Quarter, which will include:

(A) a description of the Development, Construction and Commissioning Operations completed during the month and a comparison of the Corporation's spending versus it then current budget; and

(B) all necessary data, analyses, projections, studies, evaluations and other reports sufficient to provide the Technology Commercialization Committee with an accurate summary of all relevant Development, Construction and Commissioning Operations and the results of those Operations in relation to the Corporation's obligations under Article 2 of this Agreement; and

(C) an updated planning schedule describing, in reasonable detail, the expected timing for completion of the material Development, Construction and Commissioning obligations that remain to be fulfilled as at the date of the Quarterly report; and any variations in the planning schedule from Quarter to Quarter will be explained by the Corporation.

(b) Burcon's representatives will have the opportunity to ask questions regarding these periodic reports and the Corporation will use commercially reasonable efforts to respond to all of such questions in a complete and timely manner.

(c) the Corporation will use commercially reasonable efforts to incorporate and address Burcon's reasonable feedback and requests relating to the format and content of the periodic reports, so that the format and content of the periodic reports is acceptable to Burcon, acting reasonably.

(3) Application To Additional Facilities.  The Corporation will promptly give notice to Burcon if it intends to Develop, Construct, Commission or otherwise lease, license or purchase any other production facility which will be used to produce Products or Value Added Products.  The reporting obligations in this Section 5.2 will apply equally to any such production facility mutatis mutandis.

Section 5.3 Reports on Production and Sales Estimates

(1) During the Term of the License, the Corporation shall provide Burcon with the following summary reports:


(a) monthly reports with respect to production of Products by the Corporation and its Sublicensees, and Net Revenue derived therefrom, broken down by each Product, Blended Product and Value Added Product within thirty (30) days following then end of each calendar month, which reports will include, without limitation, the following information:

(i) a reconciliation of the inventory (by quantity) at each production facility where the Products, Blended Products and Value Added Products are being produced, including starting inventory, production, sales, Samples delivered, spoilage, and ending inventory; and

(ii) breakdown of Net Revenue for each sale of Products, Blended Products and Value Added Products, including for each sale, name of customer, date, price, type and weight of product sold, and full details of the calculation of Net Revenue for such sale; and

(2) Burcon's representatives will have the opportunity to ask questions regarding these summary reports and the Corporation will use commercially reasonable efforts to respond to all of such questions in a complete and timely manner.

(3) The Corporation will use commercially reasonable efforts to incorporate and address Burcon's reasonable feedback and requests relating to the format and content of the summary reports, so that the format and content of the summary reports is acceptable to Burcon, acting reasonably.

Section 5.4 Reports on Royalties

(1) Within fifteen (15) Business Days following the end of each Quarter in which there was any Net Revenue, the Corporation shall send to Burcon a complete and accurate report detailing the Net Revenue and all related information in the calculation thereof for the time period in respect of which the applicable Royalties are payable, including the information set out in Section 5.3(1)(a)(ii).  Such report shall be certified to be true, correct and complete by an officer of the Corporation.

(2) Burcon's representatives will have the opportunity to ask questions regarding these reports and the Corporation will use commercially reasonable efforts to respond to all of such questions in a complete and timely manner.

(3) The Corporation will use commercially reasonable efforts to incorporate and address Burcon's reasonable feedback and requests relating to the format and content of these reports, so that the format and content of these reports is acceptable to Burcon, acting reasonably.

Section 5.5 Records and Audit

The Corporation shall keep complete and accurate books and records with respect to the sale of Products, Blended Products and Value Added Products and Burcon shall have the right, during business hours and upon reasonable notice, once per calendar year, to have a mutually agreeable independent auditor audit and inspect such portions of such books and records as relate to the commercial exploitation of Products, Blended Products and Value Added Products, including any information necessary to determine the appropriate Royalty payable pursuant to Section 4.1.  All expenses relating to or arising out of such audits and inspections shall be borne by Burcon, unless such audit uncovers a discrepancy between amounts paid to Burcon and amounts that should have been paid greater than an aggregate of $25,000 in respect of the time period audited in Burcon's favour.  In such circumstance, the Corporation shall reimburse Burcon for the reasonable expenses relating to or arising out of such audits and inspections within ten (10) days of receiving an invoice from Burcon.  The Corporation shall keep and preserve each account and record referred to in this Section for a period of six (6) years from the date of each such account and record.  In the event the Corporation has underpaid Royalties, the Corporation shall remit to Burcon any such amounts due on or before thirty (30) days from the date of the final audit report.  In the event the Corporation has overpaid Royalties, Burcon shall remit to the Corporation any amounts due on or before thirty (30) days from the date of the final audit report.


Section 5.6 Burcon Annual Audit

The Corporation acknowledges that in order for Burcon to comply with its obligations with respect to the audit of Burcon's financial statements for its March 31 year end, Burcon may, on an annual basis, at Burcon's sole cost, through its external auditors, perform an audit of the Corporation's books and records as they relate to the Net Revenue and associated Royalties for that fiscal year.  The terms of Section 5.5 will apply fully in respect of any such audit.

Section 5.7 Process Audit

Subject to Article 9, upon written notice by Burcon to the Corporation, Burcon shall have the right, at Burcon's sole cost, during business hours, to audit and inspect The Corporation's Product commercialization and production process.  Such process inspection and audit shall be for Burcon's internal purposes and may include, without limitation, the following activities: 

(a) a review of the plans, designs, methodology, approaches and processes used in respect of the design, development and manufacture of the Products in the Flex Production Facility or any Full-commercial Production facility;

(b) a review of knowledge transfer techniques used in respect of the design, development and manufacture of the Products used in the Flex Production Facility or any Full-commercial Production Facility; and

(c) site inspections of the Flex Production Facility or any Full-commercial Production Facility. 

However, nothing in this Article 5 will allow Burcon to audit or inspect any of the Corporation's facilities that do not use Burcon Technology, provided however, that nothing in this Section 5.7 will restrict Burcon from auditing or inspecting any of the Corporation's facilities in order to assist Burcon in determining the quantity of the products produced by the Corporation that are not Products, Blended Products or Value Added Products for the purposes of Section 3.5(1).


Section 5.8 Record Keeping

Each of the Corporation and Burcon shall (a) keep complete and accurate books and records with respect to the sale of Products, Blended Products and Value Added Products and the performance of their respective obligations under this Agreement (including sale and performance by Sublicensees); and (b) preserve all such books and records in the ordinary course of business for a minimum of five (5) years.  This obligation will survive the termination of this Agreement. 

Section 5.9 Right To Audit

Each of the Corporation and Burcon shall have the right, at its sole cost, to audit the other Party's books and records at any time to determine the other Party's compliance with the terms and conditions of this Agreement.

Section 5.10 Equivalent Corporation Rights

While the license granted by the Corporation to Burcon under Section 3.8 is in effect, Burcon will have the same obligations to provide reports as described in respect of the Corporation in Section 5.3 and Section 5.4 and the same obligations described in respect of the Corporation in Section 5.5 and Section 5.7, and for such purposes such provisions will be deemed to be read as if all references to the Corporation were references to Burcon, and vice-versa.

ARTICLE 6
INFRINGEMENT, DEFENCE AND PATENT PROSECUTION

Section 6.1 Infringement

(1) Each Party shall promptly notify the other in writing of any conflicting use or apparent act of infringement or appropriation of any Burcon Technology or Burcon Patent Rights by any Person which comes to its attention.

(2) Unless and until the Corporation exercises its rights pursuant to Section 4.2(3):

(a) as long as the Exclusive License is in effect, the Corporation shall have the right, but not the obligation, at its expense, to bring suit in its own name, or if required by law, jointly with Burcon, at the Corporation's expense and on its own behalf, for infringement of Burcon's Patent Rights or misappropriation of Burcon Technology, provided that Burcon shall have the right to participate in and control any aspect of any such suit which relates to the validity of any patent included in Burcon's Patent Rights or Burcon Improvements.  In any such suit brought by the Corporation to collect damages, profits and awards of whatever nature for such infringement, the Corporation shall be entitled, subject to the provisions of this Section 6.1(2), to certain damages collected under such suit.  In connection with such suit, the Corporation also has the right to settle any Claim or suit for infringement with the prior written consent of Burcon, which consent will not be unreasonably withheld and provided that, in the reasonable opinion of Burcon's counsel, such action shall not jeopardize any Burcon Technology or Burcon Improvements.  Any money obtained from damages, profits, awards, settlements or sublicense granted to an accused infringer by the Corporation will be paid out in the following order:


[commercially sensitive information redacted]

(b) If the Corporation does not elect to pursue a suit for infringement by giving written notice to that effect to Burcon within sixty (60) days of a notice of conflicting use or apparent act of infringement or appropriation being given by either party under Section 6.1(1), or if the Corporation otherwise fails to pursue such a suit to Burcon's reasonable satisfaction, or at any time if the Non-Exclusive License is in effect, Burcon shall have the right, but not the obligation, at its expense, to take such steps as it may consider necessary to terminate any infringement or appropriation.  If Burcon has chosen to take steps to terminate the infringement or appropriation, the Corporation shall take such steps as may be reasonably requested by Burcon to assist Burcon in terminating such infringement or appropriation and shall take any action or proceeding reasonably requested by Burcon, at the expense of Burcon.  If Burcon exercises its right to take such steps as it may consider necessary to terminate or settle any infringement or appropriation under this Section 6.1(3), Burcon shall be entitled to certain damages collected in connection therewith.  If the resolution or settlement of the suit for infringement pursued by Burcon in accordance with this Section 6.1(3) requires Burcon to grant a sublicense of the Burcon Technology or the Burcon Patent Rights to the accused infringer, the Corporation will not unreasonably withhold its consent to such sublicense of rights.  Any money obtained from damages, profits, awards, settlement or sublicense granted to an accused infringer by Burcon will be paid out in the following order:

[commercially sensitive information redacted].

(3) From and after the date that the Corporation exercises its rights pursuant to Section 4.2(3) the Corporation shall have the right, but not the obligation, at its expense, to bring suit in its own name, or if required by law, jointly with Burcon, at the Corporation's expense and on its own behalf, for infringement of Burcon's Patent Rights or misappropriation of Burcon Technology.  In any such suit brought by the Corporation to collect damages, profits and awards of whatever nature for such infringement, the Corporation shall be entitled to all damages collected under such suit.  In connection with such suit, the Corporation also has the right to settle any Claim or suit for infringement,  without the prior written consent of Burcon and any money obtained from damages, profits, awards, settlements or sublicense granted to an accused infringer by the Corporation will be paid to the Corporation.


(4) Subject to the foregoing, each Party shall cooperate and assist, and cause its employees and representatives to assist, the other Party to the fullest extent possible, at the expense of the Party bringing the suit, regarding an action or proceeding brought under this Section 6.1. 

Section 6.2 Patent Prosecution

(1) As long as the Exclusive License is in effect and until the conversion and amendment of the Licence pursuant to Section 4.2(3), Burcon shall be responsible for the drafting, filing, prosecution and maintenance of all Burcon Patent Rights in the following countries: [commercially sensitive information redacted], provided that Burcon shall not be responsible to draft, file or prosecute any of the Burcon Patent Rights listed in Schedule A as of the Effective Date in any of the above countries to the extent that it is not eligible, by virtue of the passage of time, to file a patent in any such country.  Burcon covenants and agrees that, as long as the Exclusive License is in effect and until the conversion and amendment of the Licence pursuant to Section 4.2(3), it will use commercially reasonable efforts to diligently continue the prosecution of such patent rights with all practicable expedience and shall bear all fees and expenses associated with the drafting, filing, prosecution and maintenance of all Burcon Patent Rights.  Burcon shall consult with the Corporation with regard to every material decision required to be made during the drafting, filing, prosecution and maintenance of such patent rights, while the Exclusive License is in effect and until the conversion and amendment of the Licence pursuant to Section 4.2(3).  Burcon shall consider the Corporation's comments and recommendations during the prosecution and maintenance of the Burcon Patent Rights, while the Exclusive License is in effect and until the conversion and amendment of the Licence pursuant to Section 4.2(3), provided that all decisions in respect of the drafting, filing, prosecution and maintenance of the Burcon Patent Rights shall be in Burcon's sole discretion.  In the event Burcon fails, while the Exclusive License is in effect and until the conversion and amendment of the Licence pursuant to Section 4.2(3), to maintain any Burcon Patent Rights, Burcon shall notify the Corporation within thirty (30) days of making such decision and the Corporation shall have the right, but not the obligation, to assume such maintenance.  Following the conversion and amendment of the Licence pursuant to Section 4.2(3), the Corporation shall assume the foregoing prosecution and maintenance obligations with respect to all Burcon Patent Rights at the Corporation's sole cost and expense.

(2) In the event the Corporation desires, while the Exclusive License is in effect, to expand the scope of patenting of any of the applications in the Burcon Patent Rights to include additional patents covering the Burcon Technology and/or Burcon Improvements or pursue patents in additional countries beyond those set forth above, Burcon shall cooperate with such requests; provided that the Corporation agrees to pay all costs associated with the prosecution and maintenance of such filings without deduction or offset to Royalties or other fees otherwise due hereunder unless mutually agreed to otherwise, and further provided that all such filings shall be in the name of Burcon and shall be deemed to be included within the Burcon Patent Rights.  If the Corporation elects to expand the scope of patenting, the Corporation shall select the legal counsel of its choice that is acceptable, acting reasonably, to Burcon, and the Corporation will provide Burcon with copies of all documents to be filed in the prosecution of any patent application to provide Burcon with a reasonable opportunity to comment, and the Corporation will consult with Burcon with regard to every material decision required to be made during the drafting, filing, prosecution and maintenance of any such application.


Section 6.3 Defence of Actions

(1) During the term of this Agreement, each Party shall inform the other Party in writing forthwith of any action of which it becomes aware in which the validity of any patent in the Burcon Patent Rights is raised in any jurisdiction.

(2) As long as the Exclusive License is in effect, the Corporation shall have the right, but not the obligation, to defend any action in which the validity of any patent in the Burcon Patent Rights is raised in any jurisdiction and Burcon agrees to cooperate and to cause its employees and representatives to cooperate in the defence of any such action, which shall be at the Corporation's sole expense.   

(3) If the Corporation elects not to defend such action, the Corporation shall notify Burcon within thirty (30) days of making such decision and Burcon shall have the right, but not the obligation, to assume such defence, in which case Burcon shall be solely responsible for its costs thereof, and shall be wholly liable for any monetary award made as a result of such defence.  Burcon may, in its sole discretion and at its sole cost and expense, settle any action or abandon or withdraw any Burcon Technology application or registration, for which it has elected to assume defence of such action after notice from the Corporation to Burcon that the Corporation has elected not to defend the action.

Section 6.4 Exclusive Remedies

Except as otherwise set forth herein, the remedies set forth in this Article 6 shall be the exclusive remedies available to the Corporation with respect to any Claim attacking the validity of the Burcon Patent Rights in any jurisdiction or alleging infringement of any other Person's intellectual property rights by Burcon Technology in any jurisdiction, provided that nothing herein shall limit in any way either Party's remedies in respect of fraud or wilful misconduct by the other Party in connection herewith.


ARTICLE 7
GOVERNANCE AND DISPUTE RESOLUTION

Section 7.1 Technology Commercialization Committee

(1) A technology commercialization committee has been established with effect from the Effective Date (the "Technology Commercialization Committee").  Throughout the term of the License, but no less than once per Quarter, the members of such committee will discuss though written and telephonic communication, the commercialization of the Products, including, but not limited to,

(a) the progress by the Parties with respect to the budgeting, Development, Construction and Commissioning of the Flex Production Facility and the Full-commercial Production Facility (and any other production facilities that may be Developed, Constructed or Commissioned or otherwise used for the production of Products by the Corporation or any Sublicensee),

(b) the development of the commercial process to produce the Products,

(c) the development of Product specifications,

(d) the development of markets for the Products, and

(e) process improvements related to the Products.

(2) Representation on Technology Commercialization Committee.  Each Party will appoint two representatives to the Technology Commercialization Committee, and each Party may appoint one or more alternate representatives to act in the absence of its representatives and any alternate representative so acting will be deemed to be that Party's representative in respect of the matter upon which he acts.  Each Party may change its representatives and any alternate representatives at any time.  Notice of any appointment or change will be given to the other Parties.

(3) Meetings of Technology Commercialization Committee.  The Parties will hold a Technology Commercialization Committee meeting at least once every Quarter on a mutually agreed schedule.

Section 7.2 Dispute Resolution

In the event of a dispute between the Parties in respect of any matter falling within the parameters of this Agreement, whether arising during, or at any time after the expiration or termination of this Agreement, the Parties agree to use all reasonable efforts to resolve the dispute promptly and in an amicable manner by negotiation in accordance with this Section 7.2.  Either Party may refer the dispute to the corporate officer of the Corporation responsible for commercialization of the Products and the Chief Executive Officer of Burcon, and such officers shall use reasonable efforts to attempt to resolve the dispute within thirty (30) days of the referral of the dispute to each of them.  If the dispute cannot be resolved within the time period specified above, or such longer time period as the Parties may agree, either Party may submit the dispute for arbitration in accordance with Section 7.3.


Section 7.3 Arbitration

If the Parties do not reach a solution pursuant to Section 7.2 within the time periods specified therein, then upon written notice by either Party to the other, the dispute shall be finally settled by arbitration based upon the following:

(a) The arbitration shall be conducted by a single arbitrator appointed by mutual agreement of the Parties, or in the event of failure to agree within thirty (30) Business Days following delivery of the written notice by the Party initiating the arbitration to the other Party, either Party may apply to a court having jurisdiction to have the arbitrator appointed;

(b) The arbitrator shall be instructed that time is of the essence in the arbitration proceeding and, in any event, the arbitration award must be made within ninety (90) days of the submission of the dispute to arbitration;

(c) After written notice is given to refer any dispute to arbitration, the Parties will meet within fifteen (15) Business Days of delivery of the notice and will negotiate any changes in these arbitration provisions or the rules of arbitration which are herein adopted, in an effort to expedite the process and otherwise ensure that the process is appropriate given the nature of the dispute and the values at risk;

(d) The arbitration shall take place in Winnipeg, MB;

(e) The arbitration award shall be given in writing and shall be final and binding on the Parties, not subject to any appeal, and shall deal with the question of costs of arbitration and all related matters;

(f) Judgment upon any award may be entered in any court having jurisdiction or application may be made to the court for a judicial recognition of the award or an order of enforcement, as the case may be;

(g) All disputes referred to arbitration (including the scope of the agreement to arbitrate, any statute of limitations, set-off Claims, conflict of laws rules, tort Claims and interest Claims) shall be governed by the substantive law of British Columbia;

(h) The Parties agree that the arbitration shall be kept confidential and that the existence of the proceeding and any element of its (including any pleadings, briefs or other documents submitted or exchanged, any testimony or other oral submissions and any awards) shall not be disclosed beyond the arbitrator, the Parties, their counsel and any person necessary to the conduct of the proceeding, except as may lawfully be required in judicial proceedings relating to the arbitration or otherwise. 


(i) However, the arbitrator shall not decide and this Section 7.3 shall not apply to any dispute regarding the validity of or infringement of any of Burcon's Patent Rights, each of which shall be decided by a court or tribunal of competent jurisdiction.

Section 7.4 Other Remedies

Although the arbitrator will also have the power to grant injunctive or other equitable relief, nothing in this Article 7 prevents a party from seeking or obtaining an injunction, specific performance or any other equitable remedy from a court of competent jurisdiction. 

ARTICLE 8
CONFIDENTIALITY

Section 8.1 Confidentiality

(1) Each of the Corporation and Burcon recognizes that the other's Confidential Information constitutes highly valuable and proprietary confidential information.  Each of the Parties agrees that except as otherwise set out, or as is otherwise contemplated, in this Agreement:

(a) it shall not use any Confidential Information belonging to the other Party except as contemplated by this Agreement;

(b) it shall not provide, disclose, divulge or communicate orally or in writing any Confidential Information belonging to the other Party to any other Person or to any of its employees or representatives, other than those who need to have knowledge of the same for the purposes of carrying out the obligations under this Agreement;

(c) except as otherwise provided in Section 8.1(1)(d), it shall obtain from any other Person and any of its employees or representatives to whom it provides any Confidential Information belonging to the other Party an undertaking to protect the confidentiality of such Confidential Information on the terms set forth in this Article 8;

(d) a Party shall not be required to obtain a specific undertaking relating to the subject of this Agreement from any of its employees or contractors provided there is in place between such Party or any one of its Affiliates and the employee or contractor a general undertaking or agreement substantially similar to the provisions of this Article 8, and provided that the subject matter of such undertaking or agreement protects the confidentiality of information obtained from other Persons;


(e) each Party shall be responsible for any breach of this Section 8.1 caused by its Affiliates, sublicenses, and its and their employees, contractors, agents, representatives or Persons for whom it is otherwise responsible at law;

(f) each Party shall protect the Confidential Information of the other Party from all harm, loss, theft, corruption, destruction and unauthorized access, and shall ensure that it is not disclosed, published, released, transferred or otherwise made available in any form to, for the use or benefit of, any Person except as provided in this Article 8, without the other Party's prior written approval; and

(g) notwithstanding anything to the contrary, the Corporation may disclose the following types of Confidential Information to customers or potential customers of the Products, Blended Products and Value Added Products pursuant to a commercially reasonable confidentiality agreement restricting the use and disclosure of such Confidential Information: 

(i) Confidential Information relating to the composition of the Products, Blended Products and Value Added Products, including Samples;

(ii) Confidential Information relating to the use or application of the Products, Blended Products and Value Added Products;

(iii) Confidential Information related to the method of manufacturing the Products, Blended Products and Value Added Products; and

(iv) all other Confidential Information as to which Burcon has given express permission in writing to disclose until such time as Burcon revokes such permission in a written notice provided by Burcon to the Corporation.

(2) The obligations and restrictions of the Parties with respect to Confidential Information shall continue until five (5) years after this Agreement terminates.

Section 8.2 Permitted Disclosure

The provisions of this Article 8 shall not apply to any Confidential Information which:

(a) is at the date of disclosure already known to the Recipient (as evidenced by the Recipient's records);

(b) is on or prior to the date of its disclosure to the Recipient or at any time thereafter made available by, or acquired by the Recipient from, another Person, to the extent only that the Person from whom the Recipient receives the information may lawfully disclose such information;


(c) is required to be disclosed by a court of competent jurisdiction or otherwise by law, provided that prior to such disclosure and to the extent feasible, the Recipient consults with the Provider as to the proposed form and nature of the disclosure;

(d) is or becomes part of the public domain through no fault of the Recipient;

(e) is independently developed by the Recipient, provided that the Recipient shall not have relied upon, either directly or indirectly, the Confidential Information received from the Provider, and provided such independent development is documented; or

(f) is required to be released to regulatory agencies in support of applications to market, or to support applications to test, Products, Blended Products or Value Added Products.

Section 8.3 Return of Confidential Information

Except as otherwise expressly provided for in this Agreement or as otherwise agreed to by the Parties in writing, the Recipient shall (and shall cause its respective Affiliates to), within thirty (30) days after the termination of this Agreement, return to the Provider or destroy all Confidential Information then in its possession which it has received from the Provider or any Affiliate thereof, as well as all copies, summaries, records, descriptions, and duplications that it, or any of its Affiliates, has made from the documents or tangible items received from the Provider or any Affiliates thereof.

Section 8.4 Existing Confidentiality Agreement

The Parties confirm that the existing Confidentiality Agreement between Burcon NutraScience Corporation and [commercially sensitive information redacted] will continue in full force and effect with respect to all Confidential Information disclosed by either of them to the other before the Effective Date.

Section 8.5 Remedies

The Parties recognize and expressly acknowledge that they would be subject to irreparable harm should any of the provisions of this Article 8 be infringed, and that damages alone will be an inadequate remedy for any breach or violation of this Article 8, and that each Party, in addition to all other remedies, shall be entitled as a matter of right to equitable relief, including temporary or permanent injunction, to restrain such breach.


ARTICLE 9
TERM AND TERMINATION

Section 9.1 Term

Unless earlier terminated by either party in accordance with the provisions of Section 9.3, this Agreement shall become effective upon the date hereof, with the effect of superseding the Original License Agreement as of and from such date, and shall extend until the termination of the obligation to pay Royalties under Section 9.2.

Section 9.2 Termination of Royalty Obligations

(1) Unless this Agreement is terminated by either party in accordance with the provisions of Section 9.3 and subject to the Corporation's option contained in Section 4.2(3), the License granted hereunder will be perpetual, but the obligation to pay any Royalties under the License will terminate on the later of:

(a) the date of expiry of the last to expire of the Burcon Patent Rights which the Corporation is using to produce any Products; and 

(b) twenty (20) years from the Effective Date;

and thereafter any such License shall be fully-paid and non-assessable. 

(2) Unless this Agreement is terminated by either Party in accordance with the provisions of Section 9.3, any Corporation Improvements License granted hereunder will be perpetual, but the obligation to pay the Corporation Royalty will terminate on the date that the obligation to pay Royalties under the License terminates, and thereafter the Corporation Improvements License shall be fully-paid and non-assessable.

Section 9.3 Termination of Agreement

This Agreement may be terminated:

(a) by mutual agreement of the Parties;

(b) by the Corporation:

(i) sixty (60) days following receipt of notice by the Corporation to Burcon where Burcon has breached or defaulted in the performance of any of its material obligations under this Agreement and failed to remedy such breach or default within the sixty (60) day period; or

(ii) forthwith upon notice by the Corporation to Burcon following the bankruptcy, insolvency, winding-up, liquidation or dissolution of Burcon.

(c) by Burcon:


(i) sixty (60) days following receipt of notice by Burcon to the Corporation where the Corporation has breached or defaulted in the performance of any of its material obligations under this Agreement and failed to remedy such breach or default within the sixty (60) day period; or

(ii) forthwith upon notice by Burcon to the Corporation following the bankruptcy, insolvency, winding-up, liquidation or dissolution of the Corporation.

Section 9.4 Consequences of Termination of Agreement

(1) Upon termination of this Agreement, the following shall occur:

(a) each Party shall pay to the other any amounts owed to the other Party that have accrued prior to the date of termination;

(b) all license rights granted by Burcon to the Corporation hereunder shall terminate, unless otherwise expressly set forth herein and, if the termination of this Agreement is pursuant to Section 9.3(b), all license rights granted by the Corporation to Burcon hereunder shall terminate, unless expressly set forth herein;

(c) unless this Agreement was terminated by the Corporation pursuant to Section 9.3(b), the Corporation shall grant to Burcon an irrevocable, perpetual, world-wide, non-exclusive and royalty-free license, with a right to sublicense, to use the Corporation Patent Improvements to make, have made, use, market or sell any products, and any license granted to Burcon by the Corporation pursuant to Section 3.8 shall survive any termination or expiration of this Agreement and shall forthwith become irrevocable, royalty-free and perpetual;

(d) each Party shall return or destroy, as applicable, all Confidential Information belonging to the other Party and, if destroyed, shall provide evidence of such destruction; provided, however each Party may retain computer back-up tapes generated in the ordinary course of business that may contain Confidential Information and information from which Confidential Information is revealed or could be ascertained for that amount of time normally retained in the ordinary course of business; and further provided that each Party may retain a single copy of the Confidential Information for archival purposes or purposes relating to any legal dispute, such copy to be held by such Party's independent legal counsel or, upon the written undertaking of in-house legal counsel that such copy shall not be accessed by or accessible to any personnel of the Party other than the in-house legal counsel, by such Party's in-house legal counsel; all provided, however, such Party shall continue to abide by the terms of Article 8 relating to the treatment and nondisclosure of Confidential Information with respect to any such information.


(2) Termination of this Agreement for any reason shall not release either the Corporation or Burcon from any liability which at the time of such termination has already accrued to the other Party.

(3) Termination of this Agreement for any reason shall be without prejudice to any other remedies which any Party may otherwise have.

(4) Notwithstanding the termination or expiration of this Agreement, the provisions of Article 1 (Interpretation), Section 4.2(3), Article 8 (Confidentiality), Article 9 (Term and Termination), Section 10.5 and Section 10.6 (Representations, Warranties and Covenants), Article 11 (Indemnification and Insurance) and Section 7.2 (Dispute Resolution) and Section 12.3 (Severability), Section 12.4 (Governing Law) and Section 12.5 (Entire Agreement) shall survive any such termination or expiration; provided, however, Article 10 and Article 11 shall survive only for a period of five (5) years after any such termination or expiration, and Article 8 shall survive only for a period of ten (10) years after any such termination or expiration.

ARTICLE 10
REPRESENTATIONS, WARRANTIES AND COVENANTS

Section 10.1 Representations and Warranties by Burcon

Burcon represents and warrants to the Corporation, as of the Effective Date, and acknowledges that the Corporation is relying on such representations and warranties in entering into this Agreement, that:

(a) Burcon NutraScience Corporation is a corporation and is validly existing and in good standing under the laws of the Yukon;

(b) Burcon NutraScience (MB) Corp. is a corporation and is validly existing and in good standing under the laws of Manitoba;

(c) Burcon has all necessary corporate power and authority to execute, deliver and perform this Agreement and to carry out its obligations under this Agreement, and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of Burcon;

(d) this Agreement has been duly authorized, executed and delivered by Burcon and constitutes a legal, valid and binding obligation of Burcon, enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, moratorium or similar laws, or general equitable principles, whether considered in an action at law or in equity;

(e) in the fulfillment of its obligations under this Agreement, Burcon is not knowingly violating, infringing or misappropriating any rights, including any contract, statutory or intellectual property rights or any confidentiality rights of any Person;


(f) Burcon has the right to grant to the Corporation the Licenses contemplated in this Agreement;

(g) there are no other outstanding licenses granted by Burcon covering the subject matter of this Agreement and Burcon has not sold, transferred, encumbered, granted any licenses, or otherwise conveyed any rights or privileges capable of becoming a licence or option in or to the Burcon Patent Rights or the Burcon Technology to any Person;

(h) Burcon has no knowledge of any demands or any existing or threatened litigation concerning the Burcon Patent Rights or the Burcon Technology and to Burcon's knowledge, the use of Burcon's Technology by the Corporation and the sale of Products by the Corporation will not infringe any patents or other intellectual property right of a third party;

(i) as of the Effective Date, the Burcon Patent Rights comprise all of Burcon's patents and patent applications concerning the Products;

(j) the information provided by Burcon to the Corporation to describe the Burcon Technology shall be, in all material respects, and to the best of Burcon's knowledge, an accurate description of all the information Burcon possesses relating to the development and manufacture of the Products;

(k) to the best of its knowledge, Burcon has included in the definition of Burcon Patent Rights all of its patents and patent applications which would be infringed by the Corporation's manufacturing, having manufactured, using, selling or offering to sell the Products; provided, that if any such patent or patent application was not included in the definition of Burcon Patent Rights and further provided that such patent or patent application relates to the Products, such definition shall be construed as if such patent or patent application had been so included;

(l) Burcon has no knowledge of any material safety concerns with respect to the development, manufacture, use or sale of the Products, including without limitation, for human consumption or otherwise;

(m) Burcon has no knowledge of any existing or threatened acts by any Person that would infringe the Burcon Patent Rights;

(n) Burcon has no knowledge of any prior art relevant to the patentability of the Burcon Patent Rights that has not been previously disclosed to the Corporation before the Effective Date;


(o) to Burcon's knowledge, Burcon's Patent Rights are genuine, valid and enforceable; and

(p) to the knowledge of Burcon, all rules of the various patent offices which Burcon's Patent Rights relate have been and will be complied with by Burcon and its counsel in all material respects.

Section 10.2 Representations and Warranties by the Corporation

The Corporation represents and warrants to Burcon, as of the Effective Date, and acknowledges that Burcon is relying on such representations and warranties in entering into this Agreement, that:

(a) the Corporation is a corporation duly incorporated and validly existing under the laws of Canada;

(b) the Corporation has all necessary corporate power and authority to enter into this Agreement and to carry out its obligations under this Agreement, and the execution, performance and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of the Corporation;

(c) this Agreement has been duly authorized, executed and delivered by the Corporation and constitutes a legal, valid and binding obligation of the Corporation enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, moratorium or similar laws, or general equitable principles, whether considered in an action at law or in equity;

(d) in the fulfillment of its obligations under this Agreement, the Corporation is not knowingly violating, infringing or misappropriating any rights, including any contract, statutory or intellectual property rights or any confidentiality rights of any Person;

(e) the Corporation has no knowledge of any existing or threatened litigation concerning the Corporation Improvements; and

(f) the Corporation has the right to grant to Burcon the licenses contemplated in this Agreement.

Section 10.3 Corporation Covenant to Comply with Laws

The Corporation covenants that it shall comply fully with all Applicable Laws in respect of its use of the Burcon Technology, including the manufacture, sale, marketing, use and importation of Products, and that it shall obtain all regulatory approvals and licenses required for the manufacture and sale of the Products.


Section 10.4 No Other Warranties

EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, BURCON MAKES NO REPRESENTATIONS OR WARRANTIES TO THE CORPORATION REGARDING THE SUBJECT MATTER OF THIS AGREEMENT, WHETHER EXPRESS, IMPLIED OR STATUTORY, EITHER AT LAW OR IN EQUITY, INCLUDING WITHOUT LIMITATION THE BURCON TECHNOLOGY (INCLUDING THE BURCON PATENT RIGHTS) AND THE PRODUCTS, INCLUDING WITHOUT LIMITATION ANY REPRESENTATIONS OR WARRANTIES AS TO VALUE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.  Without limiting the foregoing, the Corporation acknowledges that it has not and is not relying upon any implied warranty of merchantability or fitness for a particular purpose, or upon any representation or warranty whatsoever as to product safety or the prospects (financial, regulatory or otherwise) or the reliability, suitability, ability to produce a particular result, and validity, regarding the use of the Burcon Technology to manufacture, sell or use the Products.

Section 10.5 Limitation of Liability - Food Safety Standards

The Corporation acknowledges that it will have responsibility under this Agreement for ensuring that the Products, Blended Products and Value Added Products produced in the Flex Production Facility or the Full-commercial Production Facility meet all applicable food safety standards.  Except for the warranty given in Section 10.1(l), Burcon is giving no warranties as to the safety for human consumption of the Products, Blended Products or Value Added Products and Burcon will have no liability for damages resulting from injuries or death caused by the consumption of Products, Blended Products or Value Added Products produced in the Flex Production Facility or the Full-commercial Production Facility unless Burcon or someone for whose conduct Burcon is responsible intended to injure or to cause the death of any person who consumed Products, Blended Products or Value Added Products.  The Corporation releases and discharges Burcon from any and all actions, causes of action, Claims, damages, demands, expenses, and liabilities that Burcon now or hereafter may have or incur arising from any matter for which Burcon is not liable under the foregoing sentence.

Section 10.6 Non-Solicitation

During the term of this Agreement and for a period of two (2) years after the expiry or termination of the License, neither party will solicit for employment any Person who is, at the time of such solicitation, an employee of the other Party or any of its Affiliates, or induce any such Person to leave his or her employment, provided that this provision is not meant to restrict the ability of either party to advertise generally for employees through the means of newspaper, internet or other advertising.

Section 10.7 Indemnities for Representations and Warranties

(a) Notwithstanding anything otherwise contained in this Agreement, Burcon shall be liable to the Corporation for and shall, in addition, indemnify the Corporation from and against all Claims, losses, injuries and damages sustained paid or incurred by the Corporation which would not have been suffered, sustained, paid or incurred had all of the representations and warranties contained in Section 10.1 been accurate and truthful.


(b) Notwithstanding anything otherwise contained in this Agreement, the Corporation shall be liable to Burcon for and shall, in addition, indemnify Burcon from and against all Claims, losses, injuries and damages sustained paid or incurred by Burcon which would not have been suffered, sustained, paid or incurred had all of the representations and warranties contained in Section 10.2 been accurate and truthful.

ARTICLE 11
INDEMNIFICATION AND INSURANCE

Section 11.1 Indemnification by the Corporation

In addition to Section 10.7(b) and subject to Section 11.2, the Corporation shall indemnify, defend, and hold Burcon, its Affiliates and Sublicensees, and each of their respective directors, officers, employees, consultants, representatives, researchers and agents, and each of the aforementioned Person's successors, heirs and assigns (collectively, the "Burcon Indemnitees") harmless from and against any and all Claims to the extent:

(a) caused by an intentional, reckless or negligent act or omission of the Corporation, its Affiliates and their respective officers, agents, or employees; or

(b) caused by any one or more Corporation Indemnitees as a result of a breach of this Agreement;

all provided that Burcon promptly notifies the Corporation in writing after Burcon receives notice of any Claim, and Burcon reasonably cooperates with the Corporation in the defense of any such Claim

Section 11.2 Indemnification by Burcon

In addition to Section 10.7(a) and subject to Section 11.1, Burcon shall indemnify, defend and hold the Corporation, its Affiliates and Sublicensees, and each of their respective directors, officers, employees, consultants, representatives, researchers and agents, and each of the aforementioned Person's successors, heirs and assigns (collectively, the "Corporation Indemnitees") harmless from and against any and all Claims to the extent:

(a) caused by an intentional, reckless or negligent act or omission of Burcon, its Affiliates and their respective officers, agents, or employees; or

(b) caused by any one or more Burcon Indemnitees as a result of a breach of this Agreement;


all provided that the Corporation promptly notifies Burcon in writing after the Corporation receives notice of any Claim, and the Corporation reasonably cooperates with Burcon in the defense of any such Claim.

ARTICLE 12
GENERAL

Section 12.1 Time; Force Majeure

Time is of the essence in the performance of this Agreement and such of its terms, provided that no Party shall be liable to any other, or be in default under the terms of this Agreement, for its failure to fulfill its obligations hereunder to the extent such failure arises for any reason beyond its control including, without limitation, strikes, lockouts, labor disputes, acts of God, acts of nature, acts of governments or their agencies, fire, flood, storm, power shortages or power failure, war, sabotage, inability to obtain sufficient labour, raw materials, fuel or utilities, or inability to obtain transportation (each, an "Event of Force Majeure"); provided that the Party relying on the provisions of this Section shall forthwith give to the other Party notice of its inability to observe or perform the provisions of this Agreement and the reasons for such inability to observe or perform; and provided further that the suspension of the obligations of the Party so affected will continue only for so long as such Event of Force Majeure continues.

Section 12.2 Elimination of Force Majeure Event

A Party relying on the provisions of Section 12.1 will take all commercially reasonable steps to eliminate any Force Majeure Event and, if possible, will perform its obligations under this Agreement as far as practical, but nothing herein will require the Party to question or test the validity of any Applicable Law or order of any government or governmental authority or to complete its obligations if an Event of Force Majeure renders completion impossible.

Section 12.3 Severability

Except as to matters which are fundamental to this Agreement, every part of this Agreement is severable and the invalidity or unenforceability of any part of this Agreement with respect to any Party or circumstance shall not affect the validity or enforceability of that part with respect to any other Party or circumstance, or of any other part of this Agreement.

Section 12.4 Governing Law

This Agreement shall be governed by and construed in accordance with the laws of British Columbia, without giving effect to the principles of conflicts of laws.  Subject to compliance with Section 7.3 (Arbitration), the Parties hereby irrevocably submit and attorn to the non-exclusive jurisdiction of the courts of British Columbia with respect to all matters arising out of or in connection with this Agreement.  The Parties waive any objections they may have to venue being in such courts, including any claim that such venue is an inconvenient forum.


Section 12.5 Entire Agreement

This Agreement sets forth the entire agreement between the Parties pertaining to the subject matter of this Agreement and supersedes all prior agreements, whether oral or written, between the Parties pertaining to the subject matter of this Agreement.  Except as set forth in this Agreement, there are no warranties, representations or other agreements, oral or written, between the Parties pertaining to the subject matter of this Agreement.

Section 12.6 Amendment and Waiver

No amendment or waiver of this Agreement shall be binding on a Party unless executed in writing by that Party.  No waiver of any provision of this Agreement shall constitute a waiver of any other provision nor shall such waiver constitute a continuing waiver unless otherwise expressly provided.

Section 12.7 Relationship of the Parties

The Corporation on the one hand, and Burcon on the other, are independent Parties.  The Corporation is not, and nothing in this Agreement shall constitute it as, the employer, principal or partner of, or joint venturer with, Burcon.  Neither Party shall have any authority to enter into any agreement on behalf of the other Party or to bind the other Party in any other manner, and shall not act or omit to act so as to suggest that it has such authority.  All personnel employed or otherwise engaged by any Party shall be the agents and employees of such Party only, and the other Parties shall incur no obligations or liabilities by reason of the conduct of such personnel.

Section 12.8 Public Notices

Except as may be necessary to comply with the requirements of any Applicable Law, or the requirements of any stock exchange on which the shares of the Party hereto making any announcement or statement or issuing any press release may be listed, at no time shall either Party, without the prior written consent of the other Party (which consent shall not be unreasonably withheld), make any announcement, press release or statement which relates to or refers to any of the matters related to or arising from this Agreement, provided that Burcon shall be permitted to provide its investors with regular updates on the progress of the commercialization efforts of the Parties under this Agreement so long as such updates do not contain confidential information or information of a competitive nature with respect to the Corporation.  The consent from one Party shall be granted to the other within 72 hours of the request being made.  Where an announcement, statement or issuance of a press release is time sensitive, the Party seeking consent may request that the consent be granted by the other Party within 24 hours.  In such circumstance, the request for consent must be in writing and followed up by telephone.


Section 12.9 Notices

Any notices or approvals required or permitted to be given under this Agreement shall be in writing and may be effectively given if delivered personally, sent by courier or registered mail, or sent by telecopier addressed

in the case of the Corporation to:

9th Floor, 400 St. Mary Avenue
Winnipeg, Manitoba
R3C 4K5

Attention:  Chairman and CEO
Facsimile: (204) 953-7220

With a copy to:

Taylor McCaffrey LLP

9th Floor, 400 St. Mary Avenue

Winnipeg, Manitoba

R3C 4K5

Attention: Mr. Norman K. Snyder
Facsimile: (204) 953-7220

or in the case of Burcon to:

Burcon NutraScience Corporation
1946 West Broadway
Vancouver, British Columbia
V6J 1Z2

Attention: Mr. Johann F. Tergesen
Facsimile: (604) 733-8821

with a copy to:

Stikeman Elliott LLP
1700 - 666 Burrard Street
Vancouver, B.C.  V6C 2X8

Attention:  Mr. John E. Stark
Facsimile:  (604) 681-1825

Any such notice shall be deemed to have been given and received, if delivered, on the same day of delivery and, if given by telecopier, on the day it was dispatched; provided that any notice given and received, whether by delivery or telecopier shall, if not given on a Business Day, be deemed to have been given and received on the first Business Day following such day.  Any Party may change its address for service from time to time by notice given in accordance with the foregoing.


Section 12.10 Assignability

This Agreement may not be assigned whether by operation of law or otherwise, by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld.  The permitted assignee shall, from and after the effective date of the assignment, assume all obligations of the assigning Party under this Agreement and shall deliver to the non-assigning Party written acknowledgement of such assumption of obligations in a form satisfactory to the non-assigning Party.  Any assignment contrary to the foregoing shall be null and void and shall not be binding.  This Agreement shall be binding upon the Parties and their respective successors and permitted assigns.

Section 12.11 Further Assurances

The Parties shall with reasonable diligence do all such things and provide all such reasonable assurances as may be required to consummate the transactions contemplated by this Agreement including, without limitation, the registration or protection of any intellectual property rights, and each Party shall provide such further documents or instruments required by the other Party as may be reasonably necessary or desirable to effect the purpose of this Agreement and carry out its provisions.

Section 12.12 Anti-Corruption

Each of the Corporation and Burcon represents, warrants and covenants to the other Party that:

(a) the performance of its obligations herein will not violate any law, regulation or obligation by which it is bound, and will not conflict with or violate any agreement or instrument to which it is a party or by which it is bound;

(b) it will carry out its obligations under this Agreement in accordance with all Applicable Laws, regulations or orders issued by any government authority having jurisdiction over the territory in which any part of such obligations will be performed;

(c) except to the extent previously disclosed to the other Party in writing, each of the Corporation and Burcon and each and every director, owner, employee or any Person acting on its behalf in connection with this Agreement are not employees of any government, government agency, public international organization and are not officials of a political party or candidates for political office;


(d) any expenses submitted by it for reimbursement under this Agreement shall have been legally incurred in connection with its obligations under this Agreement;

(e) in the performance of its obligations under this Agreement, no services, money or other items of value, whether or not reimbursable under this Agreement, will be paid, promised, offered or authorized by it, or any Person acting on its behalf, directly or indirectly, to any Person employed by or acting on behalf of any government, government agency, political party, officials of a political party, or candidate for political office for the purpose of or having the effect of

(i) bribery, kickbacks or other corrupt practices,

(ii) influencing any act or decision of such Person or organization,

(iii) inducing any such Person or organization to do or omit to do any act in violation of their lawful duty, or

(iv) inducing any such Person to use their influence with any government, government agency, public international organization, political party, party official or candidate for political office in order to secure any improper advantage for, or to obtain or retain business on behalf of, Burcon or the Corporation, as the case may be.

If at any time during the term of this Agreement any of these representations and warranties ceases to be accurate, each of the Corporation and Burcon will promptly notify the other Party.  Each of the Corporation and Burcon understands that these representations and warranties will be relied upon by the other Party in preparing accurate financial accounts and records, filing reports and preparing and filing tax returns, as required by law.

Section 12.13 Counterparts

This Agreement may be executed by the Parties in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument.

[signature page follows]


IN WITNESS OF THE FOREGOING, the Parties have executed this Agreement by their authorized signatories below, each of whom represent and warrant that they are authorized to execute this Agreement for and on behalf of the Party for whom they are signing:

BURCON NUTRASCIENCE CORPORATION

 "Johann Tergesen" (signed)

Per:__________________________________
Name: Johann Tergesen
Title President & Chief Executive Officer

 "Lorne Tyrrell" (signed)

Per:__________________________________
Name: Lorne Tyrrell
Title Director & Chairman

 

BURCON NUTRASCIENCE (MB) CORP.

 "Johann Tergesen" (signed)

Per:__________________________________
Name: Johann Tergesen
Title  President

 

MERIT FUNCTIONAL FOODS CORPORATION

 "Ryan Bracken" (signed)

Per:__________________________________
Name:  Ryan Bracken
Title:  President & Co-CEO

[Signature Page to Amended and Restated License and Production Agreement]


SCHEDULE A
BURCON PATENT RIGHTS

[commercially sensitive information redacted]




News Release

Burcon Announces Results of Shareholder Meeting

Vancouver, British Columbia, September 18, 2020 - Burcon NutraScience Corporation (TSX: BU  OTCQB: BUROF) a global technology leader in the development of plant-based proteins, is pleased to announce the results from its 2020 annual meeting of shareholders (the "Meeting") held on September 17, 2020.  All of the eight nominees set out in Burcon's management proxy circular dated July 31, 2020 proposed by management for election to the board of directors at the Meeting were elected to the board.  Each director elected will hold office until the conclusion of the next annual meeting of shareholders of Burcon or until his or her successor is elected or appointed, unless his or her office is earlier vacated in accordance with Burcon's by-laws or with applicable law.

The results of the voting on the election of the directors are as follows:

Director Nominee

Votes For

% Votes For

Votes Withheld

% Votes Withheld

Non Votes

Rosanna Chau

32,895,237

95.14

1,682,035

4.86

3,060,577

David Lorne John Tyrrell

33,287,828

96.27

1,289,444

3.73

3,060,577

Alan Chan

32,271,402

93.33

2,305,870

6.67

3,060,577

J. Douglas Gilpin

34,076,928

98.55

500,344

1.45

3,060,577

Peter H. Kappel

33,510,587

96.92

1,066,685

3.08

3,060,577

David Ju

32,114,742

92.88

2,462,530

7.12

3,060,577

Calvin Chi Leung Ng

31,485,790

91.06

3,091,482

8.94

3,060,577

Debora S. Fang

34,084,498

98.57

492,774

1.43

3,060,577

Shareholders of the Corporation also approved the appointment of PricewaterhouseCoopers LLP as auditors of the Corporation, re-approved the amended and restated 2001 share option plan and approved the continuation of the Corporation into the Province of British Columba pursuant to the Business Corporations Act (British Columbia).

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.


Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.

Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca

www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



VIA SEDAR

September 18, 2020

British Columbia Securities Commission Alberta Securities Commission
Saskatchewan Securities Commission Manitoba Securities Commission
Ontario Securities Commission Office of the Administrator of Securities, New Brunswick
Nova Scotia Securities Commission The Toronto Stock Exchange

 

Dear Sirs:

Re: Burcon NutraScience Corporation - Report of Voting Results

In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure, the matters voted upon and the outcome of the votes at the Annual and Special Meeting of Shareholders (the "Meeting") of Burcon NutraScience Corporation (the "Corporation") held on September 17, 2020 in Vancouver, British Columbia are as follows:

1. Election of Directors

According to proxies received and a vote by ballot, the following individuals were elected as directors of the Corporation, with the following results:

Director Nominee

Votes For

% Votes For

Votes Withheld

% Votes Withheld

Non Votes

Rosanna Chau

32,895,237

95.14

1,682,035

4.86

3,060,577

David Lorne John Tyrrell

33,287,828

96.27

1,289,444

3.73

3,060,577

Alan Chan

32,271,402

93.33

2,305,870

6.67

3,060,577

J. Douglas Gilpin

34,076,928

98.55

500,344

1.45

3,060,577

Peter H. Kappel

33,510,587

96.92

1,066,685

3.08

3,060,577

David Ju

32,114,742

92.88

2,462,530

7.12

3,060,577

Calvin Chi Leung Ng

31,485,790

91.06

3,091,482

8.94

3,060,577

Debora S. Fang

34,084,498

98.57

492,774

1.43

3,060,577

2. Appointment of Auditors

According to proxies received and a vote by ballot, PricewaterhouseCoopers LLP were re-appointed as auditors of the Corporation for the ensuing year, with the following results:

Votes For

%

Votes Withheld

%

Non-Vote

37,358,012

99.49

189,755

0.51

90,082



3. Re-approval of Amended and Restated 2001 Share Option Plan

According to proxies received and a vote by ballot, the Amended and Restated 2001 Option Plan was re-approved by ordinary resolution of the shareholders, with the following results:

Votes For

%

Votes Against

%

Non-Vote

33,235,998

96.12

1,341,274

3.88

3,060,577

4. Continuation in the Province of British Columbia Pursuant to the Business Corporations Act (British Columbia)

According to proxies received and a vote by ballot, the continuation of the Corporation in the Province of British Columbia pursuant to the Business Corporations Act (British Columbia), was approved by special resolution of the shareholders, with the following results:

Votes For

%

Votes Against

%

Non-Vote

33,763,822

97.65

813,450

2.35

3,060,577


 

 

 

 

 

 

 

BURCON NUTRASCIENCE CORPORATION

 

By:

"Dorothy K.T. Law"

 

Name: Dorothy K.T. Law
Title: Senior Vice President, Legal and Corporate Secretary




 

Burcon NutraScience Corporation

Condensed Consolidated Interim Financial Statements

Three and six months ended September 30, 2020 and 2019

(Unaudited)

(Prepared in Canadian dollars)

 


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Balance Sheets

(Unaudited)

As at September 30, 2020 and March 31, 2020

(Prepared in Canadian dollars)

    September
30,
2020

$
    March
31,
2020

$
 
             
ASSETS            
             
Current assets            
  Cash and cash equivalents   12,398,727     15,030,988  
  Amounts receivable (notes 3 and 9)   244,358     332,248  
  Inventory   283,565     132,142  
  Prepaid expenses   143,075     289,278  
    13,069,725     15,784,656  
             
Property and equipment   998,395     470,504  
Deferred development costs - net of accumulated amortization of $nil (2019 - $nil)   2,757,013     1,554,584  
Investment in and loan to Merit Functional Foods Corporation (note 3)   17,407,769     12,204,538  
Goodwill   1,254,930     1,254,930  
             
    35,487,832     31,269,212  
             
LIABILITIES            
Current liabilities            
  Accounts payable and accrued liabilities (note 9)   1,084,082     1,067,251  
  Deferred revenue   275,578     275,578  
  Lease liability   47,281     -  
  Accrued interest (note 4)   -     249,310  
    1,406,941     1,592,139  
             
Lease liability   8,912     -  
Convertible debentures (note 4)   -     6,731,350  
             
    1,415,853     8,323,489  
             
SHAREHOLDERS' EQUITY (note 5)            
Capital stock   108,737,432     98,046,103  
Contributed surplus   14,058,654     9,030,861  
Options   5,039,684     9,673,821  
Warrants   1,619,783     1,792,168  
Convertible debentures (note 4)   -     2,762,927  
Deficit   (95,383,574 )   (98,360,157 )
             
    34,071,979     22,945,723  
             
    35,487,832     31,269,212  

Approved by the Audit Committee of the Board of Directors

"Douglas Gilpin"   "David Ju"
Director   Director

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

For the three and six months ended September 30, 2020 and 2019

(Prepared in Canadian dollars)

    Three months ended     Six months ended  
    September 30     September 30  
             
    2020
$
    2019
$
    2020
$
    2019
$
 
                         
REVENUE                        
Royalty income (note 1(b))   131     7,055     8,646     22,691  
                         
EXPENSES                        
Research and development (note 6)   50,753     160,719     151,243     516,850  
Intellectual property   173,444     190,045     312,219     551,305  
General and administrative (note 7)   827,124     422,378     1,484,072     819,456  
                         
    1,051,321     773,142     1,947,534     1,887,611  
                         
LOSS FROM OPERATIONS   (1,051,190 )   (766,087 )   (1,938,888 )   (1,864,920 )
                         
INTEREST AND OTHER INCOME (notes 3 and 9)   219,109     19,005     368,670     25,063  
                         
MANAGEMENT FEE INCOME (notes 3 and 9)   54,232     145,665     163,547     150,884  
                         
GAIN ON DILUTION OF INVESTMENT IN MERIT FOODS (note 3)   6,384,942     -     6,384,942     -  
                         
SHARE OF LOSS IN MERIT FUNCTIONAL FOODS CORP. (note 3)   (948,972 )   (95,742 )   (1,331,148 )   (142,504 )
                         
INTEREST EXPENSE (note 4)   (280,206 )   -     (668,229 )   (117,258 )
                         
WARRANT VALUATION ADJUSTMENT   -     -     -     (85,421 )
                         
OTHER   (632 )   (478 )   (2,311 )   4,539  
                         
INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD   4,377,283     (697,637 )   2,976,583     (2,029,617 )
                         
BASIC AND DILUTED INCOME (LOSS) PER SHARE (note 8)   0.04     (0.01 )   0.03     (0.03 )

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity

(Unaudited)

For the six months ended September 30, 2020 and 2019

(Prepared in Canadian dollars)

    Number of
fully paid
common
shares 
    Capital
stock
$
    Contributed
surplus
$
    Options
$
    Warrants
$
    Convertible debentures
$ 
    Deficit
$
    Total
shareholders'
equity
$
 
                                                 
Balance - March 31, 2019   43,941,536     73,361,133     9,001,467     9,184,852     199,117     -     (93,726,663 )   (1,980,094 )
                                                 
Loss and comprehensive loss for the year   -     -     -     -     -           (2,029,617 )   (2,029,617 )
                                                 
Shares issued   44,083,203     15,429,121     -     -     -     -     -     15,429,121  
                                                 
Issue costs   -     (159,753 )   -     -     -     -     -     (159,753 )
                                                 
Options exercised   171,667     116,854     -     (46,703 )   -     -     -     70,151  
                                                 
Warrant valuation adjustment   -     -     -     -     85,421     -     -     85,421  
                                                 
Stock-based compensation expense   -     -     -     72,044     -     -     -     72,044  
                                                 
Balance - September 30, 2019   88,196,406     88,747,355     9,001,467     9,210,193     284,538     -     (95,756,280 )   11,487,273  
                                                 
Balance, March 31, 2020   96,799,638     98,046,103     9,030,861     9,673,821     1,792,168     2,762,927     (98,360,157 )   22,945,723  
                                                 
Income and comprehensive income for the year   -     -     -     -     -     -     2,976,583     2,976,583  
                                                 
Shares issued   9,405,101     10,695,613     -     -     (171,600 )   (2,762,927 )   -     7,761,086  
                                                 
Issue costs   -     (4,284 )   -     -     (785 )   -     -     (5,069 )
                                                 
Options expired   -     -     5,027,793     (5,027,793 )   -     -     -     -  
                                                 
Stock-based compensation expense   -     -     -     393,656     -     -     -     393,656  
                                                 
Balance - September 30, 2020   106,204,739     108,737,432     14,058,654     5,039,684     1,619,783     -     (95,383,574 )   34,071,979  

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Cash Flows

(Unaudited)

For the six months ended September 30, 2020 and 2019

(Prepared in Canadian dollars)

     2020
$
    2019
$
 
CASH FLOWS FROM OPERATING ACTIVITIES            
Income (loss) for the period   2,976,583     (2,029,617 )
Items not affecting cash            
Amortization of property and equipment   53,931     19,215  
Unrealized foreign exchange loss    2,138     153  
Interest accretion   (149,437 )   -  
Interest expense   314,735     -  
Change in fair value of derivative liability   -     (5,384 )
Gain on dilution of investment in Merit Functional Foods Corporation   (6,384,942 )   -  
Share in loss of Merit Functional Foods Corporation   1,331,148     142,504  
Loss on disposal of equipment   -     747  
Warrant valuation adjustment   -     85,421  
Stock-based compensation expense   292,461     57,175  
    (1,563,383 )   (1,729,786 )
Changes in non-cash working capital items            
Amounts receivable   87,890     (271,975 )
Inventory   (151,423 )   (84,348 )
Prepaid expenses   146,203     186,718  
Accounts payable and accrued liabilities   311,555     169,883  
Accrued interest   (249,310 )   (564,251 )
    (1,418,468 )   (2,293,759 )
             
CASH FLOWS FROM INVESTING ACTIVITIES            
Investment in Merit Functional Foods Corporation   -     (8,000,001 )
Development costs deferred   (1,048,117 )   (493,953 )
Acquisition of property and equipment   (700,211 )   (4,141 )
    (1,748,328 )   (8,498,095 )
             
CASH FLOWS FROM FINANCING ACTIVITIES            
Issue of capital stock   715,000     15,499,271  
Share issue costs   (234,520 )   (158,070 )
Lease liability   56,193     -  
Short-term loan   -     250,000  
Repayment of convertible note   -     (1,990,687 )
Repayment of short-term loan   -     (1,500,000 )
    536,673     12,100,514  
             
FOREIGN EXCHANGE LOSS ON CASH AND CASH EQUIVALENTS   (2,138 )   (153 )
             
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (2,632,261 )   1,308,507  
             
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD   15,030,988     489,215  
             
CASH AND CASH EQUIVALENTS - END OF PERIOD   12,398,727     1,797,722  
             
INTEREST RECEIVED   135,103     28,855  

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

1. Nature of operations

Burcon NutraScience Corporation ("Burcon" or the "Company") is an incorporated entity headquartered in Vancouver, British Columbia, Canada.

Burcon is a research and development company that has developed plant protein extraction and purification technology in the field of functional, renewable plant proteins.  The Company has an extensive portfolio of composition, application and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. 

a) Peazazz®, Peazac®, Puratein®, Supertein® and Nutratein®

Burcon has developed novel pea proteins that it has branded Peazazz® and Peazac®.  In 2017, Peazazz® and Peazac® pea proteins achieved US self-affirmed GRAS ("Generally Recognized As Safe") status, and the US Food and Drug Administration ("US-FDA") formally acknowledged receipt of Burcon's GRAS notification for Peazazz® and Peazac® in October 2019.

Burcon has developed three canola protein products, Puratein®, Supertein® and Nutratein®.  In 2008, Puratein® and Supertein® achieved US self-affirmed GRAS status, and the US-FDA formally acknowledged receipt of Burcon's GRAS notification for Puratein® and Supertein® in 2010.

On May 23, 2019, Burcon, entered into a shareholders' agreement with two other entities to become shareholders of Merit Functional Foods Corporation ("Merit Foods"), to build a new commercial production facility in Western Canada to produce its pea and canola protein  products.  See note 3 for further details.

On May 23, 2019, Burcon entered into a license agreement with Merit Foods granting Merit Foods an exclusive, royalty-bearing, worldwide license to use and exploit Burcon's pea, pulse, and canola protein technologies required to produce, market and sell Burcon's pea, pulse and canola proteins (collectively the "Products").  See note 3 for further details.

b) CLARISOY®

Burcon had a license and production agreement (the "Soy Agreement") with Archer Daniels Midland Company ("ADM") to license its CLARISOY® technology to ADM on an exclusive basis to produce market and sell CLARISOY® soy protein worldwide.  On August 7, 2020, Burcon and ADM agreed to terminate the Soy Agreement.  As part of the agreement to terminate the exclusive license, the CLARISOY trademark reverted back to Burcon. 

c) COVID-19

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  To-date, the COVID-19 pandemic has not had significant adverse effect on Burcon's business.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

2. Significant accounting policies

Basis of presentation

These condensed consolidated interim financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") applicable to the preparation of interim financial statements, including International Accounting Standards ("IAS") 34, Interim Financial Reporting, and interpretations issued by the IFRS Interpretations Committee ("IFRIC") on a basis consistent with those accounting policies followed in the most recent annual consolidated financial statements.  These condensed consolidated financial statements do not include all of the information required for full annual financial statements and were approved and authorized for issue by the Audit Committee of the Board of Directors on November 12, 2020.

The condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated annual financial statements for the year ended March 31, 2020. 

Principles of consolidation

These condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries, Burcon NutraScience (MB) Corp. ("Burcon-MB") and Burcon NutraScience Holdings Corp. ("Burcon Holdings").  A subsidiary is an entity in which the Company has control, directly or indirectly.  Under IFRS 10, an investor controls an investee if and only if the investor has power over the investee, exposure, or rights, to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect the amount of the investor's returns.  All material intercompany transactions and balances have been eliminated on consolidation.

Details of the Company's subsidiary at September 30, 2020 are as follows:

    Place of
incorporation
  Interest
%
  Principal activity
             
Burcon NutraScience (MB) Corp.   Manitoba, Canada   100   Research and development
Burcon NutraScience Holdings Corp.   Canada   100   Investment holding


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

3. Investment in and loan to Merit Functional Foods Corporation

On May 23, 2019, Burcon, through a new wholly-owned subsidiary incorporated on May 22, 2019, Burcon Holdings, entered into a shareholders' agreement (the "Shareholders' Agreement") with two other entities (the "Partners") to become shareholders of Merit Foods, to build and own a new commercial production facility in Western Canada to produce, sell, market and distribute Burcon's Peazazz® and Peazac® pea proteins, Burcon's Puratein®, Supertein® and Nutratein® canola proteins, as well as Burcon's new pea and canola protein blends that it has branded Nutratein-PS and Nutratein-TZ

On inception, Burcon Holdings held 40% of the issued and outstanding shares of Merit Foods, and the two other parties held 40% and 20%, respectively.  Each shareholder made its respective capital loan advances in June, September, December 2019 and February 2020 by way of shareholder loans totalling $32.5 million (the "Merit Shareholder Loans").

On August 27, 2020, Bunge Limited ("Bunge") made an investment of $30 million into Merit Foods. In addition to purchasing equity directly from Merit Foods, Bunge purchased additional shares and debt from the other shareholders of Merit Foods.  As a result of these transactions, Bunge became a 25% shareholder in Merit Foods and Burcon's ownership interest in Merit Foods is now at 33.3%.  As a result of the dilution in Burcon's ownership interest in Merit Foods, Burcon has recorded a dilution gain of $6,384,942.

Summary financial position for Merit Foods as at September 30, 2020

    As at September 30, 2020     As at March 31, 2020  
    $     $  
             
Current assets   35,402,061     5,828,739  
Non-current assets   103,823,711     36,056,689  
Current liabilities   15,680,203     11,369,931  
Non-current liabilities   74,507,800     6,653,724  

Summary financial results for Merit Foods

    Three months ended     Period ended  
    September 30     September 30  
                         
    2020
$
    2019
$
    2020
$
    2019
$
 
                         
Total revenue   100,098     -     638,642     -  
                         
Loss and comprehensive loss for the period   (2,610,822 )   (239,353 )   (3,566,262 )   (356,259 )


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

To-date, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans.

    Investment in Share capital
$
    Capital Contribution
$
    Loan receivable
$
    Total net investment
$
 
                         
From inception to December 31, 2019   1     -     11,000,000     11,000,001  
Modification to loan terms         8,871,512     (8,871,512 )   -  
Capital loan advance, February 2020   -     1,613,002     386,998     2,000,000  
Share of loss in Merit Foods   -     (939,806 )   -     (939,806 )
Interest accretion   -     -     144,343     144,343  
                         
Net Investment in Merit Foods, March 31, 2020   1     9,544,708     2,659,829     12,204,538  
                         
Share of loss in Merit Foods   -     (1,331,148 )   -     (1,331,148 )
Gain on dilution of Investment in Merit Foods   -     6,384,942     -     6,384,942  
Interest accretion   -     -     149,437     149,437  
                         
Net Investment in Merit Foods, September 30, 2020   1     14,598,502     2,809,266     17,407,769  

From inception to December 2019, the Merit Shareholder Loans were recorded as loan receivable.  In December 2019, the terms of the Merit Shareholder Loans were finalized.  The loans are non-interest bearing, unsecured, subordinated to Merit Foods' other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder's loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts.  As a result, Burcon recalculated the fair value at that date, resulting in a reduction of the fair value of the loan receivable that was transferred to a capital contribution account.  Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest.  For the three and six months ended September 30, 2020, the Company has recorded interest accretion of $75,628 and $149,437, respectively (2019 - $nil).

Burcon has a license agreement (the "License Agreement") with Merit Foods for an exclusive, royalty-bearing, worldwide license to use and exploit Burcon's Products.  As part of the Bunge transaction, Bunge, Burcon and the Partners have amended the License Agreement (the "Amended License Agreement") and Burcon, Bunge and the Partners have also amended the Shareholders Agreement (the "Amended Shareholders Agreement").  Under the Amended License Agreement and Amended Shareholders Agreement, Burcon, Bunge and the Partners have agreed to certain contractual rights, including a right, but not an obligation, of Burcon, in certain circumstances, to participate in a sale of all but not less than all of its shares in Merit Foods, and that in certain circumstances, Merit Foods will have the right to buy out from Burcon the Amended License Agreement for an amount representing the discounted future royalties over the life of the Amended License Agreement.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  For the three and six months ended September 30, 2020, included in management fee income are $53,638 and $158,238, respectively, (2019 - $141,734 and $142,694) for services provided and $132,204 and $212,144, respectively, (2019 - $24,725 and $24,725) for samples sold to Merit Foods, of which $80,541 was included in amounts receivable at September 30, 2020 (March 31, 2020 - $110,594).

Merit Foods also provides certain technical and consulting services to Burcon.  For the three and six months ended September 30, 2020, Burcon recorded professional fee expense of $2,320 and $10,720 (2019 - $nil), respectively, of which $nil was outstanding as at September 30, 2020.

In May 2020, Burcon announced that Merit Foods had secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada ("EDC"), Farm Credit Canada ("FCC") and the Canadian Imperial Bank of Commerce.  All of Merit Foods' shareholders, including Burcon Holdings, have pledged their shares in Merit Foods as security under the loan facilities with EDC and FCC.  In connection with the loan facilities from EDC, Merit Foods must fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility.  Of the prescribed amount, $6.5 million is permitted to be funded by way of a letter of credit ("LC").  To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada ("HSBC") in April 2020, which was secured by a term deposit with HSBC in the same amount.  The LC was released on August 28, 2020.

In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the "Merit Loan Agreement") with Merit Foods in the amount of $6.5 million (the "Merit Loan").  The Merit Loan bore interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term.  As the LC was terminated on August 28, 2020, the Merit Loan Agreement was also terminated on August 28, 2020.  For the three and six months ended September 30, 2020, Burcon recorded interest income of $52,534 and $120,205, respectively, (2019 - $nil) related to the Merit Loan, of which $nil was outstanding as at September 30, 2020 (March 31, 2020 - $nil).

In addition, Burcon provided a guarantee to EDC and FCC in connection with the $85 million financing package (the "Guarantees"), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC, FCC and Merit Foods.  The aggregate maximum liability of Burcon under the Guarantees was limited to $4.0 million.  As part of the investment by Bunge into Merit Foods, EDC and FCC released the Guarantees on August 28, 2020.

In June 2020, Burcon announced that Merit Foods had secured additional debt financing of $10 million in the form of a 10-year interest-free loan from Agriculture and Agri-Food Canada (the "AIP Loan").  Burcon Holdings and the Partners provided a guarantee for the AIP Loan (the "AIP Guarantee").  The obligations of the AIP Guarantee are joint and several.  However, Burcon Holdings and the Partners (the "AIP Guarantors") have entered into a reciprocal indemnity agreement (the "Indemnity Agreement').  Under the Indemnity Agreement, if any AIP Guarantor (each, a "Paying Guarantor") is required to make payment under the AIP Guarantee and any other AIP Guarantor (each, a "Contributing Guarantor") has not made a corresponding payment equal to its share based on its shareholdings in Merit Foods ("Contributive Share"), such Contributing Guarantor(s) shall pay the Paying Guarantor such amounts so that, after payment, all obligations and liabilities under the AIP Guarantee will have been borne by the AIP Guarantors in their respective shareholding percentage in Merit Foods.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

4. Convertible debentures

Convertible debentures

On December 10, 2019, the Company issued convertible debentures (the "Debentures") through a non-brokered private placement for an aggregate principal amount of $9.5 million.  Certain directors and an officer of the Company subscribed for Debentures totalling $2 million in principal amount.  Each Debenture consisted of $1,000 principal amount, bore interest at a rate of 8.5% per annum, payable semi-annually in arrears and was unsecured.  The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon were to be payable in cash on December 10, 2022.  The Company incurred issue costs of $228,432, of which $156,600 were finder's fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders. 

The Debentures were convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share.  During the three and six months ended September 30, 2020, the holders of the Debentures converted principal amounts of $744,500 and $1,704,500, respectively, for the issuance of 709,044 and 1,623,327 common shares, respectively, of the Company. 

Burcon had the right, at its sole discretion, to force the conversion of the Debentures if the shares traded at or above $2.15 for a period of 14 consecutive trading days.  The Company determined it had met this condition between August 12 to August 31, 2020 and issued a notice to the holders of the Debentures for conversion of the Debentures to common shares on September 8, 2020.  As a result of the conversion of $7,795,500 of outstanding principal amount of the Debentures, an aggregate of 7,424,274 common shares were issued to the holders of the Debentures.

The Debentures were a level 3 financial liability with an embedded conversion feature.  The debt and equity components were bifurcated, and the instrument valued to par at the issuance date.  The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option.  From the date of issuance, the liability component was accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive income (loss).  The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641.  The residual amount of $2,762,927 was recognized within equity as the value of the conversion option.  For the three and six months ended September 30, 2020, the Company recorded interest expense of $262,198 and $637,522, respectively (2019 - $nil).


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

5. Shareholders' equity

a) Capital stock

Authorized

Unlimited number of common shares without par value

Equity Offering

On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the "Units") at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the "Offering") and net proceeds of $10.3 million.

Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant").  Each Warrant is exercisable to acquire one common share (a "Warrant Share") until February 19, 2022 at an exercise price of $2.00 per Warrant Share.  The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model and has been included in Warrants.  During the three months ended September 30, 2020, Warrants were exercised for 357,500 common shares of the Company.  As at September 30, 2020, 3,871,786 Warrants were outstanding.  Subsequent to September 30, 2020, 6,000 Warrants were exercised.

The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents' Warrants) entitling the agents to purchase up to 519,386 common shares.  Each Agent's Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022.  The fair value of the Agents' Warrants was estimated at $249,305 using the Black-Scholes pricing model and has been included in Warrants.  At September 30, 2020, all of the Agents' Warrants were outstanding.

In addition to the Agents' Warrants, the Company incurred total issue costs of $1.2 million related to the Offering.

b) Contributed surplus

Contributed surplus comprises the value ascribed to expired warrants and options and forfeited vested options, previously categorized in either warrants or options, as applicable, within shareholders' equity. 


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

c) Options

The Company has a stock option plan in which all directors, officers, employees and consultants of the Company and its subsidiary are eligible to participate.

At September 30, 2020, 3,852,106 (March 31, 2020 - 4,507,606) options to purchase common stock are outstanding from the stock option plan.  These options, when vested under the terms of the plan, are exercisable at prices ranging between $0.23 and $8.05 per common share.  An additional 6,768,367 (March 31, 2020 - 5,172,357) options may be granted in future years under this plan.  Unless otherwise determined by the board of directors, the options have a term of 10 years from the date of grant.  The vesting terms are determined at the discretion of the board of directors at the time of grant.  All grants are recognized using graded vesting, with each vesting tranche being valued separately, and the fair value of each tranche recognized over its respective vesting period.

    Six months ended Sep. 30, 2020     Year ended March 31, 2020  
                         
    Number of
options
 
    Weighted
average
exercise
price

$
    Number of
options
 
    Weighted
average
exercise
price

$
 
                         
Outstanding - Beginning of period   4,507,606     3.32     3,953,739     3.46  
                         
Granted   62,000     2.47     757,000     1.88  
Exercised   -     -     (173,000 )   0.41  
Expired   (717,500 )   9.51     -     0.41  
Cancelled   -     -     (30,133 )   1.96  
                         
Outstanding - End of period   3,852,106     2.15     4,507,606     3.32  

The following table summarizes information about stock options outstanding and exercisable at September 30, 2020:

      Options outstanding     Options exercisable  
Range of
exercise prices

$
    Number
outstanding
at Sep. 30,
2020
    Weighted
average
remaining
contractual
life

(years)
    Weighted
average
exercise
price
$
    Number
exercisable
at Sep.30,
2020
    Weighted
average
exercise
price
$
 
                                 
0.23 - 0.69     926,333     7.95     0.41     508,992     0.46  
1.88 - 4.16     2,825,773     5.83     2.54     2,336,773     2.67  
6.78 - 8.05     100,000     1.07     7.54     100,000     7.54  
                                 
      3,852,106     6.22     2.15     2,945,765     2.46  


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

The fair value of each option is estimated as at the date of grant or other measurement date using the Black-Scholes option pricing model and the following weighted average assumptions:

    Six months
ended
September 30,
2020
  Year ended
March 31, 2020
         
Dividend yield   0.0%   0.0%
Expected volatility   74.4%   75.1%
Risk-free interest rate   0.5%   1.3%
Expected forfeitures   7.4%   7.7%
Expected average option term (years)   8.3   7.9

The expected volatility and expected forfeitures are based on historical volatility and forfeitures. The risk-free rate of return is the yield on a zero-coupon Canadian treasury bill of a term consistent with the expected average option term. The expected average option term is the average expected period to exercise, based on the historical activity patterns for each individually vesting tranche.

The weighted average fair value of the options granted during the six months ended September 30, 2020 was $1.78 per option (year ended March 31, 2020 - $1.36).

For the three and six months ended September 30, 2020, included in research and development expenses (salaries and benefits) is $nil and $nil, respectively, (2019 - $nil and $16,757) (note 6) of stock-based compensation and included in general and administrative expenses (salaries and benefits) is $191,000 and $240,375, respectively, (2019 - $17,009 and $33,151) (note 7) of stock-based compensation.  Included in deferred development costs is $151,855 (March 31, 2020 - $50,660) of stock-based compensation.

6. Research and development

    Three months ended     Six months ended  
    September 30     September 30  
    2020
$
    2019
$
    2020
$
    2019
$
 
Salaries and benefits   44,366     129,338     131,943     379,194  
Laboratory operation   3,207     20,870     8,770     77,668  
Rent   2,692     9,932     8,086     29,276  
Amortization of property and equipment   488     579     2,444     13,141  
Analyses and testing   -     -     -     17,571  
    50,753     160,719     151,243     516,850  


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

7. General and administrative

    Three months ended     Six months ended  
    September 30     September 30  
                         
    2020
$
    2019
$
    2020
$
    2019
$
 
                         
Salaries and benefits   458,534     217,589     918,138     444,091  
Professional fees   195,571     57,279     287,998     123,964  
Investor relations   77,366     42,374     112,083     64,080  
Office supplies and services   41,461     39,800     84,494     80,936  
Transfer agent and filing fees   26,894     14,089     30,820     17,538  
Financing expense   13,883     368     23,790     3,499  
Other   13,415     20,983     26,726     40,888  
Travel and meals   -     29,896     23     44,460  
                         
    827,124     422,378     1,484,072     819,456  

8. Basic and diluted income (loss) per share

The following table sets forth the computation of basic and diluted income (loss) per share:

    Three months ended     Six months ended  
    September 30     September 30  
                         
    2020
$
    2019
$
    2020
$
    2019
$
 
                         
Income (loss) for the period, being
   loss attributable to common
   shareholders - basic and diluted
  4,377,283     (697,637 )   2,976,583     (2,029,617 )
                         
    Shares     Shares     Shares     Shares  
                         
Weighted average common shares
- basic
  100,124,413     88,195,754     98,658,098     67,661,230  
Weighted average common shares
- diluted
  107,848,305     88,195,754     106,381,990     67,661,230  
                         
Basic and diluted income (loss) per share   0.04     (0.01 )   0.03     (0.03 )

For the three and six months ended September 30, 2019, the Company excluded all potential common share equivalents from the diluted loss per share calculation as they were anti-dilutive.

9. Related party transactions

The Company engaged an entity that is related by virtue of common officers for the following related party transactions:


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Included in general and administrative expenses (office supplies and services) for the three and six months ended September 30, 2020 is $nil and $4,584, respectively, (2019 - $18,752 and $37,503) for office space rental.

For the three and six months ended September 30, 2020, included in general and administrative expenses (management fees) are $691 and $1,339 (2019 - $29 and $488), for services provided to the Company.  At September 30, 2020, $183 (March 31, 2020 - $11) of this amount is included in accounts payable and accrued liabilities.  For the three and six months ended September 30, 2020, included in interest and other income is $594 and $5,310, respectively (2019 - $3,931 and $8,190) for management services provided by the Company.  At September 30, 2020, $196 (March 31, 2020 - $1,785), of this amount is included in amounts receivable. 

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  Merit Foods also provides certain technical and consulting services to Burcon.  See note 3 for details.

In connection with the LC, Burcon Holdings entered the Merit Loan Agreement with Merit Foods in the amount of $6.5 million.  During the three and six months ended September 30, 2020, Burcon recorded interest income of $52,534 and $120,205, respectively, (2019 - $nil) related to the Merit Loan, of which $nil was included in amounts receivable as at September 30, 2020 (March 31, 2020 - $nil).

Certain directors and an officer subscribed for $2.0 million of the Debentures.  During the three and six months ended September 30, 2020, the Company made total convertible debenture interest payments of $41,803 and $126,803, respectively, to these directors and officer.

10. Key management compensation

Key management includes the Company's CEO.  Remuneration of directors and key management personnel comprises:

    Six months ended  
    September 30  
             
    2020
$
    2019
$
 
             
Short-term benefits   290,089     164,676  
Option-based awards   134,052     10,572  
             
    424,141     175,248  

Short-term benefits comprise salaries, director fees and employment benefits.

Option-based awards represent the cost to the group of senior management and directors' participation in the incentive stock option plan, as measured by the fair value of instruments granted accounted for in accordance with IFRS 2, Share-based Payment.  For details of these plans refer to note 5 to these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

11. Financial instruments

Credit risk

The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable.  The Company's cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks.  The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks.

Interest rate risk

All of the Company's financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, and the loan to Merit Foods that bore interest at a fixed interest rate.  Burcon's cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk.  For the three and six months ended September 30, 2020, the weighted average interest rate earned on the Company's cash and cash equivalents was 0.32% and 0.27%, respectively, per annum (2019 - 2.19% and 2.15% per annum).  The impact of a 1% strengthening or weakening of interest rates on the Company's cash and cash equivalents at September 30, 2020 is estimated to be a $124,000 increase or decrease in interest income per year.

Liquidity risk

The Company manages liquidity risk through the management of its capital structure (note 12). It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations. The Company's estimated minimum contractual undiscounted cash flow requirement for its financial liabilities at September 30, 2020 is $1,084,082, all of which is within the next 12 months. 

Fair value

The fair value of the Company's short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and accrued interest approximates their carrying values due to the short-term maturities of these financial instruments.

The fair value of the shareholder loans to Merit approximates the carrying value as at September 30, 2020 given the risk profile of Merit Foods has not changed substantially since the issue date of the loans.

The carrying values and fair values of financial instruments, by class, are as follows as at September 30, 2020 and March 31, 2020: 


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)


As at September 30, 2020                        
    At fair value
through profit
or loss
    Financial
assets at
amortized
cost
    Financial
liabilities at
amortized
cost
    Fair value  
    $     $     $     $  
Financial assets                        
Cash and cash equivalents   -     12,398,727     -     12,398,727  
Amounts receivable   -     244,358     -     244,358  
Loan to Merit Foods    -     2,809,267     -     2,809,267  
Total   -     15,452,352     -     15,452,352  
                         
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,084,082     1,084,082  
Total   -     -     1,084,082     1,084,082  

 
As at March 31, 2020
                       
                         
    At fair value
through profit
or loss
    Financial
assets at
amortized
cost
    Financial
liabilities at
amortized
cost
    Fair value  
Financial assets   $     $     $     $  
Cash and cash equivalents   -     15,030,988     -     15,030,988  
Amounts receivable   -     332,248     -     332,248  
Loan to Merit Foods   -     2,659,830     -     2,659,830  
Total   -     18,023,066     -     18,023,066  
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,067,251     1,067,251  
Accrued interest   -     -     249,310     249,310  
Convertible debentures   -     -     6,731,350     6,731,350  
Total   -     -     8,047,911     8,047,911  

Currency risk

The Company has not hedged its exposure to currency fluctuations.  As at September 30, 2020 and March 31, 2020, the Company is exposed to currency risk through the following assets and liabilities denominated in U.S. dollars:


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and six months ended September 30, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)


    September 30, 2020     March 31, 2020  
U.S. Dollars             
Cash and cash equivalents $ 25,213   $ 21,819  
Amounts receivable   97     2,528  
Accounts payable and accrued liabilities   (9,922 )   (40,556 )
Net exposure $ 15,388   $ (16,209 )
             
Canadian dollar equivalent  $ 20,526   $ (22,996 )

Based on the above net exposure at September 30, 2020, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $2,000 (March 31, 2020 - $2,000) in the Company's income (loss) from operations.

12. Capital disclosures

The Company considers its capital to be its shareholders' equity.

The Company manages its capital structure to have sufficient resources available to meet day-to-day operating requirements, continue as a going concern and fund its research and development program.  The Company is dependent on non-operating sources of cash, primarily from issuing equity and debt, to fund its operations and research development programs.  The Company monitors its capital and the expected cash flows required to achieve its business objectives to determine its future financing needs. It seeks additional capital when deemed appropriate, but there is no assurance that it will be able to secure the necessary capital when required. 

The Company is not subject to externally imposed capital requirements and there has been no change with respect to the overall capital risk management strategy during the six months ended September 30, 2020.

 



MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

 

(All amounts following are expressed in Canadian dollars unless otherwise indicated.)

This Management's Discussion and Analysis ("MD&A") has been prepared as at November 16, 2020 to provide a meaningful understanding of Burcon NutraScience Corporation's ("Burcon" or the "Company") operations, performance, and financial condition for the three and six months ended September 30, 2020.  The following information should be read in conjunction with the Company's unaudited condensed consolidated interim financial statements and accompanying notes for the periods ended September 30, 2020 and 2019, which are prepared in accordance with International Accounting Standards (IAS) 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB), as well as the audited consolidated annual financial statements for the year ended March 31, 2020.  We have prepared this MD&A with reference to National Instrument 51-102 "Continuous Disclosure Obligations" of the Canadian Securities Administrators.  Additional information relating to Burcon, including the Company's Annual Information Form ("AIF"), is available on SEDAR at www.sedar.com.

FORWARD-LOOKING STATEMENTS

This MD&A contains certain "forward-looking statements" and "forward-looking information" as defined under applicable Canadian and U.S. securities laws (collectively, "forward-looking statements").  All statements, other than statements of historical fact, are forward-looking statements.  When used in this MD&A the words "estimate", "project", "believe", "anticipate", "intend", "expect", "plan", "predict", "may", "should", "will", or the negatives of these words or other variations thereof and comparable terminology are intended to identify forward-looking statements.  The forward-looking statements pertain to, among other things:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

The forward-looking statements are based on a number of key expectations and assumptions made by management of the Company, including, but not limited to:

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on such forward-looking statements.  The forward-looking statements reflect the Company's current views with respect to future events based on currently available information and are inherently subject to risks and uncertainties.  Many factors, both known and unknown could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements contained in this MD&A, including, but not limited to:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected.  The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Although the Company has attempted to identify important factors that could cause actual results to differ materially from forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated, described or intended.  The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect changes in assumptions or the occurrence of anticipated or unanticipated events, except as required by law.

The Company qualifies all the forward-looking statements contained in this MD&A by the foregoing cautionary statements.

OVERVIEW OF THE COMPANY AND ITS BUSINESS

Since 1999, Burcon has developed an extensive portfolio of composition, application, and process patents originating from our core protein extraction and purification technology.  Our technology cover novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation ("Merit Foods") was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a commercial production facility in Manitoba, Canada where it will produce, under license, Burcon's novel pea and canola protein ingredients.  Our environmentally friendly and sustainable technologies have been developed at our own research facility led by our team of highly specialized scientists and engineers.  Our patent portfolio currently consists of 296 issued patents worldwide, including 70 issued U.S. patents, and in excess of 230 additional patent applications, 37 of which are U.S. patent applications.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

CONTINATION UNDER THE BUSINESS CORPORATIONS ACT (BRITISH COLUMBIA)

Burcon was incorporated under the Business Corporation Act (Yukon) (the "YBCA") on November 3, 1998, and extra-provincially registered in British Columbia on February 5, 1999.  The Board of Directors has determined that it would be more expedient and cost effective to have the Company continue into the Province of British Columbia pursuant to the Business Corporation Act (British Columbia), as amended (the "BCA").  The shareholders of the Company approved the continuance at the 2020 annual general meeting ("AGM").  A summary comparison of the provisions of the BCA and the YBCA that pertain to the rights of the shareholders has been provided in the 2020 management proxy circular, which is available at www.sedar.com.

MERIT FUNCTIONAL FOODS CORPORATION

On May 23, 2019, Burcon, through its newly-formed wholly-owned subsidiary, Burcon NutraScience Holdings Corp. ("Burcon Holdings"), entered into a shareholders agreement (the "Shareholders Agreement") with RBT Holdco Ltd. ("RBT Holdco") and 10039406 Manitoba Ltd. ("Crew Holdco") (RBT Holdco and Crew Holdco together referred to as the "Partners") to become shareholders of Merit Functional Foods Corporation ("Merit Foods").  The business of Merit Foods is the commercial production, sales, marketing and distribution worldwide of Burcon's pea protein, pulse protein and canola protein products.  Merit Foods is currently building and commissioning an initial protein production facility (the "Flex Production Facility") in Winnipeg, Manitoba. 

On inception, Burcon Holdings held 40%, RBT Holdco held 40% and Crew Holdco held 20% of the issued and outstanding shares of Merit Foods.  Each of Ryan Bracken and Barry Tomiski (and their respective family) beneficially owns a 50% interest in RBT Holdco. 

Burcon has a license and production agreement (the "License Agreement') with Merit Foods to license the technology required to produce, market and sell Burcon's pulse protein ingredients, including Peazazz® and Peazac® pea proteins and Burcon's canola proteins, Supertein®, Puratein® and Nutratein® (collectively the "Products").  Under the terms of the License Agreement, Merit Foods has the exclusive rights over Burcon's pulse proteins (including pea) and canola protein technologies across all geographic regions and all product uses (the "License").  Burcon will receive running royalties on the net revenue (as defined in the License Agreement) from the sales of the Products by Merit Foods. 

On August 27, 2020, Bunge Limited ("Bunge") made an investment of $30 million into Merit Foods.  In addition to purchasing equity directly from Merit Foods, Bunge purchased additional shares and debt from the Partners.  Bunge (NYSE:  BG) is a world leader in sourcing, processing and supplying oilseed and grain products and ingredients.  As a result of these transactions, Bunge became a 25% shareholder in Merit Foods, Burcon's ownership interest in Merit Foods is now at 33.3%.  As a result of the dilution in Burcon's ownership interest in Merit Foods, Burcon has recorded a dilution gain of $6,384,942.

As part of the Bunge transaction, Burcon and the Partners have amended the License Agreement (the "Amended License Agreement") and Burcon, Bunge and the Partners have also amended the Shareholders Agreement (the "Amended Shareholders Agreement").  Under the Amended License Agreement and Amended Shareholders Agreement, Burcon, Bunge and the Partners have agreed to certain contractual rights, including a right, but not an obligation, of Burcon, in certain circumstances, to participate in a sale of all but not less than all of its shares in Merit Foods, and that in certain circumstances, Merit Foods will have the right to buy out from Burcon the Amended License Agreement for an amount representing the discounted future royalties over the life of the Amended License Agreement.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement. 

In accordance with the Shareholders Agreement, Burcon Holdings and the Partners made their capital loan advances (the "Initial Capital Loan Advances") in June 2019 by way of shareholder loans to Merit Foods in the aggregate of $10.0 million.  Burcon Holdings and the Partners made further loan advances to Merit Foods in the amounts of $10.0 million in September 2019, $7.5 million in December 2019 and $5.0 million in February 2020 (the "Additional Capital Loan Advances") (the Initial Capital Loan Advances and the Additional Capital Loan Advances, together referred to as the "Merit Shareholder Loans"). 

As at September 30, 2020, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans. 

(in thousands of dollars):

    Investment in
Share capital

    Capital
Contribution

    Loan receivable
    Total net
investment

 
                         
At inception to December 31, 2019   -     -     11,000     11,000  
Modification to loan terms   -     8,872     (8,872 )   -  
Capital loan advance, February 2020   -     1,613     387     2,000  
Share of loss in Merit Foods   -     (940 )   -     (940 )
Interest accretion   -     -     145     145  
                         
Net Investment in Merit Foods, March 31, 2020   -     9,545     2,660     12,205  
Share of loss in Merit Foods   -     (1,331 )   -     (1,331 )
Gain on dilution of investment in Merit Foods   -     6,385     -     6,385  
Interest accretion   -     -     149     149  
                         
Net Investment in Merit Foods, September 30, 2020   -     14,599     2,809     17,408  

On inception, the Merit Shareholder Loans were recorded as a loan receivable.  In December 2019, the terms of the Merit Shareholder Loans were finalized.  The loans are non-interest bearing, unsecured, subordinated to Merit Foods' other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder's loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts.  As a result, Burcon recalculated the fair value at this date, resulting in a reduction of the fair value was been transferred to a capital contribution account.  Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest.  For the three and six months ended September 30, 2020, Burcon has recorded interest accretion of $75,628 and $149,437, respectively (2019 - $nil).


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

Merit Foods is building a 94,000 square foot production facility to produce the Products and the Flex Production Facility is expected to be completed in the fourth calendar quarter of 2020.  Merit Foods believes it will be the only commercial facility in the world with the capability to produce food grade non-GMO canola proteins. 

Merit Foods has a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada ("EDC"), Farm Credit Canada ("FCC") and the Canadian Imperial Bank of Commerce.  Merit Foods' shareholders, including Burcon Holdings and Bunge, have pledged their shares in Merit Foods as security under the loan facilities from EDC and FCC.  In connection with the loan facilities from EDC, Merit Foods must fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility.  Of the prescribed amount, $6.5 million is permitted to be funded by way of a letter of credit ("LC").  To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada ("HSBC") in April 2020, which was secured by a term deposit with HSBC in the same amount.  The LC was released on August 28, 2020.

In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the "Merit Loan Agreement") with Merit Foods in the amount of $6.5 million (the "Merit Loan").  The Merit Loan bore interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term.  As the LC was terminated on August 28, 2020, the Merit Loan Agreement was also terminated on the same date.  For the three and six months ended September 30, 2020, Burcon recorded interest income of $52,534 and $120,205, respectively (2019 - $nil) related to the Merit Loan, of which $nil was outstanding as at September 30, 2020 (March 31, 2020 - $nil). 

In addition, Burcon provided a guarantee to EDC and FCC in connection with the $85 million financing package (the "Guarantees"), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC, FCC and Merit Foods.  The aggregate maximum liability of Burcon under the Guarantees was limited to $4.0 million.  As part of the investment by Bunge into Merit Foods, EDC and FCC released the Guarantees on August 28, 2020.   

Merit Foods also has financing of $10 million in the form of a 10-year interest-free loan from Agriculture and Agri-Food Canada's Agrilnnovate Program ("AIP").  Merit now has a total of $99.2 million financing package from the Government of Canada that includes the financing noted above from EDC, FCC, AIP and PIC.  Burcon Holdings and the Partners have provided a guarantee for the AIP Loan (the "AIP Guarantee").  The obligations of the AIP Guarantee are joint and several.  However, Burcon Holdings and the Partners (the "AIP Guarantors") have entered into a reciprocal indemnity agreement (the "Indemnity Agreement').  Under the Indemnity Agreement, if any AIP Guarantor (each, a "Paying Guarantor") is required to make payment under the AIP Guarantee and any other AIP Guarantor (each, a "Contributing Guarantor") has not made a corresponding payment equal to its share based on its shareholdings in Merit Foods ("Contributive Share"), such Contributing Guarantor(s) shall pay the Paying Guarantor such amounts so that, after payment, all obligations and liabilities under the AIP Guarantee will have been borne by the AIP Guarantors in their respective shareholding percentage in Merit Foods.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

As at September 30, 2020, Burcon had a 33.3% ownership interest in Merit Foods.  There is no contingent issuance of securities by the equity investee that might significantly affect Burcon's share of profit or loss.  The following is the summarized financial information of the investee:

Summary financial information of Merit Foods

(Unaudited, in thousands of dollars)

    September 30, 2020     March 31, 2020  
             
Total assets   139,226     41,885  
Total liabilities   90,188     18,024  

    Three months ended     Six months ended  
    September 30     September 30  
                         
    2020     2019     2020     2019  
                         
Total revenue   100     -     639     -  
                         
Loss and comprehensive loss for the period   (2,611 )   (239 )   (3,566 )   (356 )

Merit Foods has placed purchase orders for long lead-time processing equipment that will be incorporated into the Flex Production Facility and initiated collaboration discussions with several strategic food and beverage companies.  In addition, Merit Foods has added key hires and is well into the process of building out its management team.  Merit's management, together with Burcon's technical and engineering team in Winnipeg, plus third-party engineers and consultants, are working on the development of the Flex Production Facility.

NESTLE COLLABORATION

On January 24, 2020, the Company announced that Burcon, Nestlé and Merit Foods have entered into a joint development agreement to tailor Burcon and Merit's plant-based proteins for use in Nestlé food and beverage applications.  The joint agreement commences what is intended to be a long-term relationship among the parties covering ongoing innovation and the future supply of Burcon and Merit's plant-based proteins from the Flex Production Facility.  The partnership combines Nestlé's expertise in the development, production and commercialization of plant-based foods and beverages with Burcon's proprietary plant protein extraction and purification technology, while leveraging Merit Foods' plant protein production capabilities.  The aim of the joint development is to tailor the functionality of Burcon and Merit's plant proteins, to be supplied from Merit's Flex Production Facility, for use by Nestlé in plant-based meat and dairy alternatives.  The Winnipeg Technical Centre has been working with Nestlé's scientists and food developers to tailor Burcon's pea and canola proteins for product development.

CONVERTIBLE DEBENTURES

On December 10, 2019, the Company issued convertible debentures (the "Debentures") through a non-brokered private placement for an aggregate principal amount of $9.5 million.  Certain directors and an officer of the Company subscribed for Debentures totaling $2 million in principal amount.  Each Debenture consisted of $1,000 principal amount, bore interest at a rate of 8.5% per annum, payable semi-annually in arrears and was unsecured.  The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon were to be payable in cash on December 10, 2022.  The Company incurred issue costs of $228,432, of which $156,600 were finder's fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

The Debentures were convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share.  During the three and six months ended September 30, 2020, the holders of the Debentures converted principal amounts of $744,500 and $1,704,500, respectively, for the issuance of 709,044 and 1,623,327 common shares, respectively, of the Company.

Burcon had the right, at its sole discretion, to force the conversion of the Debentures if the shares traded at or above $2.15 for a period of 14 consecutive trading days.  The Company determined it had met this condition between August 12 and August 31, 2020 and issued a notice to the holders of the Debentures for conversion of the Debentures to common shares on September 8, 2020.  As a result of the conversion of $7,795,500 of outstanding principal amount of the Debentures, an aggregate of 7,424,274 common shares were issued to the holders of the Debentures.

The Debentures were a level 3 financial liability with an embedded conversion feature.  As a result, the debt and equity components were bifurcated and the instrument valued to par at the issuance date.  The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option.  From the date of issuance, the liability component was accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive income or loss.  The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641.  The residual amount of $2,762,927 was recognized within equity as the value of the conversion option.  For the three and six months ended September 30, 2020, the Company recorded interest expense of $262,198 and $637,522, respectively (2019 - $nil).

EQUITY OFFERING

On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the "Units") at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the "Offering") and net proceeds of $10.3 million.

Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant").  Each Warrant is exercisable to acquire one common share (a "Warrant Share") until February 19, 2022 at an exercise price of $2.00 per Warrant Share.  The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model and has been included in Warrants.  During the three months ended September 30, 2020, Warrants were exercised for 357,500 common shares of the Company.  As at September 30, 2020, 3,871,786 Warrants were outstanding.  Subsequent to the quarter-end, 6,000 Warrants were exercised.

The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents' Warrants) entitling the agents to purchase up to 519,386 common shares.  Each Agent's Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022.  The fair value of the Agents' Warrants was estimated at $249,305 using the Black-Scholes pricing model and has been included in Warrants.  As at September 30, 2020 and the date of this MD&A, all Agents' Warrants were outstanding.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

In addition to the Agents' Warrants, the Company incurred total issue costs of $1.2 million related to the Offering.

The Company is using the net proceeds of the Offering and the balance of the net proceeds from the Debentures for further development of its extraction and purification technologies and pursue new related products, pursue and develop new applications from functional attributes of Burcon's proteins and carry out research on protein extraction from various plant sources.  Burcon will also continue work to tailor its plant-based proteins for use in Nestlé food and beverage applications.  Burcon also intends to use the net proceeds to maintain, further strengthen and expand the Company's intellectual property portfolio.  Burcon is obligated to prosecute and maintain its pea and canola patent portfolios under its Amended License Agreement with Merit Foods.  Additionally, Burcon intends to continue to file additional patent applications to protect discoveries arising from its research and development activities.  Burcon also intends to use the net proceeds for expansion initiatives and to provide for general working capital.   

COVID-19

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  To-date, the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations or Merit Foods' construction progress.

NEW DIRECTOR APPOINTMENT

On July 6, 2020, Burcon appointed Ms. Debora Fang as a director to its board of directors.  Ms. Fang has 20 years' of experience in the consumer goods industry, across mergers and acquisitions, strategy, and marketing roles for Unilver (London, UK), Danone (Paris, France and Amsterdam, Netherlands), Kraft Foods (Sao Paulo, Brazil) and as a consultant for Bain & Company (Los Angeles, USA).  She is now an independent advisor for private equity and strategic clients in the food arena as well as a private investor.

CLARISOY®

Burcon had a license and production agreement (the "Soy Agreement") with Archer Daniels Midland Company ("ADM") to license its CLARISOY® technology to ADM on an exclusive basis to produce market and sell CLARISOY® soy protein worldwide.  Burcon and ADM have agreed to terminate the Soy Agreement, effective August 7, 2020.  As part of the agreement to terminate the exclusive license, the CLARISOY trademark reverted back to Burcon on the effective date.  In addition, Burcon and ADM are discussing opportunities for Burcon to acquire certain processing equipment for ADM's CLARISOY® processing facility. 

Burcon has not received any significant royalty revenues from ADM's sales of CLARISOY®.  For the three and six months ended September 30, 2020, Burcon recorded royalty revenues of $131 and $8,646, respectively (2019 - $7,055 and $22,691). 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

Burcon will provide additional updates on its plans for CLARISOY®.

Other

The Company was issued a research license under the Cannabis Act by Health Canada in June 2019.  Given its focus on other business initiatives, Burcon does not plan to conduct research in cannabinoid extracts this fiscal year.

Burcon continued work to further the development of a new plant-based protein process, as well as limited research work on protein extraction from various plant sources to explore potential new commercial and patenting opportunities.  Burcon's extraction and purification technologies are versatile and may be adapted to process a range of oilseed and non-oilseed meals to produce specialty proteins, such as flax and hemp.  The demand for plant-based proteins continues to grow and Burcon believes there may be niche market opportunities for its specialty protein ingredients. 

INTELLECTUAL PROPERTY

Burcon's patent strategy is to seek protection for new technologies as well as further protecting current technologies.  Over the years, Burcon has filed patent applications in various countries over its inventions.  Burcon's patent applications can be grouped into three categories:

During the current quarter, Burcon received a notice of allowance for a patent application over its pea processing technology.  Burcon continued the maintenance and prosecution of its patent applications during the quarter ended September 30, 2020. 

Burcon currently holds 70 U.S. issued patents over its canola, soy, pea and flax protein processing technologies and canola and soy protein isolate applications, as well as canola, pea and soy patents covering composition of matter.  In addition, Burcon has a further 37 patent applications currently filed with the U.S. Patent and Trademark Office.

As of the date of this MD&A, Burcon's patents and patent applications cover over 50 distinct inventions.  Burcon has also filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  Together with patents issued in other countries, Burcon now holds a total of 296 issued patents covering inventions that include the 70 granted U.S. patents.  Currently, Burcon has over 230 additional patent applications that are being reviewed by the respective patent offices in various countries.

RESULTS OF OPERATIONS

As at September 30, 2020, Burcon has not yet generated any significant revenues from its technology.  For the three and six months ended September 30, 2020, the Company recorded income of $4,377,283 and $2,976,583, respectively, ($0.04 and $0.03 per share), as compared to a loss of $697,637 and $2,029,617 ($0.01 and $0.03 per share) for the same periods last year.  Included in the six-month income (loss) amounts are the following non-cash items:  gain on dilution of investment in Merit Foods of $6,384,942 (2019 - $nil), stock-based compensation expense of $292,461 (2019 - $57,175), share of loss in Merit Foods of $1,331,148 (2019 - $142,504), amortization of property and equipment of $53,931 (2019 - $19,215), unrealized foreign exchange loss of $2,138 (2019 - $153),  interest expense of $314,735 (2019 - $nil), interest accretion of $149,437 (2019 - $nil), warrant valuation adjustment of $nil (2019 - $85,421), change in fair value of convertible note derivative liability of $nil (2019 - $5,384), and loss on disposal of equipment of $nil (2019 - $747).


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

The following provides a comparative analysis of significant changes in major expenditures items.

Research and development expenses

Components of research and development ("R&D") expenditures are as follows:

(in thousands of dollars) 

    Three months ended Sep. 30,     Six months ended Sep. 30  
    2020     2019     2020     2019  
Salaries and benefits   44     129     132     379  
Laboratory operation   3     21     9     78  
Rent   3     10     8     29  
Amortization of property and equipment   1     1     2     13  
Analyses and testing   -     -     -     17  
    51     161     151     516  

Effective July 1, 2019, the Company determined that it had met all the criteria of deferring development costs ("DDC") with respect to its pea and canola proteins and has been deferring its expenditures relating to pea and canola to deferred development costs.  For the three months and six months ended September 30, 2020, Burcon deferred approximately $340,000 and $615,000 of R&D costs, respectively.  Under the Services Agreement with Merit Foods, Burcon also has been producing inventory saleable to Merit Foods' potential customers for product evaluation.  This has contributed to about $224,000 and $377,000 of R&D costs that have been allocated to inventory production for the three and six months ended September 30, 2020, respectively.  Before the cost deferral and allocation to inventory production, total R&D costs increased by about $172,000 and $299,000, respectively, for the three and six months ended September 30, 2020.  The increase is due higher salaries and benefits, with the hiring of a new employee, as well as an employee that has returned from leave.  There were also higher laboratory operation expenses due to higher activity levels at the WTC and higher amortization expenses due to the equipment additions. 

Intellectual property expenses

(in thousands of dollars)

    Three months ended Sep. 30,     Six months ended Sep. 30  
    2020     2019     2020     2019  
Patent fees and expenses   173     188     312     548  
Trademark    -     2     -     3  
    173     190     312     551  


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

As noted in the R&D section, the Company is deferring costs related to its pea and canola technology, including the related patent fees and expenses.  During the three and six months ended September 30, 2020, Burcon deferred about $341,000 and $574,000, respectively, (2019 - $300,000 and $300,000) of patent fees and expenses for its pea and canola patent portfolio to deferred development costs. 

After taking into account the capitalized patent fees and expenses, patent legal fees and expenses did not change significantly over the same periods last year.     

From inception, Burcon has expended approximately $20.7 million on patent legal fees and disbursements to strengthen its patent portfolio in various countries of the world and file patent applications for new inventions.

General and administrative ("G&A") expenses

(in thousands of dollars) 

    Three months ended Sep. 30,     Six months ended Sep. 30  
    2020     2019     2020     2019  
Salaries and benefits   458     217     917     444  
Professional fees   196     57     288     124  
Investor relations   78     43     112     64  
Office supplies and services   41     40     85     81  
Transfer agent and filing fees   27     14     31     18  
Financing expense   14     -     24     3  
Other   13     21     27     41  
Travel and meals   -     30     -     44  
    827     422     1,484     819  

Salaries and benefits

Included in salaries and benefits for the three and six months ended September 30, 2020 is stock-based compensation expense of $191,000 and $240,000, respectively, (2019 -$17,000 and $33,000).  The higher expense incurred in the current quarter is due mainly to options granted to a director that had vested immediately. 

The cash portion of salaries and benefits increased by $67,000 and $267,000, respectively, for the three and six months ended September 30, 2020.  The increase is due mainly to fiscal 2020 bonuses of $130,000 approved during the first quarter, and salary increases effected at the beginning of the first quarter.  Directors' fees also increased by $31,000 and $47,000, respectively, for the three and six months ended September 30, 2020, due to more meetings held to-date this year, as well as the addition of a director in July 2020 and in July 2019.

Professional fees

Professional fees increased by $139,000 and $164,000 for the three and six months ended September 30, 2020, respectively, over the same periods last year.  The increase is attributable mainly to higher legal fees of $112,000 and $162,000, respectively, for the three and six months ended September incurred for the negotiations and agreements related to the Bunge investment into Merit Foods. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

Investor relations

Investor relations expenses increased by $35,000 and $48,000, respectively, for the three and six months ended September 30, 2020, due mainly to higher expenses incurred for the virtual AGM held in the second quarter of this year.  The higher investor relations expense for the six-month period is also attributable to the U.S. investor relations consulting services that commenced in September 2019, as well as to OTCQB annual fees.

LIQUIDITY AND FINANCIAL POSITION

At September 30, 2020, the Company had cash and cash equivalents of $12.4 million.  Assuming Burcon Holdings is not required to make payment under the AIP Guarantee, management estimates the cash resources to be sufficient to fund its operations to January 2023, without taking into account proceeds from outstanding convertible securities and royalty revenues from its Amended License Agreement.  If Burcon does not receive sufficient royalties from its Amended License Agreement, Burcon will require additional capital beyond this date to meet its business objectives, although there is no assurance that additional financing will be available on acceptable terms, if at all.

The net cash used in operations during the six months ended September 30, 2020 was $1,419,000, as compared to $2,294,000 last year.  The decrease in the net cash used in operations of $875,000 is mainly due to changes in non-cash working capital items that contributed to $709,000 of the decrease, higher management fee income of $13,000, interest and other income of $344,000, decrease of $338,000 in R&D expenditures and $239,000 in IP expenditures that were expensed, offset by higher G&A expenses of $435,000, interest expense of $258,000, and a decrease in royalty income of $14,000.   

At September 30, 2020, Burcon had working capital of $12.0 million (March 31, 2020 - $14.2 million).  As at September 30, 2020, Burcon was not committed to significant capital expenditures.  Burcon may incur up to $500,000 in additional capital expenditures if modifications or further upgrades are required to the Winnipeg Technical Centre ("WTC").  Burcon is continuing to limit the prosecution of certain patent applications and defer the maintenance fees for certain non-core patent applications.  This does not affect the strength of Burcon's patent portfolio.  Burcon expects to expend up to $615,000 in patent expenditures for the balance of this fiscal year.  With the termination of the ADM license and production agreement, Burcon will further review its soy patent portfolio for possible reductions in patent fees and disbursements.

FINANCIAL INSTRUMENTS

The Company's financial instruments are its cash and cash equivalents, amounts receivable, loan to Merit Foods, and accounts payable and accrued liabilities and accrued interest.

Credit risk

The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable.  The Company's cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks.  The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks.

Interest rate risk


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

All of the Company's financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, and the loan to Merit Foods that bore interest at a fixed interest rate.  Burcon's cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk.  For the three and six months ended September 30, 2020, the weighted average interest rate earned on the Company's cash and cash equivalents was 0.32% and 0.27% per annum, respectively, (2019 - 2.19% and 2.15% per annum).  The impact of a 1% strengthening or weakening of interest rate on the Company's cash and cash equivalents at September 30, 2020 is estimated to be a $124,000 increase or decrease in interest income per year.

Liquidity risk

The Company manages liquidity risk through the management of its capital structure.  It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations.  The Company's estimated minimum contractual undiscounted cash flow requirements for its financial liabilities as at September 30, 2020 is approximately $1,084,000, all of which is due within the next 12 months. 

Fair value

The fair value of the Company's short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable and accounts payable and accrued liabilities approximates their carrying values due to the short-term maturities of these financial instruments.

The fair value of the shareholder loans to Merit Foods approximates the carrying value as at September 30, 2020 given the risk profile of Merit Foods has not changed substantially since the issue date of the loans.

The carrying values and fair values of financial instruments, by class, are as follows as at September 30, 2020 and March 31, 2020:

(in thousands of dollars)

As at September 30, 2020                        
    At fair
value
through
profit or
loss
    Financial
assets at
amortized
cost
    Financial
liabilities at
amortized
cost
    Fair value  
    $     $     $     $  
Financial assets                        
Cash and cash equivalents   -     12,399     -     12,399  
Amounts receivable   -     244     -     244  
Loan to Merit Foods   -     2,809     -     2,809  
Total   -     15,452     -     15,452  
                         
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,084     1,084  
Total   -     -     1,084     1,084  


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019



As at March 31, 2020                        
    At fair
value
through
profit or
loss
    Financial
assets at
amortized
cost
    Financial
liabilities at
amortized
cost
    Fair value  
    $     $     $     $  
Financial assets                        
Cash and cash equivalents   -     15,031     -     15,031  
Amounts receivable   -     332     -     332  
Loan to Merit Foods   -     2,660     -     2,660  
Total   -     18,023     -     18,023  
                         
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,067     1,067  
Accrued interest   -     -     249     249  
Convertible debentures   -     -     6,731     6,731  
Total   -     -     8,047     8,047  

Currency risk

The Company has not hedged its exposure to currency fluctuations.  As at September 30, 2020 and March 31, 2020, the Company is exposed to currency risk through the following assets and liabilities denominated in U.S. dollars:

    September 30, 2020     March 31, 2020  
U.S. Dollars (in thousands)            
Cash and cash equivalents   25     22  
Amounts receivable   -     2  
Accounts payable and accrued liabilities   (10 )   (40 )
Net exposure   15     16  
             
Canadian dollar equivalent (in thousands)   21     (23 )


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

Based on the above net exposure at September 30, 2020, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $2,000 (March 31, 2020 - $2,000) in the Company's income or loss from operations.

OUTSTANDING SHARE DATA

As at September 30, 2020, Burcon had 106,204,739 common shares outstanding, 3,852,106 stock options outstanding exercisable at a weighted average exercise price of $2.15 per share, and 3,871,786 share purchase warrants that were convertible to an equal number of common shares at an exercise price of $2.00 per share. 

As at the date of this MD&A, Burcon has 106,210,739 common shares outstanding, and 3,852,106 stock options that are convertible to an equal number of shares at a weighted average exercise price of $2.15 per share, and 3,865,786 share purchase warrants that are convertible to an equal number of common shares at an exercise price of $2.00 per share.

QUARTERLY FINANCIAL DATA

(Derived from unaudited interim financial statements.  All figures in thousands of dollars, except per-share amounts)

    Three months ended  
    September 30,     June 30,      March 31,     December 31,  
    2020      2020     2020     2019  
Revenue, foreign exchange gain, interest
  and other income, management fee income,
  gain on dilution of investment in Merit Foods
  6,658     267     268     221  
Gain (loss) for the period   4,377     (1,401 )   (1,121 )   (788 )
Basic and diluted gain (loss) per share   0.04     (0.01 )   (0.01 )   (0.01 )

 

    Three months ended  
    September 30,     June 30,      March 31,     December 31,  
    2019     2019     2019     2018  
Revenue, foreign exchange gain, interest
  and other income
  172     27     105     34  
Loss for the period   (697 )   (1,332 )   (1,245 )   (1,155 )
Basic and diluted loss per share   (0.01 )   (0.03 )   (0.03 )   (0.03 )

Included in the second quarter of this year is the gain on dilution of the investment in Merit Foods.  Included in the first quarter of fiscal 2020 is a gain of $5,000 for the change in the fair value of the derivative liability related to the Note.  Included in the income or loss of the first and second quarters of this year, the first, second, third and fourth quarters of fiscal 2020, and the third and fourth quarter of fiscal 2019 are $64,000, $191,000, $33,000, $17,000, $12,000, $424,000, $60,000, and $60,000, respectively, of stock-based compensation expense. 

Included in the first and second quarters of this fiscal year, the fourth quarter of fiscal 2019 are foreign exchange losses of $1,000, $1,000, and $6,000, respectively.  Included in the fourth quarter of fiscal 2020, the third quarter of fiscal 2019 are foreign exchange gains of $3,000, $12,000, respectively.  Included in the first quarter of fiscal 2020 is a valuation adjustment of $85,000 from the change in exercise price of the warrants issued under the 2018 rights offering.     


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

RELATED PARTY TRANSACTIONS

Burcon engaged Burcon Group Limited, a company that is related by virtue of common officers, for the following related party transactions:

Included in general and administrative expenses (office supplies and services and other expenses) for the three and six months ended September 30, 2020 is $nil and $4,584, respectively, (2019 - $18,752 and $37,503) for office space rental. 

For the three and six months ended September 30, 2020, included in general and administrative expenses (management fees) is $691 and $1,339, respectively, (2019 - $29 and $488) for administrative services provided.  At September 30, 2020, $183 (March 31, 2020 - $11) of this amount is included in accounts payable and accrued liabilities.  For the three and six months ended September 30, 2020, included in interest and other income is $594 and $5,310, respectively, (2019 - $3,931 and $8,190) for legal and accounting services provided by the Company.  At September 30, 2020, $196 (March 31, 2020 - $1,785) of this amount is included in amounts receivable.   

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  For the three and six months ended September 30, 2020, included in interest and other income is $53,638 and $158,238, respectively, (2019 - $141,734 and $142,694) for services provided and $132,204 and $212,144, respectively, (2019 - $24,725 and $24,725) for samples sold to Merit Foods, of which $80,541 was included in amounts receivable at September 30, 2020 (March 31, 2020 - $110,594). 

Merit Foods also provides certain technical and consulting services to Burcon.  For the three and six months ended September 30, 2020, Burcon recorded professional fee expense of $2,320 and $10,720 (2019 - $nil), respectively, of which $nil was outstanding as at September 30, 2020.

In connection with the LC, Burcon Holdings entered the Merit Loan Agreement with Merit Foods in the amount of $6.5 million.  During the three and six months ended September 30, 2020, Burcon recorded interest income of $52,534 and $120,205, respectively, (2019 - $nil) related to the Merit Loan, of which $nil was included in amounts receivable as at September 30, 2020 (March 31, 2020 - $nil).

Certain directors and an officer subscribed for $2.0 million of the Debentures.  During the three and six months ended September 30, 2020, the Company made total convertible debenture interest payments of $41,803 and $126,803, respectively, to these directors and officer.

CRITICAL ACCOUNTING ESTIMATES

The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34, Interim Financial Reporting, as issued by the International Accounting Standard Board (IASB) on a basis consistent with those accounting policies followed in the most recent annual consolidated financial statements, except as discussed below. 

The preparation of condensed consolidated interim financial statements in accordance with IFRS requires management to apply judgment when making estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, the reported amount of expenses during the reporting period, and disclosures made in the accompanying notes to the financial statements.  Actual results could differ from those estimates.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

The significant areas where management's judgment is applied are in determining the fair value of stock-based compensation, derivative liability, whether all criteria for deferring development costs are met, the point at which amortization of development costs commences, the expense allocation to deferred development costs and the recoverable amount of goodwill, and the discount rate used to fair value the loans receivable from Merit Functional Foods following their modification and determining the loan and equity components of the Debentures.

DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING

The Chief Executive Officer and Chief Financial Officer, as well as other executives, have designed disclosure controls and procedures ("DC&P"), or have caused them to be designed under their supervision, to provide reasonable assurance that material information relating to the Company has been made known to them. 

These officers are also responsible for designing and maintaining internal controls over financial reporting ("ICFR") or have caused them to be designed under their supervision, to provide reasonable assurance regarding the reliability of the Company's ICFR. 

There have been no significant changes in the DC&P and ICFR that occurred during the three months ended September 30, 2020 that could have materially affected, or are reasonably likely to materially affect, such controls. 

RISKS AND UNCERTAINTIES

The Company is subject to a number of risks and uncertainties that can significantly affect its financial condition and future operations.  Key risks are outlined below.  In addition, a detailed explanation of the risk factors which we face is provided in our AIF for the year ended March 31, 2020 under the section titled "Risk Factors", which is incorporated by reference herein.  The AIF is available at www.sedar.com

Patents and proprietary rights - Burcon's success will depend, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of others or having others infringe on its rights.  Burcon has filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  As at the date of this MD&A, Burcon has been granted a total of 296 patents in various countries covering a number of key processes and uses of Burcon's soy, pea, canola and flax protein products as functional food and beverage ingredients.  Of those patents, 70 have been granted in the United States.  Although Burcon expends significant resources and efforts to patent its discoveries and innovations, there can be no assurance that our patent applications will result in the issuance of patents, or any patents issued to Burcon will provide it with adequate protection or any competitive advantages, or that such patents will not be successfully challenged by third parties.  Burcon cannot be assured that competitors will not independently develop products similar to the Company's products or manufacture products designed to circumvent the exclusive patent rights granted to the Company.  Further, Burcon may need to incur significant expenditures in prosecuting claims against others whom it believes are infringing on its rights and by defending claims of intellectual property infringement brought by its competitors and others.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

Development and commercialization - The long-term success of Puratein®, Supertein® and Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea protein  and Nutratein® pea protein/canola protein blend products hinges upon market acceptance by food and feed ingredient manufacturers and suppliers in numerous product applications.  Although Burcon has formed Merit Foods with the Partners to commercialize Burcon's pea and canola proteins, the commercial products manufactured using Burcon's protein and extraction technologies must exhibit certain functional and nutritional characteristics to garner any market share in the industries that are targeted.  There can be no assurance that Burcon's products will meet industry standards.  Even though Puratein®, Supertein® and  Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be found to be functionally acceptable in product applications, there is no assurance that they will obtain market acceptance and within a reasonable time frame.  Burcon's products have only been produced in small scale batches, and the majority of food or feed ingredient manufacturers will require a substantial testing phase and demonstration of consistent delivery and production capabilities for commercialization.  Although Merit Foods has commenced construction of the planned production facility for Burcon's pea and canola proteins, the construction may be delayed or may not be completed on time.  Therefore, it will be some time before product sales of pea and canola protein will occur.  Until large batches of products can be supplied, market acceptance of Puratein®, Supertein®, and Nutratein® canola proteins, and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be delayed.

There are many large companies in the marketplace that manufacture and produce mature and well-known protein ingredients that have been used for many years.  These companies also possess far greater financial, marketing and human resources than Burcon.  Products such as dried egg white and soy protein isolate have been used in the food processing industry for years with successful results.  These protein ingredients are proven to be functional, technologically sound, readily available and reliable

History of operating losses and financing requirements- Burcon has accumulated net losses of approximately $95.3 million from its date of incorporation through September 30, 2020.  While Merit Foods' Flex Production Facility is under construction for the production of Burcon's pea and canola proteins, there is no assurance that the production facility will be built on time or within budget or that Burcon will be able to make the transition to commercial production.  Burcon cannot predict if it will ever achieve profitability and, if it does, it may not be able to sustain or increase its profitability.  In the absence of a definitive time for when sales of products will be significant, Burcon expects such losses to increase as it continues to commercialize its products, its research and development and product and its product application trials.  Burcon expects to continue to incur substantial losses for the foreseeable future.  The commercial success of any of Burcon's products will depend on whether they receive public and industry acceptance as a food ingredient and dietary supplement, and whether they may be sold at competitive prices or are able to obtain sufficient royalty revenue from licensing, which adequately exceeds Burcon's production or business costs.

Developing Burcon's products and conducting product application trials is capital intensive.  Since acquiring its subsidiary in October 1999, Burcon has raised gross proceeds of approximately $103.1 million from the sale or issuance of equity securities and $9.5 million from the issuance of convertible debentures.  As at September 30, 2020, Burcon had approximately $12.4 million in cash and cash equivalents.  Burcon believes that it has sufficient capital to fund the current level of operations through January 2023.  Although Burcon has sufficient funds to operate until January 2023, it will need to raise additional capital on acceptable terms in order for the Company to meet its business objectives and fund its operations. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

COVID-19 - Pandemic Risk - The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  While economies began to slowly reopen starting in June 2020, governments have taken a phased approach and it is not expected that economies will fully return to its pre-COVID-19 state until a vaccine has been developed to treat the virus.  There has also been recurrence of outbreaks since then.  The duration and effects of the COVID-19 pandemic are unknown at this time.  Even though governments worldwide, including Canada have implemented significant monetary and fiscal relief programs designed to stabilize their economies, it is too early to predict the efficacy of such programs at this time.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  While the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations to-date, it is not possible to predict how long the pandemic will last and whether the financial and business conditions of Burcon and Merit Foods will be impacted in future periods. 

OUTLOOK

For the balance of this fiscal year, Burcon's primary objective is to support Merit Foods to build and commission the pea protein and canola protein production facility and to support market development activities for its protein products, which will include: 

In addition, Burcon will also:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and six months ended September 30, 2020 and 2019

 



Burcon NutraScience Corporation

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, Jade Cheng, Chief Financial Officer of Burcon NutraScience Corporation, certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Burcon NutraScience Corporation (the "issuer") for the interim period ended September 30, 2020.

2.  No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a)  designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b)  designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework:  The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Internal Control - Integrated Framework (2013) issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design:  N/A.

1


5.3 Limitation on scope of design:  N/A.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on July 1, 2020 and ended on September 30, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date:  November 16, 2020

"Jade Cheng"

______________________

Jade Cheng

Chief Financial Officer

2



Burcon NutraScience Corporation

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, Johann F. Tergesen, Chief Executive Officer of Burcon NutraScience Corporation, certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Burcon NutraScience Corporation (the "issuer") for the interim period ended September 30, 2020.

2.  No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a)  designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b)  designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework:  The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Internal Control - Integrated Framework (2013) issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design:  N/A.

1


5.3 Limitation on scope of design:  N/A.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on July 1, 2020 and ended on September 30, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date:  November 16, 2020

"Johann F. Tergesen"

______________________

Johann F. Tergesen

Chief Executive Officer

2



News Release

Burcon to Participate in the Roth Deer Valley Virtual Consumer Conference

Vancouver, British Columbia, December 7, 2020 - Burcon NutraScience Corporation (TSX: BU  OTCQB: BUROF) a global technology leader in the development of plant-based proteins, is scheduled to participate in the Roth Virtual Deer Valley Conference.  President and CEO Johann F. Tergesen will host one-on-one meetings on Friday, December 11th. Interested investors should contact their Roth representative.

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


Investor Contact

Paul Lam

Manager, Business Development

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca

www.burcon.ca

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



News Release

Burcon Announces Third Quarter 2021 Conference Call and Business
Update To Be Held on February 16, 2021

Vancouver, British Columbia, January 29, 2021 - Burcon NutraScience Corporation (TSX: BU  OTCQB: BUROF) a global technology leader in the development of plant-based proteins, will hold an investor conference call and webcast on Tuesday, February 16, 2021 at 5:00 p.m. Eastern time to provide a business update and discuss its financial results for the fiscal third quarter ended December 31, 2020.  The Company's financial results will be issued in a press release prior to the call.

A link to the live webcast of the conference call will be available on Burcon's website under "Presentations" or directly here (https://viavid.webcasts.com/starthere.jsp?ei=1420359&tp_key=aaea0985b9). The webcast will also be archived for future playback.

Investors interested in participating in the live call can dial in using the details below:

Date: Tuesday February 16, 2021

Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)

Toll-free dial-in (North America): 1-855-327-6837

Dial-in (toll/international): 1-631-891-4304

Conference ID: 10012584

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 300 issued patents and more than 230 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


Industry Contact

Paul Lam

Manager, Business Development and IRO

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca  www.burcon.ca

Investor Contact

James Carbonara

Hayden IR

Tel (646) 755-7412

james@haydenir.com

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



News Release

Burcon JV Company, Merit Functional Foods, Achieves First Commercial Production

Vancouver, British Columbia, February 9, 2021 - Burcon NutraScience Corporation (TSX: BU  OTCQB: BUROF) a global technology leader in the development of plant-based proteins, is pleased to announce that its joint venture company, Merit Functional Foods Corporation ("Merit Foods" or "Merit") has completed the first commercial production runs of Peazazz® and Peazac® pea proteins at its state-of-the-art plant protein production facility in Manitoba, Canada, dedicated to the production, under license, of Burcon's novel pea and canola protein ingredients.  Construction of the facility was formally completed on December 31, 2020.

"Burcon is thrilled that Merit Foods has realized this important milestone," said Johann F. Tergesen, Burcon's president and chief executive officer, adding: "Having completed the construction and now in the midst of commissioning and optimizing its state-of-the-art facility is an impressive accomplishment during such a challenging time.  Merit is ideally positioned to meet the growing need for highly functional and taste-forward plant-based proteins for use in foods and beverages including dairy alternatives, meat alternatives and other lifestyle nutrition products."

Unique in its design, Merit's state-of-the-art plant protein production facility has been engineered and constructed to be able to process both yellow field peas as well as non-GMO canola, thereby having the ability to produce Merit's Puratein® and Puratein® HS canola proteins in addition to its Peazazz®and Peazac® pea proteins.  Having achieved commercial production of its Peazazz® and Peazac® pea proteins, Merit intends to now turn its focus to commissioning the facility to produce canola protein.  Once commissioned, it will be the only commercial-scale facility in the world capable of producing food-grade canola protein. 

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 300 issued patents and more than 230 additional patent applications that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods has built a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.


Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.

Industry Contact

Paul Lam

Manager, Business Development and IRO

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca  www.burcon.ca

Investor Contact

James Carbonara

Hayden IR

Tel (646) 755-7412

james@haydenir.com

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



 

Burcon NutraScience Corporation

Condensed Consolidated Interim Financial Statements

Three and nine months ended December 31, 2020 and 2019

(Unaudited)

(Prepared in Canadian dollars)

 


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Balance Sheets

(Unaudited)

As at December 31, 2020 and March 31, 2020

(Prepared in Canadian dollars)

    December 31, 2020
$
    March 31, 2020
$
 
ASSETS            
             
Current assets            
  Cash and cash equivalents   12,042,479     15,030,988  
  Amounts receivable (notes 3, 5(a) and 9)   1,041,139     332,248  
  Inventory   292,189     132,142  
  Prepaid expenses   142,959     289,278  
    13,518,766     15,784,656  
             
Property and equipment   989,978     470,504  
Deferred development costs - net of accumulated amortization of $nil (2019 - $nil)   3,177,692     1,554,584  
Investment in and loan to Merit Functional Foods Corporation (note 3)   17,025,941     12,204,538  
Goodwill   1,254,930     1,254,930  
             
    35,967,307     31,269,212  
             
LIABILITIES            
Current liabilities            
  Accounts payable and accrued liabilities (note 9)   761,316     1,067,251  
  Deferred revenue   268,857     275,578  
  Lease liability   41,651     -  
  Accrued interest (note 4)   -     249,310  
    1,071,824     1,592,139  
             
Lease liability   4,648     -  
Convertible debentures (note 4)   -     6,731,350  
             
    1,076,472     8,323,489  
             
SHAREHOLDERS' EQUITY (note 5)            
Capital stock   110,961,372     98,046,103  
Contributed surplus   14,058,654     9,030,861  
Options   5,151,218     9,673,821  
Warrants   1,189,343     1,792,168  
Convertible debentures (note 4)   -     2,762,927  
Deficit   (96,469,752 )   (98,360,157 )
             
    34,890,835     22,945,723  
             
    35,967,307     31,269,212  

Subsequent events (note 13)

Approved by the Audit Committee of the Board of Directors

"Douglas Gilpin"   "Peter H. Kappel"
Director   Director

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

For the three and nine months ended December 31, 2020 and 2019

(Prepared in Canadian dollars)

    Three months ended     Nine months ended  
    December 31     December 31  
             
    2020
$
    2019
$
    2020
$
    2019
$
 
                         
REVENUE                        
Royalty income (note 1(b))   -     5,044     8,646     27,735  
                         
EXPENSES                        
Research and development (note 6)   69,156     115,459     220,400     632,309  
Intellectual property   270,569     201,983     582,788     753,288  
General and administrative (note 7)   439,619     422,509     1,923,692     1,327,386  
                         
    779,344     739,951     2,726,880     2,712,983  
                         
LOSS FROM OPERATIONS   (779,344 )   (734,907 )   (2,718,234 )   (2,685,248 )
                         
INTEREST AND OTHER INCOME
(notes 3 and 9)
  125,875     90,588     494,545     115,651  
                         
MANAGEMENT FEE INCOME 
(notes 3 and 9)
  44,768     125,422     208,315     276,306  
                         
GAIN ON DILUTION OF
INVESTMENT IN MERIT FOODS (note 3)
  -     -     6,384,942     -  
                         
SHARE OF LOSS IN MERIT
FUNCTIONAL FOODS CORP. (note 3)
  (460,130 )   (177,906 )   (1,791,278 )   (320,410 )
                         
INTEREST EXPENSE (note 4)   (15,801 )   (90,757 )   (684,030 )   (208,015 )
                         
OTHER   (1,545 )   (722 )   (3,855 )   3,817  
                         
INCOME (LOSS) AND
COMPREHENSIVE INCOME
(LOSS) FOR THE PERIOD
  (1,086,177 )   (788,282 )   1,890,405     (2,817,899 )
                         
BASIC AND DILUTED INCOME
(LOSS) PER SHARE
(note 8)
  (0.01 )   (0.01 )   0.02     (0.04 )

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity

(Unaudited)

For the nine months ended December 31, 2020 and 2019

(Prepared in Canadian dollars)

    Number of
fully paid
common
shares
    Capital
stock
$
    Contributed
surplus
$
    Options
$
    Warrants
$
    Convertible debentures
$ 
    Deficit
$
    Total
shareholders'
equity
$
 
Balance - March 31, 2019   43,941,536     73,361,133     9,001,467     9,184,852     199,117     -     (93,726,663 )   (1,980,094 )
                                                 
Loss and comprehensive loss for the period   -     -     -     -     -     -     (2,817,899 )   (2,817,899 )
Shares issued   44,083,203     15,429,121     -     -     -     -     -     15,429,121  
Issue costs   -     (170,931 )   -     -     -     -     -     (170,931 )
Options exercised   173,000     118,349     -     (47,280 )   -     -     -     71,069  
Warrant valuation adjustment   -     -     -     -     85,421     -     -     85,421  
Convertible debentures issued   -     -     -     -     -     2,762,927     -     2,762,927  
Stock-based compensation expense   -     -     -     103,653     -     -     -     103,653  
                                                 
Balance - December 31, 2019   88,197,739     88,737,672     9,001,467     9,241,225     284,538     2,762,927     (96,544,562 )   13,483,267  
                                                 
Balance, March 31, 2020   96,799,638     98,046,103     9,030,861     9,673,821     1,792,168     2,762,927     (98,360,157 )   22,945,723  
Income and comprehensive income for the period   -     -     -     -     -     -     1,890,405     1,890,405  
Conversion of convertible debentures   9,047,601     9,809,013     -     -     -     (2,762,927 )   -     7,046,086  
Warrants exercised   1,254,250     3,110,540     -     -     (602,040 )   -     -     2,508,500  
Issue costs   -     (4,284 )   -     -     (785 )   -     -     (5,069 )
Options expired   -     -     5,027,793     (5,027,793 )   -     -     -     -  
Stock-based compensation expense   -     -     -     505,190     -     -     -     505,190  
                                                 
Balance - December 31, 2020   107,101,489     110,961,372     14,058,654     5,151,218     1,189,343     -     (96,469,752 )   34,890,835  

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION

Condensed Consolidated Interim Statements of Cash Flows

(Unaudited)

For the nine months ended December 31, 2020 and 2019

(Prepared in Canadian dollars)

    2020
$
    2019
$
 
CASH FLOWS FROM OPERATING ACTIVITIES            
Income (loss) for the period   1,890,405     (2,817,899 )
Items not affecting cash            
Amortization of property and equipment   104,228     25,417  
Unrealized foreign exchange loss    3,683     676  
Interest accretion   (227,739 )   (76,259 )
Interest expense   314,735     42,219  
Change in fair value of derivative liability   -     (5,384 )
Gain on dilution of investment in Merit Functional Foods Corporation   (6,384,942 )   -  
Share of loss of Merit Functional Foods Corporation   1,791,278     320,410  
Loss on disposal of equipment   -     949  
Warrant valuation adjustment   -     85,420  
Stock-based compensation expense   380,381     74,322  
    (2,127,971 )   (2,350,129 )
Changes in non-cash working capital items            
Amounts receivable   (708,891 )   (223,421 )
Inventory   (160,047 )   (165,802 )
Prepaid expenses   146,319     226,273  
Accounts payable and accrued liabilities   37,857     (54,519 )
Accrued interest   (249,310 )   (515,713 )
    (3,062,043 )   (3,083,311 )
CASH FLOWS FROM INVESTING ACTIVITIES            
Investment in Merit Functional Foods Corporation   -     (11,000,000 )
Development costs deferred   (1,419,709 )   (969,162 )
Acquisition of property and equipment   (818,284 )   (27,071 )
    (2,237,993 )   (11,996,233 )
CASH FLOWS FROM FINANCING ACTIVITIES            
Issue of capital stock   2,508,500     15,500,191  
Issue of convertible debentures   -     9,500,000  
Issue costs   (239,589 )   (337,941 )
Lease liability   46,299     -  
Short-term loan   -     250,000  
Repayment of convertible note   -     (1,990,687 )
Repayment of short-term loan   -     (1,500,000 )
    2,315,210     21,421,563  
FOREIGN EXCHANGE LOSS ON CASH AND CASH EQUIVALENTS   (3,683 )   (676 )
             
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (2,988,509 )   6,341,343  
             
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD   15,030,988     489,215  
             
CASH AND CASH EQUIVALENTS - END OF PERIOD   12,042,479     6,830,558  
             
INTEREST RECEIVED   144,128     43,033  

The accompanying notes are an integral part of these condensed consolidated interim financial statements.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

1. Nature of operations

Burcon NutraScience Corporation ("Burcon" or the "Company") is an incorporated entity headquartered in Vancouver, British Columbia, Canada.

Burcon is a research and development company that has developed plant protein extraction and purification technology in the field of functional, renewable plant proteins.  The Company has an extensive portfolio of composition, application and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. 

a) Peazazz®, Peazac®, Puratein®, Supertein® and Nutratein®

Burcon has developed novel pea proteins that it has branded Peazazz® and Peazac® and three canola protein products, Puratein®, Supertein® and Nutratein®

On May 23, 2019, Burcon, entered into a shareholders' agreement with two other entities to become shareholders of Merit Functional Foods Corporation ("Merit Foods"), to build a new commercial production facility in Western Canada to produce its pea and canola protein  products, as well as its new pea and canola protein blends.  See note 3 for further details.

On May 23, 2019, Burcon entered into a license agreement with Merit Foods granting Merit Foods an exclusive, royalty-bearing, worldwide license to use and exploit Burcon's pea, pulse, and canola protein technologies required to produce, market and sell Burcon's pea, pulse and canola proteins (collectively the "Products").  See note 3 for further details.

b) CLARISOY®

Burcon had a license and production agreement (the "Soy Agreement") with Archer Daniels Midland Company ("ADM") to license its CLARISOY® technology to ADM on an exclusive basis to produce market and sell CLARISOY® soy protein worldwide.  On August 7, 2020, Burcon and ADM agreed to terminate the Soy Agreement.  As part of the agreement to terminate the exclusive license, the CLARISOY trademark reverted back to Burcon. 

c) COVID-19

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  To-date, the COVID-19 pandemic has not had significant adverse effect on Burcon's business.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

2. Significant accounting policies

Basis of presentation

These condensed consolidated interim financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") applicable to the preparation of interim financial statements, including International Accounting Standards ("IAS") 34, Interim Financial Reporting, and interpretations issued by the IFRS Interpretations Committee ("IFRIC") on a basis consistent with those accounting policies followed in the most recent annual consolidated financial statements.  These condensed consolidated financial statements do not include all of the information required for full annual financial statements and were approved and authorized for issue by the Audit Committee of the Board of Directors on February 11, 2021.

The condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated annual financial statements for the year ended March 31, 2020. 

Principles of consolidation

These condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries, Burcon NutraScience (MB) Corp. ("Burcon-MB") and Burcon NutraScience Holdings Corp. ("Burcon Holdings").  A subsidiary is an entity in which the Company has control, directly or indirectly.  Under IFRS 10, an investor controls an investee if and only if the investor has power over the investee, exposure, or rights, to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect the amount of the investor's returns.  All material intercompany transactions and balances have been eliminated on consolidation.

Details of the Company's subsidiaries at December 31, 2020 are as follows:

 

 

Place of

incorporation

 

Interest

%

 

Principal activity

 

 

 

 

 

 

 

Burcon NutraScience (MB) Corp.

 

Manitoba, Canada

 

100

 

Research and development

Burcon NutraScience Holdings Corp.

 

Canada

 

100

 

Investment holding

3. Investment in and loan to Merit Functional Foods Corporation

On May 23, 2019, Burcon, through a new wholly-owned subsidiary incorporated on May 22, 2019, Burcon Holdings, entered into a shareholders' agreement (the "Shareholders' Agreement") with two other entities (the "Partners") to become shareholders of Merit Foods, to build and own a new commercial production facility in Western Canada to produce, sell, market and distribute Burcon's Peazazz® and Peazac® pea proteins, Burcon's Puratein®, Supertein® and Nutratein® canola proteins, as well as Burcon's new pea and canola protein blends that it has branded Nutratein-PS and Nutratein-TZ


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

On inception, Burcon Holdings held 40% of the issued and outstanding shares of Merit Foods, and the two other parties held 40% and 20%, respectively.  Each shareholder made its respective capital loan advances in June, September, December 2019 and February 2020 by way of shareholder loans totalling $32.5 million (the "Merit Shareholder Loans").

On August 27, 2020, Bunge Limited ("Bunge") made an investment of $30 million into Merit Foods. In addition to purchasing equity directly from Merit Foods, Bunge purchased additional shares and debt from the other shareholders of Merit Foods.  As a result of these transactions, Bunge became a 25% shareholder in Merit Foods and Burcon's ownership interest in Merit Foods decreased to 33.3%.  As a result of the dilution in Burcon's ownership interest in Merit Foods, Burcon has recorded a dilution gain of $6,384,942.

Summary financial position for Merit Foods as at December 31, 2020

    As at
December
31, 2020
    As at March 31,
2020
 
    $     $  
             
Current assets   30,371,584     5,828,739  
Non-current assets   118,796,056     36,056,689  
Current liabilities   11,939,766     11,369,931  
Non-current liabilities   89,883,322     6,653,724  

Summary financial results for Merit Foods

    Three months ended     Period ended  
    December 31     December 31  
                         
    2020
$
    2019
$
    2020
$
    20191 
$
 
                         
Total revenue   800,229     541,293     1,438,872     567,647  
                         
 Loss and comprehensive loss for the period   (1,380,390 )   (444,765 )   (4,946,652 )   (801,024 )

To-date, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans.

_______________________________________
1
Merit Foods was incorporated on May 15, 2019.  As a result, information in this table represents certain financial information of Merit Foods from the date of its incorporation to December 31, 2019.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)


    Investment in
Share capital

$
    Capital
Contribution

$
    Loan receivable
$
    Total net
investment

$
 
                         
From inception to December 31, 2019   1     -     11,000,000     11,000,001  
Modification to loan terms         8,871,512     (8,871,512 )   -  
Capital loan advance, February 2020   -     1,613,002     386,998     2,000,000  
Share of loss in Merit Foods   -     (939,806 )   -     (939,806 )
Interest accretion   -     -     144,343     144,343  
                         
Net Investment in Merit
Foods, March 31, 2020
  1     9,544,708     2,659,829     12,204,538  
                         
Share of loss in Merit Foods   -     (1,791,278 )   -     (1,791,278 )
Gain on dilution of Investment in Merit Foods   -     6,384,942     -     6,384,942  
Interest accretion   -     -     227,739     227,739  
                         
Net Investment in Merit
Foods, December 31, 2020
  1     14,138,372     2,887,568     17,025,941  

From inception to December 2019, the Merit Shareholder Loans were recorded as loan receivable.  In December 2019, the terms of the Merit Shareholder Loans were finalized.  The loans are non-interest bearing, unsecured, subordinated to Merit Foods' other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder's loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts.  As a result, Burcon recalculated the fair value at that date, resulting in a reduction of the fair value of the loan receivable that was transferred to a capital contribution account.  Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest.  For the three and nine months ended December 31, 2020, the Company has recorded interest accretion of $78,302 and $227,739, respectively (2019 - $76,259 and $76,259).

Burcon has a license agreement (the "License Agreement") with Merit Foods for an exclusive, royalty-bearing, worldwide license to use and exploit Burcon's Products.  As part of the Bunge transaction, Bunge, Burcon and the Partners have amended the License Agreement (the "Amended License Agreement") and Burcon, Bunge and the Partners have also amended the Shareholders Agreement (the "Amended Shareholders Agreement").  Under the Amended License Agreement and Amended Shareholders Agreement, Burcon, Bunge and the Partners have agreed to certain contractual rights, including a right, but not an obligation, of Burcon, in certain circumstances, to participate in a sale of all but not less than all of its shares in Merit Foods, and that in certain circumstances, Merit Foods will have the right to buy out from Burcon the Amended License Agreement for an amount representing the discounted future royalties over the life of the Amended License Agreement.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  For the three and nine months ended December 31, 2020, included in management fee income are $43,853 and $202,090, respectively, (2019 - $123,190 and $265,884) for services provided and $250,179 and $462,323, respectively, (2019 - $26,063 and $50,787) for samples sold to Merit Foods, of which $73,642 was included in amounts receivable at December 31, 2020 (March 31, 2020 - $110,594).

Merit Foods also provides certain technical and consulting services to Burcon.  For the nine months ended December 31, 2020, Burcon recorded professional fee expense of $10,720 (2019 - $nil), of which $nil was outstanding as at December 31, 2020.

In May 2020, Burcon announced that Merit Foods had secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada ("EDC"), Farm Credit Canada ("FCC") and the Canadian Imperial Bank of Commerce.  All of Merit Foods' shareholders, including Burcon Holdings, have pledged their shares in Merit Foods as security under the loan facilities with EDC and FCC.  In connection with the loan facilities from EDC, Merit Foods must fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility.  Of the prescribed amount, $6.5 million is permitted to be funded by way of a letter of credit ("LC").  To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada ("HSBC") in April 2020, which was secured by a term deposit with HSBC in the same amount.  As part of the investment by Bunge into Merit Foods, the LC was released on August 28, 2020.

In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the "Merit Loan Agreement") with Merit Foods in the amount of $6.5 million (the "Merit Loan").  The Merit Loan bore interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term.  Concurrent with the termination of the LC on August 28, 2020, the Merit Loan Agreement was also terminated on the same date.  For the nine months ended December 31, 2020, Burcon recorded interest income of $120,205 (2019 - $nil) related to the Merit Loan, of which $nil was outstanding as at December 31, 2020 (March 31, 2020 - $nil).

In addition, Burcon provided a guarantee to EDC and FCC in connection with the $85 million financing package (the "Guarantees"), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC, FCC and Merit Foods.  The aggregate maximum liability of Burcon under the Guarantees was limited to $4.0 million.  As part of the investment by Bunge into Merit Foods, EDC and FCC released the Guarantees on August 28, 2020.

In June 2020, Burcon announced that Merit Foods had secured additional debt financing of $10 million in the form of a 10-year interest-free loan from Agriculture and Agri-Food Canada (the "AIP Loan").  Burcon Holdings and the Partners provided a guarantee for the AIP Loan (the "AIP Guarantee").  The obligations of the AIP Guarantee are joint and several.  However, Burcon Holdings and the Partners (the "AIP Guarantors") have entered into a reciprocal indemnity agreement (the "Indemnity Agreement').  Under the Indemnity Agreement, if any AIP Guarantor (each, a "Paying Guarantor") is required to make payment under the AIP Guarantee and any other AIP Guarantor (each, a "Contributing Guarantor") has not made a corresponding payment equal to its share based on its shareholdings in Merit Foods ("Contributive Share"), such Contributing Guarantor(s) shall pay the Paying Guarantor such amounts so that, after payment, all obligations and liabilities under the AIP Guarantee will have been borne by the AIP Guarantors in their respective shareholding percentage in Merit Foods.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

4. Convertible debentures

Convertible debentures

On December 10, 2019, the Company issued convertible debentures (the "Debentures") through a non-brokered private placement for an aggregate principal amount of $9.5 million.  Certain directors and an officer of the Company subscribed for Debentures totalling $2 million in principal amount.  Each Debenture consisted of $1,000 principal amount, bore interest at a rate of 8.5% per annum, payable semi-annually in arrears and was unsecured.  The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon were to be payable in cash on December 10, 2022.  The Company incurred issue costs of $228,432, of which $156,600 were finder's fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders. 

The Debentures were convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share.  During the nine months ended December 31, 2020, the holders of the Debentures converted principal amounts of $1,704,500 for the issuance of 1,623,327 common shares of the Company. 

Burcon had the right, at its sole discretion, to force the conversion of the Debentures if the shares traded at or above $2.15 for a period of 14 consecutive trading days.  The Company determined it had met this condition between August 12 to August 31, 2020 and issued a notice to the holders of the Debentures for conversion of the Debentures to common shares on September 8, 2020.  As a result of the conversion of $7,795,500 of outstanding principal amount of the Debentures, an aggregate of 7,424,274 common shares were issued to the holders of the Debentures.

The Debentures were a level 3 financial liability with an embedded conversion feature.  The debt and equity components were bifurcated, and the instrument valued to par at the issuance date.  The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option.  From the date of issuance, the liability component was accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive income (loss).  The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641.  The residual amount of $2,762,927 was recognized within equity as the value of the conversion option.  For the nine months ended December 31, 2020, the Company recorded interest expense of $637,522 (2019 - $nil) related to the Debentures.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

5. Shareholders' equity

a) Capital stock

Authorized

Unlimited number of common shares without par value

Equity Offering

On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the "Units") at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the "Offering") and net proceeds of $10.3 million.

Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant").  Each Warrant is exercisable to acquire one common share (a "Warrant Share") until February 19, 2022 at an exercise price of $2.00 per Warrant Share.  The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model and has been included in Warrants.  During the three and nine months ended December 31, 2020, Warrants were exercised for 896,750 and 1,254,250 Warrant Shares, respectively, of the Company.  Warrant exercise proceeds of $846,000 was included in amounts receivable as at December 31, 2020.  As at December 31, 2020, 2,455,650 Warrants were outstanding.  Subsequent to December 31, 2020, Warrants were exercised for 737,000 Warrant Shares.

The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents' Warrants) entitling the agents to purchase up to 519,386 common shares.  Each Agent's Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022.  The fair value of the Agents' Warrants was estimated at $249,305 using the Black-Scholes pricing model and has been included in Warrants.  At December 31, 2020, all of the Agents' Warrants were outstanding.

In addition to the Agents' Warrants, the Company incurred total issue costs of $1.2 million related to the Offering.

b) Contributed surplus

Contributed surplus comprises the value ascribed to expired warrants and options and forfeited vested options, previously categorized in either warrants or options, as applicable, within shareholders' equity. 

c) Options

The Company has a stock option plan in which all directors, officers, employees and consultants of the Company and its subsidiary are eligible to participate.

At December 31, 2020, 3,852,106 (March 31, 2020 - 4,507,606) options to purchase common stock are outstanding from the stock option plan.  These options, when vested under the terms of the plan, are exercisable at prices ranging between $0.23 and $8.05 per common share.  An additional 6,768,367 (March 31, 2020 - 5,172,357) options may be granted in future years under this plan.  Unless otherwise determined by the board of directors, the options have a term of 10 years from the date of grant.  The vesting terms are determined at the discretion of the board of directors at the time of grant.  All grants are recognized using graded vesting, with each vesting tranche being valued separately, and the fair value of each tranche recognized over its respective vesting period.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)


    Nine months ended Dec. 31, 2020     Year ended March 31, 2020  
                         
    Number of
options

    Weighted
average
exercise
price

$
    Number of
options

    Weighted
average
exercise
price

$
 
                         
Outstanding - Beginning of period   4,507,606     3.32     3,953,739     3.46  
                         
Granted   62,000     2.47     757,000     1.88  
Exercised   -     -     (173,000 )   0.41  
Expired   (717,500 )   9.51     -     0.41  
Cancelled   -     -     (30,133 )   1.96  
                         
Outstanding - End of period   3,852,106     2.15     4,507,606     3.32  

The following table summarizes information about stock options outstanding and exercisable at December 31, 2020:

    Options outstanding     Options exercisable  
Range of
exercise prices

$
  Number
outstanding
at Dec. 31,
2020
    Weighted
average
remaining
contractual life
(years)
    Weighted
average
exercise
price
$
    Number
exercisable
at Dec. 31,
2020
    Weighted
average
exercise
price
$
 
                               
0.23 - 0.69   926,333     7.70     0.41     508,992     0.46  
1.88 - 4.16   2,825,773     5.58     2.54     2,336,773     2.67  
6.78 - 8.05   100,000     0.82     7.54     100,000     7.54  
                               
    3,852,106     5.97     2.15     2,945,765     2.46  


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

The fair value of each option is estimated as at the date of grant or other measurement date using the Black-Scholes option pricing model and the following weighted average assumptions:

    Nine months
ended
December 31,
2020
  Year ended
March 31,
2020
         
Dividend yield   0.0%   0.0%
Expected volatility   74.4%   75.1%
Risk-free interest rate   0.5%   1.3%
Expected forfeitures   7.4%   7.7%
Expected average option term (years)   8.3   7.9

The expected volatility and expected forfeitures are based on historical volatility and forfeitures. The risk-free rate of return is the yield on a zero-coupon Canadian treasury bill of a term consistent with the expected average option term. The expected average option term is the average expected period to exercise, based on the historical activity patterns for each individually vesting tranche.

The weighted average fair value of the options granted during the nine months ended December 31, 2020 was $1.78 per option (year ended March 31, 2020 - $1.36).

For the nine months ended December 31, 2019, included in research and development expenses (salaries and benefits) is $16,757) (note 6) of stock-based compensation and included in general and administrative expenses (salaries and benefits) is $54,002 and $294,378, respectively, (2019 - $12,441 and $45,591) (note 7) of stock-based compensation.  Included in deferred development costs is $175,469 (March 31, 2020 - $50,660) of stock-based compensation.

6. Research and development

    Three months ended     Nine months ended  
    December 31     December 31  
                         
    2020
$
    2019
$
    2020
$
    2019
$
 
                         
Salaries and benefits   392,787     328,402     1,232,749     956,580  
Laboratory operation   83,216     91,320     240,489     204,785  
Amortization of property and equipment   63,743     19,746     147,525     48,244  
Analyses and testing   38,517     10,996     54,986     35,182  
Rent   25,903     21,950     71,307     65,736  
Travel and meals   -     3,951     -     10,197  
    604,168     476,365     1,747,056     1,320,724  
To deferred development costs   (194,392 )   (247,036 )   (809,503 )   (437,245 )
To inventory production   (340,622 )   (113,870 )   (717,153 )   (251,170 )
Net research and development expenses   69,156     115,459     220,400     632,309  


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Since July 1, 2019, Burcon has deferred its research and development expenditures relating to pea and canola and capitalized such costs as deferred development costs.  Burcon also has been producing sample inventory for Merit Foods to provide its potential customers for the purpose of product evaluation and Burcon has recovered the associated research and development expenses for the samples sold to Merit Foods. 

7. General and administrative

    Three months ended     Nine months ended  
    December 31     December 31  
                         
    2020
$
    2019
$
    2020
$
    2019
$
 
Salaries and benefits   305,760     243,289     1,223,898     687,381  
Office supplies and services   43,062     42,800     127,556     123,736  
Professional fees   35,983     58,407     323,981     182,370  
Investor relations   22,675     34,109     134,758     98,189  
Transfer agent and filing fees   18,697     5,441     49,518     22,978  
Other   13,219     20,617     39,945     61,505  
Travel and meals   223     17,846     246     62,307  
Financing expense   -     -     23,790     88,920  
                         
    439,619     422,509     1,923,692     1,327,386  

8. Basic and diluted income (loss) per share

The following table sets forth the computation of basic and diluted income (loss) per share:

    Three months ended     Nine months ended  
    December 31     December 31  
                         
    2020
$
    2019
$
    2020
$
    2019
$
 
                         
Income (loss) for the period, being loss attributable to common shareholders - basic and diluted   (1,086,177 )   (788,282 )   1,890,405     (2,817,899 )
                         
    Shares     Shares     Shares     Shares  
                         
Weighted average common shares
- basic
  100,244,496     88,196,884     101,222,966     74,531,340  
Weighted average common shares
- diluted
  100,244,496     88,196,884     108,050,108     74,531,340  
                         
Basic and diluted income (loss) per share   (0.01 )   (0.01 )   0.02     (0.04 )

For the three months ended December 31, 2020 and 2019 and the nine months ended December 31, 2019, the Company excluded all potential common share equivalents from the diluted loss per share calculation as they were anti-dilutive.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

9. Related party transactions

The Company engaged an entity that is related by virtue of common officers for the following related party transactions:

Included in general and administrative expenses (office supplies and services) for the three and nine months ended December 31, 2019 are $18,752 and $56,255, respectively, for office space rental.

For the three and nine months ended December 31, 2020, included in general and administrative expenses (management fees) are $663 and $2,002 (2019 - $458 and $946), for services provided to the Company.  At December 31, 2020, $100 (March 31, 2020 - $11) of this amount is included in accounts payable and accrued liabilities.  For the three and nine months ended December 31, 2020, included in interest and other income is $915 and $6,224, respectively (2019 - $2,232 and $10,422) for management services provided by the Company.  At December 31, 2020, $268 (March 31, 2020 - $1,785), of this amount is included in amounts receivable. 

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  Merit Foods also provided certain technical and consulting services to Burcon.  See note 3 for details.

In connection with the LC, Burcon Holdings entered the Merit Loan Agreement with Merit Foods in the amount of $6.5 million.  During the nine months ended December 31, 2020, Burcon recorded interest income of $120,205 (2019 - $nil) related to the Merit Loan, of which $nil was included in amounts receivable as at December 31, 2020 (March 31, 2020 - $nil).

Certain directors and an officer subscribed for $2.0 million of the Debentures.  During the nine months ended December 31, 2020, the Company made total convertible debenture interest payments of $126,803 to these directors and officer.

10. Key management compensation

Key management includes the Company's CEO.  Remuneration of directors and key management personnel comprises:

    Nine months ended  
    December 31  
             
    2020
$
    2019
$
 
             
Short-term benefits   401,873     288,949  
Option-based awards   149,948     15,747  
             
    551,821     304,696  

Short-term benefits comprise salaries, director fees and employment benefits.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

Option-based awards represent the cost to the group of senior management and directors' participation in the incentive stock option plan, as measured by the fair value of instruments granted accounted for in accordance with IFRS 2, Share-based Payment.  For details of these plans refer to note 5 to these condensed consolidated interim financial statements.

11. Financial instruments

Credit risk

The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable.  The Company's cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks.  The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks.

Interest rate risk

All of the Company's financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, and the loan to Merit Foods that bore interest at a fixed interest rate.  Burcon's cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk.  For the three and nine months ended December 31, 2020, the weighted average interest rate earned on the Company's cash and cash equivalents was 0.40% and 0.32%, respectively, per annum (2019 - 2.15% and 2.15% per annum).  The impact of a 1% strengthening or weakening of interest rates on the Company's cash and cash equivalents at December 31, 2020 is estimated to be a $120,000 increase or decrease in interest income per year.

Liquidity risk

The Company manages liquidity risk through the management of its capital structure (note 12). It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations. The Company's estimated minimum contractual undiscounted cash flow requirement for its financial liabilities at December 31, 2020 is $761,316, all of which is within the next 12 months. 

Fair value

The fair value of the Company's short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and accrued interest approximates their carrying values due to the short-term maturities of these financial instruments.

The fair value of the shareholder loans to Merit approximates the carrying value as at December 31, 2020 given the risk profile of Merit Foods has not changed substantially since the issue date of the loans.


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)

The carrying values and fair values of financial instruments, by class, are as follows as at December 31, 2020 and March 31, 2020: 

As at December 31, 2020                        
    At fair value through profit or loss     Financial assets at amortized cost     Financial liabilities at amortized cost     Fair value  
    $     $     $     $  
Financial assets                        
Cash and cash equivalents   -     12,042,479     -     12,042,479  
Amounts receivable   -     1,041,139     -     1,041,139  
Loan to Merit Foods    -     2,887,568     -     2,887,568  
Total   -     15,971,186     -     15,971,186  
                         
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     761,316     761,316  
Total   -     -     761,316     761,316  
                         
As at March 31, 2020                        
                         
    At fair value through profit or loss     Financial assets at amortized cost     Financial liabilities at amortized cost     Fair value  
Financial assets   $     $     $     $  
Cash and cash equivalents   -     15,030,988     -     15,030,988  
Amounts receivable   -     332,248      -     332,248   
Loan to Merit Foods   -     2,659,830     -     2,659,830  
Total   -     18,023,066     -     18,023,066  
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,067,251     1,067,251  
Accrued interest   -     -     249,310     249,310  
Convertible debentures   -     -     6,731,350     6,731,350  
Total   -     -     8,047,911     8,047,911  

Currency risk

The Company has hedged certain of its liabilities from currency fluctuations.  As at December 31, 2020 and March 31, 2020, the Company is exposed to currency risk through the following assets and liabilities denominated in U.S. dollars:


BURCON NUTRASCIENCE CORPORATION
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the three and nine months ended December 31, 2020 and 2019
(Unaudited)
(Prepared in Canadian dollars)


    December 31, 2020     March 31, 2020  
U.S. Dollars             
Cash and cash equivalents $ 25,310   $ 21,819  
Amounts receivable    -      2,528  
Accounts payable and accrued liabilities   -     (40,556 )
Net exposure $ 25,310   $ (16,209 )
             
Canadian dollar equivalent  $ 32,225   $ (22,996 )

Based on the above net exposure at December 31, 2020, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $300 (March 31, 2020 - $2,000) in the Company's income (loss) from operations.

12. Capital disclosures

The Company considers its capital to be its shareholders' equity.

The Company manages its capital structure to have sufficient resources available to meet day-to-day operating requirements, continue as a going concern and fund its research and development program.  The Company is dependent on non-operating sources of cash, primarily from issuing equity and debt, to fund its operations and research development programs.  The Company monitors its capital and the expected cash flows required to achieve its business objectives to determine its future financing needs. It seeks additional capital when deemed appropriate, but there is no assurance that it will be able to secure the necessary capital when required. 

The Company is not subject to externally imposed capital requirements and there has been no change with respect to the overall capital risk management strategy during the nine months ended December 31, 2020.

13. Subsequent events

Subsequent to December 31, 2020:

a) Warrants were exercised for 737,000 Warrant Shares for proceeds of $1,474,000;

b) 86,000 options were exercised at a weighted average exercise price of $0.57 for proceeds of $35,420; and

c) 1,171,000 options were granted to directors, officers and employees with an exercise price of $4.01. 




MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

 

(All amounts following are expressed in Canadian dollars unless otherwise indicated.)

This Management's Discussion and Analysis ("MD&A") has been prepared as at February 16, 2021 to provide a meaningful understanding of Burcon NutraScience Corporation's ("Burcon" or the "Company") operations, performance, and financial condition for the three and nine months ended December 31, 2020.  The following information should be read in conjunction with the Company's unaudited condensed consolidated interim financial statements and accompanying notes for the periods ended December 31, 2020 and 2019, which are prepared in accordance with International Accounting Standards (IAS) 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB), as well as the audited consolidated annual financial statements for the year ended March 31, 2020.  We have prepared this MD&A with reference to National Instrument 51-102 "Continuous Disclosure Obligations" of the Canadian Securities Administrators.  Additional information relating to Burcon, including the Company's Annual Information Form ("AIF"), is available on SEDAR at www.sedar.com.

FORWARD-LOOKING STATEMENTS

This MD&A contains certain "forward-looking statements" and "forward-looking information" as defined under applicable Canadian and U.S. securities laws (collectively, "forward-looking statements").  All statements, other than statements of historical fact, are forward-looking statements.  When used in this MD&A the words "estimate", "project", "believe", "anticipate", "intend", "expect", "plan", "predict", "may", "should", "will", or the negatives of these words or other variations thereof and comparable terminology are intended to identify forward-looking statements.  The forward-looking statements pertain to, among other things:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

The forward-looking statements are based on a number of key expectations and assumptions made by management of the Company, including, but not limited to:

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on such forward-looking statements.  The forward-looking statements reflect the Company's current views with respect to future events based on currently available information and are inherently subject to risks and uncertainties.  Many factors, both known and unknown could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements contained in this MD&A, including, but not limited to:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected.  The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Although the Company has attempted to identify important factors that could cause actual results to differ materially from forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated, described or intended.  The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect changes in assumptions or the occurrence of anticipated or unanticipated events, except as required by law.

The Company qualifies all the forward-looking statements contained in this MD&A by the foregoing cautionary statements.

OVERVIEW OF THE COMPANY AND ITS BUSINESS

Since 1999, Burcon has developed an extensive portfolio of composition, application, and process patents originating from our core protein extraction and purification technology.  Our technology covers novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation ("Merit Foods") was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods is building a commercial production facility in Manitoba, Canada where it will produce, under license, Burcon's novel pea and canola protein ingredients.  Our environmentally friendly and sustainable technologies have been developed at our own research facility led by our team of highly specialized scientists and engineers.  Our patent portfolio currently consists of 303 issued patents worldwide, including 71 issued U.S. patents, and in excess of 225 additional patent applications, 35 of which are U.S. patent applications.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

CONTINATION UNDER THE BUSINESS CORPORATIONS ACT (BRITISH COLUMBIA)

Burcon was incorporated under the Business Corporation Act (Yukon) (the "YBCA") on November 3, 1998, and extra-provincially registered in British Columbia on February 5, 1999.  The Board of Directors has determined that it would be more expedient and cost effective to have the Company continue into the Province of British Columbia pursuant to the Business Corporation Act (British Columbia), as amended (the "BCA").  The shareholders of the Company approved the continuance at the 2020 annual general meeting ("AGM").  A summary comparison of the provisions of the BCA and the YBCA that pertain to the rights of the shareholders has been provided in the 2020 management proxy circular, which is available at www.sedar.com.

MERIT FUNCTIONAL FOODS CORPORATION

On May 23, 2019, Burcon, through its newly-formed wholly-owned subsidiary, Burcon NutraScience Holdings Corp. ("Burcon Holdings"), entered into a shareholders' agreement (the "Shareholders Agreement") with RBT Holdco Ltd. ("RBT Holdco") and 10039406 Manitoba Ltd. ("Crew Holdco") (RBT Holdco and Crew Holdco together referred to as the "Partners") to become shareholders of Merit Functional Foods Corporation ("Merit Foods").  The business of Merit Foods is the commercial production, sales, marketing and distribution worldwide of Burcon's pea protein, pulse protein and canola protein products.  Merit Foods has completed the construction of and is commissioning an initial protein production facility (the "Flex Production Facility") in Winnipeg, Manitoba. 

On inception, Burcon Holdings held 40%, RBT Holdco held 40% and Crew Holdco held 20% of the issued and outstanding shares of Merit Foods.  Each of Ryan Bracken and Barry Tomiski (and their respective family) beneficially owns a 50% interest in RBT Holdco. 

Burcon has a license and production agreement (the "License Agreement') with Merit Foods to license the technology required to produce, market and sell Burcon's pulse protein ingredients, including Peazazz® and Peazac® pea proteins and Burcon's canola proteins, Supertein®, Puratein® and Nutratein® (collectively the "Products").  Under the terms of the License Agreement, Merit Foods has the exclusive rights over Burcon's pulse proteins (including pea) and canola protein technologies across all geographic regions and all product uses (the "License").  Burcon will receive running royalties on the net revenue (as defined in the License Agreement) from the sales of the Products by Merit Foods. 

On August 27, 2020, Bunge Limited ("Bunge") made an investment of $30 million into Merit Foods.  In addition to purchasing equity directly from Merit Foods, Bunge purchased additional shares and debt from the Partners.  Bunge (NYSE:  BG) is a world leader in sourcing, processing and supplying oilseed and grain products and ingredients.  As a result of these transactions, Bunge became a 25% shareholder in Merit Foods, Burcon's ownership interest in Merit Foods decreased to 33.3%.  As a result of the dilution in Burcon's ownership interest in Merit Foods, Burcon recorded a dilution gain of $6,384,942.

As part of the Bunge transaction, Burcon and the Partners have amended the License Agreement (the "Amended License Agreement") and Burcon, Bunge and the Partners have also amended the Shareholders Agreement (the "Amended Shareholders Agreement").  Under the Amended License Agreement and Amended Shareholders Agreement, Burcon, Bunge and the Partners have agreed to certain contractual rights, including a right, but not an obligation, of Burcon, in certain circumstances, to participate in a sale of all but not less than all of its shares in Merit Foods, and that in certain circumstances, Merit Foods will have the right to buy out from Burcon the Amended License Agreement for an amount representing the discounted future royalties over the life of the Amended License Agreement.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement. 

In accordance with the Shareholders Agreement, Burcon Holdings and the Partners made their capital loan advances (the "Initial Capital Loan Advances") in June 2019 by way of shareholder loans to Merit Foods in the aggregate of $10.0 million.  Burcon Holdings and the Partners made further loan advances to Merit Foods in the amounts of $10.0 million in September 2019, $7.5 million in December 2019 and $5.0 million in February 2020 (the "Additional Capital Loan Advances") (the Initial Capital Loan Advances and the Additional Capital Loan Advances, together referred to as the "Merit Shareholder Loans"). 

As at December 31, 2020, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans. 

(in thousands of dollars):

    Investment in
Share capital

    Capital
Contribution

    Loan
receivable

    Total net
investment

 
                         
From inception to December 31, 2019   -     -     11,000     11,000  
Modification to loan terms   -     8,872     (8,872 )   -  
Capital loan advance, February 2020   -     1,613     387     2,000  
Share of loss in Merit Foods   -     (940 )   -     (940 )
Interest accretion   -     -     145     145  
                         
Net Investment in Merit
Foods, March 31, 2020
  -     9,545     2,660     12,205  
Share of loss in Merit Foods   -     (1,792 )   -     (1,792 )
Gain on dilution of investment in Merit Foods   -     6,385     -     6,385  
Interest accretion   -     -     228     228  
                         
Net Investment in Merit
Foods, December 31, 2020
  -     14,138     2,888     17,026  

On inception, the Merit Shareholder Loans were recorded as a loan receivable.  In December 2019, the terms of the Merit Shareholder Loans were finalized.  The loans are non-interest bearing, unsecured, subordinated to Merit Foods' other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder's loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts.  As a result, Burcon recalculated the fair value at this date, resulting in a reduction of the fair value that was transferred to a capital contribution account.  Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest.  For the three and nine months ended December 31, 2020, Burcon has recorded interest accretion of $78,302 and $227,739, respectively (2019 - $76,259 and $76,259).


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

As at December 31, 2020, Merit Foods has completed the construction of Phase 1 of its 94,000 square foot Flex Production Facility.  Subsequent to the quarter-end, Merit Foods achieved first commercial production of Burcon's Peazazz® and Peazac® pea proteins.  Merit Foods will now focus on commissioning the Flex Production Facility to produce canola protein.  Once commissioned, Merit Foods believes it will be the only commercial facility in the world with the capability to produce food grade non-GMO canola proteins. 

Merit Foods has a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada ("EDC"), Farm Credit Canada ("FCC") and the Canadian Imperial Bank of Commerce.  Merit Foods' shareholders, including Burcon Holdings and Bunge, have pledged their shares in Merit Foods as security under the loan facilities from EDC and FCC.  In connection with the loan facilities from EDC, Merit Foods must fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility.  Of the prescribed amount, $6.5 million is permitted to be funded by way of a letter of credit ("LC").  To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada ("HSBC") in April 2020, which was secured by a term deposit with HSBC in the same amount.  As part of the investment by Bunge into Merit Foods, the LC was released on August 28, 2020.

In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the "Merit Loan Agreement") with Merit Foods in the amount of $6.5 million (the "Merit Loan").  The Merit Loan bore interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term.  As the LC was terminated on August 28, 2020, the Merit Loan Agreement was also terminated on the same date.  For the nine months ended December 31, 2020, Burcon recorded interest income of $120,205 (2019 - $nil) related to the Merit Loan, of which $nil was outstanding as at December 31, 2020 (March 31, 2020 - $nil). 

In addition, Burcon provided a guarantee to EDC and FCC in connection with the $85 million financing package (the "Guarantees"), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC, FCC and Merit Foods.  The aggregate maximum liability of Burcon under the Guarantees was limited to $4.0 million.  As part of the investment by Bunge into Merit Foods, EDC and FCC released the Guarantees on August 28, 2020.   

Merit Foods also has financing of $10 million in the form of a 10-year interest-free loan from Agriculture and Agri-Food Canada's Agrilnnovate Program ("AIP").  Merit now has a total of $99.2 million financing package from the Government of Canada that includes the financing noted above from EDC, FCC, AIP and PIC.  Burcon Holdings and the Partners have provided a guarantee for the AIP Loan (the "AIP Guarantee").  The obligations of the AIP Guarantee are joint and several.  However, Burcon Holdings and the Partners (the "AIP Guarantors") have entered into a reciprocal indemnity agreement (the "Indemnity Agreement').  Under the Indemnity Agreement, if any AIP Guarantor (each, a "Paying Guarantor") is required to make payment under the AIP Guarantee and any other AIP Guarantor (each, a "Contributing Guarantor") has not made a corresponding payment equal to its share based on its shareholdings in Merit Foods ("Contributive Share"), such Contributing Guarantor(s) shall pay the Paying Guarantor such amounts so that, after payment, all obligations and liabilities under the AIP Guarantee will have been borne by the AIP Guarantors in their respective shareholding percentage in Merit Foods.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

As at December 31, 2020, Burcon had a 33.3% ownership interest in Merit Foods.  There is no contingent issuance of securities by the equity investee that might significantly affect Burcon's share of profit or loss.  The following is the summarized financial information of the investee:

Summary financial information of Merit Foods

(Unaudited, in thousands of dollars)

    December 31, 2020     March 31, 2020  
             
Total assets   149,168     41,885  
Total liabilities   101,823     18,024  

    Three months ended     Nine months ended  
    December 31     December 311  
                         
    2020     2019     2020     2019  
                         
Total revenue   800     541     1,439     568  
                         
Loss and comprehensive loss for the period   (1,380 )   (445 )   (4,947 )   (801 )

NESTLE COLLABORATION

On January 24, 2020, the Company announced that Burcon, Nestlé and Merit Foods had entered into a joint development agreement to tailor Burcon and Merit's plant-based proteins for use in Nestlé food and beverage applications.  The joint agreement commenced what is intended to be a long-term relationship among the parties covering ongoing innovation and the future supply of Burcon and Merit's plant-based proteins from the Flex Production Facility.  The partnership combines Nestlé's expertise in the development, production and commercialization of plant-based foods and beverages with Burcon's proprietary plant protein extraction and purification technology, while leveraging Merit Foods' plant protein production capabilities.  The aim of the joint development is to tailor the functionality of Burcon and Merit's plant proteins, to be supplied from Merit's Flex Production Facility, for use by Nestlé in plant-based meat and dairy alternatives.  The Winnipeg Technical Centre has been working with Nestlé's scientists and food developers to tailor Burcon's pea and canola proteins for product development.

WINNIPEG TECHNICAL CENTRE

During the three and nine months ended December 31, 2020, the Winnipeg Technical Centre ("WTC") continued its work to support Merit Foods in completing its construction of the Flex Production Facility.  The WTC has also been producing samples for Merit Foods to provide to its potential customers for evaluation. 

____________________________________
1 Merit Foods was incorporated on May 15, 2019.  As a result, information in this table represents certain financial information of Merit Foods from the date of its incorporation to December 31, 2019.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

Over the past year, the WTC has expanded its production capacity to produce sample products in sufficient amounts for major food and beverage companies to conduct product development trials and limited product launches.  The WTC has further expanded its research and development capacity through the lease of a satellite laboratory space.  Subsequent to the quarter-end, the WTC also expanded its scientific and technical team with the addition of two new research scientists. 

Burcon has engaged a third-party engineering firm to investigate options to potentially replace the existing WTC with an expanded innovation centre to provide additional research and development bandwidth to pursue its product opportunity pipeline.

CONVERTIBLE DEBENTURES

On December 10, 2019, the Company issued convertible debentures (the "Debentures") through a non-brokered private placement for an aggregate principal amount of $9.5 million.  Certain directors and an officer of the Company subscribed for Debentures totaling $2 million in principal amount.  Each Debenture consisted of $1,000 principal amount, bore interest at a rate of 8.5% per annum, payable semi-annually in arrears and was unsecured.  The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon were to be payable in cash on December 10, 2022.  The Company incurred issue costs of $228,432, of which $156,600 were finder's fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders. 

The Debentures were convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share.  During the nine months ended December 31, 2020, the holders of the Debentures converted principal amounts of $1,704,500 for the issuance of 1,623,327 common shares of the Company.

Burcon had the right, at its sole discretion, to force the conversion of the Debentures if the shares traded at or above $2.15 for a period of 14 consecutive trading days.  The Company determined it had met this condition between August 12 and August 31, 2020 and issued a notice to the holders of the Debentures for conversion of the Debentures to common shares on September 8, 2020.  As a result of the conversion of $7,795,500 of outstanding principal amount of the Debentures, an aggregate of 7,424,274 common shares were issued to the holders of the Debentures.

The Debentures were a level 3 financial liability with an embedded conversion feature.  As a result, the debt and equity components were bifurcated and the instrument valued to par at the issuance date.  The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option.  From the date of issuance, the liability component was accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive income or loss.  The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641.  The residual amount of $2,762,927 was recognized within equity as the value of the conversion option.  For the nine months ended December 31, 2020, the Company recorded interest expense of $637,522 (2019 - $nil) related to the Debentures.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

EQUITY OFFERING

On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the "Units") at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the "Offering") and net proceeds of $10.3 million.

Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant").  Each Warrant is exercisable to acquire one common share (a "Warrant Share") until February 19, 2022 at an exercise price of $2.00 per Warrant Share.  The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model and has been included in Warrants.  During the three and nine months ended December 31, 2020, Warrants were exercised for 896,750 and 1,254,250 Warrant Shares, respectively, of the Company.  Warrant exercise proceeds of $846,000 was included in amounts receivable as at December 31, 2020.  As at December 31, 2020, 2,455,650 Warrants were outstanding.  Subsequent to the quarter-end, Warrants were exercised for 737,000 Warrant Shares.

The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents' Warrants) entitling the agents to purchase up to 519,386 common shares.  Each Agent's Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022.  The fair value of the Agents' Warrants was estimated at $249,305 using the Black-Scholes pricing model and has been included in Warrants.  As at December 31, 2020 and the date of this MD&A, all Agents' Warrants were outstanding.

In addition to the Agents' Warrants, the Company incurred total issue costs of $1.2 million related to the Offering.

The Company is using the net proceeds of the Offering and the balance of the net proceeds from the Debentures for further development of its extraction and purification technologies and pursue new related products, pursue and develop new applications from functional attributes of Burcon's proteins and carry out research on protein extraction from various plant sources.  Burcon will also continue work to tailor its plant-based proteins for use in Nestlé food and beverage applications.  Burcon also intends to use the net proceeds to maintain, further strengthen and expand the Company's intellectual property portfolio.  Burcon is obligated to prosecute and maintain its pea and canola patent portfolios under its Amended License Agreement with Merit Foods.  Additionally, Burcon intends to continue to file additional patent applications to protect discoveries arising from its research and development activities.  Burcon also intends to use the net proceeds for expansion initiatives and to provide for general working capital.   

COVID-19

The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  To-date, the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations or Merit Foods' construction progress.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

NEW DIRECTOR APPOINTMENT

On July 6, 2020, Burcon appointed Ms. Debora Fang as a director to its board of directors.  Ms. Fang has 20 years of experience in the consumer goods industry, across mergers and acquisitions, strategy, and marketing roles for Unilver (London, UK), Danone (Paris, France and Amsterdam, Netherlands), Kraft Foods (Sao Paulo, Brazil) and as a consultant for Bain & Company (Los Angeles, USA).  She is now an independent advisor for private equity and strategic clients in the food arena as well as a private investor.

CLARISOY®

Burcon had a license and production agreement (the "Soy Agreement") with Archer Daniels Midland Company ("ADM") to license its CLARISOY® technology to ADM on an exclusive basis to produce market and sell CLARISOY® soy protein worldwide.  Burcon and ADM have agreed to terminate the Soy Agreement, effective August 7, 2020.  As part of the agreement to terminate the exclusive license, the CLARISOY trademark reverted back to Burcon on the effective date.  In addition, Burcon and ADM are discussing opportunities for Burcon to acquire certain processing equipment for ADM's CLARISOY® processing facility. 

Burcon has not received any significant royalty revenues from ADM's sales of CLARISOY®.  For the three and nine months ended December 31, 2020, Burcon recorded royalty revenues of $nil and $8,646, respectively (2019 - $5,044 and $27,735). 

Burcon will provide additional updates on its plans for CLARISOY®.

Other

The Company was issued a research license under the Cannabis Act by Health Canada in June 2019.  Given its focus on other business initiatives, Burcon does not plan to conduct research in cannabinoid extracts this fiscal year.

Burcon continued work to further the development of a new plant-based protein process, as well as limited research work on protein extraction from various plant sources to explore potential new commercial and patenting opportunities.  Burcon's extraction and purification technologies are versatile and may be adapted to process a range of oilseed and non-oilseed meals to produce specialty proteins, such as flax and hemp.  The demand for plant-based proteins continues to grow and Burcon believes there may be niche market opportunities for its specialty protein ingredients. 

INTELLECTUAL PROPERTY

Burcon's patent strategy is to seek protection for new technologies as well as further protecting current technologies.  Over the years, Burcon has filed patent applications in various countries over its inventions.  Burcon's patent applications can be grouped into three categories:


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

During the current quarter, Burcon received a patent grant and a patent allowance for a patent application over its pea processing technology.  Burcon continued the maintenance and prosecution of its patent applications during the quarter ended December 31, 2020. 

Burcon currently holds 71 U.S. issued patents over its canola, soy, pea and flax protein processing technologies and canola and soy protein isolate applications, as well as canola, pea and soy patents covering composition of matter.  In addition, Burcon has a further 35 patent applications currently filed with the U.S. Patent and Trademark Office.

As of the date of this MD&A, Burcon's patents and patent applications cover over 50 distinct inventions.  Burcon has also filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  Together with patents issued in other countries, Burcon now holds a total of 303 issued patents covering inventions that include the 71 granted U.S. patents.  Currently, Burcon has over 225 additional patent applications that are being reviewed by the respective patent offices in various countries.

RESULTS OF OPERATIONS

As at December 31, 2020, Burcon has not yet generated any significant revenues from its technology.  For the three and nine months ended December 31, 2020, the Company recorded a loss of $1,086,177 and income of $1,890,405, respectively, ($0.01 loss per share and $0.02 income per share), as compared to a loss of $788,282 and $2,817,899 ($0.01 and $0.04 per share) for the same periods last year.  Included in the nine-month (loss) income amounts are the following non-cash items:  gain on dilution of investment in Merit Foods of $6,384,942 (2019 - $nil), stock-based compensation expense of $380,381 (2019 - $74,322), share of loss in Merit Foods of $1,791,278 (2019 - $320,410), amortization of property and equipment of $104,228 (2019 - $25,417), unrealized foreign exchange loss of $3,683 (2019 - $676),  interest expense of $314,735 (2019 - $42,219), interest accretion of $227,739 (2019 - $76,259), warrant valuation adjustment of $nil (2019 - $85,420), change in fair value of convertible note derivative liability of $nil (2019 - $5,384), and loss on disposal of equipment of $nil (2019 - $949).

The following provides a comparative analysis of significant changes in major expenditures items.

Research and development expenses

Components of research and development ("R&D") expenditures are as follows:

(in thousands of dollars) 

    Three months ended Dec. 31,     Nine months ended Dec. 31  
    2020     2019     2020     2019  
Salaries and benefits   393     328     1,233     957  
Laboratory operation   83     91     240     205  
Amortization of property and equipment   64     20     148     48  
Analyses and testing   38     11     55     35  
Rent   26     22     71     66  
Travel and meals   -     4     -     10  
    604     476     1,747     1,321  
To deferred development costs   (194 )   (234 )   (810 )   (438 )
To inventory production   (341 )   (114 )   (717 )   (251 )
Net research and development expenses   69     128     220     632  


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019


Effective July 1, 2019, the Company determined that it had met all the criteria of deferring development costs ("DDC") with respect to its pea and canola proteins and has been deferring its expenditures relating to pea and canola to deferred development costs.  For the three months and nine months ended December 31, 2020, Burcon deferred approximately $194,000 and $810,000 of R&D costs, respectively.  Under the Services Agreement with Merit Foods, Burcon also has been producing inventory saleable to Merit Foods' potential customers for product evaluation.  This has contributed to about $341,000 and $717,000 of R&D costs that have been allocated to inventory production for the three and nine months ended December 31, 2020, respectively.  Before the cost deferral and allocation to inventory production, total R&D costs increased by about $128,000 and $426,000, respectively, for the three and nine months ended December 31, 2020.  The increase is attributed to higher salaries and benefits, due mainly to salary increases, hiring of new employees, as well as an employee who has returned from leave.  There were also higher external laboratory testing expenses from research activities, as well as higher amortization expenses due to the equipment additions. 

Intellectual property expenses

(in thousands of dollars)

    Three months ended Dec. 31,     Nine months ended Dec. 31  
    2020     2019     2020     2019  
Patent fees and expenses   271     199     583     747  
Trademark    -     3     -     6  
    271     202     583     753  

As noted in the R&D section, the Company is deferring costs related to its pea and canola technology, including the related patent fees and expenses.  During the three and nine months ended December 31, 2020, Burcon deferred about $222,000 and $796,000, respectively, (2019 - $250,000 and $550,000) of patent fees and expenses for its pea and canola patent portfolio to deferred development costs. 

After taking into account the capitalized patent fees and expenses, patent legal fees and expenses did not change significantly over the same periods last year.     

From inception, Burcon has expended $21.1 million on patent legal fees and disbursements to strengthen its patent portfolio in various countries of the world and file patent applications for new inventions.

General and administrative ("G&A") expenses

(in thousands of dollars) 

    Three months ended Dec. 31,     Nine months ended Dec. 31  
    2020     2019     2020     2019  
Salaries and benefits   306     242     1,223     687  
Professional fees   36     58     324     182  
Investor relations   23     35     135     98  
Office supplies and services   43     43     128     124  
Transfer agent and filing fees   19     6     50     23  
Financing expense   -     -     24     89  
Other   13     21     40     62  
Travel and meals   -     18     -     62  
    440     423     1,924     1,327  


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019


Salaries and benefits

Included in salaries and benefits for the three and nine months ended December 31, 2020 is stock-based compensation expense of about $54,000 and $294,000, respectively, (2019 -$12,000 and $46,000).  The higher expense incurred as compared to the same periods last year is due mainly to options granted that had a higher valuation, as well as options granted to a director in the second quarter of this year that had vested immediately. 

The cash portion of salaries and benefits increased by about $16,000 and $236,000, respectively, for the three and nine months ended December 31, 2020.  The increase is due mainly to fiscal 2020 bonuses of $130,000 approved during the first quarter, and salary increases effected at the beginning of this fiscal year, and the addition of an employee in the second quarter.  Directors' fees also increased by about $52,000 for the nine months ended December 31, 2020, due to more meetings held to-date this year, as well as the addition of a director in July 2020 and in July 2019.

Professional fees

For the three and nine months ended December 31, 2020, professional fees decreased by about $22,000 and increased by $142,000, respectively, over the same periods last year.  The decrease for the three-month period is due mainly to legal fees incurred for the Nestle agreement in fiscal 2020 and the increase for the nine-month period is attributable mainly to higher legal fees of $135,000 for the negotiations and agreements related to the Bunge investment into Merit Foods during this year, offset by legal fees incurred in fiscal 2020 for the Nestle agreement. 

Investor relations

Investor relations expenses did not change significantly for the current three-month period over the same period last year and increased by $37,000 for the nine months ended December 31, 2020 over the same period last year.  The increase was due mainly to higher expenses incurred for the virtual AGM held in the second quarter of this year and to U.S. investor relations consulting services that commenced in September 2019, as well as to OTCQB annual fees.  This was offset by travel expenses that decreased due to COVID-19.

LIQUIDITY AND FINANCIAL POSITION

At December 31, 2020, the Company had cash and cash equivalents of $12.0 million.  Assuming Burcon Holdings is not required to make payment under the AIP Guarantee, management estimates the cash resources to be sufficient to fund its operations to June 2023, without taking into account proceeds from outstanding convertible securities and royalty revenues from its Amended License Agreement.  If Burcon does not receive sufficient royalties from its Amended License Agreement, Burcon will require additional capital beyond this date to meet its business objectives, although there is no assurance that additional financing will be available on acceptable terms, if at all.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

The net cash used in operations during the nine months ended December 31, 2020 was $3,062,000, as compared to $3,083,000 last year.  The decrease in the net cash used in operations of $21,000 is mainly due to higher interest and other income of $227,000, decreases of $384,000 in R&D expenditures and $171,000 in IP expenditures that were expensed, offset by lower management fee income of $68,000, offset by higher G&A expenses of $313,000, interest expense of $161,000, and a decrease in royalty income of $7,000, and changes in non-cash working capital items that contributed to $161,000 of the increase.   

At December 31, 2020, Burcon had working capital of $12.3 million (March 31, 2020 - $14.2 million).  As at December 31, 2020, Burcon was not committed to significant capital expenditures.  Burcon may incur up to $500,000 in additional capital expenditures if modifications or further upgrades are required to the WTC.  Burcon is continuing to limit the prosecution of certain patent applications and defer the maintenance fees for certain non-core patent applications.  This does not affect the strength of Burcon's patent portfolio.  Burcon expects to expend $400,000 in patent expenditures for the balance of this fiscal year.  With the termination of the ADM license and production agreement, Burcon will further review its soy patent portfolio for possible reductions in patent fees and disbursements.

FINANCIAL INSTRUMENTS

The Company's financial instruments are its cash and cash equivalents, amounts receivable, loan to Merit Foods, and accounts payable and accrued liabilities and accrued interest.

Credit risk

The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable.  The Company's cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks.  The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks.

Interest rate risk

All of the Company's financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, and the loan to Merit Foods that bore interest at a fixed interest rate.  Burcon's cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk.  For the three and nine months ended December 31, 2020, the weighted average interest rate earned on the Company's cash and cash equivalents was 0.40% and 0.32% per annum, respectively, (2019 - 2.15% and 2.15% per annum).  The impact of a 1% strengthening or weakening of interest rate on the Company's cash and cash equivalents at December 31, 2020 is estimated to be a $120,000 increase or decrease in interest income per year.

Liquidity risk

The Company manages liquidity risk through the management of its capital structure.  It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations.  The Company's estimated minimum contractual undiscounted cash flow requirements for its financial liabilities as at December 31, 2020 is approximately $761,000, all of which is due within the next 12 months. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

Fair value

The fair value of the Company's short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable and accounts payable and accrued liabilities approximates their carrying values due to the short-term maturities of these financial instruments.

The fair value of the shareholder loans to Merit Foods approximates the carrying value as at December 31, 2020 given the risk profile of Merit Foods has not changed substantially since the issue date of the loans.

The carrying values and fair values of financial instruments, by class, are as follows as at December 31, 2020 and March 31, 2020:

(in thousands of dollars)

As at December 31, 2020                        
    At fair value through profit or loss     Financial assets at amortized cost     Financial liabilities at amortized cost     Fair value  
    $     $     $     $  
Financial assets                        
Cash and cash equivalents   -     12,042     -     12,042  
Amounts receivable   -     1,041     -     1,041  
Loan to Merit Foods   -     2,888     -     2,888  
Total   -     15,971     -     15,971  
                         
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     761     761  
Total   -     -     761     761  

As at March 31, 2020                        
    At fair value through profit or loss     Financial assets at amortized cost     Financial liabilities at amortized cost     Fair value  
    $     $     $     $  
Financial assets                        
Cash and cash equivalents   -     15,031     -     15,031  
Amounts receivable   -     332     -     332  
Loan to Merit Foods   -     2,660     -     2,660  
Total   -     18,023     -     18,023  
                         
Financial liabilities                        
Accounts payable and accrued liabilities   -     -     1,067     1,067  
Accrued interest   -     -     249     249  
Convertible debentures   -     -     6,731     6,731  
Total   -     -     8,047     8,047  


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

Currency risk

The Company has not hedged its exposure to currency fluctuations.  As at December 31, 2020 and March 31, 2020, the Company is exposed to currency risk through the following assets and liabilities denominated in U.S. dollars:

    December 31, 2020     March 31, 2020  
U.S. Dollars (in thousands)            
Cash and cash equivalents   25     22  
Amounts receivable   -     2  
Accounts payable and accrued liabilities   -     (40 )
Net exposure   25     (16 )
             
Canadian dollar equivalent (in thousands)   32     (23 )

Based on the above net exposure at December 31, 2020, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $300 (March 31, 2020 - $2,000) in the Company's income or loss from operations.

OUTSTANDING SHARE DATA

As at December 31, 2020, Burcon had 107,101,489 common shares outstanding, 3,852,106 stock options outstanding exercisable at a weighted average exercise price of $2.15 per share, and 2,975,036 share purchase warrants that were convertible to an equal number of common shares at an exercise price of $2.00 per share. 

As at the date of this MD&A, Burcon has 107,921,373 common shares outstanding, and 4,937,106 stock options that are convertible to an equal number of shares at a weighted average exercise of $2.62 per share, and 2,238,036 share purchase warrants that are convertible to an equal number of common shares at an exercise price of $2.00 per share.

QUARTERLY FINANCIAL DATA

(Derived from unaudited interim financial statements.  All figures in thousands of dollars, except per-share amounts)


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019


    Three months ended  
    December 31,     September     June 30,     March 31,  
    2020     30, 2020      2020     2020  
Revenue, foreign exchange gain, interest
  and other income, management fee income,
  gain on dilution of investment in Merit Foods
  171     6,658     267     268  
(Loss) income for the period   (1,086 )   4,377     (1,401 )   (1,121 )
Basic and diluted (loss) income per share   (0.01 )   0.04     (0.01 )   (0.01 )

 

    Three months ended  
    December 31,     September     June 30,     March 31,  
    2019     30, 2019      2019     2019  
Revenue, foreign exchange gain, interest
  and other income
  221     172     27     105  
Loss for the period   (788 )   (697 )   (1,332 )   (1,245 )
Basic and diluted loss per share   (0.01 )   (0.01 )   (0.03 )   (0.03 )

The loss for the quarter decreased from the second quarter of fiscal 2020 due to the deferral of R&D and pea and canola patent costs and the allocation of R&D costs to inventory production costs.  This has been offset by the recognition of our share of the loss in Merit Foods, which has been increasing each quarter since the first quarter of fiscal 2020.  The loss in the second quarter of this year was offset by the gain on dilution of the investment in Merit Foods.

RELATED PARTY TRANSACTIONS

Burcon engaged Burcon Group Limited, a company that is related by virtue of common officers, for the following related party transactions:

Included in general and administrative expenses (office supplies and services and other expenses) for the three and nine months ended December 31, 2019 are $18,752 and $56,255 for office space rental. 

For the three and nine months ended December 31, 2020, included in general and administrative expenses (management fees) is $663 and $2,002, respectively, (2019 - $458 and $946) for administrative services provided.  At December 31, 2020, $100 (March 31, 2020 - $11) of this amount is included in accounts payable and accrued liabilities.  For the three and nine months ended December 31, 2020, included in interest and other income is $915 and $6,224, respectively, (2019 - $2,232 and $10,422) for legal and accounting services provided by the Company.  At December 31, 2020, $268 (March 31, 2020 - $1,785) of this amount is included in amounts receivable.   

Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement.  For the three and nine months ended December 31, 2020, included in interest and other income is $43,853 and $200,090, respectively, (2019 - $123,190 and $265,884) for services provided and $250,179 and $462,323, respectively, (2019 - $26,063 and $50,787) for samples sold to Merit Foods, of which $73,642 was included in amounts receivable at December 31, 2020 (March 31, 2020 - $110,594). 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

Merit Foods also provides certain technical and consulting services to Burcon.  For the nine months ended December 31, 2020, Burcon recorded professional fee expense of $10,720 (2019 - $nil), of which $nil was outstanding as at December 31, 2020.

In connection with the LC, Burcon Holdings entered the Merit Loan Agreement with Merit Foods in the amount of $6.5 million.  During the nine months ended December 31, 2020, Burcon recorded interest income of $120,205 (2019 - $nil) related to the Merit Loan, of which $nil was included in amounts receivable as at December 31, 2020 (March 31, 2020 - $nil).

Certain directors and an officer subscribed for $2.0 million of the Debentures.  During the nine months ended December 31, 2020, the Company made total convertible debenture interest payments of $126,803 to these directors and officer.

CRITICAL ACCOUNTING ESTIMATES

The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34, Interim Financial Reporting, as issued by the International Accounting Standard Board (IASB) on a basis consistent with those accounting policies followed in the most recent annual consolidated financial statements, except as discussed below. 

The preparation of condensed consolidated interim financial statements in accordance with IFRS requires management to apply judgment when making estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, the reported amount of expenses during the reporting period, and disclosures made in the accompanying notes to the financial statements.  Actual results could differ from those estimates.

The significant areas where management's judgment is applied are in determining the fair value of stock-based compensation, derivative liability, whether all criteria for deferring development costs are met, the point at which amortization of development costs commences, the expense allocation to deferred development costs and the recoverable amount of goodwill, and the discount rate used to fair value the loans receivable from Merit Functional Foods following their modification and determining the loan and equity components of the Debentures.

DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING

The Chief Executive Officer and Chief Financial Officer, as well as other executives, have designed disclosure controls and procedures ("DC&P"), or have caused them to be designed under their supervision, to provide reasonable assurance that material information relating to the Company has been made known to them. 

These officers are also responsible for designing and maintaining internal controls over financial reporting ("ICFR") or have caused them to be designed under their supervision, to provide reasonable assurance regarding the reliability of the Company's ICFR. 

There have been no significant changes in the DC&P and ICFR that occurred during the three months ended December 31, 2020 that could have materially affected, or are reasonably likely to materially affect, such controls. 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

RISKS AND UNCERTAINTIES

The Company is subject to a number of risks and uncertainties that can significantly affect its financial condition and future operations.  Key risks are outlined below.  In addition, a detailed explanation of the risk factors which we face is provided in our AIF for the year ended March 31, 2020 under the section titled "Risk Factors", which is incorporated by reference herein.  The AIF is available at www.sedar.com

Patents and proprietary rights - Burcon's success will depend, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of others or having others infringe on its rights.  Burcon has filed applications for most of its inventions internationally under the Patent Cooperation Treaty of the World Intellectual Property Organization.  As at the date of this MD&A, Burcon has been granted a total of 303 patents in various countries covering a number of key processes and uses of Burcon's soy, pea, canola and flax protein products as functional food and beverage ingredients.  Of those patents, 71 have been granted in the United States.  Although Burcon expends significant resources and efforts to patent its discoveries and innovations, there can be no assurance that our patent applications will result in the issuance of patents, or any patents issued to Burcon will provide it with adequate protection or any competitive advantages, or that such patents will not be successfully challenged by third parties.  Burcon cannot be assured that competitors will not independently develop products similar to the Company's products or manufacture products designed to circumvent the exclusive patent rights granted to the Company.  Further, Burcon may need to incur significant expenditures in prosecuting claims against others whom it believes are infringing on its rights and by defending claims of intellectual property infringement brought by its competitors and others.

Development and commercialization - The long-term success of Puratein®, Supertein® and Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea protein and Nutratein® pea protein/canola protein blend products hinges upon market acceptance by food and feed ingredient manufacturers and suppliers in numerous product applications.  Although Burcon has formed Merit Foods with the Partners to commercialize Burcon's pea and canola proteins, the commercial products manufactured using Burcon's protein and extraction technologies must exhibit certain functional and nutritional characteristics to garner any market share in the industries that are targeted.  There can be no assurance that Burcon's products will meet industry standards.  Even though Puratein®, Supertein® and Nutratein® canola proteins, CLARISOY® soy protein and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be found to be functionally acceptable in product applications, there is no assurance that they will obtain market acceptance and within a reasonable time frame.  The majority of food ingredient manufacturers will require a substantial testing phase and demonstration of consistent delivery and production capabilities for commercialization.  Although Merit Foods has completed the construction of the planned production facility for Burcon's pea and canola proteins, the expected time of the commissioning process may be longer than expected.  Therefore, there may be some time before product sales of pea and canola protein will occur.  Until large batches of products can be supplied, market acceptance of Puratein®, Supertein®, and Nutratein® canola proteins, and Peazazz® and Peazac® pea proteins and Nutratein® pea protein/canola protein blend products may be delayed.

There are many large companies in the marketplace that manufacture and produce mature and well-known protein ingredients that have been used for many years.  These companies also possess far greater financial, marketing and human resources than Burcon.  Products such as dried egg white and soy protein isolate have been used in the food processing industry for years with successful results.  These protein ingredients are proven to be functional, technologically sound, readily available and reliable.


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

History of operating losses and financing requirements- Burcon has accumulated net losses of approximately $96.5 million from its date of incorporation through December 31, 2020.  While the construction of Merit Foods' Flex Production Facility has been completed, there is no assurance that the commissioning process will be completed on time or within budget or that Burcon will be able to make the transition to commercial production.  Burcon cannot predict if it will ever achieve profitability and, if it does, it may not be able to sustain or increase its profitability.  In the absence of a definitive time for when sales of products will be significant, Burcon expects such losses to increase as it continues to commercialize its products, its research and development and product and its product application trials.  The commercial success of any of Burcon's products will depend on whether they receive public and industry acceptance as a food ingredient and dietary supplement, and whether they may be sold at competitive prices or are able to obtain sufficient royalty revenue from licensing, which adequately exceeds Burcon's business costs.

Developing Burcon's products and conducting product application trials is capital intensive.  Since acquiring its subsidiary in October 1999, Burcon has raised gross proceeds of $141.8 million from the sale or issuance of equity securities and $9.5 million from the issuance of convertible debentures.  As at December 31, 2020, Burcon had approximately $12.0 million in cash and cash equivalents.  Burcon believes that it has sufficient capital to fund the current level of operations through June 2023.  Although Burcon has sufficient funds to operate until June 2023, it will need to raise additional capital on acceptable terms in order for the Company to meet its business objectives and fund its operations. 

COVID-19 - Pandemic Risk - The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020.  Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread.  Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses.  While economies began to slowly reopen starting in June 2020, governments have taken a phased approach and it is not expected that economies will fully return to its pre-COVID-19 state until a vaccine has been developed to treat the virus.  There has also been recurrence of outbreaks since then.  The duration and effects of the COVID-19 pandemic are unknown at this time.  Even though governments worldwide, including Canada have implemented significant monetary and fiscal relief programs designed to stabilize their economies, it is too early to predict the efficacy of such programs at this time.  In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver.  While the COVID-19 pandemic has not significantly affected Burcon's and Merit Foods' business operations to-date, it is not possible to predict how long the pandemic will last and whether the financial and business conditions of Burcon and Merit Foods will be impacted in future periods. 

OUTLOOK

For the balance of this fiscal year, Burcon's primary objective is to support Merit Foods to complete the commissioning of the pea protein and canola protein production facility and to support market development activities for its protein products, which will include: 


MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Three and nine months ended December 31, 2020 and 2019

In addition, Burcon will also:





Burcon NutraScience Corporation

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, Jade Cheng, Chief Financial Officer of Burcon NutraScience Corporation, certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Burcon NutraScience Corporation (the "issuer") for the interim period ended December 31, 2020.

2.  No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a)  designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b)  designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework:  The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Internal Control - Integrated Framework (2013) issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design:  N/A.

1


5.3 Limitation on scope of design:  N/A.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on October 1, 2020 and ended on December 31, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date:  February 16, 2021

"Jade Cheng"

______________________

Jade Cheng

Chief Financial Officer

2



Burcon NutraScience Corporation

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, Johann F. Tergesen, Chief Executive Officer of Burcon NutraScience Corporation, certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Burcon NutraScience Corporation (the "issuer") for the interim period ended December 31, 2020.

2.  No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a)  designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b)  designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework:  The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Internal Control - Integrated Framework (2013) issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design:  N/A.

1


5.3 Limitation on scope of design:  N/A.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on October 1, 2020 and ended on December 31, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date:  February 16, 2021

"Johann F. Tergesen"

______________________

Johann F. Tergesen

Chief Executive Officer

2



News Release

Burcon Reports Fiscal 2021 Third Quarter Results

Vancouver, British Columbia, February 16, 2021 - Burcon NutraScience Corporation (TSX: BU  OTCQB: BUROF) a global technology leader in the development of plant-based proteins, reported results for the fiscal third quarter ended December 31, 2020.

Operational highlights for the third quarter ended December 31, 2020:


Management Commentary

"We are very pleased with all that we accomplished during our 2021 fiscal third quarter and for the year-to-date.  Our fiscal third quarter was marked by continued milestone execution and a further strengthening of Burcon's financial position," said Johann F. Tergesen, Burcon's president and chief executive officer, "Our joint venture company, Merit Functional Foods, successfully completed the construction of Phase 1 of its 94,000 square foot, state-of-the-art production facility dedicated to the production, under license, of Burcon's novel pea and canola protein ingredients as well as Burcon's new protein blends.  Subsequent to the quarter-end, Merit Functional Foods achieved first commercial production of Burcon's Peazazz® and Peazac® pea proteins and will now focus on completing first runs of canola proteins.  When complete, the production facility will be the only commercial facility in the world with the capability to produce non-GMO food grade canola proteins."

"The timing couldn't be better for our novel protein ingredients to first come to market.  Food and beverage companies need innovative highly functional protein ingredients to respond to consumers' demands for better-tasting, clean-label, and sustainably produced plant-based offerings. Merit's state-of-the-art protein production facility, with its low carbon footprint design, is well-positioned to meet this demand and profit from the projected double-digit growth of dairy and meat alternative products.  Completing the construction of its state-of-the-art facility was an impressive accomplishment during such a challenging time.  We are thrilled with Merit's accomplishments and look forward to Merit achieving its first sales."

"Additionally, our team of scientists and engineers at Burcon's Winnipeg Technical Centre continued development work on our pipeline of technologies for alternative plant-based proteins.  We made progress on existing technologies by further innovating with pea and canola and also with entirely new plant-based protein sources.  Our goal is to enter into additional partnerships as a means to bring additional plant-based protein ingredients to market."

"We also engaged a third-party engineering firm during the quarter to assist the company to plan and design a potential new and expanded technology and innovation centre.  We are investigating options to replace Burcon's existing Winnipeg Technical Centre with an expanded innovation centre to provide Burcon with additional R&D bandwidth to pursue our product opportunity pipeline and to increase pilot-scale production capabilities in contemplation of partnering opportunities we are pursuing." 

"During the quarter, we continued to strengthen our intellectual property portfolio adding five patents, one of which is a U.S. patent covering our novel process for pea protein production. Our intellectual property portfolio now includes 303 issued global patents and 71 issued U.S. patents."

"As a result of improved trading in Burcon's shares subsequent to the quarter-end, Burcon believes it now meets the NASDAQ's published requirements for a dual listing on the NASDAQ stock exchange.  We believe we could raise awareness and expand our investor base both within the U.S. investment community as well as internationally through the addition of a NASDAQ dual listing.  Burcon has engaged a U.S. securities law firm to advise the company with the process of applying for a dual listing on the NASDAQ stock exchange."


Fiscal 2021 Third Quarter Financial Results (in Canadian Dollars)

Burcon's net loss totaled $1.1 million or $0.01 per basic and diluted share for fiscal Q3 2021, as compared to a net loss of $0.8 million or $0.01 per basic and diluted share in fiscal Q3 2020.

Our share of Merit's loss for fiscal Q3 2021 was about $460,000, as compared to $178,000 in the same year-ago period.  The higher loss reflects higher expenses at the Merit facility due to the construction build out, increased market development and operational activities.

Research and development expenses were about $69,000 for the three months ended December 31, 2020, as compared to $115,000 in the same year-ago period.  The Company began deferring canola and pea development expenses from the second quarter of last year and also recorded production costs for inventory.  Before the deferral and cost allocation, R&D costs increased by $128,000, due to salary increases, new hires and increased laboratory expense from increased research activities. 

Intellectual property expenses increased by about $69,000, from $202,000 in fiscal Q3 2020 to $271,000 in fiscal Q3 2021.  The Company also began deferring patent expenses in fiscal 2020 for the pea and canola patent portfolios.  Before the deferral, patent expenditures did not change significantly from the same period last year.

There was no significant change in total general and administrative expenses for fiscal Q3 2021 over the same year-ago period.  However, stock-based compensation expense increased by $42,000, which was offset by lower legal fees and investor relations travel expenses due to COVID-19.

At December 31, 2021, cash balances totaled $12.0 million compared to $15.0 million at March 31, 2020.  During fiscal Q3 2021, warrants were exercised for proceeds of $1.8 million and additional warrants were exercised after the quarter-end for further $1.4 million.

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 300 issued patents and more than 225 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods has built a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

Forward-Looking Information Cautionary Statement


The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.

Industry Contact

Paul Lam

Manager, Business Development and IRO

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca  www.burcon.ca

Investor Contact

James Carbonara

Hayden IR

Tel (646) 755-7412

james@haydenir.com

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM


Burcon NutraScience Corporation
Condensed Consolidated Interim Balance Sheets
(Unaudited)
(Prepared in Canadian dollars)

    December 31,     March 31,  
    2020     2020  
    $     $  
Assets            
Current assets            
Cash and cash equivalents   12,042,479     15,030,988  
Amounts receivable   1,041,139     332,248  
Inventory   292,189     132,142  
Prepaid expenses   142,959     289,278  
    13,518,766     15,784,656  
Property and equipment   989,978     470,504  
Deferred development costs   3,177,692     1,554,584  
Investment in and loan to Merit Functional Foods
  Corporation
  17,025,941     12,204,538  
Goodwill   1,254,930     1,254,930  
    35,967,307     31,269,212  
Liabilities            
Current liabilities            
Accounts payable and accrued liabilities   761,316     1,067,251  
Deferred revenue   268,857     275,578  
Lease liability   41,651     -  
Accrued interest   -     249,310  
    1,071,824     1,592,139  
Lease liability   4,648     -  
Convertible debentures   -     6,731,350  
    1,076,472     8,323,489  
Shareholders' Equity            
Capital stock   110,961,372     98,046,103  
Contributed surplus   14,058,654     9,030,861  
Options   5,151,218     9,673,821  
Warrants   1,189,343     1,792,168  
Convertible debentures   -     2,762,927  
Deficit   (96,469,752 )   (98,360,157 )
    34,890,835     22,945,723  
    35,967,307     31,269,212  


Burcon NutraScience Corporation
Condensed Consolidated Interim Statements of Operations and Comprehensive Income (Loss)
(Unaudited)
For the three and nine months ended December 31, 2020 and 2019
(Prepared in Canadian dollars)

    Three months ended
December 31
    Nine months ended
December 31
 
    2020     2019     2020     2019  
    $     $     $     $  
Revenue                        
Royalty income   -     5,044     8,646     27,735  
                         
Expenses                        
Research and development   69,156     115,459     220,400     632,309  
Intellectual property   270,569     201,983     582,788     753,288  
General and administrative   439,619     422,509     1,923,692     1,327,386  
    779,344     739,951     2,726,880     2,712,983  
                         
Loss from operations   (779,344 )   (734,907 )   (2,718,234 )   (2,685,248 )
                         
Interest and other income   125,875     90,588     494,545     115,651  
                         
Management fee income   44,768     125,422     208,315     276,306  
                         
Gain on dilution of investment in                        
Merit Foods   -     -     6,384,942     -  
                         
Share of loss in Merit Foods   (460,130 )   (177,906 )   (1,791,278 )   (320,410 )
                         
Interest expense   (15,801 )   (90,757 )   (684,030 )   (208,015 )
                         
Other   (1,545 )   (722 )   (3,855 )   3,817  
                         
Income (loss) and comprehensive income (loss) for the period   (1,086,177 )   (788,282 )   1,890,405     (2,817,899 )
                         
Basic and diluted income (loss) per share   (0.01 )   (0.01 )   0.02     (0.04 )



News Release

Burcon to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

Vancouver, British Columbia, March 4, 2021 - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BUROF) a global technology leader in the development of plant-based proteins, today announced that it will participate in the 33rd Annual ROTH Conference, which will be held virtually on March 15-17, 2021.

Management will host 1x1 virtual investor meetings during the conference.

For more information or to schedule a one-on-one meeting with management, please contact your ROTH representative or James@HaydenIR.com.

About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.  Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S.  For more information on ROTH, please visit www.roth.com.

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of plant-based proteins.  With over 300 issued patents and more than 225 additional patent applications that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more.  In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives.  Merit Foods has built a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.  For more information visit www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.


Industry Contact

Paul Lam

Manager, Business Development and IRO

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca  www.burcon.ca

Investor Contact

James Carbonara

Hayden IR

Tel (646) 755-7412

james@haydenir.com

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM



News Release

Burcon JV Company, Merit Functional Foods, Achieves

First Commercial Production of Canola Protein

A Global Plant-based Protein First For Canola

Vancouver, British Columbia, April 12, 2021 - Burcon NutraScience Corporation (TSX: BU)  (OTCQB: BUROF), a global technology leader in the development of clean-label, plant-based proteins for foods and beverages, is pleased to announce that its joint venture company, Merit Functional Foods Corporation ("Merit Foods" or "Merit"), has achieved first commercial production of its novel lineup of Puratein® canola proteins. Merit's new, state-of-the-art, plant-based protein production complex is now the first and only commercial-scale facility in the world capable of producing food-grade protein from canola, the world's second-largest oilseed crop. Merit intends to continue optimizing the manufacturing process in the coming weeks, with an expectation of fulfilling commercial commitments in Q2 for its better-tasting, better-functioning and better-for-you plant proteins.

"This is a truly momentous achievement for us and one that has been a long time in the making," said Johann F. Tergesen, Burcon's president and chief executive officer, adding: "Burcon first embraced the vision of canola's potential as a premium, food-grade protein source over 20 years ago. Today, Merit Foods, with its just-completed high-tech plant protein production facility, is bringing eco-friendly canola proteins to market using Burcon's patented processing technology. These proteins stand to change the way the world's consumers get their protein."

"This milestone is a significant step toward fulfilling canola's enormous global potential as an important, new, environmentally friendly source of high-quality, plant-based protein for food and beverage product development. As the world's second-largest oilseed crop, canola protein is perfectly positioned to offer a sustainable way to feed and nourish the world's growing population."

Canola was originally developed out of rapeseed in the 1970s after many years' efforts by Canadian researchers Baldur Stefansson and Keith Downey, considered the fathers of canola. This scientific advance enabled the production and use of canola oil for human consumption. Since that time, canola agricultural production has expanded globally to now be the number two oilseed in the world-behind soybeans and ahead of sunflower seed, peanuts and cottonseed. Burcon's world-leading team of food scientists and chemical engineers has worked for more than two decades to unlock the full nutritional and functional properties of canola proteins. Burcon's efforts have culminated in the opening of Merit's new plant protein processing facility, and now the commercial-scale production of Merit's novel lineup of Puratein® canola proteins.


Merit's new, ultramodern, plant-based protein production facility is dedicated to the production, of novel pea and canola protein ingredients using licensed technology from Burcon. Unique in its design and structured for rapid expansion, Merit's 94,000-square-foot facility has been engineered and constructed to be able to process both non-GMO canola and yellow field peas, giving it the ability to produce Merit's lineup of Puratein® canola proteins, its Peazazz®and Peazac® pea proteins, and its MeritPro™ protein blends. Merit's Puratein®, Peazazz®, Peazac® and MeritPro™ are ideal ways for food and beverage companies to give their products a much-needed nutritional boost while remaining dairy-free, soy-free, grain-free and gluten-free.

Broadcast-quality Burcon and canola video footage can be downloaded here (https://burcon.ca/media-kit/).

About Burcon NutraScience Corporation

Burcon is a global technology leader in the development of clean-label, plant-based proteins for foods and beverages. With over 300 issued patents and more than 225 additional patent applications developed over a span of more than 20 years, Burcon has grown an extensive portfolio of composition, application and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. In 2019, Merit Functional Foods Corporation was established in a joint venture between Burcon and three veteran food industry executives. Merit Foods has built a state-of-the-art protein production facility in Manitoba, Canada to produce, under licence, Burcon's novel pea and canola protein ingredients. For more information, visit www.burcon.ca.

Forward-Looking Information Cautionary Statement

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe," "future," "likely," "may," "should," "could," "will" and similar references to future periods. All statements included in this release, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding the expected use of proceeds contained in this press release. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations; marketing activities; adverse general economic, market or business conditions; regulatory changes; and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated June 29, 2020 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information speaks only as of the date on which it was made, and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and, accordingly, investors should not rely on such statements.

Industry Contact

Paul Lam


Manager, Business Development and IRO

Burcon NutraScience Corporation

Tel (604) 733-0896, Toll-free (888) 408-7960

plam@burcon.ca  www.burcon.ca

Investor Contact

James Carbonara

Hayden IR

Tel (646) 755-7412

james@haydenir.com

Media Contact:

Steve Campbell, APR

President

Campbell & Company Public Relations

Tel (604) 888-5267

TECH@CCOM-PR.COM

















































 



 

Consent of Independent Auditor

We hereby consent to the inclusion in the Registration Statement on Form 40-F of Burcon NutraScience Corporation of our report dated June 29, 2020, relating to the consolidated financial statements of Burcon NutraScience Corporation, which appears in Exhibit 99.6 of this Registration Statement.  We also consent to the references to us under the heading “Interest of Experts” in the Annual Information Form for the year ended March 31, 2020, which appears in Exhibit 99-10 of this Registration Statement.

 

Chartered Professional Accountants
Vancouver, British Columbia, Canada
May 14, 2021


   
 

PricewaterhouseCoopers LLP
PricewaterhouseCoopers Place, 250 Howe Street, Vancouver, BC, Canada V6C 2S7
T: +1 604 806 7000, F: +1 604 806 7208, www.pwc.com/ca

PwC” refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership.